[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCNkfdS1lLUisl5JUP8eo6cFN0d7WlDPqIOR08H42jk8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Fudan University",[4],1226,false,534,181,1242472,522,409,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Breast Cancer",141,{"name":18,"count":19},"Colorectal Cancer",58,{"name":21,"count":22},"Hepatocellular Carcinoma",33,{"name":24,"count":25},"Gastric Cancer",30,{"name":27,"count":28},"Esophageal Squamous Cell Carcinoma",28,{"name":30,"count":31},"Pancreatic Cancer",25,{"name":33,"count":31},"Metastatic Breast Cancer",{"name":35,"count":36},"Nasopharyngeal Carcinoma",21,[38,43,48,53,58,63,68,73,78,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03941561","S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）","2022-01-01","S-1 for 9 months",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03125980","Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer","2022-05","capecitabine plus oxaliplatin before and after surgery",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05281003","Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)","2023-09-01","Pembrolizumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT02641847","TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","2023-12","docetaxel",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05555888","The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer","2024-03-12","PD-1 antibody",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04764227","Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)","2024-03-30","Paclitaxel",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06313554","Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma","2024-05-20","Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05201430","Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer","2024-06","FOLFOXIRI",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT06088056","A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases","Combination use of SRT with T-DXd",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04922008","Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C\u002FD)","2024-06-30","capecitabine and trastuzumab",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,674,769,808,836,854,879,904,922,946,976,994,1012,1030,1048,1066,1305,1538,1745,1906,2085,2188,2301,2393,2471,2591,2672,2763,2865,2931,3043,3091,3217,3279,3322,3378,3431,3461,3493,3532,3558,3591,3632,3672,3694,3727,3763,3790,3816,3852,3882,3929,3965,4008,4039,4061,4090,4118,4145,4175,4201,4223,4247,4265,4283,4301,4319,4337,4361,4379,4402,4420,4446,4464,4490,4508,4526,4551,4569,4591,4609,4633,4651,4676,4694,4712,4737,4755,4773,4791,4813,4831,4849,4867,4890,4908,4934,4952,4970,4994,5012,5030,5055,5073,5098,5116,5134,5152,5170,5188,5213,5231,5256,5274,5292,5310,5328,5346,5370,5388,5406,5424,5442,5465,5483,5505,5523,5548,5566,5590,5614,5632,5650,5668,5686,5711,5729,5753,5771,5797,5815,5840,5858,6070,6290,6419,6547,6690,6766,6901,6951,7010,7077,7117,7151,7185,7239,7286,7327,7357,7390,7420,7457,7536,7578,7614,7649,7675,7750,7821,7901,7946,7979,8005,8035,8066,8092,8135,8169,8199,8225,8247,8269,8297,8328,8355,8377,8399,8421,8443,8465,8487,8513,8539,8561,8583,8605,8627,8649,8701,8742,8784,8814,8844,8868,8901,8923,8945,8984,9022,9047,9069,9101,9148,9179,9216,9242,9273,9305,9341,9372,9394,9421,9448,9470,9492,9514,9544,9562,9585,9610,9628,9650,9668,9686,9704,9722,9740,9758,9776,9794,9817,9841,9863,9881,9899,9917,9935,9953,9971,9994,10017,10035,10060,10078,10096,10124,10142,10166,10184,10202,10224,10246,10270,10293,10311,10333,10351,10369,10392,10410,10428,10452,10473,10496,10517,10540,10565,10583,10601,10619,10641,10659,10677,10695,10717,10735,10753,10771,10789,10807,10825,10843,10861,10887,10905,10926,10949,10973,10991,11009,11027,11045,11063,11081,11099,11117,11135,11153,11171,11189,11207,11225,11247,11270,11294,11312,11330,11348,11366,11391,11409,11431,11449,11471,11489,11512,11530,11548,11566,11584,11602,11620,11638,11656,11674,11699,11717,11735,11759,11784,11803,11821,11843,11866,11884,11907,11925,11949,11967,12001,12019,12037,12055,12073,12091,12109,12127,12145,12163,12181,12199,12217,12235,12253,12277,12295,12321,12339,12360,12378,12396,12414,12437,12455,12478,12501,12519,12543,12561,12579,12601,12619,12642,12660,12678,12696,12722,12740,12758,12776,12801,12819,12837,12855,12873,12898,12921,12945,12969,12987,13010,13034,13052,13074,13092,13115,13133,13151,13175,13193,13211,13229,13247,13271,13289,13313,13331,13349,13371,13394,13412,13448,13470,13488,13511,13529,13547,13565,13589,13607,13630,13648,13666,13684,13705,13728,13752,13774,13799,13817,13839,13862,13880,13905,13930,13951,13972,13990,14008,14029,14053,14071,14094,14115,14138,14163,14181,14199,14217,14235,14253,14271,14289,14313,14331,14349,14367,14385,14403,14421,14439,14461,14496,14521,14545,14577,14599,14624,14642,14660,14681,14705,14723,14746,14770,14788,14809,14840,14868,14890,14914,14935,14958,14983,15001,15023,15047,15069,15092,15113,15139,15157,15175,15193,15221,15239,15257,15279,15302,15320,15343,15370,15388,15406,15424,15443,15465,15490,15508,15530,15554,15577,15619,15656,15686,15711,15729,15759,15777,15795,15821,15844,15862,15884,15906,15929,15947,15965,15983,16010,16028,16046,16069,16096,16114,16132,16150,16173,16191,16216,16234,16260,16284,16302,16346,16392,16431,16462,16493,16520,16542,16568,16600,16618,16642,16660,16678,16702,16726,16744,16768,16789,16815,16833,16851,16874,16898,16923,16941,16963,16985,17009,17027,17045,17067,17085,17108,17132,17150,17168,17190,17215,17233,17251,17269,17290,17314,17332,17350,17374,17392,17417,17435,17459,17477,17500,17518,17536,17554,17577,17598,17619,17637,17655,17673,17691,17709,17734,17758,17776,17799,17817,17840,17858,17880,17904,17926,17944,17962,17980,18005,18023,18041,18066,18084,18107,18146,18181,18214,18240,18269,18291,18313,18339,18365,18392,18420,18442,18464,18497,18521,18539,18557,18579,18607,18625,18643,18661,18679,18697,18715,18737,18760,18782,18800,18821,18842,18865,18889,18907,18925,18946,18964,18986,19007,19025,19043,19061,19084,19117,19135,19153,19175,19197,19215,19238,19261,19279,19301,19323,19346,19371,19389,19420,19438,19456,19474,19492,19510,19528,19546,19564,19582,19604,19622,19643,19666,19688,19714,19732,19750,19768,19786,19807,19825,19847,19871,19889,19911,19932,19958,19982,20005,20027,20045,20066,20084,20106,20135,20153,20171,20189,20207,20225,20243,20261,20284,20302,20327,20351,20373,20391,20412,20430,20454,20477,20495,20513,20535,20553,20571,20593,20617,20639,20661,20679,20700,20724,20742,20760,20778,20801,20823,20849,20867,20885,20908,20926,20948,20969,20991,21013,21035,21053,21076,21094,21115,21136,21158,21176,21194,21212,21236,21258,21276,21297,21315,21333,21351,21369,21393,21415,21436,21458,21479,21497,21515,21539,21561,21582,21603,21621,21642,21666,21688,21710,21728,21751,21769,21791,21809,21827,21845,21867,21888,21910,21933,21951,21972,21993,22011,22032,22053,22074,22097,22121,22144,22162,22180,22203,22221,22239,22262,22280,22303,22324,22346,22369,22390,22408,22432,22453,22475,22493,22514,22532,22550,22568,22586,22604,22622,22640,22658,22680,22703,22726,22749,22770,22795,22813,22831,22849,22871,22889,22912,22930,22951,22973,22995,23016,23038,23071,23093,23122,23145,23169,23187,23217,23235,23253,23271,23293,23317,23344,23362,23380,23398,23421,23439,23462,23480,23503,23526,23544,23568,23593,23611,23632,23657,23675,23693,23711,23733,23754,23780,23798,23819,23843,23865,23887,23910,23935,23953,23977,23995,24013,24031,24054,24076,24099,24122,24140,24158,24182,24200,24218,24241,24265,24287,24311,24334,24352,24374,24395],{"intervention":96,"totalTrials":97,"cells":98},"Capecitabine",50,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":116,"PHASE3":479,"PHASE4":638,"NA":652},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":109,"enrollment":111,"conditions":112,"interventions":114},"NCT01474187","Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II\u002FIII Rectal Cancer","UNKNOWN",[89],"2011-11","2012-12",60,[113],"Rectal Cancer",[115,96],"Irinotecan",{"trials":117,"activeCount":478,"soonestReadout":61},[118,130,141,152,167,177,184,195,206,217,231,243,256,267,280,289,301,313,319,330,339,349,362,372,384,394,404,414,422,434,443,466],{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":97,"conditions":126,"interventions":127},"NCT07561060","Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy","RECRUITING",[89,90],"2027-12","2028-03","2024-01-01",[113],[128,96,129,96],"Tislelizumab","Oxaliplatin",{"nctId":131,"briefTitle":132,"status":121,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT06840665","MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer",[90],"2026-08-12","2027-02-12","2024-08-13",46,[139],"Locally Advanced Rectal Cancer",[62,129,96],{"nctId":142,"briefTitle":143,"status":121,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT06462053","Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer",[90],"2026-04-01","2027-03-01","2024-04-01",134,[150],"Early Low Rectal Cancer",[62,129,96],{"nctId":153,"briefTitle":154,"status":107,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":162},"NCT05438706","A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed\u002FMetastatic Triple-negative Breast Cancer",[90],"2023-11-10","2024-07-10","2022-07-10",70,[161],"Triple-negative Breast Cancer",[163,164,165,166],"chidamide","camrelizumab","carboplatin","capecitabine",{"nctId":168,"briefTitle":169,"status":107,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":175},"NCT04302441","A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy",[90],"2021-06-30","2016-11-10",550,[15],[176,96],"Vinorelbine",{"nctId":59,"briefTitle":60,"status":121,"phases":178,"primaryCompletion":61,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":183},[90],"2025-05-01","2022-12-12",34,[150],[62,96,129],{"nctId":185,"briefTitle":186,"status":107,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":25,"conditions":191,"interventions":193},"NCT04782804","Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence",[89,90],"2023-12-30","2024-05-01","2021-01-01",[192],"Cholangiocarcinoma, Intrahepatic",[96,194],"PD-1 Antibody（Tislelizumab）",{"nctId":196,"briefTitle":197,"status":107,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":204},"NCT04394598","A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer",[90],"2022-06-01","2022-12-01","2020-03-01",210,[139],[205,96,115],"Dendrobium Huoshanense Granules",{"nctId":207,"briefTitle":208,"status":107,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":215},"NCT01924078","Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer",[90],"2015-03","2015-06","2010-10",100,[15],[96,216],"aromatase Inhibitors",{"nctId":218,"briefTitle":219,"status":121,"phases":220,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":226},"NCT06928584","Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer",[90],"2030-03-10","2025-03-10",221,[225],"Locally Recurrent Rectal Cancer",[96,227,228,129,115,229,230,62],"5-fluorouracil","folinic acid","Cetuximab","Bevacizumab",{"nctId":232,"briefTitle":233,"status":121,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":241},"NCT06281405","CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer",[90],"2026-06-30","2028-12-31","2024-03-28",192,[139,240],"Neoadjuvant Therapy",[242,96,129],"PD-1 inhibitor",{"nctId":244,"briefTitle":245,"status":107,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":213,"conditions":249,"interventions":251},"NCT04745975","Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer",[90],"2023-01","2021-02-01",[250],"Triple Negative Breast Cancer",[252,253,254,176,255,96],"Personalized treatment guided by mini-PDX and RNA sequencing","Nab paclitaxel","Eribulin","Gemcitabine",{"nctId":257,"briefTitle":258,"status":107,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":265},"NCT04780347","Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel\u002FDocetaxel-resistant Advanced Breast Cancer",[90],"2022-12-30","2023-02-25","2020-12-15",92,[15],[266,166],"Albumin-bound paclitaxel plus capecitabine",{"nctId":268,"briefTitle":269,"status":270,"phases":271,"primaryCompletion":272,"completion":273,"start":145,"enrollment":137,"conditions":274,"interventions":277},"NCT07515625","Efficacy of Sintilimab Combined With Bevacizumab and XELOX\u002FSOX in Initially Unresectable AFP-positive Gastric\u002FGastroesophageal Junction Adenocarcinoma","NOT_YET_RECRUITING",[90],"2028-04-01","2029-04-01",[275,276],"Gastric Cancer (GC)","AFP Gastric or Gastroesophageal Junction Adenocarcinoma",[278,230,129,96,279],"Sintilimab","S-1",{"nctId":281,"briefTitle":282,"status":107,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":97,"conditions":287,"interventions":288},"NCT04411524","The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer",[90],"2022-04-30","2022-12-31","2020-07-01",[139],[62,96,115],{"nctId":290,"briefTitle":291,"status":107,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},"NCT05732493","Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)",[90],"2023-12-31","2024-12-31","2023-03-01",120,[298],"Locally Advanced Colon Cancer",[300,129,96],"Serplulimab",{"nctId":302,"briefTitle":303,"status":121,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":311},"NCT07562711","Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer",[90],"2027-12-31","2024-11-01",340,[309,310,18],"ctDNA","Chemotherapy",[96,312],"FOLFOX",{"nctId":314,"briefTitle":315,"status":107,"phases":316,"primaryCompletion":284,"completion":285,"start":286,"enrollment":97,"conditions":317,"interventions":318},"NCT04411537","The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer",[90],[139],[62,96,115],{"nctId":320,"briefTitle":321,"status":121,"phases":322,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":328},"NCT07150949","Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)",[90],"2027-08-31","2028-08-31","2025-08-28",138,[139,240],[129,96,329,300],"Celecoxib",{"nctId":331,"briefTitle":332,"status":121,"phases":333,"primaryCompletion":305,"completion":305,"start":306,"enrollment":334,"conditions":335,"interventions":338},"NCT07562659","Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I\u002FLow-Risk Stage II Colorectal Cancer",[90],80,[309,336,337],"Colorectal Cancer (CRC)","Adjuvant Chemotherapy",[96],{"nctId":340,"briefTitle":341,"status":107,"phases":342,"primaryCompletion":343,"completion":201,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT03702985","Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer",[90],"2019-11-01","2018-05-28",160,[139],[96,115,348],"Amifostine",{"nctId":350,"briefTitle":351,"status":121,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT05628038","The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer",[90],"2024-12-01","2025-12-01","2022-11-30",93,[358],"Recurrent Rectal Cancer",[62,96,360,228,129,115,361,229,230],"5FU","Raltitrexed",{"nctId":363,"briefTitle":364,"status":365,"phases":366,"primaryCompletion":51,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":371},"NCT04518280","Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer","COMPLETED",[90],"2025-01-01","2021-05-01",130,[139],[62,96,129],{"nctId":373,"briefTitle":374,"status":107,"phases":375,"primaryCompletion":376,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},"NCT05451719","Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy",[90],"2024-07","2025-07","2022-07",116,[18,381],"Colorectal Cancer Stage IV",[383,96],"Fruquintinib Plus Capecitabine",{"nctId":385,"briefTitle":386,"status":107,"phases":387,"primaryCompletion":388,"completion":389,"start":390,"enrollment":296,"conditions":391,"interventions":392},"NCT01963702","A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC",[90],"2013-12","2014-12","2012-08",[24],[393,129,96],"Docetaxol",{"nctId":395,"briefTitle":396,"status":270,"phases":397,"primaryCompletion":398,"completion":399,"start":400,"enrollment":137,"conditions":401,"interventions":403},"NCT06390982","Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study",[90],"2025-12","2028-12","2024-05",[402,113],"RECTAL NEOPLASMS",[128,96,129,96],{"nctId":405,"briefTitle":406,"status":365,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":412},"NCT04296162","Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)",[90],"2026-04-25","2020-03-10",182,[15],[176,96,413],"Trastuzumab",{"nctId":415,"briefTitle":416,"status":121,"phases":417,"primaryCompletion":235,"completion":418,"start":419,"enrollment":111,"conditions":420,"interventions":421},"NCT06455124","Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)",[90],"2029-12-30","2024-05-08",[113],[62,96,129],{"nctId":423,"briefTitle":424,"status":107,"phases":425,"primaryCompletion":293,"completion":85,"start":426,"enrollment":427,"conditions":428,"interventions":431},"NCT05111444","Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",[90],"2021-12-31",65,[429,430],"Gastric Neoplasms","Gastroesophageal Junction Adenocarcinoma",[432,433,96,129,67,279],"Camrelizumab","Pyrotinib",{"nctId":435,"briefTitle":436,"status":270,"phases":437,"primaryCompletion":236,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT06787339","Capecitabine in Low Risk Triple Negative Breast Cancer",[90],"2030-01-31","2025-01-15",198,[15],[96],{"nctId":444,"briefTitle":445,"status":107,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":453},"NCT04355858","Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer",[90],"2023-05-01","2025-04-01","2020-05-01",319,[15,452],"Metastatic Cancer",[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],"SHR7390","Famitinib","SHR3162","SHR1210","Everolimus","SHR2554","SHR3680","SHR6390","SHR1701","SERD","AI","VEGFi",{"nctId":467,"briefTitle":468,"status":121,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT06494995","AK104 and Low-dose Radiation in Recurrent\u002FMetastatic HNSCC After Failure of First-line Systemic Therapy",[90],"2026-07-01","2028-07-01","2024-07-03",52,[475],"Head and Neck Squamous Cell Carcinoma",[477,96],"Cadonilimab",15,{"trials":480,"activeCount":637,"soonestReadout":507},[481,491,502,512,523,534,546,558,568,585,594,606,618,627],{"nctId":482,"briefTitle":483,"status":365,"phases":484,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":490},"NCT02605265","Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1",[91],"2017-12","2023-06","2015-10",356,[139],[96,115,129],{"nctId":492,"briefTitle":493,"status":494,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT01655992","A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)","TERMINATED",[91],"2017-10","2012-01",386,[33],[166,501],"S1 generic",{"nctId":503,"briefTitle":504,"status":505,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":511},"NCT03399110","XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)","ACTIVE_NOT_RECRUITING",[91],"2026-07-25","2017-11-17",1024,[24],[129,96],{"nctId":513,"briefTitle":514,"status":121,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT06992882","A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)",[91],"2028-06-08","2030-06-10","2025-07-08",2306,[521],"HER2-positive Breast Cancer",[96,67],{"nctId":524,"briefTitle":525,"status":107,"phases":526,"primaryCompletion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT02798510","Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma",[91],"2019-04","2016-04",140,[531],"Malignant Neoplasm Other Gallbladder\u002FExtrahepatic Bile Duct",[166,533],"gemcitabine",{"nctId":535,"briefTitle":536,"status":270,"phases":537,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":543},"NCT07366840","RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure",[90,91],"2028-01-16","2029-01-16","2026-01-16",268,[521,33],[544,255,96,413,545],"Disitamab Vedotin","Inetetamab",{"nctId":547,"briefTitle":548,"status":270,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":556},"NCT07021261","Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients",[91],"2030-06-16","2032-06-16","2025-06-16",440,[15,555],"TNBC",[557,96],"Utidelone plus capecitabine",{"nctId":559,"briefTitle":560,"status":107,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT00561522","Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection",[90,91],"2012-07","2007-11",290,[21,566],"Neoplasm Metastasis",[96],{"nctId":569,"briefTitle":570,"status":107,"phases":571,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":584},"NCT03889626","The Maintenance Treatment of Apatinib\u002FCapecitabine Versus Observation in Advanced Gastric Cancer",[91],"2022-03-22","2024-03-22","2019-03-22",242,[577,578,579,580,96,581,582,583],"Stomach Neoplasms","Gastrointestinal Neoplasms","Stomach Diseases","Digestive System Neoplasms","Apatinib","Neoplasms","Molecular Mechanisms of Pharmacological Action",[581,96],{"nctId":586,"briefTitle":587,"status":107,"phases":588,"primaryCompletion":589,"completion":389,"start":590,"enrollment":591,"conditions":592,"interventions":593},"NCT01064999","A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer",[90,91],"2012-03","2010-03",240,[113],[129,96],{"nctId":595,"briefTitle":596,"status":270,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":605},"NCT07551479","SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer",[91],"2032-12-31","2035-12-31","2026-05-01",612,[603,604],"Locally Advanced Rectal Cancer (LARC)","MSS (Microsatellite Stable)",[96,129,242],{"nctId":607,"briefTitle":608,"status":121,"phases":609,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":615},"NCT04997837","Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma",[91],"2027-07-21","2027-10-21","2021-07-21",433,[24],[242,129,96,616,617,310],"Tegafur-gimeracil-oteracil potassium","5-FU",{"nctId":619,"briefTitle":620,"status":365,"phases":621,"primaryCompletion":622,"completion":622,"start":210,"enrollment":623,"conditions":624,"interventions":625},"NCT02395640","The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer",[91],"2021-02-23",438,[24],[626,129,96],"Epirubicin",{"nctId":628,"briefTitle":629,"status":107,"phases":630,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":636},"NCT04307147","NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy",[91],"2021-03-01","2021-09-01","2018-07-03",316,[15],[96,176],6,{"trials":639,"activeCount":651,"soonestReadout":644},[640],{"nctId":641,"briefTitle":642,"status":121,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":649},"NCT06090994","Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy",[92],"2027-07","2029-11","2024-10-18",756,[18],[650,96],"Huaier granule",1,{"trials":653,"activeCount":101},[654,662],{"nctId":655,"briefTitle":656,"status":107,"phases":657,"completion":658,"start":659,"enrollment":213,"conditions":660,"interventions":661},"NCT01671891","Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer",[],"2013-02","2012-02",[113],[166],{"nctId":663,"briefTitle":664,"status":107,"phases":665,"primaryCompletion":260,"completion":666,"start":667,"enrollment":345,"conditions":668,"interventions":673},"NCT04856761","A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection",[],"2024-12-30","2020-11-01",[669,670,671,672],"Biliary Tract Neoplasms","Recurrence","Cholangiocarcinoma","Gall Bladder Cancer",[279,96],{"intervention":675,"totalTrials":676,"cells":677},"Huaier Granule",8,{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":708,"PHASE4":710,"NA":767},{"trials":679,"activeCount":101},[],{"trials":681,"activeCount":101},[],{"trials":683,"activeCount":651,"soonestReadout":699},[684,695],{"nctId":685,"briefTitle":686,"status":365,"phases":687,"primaryCompletion":688,"completion":354,"start":689,"enrollment":690,"conditions":691,"interventions":693},"NCT05673824","Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.",[90],"2025-09-16","2023-01-03",76,[692],"Nephrotoxicity",[675,694],"VEGFR-TKIs",{"nctId":696,"briefTitle":697,"status":270,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":296,"conditions":702,"interventions":705},"NCT07355361","Huaier Granule and Proteinuria",[90],"2027-06-15","2028-06-15","2026-01-15",[703,704],"Proteinuria","Breast Cancer Patients",[675,706,707],"Antitumor therapy","Proteinuria Management",{"trials":709,"activeCount":101},[],{"trials":711,"activeCount":637,"soonestReadout":749},[712,720,730,741,745,756],{"nctId":713,"briefTitle":714,"status":270,"phases":715,"primaryCompletion":716,"completion":399,"start":717,"enrollment":148,"conditions":718,"interventions":719},"NCT06665334","To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery",[92],"2026-10","2024-10",[18],[650],{"nctId":721,"briefTitle":722,"status":270,"phases":723,"primaryCompletion":724,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":729},"NCT05871437","Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules",[92],"2026-01","2028-01","2025-09",232,[15],[650],{"nctId":731,"briefTitle":732,"status":270,"phases":733,"primaryCompletion":734,"completion":735,"start":736,"enrollment":737,"conditions":738,"interventions":739},"NCT07358520","Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients",[92],"2027-01-28","2028-01-28","2026-01-28",40,[703],[675,740],"Anlotinib and Bevacizumab",{"nctId":641,"briefTitle":642,"status":121,"phases":742,"primaryCompletion":644,"completion":645,"start":646,"enrollment":647,"conditions":743,"interventions":744},[92],[18],[650,96],{"nctId":746,"briefTitle":747,"status":270,"phases":748,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":755},"NCT05860907","Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis",[92],"2025-10","2027-10","2023-10",384,[754],"Breast Cancer Stage IV",[675],{"nctId":757,"briefTitle":758,"status":121,"phases":759,"primaryCompletion":305,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":766},"NCT04790305","Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer",[92],"2028-07-28","2021-06-18",1072,[764,161,765],"Carcinoma Breast","Invasive Ductal Carcinoma, Breast",[675],{"trials":768,"activeCount":101},[],{"intervention":770,"totalTrials":771,"cells":772},"tunlametinib",2,{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":792,"PHASE4":794,"NA":806},{"trials":774,"activeCount":101},[],{"trials":776,"activeCount":101},[],{"trials":778,"activeCount":651,"soonestReadout":783},[779],{"nctId":780,"briefTitle":781,"status":121,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":737,"conditions":786,"interventions":789},"NCT06970353","Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer",[90],"2026-12-30","2031-12-30","2025-05-27",[787,788],"Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation","Advanced PDTC or ATC With NRAS Mutation",[790,791],"Tunlametinib","Tunlametinib+PD-1 mAb",{"trials":793,"activeCount":101},[],{"trials":795,"activeCount":651,"soonestReadout":800},[796],{"nctId":797,"briefTitle":798,"status":121,"phases":799,"primaryCompletion":800,"completion":801,"start":736,"enrollment":802,"conditions":803,"interventions":805},"NCT07445022","RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma",[92],"2028-09-30","2029-01-31",110,[804],"Melanoma Advanced",[770],{"trials":807,"activeCount":101},[],{"intervention":809,"totalTrials":651,"cells":810},"Systematic chemotherapy",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":834},{"trials":812,"activeCount":101},[],{"trials":814,"activeCount":101},[],{"trials":816,"activeCount":101},[],{"trials":818,"activeCount":101},[],{"trials":820,"activeCount":651,"soonestReadout":825},[821],{"nctId":822,"briefTitle":823,"status":121,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":832},"NCT06230055","Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis",[92],"2026-01-01","2027-01-01","2024-01-05",37,[830,831],"HER2-negative Breast Cancer","Leptomeningeal Metastasis",[809,833],"Intrathecal chemotherapy",{"trials":835,"activeCount":101},[],{"intervention":833,"totalTrials":651,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":852},{"trials":839,"activeCount":101},[],{"trials":841,"activeCount":101},[],{"trials":843,"activeCount":101},[],{"trials":845,"activeCount":101},[],{"trials":847,"activeCount":651,"soonestReadout":825},[848],{"nctId":822,"briefTitle":823,"status":121,"phases":849,"primaryCompletion":825,"completion":826,"start":827,"enrollment":828,"conditions":850,"interventions":851},[92],[830,831],[809,833],{"trials":853,"activeCount":101},[],{"intervention":855,"totalTrials":651,"cells":856},"Befotertinib",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":877},{"trials":858,"activeCount":101},[],{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":101},[],{"trials":864,"activeCount":101},[],{"trials":866,"activeCount":651,"soonestReadout":871},[867],{"nctId":868,"briefTitle":869,"status":121,"phases":870,"primaryCompletion":871,"completion":872,"start":189,"enrollment":873,"conditions":874,"interventions":876},"NCT06561620","Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients",[92],"2027-05-01","2029-05-01",592,[875],"3-year Disease-free Survival",[855],{"trials":878,"activeCount":101},[],{"intervention":880,"totalTrials":651,"cells":881},"Tongxinluo",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":890,"NA":902},{"trials":883,"activeCount":101},[],{"trials":885,"activeCount":101},[],{"trials":887,"activeCount":101},[],{"trials":889,"activeCount":101},[],{"trials":891,"activeCount":651,"soonestReadout":896},[892],{"nctId":893,"briefTitle":894,"status":270,"phases":895,"primaryCompletion":896,"completion":897,"start":751,"enrollment":898,"conditions":899,"interventions":901},"NCT06061692","Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）",[92],"2026-06","2026-12",1052,[900],"Cerebral Small Vessel Diseases",[880],{"trials":903,"activeCount":101},[],{"intervention":740,"totalTrials":651,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":920},{"trials":907,"activeCount":101},[],{"trials":909,"activeCount":101},[],{"trials":911,"activeCount":101},[],{"trials":913,"activeCount":101},[],{"trials":915,"activeCount":651,"soonestReadout":734},[916],{"nctId":731,"briefTitle":732,"status":270,"phases":917,"primaryCompletion":734,"completion":735,"start":736,"enrollment":737,"conditions":918,"interventions":919},[92],[703],[675,740],{"trials":921,"activeCount":101},[],{"intervention":923,"totalTrials":651,"cells":924},"Inetetamab and Paclitaxel ± Pertuzumab",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":944},{"trials":926,"activeCount":101},[],{"trials":928,"activeCount":101},[],{"trials":930,"activeCount":101},[],{"trials":932,"activeCount":101},[],{"trials":934,"activeCount":651,"soonestReadout":939},[935],{"nctId":936,"briefTitle":937,"status":270,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":213,"conditions":942,"interventions":943},"NCT06578299","Inetetamab Combined With Paclitaxel With\u002FWithout Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer",[92],"2026-03-30","2027-08-30","2024-08-30",[754],[923],{"trials":945,"activeCount":101},[],{"intervention":947,"totalTrials":651,"cells":948},"dabrafenib plus trametinib with or without PD-1 antibody",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":974},{"trials":950,"activeCount":101},[],{"trials":952,"activeCount":101},[],{"trials":954,"activeCount":101},[],{"trials":956,"activeCount":101},[],{"trials":958,"activeCount":651,"soonestReadout":963},[959],{"nctId":960,"briefTitle":961,"status":121,"phases":962,"primaryCompletion":963,"completion":236,"start":964,"enrollment":965,"conditions":966,"interventions":968},"NCT06195228","A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer",[92],"2026-12-31","2020-01-01",800,[967],"Advanced Thyroid Cancer Patients Who Received Target Therapy",[947,969,970,971,972,973],"entrectinib or larotrectinib with or without anti-PD-1 antibdoy","pralsetinib or selpercatinib with or without anti-PD-1 antibdoy","anlotinib or anlotinib plus anti-PD-1 antibody","lenvatinib plus anti-PD-1 antibody","Other Targets: precise treatment based on the target",{"trials":975,"activeCount":101},[],{"intervention":969,"totalTrials":651,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":992},{"trials":979,"activeCount":101},[],{"trials":981,"activeCount":101},[],{"trials":983,"activeCount":101},[],{"trials":985,"activeCount":101},[],{"trials":987,"activeCount":651,"soonestReadout":963},[988],{"nctId":960,"briefTitle":961,"status":121,"phases":989,"primaryCompletion":963,"completion":236,"start":964,"enrollment":965,"conditions":990,"interventions":991},[92],[967],[947,969,970,971,972,973],{"trials":993,"activeCount":101},[],{"intervention":970,"totalTrials":651,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1010},{"trials":997,"activeCount":101},[],{"trials":999,"activeCount":101},[],{"trials":1001,"activeCount":101},[],{"trials":1003,"activeCount":101},[],{"trials":1005,"activeCount":651,"soonestReadout":963},[1006],{"nctId":960,"briefTitle":961,"status":121,"phases":1007,"primaryCompletion":963,"completion":236,"start":964,"enrollment":965,"conditions":1008,"interventions":1009},[92],[967],[947,969,970,971,972,973],{"trials":1011,"activeCount":101},[],{"intervention":971,"totalTrials":651,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1028},{"trials":1015,"activeCount":101},[],{"trials":1017,"activeCount":101},[],{"trials":1019,"activeCount":101},[],{"trials":1021,"activeCount":101},[],{"trials":1023,"activeCount":651,"soonestReadout":963},[1024],{"nctId":960,"briefTitle":961,"status":121,"phases":1025,"primaryCompletion":963,"completion":236,"start":964,"enrollment":965,"conditions":1026,"interventions":1027},[92],[967],[947,969,970,971,972,973],{"trials":1029,"activeCount":101},[],{"intervention":972,"totalTrials":651,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1046},{"trials":1033,"activeCount":101},[],{"trials":1035,"activeCount":101},[],{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":101},[],{"trials":1041,"activeCount":651,"soonestReadout":963},[1042],{"nctId":960,"briefTitle":961,"status":121,"phases":1043,"primaryCompletion":963,"completion":236,"start":964,"enrollment":965,"conditions":1044,"interventions":1045},[92],[967],[947,969,970,971,972,973],{"trials":1047,"activeCount":101},[],{"intervention":973,"totalTrials":651,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1064},{"trials":1051,"activeCount":101},[],{"trials":1053,"activeCount":101},[],{"trials":1055,"activeCount":101},[],{"trials":1057,"activeCount":101},[],{"trials":1059,"activeCount":651,"soonestReadout":963},[1060],{"nctId":960,"briefTitle":961,"status":121,"phases":1061,"primaryCompletion":963,"completion":236,"start":964,"enrollment":965,"conditions":1062,"interventions":1063},[92],[967],[947,969,970,971,972,973],{"trials":1065,"activeCount":101},[],{"intervention":129,"totalTrials":22,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1249,"PHASE4":1301,"NA":1303},{"trials":1069,"activeCount":101},[],{"trials":1071,"activeCount":101},[],{"trials":1073,"activeCount":1248,"soonestReadout":61},[1074,1078,1082,1093,1097,1101,1105,1109,1122,1135,1139,1152,1160,1171,1179,1183,1187,1198,1209,1224,1228,1232,1236,1240,1244],{"nctId":119,"briefTitle":120,"status":121,"phases":1075,"primaryCompletion":123,"completion":124,"start":125,"enrollment":97,"conditions":1076,"interventions":1077},[89,90],[113],[128,96,129,96],{"nctId":131,"briefTitle":132,"status":121,"phases":1079,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":1080,"interventions":1081},[90],[139],[62,129,96],{"nctId":1083,"briefTitle":1084,"status":270,"phases":1085,"primaryCompletion":272,"completion":272,"start":1086,"enrollment":25,"conditions":1087,"interventions":1091},"NCT06914687","Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric\u002FGastroesophageal Junction Adenocarcinoma",[90],"2025-03-30",[1088,1089,1090],"Gastric Adenocarcinoma","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","Peritoneal Metastasis",[128,279,129,1092,67],"Docetaxel",{"nctId":142,"briefTitle":143,"status":121,"phases":1094,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":1095,"interventions":1096},[90],[150],[62,129,96],{"nctId":59,"briefTitle":60,"status":121,"phases":1098,"primaryCompletion":61,"completion":179,"start":180,"enrollment":181,"conditions":1099,"interventions":1100},[90],[150],[62,96,129],{"nctId":218,"briefTitle":219,"status":121,"phases":1102,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":1103,"interventions":1104},[90],[225],[96,227,228,129,115,229,230,62],{"nctId":232,"briefTitle":233,"status":121,"phases":1106,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":1107,"interventions":1108},[90],[139,240],[242,96,129],{"nctId":1110,"briefTitle":1111,"status":1112,"phases":1113,"primaryCompletion":1114,"completion":1114,"start":600,"enrollment":1115,"conditions":1116,"interventions":1118},"NCT07441369","Abemaciclib Combined With FOLFOX\u002FFOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","ENROLLING_BY_INVITATION",[90],"2027-04-30",16,[1117],"Liver Metastases From Colorectal Cancer (mCRC)",[1119,129,1120,1121,115],"Abemaciclib","Calcium Folinate","5-Fluorouracil",{"nctId":1123,"briefTitle":1124,"status":270,"phases":1125,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":1130,"interventions":1132},"NCT06652412","CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC",[90],"2027-11","2028-11","2024-11",124,[1131,113],"Colon Cancer",[1133,278,1134,361,129,115],"Ultrafractionated RT and CGA Guided systemic treatment.","Fluorouracil",{"nctId":268,"briefTitle":269,"status":270,"phases":1136,"primaryCompletion":272,"completion":273,"start":145,"enrollment":137,"conditions":1137,"interventions":1138},[90],[275,276],[278,230,129,96,279],{"nctId":1140,"briefTitle":1141,"status":270,"phases":1142,"primaryCompletion":1143,"completion":1144,"start":1145,"enrollment":1146,"conditions":1147,"interventions":1149},"NCT06447636","Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric\u002FGastroesophageal Junction Adenocarcinoma",[90],"2025-08","2028-08","2024-08-01",20,[24,1148],"Gastro Esophageal Junction Cancer",[1150,278,129,1151],"Surufatinib","S1",{"nctId":1153,"briefTitle":1154,"status":107,"phases":1155,"primaryCompletion":293,"completion":1156,"start":286,"enrollment":427,"conditions":1157,"interventions":1159},"NCT03403101","The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer",[90],"2024-07-01",[1158],"Carcinoma, Pancreatic Ductal",[1151,129,115],{"nctId":1161,"briefTitle":1162,"status":107,"phases":1163,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT05435313","Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy",[90],"2024-01","2024-02","2022-07-12",39,[18],[1170,128,361,129,115],"Fruquintinib",{"nctId":1172,"briefTitle":1173,"status":121,"phases":1174,"primaryCompletion":800,"completion":800,"start":1175,"enrollment":25,"conditions":1176,"interventions":1177},"NCT07194005","Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+\u002F2+ Unresectable Gastric Cancer",[90],"2025-09-04",[24],[1178,278,279,129],"Disitamab vedotin",{"nctId":290,"briefTitle":291,"status":107,"phases":1180,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":1181,"interventions":1182},[90],[298],[300,129,96],{"nctId":320,"briefTitle":321,"status":121,"phases":1184,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":1185,"interventions":1186},[90],[139,240],[129,96,329,300],{"nctId":1188,"briefTitle":1189,"status":270,"phases":1190,"primaryCompletion":235,"completion":963,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1194},"NCT04443543","An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer",[90],"2020-06-22",222,[113],[1195,1196,129,1197,128],"Capecitabine (Xeloda) Pharmacogenetic Test Reagents","irinotecan","5Fluorouracil",{"nctId":1199,"briefTitle":1200,"status":107,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1208},"NCT02635971","Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer",[90],"2022-06","2022-12","2015-12",168,[1207],"Carcinoma, Pancreatic",[255,129],{"nctId":1210,"briefTitle":1211,"status":494,"phases":1212,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":637,"conditions":1215,"interventions":1222},"NCT05161572","Perioperative Chemoimmunotherapy With\u002FWithout Preoperative Chemoradiation for Locally Advanced Gastric Cancer",[90],"2022-09-30","2021-09-28",[577,1216,240,1217,1218,1219,1220,1221],"Esophagogastric Junction Disorder","Chemoradiotherapy","Immunotherapy","Gastrectomy","Adenocarcinoma","Adjuvant Therapy",[129,1223,278],"Tegafur-Gimeracil-Oteracil",{"nctId":350,"briefTitle":351,"status":121,"phases":1225,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":1226,"interventions":1227},[90],[358],[62,96,360,228,129,115,361,229,230],{"nctId":363,"briefTitle":364,"status":365,"phases":1229,"primaryCompletion":51,"completion":367,"start":368,"enrollment":369,"conditions":1230,"interventions":1231},[90],[139],[62,96,129],{"nctId":385,"briefTitle":386,"status":107,"phases":1233,"primaryCompletion":388,"completion":389,"start":390,"enrollment":296,"conditions":1234,"interventions":1235},[90],[24],[393,129,96],{"nctId":395,"briefTitle":396,"status":270,"phases":1237,"primaryCompletion":398,"completion":399,"start":400,"enrollment":137,"conditions":1238,"interventions":1239},[90],[402,113],[128,96,129,96],{"nctId":415,"briefTitle":416,"status":121,"phases":1241,"primaryCompletion":235,"completion":418,"start":419,"enrollment":111,"conditions":1242,"interventions":1243},[90],[113],[62,96,129],{"nctId":423,"briefTitle":424,"status":107,"phases":1245,"primaryCompletion":293,"completion":85,"start":426,"enrollment":427,"conditions":1246,"interventions":1247},[90],[429,430],[432,433,96,129,67,279],17,{"trials":1250,"activeCount":1300,"soonestReadout":507},[1251,1255,1259,1263,1267,1271,1275,1284],{"nctId":482,"briefTitle":483,"status":365,"phases":1252,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":1253,"interventions":1254},[91],[139],[96,115,129],{"nctId":503,"briefTitle":504,"status":505,"phases":1256,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":1257,"interventions":1258},[91],[24],[129,96],{"nctId":586,"briefTitle":587,"status":107,"phases":1260,"primaryCompletion":589,"completion":389,"start":590,"enrollment":591,"conditions":1261,"interventions":1262},[90,91],[113],[129,96],{"nctId":595,"briefTitle":596,"status":270,"phases":1264,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":1265,"interventions":1266},[91],[603,604],[96,129,242],{"nctId":607,"briefTitle":608,"status":121,"phases":1268,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":1269,"interventions":1270},[91],[24],[242,129,96,616,617,310],{"nctId":619,"briefTitle":620,"status":365,"phases":1272,"primaryCompletion":622,"completion":622,"start":210,"enrollment":623,"conditions":1273,"interventions":1274},[91],[24],[626,129,96],{"nctId":1276,"briefTitle":1277,"status":107,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1283},"NCT03475615","A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites",[91],"2020-12-31","2018-03-16",215,[24,577],[129,67,279],{"nctId":1285,"briefTitle":1286,"status":107,"phases":1287,"primaryCompletion":1288,"completion":1289,"start":211,"enrollment":1290,"conditions":1291,"interventions":1296},"NCT02506842","Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection",[91],"2018-12","2019-06",300,[1292,1293,1294,1295],"Stage ⅠA Pancreatic Cancer","Stage ⅠB Pancreatic Cancer","Stage ⅡA Pancreatic Cancer","Stage ⅡB Pancreatic Cancer",[1297,533,1298,228,1299],"nab-paclitaxel","oxaliplatin","fluorouracil",3,{"trials":1302,"activeCount":101},[],{"trials":1304,"activeCount":101},[],{"intervention":432,"totalTrials":1306,"cells":1307},19,{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1500,"PHASE4":1521,"NA":1523},{"trials":1309,"activeCount":101},[],{"trials":1311,"activeCount":101},[],{"trials":1313,"activeCount":1499,"soonestReadout":1355},[1314,1326,1330,1342,1351,1361,1402,1412,1421,1429,1439,1447,1459,1469,1485,1495],{"nctId":1315,"briefTitle":1316,"status":121,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":16,"conditions":1321,"interventions":1323},"NCT07100392","Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1\u002FPD-L1 and Bevacizumab",[90],"2027-08-01","2028-08-01","2025-08-14",[1322],"Hepatocellular Carcinoma (HCC)",[1324,432,1325],"tauroursodeoxycholic acid","Regorafenib",{"nctId":153,"briefTitle":154,"status":107,"phases":1327,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":1328,"interventions":1329},[90],[161],[163,164,165,166],{"nctId":1331,"briefTitle":1332,"status":270,"phases":1333,"primaryCompletion":1334,"completion":1335,"start":353,"enrollment":1336,"conditions":1337,"interventions":1340},"NCT06694324","First-line Treatment of Advanced\u002Funresectable DDLPS",[90],"2026-06-01","2026-12-01",49,[1338,1339],"Dedifferentiated Liposarcoma","Soft Tissue Sarcoma (STS)",[1341,581,432],"Liposomal Doxorubicin",{"nctId":1343,"briefTitle":1344,"status":107,"phases":1345,"primaryCompletion":426,"completion":426,"start":1346,"enrollment":111,"conditions":1347,"interventions":1349},"NCT04520035","Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell",[90],"2020-08-01",[1348],"PFS",[164,67,1350],"Neoadjuvant Chemotherapy",{"nctId":1352,"briefTitle":1353,"status":505,"phases":1354,"primaryCompletion":1355,"completion":1356,"start":1357,"enrollment":31,"conditions":1358,"interventions":1360},"NCT04706598","Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment",[89,90],"2024-07-11","2024-12","2021-06-09",[1359,1218],"Urinary Bladder Neoplasms",[432],{"nctId":1362,"briefTitle":1363,"status":121,"phases":1364,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1376},"NCT05582499","Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy",[90],"2029-09","2022-11-01",716,[1369,15,1370,1371,521,830,1372,1373,1374,1375],"Breast Neoplasm","Breast Tumors","Triple-Negative Breast Cancer (TNBC)","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer",[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],"Dalpiciclib","SHR-A1811","SHR-1316","SHR-A1921","Pertuzumab","Goserelin","Letrozole","Carboplatin","Cyclophosphamide","Fluzoparib","HB1801","LEM","TQB2102","Benmelstobart","Anlotinib","TQB2868","Ivonescimab","JS207","JSKN003","HRS-4508","SHR-4602","paclitaxel","HRS-6209","9MW2821","IBI354",{"nctId":1403,"briefTitle":1404,"status":121,"phases":1405,"primaryCompletion":896,"completion":1406,"start":1407,"enrollment":369,"conditions":1408,"interventions":1410},"NCT06516289","Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab",[90],"2027-06","2024-09-30",[1409,830],"BRCA-Mutated Breast Carcinoma",[1411,455,432],"HRS-1167",{"nctId":1413,"briefTitle":1414,"status":107,"phases":1415,"primaryCompletion":285,"completion":285,"start":1416,"enrollment":1417,"conditions":1418,"interventions":1420},"NCT04498689","Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer",[90],"2019-08-01",117,[1419],"Metastatic Pancreatic Cancer",[432,253,255],{"nctId":1422,"briefTitle":1423,"status":270,"phases":1424,"primaryCompletion":1406,"completion":123,"start":1356,"enrollment":737,"conditions":1425,"interventions":1427},"NCT06731153","JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC",[90],[1426,33],"Triple Negative Breast Cancer (TNBC)",[1428,432,254],"Ivarmacitinib",{"nctId":1430,"briefTitle":1431,"status":121,"phases":1432,"primaryCompletion":1318,"completion":1319,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1437},"NCT07105748","HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)",[90],"2025-08-15",45,[1436],"Mixed Hepatocellular-cholangiocarcinoma",[432,1438],"Rivoceranib",{"nctId":1440,"briefTitle":1441,"status":270,"phases":1442,"primaryCompletion":1443,"completion":1443,"start":1335,"enrollment":25,"conditions":1444,"interventions":1445},"NCT06196671","Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer",[90],"2028-01-01",[30],[1446,432],"H101",{"nctId":1448,"briefTitle":1449,"status":107,"phases":1450,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1457},"NCT05095636","Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer",[90],"2023-03","2023-09","2021-03-17",102,[24,1456],"Metastasis",[1458,432],"Apatinib Mesylate",{"nctId":1460,"briefTitle":1461,"status":270,"phases":1462,"primaryCompletion":305,"completion":236,"start":448,"enrollment":296,"conditions":1463,"interventions":1465},"NCT06849492","HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer",[90],[1464],"Advanced Triple Negative Breast Cancer",[432,1466,1467,1468],"Nab-paclitaxel","SKB264","Lenvatinib",{"nctId":1470,"briefTitle":1471,"status":107,"phases":1472,"primaryCompletion":1164,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1479},"NCT05193292","Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer",[90],"2025-01","2022-01",77,[1477,1478],"Colorectal Neoplasms","Intestinal Neoplasms",[432,413,1480,1481,1482,1483,1484],"XELOX regimen","mFOLFOX6 regimen","FOLFIRI regimen","mXELIRI regimen","mIRIS regimen",{"nctId":1486,"briefTitle":1487,"status":121,"phases":1488,"primaryCompletion":1489,"completion":783,"start":1490,"enrollment":31,"conditions":1491,"interventions":1493},"NCT04299581","Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma",[90],"2025-12-30","2020-07-07",[1492],"Intrahepatic Cholangiocarcinoma",[432,1494],"US\u002FCT-guided Percutaneous Cryoablation",{"nctId":423,"briefTitle":424,"status":107,"phases":1496,"primaryCompletion":293,"completion":85,"start":426,"enrollment":427,"conditions":1497,"interventions":1498},[90],[429,430],[432,433,96,129,67,279],10,{"trials":1501,"activeCount":771,"soonestReadout":367},[1502,1511],{"nctId":1503,"briefTitle":1504,"status":121,"phases":1505,"primaryCompletion":367,"completion":1443,"start":41,"enrollment":1506,"conditions":1507,"interventions":1508},"NCT05772208","Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy",[91],459,[35],[432,1509,1510],"Nimotuzumab","neoadjuvant chemotherapy and CCRT",{"nctId":1512,"briefTitle":1513,"status":121,"phases":1514,"primaryCompletion":367,"completion":826,"start":1515,"enrollment":1516,"conditions":1517,"interventions":1519},"NCT05760378","Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.",[91],"2023-03-17",223,[1518],"Triple-Negative Breast Cancer",[455,432,1520],"nab-Palitaxel\u002FCapecitabine\u002FEribulin Mesylate\u002FCarboplatin",{"trials":1522,"activeCount":101},[],{"trials":1524,"activeCount":651,"soonestReadout":1529},[1525],{"nctId":1526,"briefTitle":1527,"status":121,"phases":1528,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":1532,"interventions":1534},"NCT07147101","Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment",[],"2028-09-01","2025-09-01",150,[1533],"Advanced Hepatocellular Carcinoma (HCC)",[278,1535,432,1438,1536,1537],"Bevacizumab Biosimilar","Nivolumab","Ipilimumab",{"intervention":310,"totalTrials":1306,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1652,"PHASE4":1730,"NA":1743},{"trials":1541,"activeCount":101},[],{"trials":1543,"activeCount":101},[],{"trials":1545,"activeCount":1651,"soonestReadout":1646},[1546,1556,1568,1579,1589,1596,1604,1616,1629,1642],{"nctId":1547,"briefTitle":1548,"status":107,"phases":1549,"primaryCompletion":1550,"completion":1550,"start":1551,"enrollment":334,"conditions":1552,"interventions":1555},"NCT06120127","Postoperative Chemotherapy With\u002FWithout Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence",[90],"2025-09-25","2023-09-25",[1553,1218,1554,18],"Radiotherapy","Liver Metastases",[310,62],{"nctId":1557,"briefTitle":1558,"status":121,"phases":1559,"primaryCompletion":1560,"completion":1561,"start":1562,"enrollment":737,"conditions":1563,"interventions":1566},"NCT07079462","Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis",[90],"2026-03-01","2028-05-01","2024-03-01",[18,1564,1565],"Peritoneal (Metastatic) Cancer","FAPI PET",[1567,310],"Radiotherapy followed by immunotherapy and chemotherapy",{"nctId":1569,"briefTitle":1570,"status":121,"phases":1571,"primaryCompletion":1572,"completion":1318,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1577},"NCT06521866","Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer",[90],"2026-08-01","2025-03-01",208,[1576,1218],"Advanced Colorectal Carcinoma",[300,310,1578],"Targeted therapy",{"nctId":1580,"briefTitle":1581,"status":121,"phases":1582,"primaryCompletion":825,"completion":1583,"start":1584,"enrollment":1585,"conditions":1586,"interventions":1587},"NCT05975749","Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer",[90],"2029-01-01","2023-01-01",114,[24],[300,1588,310],"Trastuzuma",{"nctId":1590,"briefTitle":1591,"status":270,"phases":1592,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":802,"conditions":1593,"interventions":1594},"NCT06665087","CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC",[90],[1131,113],[1133,62,310,310,310,310,1595,1595],"Targeted Therapy",{"nctId":1597,"briefTitle":1598,"status":107,"phases":1599,"primaryCompletion":1204,"start":1600,"enrollment":737,"conditions":1601,"interventions":1603},"NCT01843049","Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET\u002FCT for Unresectable Thoracic Esophageal Cancer",[89,90],"2013-01",[1602],"Esophageal Cancer",[310],{"nctId":1605,"briefTitle":1606,"status":1607,"phases":1608,"primaryCompletion":1609,"completion":236,"start":1156,"enrollment":1610,"conditions":1611,"interventions":1614},"NCT06728657","Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","SUSPENDED",[90],"2025-12-31",68,[1612,1613],"Stomach Adenocarcinoma","Gastro-esophageal Junction Cancer",[1615,310],"Anti-PD-1 monoclonal antibody",{"nctId":1617,"briefTitle":1618,"status":121,"phases":1619,"primaryCompletion":1620,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1627},"NCT06699472","A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib",[90],"2026-09-30","2027-09-30","2024-10-31",22,[1625,1626],"Ewing Sarcoma","Myelosuppression",[310,1628],"Trilaciclib Injection [Cosela]",{"nctId":1630,"briefTitle":1631,"status":121,"phases":1632,"primaryCompletion":1609,"completion":305,"start":1584,"enrollment":1633,"conditions":1634,"interventions":1641},"NCT06121700","Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer",[90],55,[1220,1635,1636,1637,452,1638,1639,430,1640],"Stomach Neoplasm","Gastroesophageal-junction Cancer","Oligometastatic Disease","Metastatic Gastric Cancer","Adenocarcinoma of the Stomach","Metastatic Adenocarcinoma",[1615,413,310],{"nctId":1643,"briefTitle":1644,"status":270,"phases":1645,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":410,"conditions":1649,"interventions":1650},"NCT06152978","A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma",[90],"2025-12-15","2027-12-15","2023-12-15",[27],[278,310],7,{"trials":1653,"activeCount":1729,"soonestReadout":1658},[1654,1665,1677,1686,1696,1705,1709,1720],{"nctId":1655,"briefTitle":1656,"status":121,"phases":1657,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1663},"NCT06913777","Neoadjuvant SNF Precision Therapy Phase III",[91],"2026-10-15","2027-04-15","2025-04-08",404,[240],[1664,310],"Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib",{"nctId":1666,"briefTitle":1667,"status":270,"phases":1668,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},"NCT07005557","Chemo-free in Older (≥65) Node-Positive ER+\u002FHER2- Breast Cancer",[91],"2030-05-15","2035-05-15","2025-06-15",1244,[15,1221],[310,1675,1676],"CDK4\u002F6 Inhibitor","Endocrine therapy",{"nctId":1678,"briefTitle":1679,"status":107,"phases":1680,"primaryCompletion":1681,"completion":1682,"start":1683,"enrollment":97,"conditions":1684,"interventions":1685},"NCT04509635","Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis",[91],"2022-08-31","2024-08-31","2020-09-01",[18,1554,229],[229,310],{"nctId":1687,"briefTitle":1688,"status":121,"phases":1689,"primaryCompletion":871,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1695},"NCT06402708","Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)",[91],"2030-05-01","2024-04-09",172,[1694],"Thymic Carcinoma",[310],{"nctId":1697,"briefTitle":1698,"status":107,"phases":1699,"primaryCompletion":388,"completion":1204,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1703},"NCT01402180","Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy",[90,91],"2010-12",128,[27],[1509,1704,1704],"chemotherapy",{"nctId":607,"briefTitle":608,"status":121,"phases":1706,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":1707,"interventions":1708},[91],[24],[242,129,96,616,617,310],{"nctId":1710,"briefTitle":1711,"status":121,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1718},"NCT05909332","Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)",[91],"2029-05-30","2031-05-30","2023-06-20",764,[15,250],[1719,310],"Antivascular therapy",{"nctId":1721,"briefTitle":1722,"status":107,"phases":1723,"primaryCompletion":1724,"completion":354,"start":1725,"enrollment":213,"conditions":1726,"interventions":1728},"NCT04917289","CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients",[91],"2023-12-01","2021-06-01",[18,1727],"Circulating Tumor Cell",[310],5,{"trials":1731,"activeCount":101},[1732],{"nctId":1733,"briefTitle":1734,"status":107,"phases":1735,"primaryCompletion":1736,"completion":1737,"start":1738,"enrollment":1739,"conditions":1740,"interventions":1742},"NCT03799692","Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B\u002FHER-2 Negative Breast Cancer",[92],"2019-03-30","2019-07-30","2018-11-19",78,[1741],"HER-2 Negative Breast Cancer",[310],{"trials":1744,"activeCount":101},[],{"intervention":67,"totalTrials":1746,"cells":1747},18,{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1806,"PHASE4":1902,"NA":1904},{"trials":1749,"activeCount":101},[],{"trials":1751,"activeCount":101},[],{"trials":1753,"activeCount":1729,"soonestReadout":51},[1754,1758,1765,1769,1773,1784,1793,1797],{"nctId":1083,"briefTitle":1084,"status":270,"phases":1755,"primaryCompletion":272,"completion":272,"start":1086,"enrollment":25,"conditions":1756,"interventions":1757},[90],[1088,1089,1090],[128,279,129,1092,67],{"nctId":49,"briefTitle":50,"status":121,"phases":1759,"primaryCompletion":51,"completion":1760,"start":1761,"enrollment":1701,"conditions":1762,"interventions":1763},[90],"2026-09-01","2023-02-20",[27],[52,67,1764],"Cisplatin",{"nctId":1343,"briefTitle":1344,"status":107,"phases":1766,"primaryCompletion":426,"completion":426,"start":1346,"enrollment":111,"conditions":1767,"interventions":1768},[90],[1348],[164,67,1350],{"nctId":1362,"briefTitle":1363,"status":121,"phases":1770,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":1771,"interventions":1772},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":1774,"briefTitle":1775,"status":121,"phases":1776,"primaryCompletion":963,"completion":236,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1781},"NCT06494943","Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC",[89,90],"2024-06-26",27,[1780,475],"Head and Neck Cancer",[278,1782,67,1783],"IBI110","Cis Platinum",{"nctId":64,"briefTitle":65,"status":505,"phases":1785,"primaryCompletion":66,"completion":1786,"start":1787,"enrollment":159,"conditions":1788,"interventions":1792},[90],"2027-03-30","2020-05-30",[1789,27,1217,1790,1791],"Esophagus Cancer","Radiation Therapy","Postoperative",[67,1384],{"nctId":423,"briefTitle":424,"status":107,"phases":1794,"primaryCompletion":293,"completion":85,"start":426,"enrollment":427,"conditions":1795,"interventions":1796},[90],[429,430],[432,433,96,129,67,279],{"nctId":1798,"briefTitle":1799,"status":365,"phases":1800,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":159,"conditions":1804,"interventions":1805},"NCT02916511","Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma",[90],"2021-07-01","2023-07-01","2016-09-01",[27],[67,1384],{"trials":1807,"activeCount":1729,"soonestReadout":222},[1808,1820,1831,1835,1845,1856,1869,1873,1884,1893],{"nctId":1809,"briefTitle":1810,"status":505,"phases":1811,"primaryCompletion":222,"completion":1812,"start":1813,"enrollment":1814,"conditions":1815,"interventions":1816},"NCT04296175","Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)",[91],"2027-03","2020-03-05",808,[161],[626,1817,67,1818,1819,67,1384],"CTX","ddEpirubicin","ddCTX",{"nctId":1821,"briefTitle":1822,"status":365,"phases":1823,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":1827,"conditions":1828,"interventions":1830},"NCT04127019","Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide\u002FEpirubicin\u002FFluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)",[91],"2017-06-01","2017-06-15","2010-06-01",2079,[1829],"Primary Breast Cancer",[67,1092,1385,626,227],{"nctId":513,"briefTitle":514,"status":121,"phases":1832,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":1833,"interventions":1834},[91],[521],[96,67],{"nctId":1836,"briefTitle":1837,"status":270,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":1843,"interventions":1844},"NCT05841381","Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer",[91],"2028-05-06","2033-05-06","2023-05-06",876,[15],[433,413,67],{"nctId":1846,"briefTitle":1847,"status":270,"phases":1848,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1855},"NCT05489848","Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation",[90,91],"2028-08-20","2030-08-20","2022-08-20",294,[1854],"Endometrial Cancer",[67,1384,1764],{"nctId":1857,"briefTitle":1858,"status":107,"phases":1859,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":1864,"interventions":1866},"NCT03949634","Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)",[91],"2019-10-31","2020-10-31","2017-09-01",272,[1865],"Early Breast Cancer",[1867,1817,1092,67,1868],"PLD","Doxorubicin",{"nctId":1276,"briefTitle":1277,"status":107,"phases":1870,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1871,"interventions":1872},[91],[24,577],[129,67,279],{"nctId":1874,"briefTitle":1875,"status":365,"phases":1876,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":1881,"interventions":1883},"NCT01026116","A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old",[91],"2016-01","2016-12-23","2009-12",521,[1882],"Breast Neoplasms",[626,1385,67],{"nctId":1885,"briefTitle":1886,"status":365,"phases":1887,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":1891,"interventions":1892},"NCT04031703","Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)",[91],"2016-04-20","2011-01-01",647,[15],[67,1384,626,1385,227,1092],{"nctId":1894,"briefTitle":1895,"status":505,"phases":1896,"primaryCompletion":1897,"completion":644,"start":1898,"enrollment":1899,"conditions":1900,"interventions":1901},"NCT04193059","Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer",[91],"2026-07","2019-12-20",1560,[15],[67,1384,626,1385,413,1381,1092],{"trials":1903,"activeCount":101},[],{"trials":1905,"activeCount":101},[],{"intervention":255,"totalTrials":36,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":2011,"PHASE4":2081,"NA":2083},{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":2010,"soonestReadout":1926},[1914,1922,1932,1944,1948,1957,1961,1975,1983,1987,1996,2002],{"nctId":1915,"briefTitle":1916,"status":107,"phases":1917,"primaryCompletion":426,"completion":426,"start":1918,"enrollment":296,"conditions":1919,"interventions":1920},"NCT03929094","Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer",[90],"2019-03-01",[1419],[1921,255],"Paclitaxel for Injection（Albumin Bound）",{"nctId":1923,"briefTitle":1924,"status":121,"phases":1925,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":19,"conditions":1929,"interventions":1930},"NCT06313970","First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients",[90],"2025-10-31","2026-10-31","2024-06-20",[30],[1931,1466,255,230],"QL1706",{"nctId":1933,"briefTitle":1934,"status":107,"phases":1935,"primaryCompletion":1936,"completion":1279,"start":964,"enrollment":1290,"conditions":1937,"interventions":1942},"NCT04216758","Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer",[90],"2020-07-31",[1938,1939,1940,1941],"Stage IA Pancreatic Adenocarcinoma","Stage IB Pancreatic Adenocarcinoma","Stage IIA Pancreatic Adenocarcinoma","Stage IIB Pancreatic Adenocarcinoma",[1297,255,1943],"tegafur",{"nctId":244,"briefTitle":245,"status":107,"phases":1945,"primaryCompletion":247,"completion":247,"start":248,"enrollment":213,"conditions":1946,"interventions":1947},[90],[250],[252,253,254,176,255,96],{"nctId":1949,"briefTitle":1950,"status":365,"phases":1951,"primaryCompletion":1952,"start":1953,"enrollment":159,"conditions":1954,"interventions":1956},"NCT01797913","The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer",[90],"2015-02","2008-08",[1955],"THE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer",[533],{"nctId":1413,"briefTitle":1414,"status":107,"phases":1958,"primaryCompletion":285,"completion":285,"start":1416,"enrollment":1417,"conditions":1959,"interventions":1960},[90],[1419],[432,253,255],{"nctId":1962,"briefTitle":1963,"status":270,"phases":1964,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":1967,"interventions":1968},"NCT06370754","Newly Emerging Immunotherapy for Pancreatic Cancer Treatment",[89,90],"2026-04-30","2024-04-30",[30],[1969,1970,1971,1972,1973,1121,1974,253,255],"JS001","JS004","JS007","JS015","Irinotecan Liposome","Leucovorin",{"nctId":1976,"briefTitle":1977,"status":107,"phases":1978,"primaryCompletion":285,"completion":1979,"start":1980,"enrollment":213,"conditions":1981,"interventions":1982},"NCT04297267","A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy",[90],"2023-06-30","2017-02-07",[250],[255,1764],{"nctId":1199,"briefTitle":1200,"status":107,"phases":1984,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1985,"interventions":1986},[90],[1207],[255,129],{"nctId":1988,"briefTitle":1989,"status":121,"phases":1990,"primaryCompletion":398,"completion":750,"start":1991,"enrollment":1992,"conditions":1993,"interventions":1994},"NCT06359275","PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients",[90],"2024-06-01",81,[30],[1995,1466,255],"PD-1",{"nctId":1997,"briefTitle":1998,"status":121,"phases":1999,"primaryCompletion":1560,"completion":1443,"start":1562,"enrollment":25,"conditions":2000,"interventions":2001},"NCT06196788","Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer",[90],[30],[255,253],{"nctId":2003,"briefTitle":2004,"status":107,"phases":2005,"primaryCompletion":2006,"completion":2006,"start":388,"enrollment":345,"conditions":2007,"interventions":2009},"NCT02039518","Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients",[90],"2017-06",[2008],"Small Cell Lung Cancer",[533],4,{"trials":2012,"activeCount":1729,"soonestReadout":56},[2013,2021,2031,2035,2039,2047,2057,2065,2077],{"nctId":2014,"briefTitle":2015,"status":270,"phases":2016,"primaryCompletion":2017,"completion":2018,"start":825,"enrollment":202,"conditions":2019,"interventions":2020},"NCT07272109","Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes",[91],"2027-12-30","2028-12-30",[30],[1466,255],{"nctId":2022,"briefTitle":2023,"status":107,"phases":2024,"primaryCompletion":147,"completion":353,"start":2025,"enrollment":2026,"conditions":2027,"interventions":2029},"NCT04835064","Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.",[91],"2021-04-01",600,[2028],"Pancreatic Adenocarcinoma",[253,255,2030],"mFOLFIRINOX",{"nctId":524,"briefTitle":525,"status":107,"phases":2032,"primaryCompletion":527,"start":528,"enrollment":529,"conditions":2033,"interventions":2034},[91],[531],[166,533],{"nctId":535,"briefTitle":536,"status":270,"phases":2036,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":2037,"interventions":2038},[90,91],[521,33],[544,255,96,413,545],{"nctId":2040,"briefTitle":2041,"status":107,"phases":2042,"primaryCompletion":1279,"completion":1279,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2046},"NCT03403829","Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage",[91],"2018-01-01",360,[35],[255],{"nctId":2048,"briefTitle":2049,"status":505,"phases":2050,"primaryCompletion":1433,"completion":2051,"start":2052,"enrollment":213,"conditions":2053,"interventions":2055},"NCT06018883","Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer",[91],"2026-08-15","2023-08-20",[2054],"Metastatic Pancreatic Adenocarcinoma",[2056,253,255],"Ascorbate",{"nctId":54,"briefTitle":55,"status":505,"phases":2058,"primaryCompletion":56,"completion":123,"start":1877,"enrollment":2059,"conditions":2060,"interventions":2061},[90,91],503,[250,15],[57,2062,2063,533,2064],"doxorubicin or epirubicin","cyclophosphamide","cisplatin",{"nctId":2066,"briefTitle":2067,"status":121,"phases":2068,"primaryCompletion":2069,"completion":2070,"start":2071,"enrollment":213,"conditions":2072,"interventions":2075},"NCT06017284","Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer",[91],"2025-11-30","2026-11-30","2023-11-01",[2073,2074],"Pancreatic Cancer Stage IV","Chemotherapy-induced Nausea and Vomiting",[2076,253,255],"Thalidomide",{"nctId":1285,"briefTitle":1286,"status":107,"phases":2078,"primaryCompletion":1288,"completion":1289,"start":211,"enrollment":1290,"conditions":2079,"interventions":2080},[91],[1292,1293,1294,1295],[1297,533,1298,228,1299],{"trials":2082,"activeCount":101},[],{"trials":2084,"activeCount":101},[],{"intervention":1384,"totalTrials":2086,"cells":2087},13,{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2146,"PHASE4":2184,"NA":2186},{"trials":2089,"activeCount":101},[],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":2010,"soonestReadout":66},[2094,2098,2102,2112,2116,2129,2142],{"nctId":153,"briefTitle":154,"status":107,"phases":2095,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":2096,"interventions":2097},[90],[161],[163,164,165,166],{"nctId":1362,"briefTitle":1363,"status":121,"phases":2099,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":2100,"interventions":2101},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2103,"briefTitle":2104,"status":121,"phases":2105,"primaryCompletion":963,"completion":963,"start":2106,"enrollment":2107,"conditions":2108,"interventions":2110},"NCT04136535","Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC",[90],"2021-11-18",105,[2109],"NSCLC Stage IV",[2111,1384,1391],"Pemetrexed",{"nctId":64,"briefTitle":65,"status":505,"phases":2113,"primaryCompletion":66,"completion":1786,"start":1787,"enrollment":159,"conditions":2114,"interventions":2115},[90],[1789,27,1217,1790,1791],[67,1384],{"nctId":2117,"briefTitle":2118,"status":270,"phases":2119,"primaryCompletion":2120,"completion":2121,"start":2122,"enrollment":2123,"conditions":2124,"interventions":2126},"NCT06404736","QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer",[90],"2025-11-07","2030-11-07","2024-05-07",73,[1865,240,2125],"TNBC, Triple Negative Breast Cancer",[2127,2128,1384],"Bispecific antibody (bsAb) targeting PD-1 and CLTA-4","Albumin-bound paclitaxel",{"nctId":2130,"briefTitle":2131,"status":107,"phases":2132,"primaryCompletion":426,"completion":2133,"start":2134,"enrollment":2135,"conditions":2136,"interventions":2140},"NCT04592666","Almonertinib\u002FPemetrexed\u002FCarboplatin in EGFR T790M+ Advanced Lung Cancer",[90],"2022-06-30","2020-10-09",226,[2137,2138,2139],"Lung Cancer, Non-small Cell","EGFR T790M","EGFR Gene Mutation",[2141,2111,1384],"Almonertinib",{"nctId":1798,"briefTitle":1799,"status":365,"phases":2143,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":159,"conditions":2144,"interventions":2145},[90],[27],[67,1384],{"trials":2147,"activeCount":1729,"soonestReadout":222},[2148,2152,2162,2166,2170,2180],{"nctId":1809,"briefTitle":1810,"status":505,"phases":2149,"primaryCompletion":222,"completion":1812,"start":1813,"enrollment":1814,"conditions":2150,"interventions":2151},[91],[161],[626,1817,67,1818,1819,67,1384],{"nctId":2153,"briefTitle":2154,"status":121,"phases":2155,"primaryCompletion":896,"completion":2156,"start":2157,"enrollment":2158,"conditions":2159,"interventions":2161},"NCT05901428","TCb vs EC-T in High Risk ER+\u002FHER2- Breast Cancer",[91],"2028-06","2023-06-01",1736,[2160],"Hormone Receptor Positive HER-2 Negative Breast Cancer",[1092,1384,626,1385],{"nctId":1846,"briefTitle":1847,"status":270,"phases":2163,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":2164,"interventions":2165},[90,91],[1854],[67,1384,1764],{"nctId":1885,"briefTitle":1886,"status":365,"phases":2167,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":2168,"interventions":2169},[91],[15],[67,1384,626,1385,227,1092],{"nctId":2171,"briefTitle":2172,"status":121,"phases":2173,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2177,"interventions":2179},"NCT05883852","EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer",[91],"2031-07-01","2023-06-07",1406,[2178],"HER2 Positive Early Breast Cancer",[1092,165,413,1381,626,2063],{"nctId":1894,"briefTitle":1895,"status":505,"phases":2181,"primaryCompletion":1897,"completion":644,"start":1898,"enrollment":1899,"conditions":2182,"interventions":2183},[91],[15],[67,1384,626,1385,413,1381,1092],{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[],{"intervention":1378,"totalTrials":2189,"cells":2190},9,{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2285,"PHASE4":2297,"NA":2299},{"trials":2192,"activeCount":101},[],{"trials":2194,"activeCount":101},[],{"trials":2196,"activeCount":676,"soonestReadout":2201},[2197,2208,2212,2227,2236,2246,2257,2269],{"nctId":2198,"briefTitle":2199,"status":505,"phases":2200,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":2205,"interventions":2206},"NCT05824325","Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）",[89,90],"2025-04-10","2026-10-10","2023-03-14",56,[15],[1378,2207],"TROP2 ADC",{"nctId":1362,"briefTitle":1363,"status":121,"phases":2209,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":2210,"interventions":2211},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2213,"briefTitle":2214,"status":121,"phases":2215,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":2217,"interventions":2218},"NCT05076682","Reverse Triple Negative Immune Resistant Breast Cancer",[90],"2027-03-31",[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],"Choline","anti-PD-1 antibody and chemotherapy","Sodium Cromoglicate","Efavirenz","SHR-A2102","Mecapegfilgrastim","AK131","Theophylline",{"nctId":2228,"briefTitle":2229,"status":270,"phases":2230,"primaryCompletion":2231,"completion":2232,"start":2233,"enrollment":25,"conditions":2234,"interventions":2235},"NCT07466927","Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases",[90],"2028-01-15","2029-01-15","2026-03-15",[830],[1378,1467,52,1379],{"nctId":2237,"briefTitle":2238,"status":505,"phases":2239,"primaryCompletion":783,"completion":783,"start":2240,"enrollment":2241,"conditions":2242,"interventions":2244},"NCT05924256","A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing",[90],"2023-07-26",88,[2243],"Advanced Salivary Gland Carcinoma",[1378,2245,1380,1378],"SHR 3680 + leuprolide",{"nctId":2247,"briefTitle":2248,"status":121,"phases":2249,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":345,"conditions":2253,"interventions":2255},"NCT06649331","Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer",[90],"2026-09","2027-09","2024-10-21",[2254,33,1426,830,15],"Advanced Breast Cancer",[1378,1380,2256,2223,455,413,1400],"SHR-A2009",{"nctId":2258,"briefTitle":2259,"status":121,"phases":2260,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":2264,"conditions":2265,"interventions":2268},"NCT06718933","Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis",[89,90],"2026-08-31","2027-02-28","2025-01-08",74,[2266,2267],"Breast Cancer Metastatic","Breast Cancer Brain Metastases",[1378,230,433],{"nctId":2270,"briefTitle":2271,"status":121,"phases":2272,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":2274,"interventions":2275},"NCT05594095","SNF Platform Study of HR+\u002F HER2-advanced Breast Cancer",[90],620,[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],"PIK3CA inhibitor","AKT inhibitor","Carrelizumab","Aromatase Inhibitors or Fulvestrant","TPC","Sorafenib","SHR-1167","SHR-6209","bevacizumab",{"trials":2286,"activeCount":651,"soonestReadout":236},[2287],{"nctId":2288,"briefTitle":2289,"status":270,"phases":2290,"primaryCompletion":236,"completion":2291,"start":2292,"enrollment":2293,"conditions":2294,"interventions":2295},"NCT07382687","Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4\u002F6 Inhibitors-resistent Advanced HR+\u002FHER2- Breast Cancer With SNF4 Subtype",[91],"2029-12-31","2026-02-26",248,[15],[1378,2296],"Famitinib+SHR-A1811",{"trials":2298,"activeCount":101},[],{"trials":2300,"activeCount":101},[],{"intervention":413,"totalTrials":2086,"cells":2302},{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2371,"PHASE4":2389,"NA":2391},{"trials":2304,"activeCount":101},[],{"trials":2306,"activeCount":101},[],{"trials":2308,"activeCount":2010,"soonestReadout":1609},[2309,2320,2330,2334,2338,2342,2346,2350,2359],{"nctId":2310,"briefTitle":2311,"status":270,"phases":2312,"primaryCompletion":2313,"completion":784,"start":2314,"enrollment":2315,"conditions":2316,"interventions":2317},"NCT07179939","Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study",[90],"2030-12-30","2025-09-10",288,[521],[2318,433,1377,413,2319],"Trastuzumab rezetecan","ET: Letrozole\u002F Anastrozole\u002F Exemestane\u002F Fulvestrant\u002F Leuprorelin\u002F Goserelin.",{"nctId":2321,"briefTitle":2322,"status":107,"phases":2323,"primaryCompletion":2324,"completion":1560,"start":1366,"enrollment":2325,"conditions":2326,"interventions":2327},"NCT05577923","Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+\u002FHER2+ Advanced Breast Cancer (T-sunflower)",[90],"2024-09-01",126,[33],[413,2328,1377,2329],"pyrotinib","fulvestrant",{"nctId":1362,"briefTitle":1363,"status":121,"phases":2331,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":2332,"interventions":2333},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":1630,"briefTitle":1631,"status":121,"phases":2335,"primaryCompletion":1609,"completion":305,"start":1584,"enrollment":1633,"conditions":2336,"interventions":2337},[90],[1220,1635,1636,1637,452,1638,1639,430,1640],[1615,413,310],{"nctId":1470,"briefTitle":1471,"status":107,"phases":2339,"primaryCompletion":1164,"completion":1473,"start":1474,"enrollment":1475,"conditions":2340,"interventions":2341},[90],[1477,1478],[432,413,1480,1481,1482,1483,1484],{"nctId":2247,"briefTitle":2248,"status":121,"phases":2343,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":345,"conditions":2344,"interventions":2345},[90],[2254,33,1426,830,15],[1378,1380,2256,2223,455,413,1400],{"nctId":405,"briefTitle":406,"status":365,"phases":2347,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":2348,"interventions":2349},[90],[15],[176,96,413],{"nctId":2351,"briefTitle":2352,"status":107,"phases":2353,"primaryCompletion":367,"completion":367,"start":2354,"enrollment":2355,"conditions":2356,"interventions":2357},"NCT05574881","Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer",[89,90],"2022-09-01",72,[15],[1377,2358,1381,413],"Fulvestrant",{"nctId":2360,"briefTitle":2361,"status":107,"phases":2362,"primaryCompletion":2363,"completion":2364,"start":2365,"enrollment":828,"conditions":2366,"interventions":2368},"NCT05076695","Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer",[90],"2023-10-15","2024-10-15","2021-10-15",[2367,521],"Estrogen Receptor-positive Breast Cancer",[2369,2370,2328,2329],"Palbociclib","trastuzumab",{"trials":2372,"activeCount":2010,"soonestReadout":1897},[2373,2377,2381,2385],{"nctId":535,"briefTitle":536,"status":270,"phases":2374,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":2375,"interventions":2376},[90,91],[521,33],[544,255,96,413,545],{"nctId":1836,"briefTitle":1837,"status":270,"phases":2378,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":2379,"interventions":2380},[91],[15],[433,413,67],{"nctId":2171,"briefTitle":2172,"status":121,"phases":2382,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2383,"interventions":2384},[91],[2178],[1092,165,413,1381,626,2063],{"nctId":1894,"briefTitle":1895,"status":505,"phases":2386,"primaryCompletion":1897,"completion":644,"start":1898,"enrollment":1899,"conditions":2387,"interventions":2388},[91],[15],[67,1384,626,1385,413,1381,1092],{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"intervention":253,"totalTrials":2394,"cells":2395},12,{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2453,"PHASE4":2467,"NA":2469},{"trials":2397,"activeCount":101},[],{"trials":2399,"activeCount":101},[],{"trials":2401,"activeCount":637,"soonestReadout":2428},[2402,2412,2416,2420,2424,2433,2437,2445,2449],{"nctId":2403,"briefTitle":2404,"status":121,"phases":2405,"primaryCompletion":145,"completion":2406,"start":157,"enrollment":2264,"conditions":2407,"interventions":2409},"NCT06387628","LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer",[90],"2027-04-01",[2408],"TNBC - Triple-Negative Breast Cancer",[2410,2411,254,253],"LM-108","Toripalimab",{"nctId":1362,"briefTitle":1363,"status":121,"phases":2413,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":2414,"interventions":2415},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":244,"briefTitle":245,"status":107,"phases":2417,"primaryCompletion":247,"completion":247,"start":248,"enrollment":213,"conditions":2418,"interventions":2419},[90],[250],[252,253,254,176,255,96],{"nctId":1413,"briefTitle":1414,"status":107,"phases":2421,"primaryCompletion":285,"completion":285,"start":1416,"enrollment":1417,"conditions":2422,"interventions":2423},[90],[1419],[432,253,255],{"nctId":2425,"briefTitle":2426,"status":121,"phases":2427,"primaryCompletion":2428,"completion":1572,"start":2429,"enrollment":2430,"conditions":2431,"interventions":2432},"NCT05205200","Immune Therapy in HR-positive\u002FHER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02",[90],"2025-02-01","2022-06-06",338,[15,452],[1379,461,253,463,464],{"nctId":1962,"briefTitle":1963,"status":270,"phases":2434,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":2435,"interventions":2436},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"nctId":2438,"briefTitle":2439,"status":121,"phases":2440,"primaryCompletion":2441,"completion":236,"start":2442,"enrollment":111,"conditions":2443,"interventions":2444},"NCT06786026","QL1706 Plus Chemotherapy +\u002F- Bevacizumab in 1L Treatment of R\u002FmTNBC",[90],"2025-09-30","2024-10-09",[2125],[2284,1931,253],{"nctId":1997,"briefTitle":1998,"status":121,"phases":2446,"primaryCompletion":1560,"completion":1443,"start":1562,"enrollment":25,"conditions":2447,"interventions":2448},[90],[30],[255,253],{"nctId":444,"briefTitle":445,"status":107,"phases":2450,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":2451,"interventions":2452},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":2454,"activeCount":771,"soonestReadout":1433},[2455,2459,2463],{"nctId":2022,"briefTitle":2023,"status":107,"phases":2456,"primaryCompletion":147,"completion":353,"start":2025,"enrollment":2026,"conditions":2457,"interventions":2458},[91],[2028],[253,255,2030],{"nctId":2048,"briefTitle":2049,"status":505,"phases":2460,"primaryCompletion":1433,"completion":2051,"start":2052,"enrollment":213,"conditions":2461,"interventions":2462},[91],[2054],[2056,253,255],{"nctId":2066,"briefTitle":2067,"status":121,"phases":2464,"primaryCompletion":2069,"completion":2070,"start":2071,"enrollment":213,"conditions":2465,"interventions":2466},[91],[2073,2074],[2076,253,255],{"trials":2468,"activeCount":101},[],{"trials":2470,"activeCount":101},[],{"intervention":1092,"totalTrials":1115,"cells":2472},{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2548,"PHASE4":2587,"NA":2589},{"trials":2474,"activeCount":101},[],{"trials":2476,"activeCount":101},[],{"trials":2478,"activeCount":1300,"soonestReadout":1489},[2479,2491,2495,2505,2513,2521,2530,2540],{"nctId":2480,"briefTitle":2481,"status":270,"phases":2482,"primaryCompletion":1114,"completion":2017,"start":2069,"enrollment":2483,"conditions":2484,"interventions":2488},"NCT07268794","CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer",[90],112,[2485,2486,2487],"Metastatic Prostate Cancer","Prostate Cancer (Adenocarcinoma)","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",[2489,1092,2490],"Androgen Deprivation Therapy","PARP Inhibitors and Other Systemic Agents",{"nctId":1083,"briefTitle":1084,"status":270,"phases":2492,"primaryCompletion":272,"completion":272,"start":1086,"enrollment":25,"conditions":2493,"interventions":2494},[90],[1088,1089,1090],[128,279,129,1092,67],{"nctId":2496,"briefTitle":2497,"status":107,"phases":2498,"primaryCompletion":2499,"start":2500,"enrollment":25,"conditions":2501,"interventions":2503},"NCT01192230","Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients",[90],"2011-12","2009-06",[2502],"Carcinoma, Non-Small-Cell Lung",[2504,1092],"Endostatins",{"nctId":2506,"briefTitle":2507,"status":107,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2499,"enrollment":111,"conditions":2510,"interventions":2511},"NCT01526499","Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer",[90],"2013-07",[15],[2512,1092],"Docetaxel and Cyclophosphamide",{"nctId":2514,"briefTitle":2515,"status":107,"phases":2516,"primaryCompletion":2517,"completion":2517,"start":2518,"enrollment":137,"conditions":2519,"interventions":2520},"NCT01614938","Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer",[90],"2014-08","2010-08",[35],[229,1764,1092,1764],{"nctId":2522,"briefTitle":2523,"status":107,"phases":2524,"primaryCompletion":485,"completion":485,"start":388,"enrollment":334,"conditions":2525,"interventions":2527},"NCT02037997","Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC",[90],[2526],"Non Small Cell Lung Cancer",[57,2528,2529],"pemetrexed","Erlotinib",{"nctId":2531,"briefTitle":2532,"status":270,"phases":2533,"primaryCompletion":1489,"completion":235,"start":1802,"enrollment":2534,"conditions":2535,"interventions":2537},"NCT05910034","Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC",[90],132,[2536],"Advanced Non-Small Cell Lung Cancer",[2538,2539,1092],"Trilaciclib+Envafolimab+Docetaxel","Envafolimab+Docetaxel",{"nctId":2541,"briefTitle":2542,"status":365,"phases":2543,"primaryCompletion":2544,"completion":2544,"start":2545,"enrollment":1623,"conditions":2546,"interventions":2547},"NCT02137083","A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer",[90],"2017-07","2014-04",[33],[1092,2358],{"trials":2549,"activeCount":2010,"soonestReadout":56},[2550,2554,2558,2562,2566,2570,2574,2578],{"nctId":2153,"briefTitle":2154,"status":121,"phases":2551,"primaryCompletion":896,"completion":2156,"start":2157,"enrollment":2158,"conditions":2552,"interventions":2553},[91],[2160],[1092,1384,626,1385],{"nctId":1821,"briefTitle":1822,"status":365,"phases":2555,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":1827,"conditions":2556,"interventions":2557},[91],[1829],[67,1092,1385,626,227],{"nctId":1857,"briefTitle":1858,"status":107,"phases":2559,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":2560,"interventions":2561},[91],[1865],[1867,1817,1092,67,1868],{"nctId":54,"briefTitle":55,"status":505,"phases":2563,"primaryCompletion":56,"completion":123,"start":1877,"enrollment":2059,"conditions":2564,"interventions":2565},[90,91],[250,15],[57,2062,2063,533,2064],{"nctId":1885,"briefTitle":1886,"status":365,"phases":2567,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":2568,"interventions":2569},[91],[15],[67,1384,626,1385,227,1092],{"nctId":2171,"briefTitle":2172,"status":121,"phases":2571,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2572,"interventions":2573},[91],[2178],[1092,165,413,1381,626,2063],{"nctId":1894,"briefTitle":1895,"status":505,"phases":2575,"primaryCompletion":1897,"completion":644,"start":1898,"enrollment":1899,"conditions":2576,"interventions":2577},[91],[15],[67,1384,626,1385,413,1381,1092],{"nctId":2579,"briefTitle":2580,"status":107,"phases":2581,"primaryCompletion":306,"completion":2582,"start":2583,"enrollment":2584,"conditions":2585,"interventions":2586},"NCT03926091","Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+\u002FHER2- Early Breast Cancer",[91],"2025-11-01","2019-04-01",2172,[15],[1092,1385],{"trials":2588,"activeCount":101},[],{"trials":2590,"activeCount":101},[],{"intervention":1385,"totalTrials":2394,"cells":2592},{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2623,"PHASE4":2668,"NA":2670},{"trials":2594,"activeCount":101},[],{"trials":2596,"activeCount":101},[],{"trials":2598,"activeCount":771,"soonestReadout":2617},[2599,2609,2613],{"nctId":2600,"briefTitle":2601,"status":107,"phases":2602,"primaryCompletion":2603,"completion":1609,"start":2604,"enrollment":159,"conditions":2605,"interventions":2606},"NCT04418154","Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients",[90],"2022-09-28","2020-06-09",[250],[2607,1385,2608,2411],"epirubicin hydrochloride","Albumin bound paclitaxel",{"nctId":1362,"briefTitle":1363,"status":121,"phases":2610,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":2611,"interventions":2612},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2614,"briefTitle":2615,"status":270,"phases":2616,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":690,"conditions":2620,"interventions":2622},"NCT06404463","QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+\u002FHER2- Breast Cancer",[90],"2025-11-06","2030-11-06","2024-05-06",[1865,240,2621],"HR+HER2- Breast Cancer",[1931,2128,1868,1385,626],{"trials":2624,"activeCount":1729,"soonestReadout":56},[2625,2629,2633,2644,2648,2652,2656,2660,2664],{"nctId":2153,"briefTitle":2154,"status":121,"phases":2626,"primaryCompletion":896,"completion":2156,"start":2157,"enrollment":2158,"conditions":2627,"interventions":2628},[91],[2160],[1092,1384,626,1385],{"nctId":1821,"briefTitle":1822,"status":365,"phases":2630,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":1827,"conditions":2631,"interventions":2632},[91],[1829],[67,1092,1385,626,227],{"nctId":2634,"briefTitle":2635,"status":121,"phases":2636,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":410,"conditions":2640,"interventions":2641},"NCT07362914","Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions",[91],"2026-07-30","2027-01-30","2025-03-07",[15],[2642,2642,2643,1385],"Dexamethasone","Doxorubicin hydrochloride liposome",{"nctId":1874,"briefTitle":1875,"status":365,"phases":2645,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":2646,"interventions":2647},[91],[1882],[626,1385,67],{"nctId":54,"briefTitle":55,"status":505,"phases":2649,"primaryCompletion":56,"completion":123,"start":1877,"enrollment":2059,"conditions":2650,"interventions":2651},[90,91],[250,15],[57,2062,2063,533,2064],{"nctId":1885,"briefTitle":1886,"status":365,"phases":2653,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":2654,"interventions":2655},[91],[15],[67,1384,626,1385,227,1092],{"nctId":2171,"briefTitle":2172,"status":121,"phases":2657,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2658,"interventions":2659},[91],[2178],[1092,165,413,1381,626,2063],{"nctId":1894,"briefTitle":1895,"status":505,"phases":2661,"primaryCompletion":1897,"completion":644,"start":1898,"enrollment":1899,"conditions":2662,"interventions":2663},[91],[15],[67,1384,626,1385,413,1381,1092],{"nctId":2579,"briefTitle":2580,"status":107,"phases":2665,"primaryCompletion":306,"completion":2582,"start":2583,"enrollment":2584,"conditions":2666,"interventions":2667},[91],[15],[1092,1385],{"trials":2669,"activeCount":101},[],{"trials":2671,"activeCount":101},[],{"intervention":1386,"totalTrials":2189,"cells":2673},{"EARLY_PHASE1":2674,"PHASE1":2676,"PHASE2":2678,"PHASE3":2743,"PHASE4":2759,"NA":2761},{"trials":2675,"activeCount":101},[],{"trials":2677,"activeCount":101},[],{"trials":2679,"activeCount":637,"soonestReadout":2582},[2680,2690,2699,2703,2713,2723,2731,2739],{"nctId":2681,"briefTitle":2682,"status":270,"phases":2683,"primaryCompletion":2684,"completion":598,"start":2685,"enrollment":2686,"conditions":2687,"interventions":2688},"NCT07353437","Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)",[90],"2031-12-31","2026-03-31",334,[15],[1386,2689],"Physician choice",{"nctId":2691,"briefTitle":2692,"status":107,"phases":2693,"primaryCompletion":2694,"completion":293,"start":295,"enrollment":2695,"conditions":2696,"interventions":2698},"NCT05732129","The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.",[90],"2023-11-30",29,[2697],"Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer",[1386,115],{"nctId":1362,"briefTitle":1363,"status":121,"phases":2700,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":2701,"interventions":2702},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2704,"briefTitle":2705,"status":121,"phases":2706,"primaryCompletion":2582,"completion":2707,"start":2708,"enrollment":2709,"conditions":2710,"interventions":2711},"NCT05759546","PARP Inhibitor With CDK4\u002F6 Inhibitor and Endocrine Therapy in HR+\u002F HER2-Advanced Breast Cancer",[90],"2027-06-01","2023-02-01",200,[2266],[1386,1377,2712],"Fulvestrant\u002FAI",{"nctId":2714,"briefTitle":2715,"status":107,"phases":2716,"primaryCompletion":56,"completion":56,"start":368,"enrollment":181,"conditions":2717,"interventions":2719},"NCT05223582","Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial",[90],[2718,240],"High-risk Prostate Cancer",[2720,1386,2721,2722],"Abiraterone acetate","Prednisone","Androgen deprivation therapy",{"nctId":2724,"briefTitle":2725,"status":270,"phases":2726,"primaryCompletion":1609,"completion":235,"start":2727,"enrollment":2728,"conditions":2729,"interventions":2730},"NCT06561022","Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping",[90],"2024-08-21",260,[15],[1386,458,2358,1119],{"nctId":2732,"briefTitle":2733,"status":270,"phases":2734,"primaryCompletion":1760,"completion":2735,"start":2324,"enrollment":25,"conditions":2736,"interventions":2738},"NCT06552858","Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer",[90],"2027-01-31",[2737],"Ovarian Cancer",[1386,1377],{"nctId":2270,"briefTitle":2271,"status":121,"phases":2740,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":2741,"interventions":2742},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":2744,"activeCount":651,"soonestReadout":2749},[2745],{"nctId":2746,"briefTitle":2747,"status":121,"phases":2748,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":2752,"interventions":2753},"NCT05891093","Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+\u002FHER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)",[91],"2028-05-31","2031-05-31",766,[15],[1386,2754,1383,2755,2756,2757,1119,2758],"Anastrozole","Exemestane","Tamoxifen","Toremifene","LHRH agonist",{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[],{"intervention":2764,"totalTrials":2189,"cells":2765},"Adebrelimab",{"EARLY_PHASE1":2766,"PHASE1":2776,"PHASE2":2786,"PHASE3":2848,"PHASE4":2861,"NA":2863},{"trials":2767,"activeCount":651,"soonestReadout":2772},[2768],{"nctId":2769,"briefTitle":2770,"status":270,"phases":2771,"primaryCompletion":2772,"completion":1812,"start":1164,"enrollment":25,"conditions":2773,"interventions":2774},"NCT06156267","Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino",[88],"2026-04",[30],[2764,2775],"mRNA tumor vaccines",{"trials":2777,"activeCount":101},[2778],{"nctId":2779,"briefTitle":2780,"status":107,"phases":2781,"primaryCompletion":1530,"completion":354,"start":1802,"enrollment":25,"conditions":2782,"interventions":2784},"NCT05942378","A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors",[89],[2783],"Advanced Solid Tumors",[2785,2764],"HRXG-K-1939",{"trials":2787,"activeCount":1729,"soonestReadout":2802},[2788,2798,2809,2820,2830,2840],{"nctId":2789,"briefTitle":2790,"status":107,"phases":2791,"primaryCompletion":2792,"completion":1489,"start":2793,"enrollment":25,"conditions":2794,"interventions":2797},"NCT06251492","Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)",[90],"2025-07-30","2024-01-30",[2795,2796],"Prostate Cancer Metastatic","Castration-resistant Prostate Cancer",[2764],{"nctId":2799,"briefTitle":2800,"status":121,"phases":2801,"primaryCompletion":2802,"completion":398,"start":2803,"enrollment":2804,"conditions":2805,"interventions":2806},"NCT06475326","Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer",[90],"2025-06","2024-06-05",87,[30],[2764,2807,2808,1120,1134],"Oxaliplatin 100 MG","Irinotecan liposome",{"nctId":2810,"briefTitle":2811,"status":270,"phases":2812,"primaryCompletion":2813,"completion":826,"start":2814,"enrollment":1146,"conditions":2815,"interventions":2817},"NCT07061210","An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer",[90],"2026-10-01","2025-07-01",[2816],"Colorectal Cancer Metastatic",[2818,2764,2819],"HRS-2189","BP102",{"nctId":2821,"briefTitle":2822,"status":270,"phases":2823,"primaryCompletion":2824,"completion":1897,"start":1356,"enrollment":2825,"conditions":2826,"interventions":2829},"NCT06470672","Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer",[90],"2026-03",32,[2254,2827,2828],"Hormone-receptor-positive Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",[1380,2764],{"nctId":2831,"briefTitle":2832,"status":121,"phases":2833,"primaryCompletion":1406,"completion":124,"start":2834,"enrollment":369,"conditions":2835,"interventions":2836},"NCT06427239","Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma",[89,90],"2024-06-17",[30],[2837,2764,2838,2839],"HRS-4642","SHR-8068","Faminitib or bevacizumab",{"nctId":2841,"briefTitle":2842,"status":270,"phases":2843,"primaryCompletion":1620,"completion":2735,"start":2844,"enrollment":2845,"conditions":2846,"interventions":2847},"NCT07041437","Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer",[90],"2025-06-30",48,[2254],[2223,2764],{"trials":2849,"activeCount":651,"soonestReadout":354},[2850],{"nctId":2851,"briefTitle":2852,"status":121,"phases":2853,"primaryCompletion":354,"completion":354,"start":353,"enrollment":2854,"conditions":2855,"interventions":2858},"NCT04516681","Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer",[91],400,[18,2856,2857],"Vitamin C","GLUT3",[2859,2860,2764],"Ascorbic acid","FOLFOX Protocol",{"trials":2862,"activeCount":101},[],{"trials":2864,"activeCount":101},[],{"intervention":626,"totalTrials":2866,"cells":2867},11,{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2882,"PHASE4":2916,"NA":2929},{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[],{"trials":2873,"activeCount":771,"soonestReadout":2617},[2874,2878],{"nctId":1362,"briefTitle":1363,"status":121,"phases":2875,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":2876,"interventions":2877},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2614,"briefTitle":2615,"status":270,"phases":2879,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":690,"conditions":2880,"interventions":2881},[90],[1865,240,2621],[1931,2128,1868,1385,626],{"trials":2883,"activeCount":2010,"soonestReadout":222},[2884,2888,2892,2896,2900,2904,2908,2912],{"nctId":1809,"briefTitle":1810,"status":505,"phases":2885,"primaryCompletion":222,"completion":1812,"start":1813,"enrollment":1814,"conditions":2886,"interventions":2887},[91],[161],[626,1817,67,1818,1819,67,1384],{"nctId":2153,"briefTitle":2154,"status":121,"phases":2889,"primaryCompletion":896,"completion":2156,"start":2157,"enrollment":2158,"conditions":2890,"interventions":2891},[91],[2160],[1092,1384,626,1385],{"nctId":1821,"briefTitle":1822,"status":365,"phases":2893,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":1827,"conditions":2894,"interventions":2895},[91],[1829],[67,1092,1385,626,227],{"nctId":619,"briefTitle":620,"status":365,"phases":2897,"primaryCompletion":622,"completion":622,"start":210,"enrollment":623,"conditions":2898,"interventions":2899},[91],[24],[626,129,96],{"nctId":1874,"briefTitle":1875,"status":365,"phases":2901,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":2902,"interventions":2903},[91],[1882],[626,1385,67],{"nctId":1885,"briefTitle":1886,"status":365,"phases":2905,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":2906,"interventions":2907},[91],[15],[67,1384,626,1385,227,1092],{"nctId":2171,"briefTitle":2172,"status":121,"phases":2909,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2910,"interventions":2911},[91],[2178],[1092,165,413,1381,626,2063],{"nctId":1894,"briefTitle":1895,"status":505,"phases":2913,"primaryCompletion":1897,"completion":644,"start":1898,"enrollment":1899,"conditions":2914,"interventions":2915},[91],[15],[67,1384,626,1385,413,1381,1092],{"trials":2917,"activeCount":101},[2918],{"nctId":2919,"briefTitle":2920,"status":107,"phases":2921,"primaryCompletion":1288,"completion":2922,"start":1204,"enrollment":2923,"conditions":2924,"interventions":2927},"NCT02631499","Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation",[92],"2019-12",256,[2925,2926],"Carcinoma, Hepatocellular","Neoplastic Cells, Circulating",[626,2928],"lipiodol",{"trials":2930,"activeCount":101},[],{"intervention":1764,"totalTrials":2932,"cells":2933},14,{"EARLY_PHASE1":2934,"PHASE1":2936,"PHASE2":2938,"PHASE3":3006,"PHASE4":3039,"NA":3041},{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[],{"trials":2939,"activeCount":771,"soonestReadout":51},[2940,2949,2953,2963,2967,2979,2986,2995,2999],{"nctId":2941,"briefTitle":2942,"status":365,"phases":2943,"primaryCompletion":2944,"completion":2945,"start":1204,"enrollment":334,"conditions":2946,"interventions":2948},"NCT02980991","Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)",[90],"2018-01","2018-04",[2947],"Lung Adenocarcinoma",[2111,1764],{"nctId":49,"briefTitle":50,"status":121,"phases":2950,"primaryCompletion":51,"completion":1760,"start":1761,"enrollment":1701,"conditions":2951,"interventions":2952},[90],[27],[52,67,1764],{"nctId":2954,"briefTitle":2955,"status":365,"phases":2956,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":478,"conditions":2959,"interventions":2961},"NCT01687439","Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)",[90],"2009-10","2008-12",[2960],"Non-small Cell Lung Cancer",[2962,176,1764],"Endostar",{"nctId":2514,"briefTitle":2515,"status":107,"phases":2964,"primaryCompletion":2517,"completion":2517,"start":2518,"enrollment":137,"conditions":2965,"interventions":2966},[90],[35],[229,1764,1092,1764],{"nctId":2968,"briefTitle":2969,"status":121,"phases":2970,"primaryCompletion":2971,"completion":2972,"start":2973,"enrollment":22,"conditions":2974,"interventions":2976},"NCT06591650","Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer",[90],"2026-10-30","2027-10-30","2024-10-24",[2975],"Gallbladder Cancer Unresectable",[2977,1764,1466,2978],"gemcitabine hydrochloride","Durvalumab",{"nctId":2980,"briefTitle":2981,"status":107,"phases":2982,"primaryCompletion":388,"start":2983,"enrollment":1290,"conditions":2984,"interventions":2985},"NCT01391572","A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer",[90],"2011-04",[27],[2064,1299],{"nctId":2987,"briefTitle":2988,"status":107,"phases":2989,"primaryCompletion":1724,"completion":1573,"start":2990,"enrollment":2991,"conditions":2992,"interventions":2993},"NCT05174832","Induction of Cisplatin\u002FNab-paclitaxel\u002FPembrolizumab Followed by Olaparib\u002FPembrolizumab Maintenance in mTNBC Patients",[90],"2022-09-07",136,[250],[1764,1466,52,2994],"Olaparib",{"nctId":1976,"briefTitle":1977,"status":107,"phases":2996,"primaryCompletion":285,"completion":1979,"start":1980,"enrollment":213,"conditions":2997,"interventions":2998},[90],[250],[255,1764],{"nctId":3000,"briefTitle":3001,"status":107,"phases":3002,"primaryCompletion":2500,"completion":1879,"start":3003,"enrollment":828,"conditions":3004,"interventions":3005},"NCT00817258","Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma",[90],"2007-01",[35],[2064],{"trials":3007,"activeCount":2010,"soonestReadout":56},[3008,3015,3022,3031,3035],{"nctId":3009,"briefTitle":3010,"status":121,"phases":3011,"primaryCompletion":1926,"completion":1927,"start":1724,"enrollment":25,"conditions":3012,"interventions":3014},"NCT06095141","Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency",[90,91],[2028,3013],"Homologous Recombination Deficiency",[1764],{"nctId":3016,"briefTitle":3017,"status":121,"phases":3018,"primaryCompletion":367,"completion":826,"start":41,"enrollment":3019,"conditions":3020,"interventions":3021},"NCT05674305","Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy",[91],366,[35],[1553,1764],{"nctId":3023,"briefTitle":3024,"status":3025,"phases":3026,"primaryCompletion":1356,"completion":897,"start":1724,"enrollment":101,"conditions":3027,"interventions":3029},"NCT02633514","Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma","WITHDRAWN",[91],[3028],"Thymoma and Thymic Carcinoma",[1764,3030],"Etoposide",{"nctId":1846,"briefTitle":1847,"status":270,"phases":3032,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":3033,"interventions":3034},[90,91],[1854],[67,1384,1764],{"nctId":54,"briefTitle":55,"status":505,"phases":3036,"primaryCompletion":56,"completion":123,"start":1877,"enrollment":2059,"conditions":3037,"interventions":3038},[90,91],[250,15],[57,2062,2063,533,2064],{"trials":3040,"activeCount":101},[],{"trials":3042,"activeCount":101},[],{"intervention":455,"totalTrials":1651,"cells":3044},{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3081,"PHASE4":3087,"NA":3089},{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":101},[],{"trials":3050,"activeCount":1729,"soonestReadout":354},[3051,3055,3059,3063,3073,3077],{"nctId":1362,"briefTitle":1363,"status":121,"phases":3052,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":3053,"interventions":3054},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":1403,"briefTitle":1404,"status":121,"phases":3056,"primaryCompletion":896,"completion":1406,"start":1407,"enrollment":369,"conditions":3057,"interventions":3058},[90],[1409,830],[1411,455,432],{"nctId":2247,"briefTitle":2248,"status":121,"phases":3060,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":345,"conditions":3061,"interventions":3062},[90],[2254,33,1426,830,15],[1378,1380,2256,2223,455,413,1400],{"nctId":3064,"briefTitle":3065,"status":270,"phases":3066,"primaryCompletion":3067,"completion":3067,"start":1530,"enrollment":3068,"conditions":3069,"interventions":3071},"NCT07147088","Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.",[90],"2027-09-01",36,[3070],"Advanced Intrahepatic Cholangiocarcinoma",[3072,455],"SHR-1701",{"nctId":444,"briefTitle":445,"status":107,"phases":3074,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":3075,"interventions":3076},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"nctId":2270,"briefTitle":2271,"status":121,"phases":3078,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":3079,"interventions":3080},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":3082,"activeCount":651,"soonestReadout":367},[3083],{"nctId":1512,"briefTitle":1513,"status":121,"phases":3084,"primaryCompletion":367,"completion":826,"start":1515,"enrollment":1516,"conditions":3085,"interventions":3086},[91],[1518],[455,432,1520],{"trials":3088,"activeCount":101},[],{"trials":3090,"activeCount":101},[],{"intervention":581,"totalTrials":478,"cells":3092},{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3107,"PHASE3":3188,"PHASE4":3213,"NA":3215},{"trials":3094,"activeCount":101},[],{"trials":3096,"activeCount":101},[3097],{"nctId":3098,"briefTitle":3099,"status":107,"phases":3100,"primaryCompletion":3101,"completion":3101,"start":3102,"enrollment":1746,"conditions":3103,"interventions":3105},"NCT00633490","Study of Apatinib as an Inhibitor of Tumor Angiogenesis",[89],"2008-06","2007-07",[3104],"Tumor",[3106],"apatinib",{"trials":3108,"activeCount":2010,"soonestReadout":2582},[3109,3116,3125,3129,3133,3140,3150,3160,3169,3176,3184],{"nctId":3110,"briefTitle":3111,"status":365,"phases":3112,"primaryCompletion":3113,"completion":3113,"start":109,"enrollment":1146,"conditions":3114,"interventions":3115},"NCT01653561","A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer",[90],"2012-10",[1882],[581],{"nctId":3117,"briefTitle":3118,"status":107,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":1633,"conditions":3123,"interventions":3124},"NCT03427242","Apatinib for Advanced Biliary Carcinoma",[90],"2021-10-31","2022-10-31","2017-11-01",[669],[581],{"nctId":1331,"briefTitle":1332,"status":270,"phases":3126,"primaryCompletion":1334,"completion":1335,"start":353,"enrollment":1336,"conditions":3127,"interventions":3128},[90],[1338,1339],[1341,581,432],{"nctId":1362,"briefTitle":1363,"status":121,"phases":3130,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":3131,"interventions":3132},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":3134,"briefTitle":3135,"status":107,"phases":3136,"primaryCompletion":426,"completion":426,"start":3137,"enrollment":2325,"conditions":3138,"interventions":3139},"NCT04101929","Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen",[90],"2019-10-01",[1419],[581,279,115],{"nctId":3141,"briefTitle":3142,"status":365,"phases":3143,"primaryCompletion":3144,"completion":3144,"start":3145,"enrollment":3146,"conditions":3147,"interventions":3149},"NCT03254654","Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer",[90],"2021-08-01","2017-08-16",66,[3148],"Advanced Triple-Negative Breast Cancer",[176,581],{"nctId":3151,"briefTitle":3152,"status":365,"phases":3153,"primaryCompletion":3154,"completion":3155,"start":3156,"enrollment":737,"conditions":3157,"interventions":3159},"NCT03274011","Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",[90],"2019-03-15","2019-06-26","2017-07-01",[3158],"Esophageal Neoplasms",[581],{"nctId":3161,"briefTitle":3162,"status":365,"phases":3163,"primaryCompletion":3164,"completion":3165,"start":3166,"enrollment":111,"conditions":3167,"interventions":3168},"NCT01176669","Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients",[90],"2014-06","2014-09","2010-06",[33],[581],{"nctId":3170,"briefTitle":3171,"status":121,"phases":3172,"primaryCompletion":2582,"completion":2707,"start":2708,"enrollment":3173,"conditions":3174,"interventions":3175},"NCT05759572","Apatinib With CDK4\u002F6 Inhibitor and Endocrine Therapy in HR+\u002F HER2- Advanced Breast Cancer",[90],145,[2266],[581,1377,2712],{"nctId":3177,"briefTitle":3178,"status":107,"phases":3179,"primaryCompletion":3180,"completion":3181,"start":2043,"enrollment":22,"conditions":3182,"interventions":3183},"NCT03403452","Apatinib in the Treatment of Metastatic Colorectal Cancer",[90],"2019-06-30","2019-12-31",[18],[581],{"nctId":2270,"briefTitle":2271,"status":121,"phases":3185,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":3186,"interventions":3187},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":3189,"activeCount":651,"soonestReadout":3205},[3190,3197,3201],{"nctId":3191,"briefTitle":3192,"status":365,"phases":3193,"primaryCompletion":212,"completion":1700,"start":2500,"enrollment":16,"conditions":3194,"interventions":3196},"NCT00970138","Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer",[90,91],[3195],"Gastric Carcinoma",[3106],{"nctId":569,"briefTitle":570,"status":107,"phases":3198,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":3199,"interventions":3200},[91],[577,578,579,580,96,581,582,583],[581,96],{"nctId":3202,"briefTitle":3203,"status":121,"phases":3204,"primaryCompletion":3205,"completion":3206,"start":3207,"enrollment":3208,"conditions":3209,"interventions":3211},"NCT06447623","Apatinib Combined With cdk4\u002F6i in First-line Treatment for HR+\u002FHER2- SNF4 Subtype Breast Cancer",[91],"2027-02-01","2029-02-01","2024-02-01",184,[2254,3210],"HR+\u002FHER2- Breast Cancer",[581,1675,3212],"Aromatase inhibitor and Fulvestrant",{"trials":3214,"activeCount":101},[],{"trials":3216,"activeCount":101},[],{"intervention":1466,"totalTrials":1499,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3265,"PHASE4":3275,"NA":3277},{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":2010,"soonestReadout":1926},[3225,3229,3233,3237,3241,3245,3253,3261],{"nctId":1923,"briefTitle":1924,"status":121,"phases":3226,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":19,"conditions":3227,"interventions":3228},[90],[30],[1931,1466,255,230],{"nctId":1933,"briefTitle":1934,"status":107,"phases":3230,"primaryCompletion":1936,"completion":1279,"start":964,"enrollment":1290,"conditions":3231,"interventions":3232},[90],[1938,1939,1940,1941],[1297,255,1943],{"nctId":2968,"briefTitle":2969,"status":121,"phases":3234,"primaryCompletion":2971,"completion":2972,"start":2973,"enrollment":22,"conditions":3235,"interventions":3236},[90],[2975],[2977,1764,1466,2978],{"nctId":1460,"briefTitle":1461,"status":270,"phases":3238,"primaryCompletion":305,"completion":236,"start":448,"enrollment":296,"conditions":3239,"interventions":3240},[90],[1464],[432,1466,1467,1468],{"nctId":2987,"briefTitle":2988,"status":107,"phases":3242,"primaryCompletion":1724,"completion":1573,"start":2990,"enrollment":2991,"conditions":3243,"interventions":3244},[90],[250],[1764,1466,52,2994],{"nctId":3246,"briefTitle":3247,"status":107,"phases":3248,"primaryCompletion":2354,"completion":295,"start":343,"enrollment":296,"conditions":3249,"interventions":3251},"NCT04581876","The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer",[90],[30,3250],"Chemotherapy Effect",[3252,1297],"raltitrexed for",{"nctId":3254,"briefTitle":3255,"status":107,"phases":3256,"primaryCompletion":85,"completion":85,"start":2025,"enrollment":3257,"conditions":3258,"interventions":3259},"NCT04734262","A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",[90],98,[33],[3260,128,1466],"Sitravatinib",{"nctId":1988,"briefTitle":1989,"status":121,"phases":3262,"primaryCompletion":398,"completion":750,"start":1991,"enrollment":1992,"conditions":3263,"interventions":3264},[90],[30],[1995,1466,255],{"trials":3266,"activeCount":651,"soonestReadout":2017},[3267,3271],{"nctId":2014,"briefTitle":2015,"status":270,"phases":3268,"primaryCompletion":2017,"completion":2018,"start":825,"enrollment":202,"conditions":3269,"interventions":3270},[91],[30],[1466,255],{"nctId":1285,"briefTitle":1286,"status":107,"phases":3272,"primaryCompletion":1288,"completion":1289,"start":211,"enrollment":1290,"conditions":3273,"interventions":3274},[91],[1292,1293,1294,1295],[1297,533,1298,228,1299],{"trials":3276,"activeCount":101},[],{"trials":3278,"activeCount":101},[],{"intervention":242,"totalTrials":1729,"cells":3280},{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3291,"PHASE4":3312,"NA":3314},{"trials":3282,"activeCount":101},[],{"trials":3284,"activeCount":101},[],{"trials":3286,"activeCount":651,"soonestReadout":235},[3287],{"nctId":232,"briefTitle":233,"status":121,"phases":3288,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":3289,"interventions":3290},[90],[139,240],[242,96,129],{"trials":3292,"activeCount":1300,"soonestReadout":610},[3293,3304,3308],{"nctId":3294,"briefTitle":3295,"status":121,"phases":3296,"primaryCompletion":3297,"completion":3298,"start":2428,"enrollment":3299,"conditions":3300,"interventions":3302},"NCT06964568","CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC",[91],"2029-02","2031-02",452,[3301,1553,1218],"Esophageal Carcinoma",[242,3303],"TP regimen",{"nctId":595,"briefTitle":596,"status":270,"phases":3305,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":3306,"interventions":3307},[91],[603,604],[96,129,242],{"nctId":607,"briefTitle":608,"status":121,"phases":3309,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":3310,"interventions":3311},[91],[24],[242,129,96,616,617,310],{"trials":3313,"activeCount":101},[],{"trials":3315,"activeCount":651,"soonestReadout":1318},[3316],{"nctId":3317,"briefTitle":3318,"status":121,"phases":3319,"primaryCompletion":1318,"completion":1319,"start":1433,"enrollment":97,"conditions":3320,"interventions":3321},"NCT07100405","TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment",[],[21],[242],{"intervention":433,"totalTrials":2189,"cells":3323},{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3328,"PHASE3":3368,"PHASE4":3374,"NA":3376},{"trials":3325,"activeCount":101},[],{"trials":3327,"activeCount":101},[],{"trials":3329,"activeCount":1300,"soonestReadout":2261},[3330,3334,3338,3348,3352,3356,3360,3364],{"nctId":2310,"briefTitle":2311,"status":270,"phases":3331,"primaryCompletion":2313,"completion":784,"start":2314,"enrollment":2315,"conditions":3332,"interventions":3333},[90],[521],[2318,433,1377,413,2319],{"nctId":2321,"briefTitle":2322,"status":107,"phases":3335,"primaryCompletion":2324,"completion":1560,"start":1366,"enrollment":2325,"conditions":3336,"interventions":3337},[90],[33],[413,2328,1377,2329],{"nctId":3339,"briefTitle":3340,"status":107,"phases":3341,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":3345,"conditions":3346,"interventions":3347},"NCT03772353","Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+\u002FHER2+) Advanced Breast Cancer",[89,90],"2023-06-10","2025-12-10","2019-05-12",59,[15],[1377,433,1383,2358],{"nctId":1362,"briefTitle":1363,"status":121,"phases":3349,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":3350,"interventions":3351},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2258,"briefTitle":2259,"status":121,"phases":3353,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":2264,"conditions":3354,"interventions":3355},[89,90],[2266,2267],[1378,230,433],{"nctId":423,"briefTitle":424,"status":107,"phases":3357,"primaryCompletion":293,"completion":85,"start":426,"enrollment":427,"conditions":3358,"interventions":3359},[90],[429,430],[432,433,96,129,67,279],{"nctId":2360,"briefTitle":2361,"status":107,"phases":3361,"primaryCompletion":2363,"completion":2364,"start":2365,"enrollment":828,"conditions":3362,"interventions":3363},[90],[2367,521],[2369,2370,2328,2329],{"nctId":444,"briefTitle":445,"status":107,"phases":3365,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":3366,"interventions":3367},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":3369,"activeCount":651,"soonestReadout":1839},[3370],{"nctId":1836,"briefTitle":1837,"status":270,"phases":3371,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":3372,"interventions":3373},[91],[15],[433,413,67],{"trials":3375,"activeCount":101},[],{"trials":3377,"activeCount":101},[],{"intervention":458,"totalTrials":637,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3414,"PHASE4":3427,"NA":3429},{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":1300,"soonestReadout":354},[3386,3396,3402,3406,3410],{"nctId":3387,"briefTitle":3388,"status":107,"phases":3389,"primaryCompletion":56,"completion":1356,"start":3390,"enrollment":25,"conditions":3391,"interventions":3393},"NCT05124431","Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma",[90],"2021-12",[3392],"Renal Cell Carcinoma",[3394,3395],"Anlotinib hydrochloride","everolimus",{"nctId":3397,"briefTitle":3398,"status":270,"phases":3399,"primaryCompletion":600,"completion":1335,"start":147,"enrollment":31,"conditions":3400,"interventions":3401},"NCT06301386","Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients",[90],[1131],[458,1995],{"nctId":2724,"briefTitle":2725,"status":270,"phases":3403,"primaryCompletion":1609,"completion":235,"start":2727,"enrollment":2728,"conditions":3404,"interventions":3405},[90],[15],[1386,458,2358,1119],{"nctId":444,"briefTitle":445,"status":107,"phases":3407,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":3408,"interventions":3409},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"nctId":2270,"briefTitle":2271,"status":121,"phases":3411,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":3412,"interventions":3413},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":3415,"activeCount":651,"soonestReadout":1143},[3416],{"nctId":3417,"briefTitle":3418,"status":121,"phases":3419,"primaryCompletion":1143,"completion":3420,"start":3421,"enrollment":3422,"conditions":3423,"interventions":3425},"NCT05954442","Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype",[91],"2026-08","2023-09-13",203,[250,33,3424],"Mutation",[458,3426],"Investigator's Choice of Chemotherapy",{"trials":3428,"activeCount":101},[],{"trials":3430,"activeCount":101},[],{"intervention":1381,"totalTrials":2010,"cells":3432},{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3437,"PHASE3":3447,"PHASE4":3457,"NA":3459},{"trials":3434,"activeCount":101},[],{"trials":3436,"activeCount":101},[],{"trials":3438,"activeCount":651,"soonestReadout":305},[3439,3443],{"nctId":1362,"briefTitle":1363,"status":121,"phases":3440,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":3441,"interventions":3442},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2351,"briefTitle":2352,"status":107,"phases":3444,"primaryCompletion":367,"completion":367,"start":2354,"enrollment":2355,"conditions":3445,"interventions":3446},[89,90],[15],[1377,2358,1381,413],{"trials":3448,"activeCount":771,"soonestReadout":1897},[3449,3453],{"nctId":2171,"briefTitle":2172,"status":121,"phases":3450,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":3451,"interventions":3452},[91],[2178],[1092,165,413,1381,626,2063],{"nctId":1894,"briefTitle":1895,"status":505,"phases":3454,"primaryCompletion":1897,"completion":644,"start":1898,"enrollment":1899,"conditions":3455,"interventions":3456},[91],[15],[67,1384,626,1385,413,1381,1092],{"trials":3458,"activeCount":101},[],{"trials":3460,"activeCount":101},[],{"intervention":1675,"totalTrials":1300,"cells":3462},{"EARLY_PHASE1":3463,"PHASE1":3465,"PHASE2":3467,"PHASE3":3479,"PHASE4":3489,"NA":3491},{"trials":3464,"activeCount":101},[],{"trials":3466,"activeCount":101},[],{"trials":3468,"activeCount":651,"soonestReadout":3420},[3469],{"nctId":3470,"briefTitle":3471,"status":121,"phases":3472,"primaryCompletion":3420,"completion":3473,"start":1550,"enrollment":737,"conditions":3474,"interventions":3475},"NCT07117630","An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+\u002FHER2- Advanced Breast Cancer After Progression on Standard Therapy",[90],"2027-08",[15],[3476,3477,2358,3478],"L-Ornithine L-Aspartate","CDK4\u002F6 inhibitor","N-Acetylcysteine (NAC) Treatment",{"trials":3480,"activeCount":771,"soonestReadout":3205},[3481,3485],{"nctId":1666,"briefTitle":1667,"status":270,"phases":3482,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":3483,"interventions":3484},[91],[15,1221],[310,1675,1676],{"nctId":3202,"briefTitle":3203,"status":121,"phases":3486,"primaryCompletion":3205,"completion":3206,"start":3207,"enrollment":3208,"conditions":3487,"interventions":3488},[91],[2254,3210],[581,1675,3212],{"trials":3490,"activeCount":101},[],{"trials":3492,"activeCount":101},[],{"intervention":1676,"totalTrials":1300,"cells":3494},{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3501,"PHASE4":3528,"NA":3530},{"trials":3496,"activeCount":101},[],{"trials":3498,"activeCount":101},[],{"trials":3500,"activeCount":101},[],{"trials":3502,"activeCount":1300,"soonestReadout":3521},[3503,3507,3517],{"nctId":1666,"briefTitle":1667,"status":270,"phases":3504,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":3505,"interventions":3506},[91],[15,1221],[310,1675,1676],{"nctId":3508,"briefTitle":3509,"status":505,"phases":3510,"primaryCompletion":3511,"completion":3511,"start":2324,"enrollment":3512,"conditions":3513,"interventions":3514},"NCT06637150","Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer",[91],"2030-09-30",1388,[15],[3515,3516],"Dalpicilib","endocrine therapy",{"nctId":3518,"briefTitle":3519,"status":121,"phases":3520,"primaryCompletion":3521,"completion":3522,"start":1671,"enrollment":3523,"conditions":3524,"interventions":3525},"NCT07019363","CDK4\u002F6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+\u002FHER2+ Early Breast Cancer Patients(CHESS)",[91],"2029-05-15","2033-04-15",1903,[15,1221],[3526,3527],"Endocrine Therapy","Standard endocrine therapy combined with CDK4\u002F6 Inhibitor",{"trials":3529,"activeCount":101},[],{"trials":3531,"activeCount":101},[],{"intervention":1119,"totalTrials":1300,"cells":3533},{"EARLY_PHASE1":3534,"PHASE1":3536,"PHASE2":3538,"PHASE3":3548,"PHASE4":3554,"NA":3556},{"trials":3535,"activeCount":101},[],{"trials":3537,"activeCount":101},[],{"trials":3539,"activeCount":771,"soonestReadout":1609},[3540,3544],{"nctId":1110,"briefTitle":1111,"status":1112,"phases":3541,"primaryCompletion":1114,"completion":1114,"start":600,"enrollment":1115,"conditions":3542,"interventions":3543},[90],[1117],[1119,129,1120,1121,115],{"nctId":2724,"briefTitle":2725,"status":270,"phases":3545,"primaryCompletion":1609,"completion":235,"start":2727,"enrollment":2728,"conditions":3546,"interventions":3547},[90],[15],[1386,458,2358,1119],{"trials":3549,"activeCount":651,"soonestReadout":2749},[3550],{"nctId":2746,"briefTitle":2747,"status":121,"phases":3551,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":3552,"interventions":3553},[91],[15],[1386,2754,1383,2755,2756,2757,1119,2758],{"trials":3555,"activeCount":101},[],{"trials":3557,"activeCount":101},[],{"intervention":1178,"totalTrials":1300,"cells":3559},{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3581,"PHASE4":3587,"NA":3589},{"trials":3561,"activeCount":101},[],{"trials":3563,"activeCount":101},[],{"trials":3565,"activeCount":771,"soonestReadout":2772},[3566,3570],{"nctId":1172,"briefTitle":1173,"status":121,"phases":3567,"primaryCompletion":800,"completion":800,"start":1175,"enrollment":25,"conditions":3568,"interventions":3569},[90],[24],[1178,278,279,129],{"nctId":3571,"briefTitle":3572,"status":121,"phases":3573,"primaryCompletion":2772,"completion":3574,"start":3575,"enrollment":1146,"conditions":3576,"interventions":3579},"NCT06187506","Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer",[90],"2027-01","2023-12-18",[3577,3578],"Non-muscle Invasive Bladder Cancer","HER-2 Protein Overexpression",[1178,3580],"Bacillus Calmette Guerin Vaccine",{"trials":3582,"activeCount":651,"soonestReadout":538},[3583],{"nctId":535,"briefTitle":536,"status":270,"phases":3584,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":3585,"interventions":3586},[90,91],[521,33],[544,255,96,413,545],{"trials":3588,"activeCount":101},[],{"trials":3590,"activeCount":101},[],{"intervention":1509,"totalTrials":2010,"cells":3592},{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3618,"PHASE4":3628,"NA":3630},{"trials":3594,"activeCount":101},[],{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":651,"soonestReadout":3612},[3599,3608],{"nctId":3600,"briefTitle":3601,"status":365,"phases":3602,"primaryCompletion":2499,"completion":2499,"start":3603,"enrollment":737,"conditions":3604,"interventions":3605},"NCT00910117","Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)",[90],"2009-05",[1780],[3606,3607],"nimotuzumab","PF regimen",{"nctId":3609,"briefTitle":3610,"status":270,"phases":3611,"primaryCompletion":3612,"completion":783,"start":3613,"enrollment":3614,"conditions":3615,"interventions":3617},"NCT05316480","Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms",[90],"2025-04-30","2022-05-01",42,[3616],"Pancreatic Neuroendocrine Neoplasm",[1509],{"trials":3619,"activeCount":651,"soonestReadout":367},[3620,3624],{"nctId":1503,"briefTitle":1504,"status":121,"phases":3621,"primaryCompletion":367,"completion":1443,"start":41,"enrollment":1506,"conditions":3622,"interventions":3623},[91],[35],[432,1509,1510],{"nctId":1697,"briefTitle":1698,"status":107,"phases":3625,"primaryCompletion":388,"completion":1204,"start":1700,"enrollment":1701,"conditions":3626,"interventions":3627},[90,91],[27],[1509,1704,1704],{"trials":3629,"activeCount":101},[],{"trials":3631,"activeCount":101},[],{"intervention":3633,"totalTrials":771,"cells":3634},"Megestrol Acetate 160 MG Oral",{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3655,"PHASE4":3668,"NA":3670},{"trials":3636,"activeCount":101},[],{"trials":3638,"activeCount":101},[],{"trials":3640,"activeCount":651,"soonestReadout":3645},[3641],{"nctId":3642,"briefTitle":3643,"status":121,"phases":3644,"primaryCompletion":3645,"completion":3646,"start":3647,"enrollment":3648,"conditions":3649,"interventions":3651},"NCT05247268","Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer",[90],"2027-03-10","2027-09-10","2022-03-11",104,[3650],"Endometrial Neoplasm Malignant Stage I",[3633,3652,3653,3654],"Medroxyprogesterone Acetate 500 MG","Triprorelin Acetate","Letrozole 2.5mg",{"trials":3656,"activeCount":651,"soonestReadout":305},[3657],{"nctId":3658,"briefTitle":3659,"status":121,"phases":3660,"primaryCompletion":305,"completion":2291,"start":3661,"enrollment":2728,"conditions":3662,"interventions":3664},"NCT07319429","Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification",[90,91],"2026-01-25",[1854,3663],"Fertility",[3665,3652,3666,3667],"PD1 antibody","Megestrol Acetate 160 MG","GnRH agonist and Letrozole",{"trials":3669,"activeCount":101},[],{"trials":3671,"activeCount":101},[],{"intervention":3652,"totalTrials":771,"cells":3673},{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3684,"PHASE4":3690,"NA":3692},{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":101},[],{"trials":3679,"activeCount":651,"soonestReadout":3645},[3680],{"nctId":3642,"briefTitle":3643,"status":121,"phases":3681,"primaryCompletion":3645,"completion":3646,"start":3647,"enrollment":3648,"conditions":3682,"interventions":3683},[90],[3650],[3633,3652,3653,3654],{"trials":3685,"activeCount":651,"soonestReadout":305},[3686],{"nctId":3658,"briefTitle":3659,"status":121,"phases":3687,"primaryCompletion":305,"completion":2291,"start":3661,"enrollment":2728,"conditions":3688,"interventions":3689},[90,91],[1854,3663],[3665,3652,3666,3667],{"trials":3691,"activeCount":101},[],{"trials":3693,"activeCount":101},[],{"intervention":1218,"totalTrials":771,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3711,"PHASE4":3723,"NA":3725},{"trials":3697,"activeCount":101},[],{"trials":3699,"activeCount":101},[],{"trials":3701,"activeCount":651,"soonestReadout":1114},[3702],{"nctId":3703,"briefTitle":3704,"status":121,"phases":3705,"primaryCompletion":1114,"completion":2017,"start":3706,"enrollment":111,"conditions":3707,"interventions":3709},"NCT06943235","Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)",[90],"2025-04-25",[3708],"Limited Stage Small Cell Lung Cancer",[3710,1218],"Probiotics",{"trials":3712,"activeCount":651,"soonestReadout":3717},[3713],{"nctId":3714,"briefTitle":3715,"status":121,"phases":3716,"primaryCompletion":3717,"completion":3718,"start":306,"enrollment":3719,"conditions":3720,"interventions":3721},"NCT06676449","TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC",[91],"2028-10-31","2030-10-30",432,[3301,1553,1218],[1218,3722],"chemotherapy: Paclitaxel\u002FCisplatin or other guideline recommended regimens",{"trials":3724,"activeCount":101},[],{"trials":3726,"activeCount":101},[],{"intervention":3728,"totalTrials":771,"cells":3729},"golidocitinib",{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3734,"PHASE3":3749,"PHASE4":3759,"NA":3761},{"trials":3731,"activeCount":101},[],{"trials":3733,"activeCount":101},[],{"trials":3735,"activeCount":651,"soonestReadout":3740},[3736],{"nctId":3737,"briefTitle":3738,"status":121,"phases":3739,"primaryCompletion":3740,"completion":3741,"start":3742,"enrollment":1610,"conditions":3743,"interventions":3746},"NCT06966154","A Phase Ib\u002FII Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R\u002FR NKTCL",[89,90],"2027-05-30","2028-05-30","2025-05-26",[3744,3745],"Natural Killer\u002FT-cell Lymphoma","Relapsed or Refractory Lymphoma Including ENKL",[3747,3728,3748],"tislezumab","Selinexor",{"trials":3750,"activeCount":651,"soonestReadout":2018},[3751],{"nctId":3752,"briefTitle":3753,"status":121,"phases":3754,"primaryCompletion":2018,"completion":418,"start":3755,"enrollment":2991,"conditions":3756,"interventions":3758},"NCT07300514","Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma",[91],"2026-03-27",[3757],"Maintenance Treatment of Peripheral T-cell Lymphoma",[3728],{"trials":3760,"activeCount":101},[],{"trials":3762,"activeCount":101},[],{"intervention":2280,"totalTrials":771,"cells":3764},{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3775,"PHASE4":3786,"NA":3788},{"trials":3766,"activeCount":101},[],{"trials":3768,"activeCount":101},[],{"trials":3770,"activeCount":651,"soonestReadout":354},[3771],{"nctId":2270,"briefTitle":2271,"status":121,"phases":3772,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":3773,"interventions":3774},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":3776,"activeCount":651,"soonestReadout":600},[3777],{"nctId":3778,"briefTitle":3779,"status":121,"phases":3780,"primaryCompletion":600,"completion":3781,"start":3782,"enrollment":148,"conditions":3783,"interventions":3784},"NCT05806060","Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer",[91],"2026-11-01","2023-04-25",[1518],[3785,2280],"VEGFR and TPC",{"trials":3787,"activeCount":101},[],{"trials":3789,"activeCount":101},[],{"intervention":2056,"totalTrials":771,"cells":3791},{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3806,"PHASE4":3812,"NA":3814},{"trials":3793,"activeCount":101},[],{"trials":3795,"activeCount":101},[],{"trials":3797,"activeCount":651,"soonestReadout":1433},[3798],{"nctId":3799,"briefTitle":3800,"status":121,"phases":3801,"primaryCompletion":1433,"completion":2051,"start":3802,"enrollment":1146,"conditions":3803,"interventions":3805},"NCT06018896","Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer",[90],"2023-08-25",[1419,3804],"Terminal Cancer",[2056],{"trials":3807,"activeCount":651,"soonestReadout":1433},[3808],{"nctId":2048,"briefTitle":2049,"status":505,"phases":3809,"primaryCompletion":1433,"completion":2051,"start":2052,"enrollment":213,"conditions":3810,"interventions":3811},[91],[2054],[2056,253,255],{"trials":3813,"activeCount":101},[],{"trials":3815,"activeCount":101},[],{"intervention":3817,"totalTrials":771,"cells":3818},"4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3835,"PHASE4":3848,"NA":3850},{"trials":3820,"activeCount":101},[],{"trials":3822,"activeCount":101},[],{"trials":3824,"activeCount":651,"soonestReadout":3829},[3825],{"nctId":3826,"briefTitle":3827,"status":270,"phases":3828,"primaryCompletion":3829,"completion":3830,"start":2813,"enrollment":3831,"conditions":3832,"interventions":3833},"NCT07423611","ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive\u002FHER2-Negative Breast Cancer",[90],"2030-10-01","2030-12-31",388,[15],[3834,3817],"Aromatase inhibitor (± ovarian suppression) plus Ribociclib",{"trials":3836,"activeCount":651,"soonestReadout":3841},[3837],{"nctId":3838,"briefTitle":3839,"status":270,"phases":3840,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":3845,"interventions":3846},"NCT06996093","Chemotherapy Omission in HR-positive\u002FHER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4\u002F6 Inhibitor",[91],"2030-06-01","2034-06-01","2025-06-02",2508,[15],[3817,3847],"aromatase inhibitor (± ovarian suppression) plus CDK4\u002F6 inhibitor",{"trials":3849,"activeCount":101},[],{"trials":3851,"activeCount":101},[],{"intervention":617,"totalTrials":771,"cells":3853},{"EARLY_PHASE1":3854,"PHASE1":3856,"PHASE2":3858,"PHASE3":3872,"PHASE4":3878,"NA":3880},{"trials":3855,"activeCount":101},[],{"trials":3857,"activeCount":101},[],{"trials":3859,"activeCount":651,"soonestReadout":3864},[3860],{"nctId":3861,"briefTitle":3862,"status":121,"phases":3863,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":3867,"interventions":3868},"NCT07183865","Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)",[90],"2030-03-09","2025-03-09",44,[225],[3869,617,1974,3870,3871,230],"Irinotecan Hydrochloride Liposome","SG001","C225",{"trials":3873,"activeCount":651,"soonestReadout":610},[3874],{"nctId":607,"briefTitle":608,"status":121,"phases":3875,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":3876,"interventions":3877},[91],[24],[242,129,96,616,617,310],{"trials":3879,"activeCount":101},[],{"trials":3881,"activeCount":101},[],{"intervention":1383,"totalTrials":1729,"cells":3883},{"EARLY_PHASE1":3884,"PHASE1":3886,"PHASE2":3888,"PHASE3":3898,"PHASE4":3916,"NA":3918},{"trials":3885,"activeCount":101},[],{"trials":3887,"activeCount":101},[],{"trials":3889,"activeCount":651,"soonestReadout":305},[3890,3894],{"nctId":3339,"briefTitle":3340,"status":107,"phases":3891,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":3345,"conditions":3892,"interventions":3893},[89,90],[15],[1377,433,1383,2358],{"nctId":1362,"briefTitle":1363,"status":121,"phases":3895,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":3896,"interventions":3897},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":3899,"activeCount":651,"soonestReadout":2749},[3900,3904],{"nctId":2746,"briefTitle":2747,"status":121,"phases":3901,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":3902,"interventions":3903},[91],[15],[1386,2754,1383,2755,2756,2757,1119,2758],{"nctId":3905,"briefTitle":3906,"status":107,"phases":3907,"primaryCompletion":3166,"completion":3908,"start":3909,"enrollment":3910,"conditions":3911,"interventions":3912},"NCT00902954","Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer",[91],"2011-06","2008-03",540,[15],[3913,3914,3915],"anastrozole","letrozole","exemestane",{"trials":3917,"activeCount":101},[],{"trials":3919,"activeCount":101},[3920],{"nctId":3921,"briefTitle":3922,"status":107,"phases":3923,"primaryCompletion":3924,"completion":3925,"start":589,"enrollment":369,"conditions":3926,"interventions":3928},"NCT01814449","Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer",[],"2014-02","2014-05",[15,3927],"Hypoxia",[1383],{"intervention":3930,"totalTrials":771,"cells":3931},"Osimertinib",{"EARLY_PHASE1":3932,"PHASE1":3934,"PHASE2":3936,"PHASE3":3938,"PHASE4":3950,"NA":3952},{"trials":3933,"activeCount":101},[],{"trials":3935,"activeCount":101},[],{"trials":3937,"activeCount":101},[],{"trials":3939,"activeCount":651,"soonestReadout":2685},[3940],{"nctId":3941,"briefTitle":3942,"status":270,"phases":3943,"primaryCompletion":2685,"completion":3944,"start":147,"enrollment":2135,"conditions":3945,"interventions":3948},"NCT06323148","Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)",[91],"2029-03-31",[3946,2139,3947],"Lung Cancer","Minimal Residual Disease",[3930,3949],"No adjuvant therapy",{"trials":3951,"activeCount":101},[],{"trials":3953,"activeCount":651,"soonestReadout":3958},[3954],{"nctId":3955,"briefTitle":3956,"status":505,"phases":3957,"primaryCompletion":3958,"completion":2685,"start":3959,"enrollment":1290,"conditions":3960,"interventions":3964},"NCT07491211","Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases",[],"2025-03-31","2019-07-19",[3961,3962,3930,3963],"NSCLC (Advanced Non-small Cell Lung Cancer)","Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","Stereotactic Radiation",[3930],{"intervention":2642,"totalTrials":1300,"cells":3966},{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3971,"PHASE3":3973,"PHASE4":4004,"NA":4006},{"trials":3968,"activeCount":101},[],{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"trials":3974,"activeCount":651,"soonestReadout":2637},[3975,3979,3991],{"nctId":2634,"briefTitle":2635,"status":121,"phases":3976,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":410,"conditions":3977,"interventions":3978},[91],[15],[2642,2642,2643,1385],{"nctId":3980,"briefTitle":3981,"status":365,"phases":3982,"primaryCompletion":3983,"completion":3984,"start":189,"enrollment":3985,"conditions":3986,"interventions":3988},"NCT06331520","NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens",[91],"2025-08-01","2025-08-30",644,[2074,3987],"Highly Emetogenic Chemotherapy",[3989,3990,2642],"Netupitant \u002F Palonosetron Oral Capsule [Akynzeo]","Olanzapine",{"nctId":3992,"briefTitle":3993,"status":107,"phases":3994,"primaryCompletion":3995,"completion":188,"start":3996,"enrollment":529,"conditions":3997,"interventions":3999},"NCT04912271","Granisetron Transdermal Patch for Prophylaxis of Delayed CINV",[91],"2022-06-10","2021-06-10",[3998],"Chemotherapy-induced Nausea and Vomiting (CINV)",[4000,4001,4002,4003,2642],"Granisetron transdermal patch","Palonosetron","Aprepitant","Fosaprepitant",{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"intervention":2754,"totalTrials":1300,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4014,"PHASE3":4025,"PHASE4":4035,"NA":4037},{"trials":4011,"activeCount":101},[],{"trials":4013,"activeCount":101},[],{"trials":4015,"activeCount":101},[4016],{"nctId":4017,"briefTitle":4018,"status":3025,"phases":4019,"primaryCompletion":1204,"completion":4020,"start":4021,"enrollment":101,"conditions":4022,"interventions":4024},"NCT02140437","Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC",[90],"2016-06","2014-03",[4023],"Carcinoma Breast Stage IV",[2358,2754],{"trials":4026,"activeCount":651,"soonestReadout":2749},[4027,4031],{"nctId":2746,"briefTitle":2747,"status":121,"phases":4028,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":4029,"interventions":4030},[91],[15],[1386,2754,1383,2755,2756,2757,1119,2758],{"nctId":3905,"briefTitle":3906,"status":107,"phases":4032,"primaryCompletion":3166,"completion":3908,"start":3909,"enrollment":3910,"conditions":4033,"interventions":4034},[91],[15],[3913,3914,3915],{"trials":4036,"activeCount":101},[],{"trials":4038,"activeCount":101},[],{"intervention":1817,"totalTrials":771,"cells":4040},{"EARLY_PHASE1":4041,"PHASE1":4043,"PHASE2":4045,"PHASE3":4047,"PHASE4":4057,"NA":4059},{"trials":4042,"activeCount":101},[],{"trials":4044,"activeCount":101},[],{"trials":4046,"activeCount":101},[],{"trials":4048,"activeCount":651,"soonestReadout":222},[4049,4053],{"nctId":1809,"briefTitle":1810,"status":505,"phases":4050,"primaryCompletion":222,"completion":1812,"start":1813,"enrollment":1814,"conditions":4051,"interventions":4052},[91],[161],[626,1817,67,1818,1819,67,1384],{"nctId":1857,"briefTitle":1858,"status":107,"phases":4054,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":4055,"interventions":4056},[91],[1865],[1867,1817,1092,67,1868],{"trials":4058,"activeCount":101},[],{"trials":4060,"activeCount":101},[],{"intervention":1350,"totalTrials":771,"cells":4062},{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4073,"PHASE4":4086,"NA":4088},{"trials":4064,"activeCount":101},[],{"trials":4066,"activeCount":101},[],{"trials":4068,"activeCount":101},[4069],{"nctId":1343,"briefTitle":1344,"status":107,"phases":4070,"primaryCompletion":426,"completion":426,"start":1346,"enrollment":111,"conditions":4071,"interventions":4072},[90],[1348],[164,67,1350],{"trials":4074,"activeCount":651,"soonestReadout":872},[4075],{"nctId":4076,"briefTitle":4077,"status":270,"phases":4078,"primaryCompletion":872,"completion":4079,"start":4080,"enrollment":1205,"conditions":4081,"interventions":4084},"NCT06957938","Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma",[91],"2031-05-01","2025-04-28",[4082,4083],"Laryngeal Carcinoma","Hypopharyngeal Carcinoma",[1350,4085],"Neoadjuvant and maintenance Tislelizumab",{"trials":4087,"activeCount":101},[],{"trials":4089,"activeCount":101},[],{"intervention":77,"totalTrials":771,"cells":4091},{"EARLY_PHASE1":4092,"PHASE1":4094,"PHASE2":4096,"PHASE3":4106,"PHASE4":4114,"NA":4116},{"trials":4093,"activeCount":101},[],{"trials":4095,"activeCount":101},[],{"trials":4097,"activeCount":101},[4098],{"nctId":4099,"briefTitle":4100,"status":107,"phases":4101,"primaryCompletion":293,"completion":1609,"start":4102,"enrollment":345,"conditions":4103,"interventions":4105},"NCT04832776","FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases",[90],"2021-04-17",[4104],"Liver Metastasis Colon Cancer",[229,230,77],{"trials":4107,"activeCount":651,"soonestReadout":76},[4108],{"nctId":74,"briefTitle":75,"status":121,"phases":4109,"primaryCompletion":76,"completion":644,"start":4110,"enrollment":1290,"conditions":4111,"interventions":4112},[91],"2021-08-27",[113],[77,4113],"CapeOX",{"trials":4115,"activeCount":101},[],{"trials":4117,"activeCount":101},[],{"intervention":2643,"totalTrials":771,"cells":4119},{"EARLY_PHASE1":4120,"PHASE1":4122,"PHASE2":4124,"PHASE3":4135,"PHASE4":4141,"NA":4143},{"trials":4121,"activeCount":101},[],{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[4126],{"nctId":4127,"briefTitle":4128,"status":107,"phases":4129,"primaryCompletion":199,"completion":1366,"start":4130,"enrollment":25,"conditions":4131,"interventions":4133},"NCT05354076","Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo",[90],"2000-03-01",[4132],"Advanced Malignant Tumors",[4134],"doxorubicin hydrochloride liposome",{"trials":4136,"activeCount":651,"soonestReadout":2637},[4137],{"nctId":2634,"briefTitle":2635,"status":121,"phases":4138,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":410,"conditions":4139,"interventions":4140},[91],[15],[2642,2642,2643,1385],{"trials":4142,"activeCount":101},[],{"trials":4144,"activeCount":101},[],{"intervention":4146,"totalTrials":771,"cells":4147},"S-1 for 1 year",{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4154,"PHASE4":4171,"NA":4173},{"trials":4149,"activeCount":101},[],{"trials":4151,"activeCount":101},[],{"trials":4153,"activeCount":101},[],{"trials":4155,"activeCount":651,"soonestReadout":41},[4156,4165],{"nctId":4157,"briefTitle":4158,"status":3025,"phases":4159,"primaryCompletion":4160,"completion":1451,"start":4161,"enrollment":101,"conditions":4162,"interventions":4163},"NCT02736552","Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.",[91],"2019-03","2016-03",[24],[4164,4146],"S-1 for 6 months",{"nctId":39,"briefTitle":40,"status":121,"phases":4166,"primaryCompletion":41,"completion":871,"start":4167,"enrollment":4168,"conditions":4169,"interventions":4170},[91],"2019-01-01",1006,[24],[42,4146],{"trials":4172,"activeCount":101},[],{"trials":4174,"activeCount":101},[],{"intervention":2076,"totalTrials":771,"cells":4176},{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4181,"PHASE3":4183,"PHASE4":4197,"NA":4199},{"trials":4178,"activeCount":101},[],{"trials":4180,"activeCount":101},[],{"trials":4182,"activeCount":101},[],{"trials":4184,"activeCount":651,"soonestReadout":2069},[4185,4193],{"nctId":4186,"briefTitle":4187,"status":107,"phases":4188,"primaryCompletion":110,"completion":4189,"start":2500,"enrollment":2709,"conditions":4190,"interventions":4191},"NCT00921531","Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma",[91],"2013-04",[21],[2076,4192],"TACE",{"nctId":2066,"briefTitle":2067,"status":121,"phases":4194,"primaryCompletion":2069,"completion":2070,"start":2071,"enrollment":213,"conditions":4195,"interventions":4196},[91],[2073,2074],[2076,253,255],{"trials":4198,"activeCount":101},[],{"trials":4200,"activeCount":101},[],{"intervention":2755,"totalTrials":771,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4207,"PHASE3":4209,"PHASE4":4219,"NA":4221},{"trials":4204,"activeCount":101},[],{"trials":4206,"activeCount":101},[],{"trials":4208,"activeCount":101},[],{"trials":4210,"activeCount":651,"soonestReadout":2749},[4211,4215],{"nctId":2746,"briefTitle":2747,"status":121,"phases":4212,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":4213,"interventions":4214},[91],[15],[1386,2754,1383,2755,2756,2757,1119,2758],{"nctId":3905,"briefTitle":3906,"status":107,"phases":4216,"primaryCompletion":3166,"completion":3908,"start":3909,"enrollment":3910,"conditions":4217,"interventions":4218},[91],[15],[3913,3914,3915],{"trials":4220,"activeCount":101},[],{"trials":4222,"activeCount":101},[],{"intervention":4224,"totalTrials":651,"cells":4225},"Vitmain C plus herbal medicine",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4232,"PHASE4":4243,"NA":4245},{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[],{"trials":4231,"activeCount":101},[],{"trials":4233,"activeCount":651,"soonestReadout":4238},[4234],{"nctId":4235,"briefTitle":4236,"status":121,"phases":4237,"primaryCompletion":4238,"completion":4239,"start":4240,"enrollment":97,"conditions":4241,"interventions":4242},"NCT06601283","Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer",[90,91],"2026-11-22","2027-11-22","2024-11-22",[30],[4224],{"trials":4244,"activeCount":101},[],{"trials":4246,"activeCount":101},[],{"intervention":1664,"totalTrials":651,"cells":4248},{"EARLY_PHASE1":4249,"PHASE1":4251,"PHASE2":4253,"PHASE3":4255,"PHASE4":4261,"NA":4263},{"trials":4250,"activeCount":101},[],{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":101},[],{"trials":4256,"activeCount":651,"soonestReadout":1658},[4257],{"nctId":1655,"briefTitle":1656,"status":121,"phases":4258,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1661,"conditions":4259,"interventions":4260},[91],[240],[1664,310],{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"intervention":1818,"totalTrials":651,"cells":4266},{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4271,"PHASE3":4273,"PHASE4":4279,"NA":4281},{"trials":4268,"activeCount":101},[],{"trials":4270,"activeCount":101},[],{"trials":4272,"activeCount":101},[],{"trials":4274,"activeCount":651,"soonestReadout":222},[4275],{"nctId":1809,"briefTitle":1810,"status":505,"phases":4276,"primaryCompletion":222,"completion":1812,"start":1813,"enrollment":1814,"conditions":4277,"interventions":4278},[91],[161],[626,1817,67,1818,1819,67,1384],{"trials":4280,"activeCount":101},[],{"trials":4282,"activeCount":101},[],{"intervention":1819,"totalTrials":651,"cells":4284},{"EARLY_PHASE1":4285,"PHASE1":4287,"PHASE2":4289,"PHASE3":4291,"PHASE4":4297,"NA":4299},{"trials":4286,"activeCount":101},[],{"trials":4288,"activeCount":101},[],{"trials":4290,"activeCount":101},[],{"trials":4292,"activeCount":651,"soonestReadout":222},[4293],{"nctId":1809,"briefTitle":1810,"status":505,"phases":4294,"primaryCompletion":222,"completion":1812,"start":1813,"enrollment":1814,"conditions":4295,"interventions":4296},[91],[161],[626,1817,67,1818,1819,67,1384],{"trials":4298,"activeCount":101},[],{"trials":4300,"activeCount":101},[],{"intervention":4085,"totalTrials":651,"cells":4302},{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4307,"PHASE3":4309,"PHASE4":4315,"NA":4317},{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[],{"trials":4310,"activeCount":651,"soonestReadout":872},[4311],{"nctId":4076,"briefTitle":4077,"status":270,"phases":4312,"primaryCompletion":872,"completion":4079,"start":4080,"enrollment":1205,"conditions":4313,"interventions":4314},[91],[4082,4083],[1350,4085],{"trials":4316,"activeCount":101},[],{"trials":4318,"activeCount":101},[],{"intervention":4113,"totalTrials":651,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4327,"PHASE4":4333,"NA":4335},{"trials":4322,"activeCount":101},[],{"trials":4324,"activeCount":101},[],{"trials":4326,"activeCount":101},[],{"trials":4328,"activeCount":651,"soonestReadout":76},[4329],{"nctId":74,"briefTitle":75,"status":121,"phases":4330,"primaryCompletion":76,"completion":644,"start":4110,"enrollment":1290,"conditions":4331,"interventions":4332},[91],[113],[77,4113],{"trials":4334,"activeCount":101},[],{"trials":4336,"activeCount":101},[],{"intervention":4338,"totalTrials":651,"cells":4339},"Metronomic capecitabine group",{"EARLY_PHASE1":4340,"PHASE1":4342,"PHASE2":4344,"PHASE3":4346,"PHASE4":4357,"NA":4359},{"trials":4341,"activeCount":101},[],{"trials":4343,"activeCount":101},[],{"trials":4345,"activeCount":101},[],{"trials":4347,"activeCount":651,"soonestReadout":4352},[4348],{"nctId":4349,"briefTitle":4350,"status":121,"phases":4351,"primaryCompletion":4352,"completion":4352,"start":4353,"enrollment":4354,"conditions":4355,"interventions":4356},"NCT06313567","Metronomic Capecitabine in Stage III Gastric Cancer",[91],"2029-03-10","2024-03-10",722,[24],[4338],{"trials":4358,"activeCount":101},[],{"trials":4360,"activeCount":101},[],{"intervention":1510,"totalTrials":651,"cells":4362},{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4367,"PHASE3":4369,"PHASE4":4375,"NA":4377},{"trials":4364,"activeCount":101},[],{"trials":4366,"activeCount":101},[],{"trials":4368,"activeCount":101},[],{"trials":4370,"activeCount":651,"soonestReadout":367},[4371],{"nctId":1503,"briefTitle":1504,"status":121,"phases":4372,"primaryCompletion":367,"completion":1443,"start":41,"enrollment":1506,"conditions":4373,"interventions":4374},[91],[35],[432,1509,1510],{"trials":4376,"activeCount":101},[],{"trials":4378,"activeCount":101},[],{"intervention":4380,"totalTrials":651,"cells":4381},"Camrelizumab Plus Chemotherapy and Famitinib",{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4386,"PHASE3":4388,"PHASE4":4398,"NA":4400},{"trials":4383,"activeCount":101},[],{"trials":4385,"activeCount":101},[],{"trials":4387,"activeCount":101},[],{"trials":4389,"activeCount":651,"soonestReadout":3984},[4390],{"nctId":4391,"briefTitle":4392,"status":121,"phases":4393,"primaryCompletion":3984,"completion":940,"start":2052,"enrollment":4394,"conditions":4395,"interventions":4396},"NCT05999149","A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)",[91],424,[2408],[4380,4397],"Camrelizumab Plus Chemotherapy",{"trials":4399,"activeCount":101},[],{"trials":4401,"activeCount":101},[],{"intervention":4397,"totalTrials":651,"cells":4403},{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4408,"PHASE3":4410,"PHASE4":4416,"NA":4418},{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":651,"soonestReadout":3984},[4412],{"nctId":4391,"briefTitle":4392,"status":121,"phases":4413,"primaryCompletion":3984,"completion":940,"start":2052,"enrollment":4394,"conditions":4414,"interventions":4415},[91],[2408],[4380,4397],{"trials":4417,"activeCount":101},[],{"trials":4419,"activeCount":101},[],{"intervention":4421,"totalTrials":651,"cells":4422},"dl-3-butylphthalide",{"EARLY_PHASE1":4423,"PHASE1":4425,"PHASE2":4427,"PHASE3":4429,"PHASE4":4442,"NA":4444},{"trials":4424,"activeCount":101},[],{"trials":4426,"activeCount":101},[],{"trials":4428,"activeCount":101},[],{"trials":4430,"activeCount":651,"soonestReadout":897},[4431],{"nctId":4432,"briefTitle":4433,"status":121,"phases":4434,"primaryCompletion":897,"completion":897,"start":4435,"enrollment":4436,"conditions":4437,"interventions":4440},"NCT05976152","Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)",[91],"2024-04",3200,[4438,4439],"Stroke","Post-stroke Cognitive Impairment (PSCI)",[4421,4441],"dl-3-butylphthalide placebo",{"trials":4443,"activeCount":101},[],{"trials":4445,"activeCount":101},[],{"intervention":4441,"totalTrials":651,"cells":4447},{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4452,"PHASE3":4454,"PHASE4":4460,"NA":4462},{"trials":4449,"activeCount":101},[],{"trials":4451,"activeCount":101},[],{"trials":4453,"activeCount":101},[],{"trials":4455,"activeCount":651,"soonestReadout":897},[4456],{"nctId":4432,"briefTitle":4433,"status":121,"phases":4457,"primaryCompletion":897,"completion":897,"start":4435,"enrollment":4436,"conditions":4458,"interventions":4459},[91],[4438,4439],[4421,4441],{"trials":4461,"activeCount":101},[],{"trials":4463,"activeCount":101},[],{"intervention":4465,"totalTrials":651,"cells":4466},"PD-1 inhibitor+\u002F- chemotherapy combined with local therapy",{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4473,"PHASE4":4486,"NA":4488},{"trials":4468,"activeCount":101},[],{"trials":4470,"activeCount":101},[],{"trials":4472,"activeCount":101},[],{"trials":4474,"activeCount":651,"soonestReadout":4479},[4475],{"nctId":4476,"briefTitle":4477,"status":121,"phases":4478,"primaryCompletion":4479,"completion":4480,"start":4481,"enrollment":4482,"conditions":4483,"interventions":4484},"NCT06190782","Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor",[91],"2025-09-27","2027-09-27","2022-09-27",354,[27,1637,1553],[4465,4485],"systemic therapy alone",{"trials":4487,"activeCount":101},[],{"trials":4489,"activeCount":101},[],{"intervention":4485,"totalTrials":651,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4498,"PHASE4":4504,"NA":4506},{"trials":4493,"activeCount":101},[],{"trials":4495,"activeCount":101},[],{"trials":4497,"activeCount":101},[],{"trials":4499,"activeCount":651,"soonestReadout":4479},[4500],{"nctId":4476,"briefTitle":4477,"status":121,"phases":4501,"primaryCompletion":4479,"completion":4480,"start":4481,"enrollment":4482,"conditions":4502,"interventions":4503},[91],[27,1637,1553],[4465,4485],{"trials":4505,"activeCount":101},[],{"trials":4507,"activeCount":101},[],{"intervention":1553,"totalTrials":651,"cells":4509},{"EARLY_PHASE1":4510,"PHASE1":4512,"PHASE2":4514,"PHASE3":4516,"PHASE4":4522,"NA":4524},{"trials":4511,"activeCount":101},[],{"trials":4513,"activeCount":101},[],{"trials":4515,"activeCount":101},[],{"trials":4517,"activeCount":651,"soonestReadout":367},[4518],{"nctId":3016,"briefTitle":3017,"status":121,"phases":4519,"primaryCompletion":367,"completion":826,"start":41,"enrollment":3019,"conditions":4520,"interventions":4521},[91],[35],[1553,1764],{"trials":4523,"activeCount":101},[],{"trials":4525,"activeCount":101},[],{"intervention":4527,"totalTrials":651,"cells":4528},"fruquintinib+chemotherapy",{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4533,"PHASE3":4535,"PHASE4":4547,"NA":4549},{"trials":4530,"activeCount":101},[],{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":651,"soonestReadout":2018},[4537],{"nctId":4538,"briefTitle":4539,"status":270,"phases":4540,"primaryCompletion":2018,"completion":4541,"start":4542,"enrollment":4543,"conditions":4544,"interventions":4545},"NCT07362836","Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)",[91],"2030-01-30","2026-01-31",224,[18],[4527,4546],"bevacizumab+chemotherapy",{"trials":4548,"activeCount":101},[],{"trials":4550,"activeCount":101},[],{"intervention":4546,"totalTrials":651,"cells":4552},{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4559,"PHASE4":4565,"NA":4567},{"trials":4554,"activeCount":101},[],{"trials":4556,"activeCount":101},[],{"trials":4558,"activeCount":101},[],{"trials":4560,"activeCount":651,"soonestReadout":2018},[4561],{"nctId":4538,"briefTitle":4539,"status":270,"phases":4562,"primaryCompletion":2018,"completion":4541,"start":4542,"enrollment":4543,"conditions":4563,"interventions":4564},[91],[18],[4527,4546],{"trials":4566,"activeCount":101},[],{"trials":4568,"activeCount":101},[],{"intervention":47,"totalTrials":651,"cells":4570},{"EARLY_PHASE1":4571,"PHASE1":4573,"PHASE2":4575,"PHASE3":4577,"PHASE4":4587,"NA":4589},{"trials":4572,"activeCount":101},[],{"trials":4574,"activeCount":101},[],{"trials":4576,"activeCount":101},[],{"trials":4578,"activeCount":651,"soonestReadout":46},[4579],{"nctId":44,"briefTitle":45,"status":121,"phases":4580,"primaryCompletion":46,"completion":4581,"start":4582,"enrollment":4583,"conditions":4584,"interventions":4585},[91],"2027-05","2017-05",1370,[298],[47,4586],"capecitabine plus oxaliplatin after surgery",{"trials":4588,"activeCount":101},[],{"trials":4590,"activeCount":101},[],{"intervention":4586,"totalTrials":651,"cells":4592},{"EARLY_PHASE1":4593,"PHASE1":4595,"PHASE2":4597,"PHASE3":4599,"PHASE4":4605,"NA":4607},{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":651,"soonestReadout":46},[4601],{"nctId":44,"briefTitle":45,"status":121,"phases":4602,"primaryCompletion":46,"completion":4581,"start":4582,"enrollment":4583,"conditions":4603,"interventions":4604},[91],[298],[47,4586],{"trials":4606,"activeCount":101},[],{"trials":4608,"activeCount":101},[],{"intervention":4610,"totalTrials":651,"cells":4611},"Thymosin Alpha1",{"EARLY_PHASE1":4612,"PHASE1":4614,"PHASE2":4616,"PHASE3":4618,"PHASE4":4629,"NA":4631},{"trials":4613,"activeCount":101},[],{"trials":4615,"activeCount":101},[],{"trials":4617,"activeCount":101},[],{"trials":4619,"activeCount":651,"soonestReadout":2216},[4620],{"nctId":4621,"briefTitle":4622,"status":121,"phases":4623,"primaryCompletion":2216,"completion":2216,"start":2025,"enrollment":4624,"conditions":4625,"interventions":4628},"NCT05086614","Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer",[91],2500,[4626,4627],"Stage II Colorectal Cancer","Stage III Colorectal Cancer",[4610],{"trials":4630,"activeCount":101},[],{"trials":4632,"activeCount":101},[],{"intervention":3722,"totalTrials":651,"cells":4634},{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4639,"PHASE3":4641,"PHASE4":4647,"NA":4649},{"trials":4636,"activeCount":101},[],{"trials":4638,"activeCount":101},[],{"trials":4640,"activeCount":101},[],{"trials":4642,"activeCount":651,"soonestReadout":3717},[4643],{"nctId":3714,"briefTitle":3715,"status":121,"phases":4644,"primaryCompletion":3717,"completion":3718,"start":306,"enrollment":3719,"conditions":4645,"interventions":4646},[91],[3301,1553,1218],[1218,3722],{"trials":4648,"activeCount":101},[],{"trials":4650,"activeCount":101},[],{"intervention":4652,"totalTrials":651,"cells":4653},"3-year abemaciclib without chemo",{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4660,"PHASE4":4672,"NA":4674},{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[],{"trials":4659,"activeCount":101},[],{"trials":4661,"activeCount":651,"soonestReadout":4666},[4662],{"nctId":4663,"briefTitle":4664,"status":121,"phases":4665,"primaryCompletion":4666,"completion":1583,"start":4667,"enrollment":4668,"conditions":4669,"interventions":4670},"NCT06341621","Chemotherapy Omission in ER+\u002FHER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib",[91],"2027-02-25","2024-04-02",1900,[15],[4652,4671],"treatment of physician's choice",{"trials":4673,"activeCount":101},[],{"trials":4675,"activeCount":101},[],{"intervention":4671,"totalTrials":651,"cells":4677},{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4682,"PHASE3":4684,"PHASE4":4690,"NA":4692},{"trials":4679,"activeCount":101},[],{"trials":4681,"activeCount":101},[],{"trials":4683,"activeCount":101},[],{"trials":4685,"activeCount":651,"soonestReadout":4666},[4686],{"nctId":4663,"briefTitle":4664,"status":121,"phases":4687,"primaryCompletion":4666,"completion":1583,"start":4667,"enrollment":4668,"conditions":4688,"interventions":4689},[91],[15],[4652,4671],{"trials":4691,"activeCount":101},[],{"trials":4693,"activeCount":101},[],{"intervention":3515,"totalTrials":651,"cells":4695},{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4700,"PHASE3":4702,"PHASE4":4708,"NA":4710},{"trials":4697,"activeCount":101},[],{"trials":4699,"activeCount":101},[],{"trials":4701,"activeCount":101},[],{"trials":4703,"activeCount":651,"soonestReadout":3511},[4704],{"nctId":3508,"briefTitle":3509,"status":505,"phases":4705,"primaryCompletion":3511,"completion":3511,"start":2324,"enrollment":3512,"conditions":4706,"interventions":4707},[91],[15],[3515,3516],{"trials":4709,"activeCount":101},[],{"trials":4711,"activeCount":101},[],{"intervention":4713,"totalTrials":651,"cells":4714},"Dalpiciclib+AI ± OFS",{"EARLY_PHASE1":4715,"PHASE1":4717,"PHASE2":4719,"PHASE3":4721,"PHASE4":4733,"NA":4735},{"trials":4716,"activeCount":101},[],{"trials":4718,"activeCount":101},[],{"trials":4720,"activeCount":101},[],{"trials":4722,"activeCount":651,"soonestReadout":4727},[4723],{"nctId":4724,"briefTitle":4725,"status":270,"phases":4726,"primaryCompletion":4727,"completion":4728,"start":2685,"enrollment":4729,"conditions":4730,"interventions":4731},"NCT07432178","CDK4\u002F6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）",[91],"2031-03-31","2034-03-31",2288,[15],[4713,4732],"TC (Docetaxel + Cyclophosphamide) × 4 cycles- endocrine therapy",{"trials":4734,"activeCount":101},[],{"trials":4736,"activeCount":101},[],{"intervention":4732,"totalTrials":651,"cells":4738},{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4743,"PHASE3":4745,"PHASE4":4751,"NA":4753},{"trials":4740,"activeCount":101},[],{"trials":4742,"activeCount":101},[],{"trials":4744,"activeCount":101},[],{"trials":4746,"activeCount":651,"soonestReadout":4727},[4747],{"nctId":4724,"briefTitle":4725,"status":270,"phases":4748,"primaryCompletion":4727,"completion":4728,"start":2685,"enrollment":4729,"conditions":4749,"interventions":4750},[91],[15],[4713,4732],{"trials":4752,"activeCount":101},[],{"trials":4754,"activeCount":101},[],{"intervention":545,"totalTrials":651,"cells":4756},{"EARLY_PHASE1":4757,"PHASE1":4759,"PHASE2":4761,"PHASE3":4763,"PHASE4":4769,"NA":4771},{"trials":4758,"activeCount":101},[],{"trials":4760,"activeCount":101},[],{"trials":4762,"activeCount":101},[],{"trials":4764,"activeCount":651,"soonestReadout":538},[4765],{"nctId":535,"briefTitle":536,"status":270,"phases":4766,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":4767,"interventions":4768},[90,91],[521,33],[544,255,96,413,545],{"trials":4770,"activeCount":101},[],{"trials":4772,"activeCount":101},[],{"intervention":557,"totalTrials":651,"cells":4774},{"EARLY_PHASE1":4775,"PHASE1":4777,"PHASE2":4779,"PHASE3":4781,"PHASE4":4787,"NA":4789},{"trials":4776,"activeCount":101},[],{"trials":4778,"activeCount":101},[],{"trials":4780,"activeCount":101},[],{"trials":4782,"activeCount":651,"soonestReadout":550},[4783],{"nctId":547,"briefTitle":548,"status":270,"phases":4784,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":4785,"interventions":4786},[91],[15,555],[557,96],{"trials":4788,"activeCount":101},[],{"trials":4790,"activeCount":101},[],{"intervention":4792,"totalTrials":651,"cells":4793},"Gemcitabine, Nab-paclitaxel, Irinotecan",{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4800,"PHASE4":4809,"NA":4811},{"trials":4795,"activeCount":101},[],{"trials":4797,"activeCount":101},[],{"trials":4799,"activeCount":101},[],{"trials":4801,"activeCount":651,"soonestReadout":871},[4802],{"nctId":4803,"briefTitle":4804,"status":121,"phases":4805,"primaryCompletion":871,"completion":1561,"start":4806,"enrollment":202,"conditions":4807,"interventions":4808},"NCT06250972","Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer",[91],"2024-05-15",[2028],[4792],{"trials":4810,"activeCount":101},[],{"trials":4812,"activeCount":101},[],{"intervention":2296,"totalTrials":651,"cells":4814},{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4819,"PHASE3":4821,"PHASE4":4827,"NA":4829},{"trials":4816,"activeCount":101},[],{"trials":4818,"activeCount":101},[],{"trials":4820,"activeCount":101},[],{"trials":4822,"activeCount":651,"soonestReadout":236},[4823],{"nctId":2288,"briefTitle":2289,"status":270,"phases":4824,"primaryCompletion":236,"completion":2291,"start":2292,"enrollment":2293,"conditions":4825,"interventions":4826},[91],[15],[1378,2296],{"trials":4828,"activeCount":101},[],{"trials":4830,"activeCount":101},[],{"intervention":3785,"totalTrials":651,"cells":4832},{"EARLY_PHASE1":4833,"PHASE1":4835,"PHASE2":4837,"PHASE3":4839,"PHASE4":4845,"NA":4847},{"trials":4834,"activeCount":101},[],{"trials":4836,"activeCount":101},[],{"trials":4838,"activeCount":101},[],{"trials":4840,"activeCount":651,"soonestReadout":600},[4841],{"nctId":3778,"briefTitle":3779,"status":121,"phases":4842,"primaryCompletion":600,"completion":3781,"start":3782,"enrollment":148,"conditions":4843,"interventions":4844},[91],[1518],[3785,2280],{"trials":4846,"activeCount":101},[],{"trials":4848,"activeCount":101},[],{"intervention":3527,"totalTrials":651,"cells":4850},{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4855,"PHASE3":4857,"PHASE4":4863,"NA":4865},{"trials":4852,"activeCount":101},[],{"trials":4854,"activeCount":101},[],{"trials":4856,"activeCount":101},[],{"trials":4858,"activeCount":651,"soonestReadout":3521},[4859],{"nctId":3518,"briefTitle":3519,"status":121,"phases":4860,"primaryCompletion":3521,"completion":3522,"start":1671,"enrollment":3523,"conditions":4861,"interventions":4862},[91],[15,1221],[3526,3527],{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":101},[],{"intervention":4868,"totalTrials":651,"cells":4869},"Tislelizumab combined with GX",{"EARLY_PHASE1":4870,"PHASE1":4872,"PHASE2":4874,"PHASE3":4876,"PHASE4":4886,"NA":4888},{"trials":4871,"activeCount":101},[],{"trials":4873,"activeCount":101},[],{"trials":4875,"activeCount":101},[],{"trials":4877,"activeCount":651,"soonestReadout":897},[4878],{"nctId":4879,"briefTitle":4880,"status":121,"phases":4881,"primaryCompletion":897,"completion":123,"start":1724,"enrollment":4882,"conditions":4883,"interventions":4884},"NCT06177301","Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R\u002FM NPC",[91],266,[35],[4868,4885],"Tislelizumab combined with GP",{"trials":4887,"activeCount":101},[],{"trials":4889,"activeCount":101},[],{"intervention":4885,"totalTrials":651,"cells":4891},{"EARLY_PHASE1":4892,"PHASE1":4894,"PHASE2":4896,"PHASE3":4898,"PHASE4":4904,"NA":4906},{"trials":4893,"activeCount":101},[],{"trials":4895,"activeCount":101},[],{"trials":4897,"activeCount":101},[],{"trials":4899,"activeCount":651,"soonestReadout":897},[4900],{"nctId":4879,"briefTitle":4880,"status":121,"phases":4901,"primaryCompletion":897,"completion":123,"start":1724,"enrollment":4882,"conditions":4902,"interventions":4903},[91],[35],[4868,4885],{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[],{"intervention":4909,"totalTrials":651,"cells":4910},"Peroperative immunotherapy",{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4915,"PHASE3":4917,"PHASE4":4930,"NA":4932},{"trials":4912,"activeCount":101},[],{"trials":4914,"activeCount":101},[],{"trials":4916,"activeCount":101},[],{"trials":4918,"activeCount":651,"soonestReadout":1690},[4919],{"nctId":4920,"briefTitle":4921,"status":270,"phases":4922,"primaryCompletion":1690,"completion":4923,"start":600,"enrollment":4924,"conditions":4925,"interventions":4927},"NCT07554846","Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC",[91],"2032-05-01",759,[4926],"Resectable Stage II-IIIa NSCLC",[4909,4928,4929],"Neoadjuvant immunotherapy","Adjuvant immunotherapy",{"trials":4931,"activeCount":101},[],{"trials":4933,"activeCount":101},[],{"intervention":4928,"totalTrials":651,"cells":4935},{"EARLY_PHASE1":4936,"PHASE1":4938,"PHASE2":4940,"PHASE3":4942,"PHASE4":4948,"NA":4950},{"trials":4937,"activeCount":101},[],{"trials":4939,"activeCount":101},[],{"trials":4941,"activeCount":101},[],{"trials":4943,"activeCount":651,"soonestReadout":1690},[4944],{"nctId":4920,"briefTitle":4921,"status":270,"phases":4945,"primaryCompletion":1690,"completion":4923,"start":600,"enrollment":4924,"conditions":4946,"interventions":4947},[91],[4926],[4909,4928,4929],{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[],{"intervention":4929,"totalTrials":651,"cells":4953},{"EARLY_PHASE1":4954,"PHASE1":4956,"PHASE2":4958,"PHASE3":4960,"PHASE4":4966,"NA":4968},{"trials":4955,"activeCount":101},[],{"trials":4957,"activeCount":101},[],{"trials":4959,"activeCount":101},[],{"trials":4961,"activeCount":651,"soonestReadout":1690},[4962],{"nctId":4920,"briefTitle":4921,"status":270,"phases":4963,"primaryCompletion":1690,"completion":4923,"start":600,"enrollment":4924,"conditions":4964,"interventions":4965},[91],[4926],[4909,4928,4929],{"trials":4967,"activeCount":101},[],{"trials":4969,"activeCount":101},[],{"intervention":4971,"totalTrials":651,"cells":4972},"Tislelizumab combined with the CAPOX regimen",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4979,"PHASE4":4990,"NA":4992},{"trials":4974,"activeCount":101},[],{"trials":4976,"activeCount":101},[],{"trials":4978,"activeCount":101},[],{"trials":4980,"activeCount":651,"soonestReadout":123},[4981],{"nctId":4982,"briefTitle":4983,"status":270,"phases":4984,"primaryCompletion":123,"completion":4985,"start":1143,"enrollment":4986,"conditions":4987,"interventions":4988},"NCT07132463","Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study",[91],"2030-12",154,[113],[4971,4989],"CAPOX regimen",{"trials":4991,"activeCount":101},[],{"trials":4993,"activeCount":101},[],{"intervention":4989,"totalTrials":651,"cells":4995},{"EARLY_PHASE1":4996,"PHASE1":4998,"PHASE2":5000,"PHASE3":5002,"PHASE4":5008,"NA":5010},{"trials":4997,"activeCount":101},[],{"trials":4999,"activeCount":101},[],{"trials":5001,"activeCount":101},[],{"trials":5003,"activeCount":651,"soonestReadout":123},[5004],{"nctId":4982,"briefTitle":4983,"status":270,"phases":5005,"primaryCompletion":123,"completion":4985,"start":1143,"enrollment":4986,"conditions":5006,"interventions":5007},[91],[113],[4971,4989],{"trials":5009,"activeCount":101},[],{"trials":5011,"activeCount":101},[],{"intervention":3303,"totalTrials":651,"cells":5013},{"EARLY_PHASE1":5014,"PHASE1":5016,"PHASE2":5018,"PHASE3":5020,"PHASE4":5026,"NA":5028},{"trials":5015,"activeCount":101},[],{"trials":5017,"activeCount":101},[],{"trials":5019,"activeCount":101},[],{"trials":5021,"activeCount":651,"soonestReadout":3297},[5022],{"nctId":3294,"briefTitle":3295,"status":121,"phases":5023,"primaryCompletion":3297,"completion":3298,"start":2428,"enrollment":3299,"conditions":5024,"interventions":5025},[91],[3301,1553,1218],[242,3303],{"trials":5027,"activeCount":101},[],{"trials":5029,"activeCount":101},[],{"intervention":5031,"totalTrials":651,"cells":5032},"Docetaxel plus cyclophosphamide",{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5039,"PHASE4":5051,"NA":5053},{"trials":5034,"activeCount":101},[],{"trials":5036,"activeCount":101},[],{"trials":5038,"activeCount":101},[],{"trials":5040,"activeCount":651,"soonestReadout":1144},[5041],{"nctId":5042,"briefTitle":5043,"status":270,"phases":5044,"primaryCompletion":1144,"completion":5045,"start":5046,"enrollment":5047,"conditions":5048,"interventions":5049},"NCT06795503","Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients",[91],"2031-07","2025-02",1462,[161],[5031,5050],"Epirubicin, cyclophosphamide plus paclitaxel",{"trials":5052,"activeCount":101},[],{"trials":5054,"activeCount":101},[],{"intervention":5050,"totalTrials":651,"cells":5056},{"EARLY_PHASE1":5057,"PHASE1":5059,"PHASE2":5061,"PHASE3":5063,"PHASE4":5069,"NA":5071},{"trials":5058,"activeCount":101},[],{"trials":5060,"activeCount":101},[],{"trials":5062,"activeCount":101},[],{"trials":5064,"activeCount":651,"soonestReadout":1144},[5065],{"nctId":5042,"briefTitle":5043,"status":270,"phases":5066,"primaryCompletion":1144,"completion":5045,"start":5046,"enrollment":5047,"conditions":5067,"interventions":5068},[91],[161],[5031,5050],{"trials":5070,"activeCount":101},[],{"trials":5072,"activeCount":101},[],{"intervention":5074,"totalTrials":651,"cells":5075},"SHR- A1811",{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5080,"PHASE3":5082,"PHASE4":5094,"NA":5096},{"trials":5077,"activeCount":101},[],{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":651,"soonestReadout":123},[5084],{"nctId":5085,"briefTitle":5086,"status":270,"phases":5087,"primaryCompletion":123,"completion":2156,"start":5088,"enrollment":5089,"conditions":5090,"interventions":5091},"NCT07528716","Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy",[91],"2026-05",280,[15],[5074,5092,5093],"PCbHP","SHR- A1811+ Pyrotinib",{"trials":5095,"activeCount":101},[],{"trials":5097,"activeCount":101},[],{"intervention":5092,"totalTrials":651,"cells":5099},{"EARLY_PHASE1":5100,"PHASE1":5102,"PHASE2":5104,"PHASE3":5106,"PHASE4":5112,"NA":5114},{"trials":5101,"activeCount":101},[],{"trials":5103,"activeCount":101},[],{"trials":5105,"activeCount":101},[],{"trials":5107,"activeCount":651,"soonestReadout":123},[5108],{"nctId":5085,"briefTitle":5086,"status":270,"phases":5109,"primaryCompletion":123,"completion":2156,"start":5088,"enrollment":5089,"conditions":5110,"interventions":5111},[91],[15],[5074,5092,5093],{"trials":5113,"activeCount":101},[],{"trials":5115,"activeCount":101},[],{"intervention":5093,"totalTrials":651,"cells":5117},{"EARLY_PHASE1":5118,"PHASE1":5120,"PHASE2":5122,"PHASE3":5124,"PHASE4":5130,"NA":5132},{"trials":5119,"activeCount":101},[],{"trials":5121,"activeCount":101},[],{"trials":5123,"activeCount":101},[],{"trials":5125,"activeCount":651,"soonestReadout":123},[5126],{"nctId":5085,"briefTitle":5086,"status":270,"phases":5127,"primaryCompletion":123,"completion":2156,"start":5088,"enrollment":5089,"conditions":5128,"interventions":5129},[91],[15],[5074,5092,5093],{"trials":5131,"activeCount":101},[],{"trials":5133,"activeCount":101},[],{"intervention":2756,"totalTrials":651,"cells":5135},{"EARLY_PHASE1":5136,"PHASE1":5138,"PHASE2":5140,"PHASE3":5142,"PHASE4":5148,"NA":5150},{"trials":5137,"activeCount":101},[],{"trials":5139,"activeCount":101},[],{"trials":5141,"activeCount":101},[],{"trials":5143,"activeCount":651,"soonestReadout":2749},[5144],{"nctId":2746,"briefTitle":2747,"status":121,"phases":5145,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":5146,"interventions":5147},[91],[15],[1386,2754,1383,2755,2756,2757,1119,2758],{"trials":5149,"activeCount":101},[],{"trials":5151,"activeCount":101},[],{"intervention":2757,"totalTrials":651,"cells":5153},{"EARLY_PHASE1":5154,"PHASE1":5156,"PHASE2":5158,"PHASE3":5160,"PHASE4":5166,"NA":5168},{"trials":5155,"activeCount":101},[],{"trials":5157,"activeCount":101},[],{"trials":5159,"activeCount":101},[],{"trials":5161,"activeCount":651,"soonestReadout":2749},[5162],{"nctId":2746,"briefTitle":2747,"status":121,"phases":5163,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":5164,"interventions":5165},[91],[15],[1386,2754,1383,2755,2756,2757,1119,2758],{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":101},[],{"intervention":2758,"totalTrials":651,"cells":5171},{"EARLY_PHASE1":5172,"PHASE1":5174,"PHASE2":5176,"PHASE3":5178,"PHASE4":5184,"NA":5186},{"trials":5173,"activeCount":101},[],{"trials":5175,"activeCount":101},[],{"trials":5177,"activeCount":101},[],{"trials":5179,"activeCount":651,"soonestReadout":2749},[5180],{"nctId":2746,"briefTitle":2747,"status":121,"phases":5181,"primaryCompletion":2749,"completion":2750,"start":2157,"enrollment":2751,"conditions":5182,"interventions":5183},[91],[15],[1386,2754,1383,2755,2756,2757,1119,2758],{"trials":5185,"activeCount":101},[],{"trials":5187,"activeCount":101},[],{"intervention":5189,"totalTrials":651,"cells":5190},"mFOLFIRINOX adjuvant chemotherapy",{"EARLY_PHASE1":5191,"PHASE1":5193,"PHASE2":5195,"PHASE3":5197,"PHASE4":5209,"NA":5211},{"trials":5192,"activeCount":101},[],{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[],{"trials":5198,"activeCount":651,"soonestReadout":896},[5199],{"nctId":5200,"briefTitle":5201,"status":121,"phases":5202,"primaryCompletion":896,"completion":2156,"start":5203,"enrollment":307,"conditions":5204,"interventions":5207},"NCT05954078","Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II\u002FIII Colorectal Cancer",[91],"2023-08-01",[5205,4627,5206],"High-risk Stage II Colorectal Cancer","Circulating Tumor DNA Methylation",[5189,5208],"mFOLFOX6\u002FXELOX adjuvant chemotherapy",{"trials":5210,"activeCount":101},[],{"trials":5212,"activeCount":101},[],{"intervention":5208,"totalTrials":651,"cells":5214},{"EARLY_PHASE1":5215,"PHASE1":5217,"PHASE2":5219,"PHASE3":5221,"PHASE4":5227,"NA":5229},{"trials":5216,"activeCount":101},[],{"trials":5218,"activeCount":101},[],{"trials":5220,"activeCount":101},[],{"trials":5222,"activeCount":651,"soonestReadout":896},[5223],{"nctId":5200,"briefTitle":5201,"status":121,"phases":5224,"primaryCompletion":896,"completion":2156,"start":5203,"enrollment":307,"conditions":5225,"interventions":5226},[91],[5205,4627,5206],[5189,5208],{"trials":5228,"activeCount":101},[],{"trials":5230,"activeCount":101},[],{"intervention":5232,"totalTrials":651,"cells":5233},"Everolimus 10 mg daily",{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5252,"NA":5254},{"trials":5235,"activeCount":101},[],{"trials":5237,"activeCount":101},[],{"trials":5239,"activeCount":101},[],{"trials":5241,"activeCount":651,"soonestReadout":5246},[5242],{"nctId":5243,"briefTitle":5244,"status":270,"phases":5245,"primaryCompletion":5246,"completion":5246,"start":5247,"enrollment":5248,"conditions":5249,"interventions":5251},"NCT07407517","Adjuvant Intensification for LAR",[91],"2033-02-01","2026-02-01",904,[5250,1426],"Breast Cancer Females",[5232],{"trials":5253,"activeCount":101},[],{"trials":5255,"activeCount":101},[],{"intervention":3847,"totalTrials":651,"cells":5257},{"EARLY_PHASE1":5258,"PHASE1":5260,"PHASE2":5262,"PHASE3":5264,"PHASE4":5270,"NA":5272},{"trials":5259,"activeCount":101},[],{"trials":5261,"activeCount":101},[],{"trials":5263,"activeCount":101},[],{"trials":5265,"activeCount":651,"soonestReadout":3841},[5266],{"nctId":3838,"briefTitle":3839,"status":270,"phases":5267,"primaryCompletion":3841,"completion":3842,"start":3843,"enrollment":3844,"conditions":5268,"interventions":5269},[91],[15],[3817,3847],{"trials":5271,"activeCount":101},[],{"trials":5273,"activeCount":101},[],{"intervention":3212,"totalTrials":651,"cells":5275},{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5280,"PHASE3":5282,"PHASE4":5288,"NA":5290},{"trials":5277,"activeCount":101},[],{"trials":5279,"activeCount":101},[],{"trials":5281,"activeCount":101},[],{"trials":5283,"activeCount":651,"soonestReadout":3205},[5284],{"nctId":3202,"briefTitle":3203,"status":121,"phases":5285,"primaryCompletion":3205,"completion":3206,"start":3207,"enrollment":3208,"conditions":5286,"interventions":5287},[91],[2254,3210],[581,1675,3212],{"trials":5289,"activeCount":101},[],{"trials":5291,"activeCount":101},[],{"intervention":3665,"totalTrials":651,"cells":5293},{"EARLY_PHASE1":5294,"PHASE1":5296,"PHASE2":5298,"PHASE3":5300,"PHASE4":5306,"NA":5308},{"trials":5295,"activeCount":101},[],{"trials":5297,"activeCount":101},[],{"trials":5299,"activeCount":101},[],{"trials":5301,"activeCount":651,"soonestReadout":305},[5302],{"nctId":3658,"briefTitle":3659,"status":121,"phases":5303,"primaryCompletion":305,"completion":2291,"start":3661,"enrollment":2728,"conditions":5304,"interventions":5305},[90,91],[1854,3663],[3665,3652,3666,3667],{"trials":5307,"activeCount":101},[],{"trials":5309,"activeCount":101},[],{"intervention":3667,"totalTrials":651,"cells":5311},{"EARLY_PHASE1":5312,"PHASE1":5314,"PHASE2":5316,"PHASE3":5318,"PHASE4":5324,"NA":5326},{"trials":5313,"activeCount":101},[],{"trials":5315,"activeCount":101},[],{"trials":5317,"activeCount":101},[],{"trials":5319,"activeCount":651,"soonestReadout":305},[5320],{"nctId":3658,"briefTitle":3659,"status":121,"phases":5321,"primaryCompletion":305,"completion":2291,"start":3661,"enrollment":2728,"conditions":5322,"interventions":5323},[90,91],[1854,3663],[3665,3652,3666,3667],{"trials":5325,"activeCount":101},[],{"trials":5327,"activeCount":101},[],{"intervention":42,"totalTrials":651,"cells":5329},{"EARLY_PHASE1":5330,"PHASE1":5332,"PHASE2":5334,"PHASE3":5336,"PHASE4":5342,"NA":5344},{"trials":5331,"activeCount":101},[],{"trials":5333,"activeCount":101},[],{"trials":5335,"activeCount":101},[],{"trials":5337,"activeCount":651,"soonestReadout":41},[5338],{"nctId":39,"briefTitle":40,"status":121,"phases":5339,"primaryCompletion":41,"completion":871,"start":4167,"enrollment":4168,"conditions":5340,"interventions":5341},[91],[24],[42,4146],{"trials":5343,"activeCount":101},[],{"trials":5345,"activeCount":101},[],{"intervention":5347,"totalTrials":651,"cells":5348},"Endocrine Therapy of Physician's Choice",{"EARLY_PHASE1":5349,"PHASE1":5351,"PHASE2":5353,"PHASE3":5355,"PHASE4":5366,"NA":5368},{"trials":5350,"activeCount":101},[],{"trials":5352,"activeCount":101},[],{"trials":5354,"activeCount":101},[],{"trials":5356,"activeCount":651,"soonestReadout":5361},[5357],{"nctId":5358,"briefTitle":5359,"status":270,"phases":5360,"primaryCompletion":5361,"completion":5361,"start":1530,"enrollment":5362,"conditions":5363,"interventions":5365},"NCT07153757","De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial",[91],"2033-09-01",2934,[5364],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[5347],{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[],{"intervention":616,"totalTrials":651,"cells":5371},{"EARLY_PHASE1":5372,"PHASE1":5374,"PHASE2":5376,"PHASE3":5378,"PHASE4":5384,"NA":5386},{"trials":5373,"activeCount":101},[],{"trials":5375,"activeCount":101},[],{"trials":5377,"activeCount":101},[],{"trials":5379,"activeCount":651,"soonestReadout":610},[5380],{"nctId":607,"briefTitle":608,"status":121,"phases":5381,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":5382,"interventions":5383},[91],[24],[242,129,96,616,617,310],{"trials":5385,"activeCount":101},[],{"trials":5387,"activeCount":101},[],{"intervention":3426,"totalTrials":651,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5394,"PHASE3":5396,"PHASE4":5402,"NA":5404},{"trials":5391,"activeCount":101},[],{"trials":5393,"activeCount":101},[],{"trials":5395,"activeCount":101},[],{"trials":5397,"activeCount":651,"soonestReadout":1143},[5398],{"nctId":3417,"briefTitle":3418,"status":121,"phases":5399,"primaryCompletion":1143,"completion":3420,"start":3421,"enrollment":3422,"conditions":5400,"interventions":5401},[91],[250,33,3424],[458,3426],{"trials":5403,"activeCount":101},[],{"trials":5405,"activeCount":101},[],{"intervention":3949,"totalTrials":651,"cells":5407},{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5412,"PHASE3":5414,"PHASE4":5420,"NA":5422},{"trials":5409,"activeCount":101},[],{"trials":5411,"activeCount":101},[],{"trials":5413,"activeCount":101},[],{"trials":5415,"activeCount":651,"soonestReadout":2685},[5416],{"nctId":3941,"briefTitle":3942,"status":270,"phases":5417,"primaryCompletion":2685,"completion":3944,"start":147,"enrollment":2135,"conditions":5418,"interventions":5419},[91],[3946,2139,3947],[3930,3949],{"trials":5421,"activeCount":101},[],{"trials":5423,"activeCount":101},[],{"intervention":1719,"totalTrials":651,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5430,"PHASE3":5432,"PHASE4":5438,"NA":5440},{"trials":5427,"activeCount":101},[],{"trials":5429,"activeCount":101},[],{"trials":5431,"activeCount":101},[],{"trials":5433,"activeCount":651,"soonestReadout":1713},[5434],{"nctId":1710,"briefTitle":1711,"status":121,"phases":5435,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":5436,"interventions":5437},[91],[15,250],[1719,310],{"trials":5439,"activeCount":101},[],{"trials":5441,"activeCount":101},[],{"intervention":5443,"totalTrials":651,"cells":5444},"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab",{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5451,"PHASE4":5461,"NA":5463},{"trials":5446,"activeCount":101},[],{"trials":5448,"activeCount":101},[],{"trials":5450,"activeCount":101},[],{"trials":5452,"activeCount":651,"soonestReadout":470},[5453],{"nctId":5454,"briefTitle":5455,"status":121,"phases":5456,"primaryCompletion":470,"completion":471,"start":2157,"enrollment":5457,"conditions":5458,"interventions":5459},"NCT05862064","A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline\u002FTaxane-based Adjuvant Chemotherapy Versus Anthracycline\u002FTaxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer",[91],606,[2408],[5443,5460],"epirubicin,cyclophosphamide,paclitaxel",{"trials":5462,"activeCount":101},[],{"trials":5464,"activeCount":101},[],{"intervention":5460,"totalTrials":651,"cells":5466},{"EARLY_PHASE1":5467,"PHASE1":5469,"PHASE2":5471,"PHASE3":5473,"PHASE4":5479,"NA":5481},{"trials":5468,"activeCount":101},[],{"trials":5470,"activeCount":101},[],{"trials":5472,"activeCount":101},[],{"trials":5474,"activeCount":651,"soonestReadout":470},[5475],{"nctId":5454,"briefTitle":5455,"status":121,"phases":5476,"primaryCompletion":470,"completion":471,"start":2157,"enrollment":5457,"conditions":5477,"interventions":5478},[91],[2408],[5443,5460],{"trials":5480,"activeCount":101},[],{"trials":5482,"activeCount":101},[],{"intervention":5484,"totalTrials":651,"cells":5485},"VC plus herbal medicine",{"EARLY_PHASE1":5486,"PHASE1":5488,"PHASE2":5490,"PHASE3":5492,"PHASE4":5501,"NA":5503},{"trials":5487,"activeCount":101},[],{"trials":5489,"activeCount":101},[],{"trials":5491,"activeCount":101},[],{"trials":5493,"activeCount":651,"soonestReadout":2813},[5494],{"nctId":5495,"briefTitle":5496,"status":121,"phases":5497,"primaryCompletion":2813,"completion":5498,"start":4240,"enrollment":97,"conditions":5499,"interventions":5500},"NCT06598033","Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer",[90,91],"2027-10-01",[30],[5484],{"trials":5502,"activeCount":101},[],{"trials":5504,"activeCount":101},[],{"intervention":1520,"totalTrials":651,"cells":5506},{"EARLY_PHASE1":5507,"PHASE1":5509,"PHASE2":5511,"PHASE3":5513,"PHASE4":5519,"NA":5521},{"trials":5508,"activeCount":101},[],{"trials":5510,"activeCount":101},[],{"trials":5512,"activeCount":101},[],{"trials":5514,"activeCount":651,"soonestReadout":367},[5515],{"nctId":1512,"briefTitle":1513,"status":121,"phases":5516,"primaryCompletion":367,"completion":826,"start":1515,"enrollment":1516,"conditions":5517,"interventions":5518},[91],[1518],[455,432,1520],{"trials":5520,"activeCount":101},[],{"trials":5522,"activeCount":101},[],{"intervention":5524,"totalTrials":651,"cells":5525},"HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate",{"EARLY_PHASE1":5526,"PHASE1":5528,"PHASE2":5530,"PHASE3":5532,"PHASE4":5544,"NA":5546},{"trials":5527,"activeCount":101},[],{"trials":5529,"activeCount":101},[],{"trials":5531,"activeCount":101},[],{"trials":5533,"activeCount":651,"soonestReadout":1786},[5534],{"nctId":5535,"briefTitle":5536,"status":270,"phases":5537,"primaryCompletion":1786,"completion":5538,"start":5539,"enrollment":5540,"conditions":5541,"interventions":5542},"NCT06217042","HR070803 in Combination With Oxaliplatin, 5-fluorouracil\u002FLV Versus GX as Adjuvant Therapy for Pancreatic Cancer",[91],"2028-07-30","2024-02-05",524,[30],[5524,5543],"gemcitabine; capecitabine",{"trials":5545,"activeCount":101},[],{"trials":5547,"activeCount":101},[],{"intervention":5543,"totalTrials":651,"cells":5549},{"EARLY_PHASE1":5550,"PHASE1":5552,"PHASE2":5554,"PHASE3":5556,"PHASE4":5562,"NA":5564},{"trials":5551,"activeCount":101},[],{"trials":5553,"activeCount":101},[],{"trials":5555,"activeCount":101},[],{"trials":5557,"activeCount":651,"soonestReadout":1786},[5558],{"nctId":5535,"briefTitle":5536,"status":270,"phases":5559,"primaryCompletion":1786,"completion":5538,"start":5539,"enrollment":5540,"conditions":5560,"interventions":5561},[91],[30],[5524,5543],{"trials":5563,"activeCount":101},[],{"trials":5565,"activeCount":101},[],{"intervention":5567,"totalTrials":651,"cells":5568},"Etoposide, Cyclophosphamide, Carboplatin\u002FCisplatin",{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5575,"PHASE4":5586,"NA":5588},{"trials":5570,"activeCount":101},[],{"trials":5572,"activeCount":101},[],{"trials":5574,"activeCount":101},[],{"trials":5576,"activeCount":651,"soonestReadout":2251},[5577],{"nctId":5578,"briefTitle":5579,"status":121,"phases":5580,"primaryCompletion":2251,"completion":5581,"start":5582,"enrollment":5583,"conditions":5584,"interventions":5585},"NCT04520074","Adjuvant Chemotherapy of Three-step Regimen in BRCA1\u002F2 Wide Type Ovarian Cancer (ACTS-2)",[91],"2030-09","2021-10-08",590,[2737],[5567],{"trials":5587,"activeCount":101},[],{"trials":5589,"activeCount":101},[],{"intervention":5591,"totalTrials":651,"cells":5592},"mFOLFOXIRI plus Cetuximab",{"EARLY_PHASE1":5593,"PHASE1":5595,"PHASE2":5597,"PHASE3":5599,"PHASE4":5610,"NA":5612},{"trials":5594,"activeCount":101},[],{"trials":5596,"activeCount":101},[],{"trials":5598,"activeCount":101},[],{"trials":5600,"activeCount":651,"soonestReadout":3958},[5601],{"nctId":5602,"briefTitle":5603,"status":121,"phases":5604,"primaryCompletion":3958,"completion":1621,"start":5605,"enrollment":5606,"conditions":5607,"interventions":5608},"NCT04687631","Conversion Therapy of RAS\u002FBRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases",[91],"2021-01-14",508,[18,1554],[5591,5609],"mFOLFOXIRI Plus Bevacizumab",{"trials":5611,"activeCount":101},[],{"trials":5613,"activeCount":101},[],{"intervention":5609,"totalTrials":651,"cells":5615},{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5620,"PHASE3":5622,"PHASE4":5628,"NA":5630},{"trials":5617,"activeCount":101},[],{"trials":5619,"activeCount":101},[],{"trials":5621,"activeCount":101},[],{"trials":5623,"activeCount":651,"soonestReadout":3958},[5624],{"nctId":5602,"briefTitle":5603,"status":121,"phases":5625,"primaryCompletion":3958,"completion":1621,"start":5605,"enrollment":5606,"conditions":5626,"interventions":5627},[91],[18,1554],[5591,5609],{"trials":5629,"activeCount":101},[],{"trials":5631,"activeCount":101},[],{"intervention":2859,"totalTrials":651,"cells":5633},{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5638,"PHASE3":5640,"PHASE4":5646,"NA":5648},{"trials":5635,"activeCount":101},[],{"trials":5637,"activeCount":101},[],{"trials":5639,"activeCount":101},[],{"trials":5641,"activeCount":651,"soonestReadout":354},[5642],{"nctId":2851,"briefTitle":2852,"status":121,"phases":5643,"primaryCompletion":354,"completion":354,"start":353,"enrollment":2854,"conditions":5644,"interventions":5645},[91],[18,2856,2857],[2859,2860,2764],{"trials":5647,"activeCount":101},[],{"trials":5649,"activeCount":101},[],{"intervention":2860,"totalTrials":651,"cells":5651},{"EARLY_PHASE1":5652,"PHASE1":5654,"PHASE2":5656,"PHASE3":5658,"PHASE4":5664,"NA":5666},{"trials":5653,"activeCount":101},[],{"trials":5655,"activeCount":101},[],{"trials":5657,"activeCount":101},[],{"trials":5659,"activeCount":651,"soonestReadout":354},[5660],{"nctId":2851,"briefTitle":2852,"status":121,"phases":5661,"primaryCompletion":354,"completion":354,"start":353,"enrollment":2854,"conditions":5662,"interventions":5663},[91],[18,2856,2857],[2859,2860,2764],{"trials":5665,"activeCount":101},[],{"trials":5667,"activeCount":101},[],{"intervention":2062,"totalTrials":651,"cells":5669},{"EARLY_PHASE1":5670,"PHASE1":5672,"PHASE2":5674,"PHASE3":5676,"PHASE4":5682,"NA":5684},{"trials":5671,"activeCount":101},[],{"trials":5673,"activeCount":101},[],{"trials":5675,"activeCount":101},[],{"trials":5677,"activeCount":651,"soonestReadout":56},[5678],{"nctId":54,"briefTitle":55,"status":505,"phases":5679,"primaryCompletion":56,"completion":123,"start":1877,"enrollment":2059,"conditions":5680,"interventions":5681},[90,91],[250,15],[57,2062,2063,533,2064],{"trials":5683,"activeCount":101},[],{"trials":5685,"activeCount":101},[],{"intervention":5687,"totalTrials":651,"cells":5688},"Active Comparator: BCG induction and maintenance",{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5693,"PHASE3":5695,"PHASE4":5707,"NA":5709},{"trials":5690,"activeCount":101},[],{"trials":5692,"activeCount":101},[],{"trials":5694,"activeCount":101},[],{"trials":5696,"activeCount":651,"soonestReadout":3841},[5697],{"nctId":5698,"briefTitle":5699,"status":270,"phases":5700,"primaryCompletion":3841,"completion":5701,"start":354,"enrollment":410,"conditions":5702,"interventions":5705},"NCT07207824","DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC",[91],"2030-12-01",[5703,5704],"Bladder (Urothelial, Transitional Cell) Cancer","NMIBC",[5687,5706],"DV + BCG induction and maintenance",{"trials":5708,"activeCount":101},[],{"trials":5710,"activeCount":101},[],{"intervention":5706,"totalTrials":651,"cells":5712},{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5717,"PHASE3":5719,"PHASE4":5725,"NA":5727},{"trials":5714,"activeCount":101},[],{"trials":5716,"activeCount":101},[],{"trials":5718,"activeCount":101},[],{"trials":5720,"activeCount":651,"soonestReadout":3841},[5721],{"nctId":5698,"briefTitle":5699,"status":270,"phases":5722,"primaryCompletion":3841,"completion":5701,"start":354,"enrollment":410,"conditions":5723,"interventions":5724},[91],[5703,5704],[5687,5706],{"trials":5726,"activeCount":101},[],{"trials":5728,"activeCount":101},[],{"intervention":5730,"totalTrials":651,"cells":5731},"Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w",{"EARLY_PHASE1":5732,"PHASE1":5734,"PHASE2":5736,"PHASE3":5738,"PHASE4":5749,"NA":5751},{"trials":5733,"activeCount":101},[],{"trials":5735,"activeCount":101},[],{"trials":5737,"activeCount":101},[],{"trials":5739,"activeCount":651,"soonestReadout":2018},[5740],{"nctId":5741,"briefTitle":5742,"status":121,"phases":5743,"primaryCompletion":2018,"completion":418,"start":5744,"enrollment":5745,"conditions":5746,"interventions":5747},"NCT07615751","Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer",[91],"2025-02-12",502,[15],[5730,5748],"Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Docetaxel 75mg\u002Fm² ivgtt d1 q3w,",{"trials":5750,"activeCount":101},[],{"trials":5752,"activeCount":101},[],{"intervention":5748,"totalTrials":651,"cells":5754},{"EARLY_PHASE1":5755,"PHASE1":5757,"PHASE2":5759,"PHASE3":5761,"PHASE4":5767,"NA":5769},{"trials":5756,"activeCount":101},[],{"trials":5758,"activeCount":101},[],{"trials":5760,"activeCount":101},[],{"trials":5762,"activeCount":651,"soonestReadout":2018},[5763],{"nctId":5741,"briefTitle":5742,"status":121,"phases":5764,"primaryCompletion":2018,"completion":418,"start":5744,"enrollment":5745,"conditions":5765,"interventions":5766},[91],[15],[5730,5748],{"trials":5768,"activeCount":101},[],{"trials":5770,"activeCount":101},[],{"intervention":5772,"totalTrials":651,"cells":5773},"CDK 4\u002F6 inhibitor combined therapy",{"EARLY_PHASE1":5774,"PHASE1":5776,"PHASE2":5778,"PHASE3":5780,"PHASE4":5793,"NA":5795},{"trials":5775,"activeCount":101},[],{"trials":5777,"activeCount":101},[],{"trials":5779,"activeCount":101},[],{"trials":5781,"activeCount":651,"soonestReadout":5786},[5782],{"nctId":5783,"briefTitle":5784,"status":270,"phases":5785,"primaryCompletion":5786,"completion":5787,"start":5788,"enrollment":5789,"conditions":5790,"interventions":5791},"NCT07213206","CDK4\u002F6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer",[91],"2032-09-01","2035-09-01","2025-10-07",1500,[15],[5772,5792],"standard of care",{"trials":5794,"activeCount":101},[],{"trials":5796,"activeCount":101},[],{"intervention":5792,"totalTrials":651,"cells":5798},{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5805,"PHASE4":5811,"NA":5813},{"trials":5800,"activeCount":101},[],{"trials":5802,"activeCount":101},[],{"trials":5804,"activeCount":101},[],{"trials":5806,"activeCount":651,"soonestReadout":5786},[5807],{"nctId":5783,"briefTitle":5784,"status":270,"phases":5808,"primaryCompletion":5786,"completion":5787,"start":5788,"enrollment":5789,"conditions":5809,"interventions":5810},[91],[15],[5772,5792],{"trials":5812,"activeCount":101},[],{"trials":5814,"activeCount":101},[],{"intervention":5816,"totalTrials":651,"cells":5817},"mFOLFOX6 + Cetuximab",{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5822,"PHASE3":5824,"PHASE4":5836,"NA":5838},{"trials":5819,"activeCount":101},[],{"trials":5821,"activeCount":101},[],{"trials":5823,"activeCount":101},[],{"trials":5825,"activeCount":651,"soonestReadout":5830},[5826],{"nctId":5827,"briefTitle":5828,"status":270,"phases":5829,"primaryCompletion":5830,"completion":5830,"start":5831,"enrollment":5832,"conditions":5833,"interventions":5834},"NCT05948072","Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS\u002FBRAF Wild Type Patients With High-Risk Resectable CRLM",[91],"2026-07-15","2023-07-15",250,[18,1554],[5816,5835],"mFOLFOX 6",{"trials":5837,"activeCount":101},[],{"trials":5839,"activeCount":101},[],{"intervention":5835,"totalTrials":651,"cells":5841},{"EARLY_PHASE1":5842,"PHASE1":5844,"PHASE2":5846,"PHASE3":5848,"PHASE4":5854,"NA":5856},{"trials":5843,"activeCount":101},[],{"trials":5845,"activeCount":101},[],{"trials":5847,"activeCount":101},[],{"trials":5849,"activeCount":651,"soonestReadout":5830},[5850],{"nctId":5827,"briefTitle":5828,"status":270,"phases":5851,"primaryCompletion":5830,"completion":5830,"start":5831,"enrollment":5832,"conditions":5852,"interventions":5853},[91],[18,1554],[5816,5835],{"trials":5855,"activeCount":101},[],{"trials":5857,"activeCount":101},[],{"intervention":278,"totalTrials":1778,"cells":5859},{"EARLY_PHASE1":5860,"PHASE1":5862,"PHASE2":5864,"PHASE3":6060,"PHASE4":6062,"NA":6064},{"trials":5861,"activeCount":101},[],{"trials":5863,"activeCount":101},[],{"trials":5865,"activeCount":2086,"soonestReadout":6054},[5866,5875,5887,5897,5905,5912,5918,5924,5928,5932,5941,5949,5953,5962,5966,5978,5986,5990,5996,6005,6015,6019,6023,6031,6043,6050],{"nctId":5867,"briefTitle":5868,"status":365,"phases":5869,"primaryCompletion":5870,"completion":5871,"start":5872,"enrollment":31,"conditions":5873,"interventions":5874},"NCT04297280","TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma",[90],"2023-07-18","2025-02-25","2020-04-29",[21],[278,4192],{"nctId":5876,"briefTitle":5877,"status":107,"phases":5878,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":5881,"conditions":5882,"interventions":5883},"NCT05386524","Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC",[90],"2025-03-15","2022-06-15",41,[15],[5884,5885,5886],"sintilimab","bevacizumab biosimilar","pegylated liposomal doxorubicin",{"nctId":5888,"briefTitle":5889,"status":107,"phases":5890,"primaryCompletion":1681,"completion":5891,"start":5892,"enrollment":5893,"conditions":5894,"interventions":5895},"NCT04106180","SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC",[90],"2023-08-31","2019-09-30",63,[2109],[5896,278],"GM-CSF",{"nctId":5898,"briefTitle":5899,"status":365,"phases":5900,"primaryCompletion":5901,"completion":5901,"start":5902,"enrollment":2695,"conditions":5903,"interventions":5904},"NCT04954794","TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)",[90],"2024-04-29","2021-07-14",[21],[278,4192],{"nctId":5906,"briefTitle":5907,"status":107,"phases":5908,"primaryCompletion":1489,"completion":1489,"start":5909,"enrollment":25,"conditions":5910,"interventions":5911},"NCT05835245","Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)",[90],"2023-04-28",[3070],[278,1468],{"nctId":5913,"briefTitle":5914,"status":107,"phases":5915,"primaryCompletion":294,"completion":1609,"start":1724,"enrollment":427,"conditions":5916,"interventions":5917},"NCT06285019","Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma",[90],[21],[278,230],{"nctId":5919,"briefTitle":5920,"status":107,"phases":5921,"primaryCompletion":3613,"completion":447,"start":368,"enrollment":25,"conditions":5922,"interventions":5923},"NCT04843943","Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC",[89,90],[21],[278,1535],{"nctId":1123,"briefTitle":1124,"status":270,"phases":5925,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":5926,"interventions":5927},[90],[1131,113],[1133,278,1134,361,129,115],{"nctId":268,"briefTitle":269,"status":270,"phases":5929,"primaryCompletion":272,"completion":273,"start":145,"enrollment":137,"conditions":5930,"interventions":5931},[90],[275,276],[278,230,129,96,279],{"nctId":5933,"briefTitle":5934,"status":121,"phases":5935,"primaryCompletion":3645,"completion":5936,"start":5937,"enrollment":5938,"conditions":5939,"interventions":5940},"NCT06860490","HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)",[90],"2028-03-10","2025-03-18",164,[1322],[278,1535],{"nctId":5942,"briefTitle":5943,"status":121,"phases":5944,"primaryCompletion":5945,"completion":5945,"start":5946,"enrollment":31,"conditions":5947,"interventions":5948},"NCT05010681","Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer",[90],"2025-08-20","2021-08-24",[1492],[278,1468],{"nctId":1140,"briefTitle":1141,"status":270,"phases":5950,"primaryCompletion":1143,"completion":1144,"start":1145,"enrollment":1146,"conditions":5951,"interventions":5952},[90],[24,1148],[1150,278,129,1151],{"nctId":5954,"briefTitle":5955,"status":121,"phases":5956,"primaryCompletion":1560,"completion":5957,"start":1562,"enrollment":379,"conditions":5958,"interventions":5960},"NCT06841159","Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer",[90],"2028-03-01",[5959],"Microsatellite Stable Metastatic Colorectal Cancer",[278,5961],"Standard systemic therapy",{"nctId":1774,"briefTitle":1775,"status":121,"phases":5963,"primaryCompletion":963,"completion":236,"start":1777,"enrollment":1778,"conditions":5964,"interventions":5965},[89,90],[1780,475],[278,1782,67,1783],{"nctId":5967,"briefTitle":5968,"status":121,"phases":5969,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":5973,"conditions":5974,"interventions":5976},"NCT07492615","A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric\u002FGastroesophageal Junction Adenocarcinoma",[90],"2029-02-20","2033-02-20","2026-01-29",276,[5975],"Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",[278,5977],"S-1 & Oxaliplatin",{"nctId":5979,"briefTitle":5980,"status":121,"phases":5981,"primaryCompletion":5982,"completion":5982,"start":5983,"enrollment":31,"conditions":5984,"interventions":5985},"NCT05057052","Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis",[90],"2026-09-25","2021-09-26",[1554,2816],[278,1325,1494],{"nctId":1172,"briefTitle":1173,"status":121,"phases":5987,"primaryCompletion":800,"completion":800,"start":1175,"enrollment":25,"conditions":5988,"interventions":5989},[90],[24],[1178,278,279,129],{"nctId":5991,"briefTitle":5992,"status":365,"phases":5993,"primaryCompletion":3613,"completion":447,"start":368,"enrollment":1146,"conditions":5994,"interventions":5995},"NCT04842565","cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria",[90],[21],[278],{"nctId":5997,"briefTitle":5998,"status":365,"phases":5999,"primaryCompletion":6000,"completion":6000,"start":5946,"enrollment":28,"conditions":6001,"interventions":6002},"NCT05010668","Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma",[90],"2024-03-02",[1492],[6003,278,6004],"cryoablation","lenvatinib",{"nctId":6006,"briefTitle":6007,"status":121,"phases":6008,"primaryCompletion":6009,"completion":6009,"start":6010,"enrollment":31,"conditions":6011,"interventions":6013},"NCT05098847","Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors",[90],"2025-10-30","2021-10-29",[6012],"Liver Metastasis",[278,1468,6014],"Cryoablation",{"nctId":1643,"briefTitle":1644,"status":270,"phases":6016,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":410,"conditions":6017,"interventions":6018},[90],[27],[278,310],{"nctId":1210,"briefTitle":1211,"status":494,"phases":6020,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":637,"conditions":6021,"interventions":6022},[90],[577,1216,240,1217,1218,1219,1220,1221],[129,1223,278],{"nctId":6024,"briefTitle":6025,"status":107,"phases":6026,"primaryCompletion":1489,"completion":1489,"start":6027,"enrollment":31,"conditions":6028,"interventions":6030},"NCT05781074","Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）",[90],"2023-03-23",[6029],"Advanced Biliary Tract Cancer",[278,1468],{"nctId":6032,"briefTitle":6033,"status":107,"phases":6034,"primaryCompletion":6035,"completion":6036,"start":6037,"enrollment":1434,"conditions":6038,"interventions":6040},"NCT04356872","The Combination of Sintilimab and AI (Doxorubicin, ADM\u002FIfosfamide, IFO) for the First Line Treatment of Select Type of Metastatic\u002FUnresectable Soft Tissue Sarcoma",[90],"2022-03-30","2023-03-30","2020-04-08",[6039],"Sarcoma, Soft Tissue",[278,6041,6042],"Doxorubicin Hydrochloride","Ifosfamide",{"nctId":6044,"briefTitle":6045,"status":107,"phases":6046,"primaryCompletion":1202,"completion":1203,"start":6047,"enrollment":111,"conditions":6048,"interventions":6049},"NCT04535024","The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer",[90],"2021-03-04",[18],[278],{"nctId":6051,"briefTitle":6052,"status":121,"phases":6053,"primaryCompletion":6054,"completion":6055,"start":6056,"enrollment":473,"conditions":6057,"interventions":6059},"NCT05839275","The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma",[89,90],"2024-07-31","2029-07-31","2022-08-01",[6058],"High-Risk Localized Soft Tissue Sarcoma",[1150,278],{"trials":6061,"activeCount":101},[],{"trials":6063,"activeCount":101},[],{"trials":6065,"activeCount":651,"soonestReadout":1529},[6066],{"nctId":1526,"briefTitle":1527,"status":121,"phases":6067,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":6068,"interventions":6069},[],[1533],[278,1535,432,1438,1536,1537],{"intervention":128,"totalTrials":28,"cells":6071},{"EARLY_PHASE1":6072,"PHASE1":6074,"PHASE2":6101,"PHASE3":6278,"PHASE4":6280,"NA":6282},{"trials":6073,"activeCount":101},[],{"trials":6075,"activeCount":101},[6076,6085,6092],{"nctId":6077,"briefTitle":6078,"status":107,"phases":6079,"primaryCompletion":6080,"completion":6080,"start":6081,"enrollment":31,"conditions":6082,"interventions":6084},"NCT05303844","Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites",[89],"2025-03-20","2022-04-02",[6083],"Refractory Malignant Ascites",[1446,128],{"nctId":6086,"briefTitle":6087,"status":107,"phases":6088,"primaryCompletion":1489,"completion":1489,"start":295,"enrollment":31,"conditions":6089,"interventions":6090},"NCT05675462","Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma",[89],[21],[6091,128,1468],"Oncorine",{"nctId":6093,"briefTitle":6094,"status":365,"phases":6095,"primaryCompletion":6096,"completion":6096,"start":6097,"enrollment":2204,"conditions":6098,"interventions":6100},"NCT05303090","Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer",[89],"2024-04-23","2022-03-31",[6099],"Pancreatic Ductal Adenocarcinoma",[1446,128,6004],{"trials":6102,"activeCount":2086,"soonestReadout":6204},[6103,6107,6114,6118,6126,6135,6142,6151,6159,6168,6176,6182,6189,6200,6210,6214,6222,6230,6239,6243,6253,6257,6265,6274],{"nctId":119,"briefTitle":120,"status":121,"phases":6104,"primaryCompletion":123,"completion":124,"start":125,"enrollment":97,"conditions":6105,"interventions":6106},[89,90],[113],[128,96,129,96],{"nctId":6108,"briefTitle":6109,"status":107,"phases":6110,"primaryCompletion":1489,"completion":1489,"start":6111,"enrollment":31,"conditions":6112,"interventions":6113},"NCT05823987","Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)",[90],"2023-05-16",[6029],[1446,128,1468],{"nctId":1083,"briefTitle":1084,"status":270,"phases":6115,"primaryCompletion":272,"completion":272,"start":1086,"enrollment":25,"conditions":6116,"interventions":6117},[90],[1088,1089,1090],[128,279,129,1092,67],{"nctId":6119,"briefTitle":6120,"status":107,"phases":6121,"primaryCompletion":199,"completion":2157,"start":6122,"enrollment":6123,"conditions":6124,"interventions":6125},"NCT04913571","Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study",[90],"2021-05-27",265,[250],[254,128],{"nctId":6127,"briefTitle":6128,"status":121,"phases":6129,"primaryCompletion":398,"completion":6130,"start":295,"enrollment":31,"conditions":6131,"interventions":6133},"NCT05771181","Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients",[90],"2027-02",[18,6132],"Microsatellite Stable Colorectal Carcinoma",[6134,1170,128],"Vitamin E",{"nctId":6136,"briefTitle":6137,"status":121,"phases":6138,"primaryCompletion":6139,"completion":6139,"start":5902,"enrollment":31,"conditions":6140,"interventions":6141},"NCT04954781","TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma",[90],"2025-07-15",[1492],[128,4192],{"nctId":6143,"briefTitle":6144,"status":121,"phases":6145,"primaryCompletion":6146,"completion":6146,"start":6147,"enrollment":6148,"conditions":6149,"interventions":6150},"NCT07047586","Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1\u002FPD-L1 and Bevacizumab",[90],"2028-06-30","2025-07-02",146,[1322],[128,1468],{"nctId":6152,"briefTitle":6153,"status":107,"phases":6154,"primaryCompletion":285,"completion":293,"start":6155,"enrollment":1610,"conditions":6156,"interventions":6158},"NCT04948034","The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)",[90],"2021-08-23",[6157],"Metastatic Colorectal Cancer",[1170,128],{"nctId":6160,"briefTitle":6161,"status":270,"phases":6162,"primaryCompletion":826,"completion":871,"start":3983,"enrollment":1146,"conditions":6163,"interventions":6165},"NCT07025850","Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer",[89,90],[6164],"Colorectal Carcinoma",[6166,6167,128],"Digoxin","Fuquinitinib",{"nctId":6169,"briefTitle":6170,"status":494,"phases":6171,"primaryCompletion":6172,"completion":2603,"start":6173,"enrollment":1729,"conditions":6174,"interventions":6175},"NCT05176925","Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC",[90],"2022-06-27","2021-01-10",[2960],[128,3260],{"nctId":6177,"briefTitle":6178,"status":107,"phases":6179,"primaryCompletion":1489,"completion":1489,"start":1715,"enrollment":31,"conditions":6180,"interventions":6181},"NCT05897268","Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)",[90],[21],[128,1468],{"nctId":6183,"briefTitle":6184,"status":121,"phases":6185,"primaryCompletion":1489,"completion":1489,"start":3421,"enrollment":31,"conditions":6186,"interventions":6188},"NCT06032845","Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)",[90],[6187],"Solid Tumor, Adult",[128,1468],{"nctId":6190,"briefTitle":6191,"status":107,"phases":6192,"primaryCompletion":6193,"completion":85,"start":6194,"enrollment":737,"conditions":6195,"interventions":6199},"NCT04921995","Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma",[90],"2022-10-30","2019-04-15",[6196,6197,3250,1218,6198],"Recurrent Nasopharyngeal Carcinoma","Unresectable Nasopharyngeal Carcinoma","Stereotactic Body Radiation Therapy (SBRT)",[128],{"nctId":6201,"briefTitle":6202,"status":121,"phases":6203,"primaryCompletion":6204,"completion":1356,"start":6205,"enrollment":25,"conditions":6206,"interventions":6208},"NCT05531123","Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer",[90],"2024-09","2022-09-10",[6207],"Bladder Cancer",[128,6209],"gemcitabine and cisplatin",{"nctId":1161,"briefTitle":1162,"status":107,"phases":6211,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":6212,"interventions":6213},[90],[18],[1170,128,361,129,115],{"nctId":6215,"briefTitle":6216,"status":107,"phases":6217,"primaryCompletion":1489,"completion":1489,"start":6218,"enrollment":31,"conditions":6219,"interventions":6221},"NCT05893056","Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)",[90],"2023-06-16",[6220],"Gastric Cancer Metastatic to Liver",[128,1468],{"nctId":6223,"briefTitle":6224,"status":121,"phases":6225,"primaryCompletion":6226,"completion":6226,"start":5983,"enrollment":31,"conditions":6227,"interventions":6229},"NCT05057845","Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma",[90],"2026-09-20",[6228],"Advanced Hepatocellular Carcinoma",[128,6004,1494],{"nctId":6231,"briefTitle":6232,"status":107,"phases":6233,"primaryCompletion":157,"completion":6234,"start":6235,"enrollment":31,"conditions":6236,"interventions":6238},"NCT05406466","Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis",[90],"2024-08-16","2022-07-15",[6237],"Melanoma",[128,1468,6014],{"nctId":1188,"briefTitle":1189,"status":270,"phases":6240,"primaryCompletion":235,"completion":963,"start":1191,"enrollment":1192,"conditions":6241,"interventions":6242},[90],[113],[1195,1196,129,1197,128],{"nctId":6244,"briefTitle":6245,"status":121,"phases":6246,"primaryCompletion":6247,"completion":236,"start":1573,"enrollment":828,"conditions":6248,"interventions":6252},"NCT07109401","Perioperative Immunotherapy for Resectable Limited-Stage SCLC",[90],"2028-03-31",[6249,6250,6251],"Perioperative Immunotherapy","Limited Stage Lung Small Cell Carcinoma","Resectable Small Cell Lung Cancer",[128],{"nctId":3254,"briefTitle":3255,"status":107,"phases":6254,"primaryCompletion":85,"completion":85,"start":2025,"enrollment":3257,"conditions":6255,"interventions":6256},[90],[33],[3260,128,1466],{"nctId":6258,"briefTitle":6259,"status":107,"phases":6260,"primaryCompletion":6261,"completion":6261,"start":1346,"enrollment":1146,"conditions":6262,"interventions":6264},"NCT04996446","ALPPS Combined With Tislelizumab in Liver Malignancy",[90],"2023-08",[6263],"Liver Malignant Tumors",[128],{"nctId":6266,"briefTitle":6267,"status":121,"phases":6268,"primaryCompletion":6269,"completion":6270,"start":5937,"enrollment":263,"conditions":6271,"interventions":6273},"NCT06860477","Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)",[90],"2027-03-15","2028-03-15",[6272],"Intrahepatic Cholangiocellular Carcinoma",[128,1468,312],{"nctId":395,"briefTitle":396,"status":270,"phases":6275,"primaryCompletion":398,"completion":399,"start":400,"enrollment":137,"conditions":6276,"interventions":6277},[90],[402,113],[128,96,129,96],{"trials":6279,"activeCount":101},[],{"trials":6281,"activeCount":101},[],{"trials":6283,"activeCount":101},[6284],{"nctId":6285,"briefTitle":6286,"status":107,"phases":6287,"primaryCompletion":171,"completion":1202,"start":201,"enrollment":737,"conditions":6288,"interventions":6289},"NCT04996459","Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma",[],[21],[128],{"intervention":230,"totalTrials":1746,"cells":6291},{"EARLY_PHASE1":6292,"PHASE1":6294,"PHASE2":6296,"PHASE3":6386,"PHASE4":6408,"NA":6410},{"trials":6293,"activeCount":101},[],{"trials":6295,"activeCount":101},[],{"trials":6297,"activeCount":2394,"soonestReadout":353},[6298,6302,6311,6322,6326,6330,6340,6350,6354,6358,6362,6370,6374,6378,6382],{"nctId":1923,"briefTitle":1924,"status":121,"phases":6299,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":19,"conditions":6300,"interventions":6301},[90],[30],[1931,1466,255,230],{"nctId":6303,"briefTitle":6304,"status":270,"phases":6305,"primaryCompletion":1927,"completion":3717,"start":6306,"enrollment":828,"conditions":6307,"interventions":6309},"NCT07120451","Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker",[90],"2025-10-10",[6308],"Advanced Ovarian Cancer",[6310,230],"Senaparib",{"nctId":6312,"briefTitle":6313,"status":270,"phases":6314,"primaryCompletion":2261,"completion":323,"start":6315,"enrollment":22,"conditions":6316,"interventions":6320},"NCT07117877","Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer",[90],"2025-09-15",[6317,6318,6319],"Platinum Resistant Ovarian Cancer","Platinum Refractory Epithelial Ovarian Cancer","Ovarian Cancer (OvCa)",[3030,230,6321],"Iparomlimab and Tuvonralimab",{"nctId":218,"briefTitle":219,"status":121,"phases":6323,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":6324,"interventions":6325},[90],[225],[96,227,228,129,115,229,230,62],{"nctId":5913,"briefTitle":5914,"status":107,"phases":6327,"primaryCompletion":294,"completion":1609,"start":1724,"enrollment":427,"conditions":6328,"interventions":6329},[90],[21],[278,230],{"nctId":6331,"briefTitle":6332,"status":270,"phases":6333,"primaryCompletion":2251,"completion":6334,"start":726,"enrollment":529,"conditions":6335,"interventions":6338},"NCT07150208","T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis",[90],"2028-09",[6336,6337],"Breast Cancer With Brain Metastasis","HER2-low Expressing Breast Cancer",[230,6339],"Trastuzumab Deruxtecan",{"nctId":6341,"briefTitle":6342,"status":121,"phases":6343,"primaryCompletion":666,"completion":6344,"start":6345,"enrollment":6346,"conditions":6347,"interventions":6348},"NCT04303988","A Phase II Study of Triple-negative Breast Cancer Brain Metastases.",[90],"2025-05-30","2020-03-30",35,[15],[1379,230,6349],"Cisplatin\u002FCarboplatin",{"nctId":268,"briefTitle":269,"status":270,"phases":6351,"primaryCompletion":272,"completion":273,"start":145,"enrollment":137,"conditions":6352,"interventions":6353},[90],[275,276],[278,230,129,96,279],{"nctId":4099,"briefTitle":4100,"status":107,"phases":6355,"primaryCompletion":293,"completion":1609,"start":4102,"enrollment":345,"conditions":6356,"interventions":6357},[90],[4104],[229,230,77],{"nctId":2438,"briefTitle":2439,"status":121,"phases":6359,"primaryCompletion":2441,"completion":236,"start":2442,"enrollment":111,"conditions":6360,"interventions":6361},[90],[2125],[2284,1931,253],{"nctId":6363,"briefTitle":6364,"status":107,"phases":6365,"primaryCompletion":56,"completion":56,"start":6366,"enrollment":3614,"conditions":6367,"interventions":6368},"NCT05396937","Efficacy and Safety of T+A+RAD in HCC",[90],"2022-01-12",[21],[6369,230],"Atezolizumab Injection [Tecentriq]",{"nctId":350,"briefTitle":351,"status":121,"phases":6371,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":6372,"interventions":6373},[90],[358],[62,96,360,228,129,115,361,229,230],{"nctId":2258,"briefTitle":2259,"status":121,"phases":6375,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":2264,"conditions":6376,"interventions":6377},[89,90],[2266,2267],[1378,230,433],{"nctId":3861,"briefTitle":3862,"status":121,"phases":6379,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":6380,"interventions":6381},[90],[225],[3869,617,1974,3870,3871,230],{"nctId":2270,"briefTitle":2271,"status":121,"phases":6383,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":6384,"interventions":6385},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":6387,"activeCount":101},[6388,6398],{"nctId":6389,"briefTitle":6390,"status":107,"phases":6391,"primaryCompletion":6392,"completion":1366,"start":6393,"enrollment":6394,"conditions":6395,"interventions":6396},"NCT04525326","Conversion Therapy of RAS\u002FBRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases",[91],"2022-10-01","2020-10-01",584,[18,1554],[229,230,6397],"mFOLFOX\u002FFOLFIRI",{"nctId":6399,"briefTitle":6400,"status":107,"phases":6401,"primaryCompletion":66,"completion":939,"start":6402,"enrollment":6403,"conditions":6404,"interventions":6405},"NCT04781270","mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases",[91],"2021-04-15",308,[6164,1554],[6406,6407,230],"mFOLFOXIRI regimen","mFOLFOX regimen",{"trials":6409,"activeCount":101},[],{"trials":6411,"activeCount":651,"soonestReadout":2814},[6412],{"nctId":6413,"briefTitle":6414,"status":270,"phases":6415,"primaryCompletion":2814,"completion":471,"start":51,"enrollment":6416,"conditions":6417,"interventions":6418},"NCT05354674","Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis",[],302,[18,1554],[230],{"intervention":1468,"totalTrials":36,"cells":6420},{"EARLY_PHASE1":6421,"PHASE1":6423,"PHASE2":6433,"PHASE3":6533,"PHASE4":6535,"NA":6537},{"trials":6422,"activeCount":101},[],{"trials":6424,"activeCount":101},[6425,6429],{"nctId":6086,"briefTitle":6087,"status":107,"phases":6426,"primaryCompletion":1489,"completion":1489,"start":295,"enrollment":31,"conditions":6427,"interventions":6428},[89],[21],[6091,128,1468],{"nctId":6093,"briefTitle":6094,"status":365,"phases":6430,"primaryCompletion":6096,"completion":6096,"start":6097,"enrollment":2204,"conditions":6431,"interventions":6432},[89],[6099],[1446,128,6004],{"trials":6434,"activeCount":2866,"soonestReadout":5945},[6435,6452,6456,6460,6464,6471,6475,6479,6483,6487,6491,6495,6499,6509,6513,6517,6521,6529],{"nctId":6436,"briefTitle":6437,"status":121,"phases":6438,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":6441,"interventions":6443},"NCT07328009","A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma",[90],"2026-01-19",350,[6442],"Hepato Cellular Carcinoma (HCC)",[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],"Tislelizumab+TKI","HAIC+TKI","HAIC + Tislelizumab+TKI","QL1706+TKI","HAIC + QL1706+TKI","TUDCA + Camrelizumab+TKI","XELOX + QL1706+TKI","XELOX + Tislelizumab+TKI",{"nctId":6108,"briefTitle":6109,"status":107,"phases":6453,"primaryCompletion":1489,"completion":1489,"start":6111,"enrollment":31,"conditions":6454,"interventions":6455},[90],[6029],[1446,128,1468],{"nctId":6143,"briefTitle":6144,"status":121,"phases":6457,"primaryCompletion":6146,"completion":6146,"start":6147,"enrollment":6148,"conditions":6458,"interventions":6459},[90],[1322],[128,1468],{"nctId":5906,"briefTitle":5907,"status":107,"phases":6461,"primaryCompletion":1489,"completion":1489,"start":5909,"enrollment":25,"conditions":6462,"interventions":6463},[90],[3070],[278,1468],{"nctId":6465,"briefTitle":6466,"status":121,"phases":6467,"primaryCompletion":1318,"completion":1318,"start":5945,"enrollment":2204,"conditions":6468,"interventions":6470},"NCT07070700","Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab\u002FTuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma",[90],[6469],"Intrahepatic Cholangiocarcinoma (Icc)",[1931,1468],{"nctId":6177,"briefTitle":6178,"status":107,"phases":6472,"primaryCompletion":1489,"completion":1489,"start":1715,"enrollment":31,"conditions":6473,"interventions":6474},[90],[21],[128,1468],{"nctId":6183,"briefTitle":6184,"status":121,"phases":6476,"primaryCompletion":1489,"completion":1489,"start":3421,"enrollment":31,"conditions":6477,"interventions":6478},[90],[6187],[128,1468],{"nctId":5942,"briefTitle":5943,"status":121,"phases":6480,"primaryCompletion":5945,"completion":5945,"start":5946,"enrollment":31,"conditions":6481,"interventions":6482},[90],[1492],[278,1468],{"nctId":6215,"briefTitle":6216,"status":107,"phases":6484,"primaryCompletion":1489,"completion":1489,"start":6218,"enrollment":31,"conditions":6485,"interventions":6486},[90],[6220],[128,1468],{"nctId":1460,"briefTitle":1461,"status":270,"phases":6488,"primaryCompletion":305,"completion":236,"start":448,"enrollment":296,"conditions":6489,"interventions":6490},[90],[1464],[432,1466,1467,1468],{"nctId":6223,"briefTitle":6224,"status":121,"phases":6492,"primaryCompletion":6226,"completion":6226,"start":5983,"enrollment":31,"conditions":6493,"interventions":6494},[90],[6228],[128,6004,1494],{"nctId":6231,"briefTitle":6232,"status":107,"phases":6496,"primaryCompletion":157,"completion":6234,"start":6235,"enrollment":31,"conditions":6497,"interventions":6498},[90],[6237],[128,1468,6014],{"nctId":6500,"briefTitle":6501,"status":270,"phases":6502,"primaryCompletion":2707,"completion":6503,"start":1560,"enrollment":6504,"conditions":6505,"interventions":6507},"NCT07412054","Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC",[90],"2028-06-01",234,[6506],"HCC - Hepatocellular Carcinoma",[1468,52,6508],"Branched-Chain Amino Acids",{"nctId":5997,"briefTitle":5998,"status":365,"phases":6510,"primaryCompletion":6000,"completion":6000,"start":5946,"enrollment":28,"conditions":6511,"interventions":6512},[90],[1492],[6003,278,6004],{"nctId":6006,"briefTitle":6007,"status":121,"phases":6514,"primaryCompletion":6009,"completion":6009,"start":6010,"enrollment":31,"conditions":6515,"interventions":6516},[90],[6012],[278,1468,6014],{"nctId":6024,"briefTitle":6025,"status":107,"phases":6518,"primaryCompletion":1489,"completion":1489,"start":6027,"enrollment":31,"conditions":6519,"interventions":6520},[90],[6029],[278,1468],{"nctId":6522,"briefTitle":6523,"status":270,"phases":6524,"primaryCompletion":871,"completion":871,"start":179,"enrollment":2264,"conditions":6525,"interventions":6527},"NCT06919848","Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)",[90],[6526],"Biliary Tract Cancer (BTC)",[6528,1468,1446,312],"TORIPALIMAB",{"nctId":6266,"briefTitle":6267,"status":121,"phases":6530,"primaryCompletion":6269,"completion":6270,"start":5937,"enrollment":263,"conditions":6531,"interventions":6532},[90],[6272],[128,1468,312],{"trials":6534,"activeCount":101},[],{"trials":6536,"activeCount":101},[],{"trials":6538,"activeCount":101},[6539],{"nctId":6540,"briefTitle":6541,"status":107,"phases":6542,"primaryCompletion":2133,"completion":486,"start":6543,"enrollment":6544,"conditions":6545,"interventions":6546},"NCT03838796","Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma",[93],"2019-01-03",297,[21],[6004],{"intervention":2411,"totalTrials":1115,"cells":6548},{"EARLY_PHASE1":6549,"PHASE1":6551,"PHASE2":6553,"PHASE3":6674,"PHASE4":6676,"NA":6678},{"trials":6550,"activeCount":101},[],{"trials":6552,"activeCount":101},[],{"trials":6554,"activeCount":2189,"soonestReadout":3706},[6555,6559,6567,6571,6581,6592,6601,6611,6618,6626,6633,6641,6652,6656,6664],{"nctId":2600,"briefTitle":2601,"status":107,"phases":6556,"primaryCompletion":2603,"completion":1609,"start":2604,"enrollment":159,"conditions":6557,"interventions":6558},[90],[250],[2607,1385,2608,2411],{"nctId":6560,"briefTitle":6561,"status":121,"phases":6562,"primaryCompletion":235,"completion":963,"start":1991,"enrollment":334,"conditions":6563,"interventions":6565},"NCT06690697","Combination of Toripalimab and JS004 Therapy for ccRCC",[90],[6564],"Clear Cell Renal Cell Carcinoma",[1970,2411,6566,2281],"Axitinib",{"nctId":2403,"briefTitle":2404,"status":121,"phases":6568,"primaryCompletion":145,"completion":2406,"start":157,"enrollment":2264,"conditions":6569,"interventions":6570},[90],[2408],[2410,2411,254,253],{"nctId":6572,"briefTitle":6573,"status":107,"phases":6574,"primaryCompletion":294,"completion":1609,"start":6575,"enrollment":6576,"conditions":6577,"interventions":6580},"NCT05420597","Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal\u002FHypopharyngeal Carcinoma",[90],"2021-04-07",61,[6578,6579],"Laryngeal Cancer","Hypopharyngeal Cancer",[2411],{"nctId":6582,"briefTitle":6583,"status":107,"phases":6584,"primaryCompletion":6585,"completion":1715,"start":6586,"enrollment":6587,"conditions":6588,"interventions":6590},"NCT04472806","Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma",[90],"2022-06-20","2020-06-20",31,[6589],"Mucosal Melanoma",[2411,6591],"chemotherapy in combination with Endostar",{"nctId":6593,"briefTitle":6594,"status":121,"phases":6595,"primaryCompletion":470,"completion":6596,"start":6597,"enrollment":440,"conditions":6598,"interventions":6600},"NCT05628922","Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT",[90],"2027-07-01","2022-07-02",[6599],"Nasopharyngeal Cancer",[2411],{"nctId":6602,"briefTitle":6603,"status":107,"phases":6604,"primaryCompletion":1145,"completion":1682,"start":6605,"enrollment":6606,"conditions":6607,"interventions":6610},"NCT05907512","Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma",[90],"2020-04-01",43,[6608,6609],"Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8",[2962,2411],{"nctId":6612,"briefTitle":6613,"status":107,"phases":6614,"primaryCompletion":284,"completion":1213,"start":6393,"enrollment":1499,"conditions":6615,"interventions":6617},"NCT04524884","Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study",[90],[6616],"Thyroid Cancer",[1150,2411],{"nctId":6619,"briefTitle":6620,"status":270,"phases":6621,"primaryCompletion":235,"completion":963,"start":6622,"enrollment":25,"conditions":6623,"interventions":6624},"NCT06548763","Oral Topotecan With Toripalimab for Patients With Endometrial Cancer",[90],"2024-11-30",[1854],[6625,2411],"Topotecan",{"nctId":6627,"briefTitle":6628,"status":121,"phases":6629,"primaryCompletion":3706,"completion":408,"start":3782,"enrollment":6630,"conditions":6631,"interventions":6632},"NCT05963490","Regorafenib Alone or in Combination With Hypofractionated\u002FLow-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer",[90],108,[5959],[1325,2411,1325],{"nctId":6634,"briefTitle":6635,"status":505,"phases":6636,"primaryCompletion":1609,"completion":963,"start":667,"enrollment":213,"conditions":6637,"interventions":6638},"NCT04517214","Comparing Chemotherapy With\u002FWithout Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma",[90],[35],[2411,6639,6640],"Gemcitabine and Cisplatin Chemotherapy","Adjuvant chemotherapy with Capecitabine",{"nctId":6642,"briefTitle":6643,"status":121,"phases":6644,"primaryCompletion":783,"completion":783,"start":6645,"enrollment":1146,"conditions":6646,"interventions":6650},"NCT06354231","DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC",[90],"2023-07-20",[6647,6648,6649],"Renal Insufficiency","Upper Urinary Tract Urothelial Carcinoma","Solitary Kidney",[6651,2411],"DV",{"nctId":6522,"briefTitle":6523,"status":270,"phases":6653,"primaryCompletion":871,"completion":871,"start":179,"enrollment":2264,"conditions":6654,"interventions":6655},[90],[6526],[6528,1468,1446,312],{"nctId":6657,"briefTitle":6658,"status":107,"phases":6659,"primaryCompletion":284,"completion":284,"start":6660,"enrollment":213,"conditions":6661,"interventions":6663},"NCT04248387","Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma",[90],"2019-06-17",[6662],"Melanoma Stage IIIB-IV",[2411],{"nctId":6665,"briefTitle":6666,"status":121,"phases":6667,"primaryCompletion":3067,"completion":6668,"start":6669,"enrollment":6670,"conditions":6671,"interventions":6673},"NCT06039631","Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal\u002FHypopharyngeal Cancer",[90],"2029-09-01","2023-08-22",82,[6672,6579],"Larynx Cancer",[2411],{"trials":6675,"activeCount":101},[],{"trials":6677,"activeCount":101},[],{"trials":6679,"activeCount":651,"soonestReadout":6684},[6680],{"nctId":6681,"briefTitle":6682,"status":270,"phases":6683,"primaryCompletion":6684,"completion":1144,"start":6685,"enrollment":6686,"conditions":6687,"interventions":6689},"NCT07308379","Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer",[],"2028-02","2026-02",1200,[6688,2411],"SCLC, Extensive Stage",[2411],{"intervention":62,"totalTrials":2086,"cells":6691},{"EARLY_PHASE1":6692,"PHASE1":6694,"PHASE2":6696,"PHASE3":6760,"PHASE4":6762,"NA":6764},{"trials":6693,"activeCount":101},[],{"trials":6695,"activeCount":101},[],{"trials":6697,"activeCount":676,"soonestReadout":61},[6698,6702,6706,6710,6714,6718,6722,6729,6740,6744,6748,6752,6756],{"nctId":131,"briefTitle":132,"status":121,"phases":6699,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":6700,"interventions":6701},[90],[139],[62,129,96],{"nctId":1547,"briefTitle":1548,"status":107,"phases":6703,"primaryCompletion":1550,"completion":1550,"start":1551,"enrollment":334,"conditions":6704,"interventions":6705},[90],[1553,1218,1554,18],[310,62],{"nctId":142,"briefTitle":143,"status":121,"phases":6707,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":6708,"interventions":6709},[90],[150],[62,129,96],{"nctId":59,"briefTitle":60,"status":121,"phases":6711,"primaryCompletion":61,"completion":179,"start":180,"enrollment":181,"conditions":6712,"interventions":6713},[90],[150],[62,96,129],{"nctId":1590,"briefTitle":1591,"status":270,"phases":6715,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":802,"conditions":6716,"interventions":6717},[90],[1131,113],[1133,62,310,310,310,310,1595,1595],{"nctId":218,"briefTitle":219,"status":121,"phases":6719,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":6720,"interventions":6721},[90],[225],[96,227,228,129,115,229,230,62],{"nctId":6723,"briefTitle":6724,"status":121,"phases":6725,"primaryCompletion":1318,"completion":801,"start":1965,"enrollment":3648,"conditions":6726,"interventions":6727},"NCT07403136","Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC",[90],[27],[6728,62],"Vebrekotuzumab",{"nctId":6730,"briefTitle":6731,"status":107,"phases":6732,"primaryCompletion":1609,"completion":1609,"start":6733,"enrollment":16,"conditions":6734,"interventions":6737},"NCT05468138","PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery",[90],"2022-08-25",[6735,6736,24,1221],"MSI-H","PD-1 Immunotherapy",[6738,6739,62],"SOX","XELOX",{"nctId":281,"briefTitle":282,"status":107,"phases":6741,"primaryCompletion":284,"completion":285,"start":286,"enrollment":97,"conditions":6742,"interventions":6743},[90],[139],[62,96,115],{"nctId":314,"briefTitle":315,"status":107,"phases":6745,"primaryCompletion":284,"completion":285,"start":286,"enrollment":97,"conditions":6746,"interventions":6747},[90],[139],[62,96,115],{"nctId":350,"briefTitle":351,"status":121,"phases":6749,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":6750,"interventions":6751},[90],[358],[62,96,360,228,129,115,361,229,230],{"nctId":363,"briefTitle":364,"status":365,"phases":6753,"primaryCompletion":51,"completion":367,"start":368,"enrollment":369,"conditions":6754,"interventions":6755},[90],[139],[62,96,129],{"nctId":415,"briefTitle":416,"status":121,"phases":6757,"primaryCompletion":235,"completion":418,"start":419,"enrollment":111,"conditions":6758,"interventions":6759},[90],[113],[62,96,129],{"trials":6761,"activeCount":101},[],{"trials":6763,"activeCount":101},[],{"trials":6765,"activeCount":101},[],{"intervention":115,"totalTrials":1623,"cells":6767},{"EARLY_PHASE1":6768,"PHASE1":6770,"PHASE2":6776,"PHASE3":6883,"PHASE4":6897,"NA":6899},{"trials":6769,"activeCount":101},[],{"trials":6771,"activeCount":101},[6772],{"nctId":105,"briefTitle":106,"status":107,"phases":6773,"primaryCompletion":109,"completion":110,"start":109,"enrollment":111,"conditions":6774,"interventions":6775},[89],[113],[115,96],{"trials":6777,"activeCount":637,"soonestReadout":353},[6778,6782,6789,6793,6801,6809,6813,6822,6826,6839,6843,6847,6851,6855,6859,6863,6867,6871,6875],{"nctId":2691,"briefTitle":2692,"status":107,"phases":6779,"primaryCompletion":2694,"completion":293,"start":295,"enrollment":2695,"conditions":6780,"interventions":6781},[90],[2697],[1386,115],{"nctId":6783,"briefTitle":6784,"status":107,"phases":6785,"primaryCompletion":1204,"completion":6786,"start":3165,"enrollment":213,"conditions":6787,"interventions":6788},"NCT02376452","Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients",[90],"2016-12",[6164],[361,115,227,1974],{"nctId":196,"briefTitle":197,"status":107,"phases":6790,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":6791,"interventions":6792},[90],[139],[205,96,115],{"nctId":6794,"briefTitle":6795,"status":107,"phases":6796,"primaryCompletion":1474,"completion":6797,"start":3137,"enrollment":296,"conditions":6798,"interventions":6799},"NCT04833036","c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI",[90],"2022-11",[18],[115,6800],"cetuximab",{"nctId":6802,"briefTitle":6803,"status":107,"phases":6804,"primaryCompletion":6805,"start":6806,"enrollment":356,"conditions":6807,"interventions":6808},"NCT02662959","Irinotecan as 3rd Line Therapy in Gastric Cancer",[90],"2018-05","2015-04",[577],[115],{"nctId":218,"briefTitle":219,"status":121,"phases":6810,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":6811,"interventions":6812},[90],[225],[96,227,228,129,115,229,230,62],{"nctId":6814,"briefTitle":6815,"status":121,"phases":6816,"primaryCompletion":6817,"completion":1609,"start":6818,"enrollment":3866,"conditions":6819,"interventions":6820},"NCT05229003","Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC",[90],"2025-05-31","2022-03-09",[6157],[1391,6821,115],"Penpulimab",{"nctId":1110,"briefTitle":1111,"status":1112,"phases":6823,"primaryCompletion":1114,"completion":1114,"start":600,"enrollment":1115,"conditions":6824,"interventions":6825},[90],[1117],[1119,129,1120,1121,115],{"nctId":6827,"briefTitle":6828,"status":107,"phases":6829,"primaryCompletion":6830,"completion":6831,"start":6832,"enrollment":97,"conditions":6833,"interventions":6836},"NCT03823079","Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia",[90],"2019-09-01","2020-02-01","2019-02-01",[6834,6835],"Recurrent Colorectal Carcinoma","Thrombopenia",[6837,1196,361,6838],"rhTPO","rhIL-11",{"nctId":3134,"briefTitle":3135,"status":107,"phases":6840,"primaryCompletion":426,"completion":426,"start":3137,"enrollment":2325,"conditions":6841,"interventions":6842},[90],[1419],[581,279,115],{"nctId":1123,"briefTitle":1124,"status":270,"phases":6844,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":6845,"interventions":6846},[90],[1131,113],[1133,278,1134,361,129,115],{"nctId":1153,"briefTitle":1154,"status":107,"phases":6848,"primaryCompletion":293,"completion":1156,"start":286,"enrollment":427,"conditions":6849,"interventions":6850},[90],[1158],[1151,129,115],{"nctId":1161,"briefTitle":1162,"status":107,"phases":6852,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":6853,"interventions":6854},[90],[18],[1170,128,361,129,115],{"nctId":281,"briefTitle":282,"status":107,"phases":6856,"primaryCompletion":284,"completion":285,"start":286,"enrollment":97,"conditions":6857,"interventions":6858},[90],[139],[62,96,115],{"nctId":314,"briefTitle":315,"status":107,"phases":6860,"primaryCompletion":284,"completion":285,"start":286,"enrollment":97,"conditions":6861,"interventions":6862},[90],[139],[62,96,115],{"nctId":1188,"briefTitle":1189,"status":270,"phases":6864,"primaryCompletion":235,"completion":963,"start":1191,"enrollment":1192,"conditions":6865,"interventions":6866},[90],[113],[1195,1196,129,1197,128],{"nctId":340,"briefTitle":341,"status":107,"phases":6868,"primaryCompletion":343,"completion":201,"start":344,"enrollment":345,"conditions":6869,"interventions":6870},[90],[139],[96,115,348],{"nctId":350,"briefTitle":351,"status":121,"phases":6872,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":6873,"interventions":6874},[90],[358],[62,96,360,228,129,115,361,229,230],{"nctId":6876,"briefTitle":6877,"status":365,"phases":6878,"primaryCompletion":1279,"completion":426,"start":6879,"enrollment":473,"conditions":6880,"interventions":6881},"NCT03797625","Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas",[90],"2017-05-04",[27],[115,6882,2962],"DDP",{"trials":6884,"activeCount":101},[6885,6889],{"nctId":482,"briefTitle":483,"status":365,"phases":6886,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":6887,"interventions":6888},[91],[139],[96,115,129],{"nctId":6890,"briefTitle":6891,"status":107,"phases":6892,"primaryCompletion":6893,"start":6894,"enrollment":5938,"conditions":6895,"interventions":6896},"NCT02935764","FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients",[91],"2019-10","2016-10",[6164],[115,227,1974],{"trials":6898,"activeCount":101},[],{"trials":6900,"activeCount":101},[],{"intervention":1377,"totalTrials":2189,"cells":6902},{"EARLY_PHASE1":6903,"PHASE1":6905,"PHASE2":6907,"PHASE3":6945,"PHASE4":6947,"NA":6949},{"trials":6904,"activeCount":101},[],{"trials":6906,"activeCount":101},[],{"trials":6908,"activeCount":637,"soonestReadout":2582},[6909,6913,6917,6921,6925,6929,6933,6937,6941],{"nctId":2310,"briefTitle":2311,"status":270,"phases":6910,"primaryCompletion":2313,"completion":784,"start":2314,"enrollment":2315,"conditions":6911,"interventions":6912},[90],[521],[2318,433,1377,413,2319],{"nctId":2321,"briefTitle":2322,"status":107,"phases":6914,"primaryCompletion":2324,"completion":1560,"start":1366,"enrollment":2325,"conditions":6915,"interventions":6916},[90],[33],[413,2328,1377,2329],{"nctId":3339,"briefTitle":3340,"status":107,"phases":6918,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":3345,"conditions":6919,"interventions":6920},[89,90],[15],[1377,433,1383,2358],{"nctId":1362,"briefTitle":1363,"status":121,"phases":6922,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":6923,"interventions":6924},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2704,"briefTitle":2705,"status":121,"phases":6926,"primaryCompletion":2582,"completion":2707,"start":2708,"enrollment":2709,"conditions":6927,"interventions":6928},[90],[2266],[1386,1377,2712],{"nctId":3170,"briefTitle":3171,"status":121,"phases":6930,"primaryCompletion":2582,"completion":2707,"start":2708,"enrollment":3173,"conditions":6931,"interventions":6932},[90],[2266],[581,1377,2712],{"nctId":2351,"briefTitle":2352,"status":107,"phases":6934,"primaryCompletion":367,"completion":367,"start":2354,"enrollment":2355,"conditions":6935,"interventions":6936},[89,90],[15],[1377,2358,1381,413],{"nctId":2732,"briefTitle":2733,"status":270,"phases":6938,"primaryCompletion":1760,"completion":2735,"start":2324,"enrollment":25,"conditions":6939,"interventions":6940},[90],[2737],[1386,1377],{"nctId":2270,"briefTitle":2271,"status":121,"phases":6942,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":6943,"interventions":6944},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":6946,"activeCount":101},[],{"trials":6948,"activeCount":101},[],{"trials":6950,"activeCount":101},[],{"intervention":300,"totalTrials":1651,"cells":6952},{"EARLY_PHASE1":6953,"PHASE1":6955,"PHASE2":6957,"PHASE3":7004,"PHASE4":7006,"NA":7008},{"trials":6954,"activeCount":101},[],{"trials":6956,"activeCount":101},[],{"trials":6958,"activeCount":637,"soonestReadout":825},[6959,6967,6977,6981,6985,6996,7000],{"nctId":6960,"briefTitle":6961,"status":121,"phases":6962,"primaryCompletion":6963,"completion":323,"start":6645,"enrollment":97,"conditions":6964,"interventions":6965},"NCT05954429","A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study",[90],"2026-12-28",[18],[6966,1170],"serplulimab",{"nctId":6968,"briefTitle":6969,"status":121,"phases":6970,"primaryCompletion":3646,"completion":6971,"start":6972,"enrollment":737,"conditions":6973,"interventions":6975},"NCT07604909","A Phase II Randomized Trial of Serplulimab With Second-Line Chemo\u002FTargeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy",[90],"2029-09-10","2026-05-10",[18,6974],"Relapse",[300,6976],"Second-Line Chemo\u002FTargeted Therapy",{"nctId":1569,"briefTitle":1570,"status":121,"phases":6978,"primaryCompletion":1572,"completion":1318,"start":1573,"enrollment":1574,"conditions":6979,"interventions":6980},[90],[1576,1218],[300,310,1578],{"nctId":1580,"briefTitle":1581,"status":121,"phases":6982,"primaryCompletion":825,"completion":1583,"start":1584,"enrollment":1585,"conditions":6983,"interventions":6984},[90],[24],[300,1588,310],{"nctId":6986,"briefTitle":6987,"status":270,"phases":6988,"primaryCompletion":6989,"completion":6990,"start":896,"enrollment":6991,"conditions":6992,"interventions":6995},"NCT07527520","Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR\u002FMSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial",[90],"2028-07","2031-06",165,[113,6993,300,6994],"Moderately Hypofractionated Radiotherapy","pMMR\u002FMSS",[300],{"nctId":290,"briefTitle":291,"status":107,"phases":6997,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":6998,"interventions":6999},[90],[298],[300,129,96],{"nctId":320,"briefTitle":321,"status":121,"phases":7001,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":7002,"interventions":7003},[90],[139,240],[129,96,329,300],{"trials":7005,"activeCount":101},[],{"trials":7007,"activeCount":101},[],{"trials":7009,"activeCount":101},[],{"intervention":6339,"totalTrials":1651,"cells":7011},{"EARLY_PHASE1":7012,"PHASE1":7014,"PHASE2":7024,"PHASE3":7064,"PHASE4":7066,"NA":7068},{"trials":7013,"activeCount":101},[],{"trials":7015,"activeCount":651,"soonestReadout":963},[7016],{"nctId":7017,"briefTitle":7018,"status":121,"phases":7019,"primaryCompletion":963,"completion":7020,"start":6054,"enrollment":3614,"conditions":7021,"interventions":7022},"NCT06331169","Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer",[89],"2027-06-30",[15],[1391,7023],"Trastuzumab deruxtecan",{"trials":7025,"activeCount":1729,"soonestReadout":7039},[7026,7035,7043,7047,7055],{"nctId":7027,"briefTitle":7028,"status":270,"phases":7029,"primaryCompletion":1126,"completion":645,"start":7030,"enrollment":7031,"conditions":7032,"interventions":7033},"NCT07152782","T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis",[90],"2025-11",202,[6336,521],[7034,6339],"Neratinib",{"nctId":7036,"briefTitle":7037,"status":270,"phases":7038,"primaryCompletion":7039,"completion":3420,"start":6261,"enrollment":7040,"conditions":7041,"interventions":7042},"NCT05953168","T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients",[90],"2024-08",69,[1518],[6339],{"nctId":6331,"briefTitle":6332,"status":270,"phases":7044,"primaryCompletion":2251,"completion":6334,"start":726,"enrollment":529,"conditions":7045,"interventions":7046},[90],[6336,6337],[230,6339],{"nctId":7048,"briefTitle":7049,"status":270,"phases":7050,"primaryCompletion":7051,"completion":1659,"start":7052,"enrollment":97,"conditions":7053,"interventions":7054},"NCT06797622","Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer",[90],"2027-01-15","2025-02-15",[15,33],[7023],{"nctId":7056,"briefTitle":7057,"status":270,"phases":7058,"primaryCompletion":2707,"completion":7059,"start":540,"enrollment":7060,"conditions":7061,"interventions":7062},"NCT07368543","Sequencing SG vs. T-DXd in HER2-Low\u002FTROP2-High Metastatic Breast Cancer",[90],"2028-12-01",216,[33],[7063,6339],"Sacituzumab Govitecan",{"trials":7065,"activeCount":101},[],{"trials":7067,"activeCount":101},[],{"trials":7069,"activeCount":101},[7070],{"nctId":7071,"briefTitle":7072,"status":107,"phases":7073,"primaryCompletion":1156,"completion":1156,"start":7074,"enrollment":1531,"conditions":7075,"interventions":7076},"NCT05594082","Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer",[],"2021-11-01",[15],[6339],{"intervention":1325,"totalTrials":1729,"cells":7078},{"EARLY_PHASE1":7079,"PHASE1":7081,"PHASE2":7083,"PHASE3":7111,"PHASE4":7113,"NA":7115},{"trials":7080,"activeCount":101},[],{"trials":7082,"activeCount":101},[],{"trials":7084,"activeCount":1729,"soonestReadout":3706},[7085,7089,7093,7103,7107],{"nctId":6436,"briefTitle":6437,"status":121,"phases":7086,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":7087,"interventions":7088},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"nctId":1315,"briefTitle":1316,"status":121,"phases":7090,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":16,"conditions":7091,"interventions":7092},[90],[1322],[1324,432,1325],{"nctId":7094,"briefTitle":7095,"status":121,"phases":7096,"primaryCompletion":7097,"completion":7098,"start":1802,"enrollment":7099,"conditions":7100,"interventions":7101},"NCT05970705","Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC",[90],"2025-07-04","2026-07-04",101,[6157],[1325,7102],"Trifluridine\u002FTipiracil",{"nctId":5979,"briefTitle":5980,"status":121,"phases":7104,"primaryCompletion":5982,"completion":5982,"start":5983,"enrollment":31,"conditions":7105,"interventions":7106},[90],[1554,2816],[278,1325,1494],{"nctId":6627,"briefTitle":6628,"status":121,"phases":7108,"primaryCompletion":3706,"completion":408,"start":3782,"enrollment":6630,"conditions":7109,"interventions":7110},[90],[5959],[1325,2411,1325],{"trials":7112,"activeCount":101},[],{"trials":7114,"activeCount":101},[],{"trials":7116,"activeCount":101},[],{"intervention":1379,"totalTrials":1729,"cells":7118},{"EARLY_PHASE1":7119,"PHASE1":7121,"PHASE2":7123,"PHASE3":7145,"PHASE4":7147,"NA":7149},{"trials":7120,"activeCount":101},[],{"trials":7122,"activeCount":101},[],{"trials":7124,"activeCount":1729,"soonestReadout":666},[7125,7129,7133,7137,7141],{"nctId":1362,"briefTitle":1363,"status":121,"phases":7126,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":7127,"interventions":7128},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2213,"briefTitle":2214,"status":121,"phases":7130,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":7131,"interventions":7132},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"nctId":6341,"briefTitle":6342,"status":121,"phases":7134,"primaryCompletion":666,"completion":6344,"start":6345,"enrollment":6346,"conditions":7135,"interventions":7136},[90],[15],[1379,230,6349],{"nctId":2228,"briefTitle":2229,"status":270,"phases":7138,"primaryCompletion":2231,"completion":2232,"start":2233,"enrollment":25,"conditions":7139,"interventions":7140},[90],[830],[1378,1467,52,1379],{"nctId":2425,"briefTitle":2426,"status":121,"phases":7142,"primaryCompletion":2428,"completion":1572,"start":2429,"enrollment":2430,"conditions":7143,"interventions":7144},[90],[15,452],[1379,461,253,463,464],{"trials":7146,"activeCount":101},[],{"trials":7148,"activeCount":101},[],{"trials":7150,"activeCount":101},[],{"intervention":1380,"totalTrials":1729,"cells":7152},{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7157,"PHASE3":7179,"PHASE4":7181,"NA":7183},{"trials":7154,"activeCount":101},[],{"trials":7156,"activeCount":101},[],{"trials":7158,"activeCount":1729,"soonestReadout":354},[7159,7163,7167,7171,7175],{"nctId":1362,"briefTitle":1363,"status":121,"phases":7160,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":7161,"interventions":7162},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2237,"briefTitle":2238,"status":505,"phases":7164,"primaryCompletion":783,"completion":783,"start":2240,"enrollment":2241,"conditions":7165,"interventions":7166},[90],[2243],[1378,2245,1380,1378],{"nctId":2821,"briefTitle":2822,"status":270,"phases":7168,"primaryCompletion":2824,"completion":1897,"start":1356,"enrollment":2825,"conditions":7169,"interventions":7170},[90],[2254,2827,2828],[1380,2764],{"nctId":2247,"briefTitle":2248,"status":121,"phases":7172,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":345,"conditions":7173,"interventions":7174},[90],[2254,33,1426,830,15],[1378,1380,2256,2223,455,413,1400],{"nctId":2270,"briefTitle":2271,"status":121,"phases":7176,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":7177,"interventions":7178},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":7180,"activeCount":101},[],{"trials":7182,"activeCount":101},[],{"trials":7184,"activeCount":101},[],{"intervention":1391,"totalTrials":1651,"cells":7186},{"EARLY_PHASE1":7187,"PHASE1":7189,"PHASE2":7195,"PHASE3":7225,"PHASE4":7227,"NA":7229},{"trials":7188,"activeCount":101},[],{"trials":7190,"activeCount":651,"soonestReadout":963},[7191],{"nctId":7017,"briefTitle":7018,"status":121,"phases":7192,"primaryCompletion":963,"completion":7020,"start":6054,"enrollment":3614,"conditions":7193,"interventions":7194},[89],[15],[1391,7023],{"trials":7196,"activeCount":1300,"soonestReadout":6817},[7197,7206,7213,7217,7221],{"nctId":7198,"briefTitle":7199,"status":107,"phases":7200,"primaryCompletion":7201,"completion":426,"start":2583,"enrollment":159,"conditions":7202,"interventions":7204},"NCT03841136","Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer",[90],"2019-12-01",[7203],"Extensive-stage Small Cell Lung Cancer",[7205],"anlotinib",{"nctId":7207,"briefTitle":7208,"status":107,"phases":7209,"primaryCompletion":248,"completion":199,"start":7210,"enrollment":2086,"conditions":7211,"interventions":7212},"NCT04309136","Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer",[90],"2019-06-01",[6616],[1391],{"nctId":1362,"briefTitle":1363,"status":121,"phases":7214,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":7215,"interventions":7216},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":6814,"briefTitle":6815,"status":121,"phases":7218,"primaryCompletion":6817,"completion":1609,"start":6818,"enrollment":3866,"conditions":7219,"interventions":7220},[90],[6157],[1391,6821,115],{"nctId":2103,"briefTitle":2104,"status":121,"phases":7222,"primaryCompletion":963,"completion":963,"start":2106,"enrollment":2107,"conditions":7223,"interventions":7224},[90],[2109],[2111,1384,1391],{"trials":7226,"activeCount":101},[],{"trials":7228,"activeCount":101},[],{"trials":7230,"activeCount":651,"soonestReadout":1965},[7231],{"nctId":7232,"briefTitle":7233,"status":121,"phases":7234,"primaryCompletion":1965,"completion":963,"start":7235,"enrollment":1167,"conditions":7236,"interventions":7238},"NCT06258642","Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC",[93],"2024-04-17",[7237],"Small Cell Lung Cancer Recurrent",[1973,1391],{"intervention":52,"totalTrials":637,"cells":7240},{"EARLY_PHASE1":7241,"PHASE1":7243,"PHASE2":7245,"PHASE3":7280,"PHASE4":7282,"NA":7284},{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[],{"trials":7246,"activeCount":2010,"soonestReadout":51},[7247,7251,7258,7262,7272,7276],{"nctId":49,"briefTitle":50,"status":121,"phases":7248,"primaryCompletion":51,"completion":1760,"start":1761,"enrollment":1701,"conditions":7249,"interventions":7250},[90],[27],[52,67,1764],{"nctId":7252,"briefTitle":7253,"status":3025,"phases":7254,"primaryCompletion":1760,"completion":6668,"start":2324,"enrollment":101,"conditions":7255,"interventions":7256},"NCT06572722","Perioperative Immunotherapy for NSCLC (ECTOP-1030)",[90],[3946],[7257,1536,52],"Atezolizumab",{"nctId":2228,"briefTitle":2229,"status":270,"phases":7259,"primaryCompletion":2231,"completion":2232,"start":2233,"enrollment":25,"conditions":7260,"interventions":7261},[90],[830],[1378,1467,52,1379],{"nctId":7263,"briefTitle":7264,"status":270,"phases":7265,"primaryCompletion":7266,"completion":7267,"start":7268,"enrollment":334,"conditions":7269,"interventions":7271},"NCT06814067","Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma",[90],"2029-02-10","2030-03-01","2025-02-10",[475,7270],"Head and Neck Squamous Cell Carcinoma HNSCC",[52,1393],{"nctId":6500,"briefTitle":6501,"status":270,"phases":7273,"primaryCompletion":2707,"completion":6503,"start":1560,"enrollment":6504,"conditions":7274,"interventions":7275},[90],[6506],[1468,52,6508],{"nctId":2987,"briefTitle":2988,"status":107,"phases":7277,"primaryCompletion":1724,"completion":1573,"start":2990,"enrollment":2991,"conditions":7278,"interventions":7279},[90],[250],[1764,1466,52,2994],{"trials":7281,"activeCount":101},[],{"trials":7283,"activeCount":101},[],{"trials":7285,"activeCount":101},[],{"intervention":1393,"totalTrials":2010,"cells":7287},{"EARLY_PHASE1":7288,"PHASE1":7290,"PHASE2":7292,"PHASE3":7321,"PHASE4":7323,"NA":7325},{"trials":7289,"activeCount":101},[],{"trials":7291,"activeCount":101},[],{"trials":7293,"activeCount":2010,"soonestReadout":305},[7294,7304,7308,7312],{"nctId":7295,"briefTitle":7296,"status":121,"phases":7297,"primaryCompletion":6247,"completion":236,"start":7298,"enrollment":7299,"conditions":7300,"interventions":7302},"NCT07394218","ctDNA-guided Treatment Decision-making",[90],"2025-12-24",122,[7301,309],"Metastatic Breast Cancer ( HER2 Negative)",[7303,1393],"ADC",{"nctId":1362,"briefTitle":1363,"status":121,"phases":7305,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":7306,"interventions":7307},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":7263,"briefTitle":7264,"status":270,"phases":7309,"primaryCompletion":7266,"completion":7267,"start":7268,"enrollment":334,"conditions":7310,"interventions":7311},[90],[475,7270],[52,1393],{"nctId":7313,"briefTitle":7314,"status":270,"phases":7315,"primaryCompletion":7316,"completion":7317,"start":2802,"enrollment":7318,"conditions":7319,"interventions":7320},"NCT06977542","Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer",[90],"2029-01","2032-01",53,[2125],[1393],{"trials":7322,"activeCount":101},[],{"trials":7324,"activeCount":101},[],{"trials":7326,"activeCount":101},[],{"intervention":1931,"totalTrials":2010,"cells":7328},{"EARLY_PHASE1":7329,"PHASE1":7331,"PHASE2":7333,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7330,"activeCount":101},[],{"trials":7332,"activeCount":101},[],{"trials":7334,"activeCount":2010,"soonestReadout":2441},[7335,7339,7343,7347],{"nctId":1923,"briefTitle":1924,"status":121,"phases":7336,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":19,"conditions":7337,"interventions":7338},[90],[30],[1931,1466,255,230],{"nctId":6465,"briefTitle":6466,"status":121,"phases":7340,"primaryCompletion":1318,"completion":1318,"start":5945,"enrollment":2204,"conditions":7341,"interventions":7342},[90],[6469],[1931,1468],{"nctId":2438,"briefTitle":2439,"status":121,"phases":7344,"primaryCompletion":2441,"completion":236,"start":2442,"enrollment":111,"conditions":7345,"interventions":7346},[90],[2125],[2284,1931,253],{"nctId":2614,"briefTitle":2615,"status":270,"phases":7348,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":690,"conditions":7349,"interventions":7350},[90],[1865,240,2621],[1931,2128,1868,1385,626],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[],{"trials":7356,"activeCount":101},[],{"intervention":312,"totalTrials":2010,"cells":7358},{"EARLY_PHASE1":7359,"PHASE1":7361,"PHASE2":7363,"PHASE3":7384,"PHASE4":7386,"NA":7388},{"trials":7360,"activeCount":101},[],{"trials":7362,"activeCount":101},[],{"trials":7364,"activeCount":2010,"soonestReadout":6269},[7365,7372,7376,7380],{"nctId":7366,"briefTitle":7367,"status":121,"phases":7368,"primaryCompletion":305,"completion":305,"start":448,"enrollment":213,"conditions":7369,"interventions":7370},"NCT07562490","A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer",[90],[309,310,18],[312,7371],"Folfox plus Bevacizumab",{"nctId":302,"briefTitle":303,"status":121,"phases":7373,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":7374,"interventions":7375},[90],[309,310,18],[96,312],{"nctId":6522,"briefTitle":6523,"status":270,"phases":7377,"primaryCompletion":871,"completion":871,"start":179,"enrollment":2264,"conditions":7378,"interventions":7379},[90],[6526],[6528,1468,1446,312],{"nctId":6266,"briefTitle":6267,"status":121,"phases":7381,"primaryCompletion":6269,"completion":6270,"start":5937,"enrollment":263,"conditions":7382,"interventions":7383},[90],[6272],[128,1468,312],{"trials":7385,"activeCount":101},[],{"trials":7387,"activeCount":101},[],{"trials":7389,"activeCount":101},[],{"intervention":2223,"totalTrials":2010,"cells":7391},{"EARLY_PHASE1":7392,"PHASE1":7394,"PHASE2":7396,"PHASE3":7414,"PHASE4":7416,"NA":7418},{"trials":7393,"activeCount":101},[],{"trials":7395,"activeCount":101},[],{"trials":7397,"activeCount":2010,"soonestReadout":354},[7398,7402,7406,7410],{"nctId":2213,"briefTitle":2214,"status":121,"phases":7399,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":7400,"interventions":7401},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"nctId":2247,"briefTitle":2248,"status":121,"phases":7403,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":345,"conditions":7404,"interventions":7405},[90],[2254,33,1426,830,15],[1378,1380,2256,2223,455,413,1400],{"nctId":2270,"briefTitle":2271,"status":121,"phases":7407,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":7408,"interventions":7409},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"nctId":2841,"briefTitle":2842,"status":270,"phases":7411,"primaryCompletion":1620,"completion":2735,"start":2844,"enrollment":2845,"conditions":7412,"interventions":7413},[90],[2254],[2223,2764],{"trials":7415,"activeCount":101},[],{"trials":7417,"activeCount":101},[],{"trials":7419,"activeCount":101},[],{"intervention":1995,"totalTrials":2010,"cells":7421},{"EARLY_PHASE1":7422,"PHASE1":7424,"PHASE2":7426,"PHASE3":7451,"PHASE4":7453,"NA":7455},{"trials":7423,"activeCount":101},[],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":2010,"soonestReadout":398},[7428,7432,7439,7443],{"nctId":3397,"briefTitle":3398,"status":270,"phases":7429,"primaryCompletion":600,"completion":1335,"start":147,"enrollment":31,"conditions":7430,"interventions":7431},[90],[1131],[458,1995],{"nctId":7433,"briefTitle":7434,"status":121,"phases":7435,"primaryCompletion":1319,"completion":2018,"start":3983,"enrollment":326,"conditions":7436,"interventions":7437},"NCT07154316","Phase II RCT of LCRT vs SCRT + CAPOX\u002FPD-1i\u002FCOX-2i in MSS Locally Advanced Rectal Cancer",[90],[18],[7438,1995,329],"CAPOX",{"nctId":1988,"briefTitle":1989,"status":121,"phases":7440,"primaryCompletion":398,"completion":750,"start":1991,"enrollment":1992,"conditions":7441,"interventions":7442},[90],[30],[1995,1466,255],{"nctId":7444,"briefTitle":7445,"status":270,"phases":7446,"primaryCompletion":7059,"completion":7447,"start":2814,"enrollment":1146,"conditions":7448,"interventions":7449},"NCT06999252","Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients",[90],"2029-06-01",[1131],[7450,1995],"Rimegepant",{"trials":7452,"activeCount":101},[],{"trials":7454,"activeCount":101},[],{"trials":7456,"activeCount":101},[],{"intervention":229,"totalTrials":2394,"cells":7458},{"EARLY_PHASE1":7459,"PHASE1":7461,"PHASE2":7463,"PHASE3":7515,"PHASE4":7525,"NA":7527},{"trials":7460,"activeCount":101},[],{"trials":7462,"activeCount":101},[],{"trials":7464,"activeCount":2010,"soonestReadout":353},[7465,7469,7473,7477,7485,7489,7496,7503,7507],{"nctId":6794,"briefTitle":6795,"status":107,"phases":7466,"primaryCompletion":1474,"completion":6797,"start":3137,"enrollment":296,"conditions":7467,"interventions":7468},[90],[18],[115,6800],{"nctId":218,"briefTitle":219,"status":121,"phases":7470,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":7471,"interventions":7472},[90],[225],[96,227,228,129,115,229,230,62],{"nctId":2514,"briefTitle":2515,"status":107,"phases":7474,"primaryCompletion":2517,"completion":2517,"start":2518,"enrollment":137,"conditions":7475,"interventions":7476},[90],[35],[229,1764,1092,1764],{"nctId":7478,"briefTitle":7479,"status":270,"phases":7480,"primaryCompletion":6503,"completion":7447,"start":1334,"enrollment":6587,"conditions":7481,"interventions":7483},"NCT07490119","Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer",[90],[7482],"RAS Wild Type mCRC",[7484,229],"Becotatug Vedotin",{"nctId":4099,"briefTitle":4100,"status":107,"phases":7486,"primaryCompletion":293,"completion":1609,"start":4102,"enrollment":345,"conditions":7487,"interventions":7488},[90],[4104],[229,230,77],{"nctId":7490,"briefTitle":7491,"status":365,"phases":7492,"primaryCompletion":6393,"completion":6393,"start":7493,"enrollment":1434,"conditions":7494,"interventions":7495},"NCT04508816","Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy",[90],"2016-01-01",[35],[6800],{"nctId":7497,"briefTitle":7498,"status":365,"phases":7499,"primaryCompletion":2957,"completion":2957,"start":7500,"enrollment":6576,"conditions":7501,"interventions":7502},"NCT00699881","Study of Cetuximab to Treat Gastric Cancer",[90],"2008-05",[24],[6800],{"nctId":350,"briefTitle":351,"status":121,"phases":7504,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":7505,"interventions":7506},[90],[358],[62,96,360,228,129,115,361,229,230],{"nctId":7508,"briefTitle":7509,"status":121,"phases":7510,"primaryCompletion":1529,"completion":1529,"start":7511,"enrollment":7512,"conditions":7513,"interventions":7514},"NCT06440902","Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA",[90],"2023-12-28",1100,[2816],[229],{"trials":7516,"activeCount":101},[7517,7521],{"nctId":6389,"briefTitle":6390,"status":107,"phases":7518,"primaryCompletion":6392,"completion":1366,"start":6393,"enrollment":6394,"conditions":7519,"interventions":7520},[91],[18,1554],[229,230,6397],{"nctId":1678,"briefTitle":1679,"status":107,"phases":7522,"primaryCompletion":1681,"completion":1682,"start":1683,"enrollment":97,"conditions":7523,"interventions":7524},[91],[18,1554,229],[229,310],{"trials":7526,"activeCount":101},[],{"trials":7528,"activeCount":101},[7529],{"nctId":7530,"briefTitle":7531,"status":107,"phases":7532,"primaryCompletion":1991,"completion":294,"start":2157,"enrollment":213,"conditions":7533,"interventions":7535},"NCT05873972","Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient",[93],[7534],"Colorectal Cancer Liver Metastases",[229],{"intervention":227,"totalTrials":1651,"cells":7537},{"EARLY_PHASE1":7538,"PHASE1":7540,"PHASE2":7542,"PHASE3":7560,"PHASE4":7574,"NA":7576},{"trials":7539,"activeCount":101},[],{"trials":7541,"activeCount":101},[],{"trials":7543,"activeCount":1300,"soonestReadout":1965},[7544,7548,7552,7556],{"nctId":6783,"briefTitle":6784,"status":107,"phases":7545,"primaryCompletion":1204,"completion":6786,"start":3165,"enrollment":213,"conditions":7546,"interventions":7547},[90],[6164],[361,115,227,1974],{"nctId":218,"briefTitle":219,"status":121,"phases":7549,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":7550,"interventions":7551},[90],[225],[96,227,228,129,115,229,230,62],{"nctId":1110,"briefTitle":1111,"status":1112,"phases":7553,"primaryCompletion":1114,"completion":1114,"start":600,"enrollment":1115,"conditions":7554,"interventions":7555},[90],[1117],[1119,129,1120,1121,115],{"nctId":1962,"briefTitle":1963,"status":270,"phases":7557,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":7558,"interventions":7559},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"trials":7561,"activeCount":101},[7562,7566,7570],{"nctId":1821,"briefTitle":1822,"status":365,"phases":7563,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":1827,"conditions":7564,"interventions":7565},[91],[1829],[67,1092,1385,626,227],{"nctId":6890,"briefTitle":6891,"status":107,"phases":7567,"primaryCompletion":6893,"start":6894,"enrollment":5938,"conditions":7568,"interventions":7569},[91],[6164],[115,227,1974],{"nctId":1885,"briefTitle":1886,"status":365,"phases":7571,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":7572,"interventions":7573},[91],[15],[67,1384,626,1385,227,1092],{"trials":7575,"activeCount":101},[],{"trials":7577,"activeCount":101},[],{"intervention":3072,"totalTrials":1300,"cells":7579},{"EARLY_PHASE1":7580,"PHASE1":7582,"PHASE2":7584,"PHASE3":7608,"PHASE4":7610,"NA":7612},{"trials":7581,"activeCount":101},[],{"trials":7583,"activeCount":101},[],{"trials":7585,"activeCount":1300,"soonestReadout":398},[7586,7598,7604],{"nctId":7587,"briefTitle":7588,"status":270,"phases":7589,"primaryCompletion":7590,"completion":7591,"start":2772,"enrollment":148,"conditions":7592,"interventions":7594},"NCT07503639","Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer",[90],"2028-04","2030-04",[7593],"Locally Advanced Colorectal Cancer",[3072,2838,6739,7595,7596,7597,2837],"PD-L1 antibody","cetuximab β","HRS-7058",{"nctId":7599,"briefTitle":7600,"status":270,"phases":7601,"primaryCompletion":398,"completion":897,"start":1356,"enrollment":1146,"conditions":7602,"interventions":7603},"NCT06679673","SHR-1701 Combined with SHR2554 and BP102 for MCRC",[90],[2816],[3072,2819,459],{"nctId":3064,"briefTitle":3065,"status":270,"phases":7605,"primaryCompletion":3067,"completion":3067,"start":1530,"enrollment":3068,"conditions":7606,"interventions":7607},[90],[3070],[3072,455],{"trials":7609,"activeCount":101},[],{"trials":7611,"activeCount":101},[],{"trials":7613,"activeCount":101},[],{"intervention":7484,"totalTrials":1300,"cells":7615},{"EARLY_PHASE1":7616,"PHASE1":7618,"PHASE2":7620,"PHASE3":7643,"PHASE4":7645,"NA":7647},{"trials":7617,"activeCount":101},[],{"trials":7619,"activeCount":101},[],{"trials":7621,"activeCount":1300,"soonestReadout":6503},[7622,7632,7639],{"nctId":7623,"briefTitle":7624,"status":270,"phases":7625,"primaryCompletion":236,"completion":236,"start":7626,"enrollment":7627,"conditions":7628,"interventions":7630},"NCT07394244","Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma",[90],"2026-01-09",38,[7629],"Cutaneous Squamous Cell Carcinoma (CSCC)",[7631,7484],"Pucotenlimab",{"nctId":7633,"briefTitle":7634,"status":270,"phases":7635,"primaryCompletion":872,"completion":872,"start":600,"enrollment":1146,"conditions":7636,"interventions":7638},"NCT07497919","A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer",[90],[7637],"Penile Cancer",[7484],{"nctId":7478,"briefTitle":7479,"status":270,"phases":7640,"primaryCompletion":6503,"completion":7447,"start":1334,"enrollment":6587,"conditions":7641,"interventions":7642},[90],[7482],[7484,229],{"trials":7644,"activeCount":101},[],{"trials":7646,"activeCount":101},[],{"trials":7648,"activeCount":101},[],{"intervention":1494,"totalTrials":1300,"cells":7650},{"EARLY_PHASE1":7651,"PHASE1":7653,"PHASE2":7655,"PHASE3":7669,"PHASE4":7671,"NA":7673},{"trials":7652,"activeCount":101},[],{"trials":7654,"activeCount":101},[],{"trials":7656,"activeCount":1300,"soonestReadout":1489},[7657,7661,7665],{"nctId":5979,"briefTitle":5980,"status":121,"phases":7658,"primaryCompletion":5982,"completion":5982,"start":5983,"enrollment":31,"conditions":7659,"interventions":7660},[90],[1554,2816],[278,1325,1494],{"nctId":6223,"briefTitle":6224,"status":121,"phases":7662,"primaryCompletion":6226,"completion":6226,"start":5983,"enrollment":31,"conditions":7663,"interventions":7664},[90],[6228],[128,6004,1494],{"nctId":1486,"briefTitle":1487,"status":121,"phases":7666,"primaryCompletion":1489,"completion":783,"start":1490,"enrollment":31,"conditions":7667,"interventions":7668},[90],[1492],[432,1494],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[],{"trials":7674,"activeCount":101},[],{"intervention":279,"totalTrials":2866,"cells":7676},{"EARLY_PHASE1":7677,"PHASE1":7679,"PHASE2":7681,"PHASE3":7727,"PHASE4":7733,"NA":7744},{"trials":7678,"activeCount":101},[],{"trials":7680,"activeCount":101},[],{"trials":7682,"activeCount":1300,"soonestReadout":272},[7683,7687,7695,7699,7703,7712,7716,7723],{"nctId":1083,"briefTitle":1084,"status":270,"phases":7684,"primaryCompletion":272,"completion":272,"start":1086,"enrollment":25,"conditions":7685,"interventions":7686},[90],[1088,1089,1090],[128,279,129,1092,67],{"nctId":7688,"briefTitle":7689,"status":365,"phases":7690,"primaryCompletion":7691,"completion":7691,"start":7692,"enrollment":2107,"conditions":7693,"interventions":7694},"NCT01831531","Study of S-1 in Combination With Radiotherapy in Esophageal Cancer",[90],"2018-10","2013-03",[27],[279],{"nctId":3134,"briefTitle":3135,"status":107,"phases":7696,"primaryCompletion":426,"completion":426,"start":3137,"enrollment":2325,"conditions":7697,"interventions":7698},[90],[1419],[581,279,115],{"nctId":268,"briefTitle":269,"status":270,"phases":7700,"primaryCompletion":272,"completion":273,"start":145,"enrollment":137,"conditions":7701,"interventions":7702},[90],[275,276],[278,230,129,96,279],{"nctId":7704,"briefTitle":7705,"status":365,"phases":7706,"primaryCompletion":7707,"completion":1346,"start":7708,"enrollment":7709,"conditions":7710,"interventions":7711},"NCT03668366","S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma",[90],"2018-12-01","2013-08-01",133,[35],[279],{"nctId":1172,"briefTitle":1173,"status":121,"phases":7713,"primaryCompletion":800,"completion":800,"start":1175,"enrollment":25,"conditions":7714,"interventions":7715},[90],[24],[1178,278,279,129],{"nctId":7717,"briefTitle":7718,"status":107,"phases":7719,"primaryCompletion":1288,"start":7720,"enrollment":25,"conditions":7721,"interventions":7722},"NCT02634502","Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis",[90],"2013-10",[1207],[279],{"nctId":423,"briefTitle":424,"status":107,"phases":7724,"primaryCompletion":293,"completion":85,"start":426,"enrollment":427,"conditions":7725,"interventions":7726},[90],[429,430],[432,433,96,129,67,279],{"trials":7728,"activeCount":101},[7729],{"nctId":1276,"briefTitle":1277,"status":107,"phases":7730,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":7731,"interventions":7732},[91],[24,577],[129,67,279],{"trials":7734,"activeCount":101},[7735],{"nctId":7736,"briefTitle":7737,"status":107,"phases":7738,"primaryCompletion":1213,"completion":7739,"start":964,"enrollment":737,"conditions":7740,"interventions":7742},"NCT04217096","Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \\ Advanced Pancreatic Cancer Patients",[92],"2023-03-31",[7741],"Advanced Pancreatic Cancer",[7743,279],"Paclitaxel liposome",{"trials":7745,"activeCount":101},[7746],{"nctId":663,"briefTitle":664,"status":107,"phases":7747,"primaryCompletion":260,"completion":666,"start":667,"enrollment":345,"conditions":7748,"interventions":7749},[],[669,670,671,672],[279,96],{"intervention":2358,"totalTrials":2866,"cells":7751},{"EARLY_PHASE1":7752,"PHASE1":7754,"PHASE2":7756,"PHASE3":7796,"PHASE4":7798,"NA":7800},{"trials":7753,"activeCount":101},[],{"trials":7755,"activeCount":101},[],{"trials":7757,"activeCount":771,"soonestReadout":1609},[7758,7764,7768,7772,7776,7780,7784,7788,7792],{"nctId":7759,"briefTitle":7760,"status":107,"phases":7761,"primaryCompletion":7210,"completion":1416,"start":3156,"enrollment":97,"conditions":7762,"interventions":7763},"NCT03202862","The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer",[90],[1882],[2358],{"nctId":2321,"briefTitle":2322,"status":107,"phases":7765,"primaryCompletion":2324,"completion":1560,"start":1366,"enrollment":2325,"conditions":7766,"interventions":7767},[90],[33],[413,2328,1377,2329],{"nctId":3470,"briefTitle":3471,"status":121,"phases":7769,"primaryCompletion":3420,"completion":3473,"start":1550,"enrollment":737,"conditions":7770,"interventions":7771},[90],[15],[3476,3477,2358,3478],{"nctId":3339,"briefTitle":3340,"status":107,"phases":7773,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":3345,"conditions":7774,"interventions":7775},[89,90],[15],[1377,433,1383,2358],{"nctId":2724,"briefTitle":2725,"status":270,"phases":7777,"primaryCompletion":1609,"completion":235,"start":2727,"enrollment":2728,"conditions":7778,"interventions":7779},[90],[15],[1386,458,2358,1119],{"nctId":4017,"briefTitle":4018,"status":3025,"phases":7781,"primaryCompletion":1204,"completion":4020,"start":4021,"enrollment":101,"conditions":7782,"interventions":7783},[90],[4023],[2358,2754],{"nctId":2351,"briefTitle":2352,"status":107,"phases":7785,"primaryCompletion":367,"completion":367,"start":2354,"enrollment":2355,"conditions":7786,"interventions":7787},[89,90],[15],[1377,2358,1381,413],{"nctId":2360,"briefTitle":2361,"status":107,"phases":7789,"primaryCompletion":2363,"completion":2364,"start":2365,"enrollment":828,"conditions":7790,"interventions":7791},[90],[2367,521],[2369,2370,2328,2329],{"nctId":2541,"briefTitle":2542,"status":365,"phases":7793,"primaryCompletion":2544,"completion":2544,"start":2545,"enrollment":1623,"conditions":7794,"interventions":7795},[90],[33],[1092,2358],{"trials":7797,"activeCount":101},[],{"trials":7799,"activeCount":101},[],{"trials":7801,"activeCount":651,"soonestReadout":749},[7802,7811],{"nctId":7803,"briefTitle":7804,"status":107,"phases":7805,"primaryCompletion":1202,"completion":7806,"start":7807,"enrollment":7808,"conditions":7809,"interventions":7810},"NCT02909361","Fulvestrant 500mg in Patients With Advanced Breast Cancer",[],"2022-10","2017-10-11",500,[33],[2358],{"nctId":7812,"briefTitle":7813,"status":121,"phases":7814,"primaryCompletion":749,"completion":896,"start":7815,"enrollment":3068,"conditions":7816,"interventions":7819},"NCT06856200","A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer",[93],"2025-02-28",[7817,7818],"Advanced HR - Positive, HER2 - Negative Breast Cancer","Resistant to (Neo)Adjuvant Endocrine Therapy",[7820,2369,2358],"Sirolimus",{"intervention":1170,"totalTrials":1499,"cells":7822},{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7827,"PHASE3":7886,"PHASE4":7888,"NA":7890},{"trials":7824,"activeCount":101},[],{"trials":7826,"activeCount":101},[],{"trials":7828,"activeCount":1300,"soonestReadout":398},[7829,7833,7837,7845,7849,7859,7867,7871,7879],{"nctId":6960,"briefTitle":6961,"status":121,"phases":7830,"primaryCompletion":6963,"completion":323,"start":6645,"enrollment":97,"conditions":7831,"interventions":7832},[90],[18],[6966,1170],{"nctId":6127,"briefTitle":6128,"status":121,"phases":7834,"primaryCompletion":398,"completion":6130,"start":295,"enrollment":31,"conditions":7835,"interventions":7836},[90],[18,6132],[6134,1170,128],{"nctId":7838,"briefTitle":7839,"status":107,"phases":7840,"primaryCompletion":1452,"completion":1165,"start":7841,"enrollment":2825,"conditions":7842,"interventions":7844},"NCT05257122","A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer",[90],"2022-02",[7843],"Advanced Pancreatic Carcinoma",[1170],{"nctId":6152,"briefTitle":6153,"status":107,"phases":7846,"primaryCompletion":285,"completion":293,"start":6155,"enrollment":1610,"conditions":7847,"interventions":7848},[90],[6157],[1170,128],{"nctId":7850,"briefTitle":7851,"status":107,"phases":7852,"primaryCompletion":7853,"completion":7854,"start":7855,"enrollment":6587,"conditions":7856,"interventions":7858},"NCT05142631","Fruquintinib in the Treatment of Soft Tissue Sarcoma",[90],"2023-05-30","2023-08-30","2021-11-21",[7857],"Soft Tissue Sarcoma",[1170],{"nctId":7860,"briefTitle":7861,"status":107,"phases":7862,"primaryCompletion":398,"completion":398,"start":1203,"enrollment":1610,"conditions":7863,"interventions":7864},"NCT05634590","The Efficacy and Safety of Fruquintinib Plus FOLFIRI\u002FFOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer",[90],[6157],[1170,7865,7866],"FOLFIRI","mFOLFOX6",{"nctId":1161,"briefTitle":1162,"status":107,"phases":7868,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":7869,"interventions":7870},[90],[18],[1170,128,361,129,115],{"nctId":7872,"briefTitle":7873,"status":107,"phases":7874,"primaryCompletion":486,"completion":56,"start":7875,"enrollment":2991,"conditions":7876,"interventions":7877},"NCT04582981","Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer",[90],"2020-09-28",[1576],[7878,1170],"Fruquintinib and raltitrexed",{"nctId":7880,"briefTitle":7881,"status":270,"phases":7882,"primaryCompletion":7020,"completion":6146,"start":2814,"enrollment":6346,"conditions":7883,"interventions":7884},"NCT06973421","Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer",[90],[6317],[7885,1170],"Utidelone",{"trials":7887,"activeCount":101},[],{"trials":7889,"activeCount":101},[],{"trials":7891,"activeCount":101},[7892],{"nctId":7893,"briefTitle":7894,"status":365,"phases":7895,"primaryCompletion":2133,"completion":7896,"start":190,"enrollment":7897,"conditions":7898,"interventions":7900},"NCT06202417","Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study",[],"2023-12-25",520,[18,7899,6157],"Refractory Colorectal Cancer",[1170],{"intervention":1150,"totalTrials":1729,"cells":7902},{"EARLY_PHASE1":7903,"PHASE1":7905,"PHASE2":7907,"PHASE3":7931,"PHASE4":7933,"NA":7935},{"trials":7904,"activeCount":101},[],{"trials":7906,"activeCount":101},[],{"trials":7908,"activeCount":1300,"soonestReadout":6054},[7909,7919,7923,7927],{"nctId":7910,"briefTitle":7911,"status":121,"phases":7912,"primaryCompletion":7913,"completion":7913,"start":7914,"enrollment":2825,"conditions":7915,"interventions":7917},"NCT05989425","Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer",[90],"2026-08-04","2023-08-04",[7916],"Differentiated Thyroid Cancer",[7918],"surufatinib",{"nctId":1140,"briefTitle":1141,"status":270,"phases":7920,"primaryCompletion":1143,"completion":1144,"start":1145,"enrollment":1146,"conditions":7921,"interventions":7922},[90],[24,1148],[1150,278,129,1151],{"nctId":6612,"briefTitle":6613,"status":107,"phases":7924,"primaryCompletion":284,"completion":1213,"start":6393,"enrollment":1499,"conditions":7925,"interventions":7926},[90],[6616],[1150,2411],{"nctId":6051,"briefTitle":6052,"status":121,"phases":7928,"primaryCompletion":6054,"completion":6055,"start":6056,"enrollment":473,"conditions":7929,"interventions":7930},[89,90],[6058],[1150,278],{"trials":7932,"activeCount":101},[],{"trials":7934,"activeCount":101},[],{"trials":7936,"activeCount":101},[7937],{"nctId":7938,"briefTitle":7939,"status":107,"phases":7940,"primaryCompletion":7941,"completion":1433,"start":7942,"enrollment":2695,"conditions":7943,"interventions":7945},"NCT06110650","A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma",[93],"2024-08-15","2023-11-28",[7944],"Soft Tissue Sarcoma Adult",[1150],{"intervention":2128,"totalTrials":1300,"cells":7947},{"EARLY_PHASE1":7948,"PHASE1":7950,"PHASE2":7952,"PHASE3":7962,"PHASE4":7964,"NA":7966},{"trials":7949,"activeCount":101},[],{"trials":7951,"activeCount":101},[],{"trials":7953,"activeCount":771,"soonestReadout":2617},[7954,7958],{"nctId":2117,"briefTitle":2118,"status":270,"phases":7955,"primaryCompletion":2120,"completion":2121,"start":2122,"enrollment":2123,"conditions":7956,"interventions":7957},[90],[1865,240,2125],[2127,2128,1384],{"nctId":2614,"briefTitle":2615,"status":270,"phases":7959,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":690,"conditions":7960,"interventions":7961},[90],[1865,240,2621],[1931,2128,1868,1385,626],{"trials":7963,"activeCount":101},[],{"trials":7965,"activeCount":101},[],{"trials":7967,"activeCount":651,"soonestReadout":3067},[7968],{"nctId":7969,"briefTitle":7970,"status":121,"phases":7971,"primaryCompletion":3067,"completion":1529,"start":1530,"enrollment":5832,"conditions":7972,"interventions":7974},"NCT07389876","Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G\u002FGEJ Adenocarcinoma",[],[24,7973],"Second-line Treatment",[7975,7976,7977,7978],"Albumin-bound Paclitaxel","Immune Checkpoint Inhibitor","Anti-angiogenic drug","Trastuzumab emtansine",{"intervention":1973,"totalTrials":1300,"cells":7980},{"EARLY_PHASE1":7981,"PHASE1":7983,"PHASE2":7985,"PHASE3":7995,"PHASE4":7997,"NA":7999},{"trials":7982,"activeCount":101},[],{"trials":7984,"activeCount":101},[],{"trials":7986,"activeCount":771,"soonestReadout":2802},[7987,7991],{"nctId":2799,"briefTitle":2800,"status":121,"phases":7988,"primaryCompletion":2802,"completion":398,"start":2803,"enrollment":2804,"conditions":7989,"interventions":7990},[90],[30],[2764,2807,2808,1120,1134],{"nctId":1962,"briefTitle":1963,"status":270,"phases":7992,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":7993,"interventions":7994},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"trials":7996,"activeCount":101},[],{"trials":7998,"activeCount":101},[],{"trials":8000,"activeCount":651,"soonestReadout":1965},[8001],{"nctId":7232,"briefTitle":7233,"status":121,"phases":8002,"primaryCompletion":1965,"completion":963,"start":7235,"enrollment":1167,"conditions":8003,"interventions":8004},[93],[7237],[1973,1391],{"intervention":1974,"totalTrials":2010,"cells":8006},{"EARLY_PHASE1":8007,"PHASE1":8009,"PHASE2":8011,"PHASE3":8025,"PHASE4":8031,"NA":8033},{"trials":8008,"activeCount":101},[],{"trials":8010,"activeCount":101},[],{"trials":8012,"activeCount":771,"soonestReadout":1965},[8013,8017,8021],{"nctId":6783,"briefTitle":6784,"status":107,"phases":8014,"primaryCompletion":1204,"completion":6786,"start":3165,"enrollment":213,"conditions":8015,"interventions":8016},[90],[6164],[361,115,227,1974],{"nctId":1962,"briefTitle":1963,"status":270,"phases":8018,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":8019,"interventions":8020},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"nctId":3861,"briefTitle":3862,"status":121,"phases":8022,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":8023,"interventions":8024},[90],[225],[3869,617,1974,3870,3871,230],{"trials":8026,"activeCount":101},[8027],{"nctId":6890,"briefTitle":6891,"status":107,"phases":8028,"primaryCompletion":6893,"start":6894,"enrollment":5938,"conditions":8029,"interventions":8030},[91],[6164],[115,227,1974],{"trials":8032,"activeCount":101},[],{"trials":8034,"activeCount":101},[],{"intervention":1868,"totalTrials":1300,"cells":8036},{"EARLY_PHASE1":8037,"PHASE1":8039,"PHASE2":8041,"PHASE3":8056,"PHASE4":8062,"NA":8064},{"trials":8038,"activeCount":101},[],{"trials":8040,"activeCount":101},[],{"trials":8042,"activeCount":771,"soonestReadout":2617},[8043,8052],{"nctId":8044,"briefTitle":8045,"status":121,"phases":8046,"primaryCompletion":8047,"completion":8048,"start":6733,"enrollment":473,"conditions":8049,"interventions":8050},"NCT05774275","The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma",[89,90],"2027-08-24","2029-08-24",[6058],[8051,1868,1615],"Pegylated Liposomal Doxorubicin",{"nctId":2614,"briefTitle":2615,"status":270,"phases":8053,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":690,"conditions":8054,"interventions":8055},[90],[1865,240,2621],[1931,2128,1868,1385,626],{"trials":8057,"activeCount":101},[8058],{"nctId":1857,"briefTitle":1858,"status":107,"phases":8059,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":8060,"interventions":8061},[91],[1865],[1867,1817,1092,67,1868],{"trials":8063,"activeCount":101},[],{"trials":8065,"activeCount":101},[],{"intervention":228,"totalTrials":1300,"cells":8067},{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8072,"PHASE3":8082,"PHASE4":8088,"NA":8090},{"trials":8069,"activeCount":101},[],{"trials":8071,"activeCount":101},[],{"trials":8073,"activeCount":771,"soonestReadout":353},[8074,8078],{"nctId":218,"briefTitle":219,"status":121,"phases":8075,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":8076,"interventions":8077},[90],[225],[96,227,228,129,115,229,230,62],{"nctId":350,"briefTitle":351,"status":121,"phases":8079,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":8080,"interventions":8081},[90],[358],[62,96,360,228,129,115,361,229,230],{"trials":8083,"activeCount":101},[8084],{"nctId":1285,"briefTitle":1286,"status":107,"phases":8085,"primaryCompletion":1288,"completion":1289,"start":211,"enrollment":1290,"conditions":8086,"interventions":8087},[91],[1292,1293,1294,1295],[1297,533,1298,228,1299],{"trials":8089,"activeCount":101},[],{"trials":8091,"activeCount":101},[],{"intervention":361,"totalTrials":637,"cells":8093},{"EARLY_PHASE1":8094,"PHASE1":8096,"PHASE2":8107,"PHASE3":8129,"PHASE4":8131,"NA":8133},{"trials":8095,"activeCount":101},[],{"trials":8097,"activeCount":101},[8098],{"nctId":8099,"briefTitle":8100,"status":365,"phases":8101,"primaryCompletion":8102,"completion":2844,"start":8103,"enrollment":25,"conditions":8104,"interventions":8106},"NCT04761185","Raltitrexed in HIPEC",[89],"2024-12-28","2020-09-18",[18,361,8105],"HIPEC",[361],{"trials":8108,"activeCount":771,"soonestReadout":353},[8109,8113,8117,8121,8125],{"nctId":6783,"briefTitle":6784,"status":107,"phases":8110,"primaryCompletion":1204,"completion":6786,"start":3165,"enrollment":213,"conditions":8111,"interventions":8112},[90],[6164],[361,115,227,1974],{"nctId":6827,"briefTitle":6828,"status":107,"phases":8114,"primaryCompletion":6830,"completion":6831,"start":6832,"enrollment":97,"conditions":8115,"interventions":8116},[90],[6834,6835],[6837,1196,361,6838],{"nctId":1123,"briefTitle":1124,"status":270,"phases":8118,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":8119,"interventions":8120},[90],[1131,113],[1133,278,1134,361,129,115],{"nctId":1161,"briefTitle":1162,"status":107,"phases":8122,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":8123,"interventions":8124},[90],[18],[1170,128,361,129,115],{"nctId":350,"briefTitle":351,"status":121,"phases":8126,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":8127,"interventions":8128},[90],[358],[62,96,360,228,129,115,361,229,230],{"trials":8130,"activeCount":101},[],{"trials":8132,"activeCount":101},[],{"trials":8134,"activeCount":101},[],{"intervention":1446,"totalTrials":1729,"cells":8136},{"EARLY_PHASE1":8137,"PHASE1":8139,"PHASE2":8149,"PHASE3":8163,"PHASE4":8165,"NA":8167},{"trials":8138,"activeCount":101},[],{"trials":8140,"activeCount":101},[8141,8145],{"nctId":6077,"briefTitle":6078,"status":107,"phases":8142,"primaryCompletion":6080,"completion":6080,"start":6081,"enrollment":31,"conditions":8143,"interventions":8144},[89],[6083],[1446,128],{"nctId":6093,"briefTitle":6094,"status":365,"phases":8146,"primaryCompletion":6096,"completion":6096,"start":6097,"enrollment":2204,"conditions":8147,"interventions":8148},[89],[6099],[1446,128,6004],{"trials":8150,"activeCount":771,"soonestReadout":871},[8151,8155,8159],{"nctId":6108,"briefTitle":6109,"status":107,"phases":8152,"primaryCompletion":1489,"completion":1489,"start":6111,"enrollment":31,"conditions":8153,"interventions":8154},[90],[6029],[1446,128,1468],{"nctId":1440,"briefTitle":1441,"status":270,"phases":8156,"primaryCompletion":1443,"completion":1443,"start":1335,"enrollment":25,"conditions":8157,"interventions":8158},[90],[30],[1446,432],{"nctId":6522,"briefTitle":6523,"status":270,"phases":8160,"primaryCompletion":871,"completion":871,"start":179,"enrollment":2264,"conditions":8161,"interventions":8162},[90],[6526],[6528,1468,1446,312],{"trials":8164,"activeCount":101},[],{"trials":8166,"activeCount":101},[],{"trials":8168,"activeCount":101},[],{"intervention":254,"totalTrials":2010,"cells":8170},{"EARLY_PHASE1":8171,"PHASE1":8173,"PHASE2":8175,"PHASE3":8193,"PHASE4":8195,"NA":8197},{"trials":8172,"activeCount":101},[],{"trials":8174,"activeCount":101},[],{"trials":8176,"activeCount":771,"soonestReadout":145},[8177,8181,8185,8189],{"nctId":6119,"briefTitle":6120,"status":107,"phases":8178,"primaryCompletion":199,"completion":2157,"start":6122,"enrollment":6123,"conditions":8179,"interventions":8180},[90],[250],[254,128],{"nctId":2403,"briefTitle":2404,"status":121,"phases":8182,"primaryCompletion":145,"completion":2406,"start":157,"enrollment":2264,"conditions":8183,"interventions":8184},[90],[2408],[2410,2411,254,253],{"nctId":244,"briefTitle":245,"status":107,"phases":8186,"primaryCompletion":247,"completion":247,"start":248,"enrollment":213,"conditions":8187,"interventions":8188},[90],[250],[252,253,254,176,255,96],{"nctId":1422,"briefTitle":1423,"status":270,"phases":8190,"primaryCompletion":1406,"completion":123,"start":1356,"enrollment":737,"conditions":8191,"interventions":8192},[90],[1426,33],[1428,432,254],{"trials":8194,"activeCount":101},[],{"trials":8196,"activeCount":101},[],{"trials":8198,"activeCount":101},[],{"intervention":1615,"totalTrials":1300,"cells":8200},{"EARLY_PHASE1":8201,"PHASE1":8203,"PHASE2":8205,"PHASE3":8219,"PHASE4":8221,"NA":8223},{"trials":8202,"activeCount":101},[],{"trials":8204,"activeCount":101},[],{"trials":8206,"activeCount":771,"soonestReadout":1609},[8207,8211,8215],{"nctId":8044,"briefTitle":8045,"status":121,"phases":8208,"primaryCompletion":8047,"completion":8048,"start":6733,"enrollment":473,"conditions":8209,"interventions":8210},[89,90],[6058],[8051,1868,1615],{"nctId":1605,"briefTitle":1606,"status":1607,"phases":8212,"primaryCompletion":1609,"completion":236,"start":1156,"enrollment":1610,"conditions":8213,"interventions":8214},[90],[1612,1613],[1615,310],{"nctId":1630,"briefTitle":1631,"status":121,"phases":8216,"primaryCompletion":1609,"completion":305,"start":1584,"enrollment":1633,"conditions":8217,"interventions":8218},[90],[1220,1635,1636,1637,452,1638,1639,430,1640],[1615,413,310],{"trials":8220,"activeCount":101},[],{"trials":8222,"activeCount":101},[],{"trials":8224,"activeCount":101},[],{"intervention":2838,"totalTrials":771,"cells":8226},{"EARLY_PHASE1":8227,"PHASE1":8229,"PHASE2":8231,"PHASE3":8241,"PHASE4":8243,"NA":8245},{"trials":8228,"activeCount":101},[],{"trials":8230,"activeCount":101},[],{"trials":8232,"activeCount":771,"soonestReadout":1406},[8233,8237],{"nctId":7587,"briefTitle":7588,"status":270,"phases":8234,"primaryCompletion":7590,"completion":7591,"start":2772,"enrollment":148,"conditions":8235,"interventions":8236},[90],[7593],[3072,2838,6739,7595,7596,7597,2837],{"nctId":2831,"briefTitle":2832,"status":121,"phases":8238,"primaryCompletion":1406,"completion":124,"start":2834,"enrollment":369,"conditions":8239,"interventions":8240},[89,90],[30],[2837,2764,2838,2839],{"trials":8242,"activeCount":101},[],{"trials":8244,"activeCount":101},[],{"trials":8246,"activeCount":101},[],{"intervention":2837,"totalTrials":771,"cells":8248},{"EARLY_PHASE1":8249,"PHASE1":8251,"PHASE2":8253,"PHASE3":8263,"PHASE4":8265,"NA":8267},{"trials":8250,"activeCount":101},[],{"trials":8252,"activeCount":101},[],{"trials":8254,"activeCount":771,"soonestReadout":1406},[8255,8259],{"nctId":7587,"briefTitle":7588,"status":270,"phases":8256,"primaryCompletion":7590,"completion":7591,"start":2772,"enrollment":148,"conditions":8257,"interventions":8258},[90],[7593],[3072,2838,6739,7595,7596,7597,2837],{"nctId":2831,"briefTitle":2832,"status":121,"phases":8260,"primaryCompletion":1406,"completion":124,"start":2834,"enrollment":369,"conditions":8261,"interventions":8262},[89,90],[30],[2837,2764,2838,2839],{"trials":8264,"activeCount":101},[],{"trials":8266,"activeCount":101},[],{"trials":8268,"activeCount":101},[],{"intervention":86,"totalTrials":771,"cells":8270},{"EARLY_PHASE1":8271,"PHASE1":8273,"PHASE2":8275,"PHASE3":8291,"PHASE4":8293,"NA":8295},{"trials":8272,"activeCount":101},[],{"trials":8274,"activeCount":101},[],{"trials":8276,"activeCount":771,"soonestReadout":85},[8277,8286],{"nctId":8278,"briefTitle":8279,"status":121,"phases":8280,"primaryCompletion":8281,"completion":8282,"start":6155,"enrollment":488,"conditions":8283,"interventions":8284},"NCT04383275","Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)",[90],"2025-05-15","2027-05-15",[15],[86,8285],"endocrine therapy and trastuzumab",{"nctId":83,"briefTitle":84,"status":270,"phases":8287,"primaryCompletion":85,"completion":235,"start":1801,"enrollment":488,"conditions":8288,"interventions":8289},[90],[15],[86,8290],"vinorelbine and trastuzumab",{"trials":8292,"activeCount":101},[],{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[],{"intervention":8298,"totalTrials":771,"cells":8299},"T-DXd",{"EARLY_PHASE1":8300,"PHASE1":8302,"PHASE2":8304,"PHASE3":8322,"PHASE4":8324,"NA":8326},{"trials":8301,"activeCount":101},[],{"trials":8303,"activeCount":101},[],{"trials":8305,"activeCount":771,"soonestReadout":726},[8306,8315],{"nctId":8307,"briefTitle":8308,"status":121,"phases":8309,"primaryCompletion":8310,"completion":2262,"start":8311,"enrollment":8312,"conditions":8313,"interventions":8314},"NCT07134153","Phase I\u002FII Study of Intrathecal\u002FOmmaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal\u002FBrain Metastases",[89,90],"2026-08-30","2025-04-18",139,[15],[8298],{"nctId":8316,"briefTitle":8317,"status":270,"phases":8318,"primaryCompletion":726,"completion":6334,"start":6204,"enrollment":575,"conditions":8319,"interventions":8320},"NCT06548178","T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer",[90],[521],[8298,8321],"THP",{"trials":8323,"activeCount":101},[],{"trials":8325,"activeCount":101},[],{"trials":8327,"activeCount":101},[],{"intervention":2818,"totalTrials":771,"cells":8329},{"EARLY_PHASE1":8330,"PHASE1":8332,"PHASE2":8334,"PHASE3":8349,"PHASE4":8351,"NA":8353},{"trials":8331,"activeCount":101},[],{"trials":8333,"activeCount":101},[],{"trials":8335,"activeCount":771,"soonestReadout":2813},[8336,8345],{"nctId":8337,"briefTitle":8338,"status":270,"phases":8339,"primaryCompletion":2735,"completion":323,"start":294,"enrollment":8340,"conditions":8341,"interventions":8343},"NCT06738745","Study of HRS-2189 Combined HRS-5041 in Prostate Cancer",[90],90,[8342],"Prostate Cancer Metastatic Disease",[2818,8344],"HRS-5041",{"nctId":2810,"briefTitle":2811,"status":270,"phases":8346,"primaryCompletion":2813,"completion":826,"start":2814,"enrollment":1146,"conditions":8347,"interventions":8348},[90],[2816],[2818,2764,2819],{"trials":8350,"activeCount":101},[],{"trials":8352,"activeCount":101},[],{"trials":8354,"activeCount":101},[],{"intervention":1578,"totalTrials":771,"cells":8356},{"EARLY_PHASE1":8357,"PHASE1":8359,"PHASE2":8361,"PHASE3":8371,"PHASE4":8373,"NA":8375},{"trials":8358,"activeCount":101},[],{"trials":8360,"activeCount":101},[],{"trials":8362,"activeCount":771,"soonestReadout":1572},[8363,8367],{"nctId":1569,"briefTitle":1570,"status":121,"phases":8364,"primaryCompletion":1572,"completion":1318,"start":1573,"enrollment":1574,"conditions":8365,"interventions":8366},[90],[1576,1218],[300,310,1578],{"nctId":1590,"briefTitle":1591,"status":270,"phases":8368,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":802,"conditions":8369,"interventions":8370},[90],[1131,113],[1133,62,310,310,310,310,1595,1595],{"trials":8372,"activeCount":101},[],{"trials":8374,"activeCount":101},[],{"trials":8376,"activeCount":101},[],{"intervention":1970,"totalTrials":771,"cells":8378},{"EARLY_PHASE1":8379,"PHASE1":8381,"PHASE2":8383,"PHASE3":8393,"PHASE4":8395,"NA":8397},{"trials":8380,"activeCount":101},[],{"trials":8382,"activeCount":101},[],{"trials":8384,"activeCount":771,"soonestReadout":1965},[8385,8389],{"nctId":6560,"briefTitle":6561,"status":121,"phases":8386,"primaryCompletion":235,"completion":963,"start":1991,"enrollment":334,"conditions":8387,"interventions":8388},[90],[6564],[1970,2411,6566,2281],{"nctId":1962,"briefTitle":1963,"status":270,"phases":8390,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":8391,"interventions":8392},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"trials":8394,"activeCount":101},[],{"trials":8396,"activeCount":101},[],{"trials":8398,"activeCount":101},[],{"intervention":1133,"totalTrials":771,"cells":8400},{"EARLY_PHASE1":8401,"PHASE1":8403,"PHASE2":8405,"PHASE3":8415,"PHASE4":8417,"NA":8419},{"trials":8402,"activeCount":101},[],{"trials":8404,"activeCount":101},[],{"trials":8406,"activeCount":771,"soonestReadout":1126},[8407,8411],{"nctId":1590,"briefTitle":1591,"status":270,"phases":8408,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":802,"conditions":8409,"interventions":8410},[90],[1131,113],[1133,62,310,310,310,310,1595,1595],{"nctId":1123,"briefTitle":1124,"status":270,"phases":8412,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":8413,"interventions":8414},[90],[1131,113],[1133,278,1134,361,129,115],{"trials":8416,"activeCount":101},[],{"trials":8418,"activeCount":101},[],{"trials":8420,"activeCount":101},[],{"intervention":1382,"totalTrials":771,"cells":8422},{"EARLY_PHASE1":8423,"PHASE1":8425,"PHASE2":8427,"PHASE3":8437,"PHASE4":8439,"NA":8441},{"trials":8424,"activeCount":101},[],{"trials":8426,"activeCount":101},[],{"trials":8428,"activeCount":771,"soonestReadout":354},[8429,8433],{"nctId":1362,"briefTitle":1363,"status":121,"phases":8430,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":8431,"interventions":8432},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2270,"briefTitle":2271,"status":121,"phases":8434,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":8435,"interventions":8436},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":8438,"activeCount":101},[],{"trials":8440,"activeCount":101},[],{"trials":8442,"activeCount":101},[],{"intervention":1400,"totalTrials":771,"cells":8444},{"EARLY_PHASE1":8445,"PHASE1":8447,"PHASE2":8449,"PHASE3":8459,"PHASE4":8461,"NA":8463},{"trials":8446,"activeCount":101},[],{"trials":8448,"activeCount":101},[],{"trials":8450,"activeCount":771,"soonestReadout":2250},[8451,8455],{"nctId":1362,"briefTitle":1363,"status":121,"phases":8452,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":8453,"interventions":8454},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"nctId":2247,"briefTitle":2248,"status":121,"phases":8456,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":345,"conditions":8457,"interventions":8458},[90],[2254,33,1426,830,15],[1378,1380,2256,2223,455,413,1400],{"trials":8460,"activeCount":101},[],{"trials":8462,"activeCount":101},[],{"trials":8464,"activeCount":101},[],{"intervention":1120,"totalTrials":771,"cells":8466},{"EARLY_PHASE1":8467,"PHASE1":8469,"PHASE2":8471,"PHASE3":8481,"PHASE4":8483,"NA":8485},{"trials":8468,"activeCount":101},[],{"trials":8470,"activeCount":101},[],{"trials":8472,"activeCount":771,"soonestReadout":2802},[8473,8477],{"nctId":1110,"briefTitle":1111,"status":1112,"phases":8474,"primaryCompletion":1114,"completion":1114,"start":600,"enrollment":1115,"conditions":8475,"interventions":8476},[90],[1117],[1119,129,1120,1121,115],{"nctId":2799,"briefTitle":2800,"status":121,"phases":8478,"primaryCompletion":2802,"completion":398,"start":2803,"enrollment":2804,"conditions":8479,"interventions":8480},[90],[30],[2764,2807,2808,1120,1134],{"trials":8482,"activeCount":101},[],{"trials":8484,"activeCount":101},[],{"trials":8486,"activeCount":101},[],{"intervention":477,"totalTrials":771,"cells":8488},{"EARLY_PHASE1":8489,"PHASE1":8491,"PHASE2":8493,"PHASE3":8507,"PHASE4":8509,"NA":8511},{"trials":8490,"activeCount":101},[],{"trials":8492,"activeCount":101},[],{"trials":8494,"activeCount":771,"soonestReadout":749},[8495,8503],{"nctId":8496,"briefTitle":8497,"status":505,"phases":8498,"primaryCompletion":749,"completion":1406,"start":1156,"enrollment":5881,"conditions":8499,"interventions":8502},"NCT06448910","Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC",[90],[8500,8501],"NSCLC","Locally Advanced Lung Carcinoma",[477],{"nctId":467,"briefTitle":468,"status":121,"phases":8504,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":8505,"interventions":8506},[90],[475],[477,96],{"trials":8508,"activeCount":101},[],{"trials":8510,"activeCount":101},[],{"trials":8512,"activeCount":101},[],{"intervention":2220,"totalTrials":771,"cells":8514},{"EARLY_PHASE1":8515,"PHASE1":8517,"PHASE2":8519,"PHASE3":8533,"PHASE4":8535,"NA":8537},{"trials":8516,"activeCount":101},[],{"trials":8518,"activeCount":101},[],{"trials":8520,"activeCount":771,"soonestReadout":716},[8521,8525],{"nctId":2213,"briefTitle":2214,"status":121,"phases":8522,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":8523,"interventions":8524},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"nctId":8526,"briefTitle":8527,"status":121,"phases":8528,"primaryCompletion":716,"completion":750,"start":5744,"enrollment":1499,"conditions":8529,"interventions":8531},"NCT06731140","Reverse HER2-negative Immune Resistant Breast Cancer",[90],[8530],"HER2 Negative Breast Cancer",[8532,2220],"Retinoic Acid",{"trials":8534,"activeCount":101},[],{"trials":8536,"activeCount":101},[],{"trials":8538,"activeCount":101},[],{"intervention":2819,"totalTrials":771,"cells":8540},{"EARLY_PHASE1":8541,"PHASE1":8543,"PHASE2":8545,"PHASE3":8555,"PHASE4":8557,"NA":8559},{"trials":8542,"activeCount":101},[],{"trials":8544,"activeCount":101},[],{"trials":8546,"activeCount":771,"soonestReadout":398},[8547,8551],{"nctId":7599,"briefTitle":7600,"status":270,"phases":8548,"primaryCompletion":398,"completion":897,"start":1356,"enrollment":1146,"conditions":8549,"interventions":8550},[90],[2816],[3072,2819,459],{"nctId":2810,"briefTitle":2811,"status":270,"phases":8552,"primaryCompletion":2813,"completion":826,"start":2814,"enrollment":1146,"conditions":8553,"interventions":8554},[90],[2816],[2818,2764,2819],{"trials":8556,"activeCount":101},[],{"trials":8558,"activeCount":101},[],{"trials":8560,"activeCount":101},[],{"intervention":2712,"totalTrials":771,"cells":8562},{"EARLY_PHASE1":8563,"PHASE1":8565,"PHASE2":8567,"PHASE3":8577,"PHASE4":8579,"NA":8581},{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[],{"trials":8568,"activeCount":771,"soonestReadout":2582},[8569,8573],{"nctId":2704,"briefTitle":2705,"status":121,"phases":8570,"primaryCompletion":2582,"completion":2707,"start":2708,"enrollment":2709,"conditions":8571,"interventions":8572},[90],[2266],[1386,1377,2712],{"nctId":3170,"briefTitle":3171,"status":121,"phases":8574,"primaryCompletion":2582,"completion":2707,"start":2708,"enrollment":3173,"conditions":8575,"interventions":8576},[90],[2266],[581,1377,2712],{"trials":8578,"activeCount":101},[],{"trials":8580,"activeCount":101},[],{"trials":8582,"activeCount":101},[],{"intervention":1467,"totalTrials":771,"cells":8584},{"EARLY_PHASE1":8585,"PHASE1":8587,"PHASE2":8589,"PHASE3":8599,"PHASE4":8601,"NA":8603},{"trials":8586,"activeCount":101},[],{"trials":8588,"activeCount":101},[],{"trials":8590,"activeCount":771,"soonestReadout":305},[8591,8595],{"nctId":2228,"briefTitle":2229,"status":270,"phases":8592,"primaryCompletion":2231,"completion":2232,"start":2233,"enrollment":25,"conditions":8593,"interventions":8594},[90],[830],[1378,1467,52,1379],{"nctId":1460,"briefTitle":1461,"status":270,"phases":8596,"primaryCompletion":305,"completion":236,"start":448,"enrollment":296,"conditions":8597,"interventions":8598},[90],[1464],[432,1466,1467,1468],{"trials":8600,"activeCount":101},[],{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[],{"intervention":329,"totalTrials":771,"cells":8606},{"EARLY_PHASE1":8607,"PHASE1":8609,"PHASE2":8611,"PHASE3":8621,"PHASE4":8623,"NA":8625},{"trials":8608,"activeCount":101},[],{"trials":8610,"activeCount":101},[],{"trials":8612,"activeCount":771,"soonestReadout":323},[8613,8617],{"nctId":320,"briefTitle":321,"status":121,"phases":8614,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":8615,"interventions":8616},[90],[139,240],[129,96,329,300],{"nctId":7433,"briefTitle":7434,"status":121,"phases":8618,"primaryCompletion":1319,"completion":2018,"start":3983,"enrollment":326,"conditions":8619,"interventions":8620},[90],[18],[7438,1995,329],{"trials":8622,"activeCount":101},[],{"trials":8624,"activeCount":101},[],{"trials":8626,"activeCount":101},[],{"intervention":2256,"totalTrials":771,"cells":8628},{"EARLY_PHASE1":8629,"PHASE1":8631,"PHASE2":8633,"PHASE3":8643,"PHASE4":8645,"NA":8647},{"trials":8630,"activeCount":101},[],{"trials":8632,"activeCount":101},[],{"trials":8634,"activeCount":771,"soonestReadout":354},[8635,8639],{"nctId":2247,"briefTitle":2248,"status":121,"phases":8636,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":345,"conditions":8637,"interventions":8638},[90],[2254,33,1426,830,15],[1378,1380,2256,2223,455,413,1400],{"nctId":2270,"briefTitle":2271,"status":121,"phases":8640,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":8641,"interventions":8642},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":8644,"activeCount":101},[],{"trials":8646,"activeCount":101},[],{"trials":8648,"activeCount":101},[],{"intervention":2281,"totalTrials":637,"cells":8650},{"EARLY_PHASE1":8651,"PHASE1":8653,"PHASE2":8655,"PHASE3":8687,"PHASE4":8689,"NA":8691},{"trials":8652,"activeCount":101},[],{"trials":8654,"activeCount":101},[],{"trials":8656,"activeCount":771,"soonestReadout":354},[8657,8661,8669,8675,8683],{"nctId":6560,"briefTitle":6561,"status":121,"phases":8658,"primaryCompletion":235,"completion":963,"start":1991,"enrollment":334,"conditions":8659,"interventions":8660},[90],[6564],[1970,2411,6566,2281],{"nctId":8662,"briefTitle":8663,"status":494,"phases":8664,"primaryCompletion":8665,"completion":8665,"start":3102,"enrollment":1729,"conditions":8666,"interventions":8667},"NCT00595985","Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer",[90],"2009-01",[24],[8668],"sorafenib",{"nctId":8670,"briefTitle":8671,"status":107,"phases":8672,"primaryCompletion":212,"completion":3113,"start":2957,"enrollment":25,"conditions":8673,"interventions":8674},"NCT00999843","Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer",[89,90],[21],[2281],{"nctId":8676,"briefTitle":8677,"status":107,"phases":8678,"primaryCompletion":8679,"completion":8679,"start":8680,"enrollment":6606,"conditions":8681,"interventions":8682},"NCT00839111","Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment",[90],"2010-11","2008-11",[1477],[8668,7865],{"nctId":2270,"briefTitle":2271,"status":121,"phases":8684,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":8685,"interventions":8686},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":8688,"activeCount":101},[],{"trials":8690,"activeCount":101},[],{"trials":8692,"activeCount":101},[8693],{"nctId":8694,"briefTitle":8695,"status":494,"phases":8696,"primaryCompletion":8697,"completion":8697,"start":528,"enrollment":473,"conditions":8698,"interventions":8699},"NCT02748304","Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma",[93],"2019-02-11",[21],[8668,8700],"aspirin",{"intervention":1299,"totalTrials":1729,"cells":8702},{"EARLY_PHASE1":8703,"PHASE1":8705,"PHASE2":8707,"PHASE3":8721,"PHASE4":8727,"NA":8729},{"trials":8704,"activeCount":101},[],{"trials":8706,"activeCount":101},[],{"trials":8708,"activeCount":771,"soonestReadout":2802},[8709,8713,8717],{"nctId":2799,"briefTitle":2800,"status":121,"phases":8710,"primaryCompletion":2802,"completion":398,"start":2803,"enrollment":2804,"conditions":8711,"interventions":8712},[90],[30],[2764,2807,2808,1120,1134],{"nctId":1123,"briefTitle":1124,"status":270,"phases":8714,"primaryCompletion":1126,"completion":1127,"start":1128,"enrollment":1129,"conditions":8715,"interventions":8716},[90],[1131,113],[1133,278,1134,361,129,115],{"nctId":2980,"briefTitle":2981,"status":107,"phases":8718,"primaryCompletion":388,"start":2983,"enrollment":1290,"conditions":8719,"interventions":8720},[90],[27],[2064,1299],{"trials":8722,"activeCount":101},[8723],{"nctId":1285,"briefTitle":1286,"status":107,"phases":8724,"primaryCompletion":1288,"completion":1289,"start":211,"enrollment":1290,"conditions":8725,"interventions":8726},[91],[1292,1293,1294,1295],[1297,533,1298,228,1299],{"trials":8728,"activeCount":101},[],{"trials":8730,"activeCount":101},[8731],{"nctId":8732,"briefTitle":8733,"status":365,"phases":8734,"primaryCompletion":8735,"completion":8736,"start":8737,"enrollment":8738,"conditions":8739,"interventions":8741},"NCT03532711","Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer",[],"2016-06-30","2016-12-31","2012-01-01",264,[6157,3250,8740],"Biomarker",[1299],{"intervention":2722,"totalTrials":2010,"cells":8743},{"EARLY_PHASE1":8744,"PHASE1":8746,"PHASE2":8748,"PHASE3":8768,"PHASE4":8770,"NA":8772},{"trials":8745,"activeCount":101},[],{"trials":8747,"activeCount":101},[],{"trials":8749,"activeCount":771,"soonestReadout":1609},[8750,8754,8764],{"nctId":2480,"briefTitle":2481,"status":270,"phases":8751,"primaryCompletion":1114,"completion":2017,"start":2069,"enrollment":2483,"conditions":8752,"interventions":8753},[90],[2485,2486,2487],[2489,1092,2490],{"nctId":8755,"briefTitle":8756,"status":270,"phases":8757,"primaryCompletion":1609,"completion":963,"start":447,"enrollment":8758,"conditions":8759,"interventions":8761},"NCT05717582","Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment",[90],47,[2485,8760],"Castration-Sensitive Prostate Cancer",[8762,8763],"apalutamide","androgen deprivation therapy",{"nctId":2714,"briefTitle":2715,"status":107,"phases":8765,"primaryCompletion":56,"completion":56,"start":368,"enrollment":181,"conditions":8766,"interventions":8767},[90],[2718,240],[2720,1386,2721,2722],{"trials":8769,"activeCount":101},[],{"trials":8771,"activeCount":101},[],{"trials":8773,"activeCount":101},[8774],{"nctId":8775,"briefTitle":8776,"status":107,"phases":8777,"primaryCompletion":6235,"completion":6235,"start":8778,"enrollment":25,"conditions":8779,"interventions":8782},"NCT05188911","Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial",[],"2020-07-15",[8780,2796,8781],"Prostate Cancer","Metastatic Disease",[8783,2721,2722],"Abiraterone",{"intervention":1535,"totalTrials":2010,"cells":8785},{"EARLY_PHASE1":8786,"PHASE1":8788,"PHASE2":8790,"PHASE3":8804,"PHASE4":8806,"NA":8808},{"trials":8787,"activeCount":101},[],{"trials":8789,"activeCount":101},[],{"trials":8791,"activeCount":651,"soonestReadout":3645},[8792,8796,8800],{"nctId":5876,"briefTitle":5877,"status":107,"phases":8793,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":5881,"conditions":8794,"interventions":8795},[90],[15],[5884,5885,5886],{"nctId":5919,"briefTitle":5920,"status":107,"phases":8797,"primaryCompletion":3613,"completion":447,"start":368,"enrollment":25,"conditions":8798,"interventions":8799},[89,90],[21],[278,1535],{"nctId":5933,"briefTitle":5934,"status":121,"phases":8801,"primaryCompletion":3645,"completion":5936,"start":5937,"enrollment":5938,"conditions":8802,"interventions":8803},[90],[1322],[278,1535],{"trials":8805,"activeCount":101},[],{"trials":8807,"activeCount":101},[],{"trials":8809,"activeCount":651,"soonestReadout":1529},[8810],{"nctId":1526,"briefTitle":1527,"status":121,"phases":8811,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":8812,"interventions":8813},[],[1533],[278,1535,432,1438,1536,1537],{"intervention":1536,"totalTrials":1300,"cells":8815},{"EARLY_PHASE1":8816,"PHASE1":8818,"PHASE2":8820,"PHASE3":8834,"PHASE4":8836,"NA":8838},{"trials":8817,"activeCount":101},[],{"trials":8819,"activeCount":101},[],{"trials":8821,"activeCount":651,"soonestReadout":2684},[8822,8826],{"nctId":7252,"briefTitle":7253,"status":3025,"phases":8823,"primaryCompletion":1760,"completion":6668,"start":2324,"enrollment":101,"conditions":8824,"interventions":8825},[90],[3946],[7257,1536,52],{"nctId":8827,"briefTitle":8828,"status":270,"phases":8829,"primaryCompletion":2684,"completion":8830,"start":5247,"enrollment":1585,"conditions":8831,"interventions":8833},"NCT07403877","Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H\u002FdMMR Locally Advanced Colorectal Cancer",[90],"2034-12-31",[8832],"Colorectal Cancer (MSI-H)",[1536,1537],{"trials":8835,"activeCount":101},[],{"trials":8837,"activeCount":101},[],{"trials":8839,"activeCount":651,"soonestReadout":1529},[8840],{"nctId":1526,"briefTitle":1527,"status":121,"phases":8841,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":8842,"interventions":8843},[],[1533],[278,1535,432,1438,1536,1537],{"intervention":7303,"totalTrials":771,"cells":8845},{"EARLY_PHASE1":8846,"PHASE1":8848,"PHASE2":8850,"PHASE3":8856,"PHASE4":8858,"NA":8860},{"trials":8847,"activeCount":101},[],{"trials":8849,"activeCount":101},[],{"trials":8851,"activeCount":651,"soonestReadout":6247},[8852],{"nctId":7295,"briefTitle":7296,"status":121,"phases":8853,"primaryCompletion":6247,"completion":236,"start":7298,"enrollment":7299,"conditions":8854,"interventions":8855},[90],[7301,309],[7303,1393],{"trials":8857,"activeCount":101},[],{"trials":8859,"activeCount":101},[],{"trials":8861,"activeCount":651,"soonestReadout":367},[8862],{"nctId":8863,"briefTitle":8864,"status":505,"phases":8865,"primaryCompletion":367,"completion":1573,"start":2354,"enrollment":213,"conditions":8866,"interventions":8867},"NCT05571618","The Rechallenge of ADCs in MBC Patients",[],[15],[7303],{"intervention":8869,"totalTrials":771,"cells":8870},"POLA-R-CHP",{"EARLY_PHASE1":8871,"PHASE1":8873,"PHASE2":8875,"PHASE3":8886,"PHASE4":8888,"NA":8890},{"trials":8872,"activeCount":101},[],{"trials":8874,"activeCount":101},[],{"trials":8876,"activeCount":651,"soonestReadout":123},[8877],{"nctId":8878,"briefTitle":8879,"status":121,"phases":8880,"primaryCompletion":123,"completion":8881,"start":8882,"enrollment":1146,"conditions":8883,"interventions":8885},"NCT06743945","POLA-R-CHP in the First-line Treatment of Transformed DLBCL",[90],"2029-12","2025-02-17",[8884],"Transformed Lymphoma",[8869],{"trials":8887,"activeCount":101},[],{"trials":8889,"activeCount":101},[],{"trials":8891,"activeCount":651,"soonestReadout":783},[8892],{"nctId":8893,"briefTitle":8894,"status":121,"phases":8895,"primaryCompletion":783,"completion":2017,"start":8896,"enrollment":1290,"conditions":8897,"interventions":8900},"NCT07070648","Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET",[],"2025-05-09",[8898,8899],"Diffuse Large B-Cell Lymphoma","DLBCL",[8869],{"intervention":1438,"totalTrials":771,"cells":8902},{"EARLY_PHASE1":8903,"PHASE1":8905,"PHASE2":8907,"PHASE3":8913,"PHASE4":8915,"NA":8917},{"trials":8904,"activeCount":101},[],{"trials":8906,"activeCount":101},[],{"trials":8908,"activeCount":651,"soonestReadout":1318},[8909],{"nctId":1430,"briefTitle":1431,"status":121,"phases":8910,"primaryCompletion":1318,"completion":1319,"start":1433,"enrollment":1434,"conditions":8911,"interventions":8912},[90],[1436],[432,1438],{"trials":8914,"activeCount":101},[],{"trials":8916,"activeCount":101},[],{"trials":8918,"activeCount":651,"soonestReadout":1529},[8919],{"nctId":1526,"briefTitle":1527,"status":121,"phases":8920,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":8921,"interventions":8922},[],[1533],[278,1535,432,1438,1536,1537],{"intervention":1537,"totalTrials":771,"cells":8924},{"EARLY_PHASE1":8925,"PHASE1":8927,"PHASE2":8929,"PHASE3":8935,"PHASE4":8937,"NA":8939},{"trials":8926,"activeCount":101},[],{"trials":8928,"activeCount":101},[],{"trials":8930,"activeCount":651,"soonestReadout":2684},[8931],{"nctId":8827,"briefTitle":8828,"status":270,"phases":8932,"primaryCompletion":2684,"completion":8830,"start":5247,"enrollment":1585,"conditions":8933,"interventions":8934},[90],[8832],[1536,1537],{"trials":8936,"activeCount":101},[],{"trials":8938,"activeCount":101},[],{"trials":8940,"activeCount":651,"soonestReadout":1529},[8941],{"nctId":1526,"briefTitle":1527,"status":121,"phases":8942,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":8943,"interventions":8944},[],[1533],[278,1535,432,1438,1536,1537],{"intervention":4192,"totalTrials":1729,"cells":8946},{"EARLY_PHASE1":8947,"PHASE1":8949,"PHASE2":8951,"PHASE3":8965,"PHASE4":8980,"NA":8982},{"trials":8948,"activeCount":101},[],{"trials":8950,"activeCount":101},[],{"trials":8952,"activeCount":651,"soonestReadout":6139},[8953,8957,8961],{"nctId":5867,"briefTitle":5868,"status":365,"phases":8954,"primaryCompletion":5870,"completion":5871,"start":5872,"enrollment":31,"conditions":8955,"interventions":8956},[90],[21],[278,4192],{"nctId":6136,"briefTitle":6137,"status":121,"phases":8958,"primaryCompletion":6139,"completion":6139,"start":5902,"enrollment":31,"conditions":8959,"interventions":8960},[90],[1492],[128,4192],{"nctId":5898,"briefTitle":5899,"status":365,"phases":8962,"primaryCompletion":5901,"completion":5901,"start":5902,"enrollment":2695,"conditions":8963,"interventions":8964},[90],[21],[278,4192],{"trials":8966,"activeCount":101},[8967,8971],{"nctId":4186,"briefTitle":4187,"status":107,"phases":8968,"primaryCompletion":110,"completion":4189,"start":2500,"enrollment":2709,"conditions":8969,"interventions":8970},[91],[21],[2076,4192],{"nctId":8972,"briefTitle":8973,"status":107,"phases":8974,"primaryCompletion":1288,"completion":8975,"start":1877,"enrollment":1205,"conditions":8976,"interventions":8978},"NCT03783559","TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)",[91],"2021-03",[8977],"Colorectal Adenocarcinoma Metastatic to the Liver",[4192,8979],"chemotherapy±target therapy",{"trials":8981,"activeCount":101},[],{"trials":8983,"activeCount":101},[],{"intervention":6739,"totalTrials":2010,"cells":8985},{"EARLY_PHASE1":8986,"PHASE1":8988,"PHASE2":8990,"PHASE3":9008,"PHASE4":9018,"NA":9020},{"trials":8987,"activeCount":101},[],{"trials":8989,"activeCount":101},[],{"trials":8991,"activeCount":651,"soonestReadout":7590},[8992,8996,9004],{"nctId":7587,"briefTitle":7588,"status":270,"phases":8993,"primaryCompletion":7590,"completion":7591,"start":2772,"enrollment":148,"conditions":8994,"interventions":8995},[90],[7593],[3072,2838,6739,7595,7596,7597,2837],{"nctId":8997,"briefTitle":8998,"status":107,"phases":8999,"primaryCompletion":496,"completion":496,"start":9000,"enrollment":369,"conditions":9001,"interventions":9003},"NCT02291744","A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients",[90],"2014-10",[9002],"Metastatic Colon Cancer",[6739],{"nctId":6730,"briefTitle":6731,"status":107,"phases":9005,"primaryCompletion":1609,"completion":1609,"start":6733,"enrollment":16,"conditions":9006,"interventions":9007},[90],[6735,6736,24,1221],[6738,6739,62],{"trials":9009,"activeCount":101},[9010],{"nctId":9011,"briefTitle":9012,"status":107,"phases":9013,"primaryCompletion":293,"completion":1609,"start":6605,"enrollment":9014,"conditions":9015,"interventions":9017},"NCT04416854","The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer",[91],627,[9002,9016],"Surgery",[6739,7866],{"trials":9019,"activeCount":101},[],{"trials":9021,"activeCount":101},[],{"intervention":3654,"totalTrials":771,"cells":9023},{"EARLY_PHASE1":9024,"PHASE1":9026,"PHASE2":9028,"PHASE3":9034,"PHASE4":9043,"NA":9045},{"trials":9025,"activeCount":101},[],{"trials":9027,"activeCount":101},[],{"trials":9029,"activeCount":651,"soonestReadout":3645},[9030],{"nctId":3642,"briefTitle":3643,"status":121,"phases":9031,"primaryCompletion":3645,"completion":3646,"start":3647,"enrollment":3648,"conditions":9032,"interventions":9033},[90],[3650],[3633,3652,3653,3654],{"trials":9035,"activeCount":101},[9036],{"nctId":9037,"briefTitle":9038,"status":494,"phases":9039,"primaryCompletion":354,"completion":354,"start":9040,"enrollment":2394,"conditions":9041,"interventions":9042},"NCT05454358","Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP",[90,91],"2022-08-02",[1854],[3654],{"trials":9044,"activeCount":101},[],{"trials":9046,"activeCount":101},[],{"intervention":3030,"totalTrials":771,"cells":9048},{"EARLY_PHASE1":9049,"PHASE1":9051,"PHASE2":9053,"PHASE3":9059,"PHASE4":9065,"NA":9067},{"trials":9050,"activeCount":101},[],{"trials":9052,"activeCount":101},[],{"trials":9054,"activeCount":651,"soonestReadout":2261},[9055],{"nctId":6312,"briefTitle":6313,"status":270,"phases":9056,"primaryCompletion":2261,"completion":323,"start":6315,"enrollment":22,"conditions":9057,"interventions":9058},[90],[6317,6318,6319],[3030,230,6321],{"trials":9060,"activeCount":101},[9061],{"nctId":3023,"briefTitle":3024,"status":3025,"phases":9062,"primaryCompletion":1356,"completion":897,"start":1724,"enrollment":101,"conditions":9063,"interventions":9064},[91],[3028],[1764,3030],{"trials":9066,"activeCount":101},[],{"trials":9068,"activeCount":101},[],{"intervention":9070,"totalTrials":771,"cells":9071},"Standard chemotherapy",{"EARLY_PHASE1":9072,"PHASE1":9074,"PHASE2":9076,"PHASE3":9087,"PHASE4":9097,"NA":9099},{"trials":9073,"activeCount":101},[],{"trials":9075,"activeCount":101},[],{"trials":9077,"activeCount":651,"soonestReadout":235},[9078],{"nctId":9079,"briefTitle":9080,"status":121,"phases":9081,"primaryCompletion":235,"completion":1114,"start":7815,"enrollment":9082,"conditions":9083,"interventions":9085},"NCT06856187","Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer",[90],119,[9084],"Metastatic Colorectal Cancer (CRC)",[9086,9070],"TAS-102+bevacizumab+local treatment",{"trials":9088,"activeCount":101},[9089],{"nctId":9090,"briefTitle":9091,"status":107,"phases":9092,"primaryCompletion":2157,"completion":9093,"start":9094,"enrollment":1290,"conditions":9095,"interventions":9096},"NCT03398291","Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy",[91],"2025-06-01","2018-07-01",[30,1554,9016],[9070],{"trials":9098,"activeCount":101},[],{"trials":9100,"activeCount":101},[],{"intervention":2111,"totalTrials":637,"cells":9102},{"EARLY_PHASE1":9103,"PHASE1":9105,"PHASE2":9107,"PHASE3":9142,"PHASE4":9144,"NA":9146},{"trials":9104,"activeCount":101},[],{"trials":9106,"activeCount":101},[],{"trials":9108,"activeCount":651,"soonestReadout":963},[9109,9113,9117,9126,9134,9138],{"nctId":2941,"briefTitle":2942,"status":365,"phases":9110,"primaryCompletion":2944,"completion":2945,"start":1204,"enrollment":334,"conditions":9111,"interventions":9112},[90],[2947],[2111,1764],{"nctId":2103,"briefTitle":2104,"status":121,"phases":9114,"primaryCompletion":963,"completion":963,"start":2106,"enrollment":2107,"conditions":9115,"interventions":9116},[90],[2109],[2111,1384,1391],{"nctId":9118,"briefTitle":9119,"status":107,"phases":9120,"primaryCompletion":2499,"start":1879,"enrollment":1610,"conditions":9121,"interventions":9123},"NCT01192243","Study of Gefitinib Compared With Pemetrexed\u002FCisplatin in Advanced Non-Small Cell Lung Cancer Patients",[90],[9122,2960],"Toxicity",[9124,2111,9125],"Gefitinib","Cisplatin or carboplatin",{"nctId":9127,"briefTitle":9128,"status":107,"phases":9129,"primaryCompletion":4189,"completion":9130,"start":2983,"enrollment":2825,"conditions":9131,"interventions":9133},"NCT01333696","Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck",[90],"2013-06",[9132],"Squamous Cell Carcinoma of Head and Neck",[2111],{"nctId":2522,"briefTitle":2523,"status":107,"phases":9135,"primaryCompletion":485,"completion":485,"start":388,"enrollment":334,"conditions":9136,"interventions":9137},[90],[2526],[57,2528,2529],{"nctId":2130,"briefTitle":2131,"status":107,"phases":9139,"primaryCompletion":426,"completion":2133,"start":2134,"enrollment":2135,"conditions":9140,"interventions":9141},[90],[2137,2138,2139],[2141,2111,1384],{"trials":9143,"activeCount":101},[],{"trials":9145,"activeCount":101},[],{"trials":9147,"activeCount":101},[],{"intervention":1151,"totalTrials":1300,"cells":9149},{"EARLY_PHASE1":9150,"PHASE1":9152,"PHASE2":9154,"PHASE3":9173,"PHASE4":9175,"NA":9177},{"trials":9151,"activeCount":101},[],{"trials":9153,"activeCount":101},[],{"trials":9155,"activeCount":651,"soonestReadout":1143},[9156,9165,9169],{"nctId":9157,"briefTitle":9158,"status":107,"phases":9159,"primaryCompletion":7853,"completion":9160,"start":9161,"enrollment":1499,"conditions":9162,"interventions":9163},"NCT05138159","A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen",[90],"2023-07-30","2021-12-01",[1419],[9164,1151],"Donafenib",{"nctId":1140,"briefTitle":1141,"status":270,"phases":9166,"primaryCompletion":1143,"completion":1144,"start":1145,"enrollment":1146,"conditions":9167,"interventions":9168},[90],[24,1148],[1150,278,129,1151],{"nctId":1153,"briefTitle":1154,"status":107,"phases":9170,"primaryCompletion":293,"completion":1156,"start":286,"enrollment":427,"conditions":9171,"interventions":9172},[90],[1158],[1151,129,115],{"trials":9174,"activeCount":101},[],{"trials":9176,"activeCount":101},[],{"trials":9178,"activeCount":101},[],{"intervention":9180,"totalTrials":1300,"cells":9181},"ARX788",{"EARLY_PHASE1":9182,"PHASE1":9184,"PHASE2":9186,"PHASE3":9210,"PHASE4":9212,"NA":9214},{"trials":9183,"activeCount":101},[],{"trials":9185,"activeCount":101},[],{"trials":9187,"activeCount":651,"soonestReadout":1620},[9188,9197,9203],{"nctId":9189,"briefTitle":9190,"status":107,"phases":9191,"primaryCompletion":260,"completion":1979,"start":9192,"enrollment":9193,"conditions":9194,"interventions":9196},"NCT05018676","ARX788 in Breast Cancer With Low Expression of HER2",[90],"2021-10-20",54,[9195],"Breast Cancer With Low Expression of HER2",[9180],{"nctId":9198,"briefTitle":9199,"status":270,"phases":9200,"primaryCompletion":1620,"completion":3511,"start":1407,"enrollment":3866,"conditions":9201,"interventions":9202},"NCT06578286","ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd",[90],[15],[9180],{"nctId":9204,"briefTitle":9205,"status":107,"phases":9206,"primaryCompletion":260,"completion":1979,"start":5902,"enrollment":2825,"conditions":9207,"interventions":9209},"NCT05018702","ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases",[90],[9208],"HER2-positive, Metastatic Breast Cancer",[9180],{"trials":9211,"activeCount":101},[],{"trials":9213,"activeCount":101},[],{"trials":9215,"activeCount":101},[],{"intervention":6014,"totalTrials":1300,"cells":9217},{"EARLY_PHASE1":9218,"PHASE1":9220,"PHASE2":9222,"PHASE3":9236,"PHASE4":9238,"NA":9240},{"trials":9219,"activeCount":101},[],{"trials":9221,"activeCount":101},[],{"trials":9223,"activeCount":651,"soonestReadout":6009},[9224,9228,9232],{"nctId":6231,"briefTitle":6232,"status":107,"phases":9225,"primaryCompletion":157,"completion":6234,"start":6235,"enrollment":31,"conditions":9226,"interventions":9227},[90],[6237],[128,1468,6014],{"nctId":5997,"briefTitle":5998,"status":365,"phases":9229,"primaryCompletion":6000,"completion":6000,"start":5946,"enrollment":28,"conditions":9230,"interventions":9231},[90],[1492],[6003,278,6004],{"nctId":6006,"briefTitle":6007,"status":121,"phases":9233,"primaryCompletion":6009,"completion":6009,"start":6010,"enrollment":31,"conditions":9234,"interventions":9235},[90],[6012],[278,1468,6014],{"trials":9237,"activeCount":101},[],{"trials":9239,"activeCount":101},[],{"trials":9241,"activeCount":101},[],{"intervention":8762,"totalTrials":771,"cells":9243},{"EARLY_PHASE1":9244,"PHASE1":9246,"PHASE2":9248,"PHASE3":9267,"PHASE4":9269,"NA":9271},{"trials":9245,"activeCount":101},[],{"trials":9247,"activeCount":101},[],{"trials":9249,"activeCount":651,"soonestReadout":1609},[9250,9254],{"nctId":8755,"briefTitle":8756,"status":270,"phases":9251,"primaryCompletion":1609,"completion":963,"start":447,"enrollment":8758,"conditions":9252,"interventions":9253},[90],[2485,8760],[8762,8763],{"nctId":9255,"briefTitle":9256,"status":107,"phases":9257,"primaryCompletion":1165,"completion":6204,"start":9258,"enrollment":345,"conditions":9259,"interventions":9260},"NCT05212857","Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer",[90],"2022-04",[8780],[9261,9262,9263,9264,2720,9265,9266],"Leuprolide acetate","Goserelin acetate","Triptorelin acetate","Degarelix acetate","Apalutamide","Enzalutamide",{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[],{"trials":9272,"activeCount":101},[],{"intervention":9274,"totalTrials":771,"cells":9275},"Taxane\u002FAnthracycline\u002FEribulin Mesylate\u002FVinorelbine\u002FCapecitabine\u002FCarboplatin\u002FUTD1\u002Fplatinum",{"EARLY_PHASE1":9276,"PHASE1":9278,"PHASE2":9280,"PHASE3":9299,"PHASE4":9301,"NA":9303},{"trials":9277,"activeCount":101},[],{"trials":9279,"activeCount":101},[],{"trials":9281,"activeCount":651,"soonestReadout":294},[9282,9290],{"nctId":9283,"briefTitle":9284,"status":365,"phases":9285,"primaryCompletion":367,"completion":367,"start":9286,"enrollment":1499,"conditions":9287,"interventions":9288},"NCT06355024","Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer",[90],"2024-05-11",[161],[9289,9274],"Inosine",{"nctId":9291,"briefTitle":9292,"status":121,"phases":9293,"primaryCompletion":294,"completion":9294,"start":71,"enrollment":1499,"conditions":9295,"interventions":9296},"NCT06355037","Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer",[90],"2025-01-31",[161],[9297,9298,9274],"Quercetin","Dasatinib",{"trials":9300,"activeCount":101},[],{"trials":9302,"activeCount":101},[],{"trials":9304,"activeCount":101},[],{"intervention":9306,"totalTrials":771,"cells":9307},"Zanubrutinib",{"EARLY_PHASE1":9308,"PHASE1":9310,"PHASE2":9312,"PHASE3":9335,"PHASE4":9337,"NA":9339},{"trials":9309,"activeCount":101},[],{"trials":9311,"activeCount":101},[],{"trials":9313,"activeCount":651,"soonestReadout":2824},[9314,9323],{"nctId":9315,"briefTitle":9316,"status":121,"phases":9317,"primaryCompletion":2824,"completion":2156,"start":9318,"enrollment":473,"conditions":9319,"interventions":9322},"NCT06341556","A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma",[90],"2024-05-24",[9320,9321],"Mantle Cell Lymphoma","Maintenance Therapy",[9306],{"nctId":9324,"briefTitle":9325,"status":107,"phases":9326,"primaryCompletion":9327,"completion":9328,"start":9329,"enrollment":9330,"conditions":9331,"interventions":9333},"NCT05290337","ZR-CHOP in DLBCL With Specific Gene Abnormality",[90],"2024-01-04","2026-01-04","2022-01-04",62,[9332],"Diffuse Large B Cell Lymphoma",[9334],"zanubrutinib",{"trials":9336,"activeCount":101},[],{"trials":9338,"activeCount":101},[],{"trials":9340,"activeCount":101},[],{"intervention":9342,"totalTrials":771,"cells":9343},"Furmonertinib",{"EARLY_PHASE1":9344,"PHASE1":9346,"PHASE2":9348,"PHASE3":9366,"PHASE4":9368,"NA":9370},{"trials":9345,"activeCount":101},[],{"trials":9347,"activeCount":101},[],{"trials":9349,"activeCount":651,"soonestReadout":470},[9350,9358],{"nctId":9351,"briefTitle":9352,"status":270,"phases":9353,"primaryCompletion":470,"completion":3740,"start":2582,"enrollment":1434,"conditions":9354,"interventions":9356},"NCT07193160","Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy",[90],[9355],"NSCLC (Non-small Cell Lung Cancer)",[9357,9342],"Sacituzumab Tirumotecan",{"nctId":9359,"briefTitle":9360,"status":107,"phases":9361,"primaryCompletion":293,"completion":294,"start":9362,"enrollment":9330,"conditions":9363,"interventions":9365},"NCT05255406","Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)",[90],"2021-12-09",[9364],"Non-Small-Cell Lung Cancer",[9342],{"trials":9367,"activeCount":101},[],{"trials":9369,"activeCount":101},[],{"trials":9371,"activeCount":101},[],{"intervention":459,"totalTrials":771,"cells":9373},{"EARLY_PHASE1":9374,"PHASE1":9376,"PHASE2":9378,"PHASE3":9388,"PHASE4":9390,"NA":9392},{"trials":9375,"activeCount":101},[],{"trials":9377,"activeCount":101},[],{"trials":9379,"activeCount":651,"soonestReadout":398},[9380,9384],{"nctId":7599,"briefTitle":7600,"status":270,"phases":9381,"primaryCompletion":398,"completion":897,"start":1356,"enrollment":1146,"conditions":9382,"interventions":9383},[90],[2816],[3072,2819,459],{"nctId":444,"briefTitle":445,"status":107,"phases":9385,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":9386,"interventions":9387},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":9389,"activeCount":101},[],{"trials":9391,"activeCount":101},[],{"trials":9393,"activeCount":101},[],{"intervention":6209,"totalTrials":771,"cells":9395},{"EARLY_PHASE1":9396,"PHASE1":9398,"PHASE2":9400,"PHASE3":9415,"PHASE4":9417,"NA":9419},{"trials":9397,"activeCount":101},[],{"trials":9399,"activeCount":101},[],{"trials":9401,"activeCount":651,"soonestReadout":6204},[9402,9411],{"nctId":9403,"briefTitle":9404,"status":365,"phases":9405,"primaryCompletion":9406,"completion":9407,"start":9408,"enrollment":159,"conditions":9409,"interventions":9410},"NCT00601159","Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC",[90],"2010-05","2010-09","2007-09",[33],[6209],{"nctId":6201,"briefTitle":6202,"status":121,"phases":9412,"primaryCompletion":6204,"completion":1356,"start":6205,"enrollment":25,"conditions":9413,"interventions":9414},[90],[6207],[128,6209],{"trials":9416,"activeCount":101},[],{"trials":9418,"activeCount":101},[],{"trials":9420,"activeCount":101},[],{"intervention":9422,"totalTrials":771,"cells":9423},"utidelone",{"EARLY_PHASE1":9424,"PHASE1":9426,"PHASE2":9428,"PHASE3":9442,"PHASE4":9444,"NA":9446},{"trials":9425,"activeCount":101},[],{"trials":9427,"activeCount":101},[],{"trials":9429,"activeCount":651,"soonestReadout":7020},[9430,9438],{"nctId":9431,"briefTitle":9432,"status":107,"phases":9433,"primaryCompletion":9434,"completion":3865,"start":3995,"enrollment":6576,"conditions":9435,"interventions":9437},"NCT05403333","Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer",[90],"2023-03-09",[1882,9436],"Locally Advanced or Metastatic Breast Cancer",[9422],{"nctId":7880,"briefTitle":7881,"status":270,"phases":9439,"primaryCompletion":7020,"completion":6146,"start":2814,"enrollment":6346,"conditions":9440,"interventions":9441},[90],[6317],[7885,1170],{"trials":9443,"activeCount":101},[],{"trials":9445,"activeCount":101},[],{"trials":9447,"activeCount":101},[],{"intervention":461,"totalTrials":771,"cells":9449},{"EARLY_PHASE1":9450,"PHASE1":9452,"PHASE2":9454,"PHASE3":9464,"PHASE4":9466,"NA":9468},{"trials":9451,"activeCount":101},[],{"trials":9453,"activeCount":101},[],{"trials":9455,"activeCount":651,"soonestReadout":2428},[9456,9460],{"nctId":2425,"briefTitle":2426,"status":121,"phases":9457,"primaryCompletion":2428,"completion":1572,"start":2429,"enrollment":2430,"conditions":9458,"interventions":9459},[90],[15,452],[1379,461,253,463,464],{"nctId":444,"briefTitle":445,"status":107,"phases":9461,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":9462,"interventions":9463},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":9465,"activeCount":101},[],{"trials":9467,"activeCount":101},[],{"trials":9469,"activeCount":101},[],{"intervention":463,"totalTrials":771,"cells":9471},{"EARLY_PHASE1":9472,"PHASE1":9474,"PHASE2":9476,"PHASE3":9486,"PHASE4":9488,"NA":9490},{"trials":9473,"activeCount":101},[],{"trials":9475,"activeCount":101},[],{"trials":9477,"activeCount":651,"soonestReadout":2428},[9478,9482],{"nctId":2425,"briefTitle":2426,"status":121,"phases":9479,"primaryCompletion":2428,"completion":1572,"start":2429,"enrollment":2430,"conditions":9480,"interventions":9481},[90],[15,452],[1379,461,253,463,464],{"nctId":444,"briefTitle":445,"status":107,"phases":9483,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":9484,"interventions":9485},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":9487,"activeCount":101},[],{"trials":9489,"activeCount":101},[],{"trials":9491,"activeCount":101},[],{"intervention":464,"totalTrials":771,"cells":9493},{"EARLY_PHASE1":9494,"PHASE1":9496,"PHASE2":9498,"PHASE3":9508,"PHASE4":9510,"NA":9512},{"trials":9495,"activeCount":101},[],{"trials":9497,"activeCount":101},[],{"trials":9499,"activeCount":651,"soonestReadout":2428},[9500,9504],{"nctId":2425,"briefTitle":2426,"status":121,"phases":9501,"primaryCompletion":2428,"completion":1572,"start":2429,"enrollment":2430,"conditions":9502,"interventions":9503},[90],[15,452],[1379,461,253,463,464],{"nctId":444,"briefTitle":445,"status":107,"phases":9505,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":9506,"interventions":9507},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":9509,"activeCount":101},[],{"trials":9511,"activeCount":101},[],{"trials":9513,"activeCount":101},[],{"intervention":9515,"totalTrials":771,"cells":9516},"Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab",{"EARLY_PHASE1":9517,"PHASE1":9519,"PHASE2":9521,"PHASE3":9538,"PHASE4":9540,"NA":9542},{"trials":9518,"activeCount":101},[],{"trials":9520,"activeCount":101},[],{"trials":9522,"activeCount":651,"soonestReadout":963},[9523,9531],{"nctId":9524,"briefTitle":9525,"status":107,"phases":9526,"primaryCompletion":1202,"completion":1202,"start":9527,"enrollment":1499,"conditions":9528,"interventions":9530},"NCT04979663","GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer",[89,90],"2020-12-01",[9529],"Biliary Tract Carcinoma",[9515],{"nctId":9532,"briefTitle":9533,"status":121,"phases":9534,"primaryCompletion":963,"completion":2216,"start":9535,"enrollment":356,"conditions":9536,"interventions":9537},"NCT05668884","GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma",[90],"2022-10-18",[9529],[9515],{"trials":9539,"activeCount":101},[],{"trials":9541,"activeCount":101},[],{"trials":9543,"activeCount":101},[],{"intervention":2689,"totalTrials":651,"cells":9545},{"EARLY_PHASE1":9546,"PHASE1":9548,"PHASE2":9550,"PHASE3":9556,"PHASE4":9558,"NA":9560},{"trials":9547,"activeCount":101},[],{"trials":9549,"activeCount":101},[],{"trials":9551,"activeCount":651,"soonestReadout":2684},[9552],{"nctId":2681,"briefTitle":2682,"status":270,"phases":9553,"primaryCompletion":2684,"completion":598,"start":2685,"enrollment":2686,"conditions":9554,"interventions":9555},[90],[15],[1386,2689],{"trials":9557,"activeCount":101},[],{"trials":9559,"activeCount":101},[],{"trials":9561,"activeCount":101},[],{"intervention":9563,"totalTrials":651,"cells":9564},"cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.",{"EARLY_PHASE1":9565,"PHASE1":9567,"PHASE2":9569,"PHASE3":9579,"PHASE4":9581,"NA":9583},{"trials":9566,"activeCount":101},[],{"trials":9568,"activeCount":101},[],{"trials":9570,"activeCount":651,"soonestReadout":871},[9571],{"nctId":9572,"briefTitle":9573,"status":121,"phases":9574,"primaryCompletion":871,"completion":1561,"start":9093,"enrollment":737,"conditions":9575,"interventions":9578},"NCT07003022","Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR\u002FMSI-H CRC",[90],[9576,9577],"Colo-rectal Cancer","MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers",[9563],{"trials":9580,"activeCount":101},[],{"trials":9582,"activeCount":101},[],{"trials":9584,"activeCount":101},[],{"intervention":9586,"totalTrials":651,"cells":9587},"Cnidium Monnieri Detoxification Formula",{"EARLY_PHASE1":9588,"PHASE1":9590,"PHASE2":9592,"PHASE3":9604,"PHASE4":9606,"NA":9608},{"trials":9589,"activeCount":101},[],{"trials":9591,"activeCount":101},[],{"trials":9593,"activeCount":651,"soonestReadout":9598},[9594],{"nctId":9595,"briefTitle":9596,"status":270,"phases":9597,"primaryCompletion":9598,"completion":9598,"start":353,"enrollment":9599,"conditions":9600,"interventions":9603},"NCT06705322","Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix.",[90],"2027-03-27",79,[9601,9602],"Human Papillomavirus (HPV) Infection","Cervical Cancer",[9586],{"trials":9605,"activeCount":101},[],{"trials":9607,"activeCount":101},[],{"trials":9609,"activeCount":101},[],{"intervention":2490,"totalTrials":651,"cells":9611},{"EARLY_PHASE1":9612,"PHASE1":9614,"PHASE2":9616,"PHASE3":9622,"PHASE4":9624,"NA":9626},{"trials":9613,"activeCount":101},[],{"trials":9615,"activeCount":101},[],{"trials":9617,"activeCount":651,"soonestReadout":1114},[9618],{"nctId":2480,"briefTitle":2481,"status":270,"phases":9619,"primaryCompletion":1114,"completion":2017,"start":2069,"enrollment":2483,"conditions":9620,"interventions":9621},[90],[2485,2486,2487],[2489,1092,2490],{"trials":9623,"activeCount":101},[],{"trials":9625,"activeCount":101},[],{"trials":9627,"activeCount":101},[],{"intervention":9629,"totalTrials":651,"cells":9630},"mFOLFIRINOX plus radiotherapy",{"EARLY_PHASE1":9631,"PHASE1":9633,"PHASE2":9635,"PHASE3":9644,"PHASE4":9646,"NA":9648},{"trials":9632,"activeCount":101},[],{"trials":9634,"activeCount":101},[],{"trials":9636,"activeCount":651,"soonestReadout":1926},[9637],{"nctId":9638,"briefTitle":9639,"status":121,"phases":9640,"primaryCompletion":1926,"completion":1927,"start":9641,"enrollment":25,"conditions":9642,"interventions":9643},"NCT06149689","mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer",[90],"2024-01-10",[2028],[9629],{"trials":9645,"activeCount":101},[],{"trials":9647,"activeCount":101},[],{"trials":9649,"activeCount":101},[],{"intervention":6444,"totalTrials":651,"cells":9651},{"EARLY_PHASE1":9652,"PHASE1":9654,"PHASE2":9656,"PHASE3":9662,"PHASE4":9664,"NA":9666},{"trials":9653,"activeCount":101},[],{"trials":9655,"activeCount":101},[],{"trials":9657,"activeCount":651,"soonestReadout":2232},[9658],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9659,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9660,"interventions":9661},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9663,"activeCount":101},[],{"trials":9665,"activeCount":101},[],{"trials":9667,"activeCount":101},[],{"intervention":6445,"totalTrials":651,"cells":9669},{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9674,"PHASE3":9680,"PHASE4":9682,"NA":9684},{"trials":9671,"activeCount":101},[],{"trials":9673,"activeCount":101},[],{"trials":9675,"activeCount":651,"soonestReadout":2232},[9676],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9677,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9678,"interventions":9679},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9681,"activeCount":101},[],{"trials":9683,"activeCount":101},[],{"trials":9685,"activeCount":101},[],{"intervention":6446,"totalTrials":651,"cells":9687},{"EARLY_PHASE1":9688,"PHASE1":9690,"PHASE2":9692,"PHASE3":9698,"PHASE4":9700,"NA":9702},{"trials":9689,"activeCount":101},[],{"trials":9691,"activeCount":101},[],{"trials":9693,"activeCount":651,"soonestReadout":2232},[9694],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9695,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9696,"interventions":9697},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9699,"activeCount":101},[],{"trials":9701,"activeCount":101},[],{"trials":9703,"activeCount":101},[],{"intervention":6447,"totalTrials":651,"cells":9705},{"EARLY_PHASE1":9706,"PHASE1":9708,"PHASE2":9710,"PHASE3":9716,"PHASE4":9718,"NA":9720},{"trials":9707,"activeCount":101},[],{"trials":9709,"activeCount":101},[],{"trials":9711,"activeCount":651,"soonestReadout":2232},[9712],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9713,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9714,"interventions":9715},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9717,"activeCount":101},[],{"trials":9719,"activeCount":101},[],{"trials":9721,"activeCount":101},[],{"intervention":6448,"totalTrials":651,"cells":9723},{"EARLY_PHASE1":9724,"PHASE1":9726,"PHASE2":9728,"PHASE3":9734,"PHASE4":9736,"NA":9738},{"trials":9725,"activeCount":101},[],{"trials":9727,"activeCount":101},[],{"trials":9729,"activeCount":651,"soonestReadout":2232},[9730],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9731,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9732,"interventions":9733},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9735,"activeCount":101},[],{"trials":9737,"activeCount":101},[],{"trials":9739,"activeCount":101},[],{"intervention":6449,"totalTrials":651,"cells":9741},{"EARLY_PHASE1":9742,"PHASE1":9744,"PHASE2":9746,"PHASE3":9752,"PHASE4":9754,"NA":9756},{"trials":9743,"activeCount":101},[],{"trials":9745,"activeCount":101},[],{"trials":9747,"activeCount":651,"soonestReadout":2232},[9748],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9749,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9750,"interventions":9751},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9753,"activeCount":101},[],{"trials":9755,"activeCount":101},[],{"trials":9757,"activeCount":101},[],{"intervention":6450,"totalTrials":651,"cells":9759},{"EARLY_PHASE1":9760,"PHASE1":9762,"PHASE2":9764,"PHASE3":9770,"PHASE4":9772,"NA":9774},{"trials":9761,"activeCount":101},[],{"trials":9763,"activeCount":101},[],{"trials":9765,"activeCount":651,"soonestReadout":2232},[9766],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9767,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9768,"interventions":9769},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9771,"activeCount":101},[],{"trials":9773,"activeCount":101},[],{"trials":9775,"activeCount":101},[],{"intervention":6451,"totalTrials":651,"cells":9777},{"EARLY_PHASE1":9778,"PHASE1":9780,"PHASE2":9782,"PHASE3":9788,"PHASE4":9790,"NA":9792},{"trials":9779,"activeCount":101},[],{"trials":9781,"activeCount":101},[],{"trials":9783,"activeCount":651,"soonestReadout":2232},[9784],{"nctId":6436,"briefTitle":6437,"status":121,"phases":9785,"primaryCompletion":2232,"completion":2232,"start":6439,"enrollment":6440,"conditions":9786,"interventions":9787},[90],[6442],[1468,1325,6444,6445,6446,6447,6448,6449,6450,6451],{"trials":9789,"activeCount":101},[],{"trials":9791,"activeCount":101},[],{"trials":9793,"activeCount":101},[],{"intervention":9795,"totalTrials":651,"cells":9796},"duloxetine",{"EARLY_PHASE1":9797,"PHASE1":9799,"PHASE2":9801,"PHASE3":9811,"PHASE4":9813,"NA":9815},{"trials":9798,"activeCount":101},[],{"trials":9800,"activeCount":101},[],{"trials":9802,"activeCount":651,"soonestReadout":1489},[9803],{"nctId":9804,"briefTitle":9805,"status":121,"phases":9806,"primaryCompletion":1489,"completion":1489,"start":9807,"enrollment":828,"conditions":9808,"interventions":9810},"NCT06551051","ADC-induced Neurotoxicity Treated With Duloxetine",[90],"2024-08-06",[9809],"Solid Tumour",[9795],{"trials":9812,"activeCount":101},[],{"trials":9814,"activeCount":101},[],{"trials":9816,"activeCount":101},[],{"intervention":9818,"totalTrials":651,"cells":9819},"Nimotuzumab+Adebrelimab+Chemotherapy",{"EARLY_PHASE1":9820,"PHASE1":9822,"PHASE2":9824,"PHASE3":9835,"PHASE4":9837,"NA":9839},{"trials":9821,"activeCount":101},[],{"trials":9823,"activeCount":101},[],{"trials":9825,"activeCount":651,"soonestReadout":9830},[9826],{"nctId":9827,"briefTitle":9828,"status":121,"phases":9829,"primaryCompletion":9830,"completion":9831,"start":9832,"enrollment":1610,"conditions":9833,"interventions":9834},"NCT07105592","A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma",[89,90],"2027-05-31","2029-05-31","2025-05-13",[475],[9818],{"trials":9836,"activeCount":101},[],{"trials":9838,"activeCount":101},[],{"trials":9840,"activeCount":101},[],{"intervention":9842,"totalTrials":651,"cells":9843},"Anlotinib and Benmelstobart",{"EARLY_PHASE1":9844,"PHASE1":9846,"PHASE2":9848,"PHASE3":9857,"PHASE4":9859,"NA":9861},{"trials":9845,"activeCount":101},[],{"trials":9847,"activeCount":101},[],{"trials":9849,"activeCount":651,"soonestReadout":2291},[9850],{"nctId":9851,"briefTitle":9852,"status":270,"phases":9853,"primaryCompletion":2291,"completion":3830,"start":145,"enrollment":9854,"conditions":9855,"interventions":9856},"NCT07193186","Anlotinib and Benmelstobart in DTC",[90],23,[6616],[9842],{"trials":9858,"activeCount":101},[],{"trials":9860,"activeCount":101},[],{"trials":9862,"activeCount":101},[],{"intervention":1324,"totalTrials":651,"cells":9864},{"EARLY_PHASE1":9865,"PHASE1":9867,"PHASE2":9869,"PHASE3":9875,"PHASE4":9877,"NA":9879},{"trials":9866,"activeCount":101},[],{"trials":9868,"activeCount":101},[],{"trials":9870,"activeCount":651,"soonestReadout":1318},[9871],{"nctId":1315,"briefTitle":1316,"status":121,"phases":9872,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":16,"conditions":9873,"interventions":9874},[90],[1322],[1324,432,1325],{"trials":9876,"activeCount":101},[],{"trials":9878,"activeCount":101},[],{"trials":9880,"activeCount":101},[],{"intervention":1567,"totalTrials":651,"cells":9882},{"EARLY_PHASE1":9883,"PHASE1":9885,"PHASE2":9887,"PHASE3":9893,"PHASE4":9895,"NA":9897},{"trials":9884,"activeCount":101},[],{"trials":9886,"activeCount":101},[],{"trials":9888,"activeCount":651,"soonestReadout":1560},[9889],{"nctId":1557,"briefTitle":1558,"status":121,"phases":9890,"primaryCompletion":1560,"completion":1561,"start":1562,"enrollment":737,"conditions":9891,"interventions":9892},[90],[18,1564,1565],[1567,310],{"trials":9894,"activeCount":101},[],{"trials":9896,"activeCount":101},[],{"trials":9898,"activeCount":101},[],{"intervention":7034,"totalTrials":651,"cells":9900},{"EARLY_PHASE1":9901,"PHASE1":9903,"PHASE2":9905,"PHASE3":9911,"PHASE4":9913,"NA":9915},{"trials":9902,"activeCount":101},[],{"trials":9904,"activeCount":101},[],{"trials":9906,"activeCount":651,"soonestReadout":1126},[9907],{"nctId":7027,"briefTitle":7028,"status":270,"phases":9908,"primaryCompletion":1126,"completion":645,"start":7030,"enrollment":7031,"conditions":9909,"interventions":9910},[90],[6336,521],[7034,6339],{"trials":9912,"activeCount":101},[],{"trials":9914,"activeCount":101},[],{"trials":9916,"activeCount":101},[],{"intervention":7595,"totalTrials":651,"cells":9918},{"EARLY_PHASE1":9919,"PHASE1":9921,"PHASE2":9923,"PHASE3":9929,"PHASE4":9931,"NA":9933},{"trials":9920,"activeCount":101},[],{"trials":9922,"activeCount":101},[],{"trials":9924,"activeCount":651,"soonestReadout":7590},[9925],{"nctId":7587,"briefTitle":7588,"status":270,"phases":9926,"primaryCompletion":7590,"completion":7591,"start":2772,"enrollment":148,"conditions":9927,"interventions":9928},[90],[7593],[3072,2838,6739,7595,7596,7597,2837],{"trials":9930,"activeCount":101},[],{"trials":9932,"activeCount":101},[],{"trials":9934,"activeCount":101},[],{"intervention":7596,"totalTrials":651,"cells":9936},{"EARLY_PHASE1":9937,"PHASE1":9939,"PHASE2":9941,"PHASE3":9947,"PHASE4":9949,"NA":9951},{"trials":9938,"activeCount":101},[],{"trials":9940,"activeCount":101},[],{"trials":9942,"activeCount":651,"soonestReadout":7590},[9943],{"nctId":7587,"briefTitle":7588,"status":270,"phases":9944,"primaryCompletion":7590,"completion":7591,"start":2772,"enrollment":148,"conditions":9945,"interventions":9946},[90],[7593],[3072,2838,6739,7595,7596,7597,2837],{"trials":9948,"activeCount":101},[],{"trials":9950,"activeCount":101},[],{"trials":9952,"activeCount":101},[],{"intervention":7597,"totalTrials":651,"cells":9954},{"EARLY_PHASE1":9955,"PHASE1":9957,"PHASE2":9959,"PHASE3":9965,"PHASE4":9967,"NA":9969},{"trials":9956,"activeCount":101},[],{"trials":9958,"activeCount":101},[],{"trials":9960,"activeCount":651,"soonestReadout":7590},[9961],{"nctId":7587,"briefTitle":7588,"status":270,"phases":9962,"primaryCompletion":7590,"completion":7591,"start":2772,"enrollment":148,"conditions":9963,"interventions":9964},[90],[7593],[3072,2838,6739,7595,7596,7597,2837],{"trials":9966,"activeCount":101},[],{"trials":9968,"activeCount":101},[],{"trials":9970,"activeCount":101},[],{"intervention":9972,"totalTrials":651,"cells":9973},"Adjuvant therapy",{"EARLY_PHASE1":9974,"PHASE1":9976,"PHASE2":9978,"PHASE3":9988,"PHASE4":9990,"NA":9992},{"trials":9975,"activeCount":101},[],{"trials":9977,"activeCount":101},[],{"trials":9979,"activeCount":651,"soonestReadout":2250},[9980],{"nctId":9981,"briefTitle":9982,"status":121,"phases":9983,"primaryCompletion":2250,"completion":8881,"start":9984,"enrollment":690,"conditions":9985,"interventions":9987},"NCT07067268","Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy",[90],"2024-09-14",[9986],"Nasopharyngeal Cancinoma (NPC)",[9972],{"trials":9989,"activeCount":101},[],{"trials":9991,"activeCount":101},[],{"trials":9993,"activeCount":101},[],{"intervention":9995,"totalTrials":651,"cells":9996},"Envafolimab+Lenvatinib",{"EARLY_PHASE1":9997,"PHASE1":9999,"PHASE2":10001,"PHASE3":10011,"PHASE4":10013,"NA":10015},{"trials":9998,"activeCount":101},[],{"trials":10000,"activeCount":101},[],{"trials":10002,"activeCount":651,"soonestReadout":10007},[10003],{"nctId":10004,"briefTitle":10005,"status":270,"phases":10006,"primaryCompletion":10007,"completion":3741,"start":354,"enrollment":25,"conditions":10008,"interventions":10010},"NCT07256223","A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread",[90],"2027-11-01",[10009,6012],"Clear Cell Renal Cell Cancer (ccRCC)",[9995],{"trials":10012,"activeCount":101},[],{"trials":10014,"activeCount":101},[],{"trials":10016,"activeCount":101},[],{"intervention":6134,"totalTrials":651,"cells":10018},{"EARLY_PHASE1":10019,"PHASE1":10021,"PHASE2":10023,"PHASE3":10029,"PHASE4":10031,"NA":10033},{"trials":10020,"activeCount":101},[],{"trials":10022,"activeCount":101},[],{"trials":10024,"activeCount":651,"soonestReadout":398},[10025],{"nctId":6127,"briefTitle":6128,"status":121,"phases":10026,"primaryCompletion":398,"completion":6130,"start":295,"enrollment":31,"conditions":10027,"interventions":10028},[90],[18,6132],[6134,1170,128],{"trials":10030,"activeCount":101},[],{"trials":10032,"activeCount":101},[],{"trials":10034,"activeCount":101},[],{"intervention":10036,"totalTrials":651,"cells":10037},"Sintilimab+Pegaspargase",{"EARLY_PHASE1":10038,"PHASE1":10040,"PHASE2":10042,"PHASE3":10054,"PHASE4":10056,"NA":10058},{"trials":10039,"activeCount":101},[],{"trials":10041,"activeCount":101},[],{"trials":10043,"activeCount":651,"soonestReadout":783},[10044],{"nctId":10045,"briefTitle":10046,"status":121,"phases":10047,"primaryCompletion":783,"completion":2018,"start":10048,"enrollment":202,"conditions":10049,"interventions":10051},"NCT06314334","Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK\u002FT-cell Lymphoma",[90],"2024-03-04",[10050],"Natural Killer\u002FT-Cell Lymphoma, Nasal and Nasal-Type",[10036,10052,10053],"P-GemOx","GELAD",{"trials":10055,"activeCount":101},[],{"trials":10057,"activeCount":101},[],{"trials":10059,"activeCount":101},[],{"intervention":10052,"totalTrials":651,"cells":10061},{"EARLY_PHASE1":10062,"PHASE1":10064,"PHASE2":10066,"PHASE3":10072,"PHASE4":10074,"NA":10076},{"trials":10063,"activeCount":101},[],{"trials":10065,"activeCount":101},[],{"trials":10067,"activeCount":651,"soonestReadout":783},[10068],{"nctId":10045,"briefTitle":10046,"status":121,"phases":10069,"primaryCompletion":783,"completion":2018,"start":10048,"enrollment":202,"conditions":10070,"interventions":10071},[90],[10050],[10036,10052,10053],{"trials":10073,"activeCount":101},[],{"trials":10075,"activeCount":101},[],{"trials":10077,"activeCount":101},[],{"intervention":10053,"totalTrials":651,"cells":10079},{"EARLY_PHASE1":10080,"PHASE1":10082,"PHASE2":10084,"PHASE3":10090,"PHASE4":10092,"NA":10094},{"trials":10081,"activeCount":101},[],{"trials":10083,"activeCount":101},[],{"trials":10085,"activeCount":651,"soonestReadout":783},[10086],{"nctId":10045,"briefTitle":10046,"status":121,"phases":10087,"primaryCompletion":783,"completion":2018,"start":10048,"enrollment":202,"conditions":10088,"interventions":10089},[90],[10050],[10036,10052,10053],{"trials":10091,"activeCount":101},[],{"trials":10093,"activeCount":101},[],{"trials":10095,"activeCount":101},[],{"intervention":10097,"totalTrials":651,"cells":10098},"Tislelizumab+liposomal doxorubicin+ifosfamide",{"EARLY_PHASE1":10099,"PHASE1":10101,"PHASE2":10103,"PHASE3":10118,"PHASE4":10120,"NA":10122},{"trials":10100,"activeCount":101},[],{"trials":10102,"activeCount":101},[],{"trials":10104,"activeCount":651,"soonestReadout":305},[10105],{"nctId":10106,"briefTitle":10107,"status":121,"phases":10108,"primaryCompletion":305,"completion":2291,"start":5871,"enrollment":1434,"conditions":10109,"interventions":10117},"NCT06849986","IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)",[90],[10110,10111,10112,10113,10114,10115,10116],"Soft Tissue Sarcomas","Angiosarcoma","Fibrosarcoma","Leiomyosarcoma","Pleomorphic Liposarcoma","Malignant Peripheral Nerve Sheath Tumor (MPNST)","Desmoplastic Small Round Cell Tumor",[10097],{"trials":10119,"activeCount":101},[],{"trials":10121,"activeCount":101},[],{"trials":10123,"activeCount":101},[],{"intervention":6976,"totalTrials":651,"cells":10125},{"EARLY_PHASE1":10126,"PHASE1":10128,"PHASE2":10130,"PHASE3":10136,"PHASE4":10138,"NA":10140},{"trials":10127,"activeCount":101},[],{"trials":10129,"activeCount":101},[],{"trials":10131,"activeCount":651,"soonestReadout":3646},[10132],{"nctId":6968,"briefTitle":6969,"status":121,"phases":10133,"primaryCompletion":3646,"completion":6971,"start":6972,"enrollment":737,"conditions":10134,"interventions":10135},[90],[18,6974],[300,6976],{"trials":10137,"activeCount":101},[],{"trials":10139,"activeCount":101},[],{"trials":10141,"activeCount":101},[],{"intervention":10143,"totalTrials":651,"cells":10144},"A",{"EARLY_PHASE1":10145,"PHASE1":10147,"PHASE2":10149,"PHASE3":10160,"PHASE4":10162,"NA":10164},{"trials":10146,"activeCount":101},[],{"trials":10148,"activeCount":101},[],{"trials":10150,"activeCount":651,"soonestReadout":353},[10151],{"nctId":10152,"briefTitle":10153,"status":121,"phases":10154,"primaryCompletion":353,"completion":294,"start":10155,"enrollment":1146,"conditions":10156,"interventions":10157},"NCT04215003","A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC",[89,90],"2020-01-20",[15],[10143,10158,10159],"B","CL4",{"trials":10161,"activeCount":101},[],{"trials":10163,"activeCount":101},[],{"trials":10165,"activeCount":101},[],{"intervention":10158,"totalTrials":651,"cells":10167},{"EARLY_PHASE1":10168,"PHASE1":10170,"PHASE2":10172,"PHASE3":10178,"PHASE4":10180,"NA":10182},{"trials":10169,"activeCount":101},[],{"trials":10171,"activeCount":101},[],{"trials":10173,"activeCount":651,"soonestReadout":353},[10174],{"nctId":10152,"briefTitle":10153,"status":121,"phases":10175,"primaryCompletion":353,"completion":294,"start":10155,"enrollment":1146,"conditions":10176,"interventions":10177},[89,90],[15],[10143,10158,10159],{"trials":10179,"activeCount":101},[],{"trials":10181,"activeCount":101},[],{"trials":10183,"activeCount":101},[],{"intervention":10159,"totalTrials":651,"cells":10185},{"EARLY_PHASE1":10186,"PHASE1":10188,"PHASE2":10190,"PHASE3":10196,"PHASE4":10198,"NA":10200},{"trials":10187,"activeCount":101},[],{"trials":10189,"activeCount":101},[],{"trials":10191,"activeCount":651,"soonestReadout":353},[10192],{"nctId":10152,"briefTitle":10153,"status":121,"phases":10193,"primaryCompletion":353,"completion":294,"start":10155,"enrollment":1146,"conditions":10194,"interventions":10195},[89,90],[15],[10143,10158,10159],{"trials":10197,"activeCount":101},[],{"trials":10199,"activeCount":101},[],{"trials":10201,"activeCount":101},[],{"intervention":10203,"totalTrials":651,"cells":10204},"QL1706 + Eribulin + Anlotinib + Radiotherapy",{"EARLY_PHASE1":10205,"PHASE1":10207,"PHASE2":10209,"PHASE3":10218,"PHASE4":10220,"NA":10222},{"trials":10206,"activeCount":101},[],{"trials":10208,"activeCount":101},[],{"trials":10210,"activeCount":651,"soonestReadout":305},[10211],{"nctId":10212,"briefTitle":10213,"status":270,"phases":10214,"primaryCompletion":305,"completion":305,"start":10215,"enrollment":137,"conditions":10216,"interventions":10217},"NCT07205185","A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.",[90],"2025-10-01",[1339],[10203],{"trials":10219,"activeCount":101},[],{"trials":10221,"activeCount":101},[],{"trials":10223,"activeCount":101},[],{"intervention":10225,"totalTrials":651,"cells":10226},"PD-1\u002FPD-L1 inhibitor combined with platinum-based chemotherapy",{"EARLY_PHASE1":10227,"PHASE1":10229,"PHASE2":10231,"PHASE3":10240,"PHASE4":10242,"NA":10244},{"trials":10228,"activeCount":101},[],{"trials":10230,"activeCount":101},[],{"trials":10232,"activeCount":651,"soonestReadout":2844},[10233],{"nctId":10234,"briefTitle":10235,"status":121,"phases":10236,"primaryCompletion":2844,"completion":1609,"start":10237,"enrollment":6148,"conditions":10238,"interventions":10239},"NCT06313541","Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy",[90],"2024-04-10",[2109],[10225],{"trials":10241,"activeCount":101},[],{"trials":10243,"activeCount":101},[],{"trials":10245,"activeCount":101},[],{"intervention":10247,"totalTrials":651,"cells":10248},"MRG003 in combination with pucotenlimab",{"EARLY_PHASE1":10249,"PHASE1":10251,"PHASE2":10253,"PHASE3":10264,"PHASE4":10266,"NA":10268},{"trials":10250,"activeCount":101},[],{"trials":10252,"activeCount":101},[],{"trials":10254,"activeCount":651,"soonestReadout":10259},[10255],{"nctId":10256,"briefTitle":10257,"status":121,"phases":10258,"primaryCompletion":10259,"completion":10260,"start":10261,"enrollment":111,"conditions":10262,"interventions":10263},"NCT07235566","MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC\u002FPDTC",[90],"2029-04","2031-04","2025-04-21",[6616],[10247],{"trials":10265,"activeCount":101},[],{"trials":10267,"activeCount":101},[],{"trials":10269,"activeCount":101},[],{"intervention":10271,"totalTrials":651,"cells":10272},"Metformin or insulin treatment",{"EARLY_PHASE1":10273,"PHASE1":10275,"PHASE2":10277,"PHASE3":10287,"PHASE4":10289,"NA":10291},{"trials":10274,"activeCount":101},[],{"trials":10276,"activeCount":101},[],{"trials":10278,"activeCount":651,"soonestReadout":3958},[10279],{"nctId":10280,"briefTitle":10281,"status":505,"phases":10282,"primaryCompletion":3958,"completion":1609,"start":6056,"enrollment":1146,"conditions":10283,"interventions":10286},"NCT05306028","Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)",[90],[10284,10285],"Pancretic Cancer","Diabete Mellitus",[10271],{"trials":10288,"activeCount":101},[],{"trials":10290,"activeCount":101},[],{"trials":10292,"activeCount":101},[],{"intervention":8285,"totalTrials":651,"cells":10294},{"EARLY_PHASE1":10295,"PHASE1":10297,"PHASE2":10299,"PHASE3":10305,"PHASE4":10307,"NA":10309},{"trials":10296,"activeCount":101},[],{"trials":10298,"activeCount":101},[],{"trials":10300,"activeCount":651,"soonestReadout":8281},[10301],{"nctId":8278,"briefTitle":8279,"status":121,"phases":10302,"primaryCompletion":8281,"completion":8282,"start":6155,"enrollment":488,"conditions":10303,"interventions":10304},[90],[15],[86,8285],{"trials":10306,"activeCount":101},[],{"trials":10308,"activeCount":101},[],{"trials":10310,"activeCount":101},[],{"intervention":10312,"totalTrials":651,"cells":10313},"combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX\u002FTOMIRI) Maintenance: Fruquintinib plus Camrelizumab",{"EARLY_PHASE1":10314,"PHASE1":10316,"PHASE2":10318,"PHASE3":10327,"PHASE4":10329,"NA":10331},{"trials":10315,"activeCount":101},[],{"trials":10317,"activeCount":101},[],{"trials":10319,"activeCount":651,"soonestReadout":1897},[10320],{"nctId":10321,"briefTitle":10322,"status":270,"phases":10323,"primaryCompletion":1897,"completion":644,"start":400,"enrollment":10324,"conditions":10325,"interventions":10326},"NCT06423937","Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer",[90],129,[18],[10312],{"trials":10328,"activeCount":101},[],{"trials":10330,"activeCount":101},[],{"trials":10332,"activeCount":101},[],{"intervention":2318,"totalTrials":651,"cells":10334},{"EARLY_PHASE1":10335,"PHASE1":10337,"PHASE2":10339,"PHASE3":10345,"PHASE4":10347,"NA":10349},{"trials":10336,"activeCount":101},[],{"trials":10338,"activeCount":101},[],{"trials":10340,"activeCount":651,"soonestReadout":2313},[10341],{"nctId":2310,"briefTitle":2311,"status":270,"phases":10342,"primaryCompletion":2313,"completion":784,"start":2314,"enrollment":2315,"conditions":10343,"interventions":10344},[90],[521],[2318,433,1377,413,2319],{"trials":10346,"activeCount":101},[],{"trials":10348,"activeCount":101},[],{"trials":10350,"activeCount":101},[],{"intervention":2319,"totalTrials":651,"cells":10352},{"EARLY_PHASE1":10353,"PHASE1":10355,"PHASE2":10357,"PHASE3":10363,"PHASE4":10365,"NA":10367},{"trials":10354,"activeCount":101},[],{"trials":10356,"activeCount":101},[],{"trials":10358,"activeCount":651,"soonestReadout":2313},[10359],{"nctId":2310,"briefTitle":2311,"status":270,"phases":10360,"primaryCompletion":2313,"completion":784,"start":2314,"enrollment":2315,"conditions":10361,"interventions":10362},[90],[521],[2318,433,1377,413,2319],{"trials":10364,"activeCount":101},[],{"trials":10366,"activeCount":101},[],{"trials":10368,"activeCount":101},[],{"intervention":10370,"totalTrials":651,"cells":10371},"Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone).",{"EARLY_PHASE1":10372,"PHASE1":10374,"PHASE2":10376,"PHASE3":10386,"PHASE4":10388,"NA":10390},{"trials":10373,"activeCount":101},[],{"trials":10375,"activeCount":101},[],{"trials":10377,"activeCount":651,"soonestReadout":750},[10378],{"nctId":10379,"briefTitle":10380,"status":270,"phases":10381,"primaryCompletion":750,"completion":10382,"start":398,"enrollment":3257,"conditions":10383,"interventions":10384},"NCT07296666","Adjuvant Chemotherapy for BTC Based on 3D-PTA",[90],"2028-10",[671],[10370,10385],"capecitabine alone as adjuvant treatment",{"trials":10387,"activeCount":101},[],{"trials":10389,"activeCount":101},[],{"trials":10391,"activeCount":101},[],{"intervention":10385,"totalTrials":651,"cells":10393},{"EARLY_PHASE1":10394,"PHASE1":10396,"PHASE2":10398,"PHASE3":10404,"PHASE4":10406,"NA":10408},{"trials":10395,"activeCount":101},[],{"trials":10397,"activeCount":101},[],{"trials":10399,"activeCount":651,"soonestReadout":750},[10400],{"nctId":10379,"briefTitle":10380,"status":270,"phases":10401,"primaryCompletion":750,"completion":10382,"start":398,"enrollment":3257,"conditions":10402,"interventions":10403},[90],[671],[10370,10385],{"trials":10405,"activeCount":101},[],{"trials":10407,"activeCount":101},[],{"trials":10409,"activeCount":101},[],{"intervention":1341,"totalTrials":651,"cells":10411},{"EARLY_PHASE1":10412,"PHASE1":10414,"PHASE2":10416,"PHASE3":10422,"PHASE4":10424,"NA":10426},{"trials":10413,"activeCount":101},[],{"trials":10415,"activeCount":101},[],{"trials":10417,"activeCount":651,"soonestReadout":1334},[10418],{"nctId":1331,"briefTitle":1332,"status":270,"phases":10419,"primaryCompletion":1334,"completion":1335,"start":353,"enrollment":1336,"conditions":10420,"interventions":10421},[90],[1338,1339],[1341,581,432],{"trials":10423,"activeCount":101},[],{"trials":10425,"activeCount":101},[],{"trials":10427,"activeCount":101},[],{"intervention":10429,"totalTrials":651,"cells":10430},"pinoxin",{"EARLY_PHASE1":10431,"PHASE1":10433,"PHASE2":10435,"PHASE3":10446,"PHASE4":10448,"NA":10450},{"trials":10432,"activeCount":101},[],{"trials":10434,"activeCount":101},[],{"trials":10436,"activeCount":651,"soonestReadout":10441},[10437],{"nctId":10438,"briefTitle":10439,"status":121,"phases":10440,"primaryCompletion":10441,"completion":963,"start":10442,"enrollment":7031,"conditions":10443,"interventions":10445},"NCT07545720","Pinoxin for the Prevention of Radiation-Induced Skin Injury",[90],"2026-05-31","2024-09-05",[10444],"Cancer Patients Undergoning Radiotherapy",[10429],{"trials":10447,"activeCount":101},[],{"trials":10449,"activeCount":101},[],{"trials":10451,"activeCount":101},[],{"intervention":10453,"totalTrials":651,"cells":10454},"TQB2450 injection + oral progestin",{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10459,"PHASE3":10467,"PHASE4":10469,"NA":10471},{"trials":10456,"activeCount":101},[],{"trials":10458,"activeCount":101},[],{"trials":10460,"activeCount":651,"soonestReadout":5498},[10461],{"nctId":10462,"briefTitle":10463,"status":121,"phases":10464,"primaryCompletion":5498,"completion":273,"start":10261,"enrollment":1499,"conditions":10465,"interventions":10466},"NCT06914297","TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC",[90],[1854],[10453],{"trials":10468,"activeCount":101},[],{"trials":10470,"activeCount":101},[],{"trials":10472,"activeCount":101},[],{"intervention":10474,"totalTrials":651,"cells":10475},"Ivosidenib",{"EARLY_PHASE1":10476,"PHASE1":10478,"PHASE2":10480,"PHASE3":10490,"PHASE4":10492,"NA":10494},{"trials":10477,"activeCount":101},[],{"trials":10479,"activeCount":101},[],{"trials":10481,"activeCount":651,"soonestReadout":3781},[10482],{"nctId":10483,"briefTitle":10484,"status":270,"phases":10485,"primaryCompletion":3781,"completion":3781,"start":306,"enrollment":3068,"conditions":10486,"interventions":10489},"NCT06593548","Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer",[90],[10487,10488,452],"CRC","MSS",[10474],{"trials":10491,"activeCount":101},[],{"trials":10493,"activeCount":101},[],{"trials":10495,"activeCount":101},[],{"intervention":10497,"totalTrials":651,"cells":10498},"Vebreltinib Enteric",{"EARLY_PHASE1":10499,"PHASE1":10501,"PHASE2":10503,"PHASE3":10511,"PHASE4":10513,"NA":10515},{"trials":10500,"activeCount":101},[],{"trials":10502,"activeCount":101},[],{"trials":10504,"activeCount":651,"soonestReadout":1621},[10505],{"nctId":10506,"briefTitle":10507,"status":270,"phases":10508,"primaryCompletion":1621,"completion":3511,"start":2441,"enrollment":25,"conditions":10509,"interventions":10510},"NCT07156604","Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)",[90],[8500,240],[10497],{"trials":10512,"activeCount":101},[],{"trials":10514,"activeCount":101},[],{"trials":10516,"activeCount":101},[],{"intervention":10518,"totalTrials":651,"cells":10519},"Standard Systemic Therapy for Gastric Cancer",{"EARLY_PHASE1":10520,"PHASE1":10522,"PHASE2":10524,"PHASE3":10534,"PHASE4":10536,"NA":10538},{"trials":10521,"activeCount":101},[],{"trials":10523,"activeCount":101},[],{"trials":10525,"activeCount":651,"soonestReadout":10530},[10526],{"nctId":10527,"briefTitle":10528,"status":121,"phases":10529,"primaryCompletion":10530,"completion":10531,"start":825,"enrollment":2026,"conditions":10532,"interventions":10533},"NCT07517107","Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer",[90],"2028-10-01","2029-10-01",[24],[10518],{"trials":10535,"activeCount":101},[],{"trials":10537,"activeCount":101},[],{"trials":10539,"activeCount":101},[],{"intervention":10541,"totalTrials":651,"cells":10542},"SHR-1701 combined with platinum-doublet chemotherapy induction therapy",{"EARLY_PHASE1":10543,"PHASE1":10545,"PHASE2":10547,"PHASE3":10559,"PHASE4":10561,"NA":10563},{"trials":10544,"activeCount":101},[],{"trials":10546,"activeCount":101},[],{"trials":10548,"activeCount":651,"soonestReadout":6989},[10549],{"nctId":10550,"briefTitle":10551,"status":270,"phases":10552,"primaryCompletion":6989,"completion":4985,"start":1897,"enrollment":10553,"conditions":10554,"interventions":10556},"NCT07619911","SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer",[90],84,[10555,3072,1217],"NSCLC Stage III",[10541,10557,10558],"SHR-1701 consolidation therapy","Platinum-doublet chemotherapy",{"trials":10560,"activeCount":101},[],{"trials":10562,"activeCount":101},[],{"trials":10564,"activeCount":101},[],{"intervention":10557,"totalTrials":651,"cells":10566},{"EARLY_PHASE1":10567,"PHASE1":10569,"PHASE2":10571,"PHASE3":10577,"PHASE4":10579,"NA":10581},{"trials":10568,"activeCount":101},[],{"trials":10570,"activeCount":101},[],{"trials":10572,"activeCount":651,"soonestReadout":6989},[10573],{"nctId":10550,"briefTitle":10551,"status":270,"phases":10574,"primaryCompletion":6989,"completion":4985,"start":1897,"enrollment":10553,"conditions":10575,"interventions":10576},[90],[10555,3072,1217],[10541,10557,10558],{"trials":10578,"activeCount":101},[],{"trials":10580,"activeCount":101},[],{"trials":10582,"activeCount":101},[],{"intervention":10558,"totalTrials":651,"cells":10584},{"EARLY_PHASE1":10585,"PHASE1":10587,"PHASE2":10589,"PHASE3":10595,"PHASE4":10597,"NA":10599},{"trials":10586,"activeCount":101},[],{"trials":10588,"activeCount":101},[],{"trials":10590,"activeCount":651,"soonestReadout":6989},[10591],{"nctId":10550,"briefTitle":10551,"status":270,"phases":10592,"primaryCompletion":6989,"completion":4985,"start":1897,"enrollment":10553,"conditions":10593,"interventions":10594},[90],[10555,3072,1217],[10541,10557,10558],{"trials":10596,"activeCount":101},[],{"trials":10598,"activeCount":101},[],{"trials":10600,"activeCount":101},[],{"intervention":7631,"totalTrials":651,"cells":10602},{"EARLY_PHASE1":10603,"PHASE1":10605,"PHASE2":10607,"PHASE3":10613,"PHASE4":10615,"NA":10617},{"trials":10604,"activeCount":101},[],{"trials":10606,"activeCount":101},[],{"trials":10608,"activeCount":651,"soonestReadout":236},[10609],{"nctId":7623,"briefTitle":7624,"status":270,"phases":10610,"primaryCompletion":236,"completion":236,"start":7626,"enrollment":7627,"conditions":10611,"interventions":10612},[90],[7629],[7631,7484],{"trials":10614,"activeCount":101},[],{"trials":10616,"activeCount":101},[],{"trials":10618,"activeCount":101},[],{"intervention":10620,"totalTrials":651,"cells":10621},"HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab",{"EARLY_PHASE1":10622,"PHASE1":10624,"PHASE2":10626,"PHASE3":10635,"PHASE4":10637,"NA":10639},{"trials":10623,"activeCount":101},[],{"trials":10625,"activeCount":101},[],{"trials":10627,"activeCount":651,"soonestReadout":6817},[10628],{"nctId":10629,"briefTitle":10630,"status":270,"phases":10631,"primaryCompletion":6817,"completion":10441,"start":1156,"enrollment":3614,"conditions":10632,"interventions":10634},"NCT06441019","Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma",[90],[10633],"Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab",[10620],{"trials":10636,"activeCount":101},[],{"trials":10638,"activeCount":101},[],{"trials":10640,"activeCount":101},[],{"intervention":3653,"totalTrials":651,"cells":10642},{"EARLY_PHASE1":10643,"PHASE1":10645,"PHASE2":10647,"PHASE3":10653,"PHASE4":10655,"NA":10657},{"trials":10644,"activeCount":101},[],{"trials":10646,"activeCount":101},[],{"trials":10648,"activeCount":651,"soonestReadout":3645},[10649],{"nctId":3642,"briefTitle":3643,"status":121,"phases":10650,"primaryCompletion":3645,"completion":3646,"start":3647,"enrollment":3648,"conditions":10651,"interventions":10652},[90],[3650],[3633,3652,3653,3654],{"trials":10654,"activeCount":101},[],{"trials":10656,"activeCount":101},[],{"trials":10658,"activeCount":101},[],{"intervention":8344,"totalTrials":651,"cells":10660},{"EARLY_PHASE1":10661,"PHASE1":10663,"PHASE2":10665,"PHASE3":10671,"PHASE4":10673,"NA":10675},{"trials":10662,"activeCount":101},[],{"trials":10664,"activeCount":101},[],{"trials":10666,"activeCount":651,"soonestReadout":2735},[10667],{"nctId":8337,"briefTitle":8338,"status":270,"phases":10668,"primaryCompletion":2735,"completion":323,"start":294,"enrollment":8340,"conditions":10669,"interventions":10670},[90],[8342],[2818,8344],{"trials":10672,"activeCount":101},[],{"trials":10674,"activeCount":101},[],{"trials":10676,"activeCount":101},[],{"intervention":6310,"totalTrials":651,"cells":10678},{"EARLY_PHASE1":10679,"PHASE1":10681,"PHASE2":10683,"PHASE3":10689,"PHASE4":10691,"NA":10693},{"trials":10680,"activeCount":101},[],{"trials":10682,"activeCount":101},[],{"trials":10684,"activeCount":651,"soonestReadout":1927},[10685],{"nctId":6303,"briefTitle":6304,"status":270,"phases":10686,"primaryCompletion":1927,"completion":3717,"start":6306,"enrollment":828,"conditions":10687,"interventions":10688},[90],[6308],[6310,230],{"trials":10690,"activeCount":101},[],{"trials":10692,"activeCount":101},[],{"trials":10694,"activeCount":101},[],{"intervention":10696,"totalTrials":651,"cells":10697},"Standard Medical Therapy",{"EARLY_PHASE1":10698,"PHASE1":10700,"PHASE2":10702,"PHASE3":10711,"PHASE4":10713,"NA":10715},{"trials":10699,"activeCount":101},[],{"trials":10701,"activeCount":101},[],{"trials":10703,"activeCount":651,"soonestReadout":2250},[10704],{"nctId":10705,"briefTitle":10706,"status":121,"phases":10707,"primaryCompletion":2250,"completion":897,"start":10708,"enrollment":2709,"conditions":10709,"interventions":10710},"NCT06655259","Combination of TURP and Standard Systemic Therapy for MPCa",[90],"2024-09-21",[2485],[10696],{"trials":10712,"activeCount":101},[],{"trials":10714,"activeCount":101},[],{"trials":10716,"activeCount":101},[],{"intervention":6566,"totalTrials":651,"cells":10718},{"EARLY_PHASE1":10719,"PHASE1":10721,"PHASE2":10723,"PHASE3":10729,"PHASE4":10731,"NA":10733},{"trials":10720,"activeCount":101},[],{"trials":10722,"activeCount":101},[],{"trials":10724,"activeCount":651,"soonestReadout":235},[10725],{"nctId":6560,"briefTitle":6561,"status":121,"phases":10726,"primaryCompletion":235,"completion":963,"start":1991,"enrollment":334,"conditions":10727,"interventions":10728},[90],[6564],[1970,2411,6566,2281],{"trials":10730,"activeCount":101},[],{"trials":10732,"activeCount":101},[],{"trials":10734,"activeCount":101},[],{"intervention":7371,"totalTrials":651,"cells":10736},{"EARLY_PHASE1":10737,"PHASE1":10739,"PHASE2":10741,"PHASE3":10747,"PHASE4":10749,"NA":10751},{"trials":10738,"activeCount":101},[],{"trials":10740,"activeCount":101},[],{"trials":10742,"activeCount":651,"soonestReadout":305},[10743],{"nctId":7366,"briefTitle":7367,"status":121,"phases":10744,"primaryCompletion":305,"completion":305,"start":448,"enrollment":213,"conditions":10745,"interventions":10746},[90],[309,310,18],[312,7371],{"trials":10748,"activeCount":101},[],{"trials":10750,"activeCount":101},[],{"trials":10752,"activeCount":101},[],{"intervention":6321,"totalTrials":651,"cells":10754},{"EARLY_PHASE1":10755,"PHASE1":10757,"PHASE2":10759,"PHASE3":10765,"PHASE4":10767,"NA":10769},{"trials":10756,"activeCount":101},[],{"trials":10758,"activeCount":101},[],{"trials":10760,"activeCount":651,"soonestReadout":2261},[10761],{"nctId":6312,"briefTitle":6313,"status":270,"phases":10762,"primaryCompletion":2261,"completion":323,"start":6315,"enrollment":22,"conditions":10763,"interventions":10764},[90],[6317,6318,6319],[3030,230,6321],{"trials":10766,"activeCount":101},[],{"trials":10768,"activeCount":101},[],{"trials":10770,"activeCount":101},[],{"intervention":3476,"totalTrials":651,"cells":10772},{"EARLY_PHASE1":10773,"PHASE1":10775,"PHASE2":10777,"PHASE3":10783,"PHASE4":10785,"NA":10787},{"trials":10774,"activeCount":101},[],{"trials":10776,"activeCount":101},[],{"trials":10778,"activeCount":651,"soonestReadout":3420},[10779],{"nctId":3470,"briefTitle":3471,"status":121,"phases":10780,"primaryCompletion":3420,"completion":3473,"start":1550,"enrollment":737,"conditions":10781,"interventions":10782},[90],[15],[3476,3477,2358,3478],{"trials":10784,"activeCount":101},[],{"trials":10786,"activeCount":101},[],{"trials":10788,"activeCount":101},[],{"intervention":3478,"totalTrials":651,"cells":10790},{"EARLY_PHASE1":10791,"PHASE1":10793,"PHASE2":10795,"PHASE3":10801,"PHASE4":10803,"NA":10805},{"trials":10792,"activeCount":101},[],{"trials":10794,"activeCount":101},[],{"trials":10796,"activeCount":651,"soonestReadout":3420},[10797],{"nctId":3470,"briefTitle":3471,"status":121,"phases":10798,"primaryCompletion":3420,"completion":3473,"start":1550,"enrollment":737,"conditions":10799,"interventions":10800},[90],[15],[3476,3477,2358,3478],{"trials":10802,"activeCount":101},[],{"trials":10804,"activeCount":101},[],{"trials":10806,"activeCount":101},[],{"intervention":2207,"totalTrials":651,"cells":10808},{"EARLY_PHASE1":10809,"PHASE1":10811,"PHASE2":10813,"PHASE3":10819,"PHASE4":10821,"NA":10823},{"trials":10810,"activeCount":101},[],{"trials":10812,"activeCount":101},[],{"trials":10814,"activeCount":651,"soonestReadout":2201},[10815],{"nctId":2198,"briefTitle":2199,"status":505,"phases":10816,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":10817,"interventions":10818},[89,90],[15],[1378,2207],{"trials":10820,"activeCount":101},[],{"trials":10822,"activeCount":101},[],{"trials":10824,"activeCount":101},[],{"intervention":1588,"totalTrials":651,"cells":10826},{"EARLY_PHASE1":10827,"PHASE1":10829,"PHASE2":10831,"PHASE3":10837,"PHASE4":10839,"NA":10841},{"trials":10828,"activeCount":101},[],{"trials":10830,"activeCount":101},[],{"trials":10832,"activeCount":651,"soonestReadout":825},[10833],{"nctId":1580,"briefTitle":1581,"status":121,"phases":10834,"primaryCompletion":825,"completion":1583,"start":1584,"enrollment":1585,"conditions":10835,"interventions":10836},[90],[24],[300,1588,310],{"trials":10838,"activeCount":101},[],{"trials":10840,"activeCount":101},[],{"trials":10842,"activeCount":101},[],{"intervention":2410,"totalTrials":651,"cells":10844},{"EARLY_PHASE1":10845,"PHASE1":10847,"PHASE2":10849,"PHASE3":10855,"PHASE4":10857,"NA":10859},{"trials":10846,"activeCount":101},[],{"trials":10848,"activeCount":101},[],{"trials":10850,"activeCount":651,"soonestReadout":145},[10851],{"nctId":2403,"briefTitle":2404,"status":121,"phases":10852,"primaryCompletion":145,"completion":2406,"start":157,"enrollment":2264,"conditions":10853,"interventions":10854},[90],[2408],[2410,2411,254,253],{"trials":10856,"activeCount":101},[],{"trials":10858,"activeCount":101},[],{"trials":10860,"activeCount":101},[],{"intervention":10862,"totalTrials":651,"cells":10863},"Concurrent chemoradiotherapy",{"EARLY_PHASE1":10864,"PHASE1":10866,"PHASE2":10868,"PHASE3":10881,"PHASE4":10883,"NA":10885},{"trials":10865,"activeCount":101},[],{"trials":10867,"activeCount":101},[],{"trials":10869,"activeCount":651,"soonestReadout":236},[10870],{"nctId":10871,"briefTitle":10872,"status":270,"phases":10873,"primaryCompletion":236,"completion":10874,"start":10875,"enrollment":97,"conditions":10876,"interventions":10879},"NCT07469241","Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.",[90],"2029-06-30","2026-03-10",[10877,10878],"Advanced Esophageal Squamous Cell Carcinoma","Unresectable Esophageal Squamous Cell Carcinoma",[10862,10880],"Induced treatment",{"trials":10882,"activeCount":101},[],{"trials":10884,"activeCount":101},[],{"trials":10886,"activeCount":101},[],{"intervention":10880,"totalTrials":651,"cells":10888},{"EARLY_PHASE1":10889,"PHASE1":10891,"PHASE2":10893,"PHASE3":10899,"PHASE4":10901,"NA":10903},{"trials":10890,"activeCount":101},[],{"trials":10892,"activeCount":101},[],{"trials":10894,"activeCount":651,"soonestReadout":236},[10895],{"nctId":10871,"briefTitle":10872,"status":270,"phases":10896,"primaryCompletion":236,"completion":10874,"start":10875,"enrollment":97,"conditions":10897,"interventions":10898},[90],[10877,10878],[10862,10880],{"trials":10900,"activeCount":101},[],{"trials":10902,"activeCount":101},[],{"trials":10904,"activeCount":101},[],{"intervention":10906,"totalTrials":651,"cells":10907},"CAPEOX regimen",{"EARLY_PHASE1":10908,"PHASE1":10910,"PHASE2":10912,"PHASE3":10920,"PHASE4":10922,"NA":10924},{"trials":10909,"activeCount":101},[],{"trials":10911,"activeCount":101},[],{"trials":10913,"activeCount":651,"soonestReadout":305},[10914],{"nctId":10915,"briefTitle":10916,"status":121,"phases":10917,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":10918,"interventions":10919},"NCT07562503","Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer",[90],[309,18,310],[10906,10906],{"trials":10921,"activeCount":101},[],{"trials":10923,"activeCount":101},[],{"trials":10925,"activeCount":101},[],{"intervention":10927,"totalTrials":651,"cells":10928},"Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin",{"EARLY_PHASE1":10929,"PHASE1":10931,"PHASE2":10933,"PHASE3":10943,"PHASE4":10945,"NA":10947},{"trials":10930,"activeCount":101},[],{"trials":10932,"activeCount":101},[],{"trials":10934,"activeCount":651,"soonestReadout":10939},[10935],{"nctId":10936,"briefTitle":10937,"status":121,"phases":10938,"primaryCompletion":10939,"completion":10939,"start":10940,"enrollment":369,"conditions":10941,"interventions":10942},"NCT07001540","Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation",[90],"2027-11-15","2025-05-08",[8898],[10927],{"trials":10944,"activeCount":101},[],{"trials":10946,"activeCount":101},[],{"trials":10948,"activeCount":101},[],{"intervention":10950,"totalTrials":651,"cells":10951},"sunvozertinib 300mg",{"EARLY_PHASE1":10952,"PHASE1":10954,"PHASE2":10956,"PHASE3":10967,"PHASE4":10969,"NA":10971},{"trials":10953,"activeCount":101},[],{"trials":10955,"activeCount":101},[],{"trials":10957,"activeCount":651,"soonestReadout":10962},[10958],{"nctId":10959,"briefTitle":10960,"status":121,"phases":10961,"primaryCompletion":10962,"completion":3740,"start":10963,"enrollment":181,"conditions":10964,"interventions":10965},"NCT07117890","Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations",[90],"2027-02-20","2025-02-07",[2526],[10950,10966],"sunvozertinib 200mg",{"trials":10968,"activeCount":101},[],{"trials":10970,"activeCount":101},[],{"trials":10972,"activeCount":101},[],{"intervention":10966,"totalTrials":651,"cells":10974},{"EARLY_PHASE1":10975,"PHASE1":10977,"PHASE2":10979,"PHASE3":10985,"PHASE4":10987,"NA":10989},{"trials":10976,"activeCount":101},[],{"trials":10978,"activeCount":101},[],{"trials":10980,"activeCount":651,"soonestReadout":10962},[10981],{"nctId":10959,"briefTitle":10960,"status":121,"phases":10982,"primaryCompletion":10962,"completion":3740,"start":10963,"enrollment":181,"conditions":10983,"interventions":10984},[90],[2526],[10950,10966],{"trials":10986,"activeCount":101},[],{"trials":10988,"activeCount":101},[],{"trials":10990,"activeCount":101},[],{"intervention":6166,"totalTrials":651,"cells":10992},{"EARLY_PHASE1":10993,"PHASE1":10995,"PHASE2":10997,"PHASE3":11003,"PHASE4":11005,"NA":11007},{"trials":10994,"activeCount":101},[],{"trials":10996,"activeCount":101},[],{"trials":10998,"activeCount":651,"soonestReadout":826},[10999],{"nctId":6160,"briefTitle":6161,"status":270,"phases":11000,"primaryCompletion":826,"completion":871,"start":3983,"enrollment":1146,"conditions":11001,"interventions":11002},[89,90],[6164],[6166,6167,128],{"trials":11004,"activeCount":101},[],{"trials":11006,"activeCount":101},[],{"trials":11008,"activeCount":101},[],{"intervention":6167,"totalTrials":651,"cells":11010},{"EARLY_PHASE1":11011,"PHASE1":11013,"PHASE2":11015,"PHASE3":11021,"PHASE4":11023,"NA":11025},{"trials":11012,"activeCount":101},[],{"trials":11014,"activeCount":101},[],{"trials":11016,"activeCount":651,"soonestReadout":826},[11017],{"nctId":6160,"briefTitle":6161,"status":270,"phases":11018,"primaryCompletion":826,"completion":871,"start":3983,"enrollment":1146,"conditions":11019,"interventions":11020},[89,90],[6164],[6166,6167,128],{"trials":11022,"activeCount":101},[],{"trials":11024,"activeCount":101},[],{"trials":11026,"activeCount":101},[],{"intervention":1387,"totalTrials":651,"cells":11028},{"EARLY_PHASE1":11029,"PHASE1":11031,"PHASE2":11033,"PHASE3":11039,"PHASE4":11041,"NA":11043},{"trials":11030,"activeCount":101},[],{"trials":11032,"activeCount":101},[],{"trials":11034,"activeCount":651,"soonestReadout":305},[11035],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11036,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11037,"interventions":11038},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11040,"activeCount":101},[],{"trials":11042,"activeCount":101},[],{"trials":11044,"activeCount":101},[],{"intervention":1388,"totalTrials":651,"cells":11046},{"EARLY_PHASE1":11047,"PHASE1":11049,"PHASE2":11051,"PHASE3":11057,"PHASE4":11059,"NA":11061},{"trials":11048,"activeCount":101},[],{"trials":11050,"activeCount":101},[],{"trials":11052,"activeCount":651,"soonestReadout":305},[11053],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11054,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11055,"interventions":11056},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11058,"activeCount":101},[],{"trials":11060,"activeCount":101},[],{"trials":11062,"activeCount":101},[],{"intervention":1389,"totalTrials":651,"cells":11064},{"EARLY_PHASE1":11065,"PHASE1":11067,"PHASE2":11069,"PHASE3":11075,"PHASE4":11077,"NA":11079},{"trials":11066,"activeCount":101},[],{"trials":11068,"activeCount":101},[],{"trials":11070,"activeCount":651,"soonestReadout":305},[11071],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11072,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11073,"interventions":11074},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11076,"activeCount":101},[],{"trials":11078,"activeCount":101},[],{"trials":11080,"activeCount":101},[],{"intervention":1390,"totalTrials":651,"cells":11082},{"EARLY_PHASE1":11083,"PHASE1":11085,"PHASE2":11087,"PHASE3":11093,"PHASE4":11095,"NA":11097},{"trials":11084,"activeCount":101},[],{"trials":11086,"activeCount":101},[],{"trials":11088,"activeCount":651,"soonestReadout":305},[11089],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11090,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11091,"interventions":11092},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11094,"activeCount":101},[],{"trials":11096,"activeCount":101},[],{"trials":11098,"activeCount":101},[],{"intervention":1392,"totalTrials":651,"cells":11100},{"EARLY_PHASE1":11101,"PHASE1":11103,"PHASE2":11105,"PHASE3":11111,"PHASE4":11113,"NA":11115},{"trials":11102,"activeCount":101},[],{"trials":11104,"activeCount":101},[],{"trials":11106,"activeCount":651,"soonestReadout":305},[11107],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11108,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11109,"interventions":11110},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11112,"activeCount":101},[],{"trials":11114,"activeCount":101},[],{"trials":11116,"activeCount":101},[],{"intervention":1394,"totalTrials":651,"cells":11118},{"EARLY_PHASE1":11119,"PHASE1":11121,"PHASE2":11123,"PHASE3":11129,"PHASE4":11131,"NA":11133},{"trials":11120,"activeCount":101},[],{"trials":11122,"activeCount":101},[],{"trials":11124,"activeCount":651,"soonestReadout":305},[11125],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11126,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11127,"interventions":11128},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11130,"activeCount":101},[],{"trials":11132,"activeCount":101},[],{"trials":11134,"activeCount":101},[],{"intervention":1395,"totalTrials":651,"cells":11136},{"EARLY_PHASE1":11137,"PHASE1":11139,"PHASE2":11141,"PHASE3":11147,"PHASE4":11149,"NA":11151},{"trials":11138,"activeCount":101},[],{"trials":11140,"activeCount":101},[],{"trials":11142,"activeCount":651,"soonestReadout":305},[11143],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11144,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11145,"interventions":11146},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11148,"activeCount":101},[],{"trials":11150,"activeCount":101},[],{"trials":11152,"activeCount":101},[],{"intervention":1396,"totalTrials":651,"cells":11154},{"EARLY_PHASE1":11155,"PHASE1":11157,"PHASE2":11159,"PHASE3":11165,"PHASE4":11167,"NA":11169},{"trials":11156,"activeCount":101},[],{"trials":11158,"activeCount":101},[],{"trials":11160,"activeCount":651,"soonestReadout":305},[11161],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11162,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11163,"interventions":11164},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11166,"activeCount":101},[],{"trials":11168,"activeCount":101},[],{"trials":11170,"activeCount":101},[],{"intervention":1397,"totalTrials":651,"cells":11172},{"EARLY_PHASE1":11173,"PHASE1":11175,"PHASE2":11177,"PHASE3":11183,"PHASE4":11185,"NA":11187},{"trials":11174,"activeCount":101},[],{"trials":11176,"activeCount":101},[],{"trials":11178,"activeCount":651,"soonestReadout":305},[11179],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11180,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11181,"interventions":11182},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11184,"activeCount":101},[],{"trials":11186,"activeCount":101},[],{"trials":11188,"activeCount":101},[],{"intervention":1399,"totalTrials":651,"cells":11190},{"EARLY_PHASE1":11191,"PHASE1":11193,"PHASE2":11195,"PHASE3":11201,"PHASE4":11203,"NA":11205},{"trials":11192,"activeCount":101},[],{"trials":11194,"activeCount":101},[],{"trials":11196,"activeCount":651,"soonestReadout":305},[11197],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11198,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11199,"interventions":11200},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11202,"activeCount":101},[],{"trials":11204,"activeCount":101},[],{"trials":11206,"activeCount":101},[],{"intervention":1401,"totalTrials":651,"cells":11208},{"EARLY_PHASE1":11209,"PHASE1":11211,"PHASE2":11213,"PHASE3":11219,"PHASE4":11221,"NA":11223},{"trials":11210,"activeCount":101},[],{"trials":11212,"activeCount":101},[],{"trials":11214,"activeCount":651,"soonestReadout":305},[11215],{"nctId":1362,"briefTitle":1363,"status":121,"phases":11216,"primaryCompletion":305,"completion":1365,"start":1366,"enrollment":1367,"conditions":11217,"interventions":11218},[90],[1369,15,1370,1371,521,830,1372,1373,1374,1375],[1377,433,1378,1379,432,1380,1381,413,1382,1383,253,1384,626,1385,1386,581,455,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401],{"trials":11220,"activeCount":101},[],{"trials":11222,"activeCount":101},[],{"trials":11224,"activeCount":101},[],{"intervention":11226,"totalTrials":651,"cells":11227},"Irinotecan liposomes combined with cetuximab + vermofenib",{"EARLY_PHASE1":11228,"PHASE1":11230,"PHASE2":11232,"PHASE3":11241,"PHASE4":11243,"NA":11245},{"trials":11229,"activeCount":101},[],{"trials":11231,"activeCount":101},[],{"trials":11233,"activeCount":651,"soonestReadout":963},[11234],{"nctId":11235,"briefTitle":11236,"status":121,"phases":11237,"primaryCompletion":963,"completion":963,"start":11238,"enrollment":3068,"conditions":11239,"interventions":11240},"NCT06763029","Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer",[90],"2025-02-26",[2816],[11226],{"trials":11242,"activeCount":101},[],{"trials":11244,"activeCount":101},[],{"trials":11246,"activeCount":101},[],{"intervention":11248,"totalTrials":651,"cells":11249},"SHR-1701 + SBRT",{"EARLY_PHASE1":11250,"PHASE1":11252,"PHASE2":11254,"PHASE3":11264,"PHASE4":11266,"NA":11268},{"trials":11251,"activeCount":101},[],{"trials":11253,"activeCount":101},[],{"trials":11255,"activeCount":651,"soonestReadout":6247},[11256],{"nctId":11257,"briefTitle":11258,"status":121,"phases":11259,"primaryCompletion":6247,"completion":236,"start":11260,"enrollment":3146,"conditions":11261,"interventions":11263},"NCT07451795","SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC",[90],"2026-03-02",[8780,11262],"mCRPC (Metastatic Castration-resistant Prostate Cancer)",[11248],{"trials":11265,"activeCount":101},[],{"trials":11267,"activeCount":101},[],{"trials":11269,"activeCount":101},[],{"intervention":11271,"totalTrials":651,"cells":11272},"PD-1 antibody+ HDAC inhibitor",{"EARLY_PHASE1":11273,"PHASE1":11275,"PHASE2":11277,"PHASE3":11288,"PHASE4":11290,"NA":11292},{"trials":11274,"activeCount":101},[],{"trials":11276,"activeCount":101},[],{"trials":11278,"activeCount":651,"soonestReadout":1335},[11279],{"nctId":11280,"briefTitle":11281,"status":121,"phases":11282,"primaryCompletion":1335,"completion":963,"start":11283,"enrollment":11284,"conditions":11285,"interventions":11287},"NCT04512534","Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma",[90],"2020-11-13",51,[11286],"Peripheral T-cell Lymphoma",[11271],{"trials":11289,"activeCount":101},[],{"trials":11291,"activeCount":101},[],{"trials":11293,"activeCount":101},[],{"intervention":6821,"totalTrials":651,"cells":11295},{"EARLY_PHASE1":11296,"PHASE1":11298,"PHASE2":11300,"PHASE3":11306,"PHASE4":11308,"NA":11310},{"trials":11297,"activeCount":101},[],{"trials":11299,"activeCount":101},[],{"trials":11301,"activeCount":651,"soonestReadout":6817},[11302],{"nctId":6814,"briefTitle":6815,"status":121,"phases":11303,"primaryCompletion":6817,"completion":1609,"start":6818,"enrollment":3866,"conditions":11304,"interventions":11305},[90],[6157],[1391,6821,115],{"trials":11307,"activeCount":101},[],{"trials":11309,"activeCount":101},[],{"trials":11311,"activeCount":101},[],{"intervention":7102,"totalTrials":651,"cells":11313},{"EARLY_PHASE1":11314,"PHASE1":11316,"PHASE2":11318,"PHASE3":11324,"PHASE4":11326,"NA":11328},{"trials":11315,"activeCount":101},[],{"trials":11317,"activeCount":101},[],{"trials":11319,"activeCount":651,"soonestReadout":7097},[11320],{"nctId":7094,"briefTitle":7095,"status":121,"phases":11321,"primaryCompletion":7097,"completion":7098,"start":1802,"enrollment":7099,"conditions":11322,"interventions":11323},[90],[6157],[1325,7102],{"trials":11325,"activeCount":101},[],{"trials":11327,"activeCount":101},[],{"trials":11329,"activeCount":101},[],{"intervention":2977,"totalTrials":651,"cells":11331},{"EARLY_PHASE1":11332,"PHASE1":11334,"PHASE2":11336,"PHASE3":11342,"PHASE4":11344,"NA":11346},{"trials":11333,"activeCount":101},[],{"trials":11335,"activeCount":101},[],{"trials":11337,"activeCount":651,"soonestReadout":2971},[11338],{"nctId":2968,"briefTitle":2969,"status":121,"phases":11339,"primaryCompletion":2971,"completion":2972,"start":2973,"enrollment":22,"conditions":11340,"interventions":11341},[90],[2975],[2977,1764,1466,2978],{"trials":11343,"activeCount":101},[],{"trials":11345,"activeCount":101},[],{"trials":11347,"activeCount":101},[],{"intervention":1411,"totalTrials":651,"cells":11349},{"EARLY_PHASE1":11350,"PHASE1":11352,"PHASE2":11354,"PHASE3":11360,"PHASE4":11362,"NA":11364},{"trials":11351,"activeCount":101},[],{"trials":11353,"activeCount":101},[],{"trials":11355,"activeCount":651,"soonestReadout":896},[11356],{"nctId":1403,"briefTitle":1404,"status":121,"phases":11357,"primaryCompletion":896,"completion":1406,"start":1407,"enrollment":369,"conditions":11358,"interventions":11359},[90],[1409,830],[1411,455,432],{"trials":11361,"activeCount":101},[],{"trials":11363,"activeCount":101},[],{"trials":11365,"activeCount":101},[],{"intervention":11367,"totalTrials":651,"cells":11368},"G-CSF+IL-11",{"EARLY_PHASE1":11369,"PHASE1":11371,"PHASE2":11373,"PHASE3":11385,"PHASE4":11387,"NA":11389},{"trials":11370,"activeCount":101},[],{"trials":11372,"activeCount":101},[],{"trials":11374,"activeCount":651,"soonestReadout":783},[11375],{"nctId":11376,"briefTitle":11377,"status":121,"phases":11378,"primaryCompletion":783,"completion":783,"start":825,"enrollment":4543,"conditions":11379,"interventions":11383},"NCT07362810","G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation",[90],[11380,11381,11382],"Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)","Hematopoetic Stem Cell Transplantation","Hemato-oncologic Patients",[11367,11384],"G-CSF Granulocyte-Colony Stimulating Factor",{"trials":11386,"activeCount":101},[],{"trials":11388,"activeCount":101},[],{"trials":11390,"activeCount":101},[],{"intervention":11384,"totalTrials":651,"cells":11392},{"EARLY_PHASE1":11393,"PHASE1":11395,"PHASE2":11397,"PHASE3":11403,"PHASE4":11405,"NA":11407},{"trials":11394,"activeCount":101},[],{"trials":11396,"activeCount":101},[],{"trials":11398,"activeCount":651,"soonestReadout":783},[11399],{"nctId":11376,"briefTitle":11377,"status":121,"phases":11400,"primaryCompletion":783,"completion":783,"start":825,"enrollment":4543,"conditions":11401,"interventions":11402},[90],[11380,11381,11382],[11367,11384],{"trials":11404,"activeCount":101},[],{"trials":11406,"activeCount":101},[],{"trials":11408,"activeCount":101},[],{"intervention":11410,"totalTrials":651,"cells":11411},"Cadonilimab + bevacizumab + FOLFOX",{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11416,"PHASE3":11425,"PHASE4":11427,"NA":11429},{"trials":11413,"activeCount":101},[],{"trials":11415,"activeCount":101},[],{"trials":11417,"activeCount":651,"soonestReadout":1609},[11418],{"nctId":11419,"briefTitle":11420,"status":121,"phases":11421,"primaryCompletion":1609,"completion":963,"start":125,"enrollment":7318,"conditions":11422,"interventions":11424},"NCT06218810","Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer",[90],[6157,6132,11423,477],"RAS Mutation",[11410],{"trials":11426,"activeCount":101},[],{"trials":11428,"activeCount":101},[],{"trials":11430,"activeCount":101},[],{"intervention":9357,"totalTrials":651,"cells":11432},{"EARLY_PHASE1":11433,"PHASE1":11435,"PHASE2":11437,"PHASE3":11443,"PHASE4":11445,"NA":11447},{"trials":11434,"activeCount":101},[],{"trials":11436,"activeCount":101},[],{"trials":11438,"activeCount":651,"soonestReadout":470},[11439],{"nctId":9351,"briefTitle":9352,"status":270,"phases":11440,"primaryCompletion":470,"completion":3740,"start":2582,"enrollment":1434,"conditions":11441,"interventions":11442},[90],[9355],[9357,9342],{"trials":11444,"activeCount":101},[],{"trials":11446,"activeCount":101},[],{"trials":11448,"activeCount":101},[],{"intervention":11450,"totalTrials":651,"cells":11451},"Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin",{"EARLY_PHASE1":11452,"PHASE1":11454,"PHASE2":11456,"PHASE3":11465,"PHASE4":11467,"NA":11469},{"trials":11453,"activeCount":101},[],{"trials":11455,"activeCount":101},[],{"trials":11457,"activeCount":651,"soonestReadout":179},[11458],{"nctId":11459,"briefTitle":11460,"status":121,"phases":11461,"primaryCompletion":179,"completion":1760,"start":189,"enrollment":737,"conditions":11462,"interventions":11464},"NCT06406426","Study of The Second-line Treatment of Advanced Gastric \u002F Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin",[90],[11463],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma",[11450],{"trials":11466,"activeCount":101},[],{"trials":11468,"activeCount":101},[],{"trials":11470,"activeCount":101},[],{"intervention":3710,"totalTrials":651,"cells":11472},{"EARLY_PHASE1":11473,"PHASE1":11475,"PHASE2":11477,"PHASE3":11483,"PHASE4":11485,"NA":11487},{"trials":11474,"activeCount":101},[],{"trials":11476,"activeCount":101},[],{"trials":11478,"activeCount":651,"soonestReadout":1114},[11479],{"nctId":3703,"briefTitle":3704,"status":121,"phases":11480,"primaryCompletion":1114,"completion":2017,"start":3706,"enrollment":111,"conditions":11481,"interventions":11482},[90],[3708],[3710,1218],{"trials":11484,"activeCount":101},[],{"trials":11486,"activeCount":101},[],{"trials":11488,"activeCount":101},[],{"intervention":11490,"totalTrials":651,"cells":11491},"Tamoxifen 20 mg",{"EARLY_PHASE1":11492,"PHASE1":11494,"PHASE2":11496,"PHASE3":11506,"PHASE4":11508,"NA":11510},{"trials":11493,"activeCount":101},[],{"trials":11495,"activeCount":101},[],{"trials":11497,"activeCount":651,"soonestReadout":2262},[11498],{"nctId":11499,"briefTitle":11500,"status":121,"phases":11501,"primaryCompletion":2262,"completion":11502,"start":6080,"enrollment":25,"conditions":11503,"interventions":11505},"NCT06914674","Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas",[90],"2028-02-28",[11504],"Pancreatic Neoplasms",[11490],{"trials":11507,"activeCount":101},[],{"trials":11509,"activeCount":101},[],{"trials":11511,"activeCount":101},[],{"intervention":6728,"totalTrials":651,"cells":11513},{"EARLY_PHASE1":11514,"PHASE1":11516,"PHASE2":11518,"PHASE3":11524,"PHASE4":11526,"NA":11528},{"trials":11515,"activeCount":101},[],{"trials":11517,"activeCount":101},[],{"trials":11519,"activeCount":651,"soonestReadout":1318},[11520],{"nctId":6723,"briefTitle":6724,"status":121,"phases":11521,"primaryCompletion":1318,"completion":801,"start":1965,"enrollment":3648,"conditions":11522,"interventions":11523},[90],[27],[6728,62],{"trials":11525,"activeCount":101},[],{"trials":11527,"activeCount":101},[],{"trials":11529,"activeCount":101},[],{"intervention":2807,"totalTrials":651,"cells":11531},{"EARLY_PHASE1":11532,"PHASE1":11534,"PHASE2":11536,"PHASE3":11542,"PHASE4":11544,"NA":11546},{"trials":11533,"activeCount":101},[],{"trials":11535,"activeCount":101},[],{"trials":11537,"activeCount":651,"soonestReadout":2802},[11538],{"nctId":2799,"briefTitle":2800,"status":121,"phases":11539,"primaryCompletion":2802,"completion":398,"start":2803,"enrollment":2804,"conditions":11540,"interventions":11541},[90],[30],[2764,2807,2808,1120,1134],{"trials":11543,"activeCount":101},[],{"trials":11545,"activeCount":101},[],{"trials":11547,"activeCount":101},[],{"intervention":2219,"totalTrials":651,"cells":11549},{"EARLY_PHASE1":11550,"PHASE1":11552,"PHASE2":11554,"PHASE3":11560,"PHASE4":11562,"NA":11564},{"trials":11551,"activeCount":101},[],{"trials":11553,"activeCount":101},[],{"trials":11555,"activeCount":651,"soonestReadout":963},[11556],{"nctId":2213,"briefTitle":2214,"status":121,"phases":11557,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":11558,"interventions":11559},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"trials":11561,"activeCount":101},[],{"trials":11563,"activeCount":101},[],{"trials":11565,"activeCount":101},[],{"intervention":2221,"totalTrials":651,"cells":11567},{"EARLY_PHASE1":11568,"PHASE1":11570,"PHASE2":11572,"PHASE3":11578,"PHASE4":11580,"NA":11582},{"trials":11569,"activeCount":101},[],{"trials":11571,"activeCount":101},[],{"trials":11573,"activeCount":651,"soonestReadout":963},[11574],{"nctId":2213,"briefTitle":2214,"status":121,"phases":11575,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":11576,"interventions":11577},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"trials":11579,"activeCount":101},[],{"trials":11581,"activeCount":101},[],{"trials":11583,"activeCount":101},[],{"intervention":2222,"totalTrials":651,"cells":11585},{"EARLY_PHASE1":11586,"PHASE1":11588,"PHASE2":11590,"PHASE3":11596,"PHASE4":11598,"NA":11600},{"trials":11587,"activeCount":101},[],{"trials":11589,"activeCount":101},[],{"trials":11591,"activeCount":651,"soonestReadout":963},[11592],{"nctId":2213,"briefTitle":2214,"status":121,"phases":11593,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":11594,"interventions":11595},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"trials":11597,"activeCount":101},[],{"trials":11599,"activeCount":101},[],{"trials":11601,"activeCount":101},[],{"intervention":2224,"totalTrials":651,"cells":11603},{"EARLY_PHASE1":11604,"PHASE1":11606,"PHASE2":11608,"PHASE3":11614,"PHASE4":11616,"NA":11618},{"trials":11605,"activeCount":101},[],{"trials":11607,"activeCount":101},[],{"trials":11609,"activeCount":651,"soonestReadout":963},[11610],{"nctId":2213,"briefTitle":2214,"status":121,"phases":11611,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":11612,"interventions":11613},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"trials":11615,"activeCount":101},[],{"trials":11617,"activeCount":101},[],{"trials":11619,"activeCount":101},[],{"intervention":2225,"totalTrials":651,"cells":11621},{"EARLY_PHASE1":11622,"PHASE1":11624,"PHASE2":11626,"PHASE3":11632,"PHASE4":11634,"NA":11636},{"trials":11623,"activeCount":101},[],{"trials":11625,"activeCount":101},[],{"trials":11627,"activeCount":651,"soonestReadout":963},[11628],{"nctId":2213,"briefTitle":2214,"status":121,"phases":11629,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":11630,"interventions":11631},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"trials":11633,"activeCount":101},[],{"trials":11635,"activeCount":101},[],{"trials":11637,"activeCount":101},[],{"intervention":2226,"totalTrials":651,"cells":11639},{"EARLY_PHASE1":11640,"PHASE1":11642,"PHASE2":11644,"PHASE3":11650,"PHASE4":11652,"NA":11654},{"trials":11641,"activeCount":101},[],{"trials":11643,"activeCount":101},[],{"trials":11645,"activeCount":651,"soonestReadout":963},[11646],{"nctId":2213,"briefTitle":2214,"status":121,"phases":11647,"primaryCompletion":963,"completion":2216,"start":2133,"enrollment":334,"conditions":11648,"interventions":11649},[90],[161],[2219,2220,2221,2222,1378,2223,1379,2224,2225,2226],{"trials":11651,"activeCount":101},[],{"trials":11653,"activeCount":101},[],{"trials":11655,"activeCount":101},[],{"intervention":6349,"totalTrials":651,"cells":11657},{"EARLY_PHASE1":11658,"PHASE1":11660,"PHASE2":11662,"PHASE3":11668,"PHASE4":11670,"NA":11672},{"trials":11659,"activeCount":101},[],{"trials":11661,"activeCount":101},[],{"trials":11663,"activeCount":651,"soonestReadout":666},[11664],{"nctId":6341,"briefTitle":6342,"status":121,"phases":11665,"primaryCompletion":666,"completion":6344,"start":6345,"enrollment":6346,"conditions":11666,"interventions":11667},[90],[15],[1379,230,6349],{"trials":11669,"activeCount":101},[],{"trials":11671,"activeCount":101},[],{"trials":11673,"activeCount":101},[],{"intervention":11675,"totalTrials":651,"cells":11676},"Albumin-paclitaxel",{"EARLY_PHASE1":11677,"PHASE1":11679,"PHASE2":11681,"PHASE3":11693,"PHASE4":11695,"NA":11697},{"trials":11678,"activeCount":101},[],{"trials":11680,"activeCount":101},[],{"trials":11682,"activeCount":651,"soonestReadout":783},[11683],{"nctId":11684,"briefTitle":11685,"status":121,"phases":11686,"primaryCompletion":783,"completion":2017,"start":6622,"enrollment":213,"conditions":11687,"interventions":11692},"NCT06684327","Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors",[90],[11688,11689,11690,7637,11691],"Paget Disease, Extramammary","Rhabdomyosarcoma","Testicular Cancer","Urachal Cancer",[11675],{"trials":11694,"activeCount":101},[],{"trials":11696,"activeCount":101},[],{"trials":11698,"activeCount":101},[],{"intervention":3747,"totalTrials":651,"cells":11700},{"EARLY_PHASE1":11701,"PHASE1":11703,"PHASE2":11705,"PHASE3":11711,"PHASE4":11713,"NA":11715},{"trials":11702,"activeCount":101},[],{"trials":11704,"activeCount":101},[],{"trials":11706,"activeCount":651,"soonestReadout":3740},[11707],{"nctId":3737,"briefTitle":3738,"status":121,"phases":11708,"primaryCompletion":3740,"completion":3741,"start":3742,"enrollment":1610,"conditions":11709,"interventions":11710},[89,90],[3744,3745],[3747,3728,3748],{"trials":11712,"activeCount":101},[],{"trials":11714,"activeCount":101},[],{"trials":11716,"activeCount":101},[],{"intervention":3748,"totalTrials":651,"cells":11718},{"EARLY_PHASE1":11719,"PHASE1":11721,"PHASE2":11723,"PHASE3":11729,"PHASE4":11731,"NA":11733},{"trials":11720,"activeCount":101},[],{"trials":11722,"activeCount":101},[],{"trials":11724,"activeCount":651,"soonestReadout":3740},[11725],{"nctId":3737,"briefTitle":3738,"status":121,"phases":11726,"primaryCompletion":3740,"completion":3741,"start":3742,"enrollment":1610,"conditions":11727,"interventions":11728},[89,90],[3744,3745],[3747,3728,3748],{"trials":11730,"activeCount":101},[],{"trials":11732,"activeCount":101},[],{"trials":11734,"activeCount":101},[],{"intervention":11736,"totalTrials":651,"cells":11737},"R-CDOP+intrathecal MTX",{"EARLY_PHASE1":11738,"PHASE1":11740,"PHASE2":11742,"PHASE3":11753,"PHASE4":11755,"NA":11757},{"trials":11739,"activeCount":101},[],{"trials":11741,"activeCount":101},[],{"trials":11743,"activeCount":651,"soonestReadout":783},[11744],{"nctId":11745,"briefTitle":11746,"status":121,"phases":11747,"primaryCompletion":783,"completion":2018,"start":11748,"enrollment":11749,"conditions":11750,"interventions":11752},"NCT05257018","R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse",[90],"2022-02-26",83,[11751],"Diffuse Large B-cell Lymphoma",[11736],{"trials":11754,"activeCount":101},[],{"trials":11756,"activeCount":101},[],{"trials":11758,"activeCount":101},[],{"intervention":11760,"totalTrials":651,"cells":11761},"EGFR-TK Inhibitor",{"EARLY_PHASE1":11762,"PHASE1":11764,"PHASE2":11766,"PHASE3":11778,"PHASE4":11780,"NA":11782},{"trials":11763,"activeCount":101},[],{"trials":11765,"activeCount":101},[],{"trials":11767,"activeCount":651,"soonestReadout":11772},[11768],{"nctId":11769,"briefTitle":11770,"status":505,"phases":11771,"primaryCompletion":11772,"completion":11773,"start":11774,"enrollment":7031,"conditions":11775,"interventions":11777},"NCT06020066","SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI",[90],"2027-08-10","2028-08-10","2023-08-10",[11776,2960],"Brain Metastases",[11760],{"trials":11779,"activeCount":101},[],{"trials":11781,"activeCount":101},[],{"trials":11783,"activeCount":101},[],{"intervention":81,"totalTrials":651,"cells":11785},{"EARLY_PHASE1":11786,"PHASE1":11788,"PHASE2":11790,"PHASE3":11797,"PHASE4":11799,"NA":11801},{"trials":11787,"activeCount":101},[],{"trials":11789,"activeCount":101},[],{"trials":11791,"activeCount":651,"soonestReadout":76},[11792],{"nctId":79,"briefTitle":80,"status":270,"phases":11793,"primaryCompletion":76,"completion":1897,"start":11794,"enrollment":1248,"conditions":11795,"interventions":11796},[90],"2023-11",[15,11776,1553],[81],{"trials":11798,"activeCount":101},[],{"trials":11800,"activeCount":101},[],{"trials":11802,"activeCount":101},[],{"intervention":1428,"totalTrials":651,"cells":11804},{"EARLY_PHASE1":11805,"PHASE1":11807,"PHASE2":11809,"PHASE3":11815,"PHASE4":11817,"NA":11819},{"trials":11806,"activeCount":101},[],{"trials":11808,"activeCount":101},[],{"trials":11810,"activeCount":651,"soonestReadout":1406},[11811],{"nctId":1422,"briefTitle":1423,"status":270,"phases":11812,"primaryCompletion":1406,"completion":123,"start":1356,"enrollment":737,"conditions":11813,"interventions":11814},[90],[1426,33],[1428,432,254],{"trials":11816,"activeCount":101},[],{"trials":11818,"activeCount":101},[],{"trials":11820,"activeCount":101},[],{"intervention":11822,"totalTrials":651,"cells":11823},"Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin",{"EARLY_PHASE1":11824,"PHASE1":11826,"PHASE2":11828,"PHASE3":11837,"PHASE4":11839,"NA":11841},{"trials":11825,"activeCount":101},[],{"trials":11827,"activeCount":101},[],{"trials":11829,"activeCount":651,"soonestReadout":10259},[11830],{"nctId":11831,"briefTitle":11832,"status":270,"phases":11833,"primaryCompletion":10259,"completion":10259,"start":2772,"enrollment":828,"conditions":11834,"interventions":11836},"NCT07514793","Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma",[90],[11835],"Mesothelioma",[11822],{"trials":11838,"activeCount":101},[],{"trials":11840,"activeCount":101},[],{"trials":11842,"activeCount":101},[],{"intervention":11844,"totalTrials":651,"cells":11845},"HAIC combined with sintilimab and donafenib",{"EARLY_PHASE1":11846,"PHASE1":11848,"PHASE2":11850,"PHASE3":11860,"PHASE4":11862,"NA":11864},{"trials":11847,"activeCount":101},[],{"trials":11849,"activeCount":101},[],{"trials":11851,"activeCount":651,"soonestReadout":963},[11852],{"nctId":11853,"briefTitle":11854,"status":121,"phases":11855,"primaryCompletion":963,"completion":11856,"start":367,"enrollment":6991,"conditions":11857,"interventions":11858},"NCT06812039","HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence",[90],"2028-01-31",[6442],[11844,11859],"Sintilimab and Donafenib",{"trials":11861,"activeCount":101},[],{"trials":11863,"activeCount":101},[],{"trials":11865,"activeCount":101},[],{"intervention":11859,"totalTrials":651,"cells":11867},{"EARLY_PHASE1":11868,"PHASE1":11870,"PHASE2":11872,"PHASE3":11878,"PHASE4":11880,"NA":11882},{"trials":11869,"activeCount":101},[],{"trials":11871,"activeCount":101},[],{"trials":11873,"activeCount":651,"soonestReadout":963},[11874],{"nctId":11853,"briefTitle":11854,"status":121,"phases":11875,"primaryCompletion":963,"completion":11856,"start":367,"enrollment":6991,"conditions":11876,"interventions":11877},[90],[6442],[11844,11859],{"trials":11879,"activeCount":101},[],{"trials":11881,"activeCount":101},[],{"trials":11883,"activeCount":101},[],{"intervention":11885,"totalTrials":651,"cells":11886},"Cohort2: ATRA+Toripalimab+TPC",{"EARLY_PHASE1":11887,"PHASE1":11889,"PHASE2":11891,"PHASE3":11901,"PHASE4":11903,"NA":11905},{"trials":11888,"activeCount":101},[],{"trials":11890,"activeCount":101},[],{"trials":11892,"activeCount":651,"soonestReadout":1365},[11893],{"nctId":11894,"briefTitle":11895,"status":121,"phases":11896,"primaryCompletion":1365,"completion":1365,"start":11897,"enrollment":10324,"conditions":11898,"interventions":11899},"NCT06636981","All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial",[90],"2024-11-04",[1426],[11885,11900],"Cohort1: ATRA+Toripalimab+chemo",{"trials":11902,"activeCount":101},[],{"trials":11904,"activeCount":101},[],{"trials":11906,"activeCount":101},[],{"intervention":11900,"totalTrials":651,"cells":11908},{"EARLY_PHASE1":11909,"PHASE1":11911,"PHASE2":11913,"PHASE3":11919,"PHASE4":11921,"NA":11923},{"trials":11910,"activeCount":101},[],{"trials":11912,"activeCount":101},[],{"trials":11914,"activeCount":651,"soonestReadout":1365},[11915],{"nctId":11894,"briefTitle":11895,"status":121,"phases":11916,"primaryCompletion":1365,"completion":1365,"start":11897,"enrollment":10324,"conditions":11917,"interventions":11918},[90],[1426],[11885,11900],{"trials":11920,"activeCount":101},[],{"trials":11922,"activeCount":101},[],{"trials":11924,"activeCount":101},[],{"intervention":11926,"totalTrials":651,"cells":11927},"Metfomin",{"EARLY_PHASE1":11928,"PHASE1":11930,"PHASE2":11932,"PHASE3":11943,"PHASE4":11945,"NA":11947},{"trials":11929,"activeCount":101},[],{"trials":11931,"activeCount":101},[],{"trials":11933,"activeCount":651,"soonestReadout":1620},[11934],{"nctId":11935,"briefTitle":11936,"status":121,"phases":11937,"primaryCompletion":1620,"completion":1620,"start":1530,"enrollment":9193,"conditions":11938,"interventions":11942},"NCT07395960","The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment",[89,90],[11939,11940,11941],"Mild Cognitive Impairment","Overweight or Obesity","Elderly",[11926],{"trials":11944,"activeCount":101},[],{"trials":11946,"activeCount":101},[],{"trials":11948,"activeCount":101},[],{"intervention":791,"totalTrials":651,"cells":11950},{"EARLY_PHASE1":11951,"PHASE1":11953,"PHASE2":11955,"PHASE3":11961,"PHASE4":11963,"NA":11965},{"trials":11952,"activeCount":101},[],{"trials":11954,"activeCount":101},[],{"trials":11956,"activeCount":651,"soonestReadout":783},[11957],{"nctId":780,"briefTitle":781,"status":121,"phases":11958,"primaryCompletion":783,"completion":784,"start":785,"enrollment":737,"conditions":11959,"interventions":11960},[90],[787,788],[790,791],{"trials":11962,"activeCount":101},[],{"trials":11964,"activeCount":101},[],{"trials":11966,"activeCount":101},[],{"intervention":11968,"totalTrials":651,"cells":11969},"A1: SHR-A1811",{"EARLY_PHASE1":11970,"PHASE1":11972,"PHASE2":11974,"PHASE3":11995,"PHASE4":11997,"NA":11999},{"trials":11971,"activeCount":101},[],{"trials":11973,"activeCount":101},[],{"trials":11975,"activeCount":651,"soonestReadout":305},[11976],{"nctId":11977,"briefTitle":11978,"status":121,"phases":11979,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":11980,"interventions":11981},"NCT05749588","FUSCC Refractory TNBC Platform Study (FUTURE2.0)",[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],"A2: SHR-A1811 with Camrelizumab with famitinib","B1: TROP2 ADC","B2: TROP2 ADC with Camrelizumab","C1: SHR-A1811","C2: SHR-A1811 with BP102","D1: TROP2 ADC","D2: TROP2 ADC with BP102","E1: SHR-A1811","F1: TROP2 ADC","G1: SHR-A1811","H1: TROP2 ADC","E2: SHR-A1811 with everolimus","TQB2102 with TQB2868",{"trials":11996,"activeCount":101},[],{"trials":11998,"activeCount":101},[],{"trials":12000,"activeCount":101},[],{"intervention":11982,"totalTrials":651,"cells":12002},{"EARLY_PHASE1":12003,"PHASE1":12005,"PHASE2":12007,"PHASE3":12013,"PHASE4":12015,"NA":12017},{"trials":12004,"activeCount":101},[],{"trials":12006,"activeCount":101},[],{"trials":12008,"activeCount":651,"soonestReadout":305},[12009],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12010,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12011,"interventions":12012},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12014,"activeCount":101},[],{"trials":12016,"activeCount":101},[],{"trials":12018,"activeCount":101},[],{"intervention":11983,"totalTrials":651,"cells":12020},{"EARLY_PHASE1":12021,"PHASE1":12023,"PHASE2":12025,"PHASE3":12031,"PHASE4":12033,"NA":12035},{"trials":12022,"activeCount":101},[],{"trials":12024,"activeCount":101},[],{"trials":12026,"activeCount":651,"soonestReadout":305},[12027],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12028,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12029,"interventions":12030},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12032,"activeCount":101},[],{"trials":12034,"activeCount":101},[],{"trials":12036,"activeCount":101},[],{"intervention":11984,"totalTrials":651,"cells":12038},{"EARLY_PHASE1":12039,"PHASE1":12041,"PHASE2":12043,"PHASE3":12049,"PHASE4":12051,"NA":12053},{"trials":12040,"activeCount":101},[],{"trials":12042,"activeCount":101},[],{"trials":12044,"activeCount":651,"soonestReadout":305},[12045],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12046,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12047,"interventions":12048},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12050,"activeCount":101},[],{"trials":12052,"activeCount":101},[],{"trials":12054,"activeCount":101},[],{"intervention":11985,"totalTrials":651,"cells":12056},{"EARLY_PHASE1":12057,"PHASE1":12059,"PHASE2":12061,"PHASE3":12067,"PHASE4":12069,"NA":12071},{"trials":12058,"activeCount":101},[],{"trials":12060,"activeCount":101},[],{"trials":12062,"activeCount":651,"soonestReadout":305},[12063],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12064,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12065,"interventions":12066},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12068,"activeCount":101},[],{"trials":12070,"activeCount":101},[],{"trials":12072,"activeCount":101},[],{"intervention":11986,"totalTrials":651,"cells":12074},{"EARLY_PHASE1":12075,"PHASE1":12077,"PHASE2":12079,"PHASE3":12085,"PHASE4":12087,"NA":12089},{"trials":12076,"activeCount":101},[],{"trials":12078,"activeCount":101},[],{"trials":12080,"activeCount":651,"soonestReadout":305},[12081],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12082,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12083,"interventions":12084},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12086,"activeCount":101},[],{"trials":12088,"activeCount":101},[],{"trials":12090,"activeCount":101},[],{"intervention":11987,"totalTrials":651,"cells":12092},{"EARLY_PHASE1":12093,"PHASE1":12095,"PHASE2":12097,"PHASE3":12103,"PHASE4":12105,"NA":12107},{"trials":12094,"activeCount":101},[],{"trials":12096,"activeCount":101},[],{"trials":12098,"activeCount":651,"soonestReadout":305},[12099],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12100,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12101,"interventions":12102},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12104,"activeCount":101},[],{"trials":12106,"activeCount":101},[],{"trials":12108,"activeCount":101},[],{"intervention":11988,"totalTrials":651,"cells":12110},{"EARLY_PHASE1":12111,"PHASE1":12113,"PHASE2":12115,"PHASE3":12121,"PHASE4":12123,"NA":12125},{"trials":12112,"activeCount":101},[],{"trials":12114,"activeCount":101},[],{"trials":12116,"activeCount":651,"soonestReadout":305},[12117],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12118,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12119,"interventions":12120},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12122,"activeCount":101},[],{"trials":12124,"activeCount":101},[],{"trials":12126,"activeCount":101},[],{"intervention":11989,"totalTrials":651,"cells":12128},{"EARLY_PHASE1":12129,"PHASE1":12131,"PHASE2":12133,"PHASE3":12139,"PHASE4":12141,"NA":12143},{"trials":12130,"activeCount":101},[],{"trials":12132,"activeCount":101},[],{"trials":12134,"activeCount":651,"soonestReadout":305},[12135],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12136,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12137,"interventions":12138},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12140,"activeCount":101},[],{"trials":12142,"activeCount":101},[],{"trials":12144,"activeCount":101},[],{"intervention":11990,"totalTrials":651,"cells":12146},{"EARLY_PHASE1":12147,"PHASE1":12149,"PHASE2":12151,"PHASE3":12157,"PHASE4":12159,"NA":12161},{"trials":12148,"activeCount":101},[],{"trials":12150,"activeCount":101},[],{"trials":12152,"activeCount":651,"soonestReadout":305},[12153],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12154,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12155,"interventions":12156},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12158,"activeCount":101},[],{"trials":12160,"activeCount":101},[],{"trials":12162,"activeCount":101},[],{"intervention":11991,"totalTrials":651,"cells":12164},{"EARLY_PHASE1":12165,"PHASE1":12167,"PHASE2":12169,"PHASE3":12175,"PHASE4":12177,"NA":12179},{"trials":12166,"activeCount":101},[],{"trials":12168,"activeCount":101},[],{"trials":12170,"activeCount":651,"soonestReadout":305},[12171],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12172,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12173,"interventions":12174},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12176,"activeCount":101},[],{"trials":12178,"activeCount":101},[],{"trials":12180,"activeCount":101},[],{"intervention":11992,"totalTrials":651,"cells":12182},{"EARLY_PHASE1":12183,"PHASE1":12185,"PHASE2":12187,"PHASE3":12193,"PHASE4":12195,"NA":12197},{"trials":12184,"activeCount":101},[],{"trials":12186,"activeCount":101},[],{"trials":12188,"activeCount":651,"soonestReadout":305},[12189],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12190,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12191,"interventions":12192},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12194,"activeCount":101},[],{"trials":12196,"activeCount":101},[],{"trials":12198,"activeCount":101},[],{"intervention":11993,"totalTrials":651,"cells":12200},{"EARLY_PHASE1":12201,"PHASE1":12203,"PHASE2":12205,"PHASE3":12211,"PHASE4":12213,"NA":12215},{"trials":12202,"activeCount":101},[],{"trials":12204,"activeCount":101},[],{"trials":12206,"activeCount":651,"soonestReadout":305},[12207],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12208,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12209,"interventions":12210},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12212,"activeCount":101},[],{"trials":12214,"activeCount":101},[],{"trials":12216,"activeCount":101},[],{"intervention":11994,"totalTrials":651,"cells":12218},{"EARLY_PHASE1":12219,"PHASE1":12221,"PHASE2":12223,"PHASE3":12229,"PHASE4":12231,"NA":12233},{"trials":12220,"activeCount":101},[],{"trials":12222,"activeCount":101},[],{"trials":12224,"activeCount":651,"soonestReadout":305},[12225],{"nctId":11977,"briefTitle":11978,"status":121,"phases":12226,"primaryCompletion":305,"completion":236,"start":6036,"enrollment":296,"conditions":12227,"interventions":12228},[90],[161],[11968,11982,11983,11984,11985,11986,11987,11988,11989,11990,11991,11992,11993,11994],{"trials":12230,"activeCount":101},[],{"trials":12232,"activeCount":101},[],{"trials":12234,"activeCount":101},[],{"intervention":5961,"totalTrials":651,"cells":12236},{"EARLY_PHASE1":12237,"PHASE1":12239,"PHASE2":12241,"PHASE3":12247,"PHASE4":12249,"NA":12251},{"trials":12238,"activeCount":101},[],{"trials":12240,"activeCount":101},[],{"trials":12242,"activeCount":651,"soonestReadout":1560},[12243],{"nctId":5954,"briefTitle":5955,"status":121,"phases":12244,"primaryCompletion":1560,"completion":5957,"start":1562,"enrollment":379,"conditions":12245,"interventions":12246},[90],[5959],[278,5961],{"trials":12248,"activeCount":101},[],{"trials":12250,"activeCount":101},[],{"trials":12252,"activeCount":101},[],{"intervention":12254,"totalTrials":651,"cells":12255},"Serplulimab + chemotherapy",{"EARLY_PHASE1":12256,"PHASE1":12258,"PHASE2":12260,"PHASE3":12271,"PHASE4":12273,"NA":12275},{"trials":12257,"activeCount":101},[],{"trials":12259,"activeCount":101},[],{"trials":12261,"activeCount":651,"soonestReadout":305},[12262],{"nctId":12263,"briefTitle":12264,"status":121,"phases":12265,"primaryCompletion":305,"completion":2291,"start":12266,"enrollment":379,"conditions":12267,"interventions":12269},"NCT07398937","Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC",[90],"2026-02-05",[12268],"Resectable Stage II-IIIa Squamous NSCLC",[12254,12270],"Nivolumab + chemotherapy",{"trials":12272,"activeCount":101},[],{"trials":12274,"activeCount":101},[],{"trials":12276,"activeCount":101},[],{"intervention":12270,"totalTrials":651,"cells":12278},{"EARLY_PHASE1":12279,"PHASE1":12281,"PHASE2":12283,"PHASE3":12289,"PHASE4":12291,"NA":12293},{"trials":12280,"activeCount":101},[],{"trials":12282,"activeCount":101},[],{"trials":12284,"activeCount":651,"soonestReadout":305},[12285],{"nctId":12263,"briefTitle":12264,"status":121,"phases":12286,"primaryCompletion":305,"completion":2291,"start":12266,"enrollment":379,"conditions":12287,"interventions":12288},[90],[12268],[12254,12270],{"trials":12290,"activeCount":101},[],{"trials":12292,"activeCount":101},[],{"trials":12294,"activeCount":101},[],{"intervention":12296,"totalTrials":651,"cells":12297},"AK104 with radiotherapy",{"EARLY_PHASE1":12298,"PHASE1":12300,"PHASE2":12302,"PHASE3":12315,"PHASE4":12317,"NA":12319},{"trials":12299,"activeCount":101},[],{"trials":12301,"activeCount":101},[],{"trials":12303,"activeCount":651,"soonestReadout":12308},[12304],{"nctId":12305,"briefTitle":12306,"status":121,"phases":12307,"primaryCompletion":12308,"completion":12309,"start":12310,"enrollment":2123,"conditions":12311,"interventions":12313},"NCT07544784","AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR\u002FMSS CRLM (APSOC)",[90],"2027-12-01","2028-11-01","2025-11-04",[12312],"Colorectal Cancer Liver Metastases (CRLM)",[12296,12314],"Standard of therapy",{"trials":12316,"activeCount":101},[],{"trials":12318,"activeCount":101},[],{"trials":12320,"activeCount":101},[],{"intervention":12314,"totalTrials":651,"cells":12322},{"EARLY_PHASE1":12323,"PHASE1":12325,"PHASE2":12327,"PHASE3":12333,"PHASE4":12335,"NA":12337},{"trials":12324,"activeCount":101},[],{"trials":12326,"activeCount":101},[],{"trials":12328,"activeCount":651,"soonestReadout":12308},[12329],{"nctId":12305,"briefTitle":12306,"status":121,"phases":12330,"primaryCompletion":12308,"completion":12309,"start":12310,"enrollment":2123,"conditions":12331,"interventions":12332},[90],[12312],[12296,12314],{"trials":12334,"activeCount":101},[],{"trials":12336,"activeCount":101},[],{"trials":12338,"activeCount":101},[],{"intervention":12340,"totalTrials":651,"cells":12341},"PD-L1\u002FPD-1 inhibitor and chemotherapy",{"EARLY_PHASE1":12342,"PHASE1":12344,"PHASE2":12346,"PHASE3":12354,"PHASE4":12356,"NA":12358},{"trials":12343,"activeCount":101},[],{"trials":12345,"activeCount":101},[],{"trials":12347,"activeCount":651,"soonestReadout":1897},[12348],{"nctId":12349,"briefTitle":12350,"status":121,"phases":12351,"primaryCompletion":1897,"completion":644,"start":1156,"enrollment":9193,"conditions":12352,"interventions":12353},"NCT06501391","Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis",[90],[2109,11776],[12340],{"trials":12355,"activeCount":101},[],{"trials":12357,"activeCount":101},[],{"trials":12359,"activeCount":101},[],{"intervention":1782,"totalTrials":651,"cells":12361},{"EARLY_PHASE1":12362,"PHASE1":12364,"PHASE2":12366,"PHASE3":12372,"PHASE4":12374,"NA":12376},{"trials":12363,"activeCount":101},[],{"trials":12365,"activeCount":101},[],{"trials":12367,"activeCount":651,"soonestReadout":963},[12368],{"nctId":1774,"briefTitle":1775,"status":121,"phases":12369,"primaryCompletion":963,"completion":236,"start":1777,"enrollment":1778,"conditions":12370,"interventions":12371},[89,90],[1780,475],[278,1782,67,1783],{"trials":12373,"activeCount":101},[],{"trials":12375,"activeCount":101},[],{"trials":12377,"activeCount":101},[],{"intervention":1783,"totalTrials":651,"cells":12379},{"EARLY_PHASE1":12380,"PHASE1":12382,"PHASE2":12384,"PHASE3":12390,"PHASE4":12392,"NA":12394},{"trials":12381,"activeCount":101},[],{"trials":12383,"activeCount":101},[],{"trials":12385,"activeCount":651,"soonestReadout":963},[12386],{"nctId":1774,"briefTitle":1775,"status":121,"phases":12387,"primaryCompletion":963,"completion":236,"start":1777,"enrollment":1778,"conditions":12388,"interventions":12389},[89,90],[1780,475],[278,1782,67,1783],{"trials":12391,"activeCount":101},[],{"trials":12393,"activeCount":101},[],{"trials":12395,"activeCount":101},[],{"intervention":1628,"totalTrials":651,"cells":12397},{"EARLY_PHASE1":12398,"PHASE1":12400,"PHASE2":12402,"PHASE3":12408,"PHASE4":12410,"NA":12412},{"trials":12399,"activeCount":101},[],{"trials":12401,"activeCount":101},[],{"trials":12403,"activeCount":651,"soonestReadout":1620},[12404],{"nctId":1617,"briefTitle":1618,"status":121,"phases":12405,"primaryCompletion":1620,"completion":1621,"start":1622,"enrollment":1623,"conditions":12406,"interventions":12407},[90],[1625,1626],[310,1628],{"trials":12409,"activeCount":101},[],{"trials":12411,"activeCount":101},[],{"trials":12413,"activeCount":101},[],{"intervention":12415,"totalTrials":651,"cells":12416},"X-396(Ensartinib)",{"EARLY_PHASE1":12417,"PHASE1":12419,"PHASE2":12421,"PHASE3":12431,"PHASE4":12433,"NA":12435},{"trials":12418,"activeCount":101},[],{"trials":12420,"activeCount":101},[],{"trials":12422,"activeCount":651,"soonestReadout":2844},[12423],{"nctId":12424,"briefTitle":12425,"status":505,"phases":12426,"primaryCompletion":2844,"completion":235,"start":12427,"enrollment":1778,"conditions":12428,"interventions":12430},"NCT03753685","X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases",[90],"2019-04-12",[12429,11776],"Nonsmall Cell Lung Cancer",[12415],{"trials":12432,"activeCount":101},[],{"trials":12434,"activeCount":101},[],{"trials":12436,"activeCount":101},[],{"intervention":5977,"totalTrials":651,"cells":12438},{"EARLY_PHASE1":12439,"PHASE1":12441,"PHASE2":12443,"PHASE3":12449,"PHASE4":12451,"NA":12453},{"trials":12440,"activeCount":101},[],{"trials":12442,"activeCount":101},[],{"trials":12444,"activeCount":651,"soonestReadout":5970},[12445],{"nctId":5967,"briefTitle":5968,"status":121,"phases":12446,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":5973,"conditions":12447,"interventions":12448},[90],[5975],[278,5977],{"trials":12450,"activeCount":101},[],{"trials":12452,"activeCount":101},[],{"trials":12454,"activeCount":101},[],{"intervention":12456,"totalTrials":651,"cells":12457},"Chemotherapy, Bevacizumab, Adebrelimab",{"EARLY_PHASE1":12458,"PHASE1":12460,"PHASE2":12462,"PHASE3":12472,"PHASE4":12474,"NA":12476},{"trials":12459,"activeCount":101},[],{"trials":12461,"activeCount":101},[],{"trials":12463,"activeCount":651,"soonestReadout":145},[12464],{"nctId":12465,"briefTitle":12466,"status":270,"phases":12467,"primaryCompletion":145,"completion":12468,"start":12469,"enrollment":213,"conditions":12470,"interventions":12471},"NCT06513221","A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab",[90],"2027-04-12","2024-07-25",[6157],[12456],{"trials":12473,"activeCount":101},[],{"trials":12475,"activeCount":101},[],{"trials":12477,"activeCount":101},[],{"intervention":12479,"totalTrials":651,"cells":12480},"Imlunestrant + abemaciclib",{"EARLY_PHASE1":12481,"PHASE1":12483,"PHASE2":12485,"PHASE3":12495,"PHASE4":12497,"NA":12499},{"trials":12482,"activeCount":101},[],{"trials":12484,"activeCount":101},[],{"trials":12486,"activeCount":651,"soonestReadout":273},[12487],{"nctId":12488,"briefTitle":12489,"status":270,"phases":12490,"primaryCompletion":273,"completion":2174,"start":470,"enrollment":12491,"conditions":12492,"interventions":12493},"NCT07410559","Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer",[90],189,[15],[12479,12494],"(dd)EC*4-T*4",{"trials":12496,"activeCount":101},[],{"trials":12498,"activeCount":101},[],{"trials":12500,"activeCount":101},[],{"intervention":12494,"totalTrials":651,"cells":12502},{"EARLY_PHASE1":12503,"PHASE1":12505,"PHASE2":12507,"PHASE3":12513,"PHASE4":12515,"NA":12517},{"trials":12504,"activeCount":101},[],{"trials":12506,"activeCount":101},[],{"trials":12508,"activeCount":651,"soonestReadout":273},[12509],{"nctId":12488,"briefTitle":12489,"status":270,"phases":12510,"primaryCompletion":273,"completion":2174,"start":470,"enrollment":12491,"conditions":12511,"interventions":12512},[90],[15],[12479,12494],{"trials":12514,"activeCount":101},[],{"trials":12516,"activeCount":101},[],{"trials":12518,"activeCount":101},[],{"intervention":12520,"totalTrials":651,"cells":12521},"Orelabrutinib",{"EARLY_PHASE1":12522,"PHASE1":12524,"PHASE2":12526,"PHASE3":12537,"PHASE4":12539,"NA":12541},{"trials":12523,"activeCount":101},[],{"trials":12525,"activeCount":101},[],{"trials":12527,"activeCount":651,"soonestReadout":12532},[12528],{"nctId":12529,"briefTitle":12530,"status":505,"phases":12531,"primaryCompletion":12532,"completion":2251,"start":12533,"enrollment":97,"conditions":12534,"interventions":12536},"NCT06583837","Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma",[90],"2025-08-18","2024-09-10",[12535],"Lymphoma, B-Cell, Marginal Zone",[12520],{"trials":12538,"activeCount":101},[],{"trials":12540,"activeCount":101},[],{"trials":12542,"activeCount":101},[],{"intervention":8321,"totalTrials":651,"cells":12544},{"EARLY_PHASE1":12545,"PHASE1":12547,"PHASE2":12549,"PHASE3":12555,"PHASE4":12557,"NA":12559},{"trials":12546,"activeCount":101},[],{"trials":12548,"activeCount":101},[],{"trials":12550,"activeCount":651,"soonestReadout":726},[12551],{"nctId":8316,"briefTitle":8317,"status":270,"phases":12552,"primaryCompletion":726,"completion":6334,"start":6204,"enrollment":575,"conditions":12553,"interventions":12554},[90],[521],[8298,8321],{"trials":12556,"activeCount":101},[],{"trials":12558,"activeCount":101},[],{"trials":12560,"activeCount":101},[],{"intervention":8290,"totalTrials":651,"cells":12562},{"EARLY_PHASE1":12563,"PHASE1":12565,"PHASE2":12567,"PHASE3":12573,"PHASE4":12575,"NA":12577},{"trials":12564,"activeCount":101},[],{"trials":12566,"activeCount":101},[],{"trials":12568,"activeCount":651,"soonestReadout":85},[12569],{"nctId":83,"briefTitle":84,"status":270,"phases":12570,"primaryCompletion":85,"completion":235,"start":1801,"enrollment":488,"conditions":12571,"interventions":12572},[90],[15],[86,8290],{"trials":12574,"activeCount":101},[],{"trials":12576,"activeCount":101},[],{"trials":12578,"activeCount":101},[],{"intervention":12580,"totalTrials":651,"cells":12581},"Hyperthermic intraperitoneal chemotherapy",{"EARLY_PHASE1":12582,"PHASE1":12584,"PHASE2":12586,"PHASE3":12595,"PHASE4":12597,"NA":12599},{"trials":12583,"activeCount":101},[],{"trials":12585,"activeCount":101},[],{"trials":12587,"activeCount":651,"soonestReadout":235},[12588],{"nctId":12589,"briefTitle":12590,"status":270,"phases":12591,"primaryCompletion":235,"completion":963,"start":1682,"enrollment":12592,"conditions":12593,"interventions":12594},"NCT06544460","Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients",[90],94,[2737],[12580],{"trials":12596,"activeCount":101},[],{"trials":12598,"activeCount":101},[],{"trials":12600,"activeCount":101},[],{"intervention":2245,"totalTrials":651,"cells":12602},{"EARLY_PHASE1":12603,"PHASE1":12605,"PHASE2":12607,"PHASE3":12613,"PHASE4":12615,"NA":12617},{"trials":12604,"activeCount":101},[],{"trials":12606,"activeCount":101},[],{"trials":12608,"activeCount":651,"soonestReadout":783},[12609],{"nctId":2237,"briefTitle":2238,"status":505,"phases":12610,"primaryCompletion":783,"completion":783,"start":2240,"enrollment":2241,"conditions":12611,"interventions":12612},[90],[2243],[1378,2245,1380,1378],{"trials":12614,"activeCount":101},[],{"trials":12616,"activeCount":101},[],{"trials":12618,"activeCount":101},[],{"intervention":12620,"totalTrials":651,"cells":12621},"Rezvilutamide + ADT",{"EARLY_PHASE1":12622,"PHASE1":12624,"PHASE2":12626,"PHASE3":12636,"PHASE4":12638,"NA":12640},{"trials":12623,"activeCount":101},[],{"trials":12625,"activeCount":101},[],{"trials":12627,"activeCount":651,"soonestReadout":12632},[12628],{"nctId":12629,"briefTitle":12630,"status":270,"phases":12631,"primaryCompletion":12632,"completion":12632,"start":600,"enrollment":1290,"conditions":12633,"interventions":12635},"NCT07490210","Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer",[90],"2032-05-31",[12634],"Oligometastatic Prostate Cancer",[12620],{"trials":12637,"activeCount":101},[],{"trials":12639,"activeCount":101},[],{"trials":12641,"activeCount":101},[],{"intervention":1969,"totalTrials":651,"cells":12643},{"EARLY_PHASE1":12644,"PHASE1":12646,"PHASE2":12648,"PHASE3":12654,"PHASE4":12656,"NA":12658},{"trials":12645,"activeCount":101},[],{"trials":12647,"activeCount":101},[],{"trials":12649,"activeCount":651,"soonestReadout":1965},[12650],{"nctId":1962,"briefTitle":1963,"status":270,"phases":12651,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":12652,"interventions":12653},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"trials":12655,"activeCount":101},[],{"trials":12657,"activeCount":101},[],{"trials":12659,"activeCount":101},[],{"intervention":1971,"totalTrials":651,"cells":12661},{"EARLY_PHASE1":12662,"PHASE1":12664,"PHASE2":12666,"PHASE3":12672,"PHASE4":12674,"NA":12676},{"trials":12663,"activeCount":101},[],{"trials":12665,"activeCount":101},[],{"trials":12667,"activeCount":651,"soonestReadout":1965},[12668],{"nctId":1962,"briefTitle":1963,"status":270,"phases":12669,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":12670,"interventions":12671},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"trials":12673,"activeCount":101},[],{"trials":12675,"activeCount":101},[],{"trials":12677,"activeCount":101},[],{"intervention":1972,"totalTrials":651,"cells":12679},{"EARLY_PHASE1":12680,"PHASE1":12682,"PHASE2":12684,"PHASE3":12690,"PHASE4":12692,"NA":12694},{"trials":12681,"activeCount":101},[],{"trials":12683,"activeCount":101},[],{"trials":12685,"activeCount":651,"soonestReadout":1965},[12686],{"nctId":1962,"briefTitle":1963,"status":270,"phases":12687,"primaryCompletion":1965,"completion":1114,"start":1966,"enrollment":1417,"conditions":12688,"interventions":12689},[89,90],[30],[1969,1970,1971,1972,1973,1121,1974,253,255],{"trials":12691,"activeCount":101},[],{"trials":12693,"activeCount":101},[],{"trials":12695,"activeCount":101},[],{"intervention":12697,"totalTrials":651,"cells":12698},"MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer",{"EARLY_PHASE1":12699,"PHASE1":12701,"PHASE2":12703,"PHASE3":12716,"PHASE4":12718,"NA":12720},{"trials":12700,"activeCount":101},[],{"trials":12702,"activeCount":101},[],{"trials":12704,"activeCount":651,"soonestReadout":2017},[12705],{"nctId":12706,"briefTitle":12707,"status":121,"phases":12708,"primaryCompletion":2017,"completion":2018,"start":12310,"enrollment":12709,"conditions":12710,"interventions":12713},"NCT06889610","A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.",[90],95,[12711,12712,2816],"Triple Negative Breast Cancer Metastatic","Melanoma Metastatic",[12697,12714,12715],"MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer","MTT(Multimodal Tumor Thermal Therapy System)- Melanoma",{"trials":12717,"activeCount":101},[],{"trials":12719,"activeCount":101},[],{"trials":12721,"activeCount":101},[],{"intervention":12714,"totalTrials":651,"cells":12723},{"EARLY_PHASE1":12724,"PHASE1":12726,"PHASE2":12728,"PHASE3":12734,"PHASE4":12736,"NA":12738},{"trials":12725,"activeCount":101},[],{"trials":12727,"activeCount":101},[],{"trials":12729,"activeCount":651,"soonestReadout":2017},[12730],{"nctId":12706,"briefTitle":12707,"status":121,"phases":12731,"primaryCompletion":2017,"completion":2018,"start":12310,"enrollment":12709,"conditions":12732,"interventions":12733},[90],[12711,12712,2816],[12697,12714,12715],{"trials":12735,"activeCount":101},[],{"trials":12737,"activeCount":101},[],{"trials":12739,"activeCount":101},[],{"intervention":12715,"totalTrials":651,"cells":12741},{"EARLY_PHASE1":12742,"PHASE1":12744,"PHASE2":12746,"PHASE3":12752,"PHASE4":12754,"NA":12756},{"trials":12743,"activeCount":101},[],{"trials":12745,"activeCount":101},[],{"trials":12747,"activeCount":651,"soonestReadout":2017},[12748],{"nctId":12706,"briefTitle":12707,"status":121,"phases":12749,"primaryCompletion":2017,"completion":2018,"start":12310,"enrollment":12709,"conditions":12750,"interventions":12751},[90],[12711,12712,2816],[12697,12714,12715],{"trials":12753,"activeCount":101},[],{"trials":12755,"activeCount":101},[],{"trials":12757,"activeCount":101},[],{"intervention":6508,"totalTrials":651,"cells":12759},{"EARLY_PHASE1":12760,"PHASE1":12762,"PHASE2":12764,"PHASE3":12770,"PHASE4":12772,"NA":12774},{"trials":12761,"activeCount":101},[],{"trials":12763,"activeCount":101},[],{"trials":12765,"activeCount":651,"soonestReadout":2707},[12766],{"nctId":6500,"briefTitle":6501,"status":270,"phases":12767,"primaryCompletion":2707,"completion":6503,"start":1560,"enrollment":6504,"conditions":12768,"interventions":12769},[90],[6506],[1468,52,6508],{"trials":12771,"activeCount":101},[],{"trials":12773,"activeCount":101},[],{"trials":12775,"activeCount":101},[],{"intervention":12777,"totalTrials":651,"cells":12778},"SHR-A2102 or\u002Fand HRS-4642",{"EARLY_PHASE1":12779,"PHASE1":12781,"PHASE2":12783,"PHASE3":12795,"PHASE4":12797,"NA":12799},{"trials":12780,"activeCount":101},[],{"trials":12782,"activeCount":101},[],{"trials":12784,"activeCount":651,"soonestReadout":1812},[12785],{"nctId":12786,"briefTitle":12787,"status":121,"phases":12788,"primaryCompletion":1812,"completion":1406,"start":12789,"enrollment":345,"conditions":12790,"interventions":12791},"NCT06547736","Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer",[90],"2024-10-14",[30],[12777,12792,12793,12794],"SHR-A1904 or\u002Fand HRS-4642","SHR-A1811 or\u002Fand HRS-4642","SHR-A2102, HRS4642 and Adebrelimab",{"trials":12796,"activeCount":101},[],{"trials":12798,"activeCount":101},[],{"trials":12800,"activeCount":101},[],{"intervention":12792,"totalTrials":651,"cells":12802},{"EARLY_PHASE1":12803,"PHASE1":12805,"PHASE2":12807,"PHASE3":12813,"PHASE4":12815,"NA":12817},{"trials":12804,"activeCount":101},[],{"trials":12806,"activeCount":101},[],{"trials":12808,"activeCount":651,"soonestReadout":1812},[12809],{"nctId":12786,"briefTitle":12787,"status":121,"phases":12810,"primaryCompletion":1812,"completion":1406,"start":12789,"enrollment":345,"conditions":12811,"interventions":12812},[90],[30],[12777,12792,12793,12794],{"trials":12814,"activeCount":101},[],{"trials":12816,"activeCount":101},[],{"trials":12818,"activeCount":101},[],{"intervention":12793,"totalTrials":651,"cells":12820},{"EARLY_PHASE1":12821,"PHASE1":12823,"PHASE2":12825,"PHASE3":12831,"PHASE4":12833,"NA":12835},{"trials":12822,"activeCount":101},[],{"trials":12824,"activeCount":101},[],{"trials":12826,"activeCount":651,"soonestReadout":1812},[12827],{"nctId":12786,"briefTitle":12787,"status":121,"phases":12828,"primaryCompletion":1812,"completion":1406,"start":12789,"enrollment":345,"conditions":12829,"interventions":12830},[90],[30],[12777,12792,12793,12794],{"trials":12832,"activeCount":101},[],{"trials":12834,"activeCount":101},[],{"trials":12836,"activeCount":101},[],{"intervention":12794,"totalTrials":651,"cells":12838},{"EARLY_PHASE1":12839,"PHASE1":12841,"PHASE2":12843,"PHASE3":12849,"PHASE4":12851,"NA":12853},{"trials":12840,"activeCount":101},[],{"trials":12842,"activeCount":101},[],{"trials":12844,"activeCount":651,"soonestReadout":1812},[12845],{"nctId":12786,"briefTitle":12787,"status":121,"phases":12846,"primaryCompletion":1812,"completion":1406,"start":12789,"enrollment":345,"conditions":12847,"interventions":12848},[90],[30],[12777,12792,12793,12794],{"trials":12850,"activeCount":101},[],{"trials":12852,"activeCount":101},[],{"trials":12854,"activeCount":101},[],{"intervention":6625,"totalTrials":651,"cells":12856},{"EARLY_PHASE1":12857,"PHASE1":12859,"PHASE2":12861,"PHASE3":12867,"PHASE4":12869,"NA":12871},{"trials":12858,"activeCount":101},[],{"trials":12860,"activeCount":101},[],{"trials":12862,"activeCount":651,"soonestReadout":235},[12863],{"nctId":6619,"briefTitle":6620,"status":270,"phases":12864,"primaryCompletion":235,"completion":963,"start":6622,"enrollment":25,"conditions":12865,"interventions":12866},[90],[1854],[6625,2411],{"trials":12868,"activeCount":101},[],{"trials":12870,"activeCount":101},[],{"trials":12872,"activeCount":101},[],{"intervention":12874,"totalTrials":651,"cells":12875},"ATRA+pd-1+chemo",{"EARLY_PHASE1":12876,"PHASE1":12878,"PHASE2":12880,"PHASE3":12892,"PHASE4":12894,"NA":12896},{"trials":12877,"activeCount":101},[],{"trials":12879,"activeCount":101},[],{"trials":12881,"activeCount":651,"soonestReadout":12886},[12882],{"nctId":12883,"briefTitle":12884,"status":270,"phases":12885,"primaryCompletion":12886,"completion":12887,"start":12888,"enrollment":12889,"conditions":12890,"interventions":12891},"NCT06703047","Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma",[90],"2029-11-20","2030-10-24","2024-11-20",180,[27],[12874],{"trials":12893,"activeCount":101},[],{"trials":12895,"activeCount":101},[],{"trials":12897,"activeCount":101},[],{"intervention":12899,"totalTrials":651,"cells":12900},"a combination therapy including tislelizumab",{"EARLY_PHASE1":12901,"PHASE1":12903,"PHASE2":12905,"PHASE3":12915,"PHASE4":12917,"NA":12919},{"trials":12902,"activeCount":101},[],{"trials":12904,"activeCount":101},[],{"trials":12906,"activeCount":651,"soonestReadout":3067},[12907],{"nctId":12908,"briefTitle":12909,"status":270,"phases":12910,"primaryCompletion":3067,"completion":3067,"start":200,"enrollment":473,"conditions":12911,"interventions":12914},"NCT05359393","A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis",[90],[12912,6012,12913,6132],"Advanced Rectal Cancer","Pulmonary Metastasis",[12899],{"trials":12916,"activeCount":101},[],{"trials":12918,"activeCount":101},[],{"trials":12920,"activeCount":101},[],{"intervention":12922,"totalTrials":651,"cells":12923},"Anlotinib, Everolimus and Tislelizumab",{"EARLY_PHASE1":12924,"PHASE1":12926,"PHASE2":12928,"PHASE3":12939,"PHASE4":12941,"NA":12943},{"trials":12925,"activeCount":101},[],{"trials":12927,"activeCount":101},[],{"trials":12929,"activeCount":651,"soonestReadout":1489},[12930],{"nctId":12931,"briefTitle":12932,"status":121,"phases":12933,"primaryCompletion":1489,"completion":783,"start":12934,"enrollment":3146,"conditions":12935,"interventions":12938},"NCT06211790","Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma",[90],"2024-01-16",[12936,3392,12937],"Kidney Cancer","Renal Clear Cell Carcinoma",[12922],{"trials":12940,"activeCount":101},[],{"trials":12942,"activeCount":101},[],{"trials":12944,"activeCount":101},[],{"intervention":12946,"totalTrials":651,"cells":12947},"SHR-0302",{"EARLY_PHASE1":12948,"PHASE1":12950,"PHASE2":12952,"PHASE3":12963,"PHASE4":12965,"NA":12967},{"trials":12949,"activeCount":101},[],{"trials":12951,"activeCount":101},[],{"trials":12953,"activeCount":651,"soonestReadout":2262},[12954],{"nctId":12955,"briefTitle":12956,"status":121,"phases":12957,"primaryCompletion":2262,"completion":323,"start":12958,"enrollment":31,"conditions":12959,"interventions":12961},"NCT06519526","Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed\u002FRefractory Peripheral T Cell Lymphoma",[90],"2024-08-12",[12960],"Relapsed\u002FRefractory Peripheral T Cell Lymphoma",[12946,12962],"SHR-2554",{"trials":12964,"activeCount":101},[],{"trials":12966,"activeCount":101},[],{"trials":12968,"activeCount":101},[],{"intervention":12962,"totalTrials":651,"cells":12970},{"EARLY_PHASE1":12971,"PHASE1":12973,"PHASE2":12975,"PHASE3":12981,"PHASE4":12983,"NA":12985},{"trials":12972,"activeCount":101},[],{"trials":12974,"activeCount":101},[],{"trials":12976,"activeCount":651,"soonestReadout":2262},[12977],{"nctId":12955,"briefTitle":12956,"status":121,"phases":12978,"primaryCompletion":2262,"completion":323,"start":12958,"enrollment":31,"conditions":12979,"interventions":12980},[90],[12960],[12946,12962],{"trials":12982,"activeCount":101},[],{"trials":12984,"activeCount":101},[],{"trials":12986,"activeCount":101},[],{"intervention":12988,"totalTrials":651,"cells":12989},"Capecitabine，Pyrotinib",{"EARLY_PHASE1":12990,"PHASE1":12992,"PHASE2":12994,"PHASE3":13004,"PHASE4":13006,"NA":13008},{"trials":12991,"activeCount":101},[],{"trials":12993,"activeCount":101},[],{"trials":12995,"activeCount":651,"soonestReadout":470},[12996],{"nctId":12997,"briefTitle":12998,"status":121,"phases":12999,"primaryCompletion":470,"completion":471,"start":2157,"enrollment":13000,"conditions":13001,"interventions":13003},"NCT05861271","Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer",[90],1008,[13002],"Breast Cancer Stage I",[12988],{"trials":13005,"activeCount":101},[],{"trials":13007,"activeCount":101},[],{"trials":13009,"activeCount":101},[],{"intervention":13011,"totalTrials":651,"cells":13012},"HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450",{"EARLY_PHASE1":13013,"PHASE1":13015,"PHASE2":13017,"PHASE3":13028,"PHASE4":13030,"NA":13032},{"trials":13014,"activeCount":101},[],{"trials":13016,"activeCount":101},[],{"trials":13018,"activeCount":651,"soonestReadout":13023},[13019],{"nctId":13020,"briefTitle":13021,"status":270,"phases":13022,"primaryCompletion":13023,"completion":13024,"start":13025,"enrollment":3614,"conditions":13026,"interventions":13027},"NCT06475287","HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma",[90],"2025-07-31","2026-07-31","2024-07-20",[21],[13011],{"trials":13029,"activeCount":101},[],{"trials":13031,"activeCount":101},[],{"trials":13033,"activeCount":101},[],{"intervention":2127,"totalTrials":651,"cells":13035},{"EARLY_PHASE1":13036,"PHASE1":13038,"PHASE2":13040,"PHASE3":13046,"PHASE4":13048,"NA":13050},{"trials":13037,"activeCount":101},[],{"trials":13039,"activeCount":101},[],{"trials":13041,"activeCount":651,"soonestReadout":2120},[13042],{"nctId":2117,"briefTitle":2118,"status":270,"phases":13043,"primaryCompletion":2120,"completion":2121,"start":2122,"enrollment":2123,"conditions":13044,"interventions":13045},[90],[1865,240,2125],[2127,2128,1384],{"trials":13047,"activeCount":101},[],{"trials":13049,"activeCount":101},[],{"trials":13051,"activeCount":101},[],{"intervention":13053,"totalTrials":651,"cells":13054},"ORIENT-31 regimen",{"EARLY_PHASE1":13055,"PHASE1":13057,"PHASE2":13059,"PHASE3":13068,"PHASE4":13070,"NA":13072},{"trials":13056,"activeCount":101},[],{"trials":13058,"activeCount":101},[],{"trials":13060,"activeCount":651,"soonestReadout":963},[13061],{"nctId":13062,"briefTitle":13063,"status":121,"phases":13064,"primaryCompletion":963,"completion":1406,"start":439,"enrollment":7318,"conditions":13065,"interventions":13067},"NCT06775743","ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs",[90],[3961,13066],"EGFR Mutation Positive Advanced Non Small Cell Lung Cancer",[13053],{"trials":13069,"activeCount":101},[],{"trials":13071,"activeCount":101},[],{"trials":13073,"activeCount":101},[],{"intervention":7438,"totalTrials":651,"cells":13075},{"EARLY_PHASE1":13076,"PHASE1":13078,"PHASE2":13080,"PHASE3":13086,"PHASE4":13088,"NA":13090},{"trials":13077,"activeCount":101},[],{"trials":13079,"activeCount":101},[],{"trials":13081,"activeCount":651,"soonestReadout":1319},[13082],{"nctId":7433,"briefTitle":7434,"status":121,"phases":13083,"primaryCompletion":1319,"completion":2018,"start":3983,"enrollment":326,"conditions":13084,"interventions":13085},[90],[18],[7438,1995,329],{"trials":13087,"activeCount":101},[],{"trials":13089,"activeCount":101},[],{"trials":13091,"activeCount":101},[],{"intervention":13093,"totalTrials":651,"cells":13094},"SHR-A1921 + Bevacizumab",{"EARLY_PHASE1":13095,"PHASE1":13097,"PHASE2":13099,"PHASE3":13109,"PHASE4":13111,"NA":13113},{"trials":13096,"activeCount":101},[],{"trials":13098,"activeCount":101},[],{"trials":13100,"activeCount":651,"soonestReadout":2844},[13101],{"nctId":13102,"briefTitle":13103,"status":270,"phases":13104,"primaryCompletion":2844,"completion":235,"start":3207,"enrollment":13105,"conditions":13106,"interventions":13108},"NCT06210438","SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases",[90],24,[555,13107],"Brain Metastasis",[13093],{"trials":13110,"activeCount":101},[],{"trials":13112,"activeCount":101},[],{"trials":13114,"activeCount":101},[],{"intervention":1195,"totalTrials":651,"cells":13116},{"EARLY_PHASE1":13117,"PHASE1":13119,"PHASE2":13121,"PHASE3":13127,"PHASE4":13129,"NA":13131},{"trials":13118,"activeCount":101},[],{"trials":13120,"activeCount":101},[],{"trials":13122,"activeCount":651,"soonestReadout":235},[13123],{"nctId":1188,"briefTitle":1189,"status":270,"phases":13124,"primaryCompletion":235,"completion":963,"start":1191,"enrollment":1192,"conditions":13125,"interventions":13126},[90],[113],[1195,1196,129,1197,128],{"trials":13128,"activeCount":101},[],{"trials":13130,"activeCount":101},[],{"trials":13132,"activeCount":101},[],{"intervention":1197,"totalTrials":651,"cells":13134},{"EARLY_PHASE1":13135,"PHASE1":13137,"PHASE2":13139,"PHASE3":13145,"PHASE4":13147,"NA":13149},{"trials":13136,"activeCount":101},[],{"trials":13138,"activeCount":101},[],{"trials":13140,"activeCount":651,"soonestReadout":235},[13141],{"nctId":1188,"briefTitle":1189,"status":270,"phases":13142,"primaryCompletion":235,"completion":963,"start":1191,"enrollment":1192,"conditions":13143,"interventions":13144},[90],[113],[1195,1196,129,1197,128],{"trials":13146,"activeCount":101},[],{"trials":13148,"activeCount":101},[],{"trials":13150,"activeCount":101},[],{"intervention":13152,"totalTrials":651,"cells":13153},"Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan",{"EARLY_PHASE1":13154,"PHASE1":13156,"PHASE2":13158,"PHASE3":13169,"PHASE4":13171,"NA":13173},{"trials":13155,"activeCount":101},[],{"trials":13157,"activeCount":101},[],{"trials":13159,"activeCount":651,"soonestReadout":13164},[13160],{"nctId":13161,"briefTitle":13162,"status":121,"phases":13163,"primaryCompletion":13164,"completion":13165,"start":13166,"enrollment":1434,"conditions":13167,"interventions":13168},"NCT07471776","Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer",[90],"2028-03-11","2029-03-11","2026-03-11",[7301],[13152],{"trials":13170,"activeCount":101},[],{"trials":13172,"activeCount":101},[],{"trials":13174,"activeCount":101},[],{"intervention":9086,"totalTrials":651,"cells":13176},{"EARLY_PHASE1":13177,"PHASE1":13179,"PHASE2":13181,"PHASE3":13187,"PHASE4":13189,"NA":13191},{"trials":13178,"activeCount":101},[],{"trials":13180,"activeCount":101},[],{"trials":13182,"activeCount":651,"soonestReadout":235},[13183],{"nctId":9079,"briefTitle":9080,"status":121,"phases":13184,"primaryCompletion":235,"completion":1114,"start":7815,"enrollment":9082,"conditions":13185,"interventions":13186},[90],[9084],[9086,9070],{"trials":13188,"activeCount":101},[],{"trials":13190,"activeCount":101},[],{"trials":13192,"activeCount":101},[],{"intervention":8532,"totalTrials":651,"cells":13194},{"EARLY_PHASE1":13195,"PHASE1":13197,"PHASE2":13199,"PHASE3":13205,"PHASE4":13207,"NA":13209},{"trials":13196,"activeCount":101},[],{"trials":13198,"activeCount":101},[],{"trials":13200,"activeCount":651,"soonestReadout":716},[13201],{"nctId":8526,"briefTitle":8527,"status":121,"phases":13202,"primaryCompletion":716,"completion":750,"start":5744,"enrollment":1499,"conditions":13203,"interventions":13204},[90],[8530],[8532,2220],{"trials":13206,"activeCount":101},[],{"trials":13208,"activeCount":101},[],{"trials":13210,"activeCount":101},[],{"intervention":706,"totalTrials":651,"cells":13212},{"EARLY_PHASE1":13213,"PHASE1":13215,"PHASE2":13217,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13214,"activeCount":101},[],{"trials":13216,"activeCount":101},[],{"trials":13218,"activeCount":651,"soonestReadout":699},[13219],{"nctId":696,"briefTitle":697,"status":270,"phases":13220,"primaryCompletion":699,"completion":700,"start":701,"enrollment":296,"conditions":13221,"interventions":13222},[90],[703,704],[675,706,707],{"trials":13224,"activeCount":101},[],{"trials":13226,"activeCount":101},[],{"trials":13228,"activeCount":101},[],{"intervention":707,"totalTrials":651,"cells":13230},{"EARLY_PHASE1":13231,"PHASE1":13233,"PHASE2":13235,"PHASE3":13241,"PHASE4":13243,"NA":13245},{"trials":13232,"activeCount":101},[],{"trials":13234,"activeCount":101},[],{"trials":13236,"activeCount":651,"soonestReadout":699},[13237],{"nctId":696,"briefTitle":697,"status":270,"phases":13238,"primaryCompletion":699,"completion":700,"start":701,"enrollment":296,"conditions":13239,"interventions":13240},[90],[703,704],[675,706,707],{"trials":13242,"activeCount":101},[],{"trials":13244,"activeCount":101},[],{"trials":13246,"activeCount":101},[],{"intervention":13248,"totalTrials":651,"cells":13249},"Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab",{"EARLY_PHASE1":13250,"PHASE1":13252,"PHASE2":13254,"PHASE3":13265,"PHASE4":13267,"NA":13269},{"trials":13251,"activeCount":101},[],{"trials":13253,"activeCount":101},[],{"trials":13255,"activeCount":651,"soonestReadout":3297},[13256],{"nctId":13257,"briefTitle":13258,"status":270,"phases":13259,"primaryCompletion":3297,"completion":13260,"start":896,"enrollment":529,"conditions":13261,"interventions":13263},"NCT07581795","Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer",[90],"2031-03",[13262],"Advanced HER2-positive Breast Cancer",[13248,13264],"Taxanes combined with trastuzumab and pertuzumab.",{"trials":13266,"activeCount":101},[],{"trials":13268,"activeCount":101},[],{"trials":13270,"activeCount":101},[],{"intervention":13264,"totalTrials":651,"cells":13272},{"EARLY_PHASE1":13273,"PHASE1":13275,"PHASE2":13277,"PHASE3":13283,"PHASE4":13285,"NA":13287},{"trials":13274,"activeCount":101},[],{"trials":13276,"activeCount":101},[],{"trials":13278,"activeCount":651,"soonestReadout":3297},[13279],{"nctId":13257,"briefTitle":13258,"status":270,"phases":13280,"primaryCompletion":3297,"completion":13260,"start":896,"enrollment":529,"conditions":13281,"interventions":13282},[90],[13262],[13248,13264],{"trials":13284,"activeCount":101},[],{"trials":13286,"activeCount":101},[],{"trials":13288,"activeCount":101},[],{"intervention":13290,"totalTrials":651,"cells":13291},"Surufatinib, gemcitabine, nab-paclitaxel",{"EARLY_PHASE1":13292,"PHASE1":13294,"PHASE2":13296,"PHASE3":13307,"PHASE4":13309,"NA":13311},{"trials":13293,"activeCount":101},[],{"trials":13295,"activeCount":101},[],{"trials":13297,"activeCount":651,"soonestReadout":963},[13298],{"nctId":13299,"briefTitle":13300,"status":121,"phases":13301,"primaryCompletion":963,"completion":963,"start":13302,"enrollment":427,"conditions":13303,"interventions":13305},"NCT05969171","A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer",[90],"2023-12-05",[13304],"Pancreatic Cancer Metastatic",[13290,13306],"Nab-paclitaxel, gemcitabine",{"trials":13308,"activeCount":101},[],{"trials":13310,"activeCount":101},[],{"trials":13312,"activeCount":101},[],{"intervention":13306,"totalTrials":651,"cells":13314},{"EARLY_PHASE1":13315,"PHASE1":13317,"PHASE2":13319,"PHASE3":13325,"PHASE4":13327,"NA":13329},{"trials":13316,"activeCount":101},[],{"trials":13318,"activeCount":101},[],{"trials":13320,"activeCount":651,"soonestReadout":963},[13321],{"nctId":13299,"briefTitle":13300,"status":121,"phases":13322,"primaryCompletion":963,"completion":963,"start":13302,"enrollment":427,"conditions":13323,"interventions":13324},[90],[13304],[13290,13306],{"trials":13326,"activeCount":101},[],{"trials":13328,"activeCount":101},[],{"trials":13330,"activeCount":101},[],{"intervention":3834,"totalTrials":651,"cells":13332},{"EARLY_PHASE1":13333,"PHASE1":13335,"PHASE2":13337,"PHASE3":13343,"PHASE4":13345,"NA":13347},{"trials":13334,"activeCount":101},[],{"trials":13336,"activeCount":101},[],{"trials":13338,"activeCount":651,"soonestReadout":3829},[13339],{"nctId":3826,"briefTitle":3827,"status":270,"phases":13340,"primaryCompletion":3829,"completion":3830,"start":2813,"enrollment":3831,"conditions":13341,"interventions":13342},[90],[15],[3834,3817],{"trials":13344,"activeCount":101},[],{"trials":13346,"activeCount":101},[],{"trials":13348,"activeCount":101},[],{"intervention":13350,"totalTrials":651,"cells":13351},"Ivonescimab Combined With TROP2 ADC",{"EARLY_PHASE1":13352,"PHASE1":13354,"PHASE2":13356,"PHASE3":13365,"PHASE4":13367,"NA":13369},{"trials":13353,"activeCount":101},[],{"trials":13355,"activeCount":101},[],{"trials":13357,"activeCount":651,"soonestReadout":4542},[13358],{"nctId":13359,"briefTitle":13360,"status":121,"phases":13361,"primaryCompletion":4542,"completion":2735,"start":13362,"enrollment":1167,"conditions":13363,"interventions":13364},"NCT06793332","BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC",[90],"2024-12-17",[1371,11776],[13350],{"trials":13366,"activeCount":101},[],{"trials":13368,"activeCount":101},[],{"trials":13370,"activeCount":101},[],{"intervention":13372,"totalTrials":651,"cells":13373},"ATRA+VAC",{"EARLY_PHASE1":13374,"PHASE1":13376,"PHASE2":13378,"PHASE3":13388,"PHASE4":13390,"NA":13392},{"trials":13375,"activeCount":101},[],{"trials":13377,"activeCount":101},[],{"trials":13379,"activeCount":651,"soonestReadout":7316},[13380],{"nctId":13381,"briefTitle":13382,"status":270,"phases":13383,"primaryCompletion":7316,"completion":7316,"start":724,"enrollment":13384,"conditions":13385,"interventions":13386},"NCT07355855","A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma",[90],106,[11689],[13372,13387],"ATRA+VAC+Anlotinib",{"trials":13389,"activeCount":101},[],{"trials":13391,"activeCount":101},[],{"trials":13393,"activeCount":101},[],{"intervention":13387,"totalTrials":651,"cells":13395},{"EARLY_PHASE1":13396,"PHASE1":13398,"PHASE2":13400,"PHASE3":13406,"PHASE4":13408,"NA":13410},{"trials":13397,"activeCount":101},[],{"trials":13399,"activeCount":101},[],{"trials":13401,"activeCount":651,"soonestReadout":7316},[13402],{"nctId":13381,"briefTitle":13382,"status":270,"phases":13403,"primaryCompletion":7316,"completion":7316,"start":724,"enrollment":13384,"conditions":13404,"interventions":13405},[90],[11689],[13372,13387],{"trials":13407,"activeCount":101},[],{"trials":13409,"activeCount":101},[],{"trials":13411,"activeCount":101},[],{"intervention":13413,"totalTrials":651,"cells":13414},"Ivocizumab",{"EARLY_PHASE1":13415,"PHASE1":13417,"PHASE2":13419,"PHASE3":13442,"PHASE4":13444,"NA":13446},{"trials":13416,"activeCount":101},[],{"trials":13418,"activeCount":101},[],{"trials":13420,"activeCount":651,"soonestReadout":13425},[13421],{"nctId":13422,"briefTitle":13423,"status":121,"phases":13424,"primaryCompletion":13425,"completion":13425,"start":12888,"enrollment":2854,"conditions":13426,"interventions":13441},"NCT06683846","Ivonescimab in the Treatment of Multiple Advanced Tumors",[90],"2027-11-30",[13427,11689,11688,13428,13429,13430,11691,13431,13432,13433,7637,13434,13435,13436,13437,13438,13439,12936,13440],"Pheochromocytoma\u002FParaganglioma","Renal Angiomyolipoma","Perivascular Epithelioid Cell Tumor, Malignant","Sarcoma","Neuroendocrine Cancer","Basal Cell Carcinomas","Sarcomatoid Carcinoma","Adrenal Cortical Cancer","Germ Cell Cancer Metastatic","Non-Clear Cell Renal Cell Carcinoma","Prostate Cancers","Clear Cell Renal Cancer","Urothelial Carcinoma","Rare Tumors",[13413],{"trials":13443,"activeCount":101},[],{"trials":13445,"activeCount":101},[],{"trials":13447,"activeCount":101},[],{"intervention":13449,"totalTrials":651,"cells":13450},"1-month GnRH",{"EARLY_PHASE1":13451,"PHASE1":13453,"PHASE2":13455,"PHASE3":13464,"PHASE4":13466,"NA":13468},{"trials":13452,"activeCount":101},[],{"trials":13454,"activeCount":101},[],{"trials":13456,"activeCount":651,"soonestReadout":3067},[13457],{"nctId":13458,"briefTitle":13459,"status":270,"phases":13460,"primaryCompletion":3067,"completion":3841,"start":1334,"enrollment":213,"conditions":13461,"interventions":13462},"NCT07610733","Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.",[90],[15],[13449,13463],"3-month GnRH",{"trials":13465,"activeCount":101},[],{"trials":13467,"activeCount":101},[],{"trials":13469,"activeCount":101},[],{"intervention":13463,"totalTrials":651,"cells":13471},{"EARLY_PHASE1":13472,"PHASE1":13474,"PHASE2":13476,"PHASE3":13482,"PHASE4":13484,"NA":13486},{"trials":13473,"activeCount":101},[],{"trials":13475,"activeCount":101},[],{"trials":13477,"activeCount":651,"soonestReadout":3067},[13478],{"nctId":13458,"briefTitle":13459,"status":270,"phases":13479,"primaryCompletion":3067,"completion":3841,"start":1334,"enrollment":213,"conditions":13480,"interventions":13481},[90],[15],[13449,13463],{"trials":13483,"activeCount":101},[],{"trials":13485,"activeCount":101},[],{"trials":13487,"activeCount":101},[],{"intervention":13489,"totalTrials":651,"cells":13490},"PD-1 Inhibitor + Chemotherapy",{"EARLY_PHASE1":13491,"PHASE1":13493,"PHASE2":13495,"PHASE3":13505,"PHASE4":13507,"NA":13509},{"trials":13492,"activeCount":101},[],{"trials":13494,"activeCount":101},[],{"trials":13496,"activeCount":651,"soonestReadout":305},[13497],{"nctId":13498,"briefTitle":13499,"status":121,"phases":13500,"primaryCompletion":305,"completion":236,"start":147,"enrollment":13501,"conditions":13502,"interventions":13504},"NCT07555678","Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase",[90],241,[13503],"Anal Squamous Cell Cancer",[13489],{"trials":13506,"activeCount":101},[],{"trials":13508,"activeCount":101},[],{"trials":13510,"activeCount":101},[],{"intervention":6639,"totalTrials":651,"cells":13512},{"EARLY_PHASE1":13513,"PHASE1":13515,"PHASE2":13517,"PHASE3":13523,"PHASE4":13525,"NA":13527},{"trials":13514,"activeCount":101},[],{"trials":13516,"activeCount":101},[],{"trials":13518,"activeCount":651,"soonestReadout":1609},[13519],{"nctId":6634,"briefTitle":6635,"status":505,"phases":13520,"primaryCompletion":1609,"completion":963,"start":667,"enrollment":213,"conditions":13521,"interventions":13522},[90],[35],[2411,6639,6640],{"trials":13524,"activeCount":101},[],{"trials":13526,"activeCount":101},[],{"trials":13528,"activeCount":101},[],{"intervention":6640,"totalTrials":651,"cells":13530},{"EARLY_PHASE1":13531,"PHASE1":13533,"PHASE2":13535,"PHASE3":13541,"PHASE4":13543,"NA":13545},{"trials":13532,"activeCount":101},[],{"trials":13534,"activeCount":101},[],{"trials":13536,"activeCount":651,"soonestReadout":1609},[13537],{"nctId":6634,"briefTitle":6635,"status":505,"phases":13538,"primaryCompletion":1609,"completion":963,"start":667,"enrollment":213,"conditions":13539,"interventions":13540},[90],[35],[2411,6639,6640],{"trials":13542,"activeCount":101},[],{"trials":13544,"activeCount":101},[],{"trials":13546,"activeCount":101},[],{"intervention":2839,"totalTrials":651,"cells":13548},{"EARLY_PHASE1":13549,"PHASE1":13551,"PHASE2":13553,"PHASE3":13559,"PHASE4":13561,"NA":13563},{"trials":13550,"activeCount":101},[],{"trials":13552,"activeCount":101},[],{"trials":13554,"activeCount":651,"soonestReadout":1406},[13555],{"nctId":2831,"briefTitle":2832,"status":121,"phases":13556,"primaryCompletion":1406,"completion":124,"start":2834,"enrollment":369,"conditions":13557,"interventions":13558},[89,90],[30],[2837,2764,2838,2839],{"trials":13560,"activeCount":101},[],{"trials":13562,"activeCount":101},[],{"trials":13564,"activeCount":101},[],{"intervention":13566,"totalTrials":651,"cells":13567},"FOLFIRI+Bevacizumab",{"EARLY_PHASE1":13568,"PHASE1":13570,"PHASE2":13572,"PHASE3":13583,"PHASE4":13585,"NA":13587},{"trials":13569,"activeCount":101},[],{"trials":13571,"activeCount":101},[],{"trials":13573,"activeCount":651,"soonestReadout":13578},[13574],{"nctId":13575,"briefTitle":13576,"status":505,"phases":13577,"primaryCompletion":13578,"completion":13579,"start":13580,"enrollment":97,"conditions":13581,"interventions":13582},"NCT05969899","Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer",[90],"2025-07-10","2027-02-10","2023-07-10",[18],[13566],{"trials":13584,"activeCount":101},[],{"trials":13586,"activeCount":101},[],{"trials":13588,"activeCount":101},[],{"intervention":360,"totalTrials":651,"cells":13590},{"EARLY_PHASE1":13591,"PHASE1":13593,"PHASE2":13595,"PHASE3":13601,"PHASE4":13603,"NA":13605},{"trials":13592,"activeCount":101},[],{"trials":13594,"activeCount":101},[],{"trials":13596,"activeCount":651,"soonestReadout":353},[13597],{"nctId":350,"briefTitle":351,"status":121,"phases":13598,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":13599,"interventions":13600},[90],[358],[62,96,360,228,129,115,361,229,230],{"trials":13602,"activeCount":101},[],{"trials":13604,"activeCount":101},[],{"trials":13606,"activeCount":101},[],{"intervention":13608,"totalTrials":651,"cells":13609},"Everolimus 10 mg",{"EARLY_PHASE1":13610,"PHASE1":13612,"PHASE2":13614,"PHASE3":13624,"PHASE4":13626,"NA":13628},{"trials":13611,"activeCount":101},[],{"trials":13613,"activeCount":101},[],{"trials":13615,"activeCount":651,"soonestReadout":1897},[13616],{"nctId":13617,"briefTitle":13618,"status":121,"phases":13619,"primaryCompletion":1897,"completion":725,"start":2240,"enrollment":6123,"conditions":13620,"interventions":13621},"NCT05949541","Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+\u002FHER2- SNF1-subtype Advanced Breast Cancer",[90],[15,2254],[13608,13622,13623],"CDK4\u002F6 Inhibitor SHR6390","Aromatase inhibitor and Fulvestrant combined with CDK4\u002F6 inhibitors",{"trials":13625,"activeCount":101},[],{"trials":13627,"activeCount":101},[],{"trials":13629,"activeCount":101},[],{"intervention":13622,"totalTrials":651,"cells":13631},{"EARLY_PHASE1":13632,"PHASE1":13634,"PHASE2":13636,"PHASE3":13642,"PHASE4":13644,"NA":13646},{"trials":13633,"activeCount":101},[],{"trials":13635,"activeCount":101},[],{"trials":13637,"activeCount":651,"soonestReadout":1897},[13638],{"nctId":13617,"briefTitle":13618,"status":121,"phases":13639,"primaryCompletion":1897,"completion":725,"start":2240,"enrollment":6123,"conditions":13640,"interventions":13641},[90],[15,2254],[13608,13622,13623],{"trials":13643,"activeCount":101},[],{"trials":13645,"activeCount":101},[],{"trials":13647,"activeCount":101},[],{"intervention":13623,"totalTrials":651,"cells":13649},{"EARLY_PHASE1":13650,"PHASE1":13652,"PHASE2":13654,"PHASE3":13660,"PHASE4":13662,"NA":13664},{"trials":13651,"activeCount":101},[],{"trials":13653,"activeCount":101},[],{"trials":13655,"activeCount":651,"soonestReadout":1897},[13656],{"nctId":13617,"briefTitle":13618,"status":121,"phases":13657,"primaryCompletion":1897,"completion":725,"start":2240,"enrollment":6123,"conditions":13658,"interventions":13659},[90],[15,2254],[13608,13622,13623],{"trials":13661,"activeCount":101},[],{"trials":13663,"activeCount":101},[],{"trials":13665,"activeCount":101},[],{"intervention":6651,"totalTrials":651,"cells":13667},{"EARLY_PHASE1":13668,"PHASE1":13670,"PHASE2":13672,"PHASE3":13678,"PHASE4":13680,"NA":13682},{"trials":13669,"activeCount":101},[],{"trials":13671,"activeCount":101},[],{"trials":13673,"activeCount":651,"soonestReadout":783},[13674],{"nctId":6642,"briefTitle":6643,"status":121,"phases":13675,"primaryCompletion":783,"completion":783,"start":6645,"enrollment":1146,"conditions":13676,"interventions":13677},[90],[6647,6648,6649],[6651,2411],{"trials":13679,"activeCount":101},[],{"trials":13681,"activeCount":101},[],{"trials":13683,"activeCount":101},[],{"intervention":13685,"totalTrials":651,"cells":13686},"Paclitaxel Micelles ; Cisplatin ; 5-FU ; Serplulimab",{"EARLY_PHASE1":13687,"PHASE1":13689,"PHASE2":13691,"PHASE3":13699,"PHASE4":13701,"NA":13703},{"trials":13688,"activeCount":101},[],{"trials":13690,"activeCount":101},[],{"trials":13692,"activeCount":651,"soonestReadout":6684},[13693],{"nctId":13694,"briefTitle":13695,"status":270,"phases":13696,"primaryCompletion":6684,"completion":399,"start":6685,"enrollment":159,"conditions":13697,"interventions":13698},"NCT07418866","FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer",[90],[3961],[13685],{"trials":13700,"activeCount":101},[],{"trials":13702,"activeCount":101},[],{"trials":13704,"activeCount":101},[],{"intervention":13706,"totalTrials":651,"cells":13707},"triple-targeted anti-HER2 and CDK4\u002F6 inhibitor",{"EARLY_PHASE1":13708,"PHASE1":13710,"PHASE2":13712,"PHASE3":13722,"PHASE4":13724,"NA":13726},{"trials":13709,"activeCount":101},[],{"trials":13711,"activeCount":101},[],{"trials":13713,"activeCount":651,"soonestReadout":13718},[13714],{"nctId":13715,"briefTitle":13716,"status":270,"phases":13717,"primaryCompletion":13718,"completion":13719,"start":1609,"enrollment":3614,"conditions":13720,"interventions":13721},"NCT07290166","A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4\u002F6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.",[90],"2027-10-31","2028-04-30",[15],[13706],{"trials":13723,"activeCount":101},[],{"trials":13725,"activeCount":101},[],{"trials":13727,"activeCount":101},[],{"intervention":13729,"totalTrials":651,"cells":13730},"MRG003",{"EARLY_PHASE1":13731,"PHASE1":13733,"PHASE2":13735,"PHASE3":13746,"PHASE4":13748,"NA":13750},{"trials":13732,"activeCount":101},[],{"trials":13734,"activeCount":101},[],{"trials":13736,"activeCount":651,"soonestReadout":13741},[13737],{"nctId":13738,"briefTitle":13739,"status":121,"phases":13740,"primaryCompletion":13741,"completion":13742,"start":13743,"enrollment":737,"conditions":13744,"interventions":13745},"NCT07536789","Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma",[90],"2028-04-15","2029-04-14","2026-04-17",[6442],[13729],{"trials":13747,"activeCount":101},[],{"trials":13749,"activeCount":101},[],{"trials":13751,"activeCount":101},[],{"intervention":13753,"totalTrials":651,"cells":13754},"SHR-1501+SHR-2005",{"EARLY_PHASE1":13755,"PHASE1":13757,"PHASE2":13759,"PHASE3":13768,"PHASE4":13770,"NA":13772},{"trials":13756,"activeCount":101},[],{"trials":13758,"activeCount":101},[],{"trials":13760,"activeCount":651,"soonestReadout":5498},[13761],{"nctId":13762,"briefTitle":13763,"status":270,"phases":13764,"primaryCompletion":5498,"completion":5498,"start":13765,"enrollment":19,"conditions":13766,"interventions":13767},"NCT06588179","SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt",[89,90],"2024-10-01",[5704],[13753],{"trials":13769,"activeCount":101},[],{"trials":13771,"activeCount":101},[],{"trials":13773,"activeCount":101},[],{"intervention":13775,"totalTrials":651,"cells":13776},"QLC5513",{"EARLY_PHASE1":13777,"PHASE1":13779,"PHASE2":13781,"PHASE3":13793,"PHASE4":13795,"NA":13797},{"trials":13778,"activeCount":101},[],{"trials":13780,"activeCount":101},[],{"trials":13782,"activeCount":651,"soonestReadout":1621},[13783],{"nctId":13784,"briefTitle":13785,"status":270,"phases":13786,"primaryCompletion":1621,"completion":13787,"start":13788,"enrollment":111,"conditions":13789,"interventions":13791},"NCT07509515","QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.",[90],"2028-03-30","2026-04-15",[13790],"Triple-negative Breast Cancer (TNBC)",[13775,13792],"QLC5513+QL1706",{"trials":13794,"activeCount":101},[],{"trials":13796,"activeCount":101},[],{"trials":13798,"activeCount":101},[],{"intervention":13792,"totalTrials":651,"cells":13800},{"EARLY_PHASE1":13801,"PHASE1":13803,"PHASE2":13805,"PHASE3":13811,"PHASE4":13813,"NA":13815},{"trials":13802,"activeCount":101},[],{"trials":13804,"activeCount":101},[],{"trials":13806,"activeCount":651,"soonestReadout":1621},[13807],{"nctId":13784,"briefTitle":13785,"status":270,"phases":13808,"primaryCompletion":1621,"completion":13787,"start":13788,"enrollment":111,"conditions":13809,"interventions":13810},[90],[13790],[13775,13792],{"trials":13812,"activeCount":101},[],{"trials":13814,"activeCount":101},[],{"trials":13816,"activeCount":101},[],{"intervention":13818,"totalTrials":651,"cells":13819},"SKB264 Plus Inetetamab",{"EARLY_PHASE1":13820,"PHASE1":13822,"PHASE2":13824,"PHASE3":13833,"PHASE4":13835,"NA":13837},{"trials":13821,"activeCount":101},[],{"trials":13823,"activeCount":101},[],{"trials":13825,"activeCount":651,"soonestReadout":800},[13826],{"nctId":13827,"briefTitle":13828,"status":121,"phases":13829,"primaryCompletion":800,"completion":3206,"start":2441,"enrollment":2845,"conditions":13830,"interventions":13832},"NCT07182721","SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment",[90],[13831,1467,545],"HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer",[13818],{"trials":13834,"activeCount":101},[],{"trials":13836,"activeCount":101},[],{"trials":13838,"activeCount":101},[],{"intervention":13840,"totalTrials":651,"cells":13841},"RC48",{"EARLY_PHASE1":13842,"PHASE1":13844,"PHASE2":13846,"PHASE3":13856,"PHASE4":13858,"NA":13860},{"trials":13843,"activeCount":101},[],{"trials":13845,"activeCount":101},[],{"trials":13847,"activeCount":651,"soonestReadout":1433},[13848],{"nctId":13849,"briefTitle":13850,"status":121,"phases":13851,"primaryCompletion":1433,"completion":13852,"start":7941,"enrollment":3068,"conditions":13853,"interventions":13855},"NCT06561555","A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.",[90],"2027-08-15",[13854],"Mammary or Extramammary Paget's Disease",[13840],{"trials":13857,"activeCount":101},[],{"trials":13859,"activeCount":101},[],{"trials":13861,"activeCount":101},[],{"intervention":7450,"totalTrials":651,"cells":13863},{"EARLY_PHASE1":13864,"PHASE1":13866,"PHASE2":13868,"PHASE3":13874,"PHASE4":13876,"NA":13878},{"trials":13865,"activeCount":101},[],{"trials":13867,"activeCount":101},[],{"trials":13869,"activeCount":651,"soonestReadout":7059},[13870],{"nctId":7444,"briefTitle":7445,"status":270,"phases":13871,"primaryCompletion":7059,"completion":7447,"start":2814,"enrollment":1146,"conditions":13872,"interventions":13873},[90],[1131],[7450,1995],{"trials":13875,"activeCount":101},[],{"trials":13877,"activeCount":101},[],{"trials":13879,"activeCount":101},[],{"intervention":13881,"totalTrials":651,"cells":13882},"Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib",{"EARLY_PHASE1":13883,"PHASE1":13885,"PHASE2":13887,"PHASE3":13899,"PHASE4":13901,"NA":13903},{"trials":13884,"activeCount":101},[],{"trials":13886,"activeCount":101},[],{"trials":13888,"activeCount":651,"soonestReadout":13893},[13889],{"nctId":13890,"briefTitle":13891,"status":270,"phases":13892,"primaryCompletion":13893,"completion":13894,"start":13895,"enrollment":16,"conditions":13896,"interventions":13898},"NCT06748508","Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer",[90],"2027-07-25","2027-12-25","2024-12-25",[13897],"Gastric (Stomach) Cancer",[13881],{"trials":13900,"activeCount":101},[],{"trials":13902,"activeCount":101},[],{"trials":13904,"activeCount":101},[],{"intervention":13906,"totalTrials":651,"cells":13907},"Toripalimab combined with Endostar",{"EARLY_PHASE1":13908,"PHASE1":13910,"PHASE2":13912,"PHASE3":13924,"PHASE4":13926,"NA":13928},{"trials":13909,"activeCount":101},[],{"trials":13911,"activeCount":101},[],{"trials":13913,"activeCount":651,"soonestReadout":2018},[13914],{"nctId":13915,"briefTitle":13916,"status":121,"phases":13917,"primaryCompletion":2018,"completion":13918,"start":367,"enrollment":19,"conditions":13919,"interventions":13923},"NCT06965231","Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial",[90],"2029-03-30",[13920,13921,13922],"Melanoma of Skin","Acral Melanoma","Stage II Melanoma",[13906],{"trials":13925,"activeCount":101},[],{"trials":13927,"activeCount":101},[],{"trials":13929,"activeCount":101},[],{"intervention":13931,"totalTrials":651,"cells":13932},"Iparomlimab and Tuvoraleimab injection+Bev+nab-PC",{"EARLY_PHASE1":13933,"PHASE1":13935,"PHASE2":13937,"PHASE3":13945,"PHASE4":13947,"NA":13949},{"trials":13934,"activeCount":101},[],{"trials":13936,"activeCount":101},[],{"trials":13938,"activeCount":651,"soonestReadout":399},[13939],{"nctId":13940,"briefTitle":13941,"status":270,"phases":13942,"primaryCompletion":399,"completion":399,"start":6685,"enrollment":2845,"conditions":13943,"interventions":13944},"NCT07347444","Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma",[90],[13921,6589],[13931],{"trials":13946,"activeCount":101},[],{"trials":13948,"activeCount":101},[],{"trials":13950,"activeCount":101},[],{"intervention":13952,"totalTrials":651,"cells":13953},"mFOLFIRINOX plus IMRT",{"EARLY_PHASE1":13954,"PHASE1":13956,"PHASE2":13958,"PHASE3":13966,"PHASE4":13968,"NA":13970},{"trials":13955,"activeCount":101},[],{"trials":13957,"activeCount":101},[],{"trials":13959,"activeCount":651,"soonestReadout":1560},[13960],{"nctId":13961,"briefTitle":13962,"status":121,"phases":13963,"primaryCompletion":1560,"completion":5957,"start":147,"enrollment":25,"conditions":13964,"interventions":13965},"NCT06249321","mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy",[90],[30,1553],[13952],{"trials":13967,"activeCount":101},[],{"trials":13969,"activeCount":101},[],{"trials":13971,"activeCount":101},[],{"intervention":2538,"totalTrials":651,"cells":13973},{"EARLY_PHASE1":13974,"PHASE1":13976,"PHASE2":13978,"PHASE3":13984,"PHASE4":13986,"NA":13988},{"trials":13975,"activeCount":101},[],{"trials":13977,"activeCount":101},[],{"trials":13979,"activeCount":651,"soonestReadout":1489},[13980],{"nctId":2531,"briefTitle":2532,"status":270,"phases":13981,"primaryCompletion":1489,"completion":235,"start":1802,"enrollment":2534,"conditions":13982,"interventions":13983},[90],[2536],[2538,2539,1092],{"trials":13985,"activeCount":101},[],{"trials":13987,"activeCount":101},[],{"trials":13989,"activeCount":101},[],{"intervention":2539,"totalTrials":651,"cells":13991},{"EARLY_PHASE1":13992,"PHASE1":13994,"PHASE2":13996,"PHASE3":14002,"PHASE4":14004,"NA":14006},{"trials":13993,"activeCount":101},[],{"trials":13995,"activeCount":101},[],{"trials":13997,"activeCount":651,"soonestReadout":1489},[13998],{"nctId":2531,"briefTitle":2532,"status":270,"phases":13999,"primaryCompletion":1489,"completion":235,"start":1802,"enrollment":2534,"conditions":14000,"interventions":14001},[90],[2536],[2538,2539,1092],{"trials":14003,"activeCount":101},[],{"trials":14005,"activeCount":101},[],{"trials":14007,"activeCount":101},[],{"intervention":14009,"totalTrials":651,"cells":14010},"PD-1\u002FPD-L1 inhibitor plus chemotherapy",{"EARLY_PHASE1":14011,"PHASE1":14013,"PHASE2":14015,"PHASE3":14023,"PHASE4":14025,"NA":14027},{"trials":14012,"activeCount":101},[],{"trials":14014,"activeCount":101},[],{"trials":14016,"activeCount":651,"soonestReadout":1473},[14017],{"nctId":14018,"briefTitle":14019,"status":121,"phases":14020,"primaryCompletion":1473,"completion":377,"start":1156,"enrollment":737,"conditions":14021,"interventions":14022},"NCT06501378","Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis",[90],[2109],[14009],{"trials":14024,"activeCount":101},[],{"trials":14026,"activeCount":101},[],{"trials":14028,"activeCount":101},[],{"intervention":14030,"totalTrials":651,"cells":14031},"Iparomlimab and Tuvonralimab + GC",{"EARLY_PHASE1":14032,"PHASE1":14034,"PHASE2":14036,"PHASE3":14047,"PHASE4":14049,"NA":14051},{"trials":14033,"activeCount":101},[],{"trials":14035,"activeCount":101},[],{"trials":14037,"activeCount":651,"soonestReadout":14042},[14038],{"nctId":14039,"briefTitle":14040,"status":270,"phases":14041,"primaryCompletion":14042,"completion":236,"start":14043,"enrollment":3648,"conditions":14044,"interventions":14045},"NCT07152769","Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC",[90],"2028-02-29","2025-10-15",[3070],[14030,14046],"Sintilimab + GC",{"trials":14048,"activeCount":101},[],{"trials":14050,"activeCount":101},[],{"trials":14052,"activeCount":101},[],{"intervention":14046,"totalTrials":651,"cells":14054},{"EARLY_PHASE1":14055,"PHASE1":14057,"PHASE2":14059,"PHASE3":14065,"PHASE4":14067,"NA":14069},{"trials":14056,"activeCount":101},[],{"trials":14058,"activeCount":101},[],{"trials":14060,"activeCount":651,"soonestReadout":14042},[14061],{"nctId":14039,"briefTitle":14040,"status":270,"phases":14062,"primaryCompletion":14042,"completion":236,"start":14043,"enrollment":3648,"conditions":14063,"interventions":14064},[90],[3070],[14030,14046],{"trials":14066,"activeCount":101},[],{"trials":14068,"activeCount":101},[],{"trials":14070,"activeCount":101},[],{"intervention":14072,"totalTrials":651,"cells":14073},"Cromolyn, TQB2102, and Panpulimab",{"EARLY_PHASE1":14074,"PHASE1":14076,"PHASE2":14078,"PHASE3":14088,"PHASE4":14090,"NA":14092},{"trials":14075,"activeCount":101},[],{"trials":14077,"activeCount":101},[],{"trials":14079,"activeCount":651,"soonestReadout":2638},[14080],{"nctId":14081,"briefTitle":14082,"status":270,"phases":14083,"primaryCompletion":2638,"completion":1114,"start":14084,"enrollment":137,"conditions":14085,"interventions":14087},"NCT07419880","Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer",[90],"2026-01-30",[14086],"Triple -Negative Breast Cancer",[14072],{"trials":14089,"activeCount":101},[],{"trials":14091,"activeCount":101},[],{"trials":14093,"activeCount":101},[],{"intervention":14095,"totalTrials":651,"cells":14096},"Narlumosbart",{"EARLY_PHASE1":14097,"PHASE1":14099,"PHASE2":14101,"PHASE3":14109,"PHASE4":14111,"NA":14113},{"trials":14098,"activeCount":101},[],{"trials":14100,"activeCount":101},[],{"trials":14102,"activeCount":651,"soonestReadout":826},[14103],{"nctId":14104,"briefTitle":14105,"status":121,"phases":14106,"primaryCompletion":826,"completion":7059,"start":7052,"enrollment":1778,"conditions":14107,"interventions":14108},"NCT06738160","The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer",[90],[8500,6198,1218],[14095],{"trials":14110,"activeCount":101},[],{"trials":14112,"activeCount":101},[],{"trials":14114,"activeCount":101},[],{"intervention":14116,"totalTrials":651,"cells":14117},"Disitamab Vedotin combined with Bicalutamide",{"EARLY_PHASE1":14118,"PHASE1":14120,"PHASE2":14122,"PHASE3":14132,"PHASE4":14134,"NA":14136},{"trials":14119,"activeCount":101},[],{"trials":14121,"activeCount":101},[],{"trials":14123,"activeCount":651,"soonestReadout":2017},[14124],{"nctId":14125,"briefTitle":14126,"status":121,"phases":14127,"primaryCompletion":2017,"completion":2017,"start":3983,"enrollment":1146,"conditions":14128,"interventions":14131},"NCT07117851","A Study of Disitamab Vedotin + Bicalutamide in HER2\u002FAR-Positive Scrotal Paget's Disease",[90],[14129,14130],"Extramammary Paget Disease","Scrotum Disease",[14116],{"trials":14133,"activeCount":101},[],{"trials":14135,"activeCount":101},[],{"trials":14137,"activeCount":101},[],{"intervention":14139,"totalTrials":651,"cells":14140},"Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib",{"EARLY_PHASE1":14141,"PHASE1":14143,"PHASE2":14145,"PHASE3":14157,"PHASE4":14159,"NA":14161},{"trials":14142,"activeCount":101},[],{"trials":14144,"activeCount":101},[],{"trials":14146,"activeCount":651,"soonestReadout":724},[14147],{"nctId":14148,"briefTitle":14149,"status":121,"phases":14150,"primaryCompletion":724,"completion":725,"start":14151,"enrollment":345,"conditions":14152,"interventions":14155},"NCT06228963","Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma",[90],"2024-03",[14153,14154],"MALT Lymphoma of Stomach","Helicobacter Pylori Infection",[14139,14156],"Triple therapy for eradication of Helicobacter Pylori",{"trials":14158,"activeCount":101},[],{"trials":14160,"activeCount":101},[],{"trials":14162,"activeCount":101},[],{"intervention":14156,"totalTrials":651,"cells":14164},{"EARLY_PHASE1":14165,"PHASE1":14167,"PHASE2":14169,"PHASE3":14175,"PHASE4":14177,"NA":14179},{"trials":14166,"activeCount":101},[],{"trials":14168,"activeCount":101},[],{"trials":14170,"activeCount":651,"soonestReadout":724},[14171],{"nctId":14148,"briefTitle":14149,"status":121,"phases":14172,"primaryCompletion":724,"completion":725,"start":14151,"enrollment":345,"conditions":14173,"interventions":14174},[90],[14153,14154],[14139,14156],{"trials":14176,"activeCount":101},[],{"trials":14178,"activeCount":101},[],{"trials":14180,"activeCount":101},[],{"intervention":3869,"totalTrials":651,"cells":14182},{"EARLY_PHASE1":14183,"PHASE1":14185,"PHASE2":14187,"PHASE3":14193,"PHASE4":14195,"NA":14197},{"trials":14184,"activeCount":101},[],{"trials":14186,"activeCount":101},[],{"trials":14188,"activeCount":651,"soonestReadout":3864},[14189],{"nctId":3861,"briefTitle":3862,"status":121,"phases":14190,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":14191,"interventions":14192},[90],[225],[3869,617,1974,3870,3871,230],{"trials":14194,"activeCount":101},[],{"trials":14196,"activeCount":101},[],{"trials":14198,"activeCount":101},[],{"intervention":3870,"totalTrials":651,"cells":14200},{"EARLY_PHASE1":14201,"PHASE1":14203,"PHASE2":14205,"PHASE3":14211,"PHASE4":14213,"NA":14215},{"trials":14202,"activeCount":101},[],{"trials":14204,"activeCount":101},[],{"trials":14206,"activeCount":651,"soonestReadout":3864},[14207],{"nctId":3861,"briefTitle":3862,"status":121,"phases":14208,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":14209,"interventions":14210},[90],[225],[3869,617,1974,3870,3871,230],{"trials":14212,"activeCount":101},[],{"trials":14214,"activeCount":101},[],{"trials":14216,"activeCount":101},[],{"intervention":3871,"totalTrials":651,"cells":14218},{"EARLY_PHASE1":14219,"PHASE1":14221,"PHASE2":14223,"PHASE3":14229,"PHASE4":14231,"NA":14233},{"trials":14220,"activeCount":101},[],{"trials":14222,"activeCount":101},[],{"trials":14224,"activeCount":651,"soonestReadout":3864},[14225],{"nctId":3861,"briefTitle":3862,"status":121,"phases":14226,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":14227,"interventions":14228},[90],[225],[3869,617,1974,3870,3871,230],{"trials":14230,"activeCount":101},[],{"trials":14232,"activeCount":101},[],{"trials":14234,"activeCount":101},[],{"intervention":3580,"totalTrials":651,"cells":14236},{"EARLY_PHASE1":14237,"PHASE1":14239,"PHASE2":14241,"PHASE3":14247,"PHASE4":14249,"NA":14251},{"trials":14238,"activeCount":101},[],{"trials":14240,"activeCount":101},[],{"trials":14242,"activeCount":651,"soonestReadout":2772},[14243],{"nctId":3571,"briefTitle":3572,"status":121,"phases":14244,"primaryCompletion":2772,"completion":3574,"start":3575,"enrollment":1146,"conditions":14245,"interventions":14246},[90],[3577,3578],[1178,3580],{"trials":14248,"activeCount":101},[],{"trials":14250,"activeCount":101},[],{"trials":14252,"activeCount":101},[],{"intervention":9297,"totalTrials":651,"cells":14254},{"EARLY_PHASE1":14255,"PHASE1":14257,"PHASE2":14259,"PHASE3":14265,"PHASE4":14267,"NA":14269},{"trials":14256,"activeCount":101},[],{"trials":14258,"activeCount":101},[],{"trials":14260,"activeCount":651,"soonestReadout":294},[14261],{"nctId":9291,"briefTitle":9292,"status":121,"phases":14262,"primaryCompletion":294,"completion":9294,"start":71,"enrollment":1499,"conditions":14263,"interventions":14264},[90],[161],[9297,9298,9274],{"trials":14266,"activeCount":101},[],{"trials":14268,"activeCount":101},[],{"trials":14270,"activeCount":101},[],{"intervention":9298,"totalTrials":651,"cells":14272},{"EARLY_PHASE1":14273,"PHASE1":14275,"PHASE2":14277,"PHASE3":14283,"PHASE4":14285,"NA":14287},{"trials":14274,"activeCount":101},[],{"trials":14276,"activeCount":101},[],{"trials":14278,"activeCount":651,"soonestReadout":294},[14279],{"nctId":9291,"briefTitle":9292,"status":121,"phases":14280,"primaryCompletion":294,"completion":9294,"start":71,"enrollment":1499,"conditions":14281,"interventions":14282},[90],[161],[9297,9298,9274],{"trials":14284,"activeCount":101},[],{"trials":14286,"activeCount":101},[],{"trials":14288,"activeCount":101},[],{"intervention":14290,"totalTrials":651,"cells":14291},"HLX10",{"EARLY_PHASE1":14292,"PHASE1":14294,"PHASE2":14296,"PHASE3":14307,"PHASE4":14309,"NA":14311},{"trials":14293,"activeCount":101},[],{"trials":14295,"activeCount":101},[],{"trials":14297,"activeCount":651,"soonestReadout":2291},[14298],{"nctId":14299,"briefTitle":14300,"status":270,"phases":14301,"primaryCompletion":2291,"completion":2291,"start":145,"enrollment":2825,"conditions":14302,"interventions":14305},"NCT07507916","Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma",[90],[309,24,14303,14304],"Gastroesophageal Junction (GEJ) Adenocarcinoma","Adjuvant Treatment",[14290,14306],"SOX Chemotherapy",{"trials":14308,"activeCount":101},[],{"trials":14310,"activeCount":101},[],{"trials":14312,"activeCount":101},[],{"intervention":14306,"totalTrials":651,"cells":14314},{"EARLY_PHASE1":14315,"PHASE1":14317,"PHASE2":14319,"PHASE3":14325,"PHASE4":14327,"NA":14329},{"trials":14316,"activeCount":101},[],{"trials":14318,"activeCount":101},[],{"trials":14320,"activeCount":651,"soonestReadout":2291},[14321],{"nctId":14299,"briefTitle":14300,"status":270,"phases":14322,"primaryCompletion":2291,"completion":2291,"start":145,"enrollment":2825,"conditions":14323,"interventions":14324},[90],[309,24,14303,14304],[14290,14306],{"trials":14326,"activeCount":101},[],{"trials":14328,"activeCount":101},[],{"trials":14330,"activeCount":101},[],{"intervention":2276,"totalTrials":651,"cells":14332},{"EARLY_PHASE1":14333,"PHASE1":14335,"PHASE2":14337,"PHASE3":14343,"PHASE4":14345,"NA":14347},{"trials":14334,"activeCount":101},[],{"trials":14336,"activeCount":101},[],{"trials":14338,"activeCount":651,"soonestReadout":354},[14339],{"nctId":2270,"briefTitle":2271,"status":121,"phases":14340,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":14341,"interventions":14342},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":14344,"activeCount":101},[],{"trials":14346,"activeCount":101},[],{"trials":14348,"activeCount":101},[],{"intervention":2277,"totalTrials":651,"cells":14350},{"EARLY_PHASE1":14351,"PHASE1":14353,"PHASE2":14355,"PHASE3":14361,"PHASE4":14363,"NA":14365},{"trials":14352,"activeCount":101},[],{"trials":14354,"activeCount":101},[],{"trials":14356,"activeCount":651,"soonestReadout":354},[14357],{"nctId":2270,"briefTitle":2271,"status":121,"phases":14358,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":14359,"interventions":14360},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":14362,"activeCount":101},[],{"trials":14364,"activeCount":101},[],{"trials":14366,"activeCount":101},[],{"intervention":2278,"totalTrials":651,"cells":14368},{"EARLY_PHASE1":14369,"PHASE1":14371,"PHASE2":14373,"PHASE3":14379,"PHASE4":14381,"NA":14383},{"trials":14370,"activeCount":101},[],{"trials":14372,"activeCount":101},[],{"trials":14374,"activeCount":651,"soonestReadout":354},[14375],{"nctId":2270,"briefTitle":2271,"status":121,"phases":14376,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":14377,"interventions":14378},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":14380,"activeCount":101},[],{"trials":14382,"activeCount":101},[],{"trials":14384,"activeCount":101},[],{"intervention":2279,"totalTrials":651,"cells":14386},{"EARLY_PHASE1":14387,"PHASE1":14389,"PHASE2":14391,"PHASE3":14397,"PHASE4":14399,"NA":14401},{"trials":14388,"activeCount":101},[],{"trials":14390,"activeCount":101},[],{"trials":14392,"activeCount":651,"soonestReadout":354},[14393],{"nctId":2270,"briefTitle":2271,"status":121,"phases":14394,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":14395,"interventions":14396},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":14398,"activeCount":101},[],{"trials":14400,"activeCount":101},[],{"trials":14402,"activeCount":101},[],{"intervention":2282,"totalTrials":651,"cells":14404},{"EARLY_PHASE1":14405,"PHASE1":14407,"PHASE2":14409,"PHASE3":14415,"PHASE4":14417,"NA":14419},{"trials":14406,"activeCount":101},[],{"trials":14408,"activeCount":101},[],{"trials":14410,"activeCount":651,"soonestReadout":354},[14411],{"nctId":2270,"briefTitle":2271,"status":121,"phases":14412,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":14413,"interventions":14414},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":14416,"activeCount":101},[],{"trials":14418,"activeCount":101},[],{"trials":14420,"activeCount":101},[],{"intervention":2283,"totalTrials":651,"cells":14422},{"EARLY_PHASE1":14423,"PHASE1":14425,"PHASE2":14427,"PHASE3":14433,"PHASE4":14435,"NA":14437},{"trials":14424,"activeCount":101},[],{"trials":14426,"activeCount":101},[],{"trials":14428,"activeCount":651,"soonestReadout":354},[14429],{"nctId":2270,"briefTitle":2271,"status":121,"phases":14430,"primaryCompletion":354,"completion":1335,"start":260,"enrollment":2273,"conditions":14431,"interventions":14432},[90],[1369,15,1372,830,2254],[2276,2277,2278,455,1386,1377,1378,458,2279,1382,2280,2281,581,1380,2223,2256,2282,2283,2284],{"trials":14434,"activeCount":101},[],{"trials":14436,"activeCount":101},[],{"trials":14438,"activeCount":101},[],{"intervention":14440,"totalTrials":651,"cells":14441},"standard systemic therapy combined with high\u002Flow-dose radiotherapy plus toripalimab",{"EARLY_PHASE1":14442,"PHASE1":14444,"PHASE2":14446,"PHASE3":14455,"PHASE4":14457,"NA":14459},{"trials":14443,"activeCount":101},[],{"trials":14445,"activeCount":101},[],{"trials":14447,"activeCount":651,"soonestReadout":897},[14448],{"nctId":14449,"briefTitle":14450,"status":121,"phases":14451,"primaryCompletion":897,"completion":123,"start":147,"enrollment":14452,"conditions":14453,"interventions":14454},"NCT06525428","Standard Systemic Therapy Combined With High\u002FLow-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer",[90],96,[5959],[14440],{"trials":14456,"activeCount":101},[],{"trials":14458,"activeCount":101},[],{"trials":14460,"activeCount":101},[],{"intervention":5886,"totalTrials":2010,"cells":14462},{"EARLY_PHASE1":14463,"PHASE1":14465,"PHASE2":14467,"PHASE3":14484,"PHASE4":14486,"NA":14488},{"trials":14464,"activeCount":101},[],{"trials":14466,"activeCount":101},[],{"trials":14468,"activeCount":651,"soonestReadout":8047},[14469,14473,14477],{"nctId":5876,"briefTitle":5877,"status":107,"phases":14470,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":5881,"conditions":14471,"interventions":14472},[90],[15],[5884,5885,5886],{"nctId":8044,"briefTitle":8045,"status":121,"phases":14474,"primaryCompletion":8047,"completion":8048,"start":6733,"enrollment":473,"conditions":14475,"interventions":14476},[89,90],[6058],[8051,1868,1615],{"nctId":14478,"briefTitle":14479,"status":107,"phases":14480,"primaryCompletion":200,"completion":200,"start":14481,"enrollment":137,"conditions":14482,"interventions":14483},"NCT03071926","Metronomic PLD in Patients With Primary Endocrine Resistant ABC",[90],"2017-03-01",[2254],[8051],{"trials":14485,"activeCount":101},[],{"trials":14487,"activeCount":101},[],{"trials":14489,"activeCount":101},[14490],{"nctId":14491,"briefTitle":14492,"status":107,"phases":14493,"primaryCompletion":4435,"completion":717,"start":6261,"enrollment":1146,"conditions":14494,"interventions":14495},"NCT05976932","Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer",[],[2737],[5886],{"intervention":2978,"totalTrials":771,"cells":14497},{"EARLY_PHASE1":14498,"PHASE1":14500,"PHASE2":14502,"PHASE3":14508,"PHASE4":14510,"NA":14512},{"trials":14499,"activeCount":101},[],{"trials":14501,"activeCount":101},[],{"trials":14503,"activeCount":651,"soonestReadout":2971},[14504],{"nctId":2968,"briefTitle":2969,"status":121,"phases":14505,"primaryCompletion":2971,"completion":2972,"start":2973,"enrollment":22,"conditions":14506,"interventions":14507},[90],[2975],[2977,1764,1466,2978],{"trials":14509,"activeCount":101},[],{"trials":14511,"activeCount":101},[],{"trials":14513,"activeCount":101},[14514],{"nctId":14515,"briefTitle":14516,"status":107,"phases":14517,"primaryCompletion":2802,"completion":749,"start":14518,"enrollment":25,"conditions":14519,"interventions":14520},"NCT04517227","The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)",[93],"2021-07",[21],[2978],{"intervention":7063,"totalTrials":771,"cells":14522},{"EARLY_PHASE1":14523,"PHASE1":14525,"PHASE2":14527,"PHASE3":14533,"PHASE4":14535,"NA":14537},{"trials":14524,"activeCount":101},[],{"trials":14526,"activeCount":101},[],{"trials":14528,"activeCount":651,"soonestReadout":2707},[14529],{"nctId":7056,"briefTitle":7057,"status":270,"phases":14530,"primaryCompletion":2707,"completion":7059,"start":540,"enrollment":7060,"conditions":14531,"interventions":14532},[90],[33],[7063,6339],{"trials":14534,"activeCount":101},[],{"trials":14536,"activeCount":101},[],{"trials":14538,"activeCount":101},[14539],{"nctId":14540,"briefTitle":14541,"status":107,"phases":14542,"primaryCompletion":1573,"completion":448,"start":1562,"enrollment":1531,"conditions":14543,"interventions":14544},"NCT06356519","Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer",[],[15],[7063],{"intervention":14546,"totalTrials":771,"cells":14547},"Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells",{"EARLY_PHASE1":14548,"PHASE1":14550,"PHASE2":14569,"PHASE3":14571,"PHASE4":14573,"NA":14575},{"trials":14549,"activeCount":101},[],{"trials":14551,"activeCount":651,"soonestReadout":14556},[14552,14561],{"nctId":14553,"briefTitle":14554,"status":121,"phases":14555,"primaryCompletion":14556,"completion":14556,"start":14557,"enrollment":2394,"conditions":14558,"interventions":14560},"NCT06394622","A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors",[89],"2026-06-28","2024-04-11",[14559],"Solid Tumor",[14546],{"nctId":14562,"briefTitle":14563,"status":107,"phases":14564,"primaryCompletion":14565,"completion":14565,"start":14566,"enrollment":2189,"conditions":14567,"interventions":14568},"NCT06182735","CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma",[89],"2025-01-28","2023-07-17",[3392],[14546],{"trials":14570,"activeCount":101},[],{"trials":14572,"activeCount":101},[],{"trials":14574,"activeCount":101},[],{"trials":14576,"activeCount":101},[],{"intervention":14578,"totalTrials":651,"cells":14579},"JWCAR201",{"EARLY_PHASE1":14580,"PHASE1":14582,"PHASE2":14591,"PHASE3":14593,"PHASE4":14595,"NA":14597},{"trials":14581,"activeCount":101},[],{"trials":14583,"activeCount":651,"soonestReadout":398},[14584],{"nctId":14585,"briefTitle":14586,"status":121,"phases":14587,"primaryCompletion":398,"completion":3473,"start":14588,"enrollment":2189,"conditions":14589,"interventions":14590},"NCT06517004","An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma",[89],"2024-07-18",[9332],[14578],{"trials":14592,"activeCount":101},[],{"trials":14594,"activeCount":101},[],{"trials":14596,"activeCount":101},[],{"trials":14598,"activeCount":101},[],{"intervention":14600,"totalTrials":651,"cells":14601},"Traditional Chinese Medicine (TCM) Treatment",{"EARLY_PHASE1":14602,"PHASE1":14604,"PHASE2":14616,"PHASE3":14618,"PHASE4":14620,"NA":14622},{"trials":14603,"activeCount":101},[],{"trials":14605,"activeCount":651,"soonestReadout":2070},[14606],{"nctId":14607,"briefTitle":14608,"status":270,"phases":14609,"primaryCompletion":2070,"completion":783,"start":1489,"enrollment":3146,"conditions":14610,"interventions":14613},"NCT07286110","Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial",[89],[14611,14612],"Moyamoya Disease","Moyamoya Syndrome",[14600,14614,14615],"Conventional medical treatment","TCM Placebo",{"trials":14617,"activeCount":101},[],{"trials":14619,"activeCount":101},[],{"trials":14621,"activeCount":101},[],{"trials":14623,"activeCount":101},[],{"intervention":14614,"totalTrials":651,"cells":14625},{"EARLY_PHASE1":14626,"PHASE1":14628,"PHASE2":14634,"PHASE3":14636,"PHASE4":14638,"NA":14640},{"trials":14627,"activeCount":101},[],{"trials":14629,"activeCount":651,"soonestReadout":2070},[14630],{"nctId":14607,"briefTitle":14608,"status":270,"phases":14631,"primaryCompletion":2070,"completion":783,"start":1489,"enrollment":3146,"conditions":14632,"interventions":14633},[89],[14611,14612],[14600,14614,14615],{"trials":14635,"activeCount":101},[],{"trials":14637,"activeCount":101},[],{"trials":14639,"activeCount":101},[],{"trials":14641,"activeCount":101},[],{"intervention":14615,"totalTrials":651,"cells":14643},{"EARLY_PHASE1":14644,"PHASE1":14646,"PHASE2":14652,"PHASE3":14654,"PHASE4":14656,"NA":14658},{"trials":14645,"activeCount":101},[],{"trials":14647,"activeCount":651,"soonestReadout":2070},[14648],{"nctId":14607,"briefTitle":14608,"status":270,"phases":14649,"primaryCompletion":2070,"completion":783,"start":1489,"enrollment":3146,"conditions":14650,"interventions":14651},[89],[14611,14612],[14600,14614,14615],{"trials":14653,"activeCount":101},[],{"trials":14655,"activeCount":101},[],{"trials":14657,"activeCount":101},[],{"trials":14659,"activeCount":101},[],{"intervention":14661,"totalTrials":651,"cells":14662},"TACE+AK112",{"EARLY_PHASE1":14663,"PHASE1":14665,"PHASE2":14673,"PHASE3":14675,"PHASE4":14677,"NA":14679},{"trials":14664,"activeCount":101},[],{"trials":14666,"activeCount":651,"soonestReadout":1406},[14667],{"nctId":14668,"briefTitle":14669,"status":270,"phases":14670,"primaryCompletion":1406,"completion":123,"start":2802,"enrollment":2204,"conditions":14671,"interventions":14672},"NCT06990620","TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC",[89],[1322],[14661],{"trials":14674,"activeCount":101},[],{"trials":14676,"activeCount":101},[],{"trials":14678,"activeCount":101},[],{"trials":14680,"activeCount":101},[],{"intervention":14682,"totalTrials":651,"cells":14683},"Lutetium [177Lu]-FAP-75",{"EARLY_PHASE1":14684,"PHASE1":14686,"PHASE2":14697,"PHASE3":14699,"PHASE4":14701,"NA":14703},{"trials":14685,"activeCount":101},[],{"trials":14687,"activeCount":651,"soonestReadout":14692},[14688],{"nctId":14689,"briefTitle":14690,"status":270,"phases":14691,"primaryCompletion":14692,"completion":12532,"start":14693,"enrollment":97,"conditions":14694,"interventions":14696},"NCT06553846","A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors",[89],"2025-02-18","2024-08-19",[14695],"Solid Tumors",[14682],{"trials":14698,"activeCount":101},[],{"trials":14700,"activeCount":101},[],{"trials":14702,"activeCount":101},[],{"trials":14704,"activeCount":101},[],{"intervention":2775,"totalTrials":651,"cells":14706},{"EARLY_PHASE1":14707,"PHASE1":14713,"PHASE2":14715,"PHASE3":14717,"PHASE4":14719,"NA":14721},{"trials":14708,"activeCount":651,"soonestReadout":2772},[14709],{"nctId":2769,"briefTitle":2770,"status":270,"phases":14710,"primaryCompletion":2772,"completion":1812,"start":1164,"enrollment":25,"conditions":14711,"interventions":14712},[88],[30],[2764,2775],{"trials":14714,"activeCount":101},[],{"trials":14716,"activeCount":101},[],{"trials":14718,"activeCount":101},[],{"trials":14720,"activeCount":101},[],{"trials":14722,"activeCount":101},[],{"intervention":14724,"totalTrials":651,"cells":14725},"IDOV-SAFE",{"EARLY_PHASE1":14726,"PHASE1":14736,"PHASE2":14738,"PHASE3":14740,"PHASE4":14742,"NA":14744},{"trials":14727,"activeCount":651,"soonestReadout":1609},[14728],{"nctId":14729,"briefTitle":14730,"status":121,"phases":14731,"primaryCompletion":1609,"completion":305,"start":14732,"enrollment":7627,"conditions":14733,"interventions":14735},"NCT06718946","Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors",[88],"2024-12-10",[14734],"Advanced Malignant Solid Tumor",[14724],{"trials":14737,"activeCount":101},[],{"trials":14739,"activeCount":101},[],{"trials":14741,"activeCount":101},[],{"trials":14743,"activeCount":101},[],{"trials":14745,"activeCount":101},[],{"intervention":14747,"totalTrials":651,"cells":14748},"CAR",{"EARLY_PHASE1":14749,"PHASE1":14760,"PHASE2":14762,"PHASE3":14764,"PHASE4":14766,"NA":14768},{"trials":14750,"activeCount":651,"soonestReadout":750},[14751],{"nctId":14752,"briefTitle":14753,"status":121,"phases":14754,"primaryCompletion":750,"completion":14755,"start":14756,"enrollment":13105,"conditions":14757,"interventions":14758},"NCT05587543","Clinical Study on the EBV CAR-T \u002FTCR-T Cells in the Treatment of Nasopharyngeal Carcinoma",[88],"2030-10","2022-12-28",[35],[14747,14759],"TCR",{"trials":14761,"activeCount":101},[],{"trials":14763,"activeCount":101},[],{"trials":14765,"activeCount":101},[],{"trials":14767,"activeCount":101},[],{"trials":14769,"activeCount":101},[],{"intervention":14759,"totalTrials":651,"cells":14771},{"EARLY_PHASE1":14772,"PHASE1":14778,"PHASE2":14780,"PHASE3":14782,"PHASE4":14784,"NA":14786},{"trials":14773,"activeCount":651,"soonestReadout":750},[14774],{"nctId":14752,"briefTitle":14753,"status":121,"phases":14775,"primaryCompletion":750,"completion":14755,"start":14756,"enrollment":13105,"conditions":14776,"interventions":14777},[88],[35],[14747,14759],{"trials":14779,"activeCount":101},[],{"trials":14781,"activeCount":101},[],{"trials":14783,"activeCount":101},[],{"trials":14785,"activeCount":101},[],{"trials":14787,"activeCount":101},[],{"intervention":14789,"totalTrials":651,"cells":14790},"IDOV-SAFETM",{"EARLY_PHASE1":14791,"PHASE1":14799,"PHASE2":14801,"PHASE3":14803,"PHASE4":14805,"NA":14807},{"trials":14792,"activeCount":651,"soonestReadout":1609},[14793],{"nctId":14794,"briefTitle":14795,"status":270,"phases":14796,"primaryCompletion":1609,"completion":305,"start":2201,"enrollment":3614,"conditions":14797,"interventions":14798},"NCT06713148","Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors",[88],[14734],[14789],{"trials":14800,"activeCount":101},[],{"trials":14802,"activeCount":101},[],{"trials":14804,"activeCount":101},[],{"trials":14806,"activeCount":101},[],{"trials":14808,"activeCount":101},[],{"intervention":2369,"totalTrials":1300,"cells":14810},{"EARLY_PHASE1":14811,"PHASE1":14813,"PHASE2":14815,"PHASE3":14821,"PHASE4":14823,"NA":14825},{"trials":14812,"activeCount":101},[],{"trials":14814,"activeCount":101},[],{"trials":14816,"activeCount":101},[14817],{"nctId":2360,"briefTitle":2361,"status":107,"phases":14818,"primaryCompletion":2363,"completion":2364,"start":2365,"enrollment":828,"conditions":14819,"interventions":14820},[90],[2367,521],[2369,2370,2328,2329],{"trials":14822,"activeCount":101},[],{"trials":14824,"activeCount":101},[],{"trials":14826,"activeCount":651,"soonestReadout":749},[14827,14836],{"nctId":14828,"briefTitle":14829,"status":365,"phases":14830,"primaryCompletion":14831,"completion":14832,"start":14833,"enrollment":97,"conditions":14834,"interventions":14835},"NCT04992156","Prediction of 18F-FES-PET\u002FCT Parameters on Palbociclib Combined With ET",[],"2022-03-15","2022-04-15","2017-03-15",[33],[2369],{"nctId":7812,"briefTitle":7813,"status":121,"phases":14837,"primaryCompletion":749,"completion":896,"start":7815,"enrollment":3068,"conditions":14838,"interventions":14839},[93],[7817,7818],[7820,2369,2358],{"intervention":14841,"totalTrials":771,"cells":14842},"sirolimus",{"EARLY_PHASE1":14843,"PHASE1":14845,"PHASE2":14847,"PHASE3":14849,"PHASE4":14860,"NA":14862},{"trials":14844,"activeCount":101},[],{"trials":14846,"activeCount":101},[],{"trials":14848,"activeCount":101},[],{"trials":14850,"activeCount":101},[14851],{"nctId":14852,"briefTitle":14853,"status":107,"phases":14854,"completion":14855,"start":14856,"enrollment":14857,"conditions":14858,"interventions":14859},"NCT00554125","Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria",[91],"2013-08","2007-08",220,[21],[14841],{"trials":14861,"activeCount":101},[],{"trials":14863,"activeCount":651,"soonestReadout":749},[14864],{"nctId":7812,"briefTitle":7813,"status":121,"phases":14865,"primaryCompletion":749,"completion":896,"start":7815,"enrollment":3068,"conditions":14866,"interventions":14867},[93],[7817,7818],[7820,2369,2358],{"intervention":14869,"totalTrials":651,"cells":14870},"Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others",{"EARLY_PHASE1":14871,"PHASE1":14873,"PHASE2":14875,"PHASE3":14877,"PHASE4":14879,"NA":14881},{"trials":14872,"activeCount":101},[],{"trials":14874,"activeCount":101},[],{"trials":14876,"activeCount":101},[],{"trials":14878,"activeCount":101},[],{"trials":14880,"activeCount":101},[],{"trials":14882,"activeCount":651,"soonestReadout":2844},[14883],{"nctId":14884,"briefTitle":14885,"status":270,"phases":14886,"primaryCompletion":2844,"completion":235,"start":14887,"enrollment":213,"conditions":14888,"interventions":14889},"NCT04831528","Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study",[],"2021-04-10",[6157],[14869],{"intervention":14891,"totalTrials":651,"cells":14892},"Remifentanil",{"EARLY_PHASE1":14893,"PHASE1":14895,"PHASE2":14897,"PHASE3":14899,"PHASE4":14901,"NA":14903},{"trials":14894,"activeCount":101},[],{"trials":14896,"activeCount":101},[],{"trials":14898,"activeCount":101},[],{"trials":14900,"activeCount":101},[],{"trials":14902,"activeCount":101},[],{"trials":14904,"activeCount":651,"soonestReadout":235},[14905],{"nctId":14906,"briefTitle":14907,"status":121,"phases":14908,"primaryCompletion":235,"completion":2070,"start":14909,"enrollment":1434,"conditions":14910,"interventions":14913},"NCT07301970","Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients",[],"2025-09-22",[14911,14912],"Critical Illness","Pain",[14891],{"intervention":14915,"totalTrials":651,"cells":14916},"RET Inhibitor",{"EARLY_PHASE1":14917,"PHASE1":14919,"PHASE2":14921,"PHASE3":14923,"PHASE4":14925,"NA":14927},{"trials":14918,"activeCount":101},[],{"trials":14920,"activeCount":101},[],{"trials":14922,"activeCount":101},[],{"trials":14924,"activeCount":101},[],{"trials":14926,"activeCount":101},[],{"trials":14928,"activeCount":651,"soonestReadout":963},[14929],{"nctId":14930,"briefTitle":14931,"status":121,"phases":14932,"primaryCompletion":963,"completion":2291,"start":14588,"enrollment":2845,"conditions":14933,"interventions":14934},"NCT06530316","RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer",[],[6616],[14915],{"intervention":14936,"totalTrials":651,"cells":14937},"GemCis plus PD-1\u002FPD-L1 inhibitor",{"EARLY_PHASE1":14938,"PHASE1":14940,"PHASE2":14942,"PHASE3":14944,"PHASE4":14946,"NA":14948},{"trials":14939,"activeCount":101},[],{"trials":14941,"activeCount":101},[],{"trials":14943,"activeCount":101},[],{"trials":14945,"activeCount":101},[],{"trials":14947,"activeCount":101},[],{"trials":14949,"activeCount":651,"soonestReadout":14954},[14950],{"nctId":14951,"briefTitle":14952,"status":121,"phases":14953,"primaryCompletion":14954,"completion":2017,"start":14955,"enrollment":213,"conditions":14956,"interventions":14957},"NCT06988592","GemCis Plus PD-1\u002FPD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）",[],"2027-05-18","2025-05-23",[6029],[14936],{"intervention":14959,"totalTrials":651,"cells":14960},"Additional hCG",{"EARLY_PHASE1":14961,"PHASE1":14963,"PHASE2":14965,"PHASE3":14967,"PHASE4":14969,"NA":14971},{"trials":14962,"activeCount":101},[],{"trials":14964,"activeCount":101},[],{"trials":14966,"activeCount":101},[],{"trials":14968,"activeCount":101},[],{"trials":14970,"activeCount":101},[],{"trials":14972,"activeCount":651,"soonestReadout":1609},[14973],{"nctId":14974,"briefTitle":14975,"status":121,"phases":14976,"primaryCompletion":1609,"completion":1609,"start":190,"enrollment":137,"conditions":14977,"interventions":14981},"NCT05569577","An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients",[93],[14978,14979,14980],"Luteal Phase Deficiency","Luteal Phase Support","Idiopathic Hypogonadotropic Hypogonadism",[14959,14982],"estrogen and dydrogesterone",{"intervention":14982,"totalTrials":651,"cells":14984},{"EARLY_PHASE1":14985,"PHASE1":14987,"PHASE2":14989,"PHASE3":14991,"PHASE4":14993,"NA":14995},{"trials":14986,"activeCount":101},[],{"trials":14988,"activeCount":101},[],{"trials":14990,"activeCount":101},[],{"trials":14992,"activeCount":101},[],{"trials":14994,"activeCount":101},[],{"trials":14996,"activeCount":651,"soonestReadout":1609},[14997],{"nctId":14974,"briefTitle":14975,"status":121,"phases":14998,"primaryCompletion":1609,"completion":1609,"start":190,"enrollment":137,"conditions":14999,"interventions":15000},[93],[14978,14979,14980],[14959,14982],{"intervention":15002,"totalTrials":651,"cells":15003},"recommendations for Hp eradication treatment",{"EARLY_PHASE1":15004,"PHASE1":15006,"PHASE2":15008,"PHASE3":15010,"PHASE4":15012,"NA":15014},{"trials":15005,"activeCount":101},[],{"trials":15007,"activeCount":101},[],{"trials":15009,"activeCount":101},[],{"trials":15011,"activeCount":101},[],{"trials":15013,"activeCount":101},[],{"trials":15015,"activeCount":651,"soonestReadout":1690},[15016],{"nctId":15017,"briefTitle":15018,"status":270,"phases":15019,"primaryCompletion":1690,"completion":2313,"start":939,"enrollment":15020,"conditions":15021,"interventions":15022},"NCT06943794","Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial",[93],4824,[13897],[15002],{"intervention":15024,"totalTrials":651,"cells":15025},"Paclitaxel plus carboplatin",{"EARLY_PHASE1":15026,"PHASE1":15028,"PHASE2":15030,"PHASE3":15032,"PHASE4":15034,"NA":15036},{"trials":15027,"activeCount":101},[],{"trials":15029,"activeCount":101},[],{"trials":15031,"activeCount":101},[],{"trials":15033,"activeCount":101},[],{"trials":15035,"activeCount":101},[],{"trials":15037,"activeCount":651,"soonestReadout":1356},[15038],{"nctId":15039,"briefTitle":15040,"status":121,"phases":15041,"primaryCompletion":1356,"completion":123,"start":15042,"enrollment":15043,"conditions":15044,"interventions":15046},"NCT04519905","Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)",[93],"2020-01-06",320,[27,1217,15045],"Survival",[15024],{"intervention":15048,"totalTrials":651,"cells":15049},"third-generation EGFR TKIs",{"EARLY_PHASE1":15050,"PHASE1":15052,"PHASE2":15054,"PHASE3":15056,"PHASE4":15058,"NA":15060},{"trials":15051,"activeCount":101},[],{"trials":15053,"activeCount":101},[],{"trials":15055,"activeCount":101},[],{"trials":15057,"activeCount":101},[],{"trials":15059,"activeCount":101},[],{"trials":15061,"activeCount":651,"soonestReadout":448},[15062],{"nctId":15063,"briefTitle":15064,"status":121,"phases":15065,"primaryCompletion":448,"completion":10215,"start":1407,"enrollment":965,"conditions":15066,"interventions":15068},"NCT06604689","AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases",[],[3961,15067],"Brain Metastasases",[15048],{"intervention":15070,"totalTrials":651,"cells":15071},"CAR-T",{"EARLY_PHASE1":15072,"PHASE1":15074,"PHASE2":15076,"PHASE3":15078,"PHASE4":15080,"NA":15082},{"trials":15073,"activeCount":101},[],{"trials":15075,"activeCount":101},[],{"trials":15077,"activeCount":101},[],{"trials":15079,"activeCount":101},[],{"trials":15081,"activeCount":101},[],{"trials":15083,"activeCount":651,"soonestReadout":8310},[15084],{"nctId":15085,"briefTitle":15086,"status":121,"phases":15087,"primaryCompletion":8310,"completion":940,"start":15088,"enrollment":334,"conditions":15089,"interventions":15091},"NCT07236203","Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed\u002FRefractory Large B-Cell Lymphoma: A Clinical Study",[],"2024-02-29",[15090],"Large B-Cell Lymphoma",[15070],{"intervention":15093,"totalTrials":651,"cells":15094},"Yueju Pill + Standard Anti-tumor Therapy",{"EARLY_PHASE1":15095,"PHASE1":15097,"PHASE2":15099,"PHASE3":15101,"PHASE4":15103,"NA":15105},{"trials":15096,"activeCount":101},[],{"trials":15098,"activeCount":101},[],{"trials":15100,"activeCount":101},[],{"trials":15102,"activeCount":101},[],{"trials":15104,"activeCount":101},[],{"trials":15106,"activeCount":651,"soonestReadout":305},[15107],{"nctId":15108,"briefTitle":15109,"status":270,"phases":15110,"primaryCompletion":305,"completion":305,"start":1530,"enrollment":202,"conditions":15111,"interventions":15112},"NCT07169916","Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer",[93],[6526],[15093],{"intervention":15114,"totalTrials":651,"cells":15115},"DC Vaccine",{"EARLY_PHASE1":15116,"PHASE1":15118,"PHASE2":15120,"PHASE3":15122,"PHASE4":15124,"NA":15126},{"trials":15117,"activeCount":101},[],{"trials":15119,"activeCount":101},[],{"trials":15121,"activeCount":101},[],{"trials":15123,"activeCount":101},[],{"trials":15125,"activeCount":101},[],{"trials":15127,"activeCount":651,"soonestReadout":783},[15128],{"nctId":15129,"briefTitle":15130,"status":121,"phases":15131,"primaryCompletion":783,"completion":783,"start":15132,"enrollment":2189,"conditions":15133,"interventions":15138},"NCT06682117","A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor",[93],"2024-11-15",[15134,15135,15136,15137],"Treatment","Neoantigen","Vaccine","Solid Tumor Cancer",[15114],{"intervention":7976,"totalTrials":651,"cells":15140},{"EARLY_PHASE1":15141,"PHASE1":15143,"PHASE2":15145,"PHASE3":15147,"PHASE4":15149,"NA":15151},{"trials":15142,"activeCount":101},[],{"trials":15144,"activeCount":101},[],{"trials":15146,"activeCount":101},[],{"trials":15148,"activeCount":101},[],{"trials":15150,"activeCount":101},[],{"trials":15152,"activeCount":651,"soonestReadout":3067},[15153],{"nctId":7969,"briefTitle":7970,"status":121,"phases":15154,"primaryCompletion":3067,"completion":1529,"start":1530,"enrollment":5832,"conditions":15155,"interventions":15156},[],[24,7973],[7975,7976,7977,7978],{"intervention":7977,"totalTrials":651,"cells":15158},{"EARLY_PHASE1":15159,"PHASE1":15161,"PHASE2":15163,"PHASE3":15165,"PHASE4":15167,"NA":15169},{"trials":15160,"activeCount":101},[],{"trials":15162,"activeCount":101},[],{"trials":15164,"activeCount":101},[],{"trials":15166,"activeCount":101},[],{"trials":15168,"activeCount":101},[],{"trials":15170,"activeCount":651,"soonestReadout":3067},[15171],{"nctId":7969,"briefTitle":7970,"status":121,"phases":15172,"primaryCompletion":3067,"completion":1529,"start":1530,"enrollment":5832,"conditions":15173,"interventions":15174},[],[24,7973],[7975,7976,7977,7978],{"intervention":7978,"totalTrials":651,"cells":15176},{"EARLY_PHASE1":15177,"PHASE1":15179,"PHASE2":15181,"PHASE3":15183,"PHASE4":15185,"NA":15187},{"trials":15178,"activeCount":101},[],{"trials":15180,"activeCount":101},[],{"trials":15182,"activeCount":101},[],{"trials":15184,"activeCount":101},[],{"trials":15186,"activeCount":101},[],{"trials":15188,"activeCount":651,"soonestReadout":3067},[15189],{"nctId":7969,"briefTitle":7970,"status":121,"phases":15190,"primaryCompletion":3067,"completion":1529,"start":1530,"enrollment":5832,"conditions":15191,"interventions":15192},[],[24,7973],[7975,7976,7977,7978],{"intervention":15194,"totalTrials":651,"cells":15195},"0.25% ropivacaine",{"EARLY_PHASE1":15196,"PHASE1":15198,"PHASE2":15200,"PHASE3":15202,"PHASE4":15204,"NA":15206},{"trials":15197,"activeCount":101},[],{"trials":15199,"activeCount":101},[],{"trials":15201,"activeCount":101},[],{"trials":15203,"activeCount":101},[],{"trials":15205,"activeCount":101},[],{"trials":15207,"activeCount":651,"soonestReadout":1489},[15208],{"nctId":15209,"briefTitle":15210,"status":270,"phases":15211,"primaryCompletion":1489,"completion":1609,"start":15212,"enrollment":2355,"conditions":15213,"interventions":15218},"NCT07079436","EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve Blockade",[93],"2025-08-10",[15214,15215,15216,1882,15217],"Intercostal Nerve Block","Pulmonary Ventilation","Anesthesia, Local","Surgical Procedures, Operative",[15194,15219,15220],"0.375% Ropivacaine","0.5% Ropivacaine",{"intervention":15219,"totalTrials":651,"cells":15222},{"EARLY_PHASE1":15223,"PHASE1":15225,"PHASE2":15227,"PHASE3":15229,"PHASE4":15231,"NA":15233},{"trials":15224,"activeCount":101},[],{"trials":15226,"activeCount":101},[],{"trials":15228,"activeCount":101},[],{"trials":15230,"activeCount":101},[],{"trials":15232,"activeCount":101},[],{"trials":15234,"activeCount":651,"soonestReadout":1489},[15235],{"nctId":15209,"briefTitle":15210,"status":270,"phases":15236,"primaryCompletion":1489,"completion":1609,"start":15212,"enrollment":2355,"conditions":15237,"interventions":15238},[93],[15214,15215,15216,1882,15217],[15194,15219,15220],{"intervention":15220,"totalTrials":651,"cells":15240},{"EARLY_PHASE1":15241,"PHASE1":15243,"PHASE2":15245,"PHASE3":15247,"PHASE4":15249,"NA":15251},{"trials":15242,"activeCount":101},[],{"trials":15244,"activeCount":101},[],{"trials":15246,"activeCount":101},[],{"trials":15248,"activeCount":101},[],{"trials":15250,"activeCount":101},[],{"trials":15252,"activeCount":651,"soonestReadout":1489},[15253],{"nctId":15209,"briefTitle":15210,"status":270,"phases":15254,"primaryCompletion":1489,"completion":1609,"start":15212,"enrollment":2355,"conditions":15255,"interventions":15256},[93],[15214,15215,15216,1882,15217],[15194,15219,15220],{"intervention":15258,"totalTrials":651,"cells":15259},"Temozolomide、Fruquintinib、Cadonilimab",{"EARLY_PHASE1":15260,"PHASE1":15262,"PHASE2":15264,"PHASE3":15266,"PHASE4":15268,"NA":15270},{"trials":15261,"activeCount":101},[],{"trials":15263,"activeCount":101},[],{"trials":15265,"activeCount":101},[],{"trials":15267,"activeCount":101},[],{"trials":15269,"activeCount":101},[],{"trials":15271,"activeCount":651,"soonestReadout":1530},[15272],{"nctId":15273,"briefTitle":15274,"status":270,"phases":15275,"primaryCompletion":1530,"completion":3067,"start":2324,"enrollment":28,"conditions":15276,"interventions":15278},"NCT06553781","A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma",[93],[15277],"Malignant Melanoma",[15258],{"intervention":15280,"totalTrials":651,"cells":15281},"Pralsetinib",{"EARLY_PHASE1":15282,"PHASE1":15284,"PHASE2":15286,"PHASE3":15288,"PHASE4":15290,"NA":15292},{"trials":15283,"activeCount":101},[],{"trials":15285,"activeCount":101},[],{"trials":15287,"activeCount":101},[],{"trials":15289,"activeCount":101},[],{"trials":15291,"activeCount":101},[],{"trials":15293,"activeCount":651,"soonestReadout":305},[15294],{"nctId":15295,"briefTitle":15296,"status":270,"phases":15297,"primaryCompletion":305,"completion":236,"start":12266,"enrollment":31,"conditions":15298,"interventions":15300},"NCT07418879","A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC",[93],[2960,15299,15280],"RET Fusion",[15280,15301],"Leucogen",{"intervention":15301,"totalTrials":651,"cells":15303},{"EARLY_PHASE1":15304,"PHASE1":15306,"PHASE2":15308,"PHASE3":15310,"PHASE4":15312,"NA":15314},{"trials":15305,"activeCount":101},[],{"trials":15307,"activeCount":101},[],{"trials":15309,"activeCount":101},[],{"trials":15311,"activeCount":101},[],{"trials":15313,"activeCount":101},[],{"trials":15315,"activeCount":651,"soonestReadout":305},[15316],{"nctId":15295,"briefTitle":15296,"status":270,"phases":15317,"primaryCompletion":305,"completion":236,"start":12266,"enrollment":31,"conditions":15318,"interventions":15319},[93],[2960,15299,15280],[15280,15301],{"intervention":15321,"totalTrials":651,"cells":15322},"bevacizumab plus nab-paclitaxel and platinum",{"EARLY_PHASE1":15323,"PHASE1":15325,"PHASE2":15327,"PHASE3":15329,"PHASE4":15331,"NA":15333},{"trials":15324,"activeCount":101},[],{"trials":15326,"activeCount":101},[],{"trials":15328,"activeCount":101},[],{"trials":15330,"activeCount":101},[],{"trials":15332,"activeCount":101},[],{"trials":15334,"activeCount":651,"soonestReadout":13788},[15335],{"nctId":15336,"briefTitle":15337,"status":505,"phases":15338,"primaryCompletion":13788,"completion":8310,"start":15339,"enrollment":2204,"conditions":15340,"interventions":15342},"NCT05407155","Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer",[93],"2022-06-09",[15341],"Non-small Cell Lung Cancer Metastatic",[15321],{"intervention":15344,"totalTrials":651,"cells":15345},"Targeted drugs combined with anti-PD-1\u002FPD-L1 antibodies",{"EARLY_PHASE1":15346,"PHASE1":15348,"PHASE2":15350,"PHASE3":15352,"PHASE4":15354,"NA":15356},{"trials":15347,"activeCount":101},[],{"trials":15349,"activeCount":101},[],{"trials":15351,"activeCount":101},[],{"trials":15353,"activeCount":101},[],{"trials":15355,"activeCount":101},[],{"trials":15357,"activeCount":651,"soonestReadout":3473},[15358],{"nctId":15359,"briefTitle":15360,"status":270,"phases":15361,"primaryCompletion":3473,"completion":15362,"start":1143,"enrollment":15363,"conditions":15364,"interventions":15366},"NCT05660213","A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer",[],"2030-08",750,[15365],"Unresectable Hepatocellular Carcinoma",[15344,15367,15368,15369],"TACE (transarterial chemoembolization) combined with targeted\u002Fimmunotherapy","Lenvatinib monotherapy","Huaier granules combined with any of the above Cohorts for treatment",{"intervention":15367,"totalTrials":651,"cells":15371},{"EARLY_PHASE1":15372,"PHASE1":15374,"PHASE2":15376,"PHASE3":15378,"PHASE4":15380,"NA":15382},{"trials":15373,"activeCount":101},[],{"trials":15375,"activeCount":101},[],{"trials":15377,"activeCount":101},[],{"trials":15379,"activeCount":101},[],{"trials":15381,"activeCount":101},[],{"trials":15383,"activeCount":651,"soonestReadout":3473},[15384],{"nctId":15359,"briefTitle":15360,"status":270,"phases":15385,"primaryCompletion":3473,"completion":15362,"start":1143,"enrollment":15363,"conditions":15386,"interventions":15387},[],[15365],[15344,15367,15368,15369],{"intervention":15368,"totalTrials":651,"cells":15389},{"EARLY_PHASE1":15390,"PHASE1":15392,"PHASE2":15394,"PHASE3":15396,"PHASE4":15398,"NA":15400},{"trials":15391,"activeCount":101},[],{"trials":15393,"activeCount":101},[],{"trials":15395,"activeCount":101},[],{"trials":15397,"activeCount":101},[],{"trials":15399,"activeCount":101},[],{"trials":15401,"activeCount":651,"soonestReadout":3473},[15402],{"nctId":15359,"briefTitle":15360,"status":270,"phases":15403,"primaryCompletion":3473,"completion":15362,"start":1143,"enrollment":15363,"conditions":15404,"interventions":15405},[],[15365],[15344,15367,15368,15369],{"intervention":15369,"totalTrials":651,"cells":15407},{"EARLY_PHASE1":15408,"PHASE1":15410,"PHASE2":15412,"PHASE3":15414,"PHASE4":15416,"NA":15418},{"trials":15409,"activeCount":101},[],{"trials":15411,"activeCount":101},[],{"trials":15413,"activeCount":101},[],{"trials":15415,"activeCount":101},[],{"trials":15417,"activeCount":101},[],{"trials":15419,"activeCount":651,"soonestReadout":3473},[15420],{"nctId":15359,"briefTitle":15360,"status":270,"phases":15421,"primaryCompletion":3473,"completion":15362,"start":1143,"enrollment":15363,"conditions":15422,"interventions":15423},[],[15365],[15344,15367,15368,15369],{"intervention":72,"totalTrials":651,"cells":15425},{"EARLY_PHASE1":15426,"PHASE1":15428,"PHASE2":15430,"PHASE3":15432,"PHASE4":15434,"NA":15436},{"trials":15427,"activeCount":101},[],{"trials":15429,"activeCount":101},[],{"trials":15431,"activeCount":101},[],{"trials":15433,"activeCount":101},[],{"trials":15435,"activeCount":101},[],{"trials":15437,"activeCount":651,"soonestReadout":71},[15438],{"nctId":69,"briefTitle":70,"status":270,"phases":15439,"primaryCompletion":71,"completion":15440,"start":71,"enrollment":5893,"conditions":15441,"interventions":15442},[93],"2027-05-20",[1492],[72],{"intervention":15444,"totalTrials":651,"cells":15445},"RGL-305",{"EARLY_PHASE1":15446,"PHASE1":15448,"PHASE2":15450,"PHASE3":15452,"PHASE4":15454,"NA":15456},{"trials":15447,"activeCount":101},[],{"trials":15449,"activeCount":101},[],{"trials":15451,"activeCount":101},[],{"trials":15453,"activeCount":101},[],{"trials":15455,"activeCount":101},[],{"trials":15457,"activeCount":651,"soonestReadout":6247},[15458],{"nctId":15459,"briefTitle":15460,"status":121,"phases":15461,"primaryCompletion":6247,"completion":2684,"start":10261,"enrollment":2394,"conditions":15462,"interventions":15464},"NCT07006012","RGL-305+ Lymphoma + Exploratory Clinical Study",[93],[15463],"Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)",[15444],{"intervention":15466,"totalTrials":651,"cells":15467},"Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin",{"EARLY_PHASE1":15468,"PHASE1":15470,"PHASE2":15472,"PHASE3":15474,"PHASE4":15476,"NA":15478},{"trials":15469,"activeCount":101},[],{"trials":15471,"activeCount":101},[],{"trials":15473,"activeCount":101},[],{"trials":15475,"activeCount":101},[],{"trials":15477,"activeCount":101},[],{"trials":15479,"activeCount":651,"soonestReadout":10963},[15480],{"nctId":15481,"briefTitle":15482,"status":121,"phases":15483,"primaryCompletion":10963,"completion":15484,"start":15485,"enrollment":2932,"conditions":15486,"interventions":15488},"NCT06636591","Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer",[93],"2026-10-07","2024-11-18",[15487,830],"Breast Cancer Female",[15466,15489],"Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin",{"intervention":15489,"totalTrials":651,"cells":15491},{"EARLY_PHASE1":15492,"PHASE1":15494,"PHASE2":15496,"PHASE3":15498,"PHASE4":15500,"NA":15502},{"trials":15493,"activeCount":101},[],{"trials":15495,"activeCount":101},[],{"trials":15497,"activeCount":101},[],{"trials":15499,"activeCount":101},[],{"trials":15501,"activeCount":101},[],{"trials":15503,"activeCount":651,"soonestReadout":10963},[15504],{"nctId":15481,"briefTitle":15482,"status":121,"phases":15505,"primaryCompletion":10963,"completion":15484,"start":15485,"enrollment":2932,"conditions":15506,"interventions":15507},[93],[15487,830],[15466,15489],{"intervention":15509,"totalTrials":651,"cells":15510},"Entrectinib",{"EARLY_PHASE1":15511,"PHASE1":15513,"PHASE2":15515,"PHASE3":15517,"PHASE4":15519,"NA":15521},{"trials":15512,"activeCount":101},[],{"trials":15514,"activeCount":101},[],{"trials":15516,"activeCount":101},[],{"trials":15518,"activeCount":101},[],{"trials":15520,"activeCount":101},[],{"trials":15522,"activeCount":651,"soonestReadout":235},[15523],{"nctId":15524,"briefTitle":15525,"status":121,"phases":15526,"primaryCompletion":235,"completion":1335,"start":439,"enrollment":7627,"conditions":15527,"interventions":15529},"NCT07199959","Study on the Mechanism of Acquired Resistance of Entrectinib",[],[15528,2526],"ROS1 Fusion Positive",[15509],{"intervention":15531,"totalTrials":651,"cells":15532},"Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine",{"EARLY_PHASE1":15533,"PHASE1":15535,"PHASE2":15537,"PHASE3":15539,"PHASE4":15541,"NA":15543},{"trials":15534,"activeCount":101},[],{"trials":15536,"activeCount":101},[],{"trials":15538,"activeCount":101},[],{"trials":15540,"activeCount":101},[],{"trials":15542,"activeCount":101},[],{"trials":15544,"activeCount":651,"soonestReadout":12888},[15545],{"nctId":15546,"briefTitle":15547,"status":121,"phases":15548,"primaryCompletion":12888,"completion":15549,"start":15550,"enrollment":19,"conditions":15551,"interventions":15553},"NCT06158919","A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G\u002FGEJ Cancer",[93],"2026-11-20","2023-11-20",[15552],"Gastric Cancer\u002FAdenocarcinoma of Esophagogastric Junction",[15531],{"intervention":15555,"totalTrials":651,"cells":15556},"TACE+QL1706",{"EARLY_PHASE1":15557,"PHASE1":15559,"PHASE2":15561,"PHASE3":15563,"PHASE4":15565,"NA":15567},{"trials":15558,"activeCount":101},[],{"trials":15560,"activeCount":101},[],{"trials":15562,"activeCount":101},[],{"trials":15564,"activeCount":101},[],{"trials":15566,"activeCount":101},[],{"trials":15568,"activeCount":651,"soonestReadout":1927},[15569],{"nctId":15570,"briefTitle":15571,"status":270,"phases":15572,"primaryCompletion":1927,"completion":15573,"start":15574,"enrollment":25,"conditions":15575,"interventions":15576},"NCT07268131","TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria",[93],"2029-10-31","2025-12-20",[1322],[15555],{"intervention":15578,"totalTrials":1300,"cells":15579},"Rosuvastatin",{"EARLY_PHASE1":15580,"PHASE1":15582,"PHASE2":15584,"PHASE3":15596,"PHASE4":15605,"NA":15617},{"trials":15581,"activeCount":101},[],{"trials":15583,"activeCount":101},[],{"trials":15585,"activeCount":101},[15586],{"nctId":15587,"briefTitle":15588,"status":365,"phases":15589,"primaryCompletion":15590,"completion":15591,"start":1683,"enrollment":2845,"conditions":15592,"interventions":15594},"NCT04491643","Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma",[90],"2023-08-11","2025-04-11",[15593],"Endometrial Carcinoma Stage I",[15595,15578],"Megestrol Acetate",{"trials":15597,"activeCount":101},[15598],{"nctId":15599,"briefTitle":15600,"status":365,"phases":15601,"primaryCompletion":6585,"completion":6585,"start":1683,"enrollment":3068,"conditions":15602,"interventions":15604},"NCT04491682","Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia",[90,91],[15603],"Atypical Endometrial Hyperplasia",[15595,15578],{"trials":15606,"activeCount":101},[15607],{"nctId":15608,"briefTitle":15609,"status":107,"phases":15610,"primaryCompletion":426,"completion":426,"start":3122,"enrollment":15611,"conditions":15612,"interventions":15614},"NCT03418974","Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia",[92],10000,[15613],"Dyslipidemias",[15615,15616,15578],"Pitavastatin","Atorvastatin",{"trials":15618,"activeCount":101},[],{"intervention":15620,"totalTrials":771,"cells":15621},"Zoledronic acid",{"EARLY_PHASE1":15622,"PHASE1":15624,"PHASE2":15626,"PHASE3":15628,"PHASE4":15639,"NA":15654},{"trials":15623,"activeCount":101},[],{"trials":15625,"activeCount":101},[],{"trials":15627,"activeCount":101},[],{"trials":15629,"activeCount":101},[15630],{"nctId":15631,"briefTitle":15632,"status":365,"phases":15633,"primaryCompletion":1953,"completion":15634,"start":15635,"enrollment":111,"conditions":15636,"interventions":15638},"NCT00524849","Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis",[90,91],"2010-01","2006-11",[33,15637],"Bone Metastases",[15620,15620],{"trials":15640,"activeCount":101},[15641],{"nctId":15642,"briefTitle":15643,"status":107,"phases":15644,"primaryCompletion":2499,"completion":15645,"start":15646,"enrollment":97,"conditions":15647,"interventions":15651},"NCT01310465","The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion",[92],"2012-04","2011-01",[15648,15649,15650],"Image Changes of Lumbar Fusion","Bone Turnover Markers","Bone Mineral Density",[15652,15653],"zoledronic acid","sodium chloride",{"trials":15655,"activeCount":101},[],{"intervention":15657,"totalTrials":771,"cells":15658},"chemotherapy ± target therapy",{"EARLY_PHASE1":15659,"PHASE1":15661,"PHASE2":15663,"PHASE3":15665,"PHASE4":15675,"NA":15684},{"trials":15660,"activeCount":101},[],{"trials":15662,"activeCount":101},[],{"trials":15664,"activeCount":101},[],{"trials":15666,"activeCount":101},[15667],{"nctId":15668,"briefTitle":15669,"status":107,"phases":15670,"primaryCompletion":1279,"completion":1279,"start":15671,"enrollment":1531,"conditions":15672,"interventions":15673},"NCT03125161","Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM",[91],"2017-04-30",[8977],[15674,15657],"HAI",{"trials":15676,"activeCount":101},[15677],{"nctId":15678,"briefTitle":15679,"status":107,"phases":15680,"primaryCompletion":3181,"completion":426,"start":15671,"enrollment":2709,"conditions":15681,"interventions":15683},"NCT03127072","Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM",[92],[15682],"Colorectal Cancer Liver Metastasis",[15657],{"trials":15685,"activeCount":101},[],{"intervention":15687,"totalTrials":651,"cells":15688},"Exenatide",{"EARLY_PHASE1":15689,"PHASE1":15691,"PHASE2":15693,"PHASE3":15695,"PHASE4":15697,"NA":15709},{"trials":15690,"activeCount":101},[],{"trials":15692,"activeCount":101},[],{"trials":15694,"activeCount":101},[],{"trials":15696,"activeCount":101},[],{"trials":15698,"activeCount":101},[15699],{"nctId":15700,"briefTitle":15701,"status":365,"phases":15702,"primaryCompletion":15703,"completion":15703,"start":210,"enrollment":690,"conditions":15704,"interventions":15707},"NCT02303730","Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes",[92],"2017-11",[15705,15706],"Diabetes Mellitus, Type 2","Non-alcoholic Fatty Liver Disease",[15687,15708],"insulin glargine",{"trials":15710,"activeCount":101},[],{"intervention":15708,"totalTrials":651,"cells":15712},{"EARLY_PHASE1":15713,"PHASE1":15715,"PHASE2":15717,"PHASE3":15719,"PHASE4":15721,"NA":15727},{"trials":15714,"activeCount":101},[],{"trials":15716,"activeCount":101},[],{"trials":15718,"activeCount":101},[],{"trials":15720,"activeCount":101},[],{"trials":15722,"activeCount":101},[15723],{"nctId":15700,"briefTitle":15701,"status":365,"phases":15724,"primaryCompletion":15703,"completion":15703,"start":210,"enrollment":690,"conditions":15725,"interventions":15726},[92],[15705,15706],[15687,15708],{"trials":15728,"activeCount":101},[],{"intervention":15730,"totalTrials":651,"cells":15731},"Prourokinase",{"EARLY_PHASE1":15732,"PHASE1":15734,"PHASE2":15736,"PHASE3":15738,"PHASE4":15740,"NA":15757},{"trials":15733,"activeCount":101},[],{"trials":15735,"activeCount":101},[],{"trials":15737,"activeCount":101},[],{"trials":15739,"activeCount":101},[],{"trials":15741,"activeCount":101},[15742],{"nctId":15743,"briefTitle":15744,"status":365,"phases":15745,"primaryCompletion":15746,"completion":15747,"start":15748,"enrollment":15749,"conditions":15750,"interventions":15754},"NCT02131220","Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction",[92],"2017-08","2017-09","2015-11",362,[15751,15752,15753],"Myocardial Infarction","Percutaneous Coronary Intervention","Thrombolytic Therapy",[15730,15755,15756],"Tirofiban","normal saline",{"trials":15758,"activeCount":101},[],{"intervention":15755,"totalTrials":651,"cells":15760},{"EARLY_PHASE1":15761,"PHASE1":15763,"PHASE2":15765,"PHASE3":15767,"PHASE4":15769,"NA":15775},{"trials":15762,"activeCount":101},[],{"trials":15764,"activeCount":101},[],{"trials":15766,"activeCount":101},[],{"trials":15768,"activeCount":101},[],{"trials":15770,"activeCount":101},[15771],{"nctId":15743,"briefTitle":15744,"status":365,"phases":15772,"primaryCompletion":15746,"completion":15747,"start":15748,"enrollment":15749,"conditions":15773,"interventions":15774},[92],[15751,15752,15753],[15730,15755,15756],{"trials":15776,"activeCount":101},[],{"intervention":15756,"totalTrials":651,"cells":15778},{"EARLY_PHASE1":15779,"PHASE1":15781,"PHASE2":15783,"PHASE3":15785,"PHASE4":15787,"NA":15793},{"trials":15780,"activeCount":101},[],{"trials":15782,"activeCount":101},[],{"trials":15784,"activeCount":101},[],{"trials":15786,"activeCount":101},[],{"trials":15788,"activeCount":101},[15789],{"nctId":15743,"briefTitle":15744,"status":365,"phases":15790,"primaryCompletion":15746,"completion":15747,"start":15748,"enrollment":15749,"conditions":15791,"interventions":15792},[92],[15751,15752,15753],[15730,15755,15756],{"trials":15794,"activeCount":101},[],{"intervention":15796,"totalTrials":651,"cells":15797},"Salmeterol\u002FFluticasone Propionate",{"EARLY_PHASE1":15798,"PHASE1":15800,"PHASE2":15802,"PHASE3":15804,"PHASE4":15806,"NA":15819},{"trials":15799,"activeCount":101},[],{"trials":15801,"activeCount":101},[],{"trials":15803,"activeCount":101},[],{"trials":15805,"activeCount":101},[],{"trials":15807,"activeCount":101},[15808],{"nctId":15809,"briefTitle":15810,"status":107,"phases":15811,"primaryCompletion":15812,"completion":15813,"start":15814,"enrollment":15815,"conditions":15816,"interventions":15818},"NCT01243788","The Efficacy and Safety of Salmeterol\u002FFluticasone Propionate vs Atropium\u002FAlbuterol in Patients COPD",[92],"2011-02","2011-10","2009-07",450,[15817],"Chronic Obstructive Pulmonary Disease (COPD)",[15796],{"trials":15820,"activeCount":101},[],{"intervention":15822,"totalTrials":651,"cells":15823},"tac + folfox4",{"EARLY_PHASE1":15824,"PHASE1":15826,"PHASE2":15828,"PHASE3":15830,"PHASE4":15832,"NA":15842},{"trials":15825,"activeCount":101},[],{"trials":15827,"activeCount":101},[],{"trials":15829,"activeCount":101},[],{"trials":15831,"activeCount":101},[],{"trials":15833,"activeCount":101},[15834],{"nctId":15835,"briefTitle":15836,"status":107,"phases":15837,"primaryCompletion":1879,"completion":1879,"start":15838,"enrollment":213,"conditions":15839,"interventions":15840},"NCT00874406","Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer",[92],"2008-01",[18],[15822,15841],"folfox4",{"trials":15843,"activeCount":101},[],{"intervention":15841,"totalTrials":651,"cells":15845},{"EARLY_PHASE1":15846,"PHASE1":15848,"PHASE2":15850,"PHASE3":15852,"PHASE4":15854,"NA":15860},{"trials":15847,"activeCount":101},[],{"trials":15849,"activeCount":101},[],{"trials":15851,"activeCount":101},[],{"trials":15853,"activeCount":101},[],{"trials":15855,"activeCount":101},[15856],{"nctId":15835,"briefTitle":15836,"status":107,"phases":15857,"primaryCompletion":1879,"completion":1879,"start":15838,"enrollment":213,"conditions":15858,"interventions":15859},[92],[18],[15822,15841],{"trials":15861,"activeCount":101},[],{"intervention":15863,"totalTrials":651,"cells":15864},"Nicorandil",{"EARLY_PHASE1":15865,"PHASE1":15867,"PHASE2":15869,"PHASE3":15871,"PHASE4":15873,"NA":15882},{"trials":15866,"activeCount":101},[],{"trials":15868,"activeCount":101},[],{"trials":15870,"activeCount":101},[],{"trials":15872,"activeCount":101},[],{"trials":15874,"activeCount":101},[15875],{"nctId":15876,"briefTitle":15877,"status":365,"phases":15878,"primaryCompletion":294,"completion":294,"start":1725,"enrollment":5789,"conditions":15879,"interventions":15881},"NCT04665648","Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention",[92],[15880,15752],"ST Elevation Myocardial Infarction",[15863],{"trials":15883,"activeCount":101},[],{"intervention":15885,"totalTrials":651,"cells":15886},"Telbivudine",{"EARLY_PHASE1":15887,"PHASE1":15889,"PHASE2":15891,"PHASE3":15893,"PHASE4":15895,"NA":15904},{"trials":15888,"activeCount":101},[],{"trials":15890,"activeCount":101},[],{"trials":15892,"activeCount":101},[],{"trials":15894,"activeCount":101},[],{"trials":15896,"activeCount":101},[15897],{"nctId":15898,"briefTitle":15899,"status":107,"phases":15900,"primaryCompletion":2499,"completion":110,"start":15901,"enrollment":334,"conditions":15902,"interventions":15903},"NCT01102335","Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy",[92],"2010-04",[21],[15885],{"trials":15905,"activeCount":101},[],{"intervention":15907,"totalTrials":651,"cells":15908},"Chemotherapeutic Agent",{"EARLY_PHASE1":15909,"PHASE1":15911,"PHASE2":15913,"PHASE3":15915,"PHASE4":15917,"NA":15927},{"trials":15910,"activeCount":101},[],{"trials":15912,"activeCount":101},[],{"trials":15914,"activeCount":101},[],{"trials":15916,"activeCount":101},[],{"trials":15918,"activeCount":101},[15919],{"nctId":15920,"briefTitle":15921,"status":107,"phases":15922,"primaryCompletion":15923,"completion":6831,"start":15924,"enrollment":111,"conditions":15925,"interventions":15926},"NCT03799679","Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer",[92],"2019-11-30","2018-11-26",[250],[15907],{"trials":15928,"activeCount":101},[],{"intervention":15615,"totalTrials":651,"cells":15930},{"EARLY_PHASE1":15931,"PHASE1":15933,"PHASE2":15935,"PHASE3":15937,"PHASE4":15939,"NA":15945},{"trials":15932,"activeCount":101},[],{"trials":15934,"activeCount":101},[],{"trials":15936,"activeCount":101},[],{"trials":15938,"activeCount":101},[],{"trials":15940,"activeCount":101},[15941],{"nctId":15608,"briefTitle":15609,"status":107,"phases":15942,"primaryCompletion":426,"completion":426,"start":3122,"enrollment":15611,"conditions":15943,"interventions":15944},[92],[15613],[15615,15616,15578],{"trials":15946,"activeCount":101},[],{"intervention":15616,"totalTrials":651,"cells":15948},{"EARLY_PHASE1":15949,"PHASE1":15951,"PHASE2":15953,"PHASE3":15955,"PHASE4":15957,"NA":15963},{"trials":15950,"activeCount":101},[],{"trials":15952,"activeCount":101},[],{"trials":15954,"activeCount":101},[],{"trials":15956,"activeCount":101},[],{"trials":15958,"activeCount":101},[15959],{"nctId":15608,"briefTitle":15609,"status":107,"phases":15960,"primaryCompletion":426,"completion":426,"start":3122,"enrollment":15611,"conditions":15961,"interventions":15962},[92],[15613],[15615,15616,15578],{"trials":15964,"activeCount":101},[],{"intervention":7743,"totalTrials":651,"cells":15966},{"EARLY_PHASE1":15967,"PHASE1":15969,"PHASE2":15971,"PHASE3":15973,"PHASE4":15975,"NA":15981},{"trials":15968,"activeCount":101},[],{"trials":15970,"activeCount":101},[],{"trials":15972,"activeCount":101},[],{"trials":15974,"activeCount":101},[],{"trials":15976,"activeCount":101},[15977],{"nctId":7736,"briefTitle":7737,"status":107,"phases":15978,"primaryCompletion":1213,"completion":7739,"start":964,"enrollment":737,"conditions":15979,"interventions":15980},[92],[7741],[7743,279],{"trials":15982,"activeCount":101},[],{"intervention":15984,"totalTrials":651,"cells":15985},"Diltiazem",{"EARLY_PHASE1":15986,"PHASE1":15988,"PHASE2":15990,"PHASE3":15992,"PHASE4":15994,"NA":16008},{"trials":15987,"activeCount":101},[],{"trials":15989,"activeCount":101},[],{"trials":15991,"activeCount":101},[],{"trials":15993,"activeCount":101},[],{"trials":15995,"activeCount":101},[15996],{"nctId":15997,"briefTitle":15998,"status":365,"phases":15999,"primaryCompletion":16000,"completion":16001,"start":16002,"enrollment":1454,"conditions":16003,"interventions":16005},"NCT00712894","Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction",[92],"2009-04","2009-08","2006-12",[16004,15752],"Acute Myocardial Infarction",[15984,16006,16007],"Verapamil","Nitroglycerin",{"trials":16009,"activeCount":101},[],{"intervention":16006,"totalTrials":651,"cells":16011},{"EARLY_PHASE1":16012,"PHASE1":16014,"PHASE2":16016,"PHASE3":16018,"PHASE4":16020,"NA":16026},{"trials":16013,"activeCount":101},[],{"trials":16015,"activeCount":101},[],{"trials":16017,"activeCount":101},[],{"trials":16019,"activeCount":101},[],{"trials":16021,"activeCount":101},[16022],{"nctId":15997,"briefTitle":15998,"status":365,"phases":16023,"primaryCompletion":16000,"completion":16001,"start":16002,"enrollment":1454,"conditions":16024,"interventions":16025},[92],[16004,15752],[15984,16006,16007],{"trials":16027,"activeCount":101},[],{"intervention":16007,"totalTrials":651,"cells":16029},{"EARLY_PHASE1":16030,"PHASE1":16032,"PHASE2":16034,"PHASE3":16036,"PHASE4":16038,"NA":16044},{"trials":16031,"activeCount":101},[],{"trials":16033,"activeCount":101},[],{"trials":16035,"activeCount":101},[],{"trials":16037,"activeCount":101},[],{"trials":16039,"activeCount":101},[16040],{"nctId":15997,"briefTitle":15998,"status":365,"phases":16041,"primaryCompletion":16000,"completion":16001,"start":16002,"enrollment":1454,"conditions":16042,"interventions":16043},[92],[16004,15752],[15984,16006,16007],{"trials":16045,"activeCount":101},[],{"intervention":16047,"totalTrials":651,"cells":16048},"Berberine",{"EARLY_PHASE1":16049,"PHASE1":16051,"PHASE2":16053,"PHASE3":16055,"PHASE4":16057,"NA":16067},{"trials":16050,"activeCount":101},[],{"trials":16052,"activeCount":101},[],{"trials":16054,"activeCount":101},[],{"trials":16056,"activeCount":101},[],{"trials":16058,"activeCount":101},[16059],{"nctId":16060,"briefTitle":16061,"status":107,"phases":16062,"primaryCompletion":188,"completion":16063,"start":3145,"enrollment":296,"conditions":16064,"interventions":16066},"NCT03198572","Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis",[92],"2024-07-30",[16065],"Non-alcoholic Steatohepatitis",[16047],{"trials":16068,"activeCount":101},[],{"intervention":16070,"totalTrials":651,"cells":16071},"B1S5",{"EARLY_PHASE1":16072,"PHASE1":16074,"PHASE2":16076,"PHASE3":16078,"PHASE4":16080,"NA":16094},{"trials":16073,"activeCount":101},[],{"trials":16075,"activeCount":101},[],{"trials":16077,"activeCount":101},[],{"trials":16079,"activeCount":101},[],{"trials":16081,"activeCount":101},[16082],{"nctId":16083,"briefTitle":16084,"status":365,"phases":16085,"primaryCompletion":16086,"completion":16087,"start":16088,"enrollment":2204,"conditions":16089,"interventions":16091},"NCT03395600","Onset of Labour Epidural Analgesia With Different Concentration Bupivacaine and Different Doses of Sufentanyl",[92],"2018-08-31","2018-10-31","2018-02-10",[16090],"Pregnant Women Who Requested Epidural Analgesia in the Early Stage of Labor",[16070,16092,16093],"B125S5","B1S10",{"trials":16095,"activeCount":101},[],{"intervention":16092,"totalTrials":651,"cells":16097},{"EARLY_PHASE1":16098,"PHASE1":16100,"PHASE2":16102,"PHASE3":16104,"PHASE4":16106,"NA":16112},{"trials":16099,"activeCount":101},[],{"trials":16101,"activeCount":101},[],{"trials":16103,"activeCount":101},[],{"trials":16105,"activeCount":101},[],{"trials":16107,"activeCount":101},[16108],{"nctId":16083,"briefTitle":16084,"status":365,"phases":16109,"primaryCompletion":16086,"completion":16087,"start":16088,"enrollment":2204,"conditions":16110,"interventions":16111},[92],[16090],[16070,16092,16093],{"trials":16113,"activeCount":101},[],{"intervention":16093,"totalTrials":651,"cells":16115},{"EARLY_PHASE1":16116,"PHASE1":16118,"PHASE2":16120,"PHASE3":16122,"PHASE4":16124,"NA":16130},{"trials":16117,"activeCount":101},[],{"trials":16119,"activeCount":101},[],{"trials":16121,"activeCount":101},[],{"trials":16123,"activeCount":101},[],{"trials":16125,"activeCount":101},[16126],{"nctId":16083,"briefTitle":16084,"status":365,"phases":16127,"primaryCompletion":16086,"completion":16087,"start":16088,"enrollment":2204,"conditions":16128,"interventions":16129},[92],[16090],[16070,16092,16093],{"trials":16131,"activeCount":101},[],{"intervention":15653,"totalTrials":651,"cells":16133},{"EARLY_PHASE1":16134,"PHASE1":16136,"PHASE2":16138,"PHASE3":16140,"PHASE4":16142,"NA":16148},{"trials":16135,"activeCount":101},[],{"trials":16137,"activeCount":101},[],{"trials":16139,"activeCount":101},[],{"trials":16141,"activeCount":101},[],{"trials":16143,"activeCount":101},[16144],{"nctId":15642,"briefTitle":15643,"status":107,"phases":16145,"primaryCompletion":2499,"completion":15645,"start":15646,"enrollment":97,"conditions":16146,"interventions":16147},[92],[15648,15649,15650],[15652,15653],{"trials":16149,"activeCount":101},[],{"intervention":16151,"totalTrials":651,"cells":16152},"dexmedetomidine",{"EARLY_PHASE1":16153,"PHASE1":16155,"PHASE2":16157,"PHASE3":16159,"PHASE4":16161,"NA":16171},{"trials":16154,"activeCount":101},[],{"trials":16156,"activeCount":101},[],{"trials":16158,"activeCount":101},[],{"trials":16160,"activeCount":101},[],{"trials":16162,"activeCount":101},[16163],{"nctId":16164,"briefTitle":16165,"status":365,"phases":16166,"primaryCompletion":16167,"completion":16167,"start":8679,"enrollment":802,"conditions":16168,"interventions":16170},"NCT02035930","Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle",[92],"2012-11",[16169],"Abnormal Menstrual Cycle",[16151],{"trials":16172,"activeCount":101},[],{"intervention":2928,"totalTrials":651,"cells":16174},{"EARLY_PHASE1":16175,"PHASE1":16177,"PHASE2":16179,"PHASE3":16181,"PHASE4":16183,"NA":16189},{"trials":16176,"activeCount":101},[],{"trials":16178,"activeCount":101},[],{"trials":16180,"activeCount":101},[],{"trials":16182,"activeCount":101},[],{"trials":16184,"activeCount":101},[16185],{"nctId":2919,"briefTitle":2920,"status":107,"phases":16186,"primaryCompletion":1288,"completion":2922,"start":1204,"enrollment":2923,"conditions":16187,"interventions":16188},[92],[2925,2926],[626,2928],{"trials":16190,"activeCount":101},[],{"intervention":16192,"totalTrials":651,"cells":16193},"rocuronium",{"EARLY_PHASE1":16194,"PHASE1":16196,"PHASE2":16198,"PHASE3":16200,"PHASE4":16202,"NA":16214},{"trials":16195,"activeCount":101},[],{"trials":16197,"activeCount":101},[],{"trials":16199,"activeCount":101},[],{"trials":16201,"activeCount":101},[],{"trials":16203,"activeCount":101},[16204],{"nctId":16205,"briefTitle":16206,"status":365,"phases":16207,"primaryCompletion":7493,"completion":16208,"start":16209,"enrollment":213,"conditions":16210,"interventions":16212},"NCT02194855","Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis",[92],"2016-06-01","2015-01-01",[16211],"C.Delivery; Surgery (Previous), Gynecological",[16192,16213],"cisatracurium",{"trials":16215,"activeCount":101},[],{"intervention":16213,"totalTrials":651,"cells":16217},{"EARLY_PHASE1":16218,"PHASE1":16220,"PHASE2":16222,"PHASE3":16224,"PHASE4":16226,"NA":16232},{"trials":16219,"activeCount":101},[],{"trials":16221,"activeCount":101},[],{"trials":16223,"activeCount":101},[],{"trials":16225,"activeCount":101},[],{"trials":16227,"activeCount":101},[16228],{"nctId":16205,"briefTitle":16206,"status":365,"phases":16229,"primaryCompletion":7493,"completion":16208,"start":16209,"enrollment":213,"conditions":16230,"interventions":16231},[92],[16211],[16192,16213],{"trials":16233,"activeCount":101},[],{"intervention":16235,"totalTrials":651,"cells":16236},"Tenofovir Alafenamide 25 MG",{"EARLY_PHASE1":16237,"PHASE1":16239,"PHASE2":16241,"PHASE3":16243,"PHASE4":16245,"NA":16258},{"trials":16238,"activeCount":101},[],{"trials":16240,"activeCount":101},[],{"trials":16242,"activeCount":101},[],{"trials":16244,"activeCount":101},[],{"trials":16246,"activeCount":101},[16247],{"nctId":16248,"briefTitle":16249,"status":107,"phases":16250,"primaryCompletion":16251,"completion":16252,"start":16253,"enrollment":1531,"conditions":16254,"interventions":16257},"NCT05063071","Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant",[92],"2022-07-29","2022-12-29","2021-07-29",[16255,16256],"HBV","POST LIVER TRANSPLANT",[16235],{"trials":16259,"activeCount":101},[],{"intervention":16261,"totalTrials":651,"cells":16262},"12 cycles of oxaliplatine based adjuvant chemotherapy",{"EARLY_PHASE1":16263,"PHASE1":16265,"PHASE2":16267,"PHASE3":16269,"PHASE4":16271,"NA":16282},{"trials":16264,"activeCount":101},[],{"trials":16266,"activeCount":101},[],{"trials":16268,"activeCount":101},[],{"trials":16270,"activeCount":101},[],{"trials":16272,"activeCount":101},[16273],{"nctId":16274,"briefTitle":16275,"status":365,"phases":16276,"primaryCompletion":16277,"completion":16277,"start":16278,"enrollment":2854,"conditions":16279,"interventions":16280},"NCT00868816","Oxaliplatine Based Adjuvant Chemotherapy for Stage II\u002FIII Colorectal Cancer: 8 Cycles Versus 12 Cycles",[92],"2007-12","2005-01",[18],[16261,16281],"8 cycles of oxaliplatine based adjuvant chemotherapy",{"trials":16283,"activeCount":101},[],{"intervention":16281,"totalTrials":651,"cells":16285},{"EARLY_PHASE1":16286,"PHASE1":16288,"PHASE2":16290,"PHASE3":16292,"PHASE4":16294,"NA":16300},{"trials":16287,"activeCount":101},[],{"trials":16289,"activeCount":101},[],{"trials":16291,"activeCount":101},[],{"trials":16293,"activeCount":101},[],{"trials":16295,"activeCount":101},[16296],{"nctId":16274,"briefTitle":16275,"status":365,"phases":16297,"primaryCompletion":16277,"completion":16277,"start":16278,"enrollment":2854,"conditions":16298,"interventions":16299},[92],[18],[16261,16281],{"trials":16301,"activeCount":101},[],{"intervention":176,"totalTrials":1651,"cells":16303},{"EARLY_PHASE1":16304,"PHASE1":16306,"PHASE2":16308,"PHASE3":16336,"PHASE4":16342,"NA":16344},{"trials":16305,"activeCount":101},[],{"trials":16307,"activeCount":101},[],{"trials":16309,"activeCount":101},[16310,16314,16318,16322,16326,16330],{"nctId":168,"briefTitle":169,"status":107,"phases":16311,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":16312,"interventions":16313},[90],[15],[176,96],{"nctId":2954,"briefTitle":2955,"status":365,"phases":16315,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":478,"conditions":16316,"interventions":16317},[90],[2960],[2962,176,1764],{"nctId":244,"briefTitle":245,"status":107,"phases":16319,"primaryCompletion":247,"completion":247,"start":248,"enrollment":213,"conditions":16320,"interventions":16321},[90],[250],[252,253,254,176,255,96],{"nctId":3141,"briefTitle":3142,"status":365,"phases":16323,"primaryCompletion":3144,"completion":3144,"start":3145,"enrollment":3146,"conditions":16324,"interventions":16325},[90],[3148],[176,581],{"nctId":405,"briefTitle":406,"status":365,"phases":16327,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":16328,"interventions":16329},[90],[15],[176,96,413],{"nctId":16331,"briefTitle":16332,"status":107,"phases":16333,"primaryCompletion":1203,"completion":1203,"start":15748,"enrollment":10553,"conditions":16334,"interventions":16335},"NCT02607215","Platinum Rechallenge in Patients With Platinum-sensitive mTNBC",[90],[33],[176,6882],{"trials":16337,"activeCount":101},[16338],{"nctId":628,"briefTitle":629,"status":107,"phases":16339,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":16340,"interventions":16341},[91],[15],[96,176],{"trials":16343,"activeCount":101},[],{"trials":16345,"activeCount":101},[],{"intervention":15595,"totalTrials":1729,"cells":16347},{"EARLY_PHASE1":16348,"PHASE1":16350,"PHASE2":16352,"PHASE3":16358,"PHASE4":16388,"NA":16390},{"trials":16349,"activeCount":101},[],{"trials":16351,"activeCount":101},[],{"trials":16353,"activeCount":101},[16354],{"nctId":15587,"briefTitle":15588,"status":365,"phases":16355,"primaryCompletion":15590,"completion":15591,"start":1683,"enrollment":2845,"conditions":16356,"interventions":16357},[90],[15593],[15595,15578],{"trials":16359,"activeCount":101},[16360,16368,16372,16379],{"nctId":16361,"briefTitle":16362,"status":365,"phases":16363,"primaryCompletion":16364,"completion":16364,"start":16365,"enrollment":12889,"conditions":16366,"interventions":16367},"NCT03241888","Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia",[90,91],"2020-06-18","2017-07-04",[15603],[15595],{"nctId":15599,"briefTitle":15600,"status":365,"phases":16369,"primaryCompletion":6585,"completion":6585,"start":1683,"enrollment":3068,"conditions":16370,"interventions":16371},[90,91],[15603],[15595,15578],{"nctId":16373,"briefTitle":16374,"status":365,"phases":16375,"primaryCompletion":16364,"completion":16364,"start":16365,"enrollment":16376,"conditions":16377,"interventions":16378},"NCT03241914","Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer",[90,91],64,[3650],[15595],{"nctId":16380,"briefTitle":16381,"status":494,"phases":16382,"primaryCompletion":16383,"completion":16383,"start":16384,"enrollment":2394,"conditions":16385,"interventions":16386},"NCT04607252","Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia",[90,91],"2021-06-03","2021-01-11",[15603],[16387,15595],"Metformin plus Megestrol acetate",{"trials":16389,"activeCount":101},[],{"trials":16391,"activeCount":101},[],{"intervention":16393,"totalTrials":1300,"cells":16394},"Gemcitabine,cisplatin",{"EARLY_PHASE1":16395,"PHASE1":16397,"PHASE2":16399,"PHASE3":16418,"PHASE4":16427,"NA":16429},{"trials":16396,"activeCount":101},[],{"trials":16398,"activeCount":101},[],{"trials":16400,"activeCount":101},[16401,16410],{"nctId":16402,"briefTitle":16403,"status":107,"phases":16404,"primaryCompletion":16405,"completion":3121,"start":16406,"enrollment":345,"conditions":16407,"interventions":16408},"NCT04517292","Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)",[90],"2022-07-30","2020-10-08",[15],[16409,16393],"Eribulin,cisplatin",{"nctId":16411,"briefTitle":16412,"status":107,"phases":16413,"primaryCompletion":1203,"completion":1203,"start":16414,"enrollment":1531,"conditions":16415,"interventions":16416},"NCT02341911","Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)",[90],"2015-01",[15],[16393,16417],"Gemcitabine,carboplatin",{"trials":16419,"activeCount":101},[16420],{"nctId":16421,"briefTitle":16422,"status":365,"phases":16423,"primaryCompletion":4021,"completion":4021,"start":15646,"enrollment":591,"conditions":16424,"interventions":16425},"NCT01287624","Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)",[91],[15],[16393,16426],"Gemcitabine, Paclitaxel",{"trials":16428,"activeCount":101},[],{"trials":16430,"activeCount":101},[],{"intervention":16432,"totalTrials":771,"cells":16433},"Lamivudine",{"EARLY_PHASE1":16434,"PHASE1":16436,"PHASE2":16438,"PHASE3":16449,"PHASE4":16458,"NA":16460},{"trials":16435,"activeCount":101},[],{"trials":16437,"activeCount":101},[],{"trials":16439,"activeCount":101},[16440],{"nctId":16441,"briefTitle":16442,"status":107,"phases":16443,"primaryCompletion":1204,"completion":6786,"start":658,"enrollment":6670,"conditions":16444,"interventions":16447},"NCT01914744","Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL",[90],[16445,16446],"Non-Hodgkin Lymphoma","Hepatitis B Reactivation",[16448,16432],"Entecavir",{"trials":16450,"activeCount":101},[16451],{"nctId":16452,"briefTitle":16453,"status":107,"phases":16454,"primaryCompletion":3390,"completion":56,"start":14855,"enrollment":2483,"conditions":16455,"interventions":16456},"NCT01936233","Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery",[91],[21,670],[16457,16432],"Aspirin",{"trials":16459,"activeCount":101},[],{"trials":16461,"activeCount":101},[],{"intervention":16463,"totalTrials":771,"cells":16464},"rhubarb",{"EARLY_PHASE1":16465,"PHASE1":16467,"PHASE2":16469,"PHASE3":16479,"PHASE4":16489,"NA":16491},{"trials":16466,"activeCount":101},[],{"trials":16468,"activeCount":101},[],{"trials":16470,"activeCount":101},[16471],{"nctId":16472,"briefTitle":16473,"status":107,"phases":16474,"start":8665,"enrollment":213,"conditions":16475,"interventions":16478},"NCT00789269","Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From a Stroke",[90],[16476,16477],"Pneumonia","Acute Stroke",[16463],{"trials":16480,"activeCount":101},[16481],{"nctId":16482,"briefTitle":16483,"status":107,"phases":16484,"start":8665,"enrollment":213,"conditions":16485,"interventions":16488},"NCT00815737","Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage",[90,91],[16486,16487,16476],"Lung Infection","Cerebral Hemorrhage",[16463],{"trials":16490,"activeCount":101},[],{"trials":16492,"activeCount":101},[],{"intervention":2030,"totalTrials":771,"cells":16494},{"EARLY_PHASE1":16495,"PHASE1":16497,"PHASE2":16499,"PHASE3":16501,"PHASE4":16516,"NA":16518},{"trials":16496,"activeCount":101},[],{"trials":16498,"activeCount":101},[],{"trials":16500,"activeCount":101},[],{"trials":16502,"activeCount":101},[16503,16507],{"nctId":2022,"briefTitle":2023,"status":107,"phases":16504,"primaryCompletion":147,"completion":353,"start":2025,"enrollment":2026,"conditions":16505,"interventions":16506},[91],[2028],[253,255,2030],{"nctId":16508,"briefTitle":16509,"status":107,"phases":16510,"primaryCompletion":6204,"completion":6204,"start":632,"enrollment":1290,"conditions":16511,"interventions":16514},"NCT04617821","AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer",[91],[16512,16513],"Borderline Resectable Pancreatic Cancer","Locally Advanced Pancreatic Adenocarcinoma",[16515,2030],"Nab paclitaxel plus gemcitabine",{"trials":16517,"activeCount":101},[],{"trials":16519,"activeCount":101},[],{"intervention":7866,"totalTrials":771,"cells":16521},{"EARLY_PHASE1":16522,"PHASE1":16524,"PHASE2":16526,"PHASE3":16532,"PHASE4":16538,"NA":16540},{"trials":16523,"activeCount":101},[],{"trials":16525,"activeCount":101},[],{"trials":16527,"activeCount":101},[16528],{"nctId":7860,"briefTitle":7861,"status":107,"phases":16529,"primaryCompletion":398,"completion":398,"start":1203,"enrollment":1610,"conditions":16530,"interventions":16531},[90],[6157],[1170,7865,7866],{"trials":16533,"activeCount":101},[16534],{"nctId":9011,"briefTitle":9012,"status":107,"phases":16535,"primaryCompletion":293,"completion":1609,"start":6605,"enrollment":9014,"conditions":16536,"interventions":16537},[91],[9002,9016],[6739,7866],{"trials":16539,"activeCount":101},[],{"trials":16541,"activeCount":101},[],{"intervention":4002,"totalTrials":771,"cells":16543},{"EARLY_PHASE1":16544,"PHASE1":16546,"PHASE2":16548,"PHASE3":16550,"PHASE4":16564,"NA":16566},{"trials":16545,"activeCount":101},[],{"trials":16547,"activeCount":101},[],{"trials":16549,"activeCount":101},[],{"trials":16551,"activeCount":101},[16552,16560],{"nctId":16553,"briefTitle":16554,"status":365,"phases":16555,"primaryCompletion":3390,"completion":3390,"start":389,"enrollment":16556,"conditions":16557,"interventions":16558},"NCT02336750","Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis",[91],212,[15],[4002,16559],"Mirtazapine",{"nctId":3992,"briefTitle":3993,"status":107,"phases":16561,"primaryCompletion":3995,"completion":188,"start":3996,"enrollment":529,"conditions":16562,"interventions":16563},[91],[3998],[4000,4001,4002,4003,2642],{"trials":16565,"activeCount":101},[],{"trials":16567,"activeCount":101},[],{"intervention":16569,"totalTrials":771,"cells":16570},"R-CHOP",{"EARLY_PHASE1":16571,"PHASE1":16573,"PHASE2":16575,"PHASE3":16584,"PHASE4":16596,"NA":16598},{"trials":16572,"activeCount":101},[],{"trials":16574,"activeCount":101},[],{"trials":16576,"activeCount":101},[16577],{"nctId":16578,"briefTitle":16579,"status":107,"phases":16580,"primaryCompletion":1204,"completion":485,"start":658,"enrollment":16581,"conditions":16582,"interventions":16583},"NCT01804127","Interim PET\u002FCT Guided Cycle Numbers of R-CHOP in DLBCL",[90],196,[11751],[16569],{"trials":16585,"activeCount":101},[16586],{"nctId":16587,"briefTitle":16588,"status":107,"phases":16589,"primaryCompletion":16590,"completion":16590,"start":16591,"enrollment":16592,"conditions":16593,"interventions":16594},"NCT03318835","Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients",[91],"2020-08-22","2017-08-22",162,[2076],[16595,16569],"Thalidomide combined with R-CHOP",{"trials":16597,"activeCount":101},[],{"trials":16599,"activeCount":101},[],{"intervention":6397,"totalTrials":651,"cells":16601},{"EARLY_PHASE1":16602,"PHASE1":16604,"PHASE2":16606,"PHASE3":16608,"PHASE4":16614,"NA":16616},{"trials":16603,"activeCount":101},[],{"trials":16605,"activeCount":101},[],{"trials":16607,"activeCount":101},[],{"trials":16609,"activeCount":101},[16610],{"nctId":6389,"briefTitle":6390,"status":107,"phases":16611,"primaryCompletion":6392,"completion":1366,"start":6393,"enrollment":6394,"conditions":16612,"interventions":16613},[91],[18,1554],[229,230,6397],{"trials":16615,"activeCount":101},[],{"trials":16617,"activeCount":101},[],{"intervention":16619,"totalTrials":651,"cells":16620},"Docetaxel Cyclophosphamide",{"EARLY_PHASE1":16621,"PHASE1":16623,"PHASE2":16625,"PHASE3":16627,"PHASE4":16638,"NA":16640},{"trials":16622,"activeCount":101},[],{"trials":16624,"activeCount":101},[],{"trials":16626,"activeCount":101},[],{"trials":16628,"activeCount":101},[16629],{"nctId":16630,"briefTitle":16631,"status":365,"phases":16632,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":16633,"conditions":16634,"interventions":16635},"NCT01314833","Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy",[91],1570,[1829],[16619,16636,16637],"Cyclophosphamide Fluorouracil Epirubicin Docetaxel","Epirubicin Cyclophosphamide Paclitaxel",{"trials":16639,"activeCount":101},[],{"trials":16641,"activeCount":101},[],{"intervention":16636,"totalTrials":651,"cells":16643},{"EARLY_PHASE1":16644,"PHASE1":16646,"PHASE2":16648,"PHASE3":16650,"PHASE4":16656,"NA":16658},{"trials":16645,"activeCount":101},[],{"trials":16647,"activeCount":101},[],{"trials":16649,"activeCount":101},[],{"trials":16651,"activeCount":101},[16652],{"nctId":16630,"briefTitle":16631,"status":365,"phases":16653,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":16633,"conditions":16654,"interventions":16655},[91],[1829],[16619,16636,16637],{"trials":16657,"activeCount":101},[],{"trials":16659,"activeCount":101},[],{"intervention":16637,"totalTrials":651,"cells":16661},{"EARLY_PHASE1":16662,"PHASE1":16664,"PHASE2":16666,"PHASE3":16668,"PHASE4":16674,"NA":16676},{"trials":16663,"activeCount":101},[],{"trials":16665,"activeCount":101},[],{"trials":16667,"activeCount":101},[],{"trials":16669,"activeCount":101},[16670],{"nctId":16630,"briefTitle":16631,"status":365,"phases":16671,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":16633,"conditions":16672,"interventions":16673},[91],[1829],[16619,16636,16637],{"trials":16675,"activeCount":101},[],{"trials":16677,"activeCount":101},[],{"intervention":16679,"totalTrials":651,"cells":16680},"Standard adjuvant systemic chemotherapy",{"EARLY_PHASE1":16681,"PHASE1":16683,"PHASE2":16685,"PHASE3":16687,"PHASE4":16698,"NA":16700},{"trials":16682,"activeCount":101},[],{"trials":16684,"activeCount":101},[],{"trials":16686,"activeCount":101},[],{"trials":16688,"activeCount":101},[16689],{"nctId":16690,"briefTitle":16691,"status":107,"phases":16692,"primaryCompletion":16693,"completion":11794,"start":16694,"enrollment":16695,"conditions":16696,"interventions":16697},"NCT02965248","Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)",[91],"2021-11","2016-11",147,[7593],[16679],{"trials":16699,"activeCount":101},[],{"trials":16701,"activeCount":101},[],{"intervention":16703,"totalTrials":651,"cells":16704},"tissue-of-origin (ORIGIN-PanCA○R) profiling",{"EARLY_PHASE1":16705,"PHASE1":16707,"PHASE2":16709,"PHASE3":16711,"PHASE4":16722,"NA":16724},{"trials":16706,"activeCount":101},[],{"trials":16708,"activeCount":101},[],{"trials":16710,"activeCount":101},[],{"trials":16712,"activeCount":101},[16713],{"nctId":16714,"briefTitle":16715,"status":365,"phases":16716,"primaryCompletion":16717,"completion":16717,"start":16718,"enrollment":410,"conditions":16719,"interventions":16721},"NCT03278600","Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary",[91],"2021-03-18","2017-09-18",[16720],"Cancer of Unknown Primary Site",[16703],{"trials":16723,"activeCount":101},[],{"trials":16725,"activeCount":101},[],{"intervention":501,"totalTrials":651,"cells":16727},{"EARLY_PHASE1":16728,"PHASE1":16730,"PHASE2":16732,"PHASE3":16734,"PHASE4":16740,"NA":16742},{"trials":16729,"activeCount":101},[],{"trials":16731,"activeCount":101},[],{"trials":16733,"activeCount":101},[],{"trials":16735,"activeCount":101},[16736],{"nctId":492,"briefTitle":493,"status":494,"phases":16737,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":16738,"interventions":16739},[91],[33],[166,501],{"trials":16741,"activeCount":101},[],{"trials":16743,"activeCount":101},[],{"intervention":16745,"totalTrials":651,"cells":16746},"XELOX or FOLFOX chemotherapy",{"EARLY_PHASE1":16747,"PHASE1":16749,"PHASE2":16751,"PHASE3":16753,"PHASE4":16764,"NA":16766},{"trials":16748,"activeCount":101},[],{"trials":16750,"activeCount":101},[],{"trials":16752,"activeCount":101},[],{"trials":16754,"activeCount":101},[16755],{"nctId":16756,"briefTitle":16757,"status":107,"phases":16758,"primaryCompletion":6893,"completion":16759,"start":6894,"enrollment":16760,"conditions":16761,"interventions":16763},"NCT02777437","Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer",[90,91],"2021-10",1960,[16762],"Colonic Neoplasms",[16745],{"trials":16765,"activeCount":101},[],{"trials":16767,"activeCount":101},[],{"intervention":16769,"totalTrials":651,"cells":16770},"Trans arterial chemoembolization with Irinotecan Drug-eluting Beads",{"EARLY_PHASE1":16771,"PHASE1":16773,"PHASE2":16775,"PHASE3":16777,"PHASE4":16785,"NA":16787},{"trials":16772,"activeCount":101},[],{"trials":16774,"activeCount":101},[],{"trials":16776,"activeCount":101},[],{"trials":16778,"activeCount":101},[16779],{"nctId":16780,"briefTitle":16781,"status":107,"phases":16782,"primaryCompletion":200,"completion":2157,"start":3144,"enrollment":334,"conditions":16783,"interventions":16784},"NCT04912258","Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis",[91],[18,1554],[16769],{"trials":16786,"activeCount":101},[],{"trials":16788,"activeCount":101},[],{"intervention":16790,"totalTrials":651,"cells":16791},"Paclitaxel and Cisplatin",{"EARLY_PHASE1":16792,"PHASE1":16794,"PHASE2":16796,"PHASE3":16798,"PHASE4":16811,"NA":16813},{"trials":16793,"activeCount":101},[],{"trials":16795,"activeCount":101},[],{"trials":16797,"activeCount":101},[],{"trials":16799,"activeCount":101},[16800],{"nctId":16801,"briefTitle":16802,"status":365,"phases":16803,"primaryCompletion":286,"completion":7841,"start":16804,"enrollment":16805,"conditions":16806,"interventions":16808},"NCT02459457","A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer",[91],"2015-07-01",321,[16807],"Stage III Esophageal Squamous Cell Carcinoma",[16790,16809,16810],"Paclitaxel and Fluorouracil","Paclitaxel and Carboplatin",{"trials":16812,"activeCount":101},[],{"trials":16814,"activeCount":101},[],{"intervention":16809,"totalTrials":651,"cells":16816},{"EARLY_PHASE1":16817,"PHASE1":16819,"PHASE2":16821,"PHASE3":16823,"PHASE4":16829,"NA":16831},{"trials":16818,"activeCount":101},[],{"trials":16820,"activeCount":101},[],{"trials":16822,"activeCount":101},[],{"trials":16824,"activeCount":101},[16825],{"nctId":16801,"briefTitle":16802,"status":365,"phases":16826,"primaryCompletion":286,"completion":7841,"start":16804,"enrollment":16805,"conditions":16827,"interventions":16828},[91],[16807],[16790,16809,16810],{"trials":16830,"activeCount":101},[],{"trials":16832,"activeCount":101},[],{"intervention":16810,"totalTrials":651,"cells":16834},{"EARLY_PHASE1":16835,"PHASE1":16837,"PHASE2":16839,"PHASE3":16841,"PHASE4":16847,"NA":16849},{"trials":16836,"activeCount":101},[],{"trials":16838,"activeCount":101},[],{"trials":16840,"activeCount":101},[],{"trials":16842,"activeCount":101},[16843],{"nctId":16801,"briefTitle":16802,"status":365,"phases":16844,"primaryCompletion":286,"completion":7841,"start":16804,"enrollment":16805,"conditions":16845,"interventions":16846},[91],[16807],[16790,16809,16810],{"trials":16848,"activeCount":101},[],{"trials":16850,"activeCount":101},[],{"intervention":16852,"totalTrials":651,"cells":16853},"Herbal Medicinal Mixture",{"EARLY_PHASE1":16854,"PHASE1":16856,"PHASE2":16858,"PHASE3":16860,"PHASE4":16870,"NA":16872},{"trials":16855,"activeCount":101},[],{"trials":16857,"activeCount":101},[],{"trials":16859,"activeCount":101},[],{"trials":16861,"activeCount":101},[16862],{"nctId":16863,"briefTitle":16864,"status":365,"phases":16865,"primaryCompletion":9407,"completion":15812,"start":1953,"enrollment":16866,"conditions":16867,"interventions":16869},"NCT00656253","Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease",[90,91],158,[16868],"Parkinson's Disease",[16852],{"trials":16871,"activeCount":101},[],{"trials":16873,"activeCount":101},[],{"intervention":16875,"totalTrials":651,"cells":16876},"XSCR",{"EARLY_PHASE1":16877,"PHASE1":16879,"PHASE2":16881,"PHASE3":16883,"PHASE4":16894,"NA":16896},{"trials":16878,"activeCount":101},[],{"trials":16880,"activeCount":101},[],{"trials":16882,"activeCount":101},[],{"trials":16884,"activeCount":101},[16885],{"nctId":16886,"briefTitle":16887,"status":107,"phases":16888,"primaryCompletion":16889,"start":16890,"enrollment":369,"conditions":16891,"interventions":16893},"NCT00710164","Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke",[90,91],"2010-07","2008-09",[16892],"Acute Ischemic Stroke",[16875],{"trials":16895,"activeCount":101},[],{"trials":16897,"activeCount":101},[],{"intervention":16899,"totalTrials":651,"cells":16900},"Infliximab",{"EARLY_PHASE1":16901,"PHASE1":16903,"PHASE2":16905,"PHASE3":16907,"PHASE4":16919,"NA":16921},{"trials":16902,"activeCount":101},[],{"trials":16904,"activeCount":101},[],{"trials":16906,"activeCount":101},[],{"trials":16908,"activeCount":101},[16909],{"nctId":16910,"briefTitle":16911,"status":365,"phases":16912,"primaryCompletion":16913,"completion":16914,"start":1600,"enrollment":737,"conditions":16915,"interventions":16917},"NCT02298062","Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial",[91],"2015-07","2015-09",[16916],"Kawasaki Disease",[16899,16918],"IVIG",{"trials":16920,"activeCount":101},[],{"trials":16922,"activeCount":101},[],{"intervention":16918,"totalTrials":651,"cells":16924},{"EARLY_PHASE1":16925,"PHASE1":16927,"PHASE2":16929,"PHASE3":16931,"PHASE4":16937,"NA":16939},{"trials":16926,"activeCount":101},[],{"trials":16928,"activeCount":101},[],{"trials":16930,"activeCount":101},[],{"trials":16932,"activeCount":101},[16933],{"nctId":16910,"briefTitle":16911,"status":365,"phases":16934,"primaryCompletion":16913,"completion":16914,"start":1600,"enrollment":737,"conditions":16935,"interventions":16936},[91],[16916],[16899,16918],{"trials":16938,"activeCount":101},[],{"trials":16940,"activeCount":101},[],{"intervention":16942,"totalTrials":651,"cells":16943},"QingyiHuaji optimized formula",{"EARLY_PHASE1":16944,"PHASE1":16946,"PHASE2":16948,"PHASE3":16950,"PHASE4":16959,"NA":16961},{"trials":16945,"activeCount":101},[],{"trials":16947,"activeCount":101},[],{"trials":16949,"activeCount":101},[],{"trials":16951,"activeCount":101},[16952],{"nctId":16953,"briefTitle":16954,"status":365,"phases":16955,"primaryCompletion":1489,"completion":1489,"start":1584,"enrollment":16956,"conditions":16957,"interventions":16958},"NCT05840341","Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer",[91],305,[11504],[16942],{"trials":16960,"activeCount":101},[],{"trials":16962,"activeCount":101},[],{"intervention":16964,"totalTrials":651,"cells":16965},"Thymopentin",{"EARLY_PHASE1":16966,"PHASE1":16968,"PHASE2":16970,"PHASE3":16972,"PHASE4":16981,"NA":16983},{"trials":16967,"activeCount":101},[],{"trials":16969,"activeCount":101},[],{"trials":16971,"activeCount":101},[],{"trials":16973,"activeCount":101},[16974],{"nctId":16975,"briefTitle":16976,"status":107,"phases":16977,"completion":659,"start":16978,"enrollment":14857,"conditions":16979,"interventions":16980},"NCT00460681","Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma",[91],"2007-02",[21],[16964],{"trials":16982,"activeCount":101},[],{"trials":16984,"activeCount":101},[],{"intervention":16986,"totalTrials":651,"cells":16987},"VIC",{"EARLY_PHASE1":16988,"PHASE1":16990,"PHASE2":16992,"PHASE3":16994,"PHASE4":17005,"NA":17007},{"trials":16989,"activeCount":101},[],{"trials":16991,"activeCount":101},[],{"trials":16993,"activeCount":101},[],{"trials":16995,"activeCount":101},[16996],{"nctId":16997,"briefTitle":16998,"status":107,"phases":16999,"primaryCompletion":17000,"completion":260,"start":17001,"enrollment":1739,"conditions":17002,"interventions":17003},"NCT05540951","VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer",[91],"2022-08-30","2018-06-01",[18],[16986,17004],"Bevacizumab Plus Chemotherapy",{"trials":17006,"activeCount":101},[],{"trials":17008,"activeCount":101},[],{"intervention":17004,"totalTrials":651,"cells":17010},{"EARLY_PHASE1":17011,"PHASE1":17013,"PHASE2":17015,"PHASE3":17017,"PHASE4":17023,"NA":17025},{"trials":17012,"activeCount":101},[],{"trials":17014,"activeCount":101},[],{"trials":17016,"activeCount":101},[],{"trials":17018,"activeCount":101},[17019],{"nctId":16997,"briefTitle":16998,"status":107,"phases":17020,"primaryCompletion":17000,"completion":260,"start":17001,"enrollment":1739,"conditions":17021,"interventions":17022},[91],[18],[16986,17004],{"trials":17024,"activeCount":101},[],{"trials":17026,"activeCount":101},[],{"intervention":4164,"totalTrials":651,"cells":17028},{"EARLY_PHASE1":17029,"PHASE1":17031,"PHASE2":17033,"PHASE3":17035,"PHASE4":17041,"NA":17043},{"trials":17030,"activeCount":101},[],{"trials":17032,"activeCount":101},[],{"trials":17034,"activeCount":101},[],{"trials":17036,"activeCount":101},[17037],{"nctId":4157,"briefTitle":4158,"status":3025,"phases":17038,"primaryCompletion":4160,"completion":1451,"start":4161,"enrollment":101,"conditions":17039,"interventions":17040},[91],[24],[4164,4146],{"trials":17042,"activeCount":101},[],{"trials":17044,"activeCount":101},[],{"intervention":17046,"totalTrials":651,"cells":17047},"Paclitaxel Cisplatin",{"EARLY_PHASE1":17048,"PHASE1":17050,"PHASE2":17052,"PHASE3":17054,"PHASE4":17063,"NA":17065},{"trials":17049,"activeCount":101},[],{"trials":17051,"activeCount":101},[],{"trials":17053,"activeCount":101},[],{"trials":17055,"activeCount":101},[17056],{"nctId":17057,"briefTitle":17058,"status":365,"phases":17059,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":17060,"interventions":17061},"NCT01216111","Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)",[91],[250],[17046,17062],"fluorouracil epirubicin cyclophosphamide and docetaxel",{"trials":17064,"activeCount":101},[],{"trials":17066,"activeCount":101},[],{"intervention":17062,"totalTrials":651,"cells":17068},{"EARLY_PHASE1":17069,"PHASE1":17071,"PHASE2":17073,"PHASE3":17075,"PHASE4":17081,"NA":17083},{"trials":17070,"activeCount":101},[],{"trials":17072,"activeCount":101},[],{"trials":17074,"activeCount":101},[],{"trials":17076,"activeCount":101},[17077],{"nctId":17057,"briefTitle":17058,"status":365,"phases":17078,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":17079,"interventions":17080},[91],[250],[17046,17062],{"trials":17082,"activeCount":101},[],{"trials":17084,"activeCount":101},[],{"intervention":17086,"totalTrials":651,"cells":17087},"Traditional Chinese Medicinal Mixture",{"EARLY_PHASE1":17088,"PHASE1":17090,"PHASE2":17092,"PHASE3":17094,"PHASE4":17104,"NA":17106},{"trials":17089,"activeCount":101},[],{"trials":17091,"activeCount":101},[],{"trials":17093,"activeCount":101},[],{"trials":17095,"activeCount":101},[17096],{"nctId":17097,"briefTitle":17098,"status":107,"phases":17099,"primaryCompletion":2518,"start":8680,"enrollment":17100,"conditions":17101,"interventions":17103},"NCT00629161","Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease",[90,91],144,[17102],"Parkinson Disease",[17086],{"trials":17105,"activeCount":101},[],{"trials":17107,"activeCount":101},[],{"intervention":17109,"totalTrials":651,"cells":17110},"Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide",{"EARLY_PHASE1":17111,"PHASE1":17113,"PHASE2":17115,"PHASE3":17117,"PHASE4":17128,"NA":17130},{"trials":17112,"activeCount":101},[],{"trials":17114,"activeCount":101},[],{"trials":17116,"activeCount":101},[],{"trials":17118,"activeCount":101},[17119],{"nctId":17120,"briefTitle":17121,"status":107,"phases":17122,"completion":211,"start":17123,"enrollment":17124,"conditions":17125,"interventions":17127},"NCT00525642","Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer",[90,91],"2003-06",603,[1882,17126,310],"Adjuvant",[17109,17109],{"trials":17129,"activeCount":101},[],{"trials":17131,"activeCount":101},[],{"intervention":3989,"totalTrials":651,"cells":17133},{"EARLY_PHASE1":17134,"PHASE1":17136,"PHASE2":17138,"PHASE3":17140,"PHASE4":17146,"NA":17148},{"trials":17135,"activeCount":101},[],{"trials":17137,"activeCount":101},[],{"trials":17139,"activeCount":101},[],{"trials":17141,"activeCount":101},[17142],{"nctId":3980,"briefTitle":3981,"status":365,"phases":17143,"primaryCompletion":3983,"completion":3984,"start":189,"enrollment":3985,"conditions":17144,"interventions":17145},[91],[2074,3987],[3989,3990,2642],{"trials":17147,"activeCount":101},[],{"trials":17149,"activeCount":101},[],{"intervention":3990,"totalTrials":651,"cells":17151},{"EARLY_PHASE1":17152,"PHASE1":17154,"PHASE2":17156,"PHASE3":17158,"PHASE4":17164,"NA":17166},{"trials":17153,"activeCount":101},[],{"trials":17155,"activeCount":101},[],{"trials":17157,"activeCount":101},[],{"trials":17159,"activeCount":101},[17160],{"nctId":3980,"briefTitle":3981,"status":365,"phases":17161,"primaryCompletion":3983,"completion":3984,"start":189,"enrollment":3985,"conditions":17162,"interventions":17163},[91],[2074,3987],[3989,3990,2642],{"trials":17165,"activeCount":101},[],{"trials":17167,"activeCount":101},[],{"intervention":17169,"totalTrials":651,"cells":17170},"cisplatin plus pemetrexed",{"EARLY_PHASE1":17171,"PHASE1":17173,"PHASE2":17175,"PHASE3":17177,"PHASE4":17186,"NA":17188},{"trials":17172,"activeCount":101},[],{"trials":17174,"activeCount":101},[],{"trials":17176,"activeCount":101},[],{"trials":17178,"activeCount":101},[17179],{"nctId":17180,"briefTitle":17181,"status":107,"phases":17182,"primaryCompletion":125,"completion":1609,"start":2043,"enrollment":1290,"conditions":17183,"interventions":17185},"NCT03380468","Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma",[90,91],[17184],"Lung Neoplasms",[17169],{"trials":17187,"activeCount":101},[],{"trials":17189,"activeCount":101},[],{"intervention":17191,"totalTrials":651,"cells":17192},"CEOP regimen",{"EARLY_PHASE1":17193,"PHASE1":17195,"PHASE2":17197,"PHASE3":17199,"PHASE4":17211,"NA":17213},{"trials":17194,"activeCount":101},[],{"trials":17196,"activeCount":101},[],{"trials":17198,"activeCount":101},[],{"trials":17200,"activeCount":101},[17201],{"nctId":17202,"briefTitle":17203,"status":365,"phases":17204,"primaryCompletion":110,"completion":658,"start":17205,"enrollment":17206,"conditions":17207,"interventions":17209},"NCT00854568","Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL",[91],"2009-03",398,[17208],"Lymphoma",[17191,17210],"CHOP regimen",{"trials":17212,"activeCount":101},[],{"trials":17214,"activeCount":101},[],{"intervention":17210,"totalTrials":651,"cells":17216},{"EARLY_PHASE1":17217,"PHASE1":17219,"PHASE2":17221,"PHASE3":17223,"PHASE4":17229,"NA":17231},{"trials":17218,"activeCount":101},[],{"trials":17220,"activeCount":101},[],{"trials":17222,"activeCount":101},[],{"trials":17224,"activeCount":101},[17225],{"nctId":17202,"briefTitle":17203,"status":365,"phases":17226,"primaryCompletion":110,"completion":658,"start":17205,"enrollment":17206,"conditions":17227,"interventions":17228},[91],[17208],[17191,17210],{"trials":17230,"activeCount":101},[],{"trials":17232,"activeCount":101},[],{"intervention":16559,"totalTrials":651,"cells":17234},{"EARLY_PHASE1":17235,"PHASE1":17237,"PHASE2":17239,"PHASE3":17241,"PHASE4":17247,"NA":17249},{"trials":17236,"activeCount":101},[],{"trials":17238,"activeCount":101},[],{"trials":17240,"activeCount":101},[],{"trials":17242,"activeCount":101},[17243],{"nctId":16553,"briefTitle":16554,"status":365,"phases":17244,"primaryCompletion":3390,"completion":3390,"start":389,"enrollment":16556,"conditions":17245,"interventions":17246},[91],[15],[4002,16559],{"trials":17248,"activeCount":101},[],{"trials":17250,"activeCount":101},[],{"intervention":16426,"totalTrials":651,"cells":17252},{"EARLY_PHASE1":17253,"PHASE1":17255,"PHASE2":17257,"PHASE3":17259,"PHASE4":17265,"NA":17267},{"trials":17254,"activeCount":101},[],{"trials":17256,"activeCount":101},[],{"trials":17258,"activeCount":101},[],{"trials":17260,"activeCount":101},[17261],{"nctId":16421,"briefTitle":16422,"status":365,"phases":17262,"primaryCompletion":4021,"completion":4021,"start":15646,"enrollment":591,"conditions":17263,"interventions":17264},[91],[15],[16393,16426],{"trials":17266,"activeCount":101},[],{"trials":17268,"activeCount":101},[],{"intervention":17270,"totalTrials":651,"cells":17271},"Zoladex",{"EARLY_PHASE1":17272,"PHASE1":17274,"PHASE2":17276,"PHASE3":17278,"PHASE4":17286,"NA":17288},{"trials":17273,"activeCount":101},[],{"trials":17275,"activeCount":101},[],{"trials":17277,"activeCount":101},[],{"trials":17279,"activeCount":101},[17280],{"nctId":17281,"briefTitle":17282,"status":365,"phases":17283,"primaryCompletion":15746,"completion":15746,"start":2500,"enrollment":7060,"conditions":17284,"interventions":17285},"NCT01712893","Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer",[91],[15],[17270],{"trials":17287,"activeCount":101},[],{"trials":17289,"activeCount":101},[],{"intervention":17291,"totalTrials":651,"cells":17292},"ABX, cisplatin",{"EARLY_PHASE1":17293,"PHASE1":17295,"PHASE2":17297,"PHASE3":17299,"PHASE4":17310,"NA":17312},{"trials":17294,"activeCount":101},[],{"trials":17296,"activeCount":101},[],{"trials":17298,"activeCount":101},[],{"trials":17300,"activeCount":101},[17301],{"nctId":17302,"briefTitle":17303,"status":365,"phases":17304,"primaryCompletion":17305,"completion":17305,"start":4161,"enrollment":17306,"conditions":17307,"interventions":17308},"NCT02546934","ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)",[91],"2020-04",254,[15],[17291,17309],"Gemcitabine, Cisplatin",{"trials":17311,"activeCount":101},[],{"trials":17313,"activeCount":101},[],{"intervention":17309,"totalTrials":651,"cells":17315},{"EARLY_PHASE1":17316,"PHASE1":17318,"PHASE2":17320,"PHASE3":17322,"PHASE4":17328,"NA":17330},{"trials":17317,"activeCount":101},[],{"trials":17319,"activeCount":101},[],{"trials":17321,"activeCount":101},[],{"trials":17323,"activeCount":101},[17324],{"nctId":17302,"briefTitle":17303,"status":365,"phases":17325,"primaryCompletion":17305,"completion":17305,"start":4161,"enrollment":17306,"conditions":17326,"interventions":17327},[91],[15],[17291,17309],{"trials":17329,"activeCount":101},[],{"trials":17331,"activeCount":101},[],{"intervention":15674,"totalTrials":651,"cells":17333},{"EARLY_PHASE1":17334,"PHASE1":17336,"PHASE2":17338,"PHASE3":17340,"PHASE4":17346,"NA":17348},{"trials":17335,"activeCount":101},[],{"trials":17337,"activeCount":101},[],{"trials":17339,"activeCount":101},[],{"trials":17341,"activeCount":101},[17342],{"nctId":15668,"briefTitle":15669,"status":107,"phases":17343,"primaryCompletion":1279,"completion":1279,"start":15671,"enrollment":1531,"conditions":17344,"interventions":17345},[91],[8977],[15674,15657],{"trials":17347,"activeCount":101},[],{"trials":17349,"activeCount":101},[],{"intervention":17351,"totalTrials":651,"cells":17352},"Trastuzumab plus chemotherapy",{"EARLY_PHASE1":17353,"PHASE1":17355,"PHASE2":17357,"PHASE3":17359,"PHASE4":17370,"NA":17372},{"trials":17354,"activeCount":101},[],{"trials":17356,"activeCount":101},[],{"trials":17358,"activeCount":101},[],{"trials":17360,"activeCount":101},[17361],{"nctId":17362,"briefTitle":17363,"status":107,"phases":17364,"primaryCompletion":17365,"completion":1622,"start":17366,"enrollment":591,"conditions":17367,"interventions":17368},"NCT05346861","Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab",[91],"2023-10-31","2021-09-15",[521,33],[17351,17369],"Trastuzumab in combination with pyrotinib plus chemotherapy",{"trials":17371,"activeCount":101},[],{"trials":17373,"activeCount":101},[],{"intervention":17369,"totalTrials":651,"cells":17375},{"EARLY_PHASE1":17376,"PHASE1":17378,"PHASE2":17380,"PHASE3":17382,"PHASE4":17388,"NA":17390},{"trials":17377,"activeCount":101},[],{"trials":17379,"activeCount":101},[],{"trials":17381,"activeCount":101},[],{"trials":17383,"activeCount":101},[17384],{"nctId":17362,"briefTitle":17363,"status":107,"phases":17385,"primaryCompletion":17365,"completion":1622,"start":17366,"enrollment":591,"conditions":17386,"interventions":17387},[91],[521,33],[17351,17369],{"trials":17389,"activeCount":101},[],{"trials":17391,"activeCount":101},[],{"intervention":17393,"totalTrials":651,"cells":17394},"letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel",{"EARLY_PHASE1":17395,"PHASE1":17397,"PHASE2":17399,"PHASE3":17401,"PHASE4":17413,"NA":17415},{"trials":17396,"activeCount":101},[],{"trials":17398,"activeCount":101},[],{"trials":17400,"activeCount":101},[],{"trials":17402,"activeCount":101},[17403],{"nctId":17404,"briefTitle":17405,"status":365,"phases":17406,"primaryCompletion":17407,"completion":17407,"start":17408,"enrollment":17409,"conditions":17410,"interventions":17411},"NCT02980965","Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer",[91],"2017-02","2013-05",249,[15487],[17393,17412],"fluorouracil, epirubicin, cyclophosphamide, docetaxel",{"trials":17414,"activeCount":101},[],{"trials":17416,"activeCount":101},[],{"intervention":17412,"totalTrials":651,"cells":17418},{"EARLY_PHASE1":17419,"PHASE1":17421,"PHASE2":17423,"PHASE3":17425,"PHASE4":17431,"NA":17433},{"trials":17420,"activeCount":101},[],{"trials":17422,"activeCount":101},[],{"trials":17424,"activeCount":101},[],{"trials":17426,"activeCount":101},[17427],{"nctId":17404,"briefTitle":17405,"status":365,"phases":17428,"primaryCompletion":17407,"completion":17407,"start":17408,"enrollment":17409,"conditions":17429,"interventions":17430},[91],[15487],[17393,17412],{"trials":17432,"activeCount":101},[],{"trials":17434,"activeCount":101},[],{"intervention":17436,"totalTrials":651,"cells":17437},"Paclitaxel plus 5-fluorouracil",{"EARLY_PHASE1":17438,"PHASE1":17440,"PHASE2":17442,"PHASE3":17444,"PHASE4":17455,"NA":17457},{"trials":17439,"activeCount":101},[],{"trials":17441,"activeCount":101},[],{"trials":17443,"activeCount":101},[],{"trials":17445,"activeCount":101},[17446],{"nctId":17447,"briefTitle":17448,"status":365,"phases":17449,"primaryCompletion":17450,"completion":17450,"start":15645,"enrollment":17451,"conditions":17452,"interventions":17453},"NCT01591135","A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma",[91],"2018-08",436,[27],[17436,17454],"Cisplatin plus 5-fluorouracil",{"trials":17456,"activeCount":101},[],{"trials":17458,"activeCount":101},[],{"intervention":17454,"totalTrials":651,"cells":17460},{"EARLY_PHASE1":17461,"PHASE1":17463,"PHASE2":17465,"PHASE3":17467,"PHASE4":17473,"NA":17475},{"trials":17462,"activeCount":101},[],{"trials":17464,"activeCount":101},[],{"trials":17466,"activeCount":101},[],{"trials":17468,"activeCount":101},[17469],{"nctId":17447,"briefTitle":17448,"status":365,"phases":17470,"primaryCompletion":17450,"completion":17450,"start":15645,"enrollment":17451,"conditions":17471,"interventions":17472},[91],[27],[17436,17454],{"trials":17474,"activeCount":101},[],{"trials":17476,"activeCount":101},[],{"intervention":17478,"totalTrials":651,"cells":17479},"TPF neoadjuvant chemotherapy",{"EARLY_PHASE1":17480,"PHASE1":17482,"PHASE2":17484,"PHASE3":17486,"PHASE4":17496,"NA":17498},{"trials":17481,"activeCount":101},[],{"trials":17483,"activeCount":101},[],{"trials":17485,"activeCount":101},[],{"trials":17487,"activeCount":101},[17488],{"nctId":17489,"briefTitle":17490,"status":365,"phases":17491,"primaryCompletion":4161,"completion":15746,"start":562,"enrollment":345,"conditions":17492,"interventions":17493},"NCT02012062","Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC",[91],[35],[17478,17494,17495],"Concurrent chemotherapy with cisplatin during radiotherapy","Concurrent nimotuzumab during radiotherapy",{"trials":17497,"activeCount":101},[],{"trials":17499,"activeCount":101},[],{"intervention":17494,"totalTrials":651,"cells":17501},{"EARLY_PHASE1":17502,"PHASE1":17504,"PHASE2":17506,"PHASE3":17508,"PHASE4":17514,"NA":17516},{"trials":17503,"activeCount":101},[],{"trials":17505,"activeCount":101},[],{"trials":17507,"activeCount":101},[],{"trials":17509,"activeCount":101},[17510],{"nctId":17489,"briefTitle":17490,"status":365,"phases":17511,"primaryCompletion":4161,"completion":15746,"start":562,"enrollment":345,"conditions":17512,"interventions":17513},[91],[35],[17478,17494,17495],{"trials":17515,"activeCount":101},[],{"trials":17517,"activeCount":101},[],{"intervention":17495,"totalTrials":651,"cells":17519},{"EARLY_PHASE1":17520,"PHASE1":17522,"PHASE2":17524,"PHASE3":17526,"PHASE4":17532,"NA":17534},{"trials":17521,"activeCount":101},[],{"trials":17523,"activeCount":101},[],{"trials":17525,"activeCount":101},[],{"trials":17527,"activeCount":101},[17528],{"nctId":17489,"briefTitle":17490,"status":365,"phases":17529,"primaryCompletion":4161,"completion":15746,"start":562,"enrollment":345,"conditions":17530,"interventions":17531},[91],[35],[17478,17494,17495],{"trials":17533,"activeCount":101},[],{"trials":17535,"activeCount":101},[],{"intervention":16595,"totalTrials":651,"cells":17537},{"EARLY_PHASE1":17538,"PHASE1":17540,"PHASE2":17542,"PHASE3":17544,"PHASE4":17550,"NA":17552},{"trials":17539,"activeCount":101},[],{"trials":17541,"activeCount":101},[],{"trials":17543,"activeCount":101},[],{"trials":17545,"activeCount":101},[17546],{"nctId":16587,"briefTitle":16588,"status":107,"phases":17547,"primaryCompletion":16590,"completion":16590,"start":16591,"enrollment":16592,"conditions":17548,"interventions":17549},[91],[2076],[16595,16569],{"trials":17551,"activeCount":101},[],{"trials":17553,"activeCount":101},[],{"intervention":17555,"totalTrials":651,"cells":17556},"Standard endocrine therapy plus Apatinib",{"EARLY_PHASE1":17557,"PHASE1":17559,"PHASE2":17561,"PHASE3":17563,"PHASE4":17573,"NA":17575},{"trials":17558,"activeCount":101},[],{"trials":17560,"activeCount":101},[],{"trials":17562,"activeCount":101},[],{"trials":17564,"activeCount":101},[17565],{"nctId":17566,"briefTitle":17567,"status":107,"phases":17568,"primaryCompletion":1334,"completion":1334,"start":2157,"enrollment":17569,"conditions":17570,"interventions":17572},"NCT05889871","A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+\u002F HER2-SNF4 Early Breast Cancer",[91],916,[17571],"HR+\u002FHER2-breast Cancer",[17555],{"trials":17574,"activeCount":101},[],{"trials":17576,"activeCount":101},[],{"intervention":17578,"totalTrials":651,"cells":17579},"Angongniuhuang Pill",{"EARLY_PHASE1":17580,"PHASE1":17582,"PHASE2":17584,"PHASE3":17586,"PHASE4":17594,"NA":17596},{"trials":17581,"activeCount":101},[],{"trials":17583,"activeCount":101},[],{"trials":17585,"activeCount":101},[],{"trials":17587,"activeCount":101},[17588],{"nctId":17589,"briefTitle":17590,"status":107,"phases":17591,"enrollment":111,"conditions":17592,"interventions":17593},"NCT00817609","Effectiveness and Safety of Angongniuhuang Pill on Restoring Consciousness for Patients Who Have Suffered From a Stroke",[90,91],[4438,16892],[17578],{"trials":17595,"activeCount":101},[],{"trials":17597,"activeCount":101},[],{"intervention":17599,"totalTrials":651,"cells":17600},"nucleoside analog reverse transcriptase inhibitor",{"EARLY_PHASE1":17601,"PHASE1":17603,"PHASE2":17605,"PHASE3":17607,"PHASE4":17615,"NA":17617},{"trials":17602,"activeCount":101},[],{"trials":17604,"activeCount":101},[],{"trials":17606,"activeCount":101},[],{"trials":17608,"activeCount":101},[17609],{"nctId":17610,"briefTitle":17611,"status":107,"phases":17612,"primaryCompletion":2517,"completion":2517,"start":212,"enrollment":802,"conditions":17613,"interventions":17614},"NCT01210287","Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative\u002FHBcAb Positive Lymphoma Patients Treated With RCHOP",[90,91],[17208],[17599],{"trials":17616,"activeCount":101},[],{"trials":17618,"activeCount":101},[],{"intervention":16515,"totalTrials":651,"cells":17620},{"EARLY_PHASE1":17621,"PHASE1":17623,"PHASE2":17625,"PHASE3":17627,"PHASE4":17633,"NA":17635},{"trials":17622,"activeCount":101},[],{"trials":17624,"activeCount":101},[],{"trials":17626,"activeCount":101},[],{"trials":17628,"activeCount":101},[17629],{"nctId":16508,"briefTitle":16509,"status":107,"phases":17630,"primaryCompletion":6204,"completion":6204,"start":632,"enrollment":1290,"conditions":17631,"interventions":17632},[91],[16512,16513],[16515,2030],{"trials":17634,"activeCount":101},[],{"trials":17636,"activeCount":101},[],{"intervention":1867,"totalTrials":651,"cells":17638},{"EARLY_PHASE1":17639,"PHASE1":17641,"PHASE2":17643,"PHASE3":17645,"PHASE4":17651,"NA":17653},{"trials":17640,"activeCount":101},[],{"trials":17642,"activeCount":101},[],{"trials":17644,"activeCount":101},[],{"trials":17646,"activeCount":101},[17647],{"nctId":1857,"briefTitle":1858,"status":107,"phases":17648,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":17649,"interventions":17650},[91],[1865],[1867,1817,1092,67,1868],{"trials":17652,"activeCount":101},[],{"trials":17654,"activeCount":101},[],{"intervention":4000,"totalTrials":651,"cells":17656},{"EARLY_PHASE1":17657,"PHASE1":17659,"PHASE2":17661,"PHASE3":17663,"PHASE4":17669,"NA":17671},{"trials":17658,"activeCount":101},[],{"trials":17660,"activeCount":101},[],{"trials":17662,"activeCount":101},[],{"trials":17664,"activeCount":101},[17665],{"nctId":3992,"briefTitle":3993,"status":107,"phases":17666,"primaryCompletion":3995,"completion":188,"start":3996,"enrollment":529,"conditions":17667,"interventions":17668},[91],[3998],[4000,4001,4002,4003,2642],{"trials":17670,"activeCount":101},[],{"trials":17672,"activeCount":101},[],{"intervention":4001,"totalTrials":651,"cells":17674},{"EARLY_PHASE1":17675,"PHASE1":17677,"PHASE2":17679,"PHASE3":17681,"PHASE4":17687,"NA":17689},{"trials":17676,"activeCount":101},[],{"trials":17678,"activeCount":101},[],{"trials":17680,"activeCount":101},[],{"trials":17682,"activeCount":101},[17683],{"nctId":3992,"briefTitle":3993,"status":107,"phases":17684,"primaryCompletion":3995,"completion":188,"start":3996,"enrollment":529,"conditions":17685,"interventions":17686},[91],[3998],[4000,4001,4002,4003,2642],{"trials":17688,"activeCount":101},[],{"trials":17690,"activeCount":101},[],{"intervention":4003,"totalTrials":651,"cells":17692},{"EARLY_PHASE1":17693,"PHASE1":17695,"PHASE2":17697,"PHASE3":17699,"PHASE4":17705,"NA":17707},{"trials":17694,"activeCount":101},[],{"trials":17696,"activeCount":101},[],{"trials":17698,"activeCount":101},[],{"trials":17700,"activeCount":101},[17701],{"nctId":3992,"briefTitle":3993,"status":107,"phases":17702,"primaryCompletion":3995,"completion":188,"start":3996,"enrollment":529,"conditions":17703,"interventions":17704},[91],[3998],[4000,4001,4002,4003,2642],{"trials":17706,"activeCount":101},[],{"trials":17708,"activeCount":101},[],{"intervention":17710,"totalTrials":651,"cells":17711},"chemotherapy ± targeted therapy",{"EARLY_PHASE1":17712,"PHASE1":17714,"PHASE2":17716,"PHASE3":17718,"PHASE4":17730,"NA":17732},{"trials":17713,"activeCount":101},[],{"trials":17715,"activeCount":101},[],{"trials":17717,"activeCount":101},[],{"trials":17719,"activeCount":101},[17720],{"nctId":17721,"briefTitle":17722,"status":365,"phases":17723,"primaryCompletion":17724,"completion":17724,"start":17725,"enrollment":15043,"conditions":17726,"interventions":17729},"NCT01307878","New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases",[91],"2021-06","2012-06",[1477,566,17727,17728],"Liver Neoplasms","Chemotherapy; Maternal, Affecting Fetus",[17710],{"trials":17731,"activeCount":101},[],{"trials":17733,"activeCount":101},[],{"intervention":17735,"totalTrials":651,"cells":17736},"Zoladex+AI",{"EARLY_PHASE1":17737,"PHASE1":17739,"PHASE2":17741,"PHASE3":17743,"PHASE4":17754,"NA":17756},{"trials":17738,"activeCount":101},[],{"trials":17740,"activeCount":101},[],{"trials":17742,"activeCount":101},[],{"trials":17744,"activeCount":101},[17745],{"nctId":17746,"briefTitle":17747,"status":107,"phases":17748,"primaryCompletion":17749,"completion":2945,"start":7500,"enrollment":17750,"conditions":17751,"interventions":17752},"NCT01352091","Adjuvant AI Combined With Zoladex",[91],"2015-05",670,[15],[17735,17753],"TAM",{"trials":17755,"activeCount":101},[],{"trials":17757,"activeCount":101},[],{"intervention":17753,"totalTrials":651,"cells":17759},{"EARLY_PHASE1":17760,"PHASE1":17762,"PHASE2":17764,"PHASE3":17766,"PHASE4":17772,"NA":17774},{"trials":17761,"activeCount":101},[],{"trials":17763,"activeCount":101},[],{"trials":17765,"activeCount":101},[],{"trials":17767,"activeCount":101},[17768],{"nctId":17746,"briefTitle":17747,"status":107,"phases":17769,"primaryCompletion":17749,"completion":2945,"start":7500,"enrollment":17750,"conditions":17770,"interventions":17771},[91],[15],[17735,17753],{"trials":17773,"activeCount":101},[],{"trials":17775,"activeCount":101},[],{"intervention":17777,"totalTrials":651,"cells":17778},"Cisplatin Combined With S-1",{"EARLY_PHASE1":17779,"PHASE1":17781,"PHASE2":17783,"PHASE3":17785,"PHASE4":17795,"NA":17797},{"trials":17780,"activeCount":101},[],{"trials":17782,"activeCount":101},[],{"trials":17784,"activeCount":101},[],{"trials":17786,"activeCount":101},[17787],{"nctId":17788,"briefTitle":17789,"status":107,"phases":17790,"primaryCompletion":17791,"completion":17791,"start":1877,"enrollment":541,"conditions":17792,"interventions":17793},"NCT02677597","Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma",[91],"2019-01",[27],[17777,17794],"Cisplatin Combined With Paclitaxel",{"trials":17796,"activeCount":101},[],{"trials":17798,"activeCount":101},[],{"intervention":17794,"totalTrials":651,"cells":17800},{"EARLY_PHASE1":17801,"PHASE1":17803,"PHASE2":17805,"PHASE3":17807,"PHASE4":17813,"NA":17815},{"trials":17802,"activeCount":101},[],{"trials":17804,"activeCount":101},[],{"trials":17806,"activeCount":101},[],{"trials":17808,"activeCount":101},[17809],{"nctId":17788,"briefTitle":17789,"status":107,"phases":17810,"primaryCompletion":17791,"completion":17791,"start":1877,"enrollment":541,"conditions":17811,"interventions":17812},[91],[27],[17777,17794],{"trials":17814,"activeCount":101},[],{"trials":17816,"activeCount":101},[],{"intervention":17818,"totalTrials":651,"cells":17819},"Pre-radiotherapy commencement of Arimidex",{"EARLY_PHASE1":17820,"PHASE1":17822,"PHASE2":17824,"PHASE3":17826,"PHASE4":17836,"NA":17838},{"trials":17821,"activeCount":101},[],{"trials":17823,"activeCount":101},[],{"trials":17825,"activeCount":101},[],{"trials":17827,"activeCount":101},[17828],{"nctId":17829,"briefTitle":17830,"status":107,"phases":17831,"primaryCompletion":389,"completion":16913,"start":17832,"enrollment":14857,"conditions":17833,"interventions":17834},"NCT01402193","Study of Arimidex and Radiotherapy Sequencing",[91],"2011-07",[15],[17818,17835],"Post radiotherapy commencement of Arimidex",{"trials":17837,"activeCount":101},[],{"trials":17839,"activeCount":101},[],{"intervention":17835,"totalTrials":651,"cells":17841},{"EARLY_PHASE1":17842,"PHASE1":17844,"PHASE2":17846,"PHASE3":17848,"PHASE4":17854,"NA":17856},{"trials":17843,"activeCount":101},[],{"trials":17845,"activeCount":101},[],{"trials":17847,"activeCount":101},[],{"trials":17849,"activeCount":101},[17850],{"nctId":17829,"briefTitle":17830,"status":107,"phases":17851,"primaryCompletion":389,"completion":16913,"start":17832,"enrollment":14857,"conditions":17852,"interventions":17853},[91],[15],[17818,17835],{"trials":17855,"activeCount":101},[],{"trials":17857,"activeCount":101},[],{"intervention":17859,"totalTrials":651,"cells":17860},"Paclitaxel, Carboplatin",{"EARLY_PHASE1":17861,"PHASE1":17863,"PHASE2":17865,"PHASE3":17867,"PHASE4":17876,"NA":17878},{"trials":17862,"activeCount":101},[],{"trials":17864,"activeCount":101},[],{"trials":17866,"activeCount":101},[],{"trials":17868,"activeCount":101},[17869],{"nctId":17870,"briefTitle":17871,"status":107,"phases":17872,"primaryCompletion":1203,"completion":56,"start":17873,"enrollment":2709,"conditions":17874,"interventions":17875},"NCT05371301","Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer",[91],"2021-07-16",[2737],[17859],{"trials":17877,"activeCount":101},[],{"trials":17879,"activeCount":101},[],{"intervention":17881,"totalTrials":651,"cells":17882},"Nitric Oxide",{"EARLY_PHASE1":17883,"PHASE1":17885,"PHASE2":17887,"PHASE3":17889,"PHASE4":17900,"NA":17902},{"trials":17884,"activeCount":101},[],{"trials":17886,"activeCount":101},[],{"trials":17888,"activeCount":101},[],{"trials":17890,"activeCount":101},[17891],{"nctId":17892,"briefTitle":17893,"status":365,"phases":17894,"primaryCompletion":17895,"completion":110,"start":17896,"enrollment":2854,"conditions":17897,"interventions":17899},"NCT01503801","Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia",[90,91],"2012-09","2011-05",[17898],"Pulmonary Disease",[17881],{"trials":17901,"activeCount":101},[],{"trials":17903,"activeCount":101},[],{"intervention":17905,"totalTrials":651,"cells":17906},"Sequential Gefitinib With Pemetrexed\u002FPlatinum",{"EARLY_PHASE1":17907,"PHASE1":17909,"PHASE2":17911,"PHASE3":17913,"PHASE4":17922,"NA":17924},{"trials":17908,"activeCount":101},[],{"trials":17910,"activeCount":101},[],{"trials":17912,"activeCount":101},[],{"trials":17914,"activeCount":101},[17915],{"nctId":17916,"briefTitle":17917,"status":365,"phases":17918,"primaryCompletion":3924,"start":1879,"enrollment":1417,"conditions":17919,"interventions":17920},"NCT01769066","Clinical Value of Sequential Gefitinib With Pemetrexed\u002FPlatinum for Advanced NSCLC",[90,91],[8500],[17905,17921],"Pemetrexed\u002FPlatinum",{"trials":17923,"activeCount":101},[],{"trials":17925,"activeCount":101},[],{"intervention":17921,"totalTrials":651,"cells":17927},{"EARLY_PHASE1":17928,"PHASE1":17930,"PHASE2":17932,"PHASE3":17934,"PHASE4":17940,"NA":17942},{"trials":17929,"activeCount":101},[],{"trials":17931,"activeCount":101},[],{"trials":17933,"activeCount":101},[],{"trials":17935,"activeCount":101},[17936],{"nctId":17916,"briefTitle":17917,"status":365,"phases":17937,"primaryCompletion":3924,"start":1879,"enrollment":1417,"conditions":17938,"interventions":17939},[90,91],[8500],[17905,17921],{"trials":17941,"activeCount":101},[],{"trials":17943,"activeCount":101},[],{"intervention":6406,"totalTrials":651,"cells":17945},{"EARLY_PHASE1":17946,"PHASE1":17948,"PHASE2":17950,"PHASE3":17952,"PHASE4":17958,"NA":17960},{"trials":17947,"activeCount":101},[],{"trials":17949,"activeCount":101},[],{"trials":17951,"activeCount":101},[],{"trials":17953,"activeCount":101},[17954],{"nctId":6399,"briefTitle":6400,"status":107,"phases":17955,"primaryCompletion":66,"completion":939,"start":6402,"enrollment":6403,"conditions":17956,"interventions":17957},[91],[6164,1554],[6406,6407,230],{"trials":17959,"activeCount":101},[],{"trials":17961,"activeCount":101},[],{"intervention":6407,"totalTrials":651,"cells":17963},{"EARLY_PHASE1":17964,"PHASE1":17966,"PHASE2":17968,"PHASE3":17970,"PHASE4":17976,"NA":17978},{"trials":17965,"activeCount":101},[],{"trials":17967,"activeCount":101},[],{"trials":17969,"activeCount":101},[],{"trials":17971,"activeCount":101},[17972],{"nctId":6399,"briefTitle":6400,"status":107,"phases":17973,"primaryCompletion":66,"completion":939,"start":6402,"enrollment":6403,"conditions":17974,"interventions":17975},[91],[6164,1554],[6406,6407,230],{"trials":17977,"activeCount":101},[],{"trials":17979,"activeCount":101},[],{"intervention":17981,"totalTrials":651,"cells":17982},"Cyclosporin A",{"EARLY_PHASE1":17983,"PHASE1":17985,"PHASE2":17987,"PHASE3":17989,"PHASE4":18001,"NA":18003},{"trials":17984,"activeCount":101},[],{"trials":17986,"activeCount":101},[],{"trials":17988,"activeCount":101},[],{"trials":17990,"activeCount":101},[17991],{"nctId":17992,"briefTitle":17993,"status":107,"phases":17994,"primaryCompletion":17995,"completion":1288,"start":17996,"enrollment":752,"conditions":17997,"interventions":17999},"NCT02706470","Use of Cyclosporin A for the Treatment of Recurrent Miscarriage",[90,91],"2018-02","2016-05",[17998],"Miscarriage, Recurrent",[17981,18000],"Dydrogesterone",{"trials":18002,"activeCount":101},[],{"trials":18004,"activeCount":101},[],{"intervention":18000,"totalTrials":651,"cells":18006},{"EARLY_PHASE1":18007,"PHASE1":18009,"PHASE2":18011,"PHASE3":18013,"PHASE4":18019,"NA":18021},{"trials":18008,"activeCount":101},[],{"trials":18010,"activeCount":101},[],{"trials":18012,"activeCount":101},[],{"trials":18014,"activeCount":101},[18015],{"nctId":17992,"briefTitle":17993,"status":107,"phases":18016,"primaryCompletion":17995,"completion":1288,"start":17996,"enrollment":752,"conditions":18017,"interventions":18018},[90,91],[17998],[17981,18000],{"trials":18020,"activeCount":101},[],{"trials":18022,"activeCount":101},[],{"intervention":8979,"totalTrials":651,"cells":18024},{"EARLY_PHASE1":18025,"PHASE1":18027,"PHASE2":18029,"PHASE3":18031,"PHASE4":18037,"NA":18039},{"trials":18026,"activeCount":101},[],{"trials":18028,"activeCount":101},[],{"trials":18030,"activeCount":101},[],{"trials":18032,"activeCount":101},[18033],{"nctId":8972,"briefTitle":8973,"status":107,"phases":18034,"primaryCompletion":1288,"completion":8975,"start":1877,"enrollment":1205,"conditions":18035,"interventions":18036},[91],[8977],[4192,8979],{"trials":18038,"activeCount":101},[],{"trials":18040,"activeCount":101},[],{"intervention":18042,"totalTrials":651,"cells":18043},"Polyethylene Glycol Loxenatide",{"EARLY_PHASE1":18044,"PHASE1":18046,"PHASE2":18048,"PHASE3":18050,"PHASE4":18062,"NA":18064},{"trials":18045,"activeCount":101},[],{"trials":18047,"activeCount":101},[],{"trials":18049,"activeCount":101},[],{"trials":18051,"activeCount":101},[18052],{"nctId":18053,"briefTitle":18054,"status":365,"phases":18055,"primaryCompletion":1489,"completion":18056,"start":18057,"enrollment":25,"conditions":18058,"interventions":18061},"NCT05172999","Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia",[90,91],"2026-02-28","2022-01-08",[15603,18059,18060],"Obesity","Fertility Issues",[18042],{"trials":18063,"activeCount":101},[],{"trials":18065,"activeCount":101},[],{"intervention":16387,"totalTrials":651,"cells":18067},{"EARLY_PHASE1":18068,"PHASE1":18070,"PHASE2":18072,"PHASE3":18074,"PHASE4":18080,"NA":18082},{"trials":18069,"activeCount":101},[],{"trials":18071,"activeCount":101},[],{"trials":18073,"activeCount":101},[],{"trials":18075,"activeCount":101},[18076],{"nctId":16380,"briefTitle":16381,"status":494,"phases":18077,"primaryCompletion":16383,"completion":16383,"start":16384,"enrollment":2394,"conditions":18078,"interventions":18079},[90,91],[15603],[16387,15595],{"trials":18081,"activeCount":101},[],{"trials":18083,"activeCount":101},[],{"intervention":18085,"totalTrials":651,"cells":18086},"Traditional Chinese Medicine Formulation",{"EARLY_PHASE1":18087,"PHASE1":18089,"PHASE2":18091,"PHASE3":18093,"PHASE4":18103,"NA":18105},{"trials":18088,"activeCount":101},[],{"trials":18090,"activeCount":101},[],{"trials":18092,"activeCount":101},[],{"trials":18094,"activeCount":101},[18095],{"nctId":18096,"briefTitle":18097,"status":107,"phases":18098,"primaryCompletion":18099,"completion":18099,"start":18100,"enrollment":2709,"conditions":18101,"interventions":18102},"NCT04403529","Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer",[91],"2024-05-31","2020-05-25",[250],[18085],{"trials":18104,"activeCount":101},[],{"trials":18106,"activeCount":101},[],{"intervention":9124,"totalTrials":2010,"cells":18108},{"EARLY_PHASE1":18109,"PHASE1":18111,"PHASE2":18119,"PHASE3":18140,"PHASE4":18142,"NA":18144},{"trials":18110,"activeCount":101},[],{"trials":18112,"activeCount":101},[18113],{"nctId":18114,"briefTitle":18115,"status":107,"phases":18116,"primaryCompletion":17205,"completion":2957,"start":3102,"enrollment":2825,"conditions":18117,"interventions":18118},"NCT00497250","Phase I Study of Iressa and CRT\u002FIMRT in Chinese Patients With IIIB\u002FIV NSCLC After Failure of Platinum-Based Chemotherapy",[89],[2502],[9124],{"trials":18120,"activeCount":101},[18121,18128,18136],{"nctId":18122,"briefTitle":18123,"status":365,"phases":18124,"primaryCompletion":487,"completion":487,"start":17408,"enrollment":3068,"conditions":18125,"interventions":18127},"NCT01833572","Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)",[90],[18126],"Non-small-cell Lung Cancer",[9124],{"nctId":18129,"briefTitle":18130,"status":107,"phases":18131,"primaryCompletion":426,"completion":285,"start":18132,"enrollment":296,"conditions":18133,"interventions":18134},"NCT04425187","Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC",[90],"2020-06-08",[1348],[9124,18135],"Bevacizumab Combined With Gefitinib",{"nctId":9118,"briefTitle":9119,"status":107,"phases":18137,"primaryCompletion":2499,"start":1879,"enrollment":1610,"conditions":18138,"interventions":18139},[90],[9122,2960],[9124,2111,9125],{"trials":18141,"activeCount":101},[],{"trials":18143,"activeCount":101},[],{"trials":18145,"activeCount":101},[],{"intervention":2962,"totalTrials":2010,"cells":18147},{"EARLY_PHASE1":18148,"PHASE1":18150,"PHASE2":18152,"PHASE3":18175,"PHASE4":18177,"NA":18179},{"trials":18149,"activeCount":101},[],{"trials":18151,"activeCount":101},[],{"trials":18153,"activeCount":101},[18154,18158,18162,18171],{"nctId":2954,"briefTitle":2955,"status":365,"phases":18155,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":478,"conditions":18156,"interventions":18157},[90],[2960],[2962,176,1764],{"nctId":6602,"briefTitle":6603,"status":107,"phases":18159,"primaryCompletion":1145,"completion":1682,"start":6605,"enrollment":6606,"conditions":18160,"interventions":18161},[90],[6608,6609],[2962,2411],{"nctId":18163,"briefTitle":18164,"status":107,"phases":18165,"primaryCompletion":18166,"completion":18167,"start":1877,"enrollment":690,"conditions":18168,"interventions":18169},"NCT02665702","Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas",[90],"2018-09","2019-09",[27],[18170,6882,2962],"NVB",{"nctId":6876,"briefTitle":6877,"status":365,"phases":18172,"primaryCompletion":1279,"completion":426,"start":6879,"enrollment":473,"conditions":18173,"interventions":18174},[90],[27],[115,6882,2962],{"trials":18176,"activeCount":101},[],{"trials":18178,"activeCount":101},[],{"trials":18180,"activeCount":101},[],{"intervention":18182,"totalTrials":1300,"cells":18183},"docetaxel, cisplatin, fluorouracil",{"EARLY_PHASE1":18184,"PHASE1":18186,"PHASE2":18188,"PHASE3":18208,"PHASE4":18210,"NA":18212},{"trials":18185,"activeCount":101},[],{"trials":18187,"activeCount":101},[],{"trials":18189,"activeCount":101},[18190,18196,18202],{"nctId":18191,"briefTitle":18192,"status":107,"phases":18193,"primaryCompletion":16889,"completion":17832,"start":8665,"enrollment":213,"conditions":18194,"interventions":18195},"NCT00817583","Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)",[90],[35],[18182],{"nctId":18197,"briefTitle":18198,"status":107,"phases":18199,"primaryCompletion":1879,"completion":3166,"start":16978,"enrollment":473,"conditions":18200,"interventions":18201},"NCT00816855","Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma",[90],[35],[18182],{"nctId":18203,"briefTitle":18204,"status":107,"phases":18205,"primaryCompletion":1879,"completion":3166,"start":16978,"enrollment":16376,"conditions":18206,"interventions":18207},"NCT00816816","Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma",[90],[35],[18182],{"trials":18209,"activeCount":101},[],{"trials":18211,"activeCount":101},[],{"trials":18213,"activeCount":101},[],{"intervention":6882,"totalTrials":1300,"cells":18215},{"EARLY_PHASE1":18216,"PHASE1":18218,"PHASE2":18220,"PHASE3":18234,"PHASE4":18236,"NA":18238},{"trials":18217,"activeCount":101},[],{"trials":18219,"activeCount":101},[],{"trials":18221,"activeCount":101},[18222,18226,18230],{"nctId":18163,"briefTitle":18164,"status":107,"phases":18223,"primaryCompletion":18166,"completion":18167,"start":1877,"enrollment":690,"conditions":18224,"interventions":18225},[90],[27],[18170,6882,2962],{"nctId":16331,"briefTitle":16332,"status":107,"phases":18227,"primaryCompletion":1203,"completion":1203,"start":15748,"enrollment":10553,"conditions":18228,"interventions":18229},[90],[33],[176,6882],{"nctId":6876,"briefTitle":6877,"status":365,"phases":18231,"primaryCompletion":1279,"completion":426,"start":6879,"enrollment":473,"conditions":18232,"interventions":18233},[90],[27],[115,6882,2962],{"trials":18235,"activeCount":101},[],{"trials":18237,"activeCount":101},[],{"trials":18239,"activeCount":101},[],{"intervention":9261,"totalTrials":771,"cells":18241},{"EARLY_PHASE1":18242,"PHASE1":18244,"PHASE2":18246,"PHASE3":18263,"PHASE4":18265,"NA":18267},{"trials":18243,"activeCount":101},[],{"trials":18245,"activeCount":101},[],{"trials":18247,"activeCount":101},[18248,18252],{"nctId":9255,"briefTitle":9256,"status":107,"phases":18249,"primaryCompletion":1165,"completion":6204,"start":9258,"enrollment":345,"conditions":18250,"interventions":18251},[90],[8780],[9261,9262,9263,9264,2720,9265,9266],{"nctId":18253,"briefTitle":18254,"status":107,"phases":18255,"primaryCompletion":8975,"completion":1451,"start":16914,"enrollment":2709,"conditions":18256,"interventions":18257},"NCT02742675","Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)",[90],[8780],[18258,18259,18260,18261,18262],"Bicalutamide","goserelin acetate","flutamide","leuprolide acetate","triptorelin",{"trials":18264,"activeCount":101},[],{"trials":18266,"activeCount":101},[],{"trials":18268,"activeCount":101},[],{"intervention":9262,"totalTrials":771,"cells":18270},{"EARLY_PHASE1":18271,"PHASE1":18273,"PHASE2":18275,"PHASE3":18285,"PHASE4":18287,"NA":18289},{"trials":18272,"activeCount":101},[],{"trials":18274,"activeCount":101},[],{"trials":18276,"activeCount":101},[18277,18281],{"nctId":9255,"briefTitle":9256,"status":107,"phases":18278,"primaryCompletion":1165,"completion":6204,"start":9258,"enrollment":345,"conditions":18279,"interventions":18280},[90],[8780],[9261,9262,9263,9264,2720,9265,9266],{"nctId":18253,"briefTitle":18254,"status":107,"phases":18282,"primaryCompletion":8975,"completion":1451,"start":16914,"enrollment":2709,"conditions":18283,"interventions":18284},[90],[8780],[18258,18259,18260,18261,18262],{"trials":18286,"activeCount":101},[],{"trials":18288,"activeCount":101},[],{"trials":18290,"activeCount":101},[],{"intervention":2720,"totalTrials":771,"cells":18292},{"EARLY_PHASE1":18293,"PHASE1":18295,"PHASE2":18297,"PHASE3":18307,"PHASE4":18309,"NA":18311},{"trials":18294,"activeCount":101},[],{"trials":18296,"activeCount":101},[],{"trials":18298,"activeCount":101},[18299,18303],{"nctId":9255,"briefTitle":9256,"status":107,"phases":18300,"primaryCompletion":1165,"completion":6204,"start":9258,"enrollment":345,"conditions":18301,"interventions":18302},[90],[8780],[9261,9262,9263,9264,2720,9265,9266],{"nctId":2714,"briefTitle":2715,"status":107,"phases":18304,"primaryCompletion":56,"completion":56,"start":368,"enrollment":181,"conditions":18305,"interventions":18306},[90],[2718,240],[2720,1386,2721,2722],{"trials":18308,"activeCount":101},[],{"trials":18310,"activeCount":101},[],{"trials":18312,"activeCount":101},[],{"intervention":6091,"totalTrials":771,"cells":18314},{"EARLY_PHASE1":18315,"PHASE1":18317,"PHASE2":18323,"PHASE3":18333,"PHASE4":18335,"NA":18337},{"trials":18316,"activeCount":101},[],{"trials":18318,"activeCount":101},[18319],{"nctId":6086,"briefTitle":6087,"status":107,"phases":18320,"primaryCompletion":1489,"completion":1489,"start":295,"enrollment":31,"conditions":18321,"interventions":18322},[89],[21],[6091,128,1468],{"trials":18324,"activeCount":101},[18325],{"nctId":18326,"briefTitle":18327,"status":365,"phases":18328,"primaryCompletion":18329,"completion":18329,"start":18330,"enrollment":31,"conditions":18331,"interventions":18332},"NCT04771676","Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites",[90],"2023-01-31","2021-03-05",[6083],[6091],{"trials":18334,"activeCount":101},[],{"trials":18336,"activeCount":101},[],{"trials":18338,"activeCount":101},[],{"intervention":1482,"totalTrials":771,"cells":18340},{"EARLY_PHASE1":18341,"PHASE1":18343,"PHASE2":18345,"PHASE3":18359,"PHASE4":18361,"NA":18363},{"trials":18342,"activeCount":101},[],{"trials":18344,"activeCount":101},[],{"trials":18346,"activeCount":101},[18347,18355],{"nctId":18348,"briefTitle":18349,"status":107,"phases":18350,"primaryCompletion":389,"completion":1204,"start":18351,"enrollment":213,"conditions":18352,"interventions":18353},"NCT01736904","wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients",[90],"2012-05",[18],[18354,1482],"wXELIRI regimen",{"nctId":1470,"briefTitle":1471,"status":107,"phases":18356,"primaryCompletion":1164,"completion":1473,"start":1474,"enrollment":1475,"conditions":18357,"interventions":18358},[90],[1477,1478],[432,413,1480,1481,1482,1483,1484],{"trials":18360,"activeCount":101},[],{"trials":18362,"activeCount":101},[],{"trials":18364,"activeCount":101},[],{"intervention":18366,"totalTrials":771,"cells":18367},"Anlotinib Hydrochloride",{"EARLY_PHASE1":18368,"PHASE1":18370,"PHASE2":18372,"PHASE3":18386,"PHASE4":18388,"NA":18390},{"trials":18369,"activeCount":101},[],{"trials":18371,"activeCount":101},[],{"trials":18373,"activeCount":101},[18374,18382],{"nctId":18375,"briefTitle":18376,"status":365,"phases":18377,"primaryCompletion":199,"completion":285,"start":18378,"enrollment":2241,"conditions":18379,"interventions":18381},"NCT03951571","Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma",[90],"2019-05-13",[7944,18380],"High Grade Sarcoma",[18366],{"nctId":3387,"briefTitle":3388,"status":107,"phases":18383,"primaryCompletion":56,"completion":1356,"start":3390,"enrollment":25,"conditions":18384,"interventions":18385},[90],[3392],[3394,3395],{"trials":18387,"activeCount":101},[],{"trials":18389,"activeCount":101},[],{"trials":18391,"activeCount":101},[],{"intervention":18393,"totalTrials":771,"cells":18394},"Huachansu",{"EARLY_PHASE1":18395,"PHASE1":18397,"PHASE2":18399,"PHASE3":18414,"PHASE4":18416,"NA":18418},{"trials":18396,"activeCount":101},[],{"trials":18398,"activeCount":101},[],{"trials":18400,"activeCount":101},[18401,18408],{"nctId":18402,"briefTitle":18403,"status":365,"phases":18404,"primaryCompletion":18405,"completion":1203,"start":16914,"enrollment":2325,"conditions":18406,"interventions":18407},"NCT02647125","A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC",[90],"2022-09",[27],[18393],{"nctId":18409,"briefTitle":18410,"status":107,"phases":18411,"primaryCompletion":4020,"completion":4020,"start":562,"enrollment":296,"conditions":18412,"interventions":18413},"NCT01715532","Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+\u002FK+-ATPase",[90],[2925],[18393],{"trials":18415,"activeCount":101},[],{"trials":18417,"activeCount":101},[],{"trials":18419,"activeCount":101},[],{"intervention":3260,"totalTrials":771,"cells":18421},{"EARLY_PHASE1":18422,"PHASE1":18424,"PHASE2":18426,"PHASE3":18436,"PHASE4":18438,"NA":18440},{"trials":18423,"activeCount":101},[],{"trials":18425,"activeCount":101},[],{"trials":18427,"activeCount":101},[18428,18432],{"nctId":6169,"briefTitle":6170,"status":494,"phases":18429,"primaryCompletion":6172,"completion":2603,"start":6173,"enrollment":1729,"conditions":18430,"interventions":18431},[90],[2960],[128,3260],{"nctId":3254,"briefTitle":3255,"status":107,"phases":18433,"primaryCompletion":85,"completion":85,"start":2025,"enrollment":3257,"conditions":18434,"interventions":18435},[90],[33],[3260,128,1466],{"trials":18437,"activeCount":101},[],{"trials":18439,"activeCount":101},[],{"trials":18441,"activeCount":101},[],{"intervention":7865,"totalTrials":771,"cells":18443},{"EARLY_PHASE1":18444,"PHASE1":18446,"PHASE2":18448,"PHASE3":18458,"PHASE4":18460,"NA":18462},{"trials":18445,"activeCount":101},[],{"trials":18447,"activeCount":101},[],{"trials":18449,"activeCount":101},[18450,18454],{"nctId":7860,"briefTitle":7861,"status":107,"phases":18451,"primaryCompletion":398,"completion":398,"start":1203,"enrollment":1610,"conditions":18452,"interventions":18453},[90],[6157],[1170,7865,7866],{"nctId":8676,"briefTitle":8677,"status":107,"phases":18455,"primaryCompletion":8679,"completion":8679,"start":8680,"enrollment":6606,"conditions":18456,"interventions":18457},[90],[1477],[8668,7865],{"trials":18459,"activeCount":101},[],{"trials":18461,"activeCount":101},[],{"trials":18463,"activeCount":101},[],{"intervention":18465,"totalTrials":771,"cells":18466},"Chidamide combined with cisplatin",{"EARLY_PHASE1":18467,"PHASE1":18469,"PHASE2":18471,"PHASE3":18491,"PHASE4":18493,"NA":18495},{"trials":18468,"activeCount":101},[],{"trials":18470,"activeCount":101},[],{"trials":18472,"activeCount":101},[18473,18483],{"nctId":18474,"briefTitle":18475,"status":365,"phases":18476,"primaryCompletion":18477,"completion":18478,"start":18479,"enrollment":1623,"conditions":18480,"interventions":18482},"NCT03639168","Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)",[90],"2020-06-24","2021-06-02","2018-06-06",[18481,1764],"Adenoid Cystic Carcinomas",[18465],{"nctId":18484,"briefTitle":18485,"status":107,"phases":18486,"primaryCompletion":199,"completion":199,"start":18487,"enrollment":1633,"conditions":18488,"interventions":18489},"NCT04192903","Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer",[90],"2019-12-25",[161],[18490],"Chidamide combined with Cisplatin",{"trials":18492,"activeCount":101},[],{"trials":18494,"activeCount":101},[],{"trials":18496,"activeCount":101},[],{"intervention":18258,"totalTrials":771,"cells":18498},{"EARLY_PHASE1":18499,"PHASE1":18501,"PHASE2":18503,"PHASE3":18515,"PHASE4":18517,"NA":18519},{"trials":18500,"activeCount":101},[],{"trials":18502,"activeCount":101},[],{"trials":18504,"activeCount":101},[18505,18511],{"nctId":18506,"briefTitle":18507,"status":494,"phases":18508,"primaryCompletion":1204,"completion":1204,"start":16414,"enrollment":651,"conditions":18509,"interventions":18510},"NCT02348281","Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients",[90],[15],[18258],{"nctId":18253,"briefTitle":18254,"status":107,"phases":18512,"primaryCompletion":8975,"completion":1451,"start":16914,"enrollment":2709,"conditions":18513,"interventions":18514},[90],[8780],[18258,18259,18260,18261,18262],{"trials":18516,"activeCount":101},[],{"trials":18518,"activeCount":101},[],{"trials":18520,"activeCount":101},[],{"intervention":2607,"totalTrials":651,"cells":18522},{"EARLY_PHASE1":18523,"PHASE1":18525,"PHASE2":18527,"PHASE3":18533,"PHASE4":18535,"NA":18537},{"trials":18524,"activeCount":101},[],{"trials":18526,"activeCount":101},[],{"trials":18528,"activeCount":101},[18529],{"nctId":2600,"briefTitle":2601,"status":107,"phases":18530,"primaryCompletion":2603,"completion":1609,"start":2604,"enrollment":159,"conditions":18531,"interventions":18532},[90],[250],[2607,1385,2608,2411],{"trials":18534,"activeCount":101},[],{"trials":18536,"activeCount":101},[],{"trials":18538,"activeCount":101},[],{"intervention":2608,"totalTrials":651,"cells":18540},{"EARLY_PHASE1":18541,"PHASE1":18543,"PHASE2":18545,"PHASE3":18551,"PHASE4":18553,"NA":18555},{"trials":18542,"activeCount":101},[],{"trials":18544,"activeCount":101},[],{"trials":18546,"activeCount":101},[18547],{"nctId":2600,"briefTitle":2601,"status":107,"phases":18548,"primaryCompletion":2603,"completion":1609,"start":2604,"enrollment":159,"conditions":18549,"interventions":18550},[90],[250],[2607,1385,2608,2411],{"trials":18552,"activeCount":101},[],{"trials":18554,"activeCount":101},[],{"trials":18556,"activeCount":101},[],{"intervention":18558,"totalTrials":651,"cells":18559},"Pyrotinib combined with capecitabine",{"EARLY_PHASE1":18560,"PHASE1":18562,"PHASE2":18564,"PHASE3":18573,"PHASE4":18575,"NA":18577},{"trials":18561,"activeCount":101},[],{"trials":18563,"activeCount":101},[],{"trials":18565,"activeCount":101},[18566],{"nctId":18567,"briefTitle":18568,"status":107,"phases":18569,"primaryCompletion":18570,"completion":293,"start":3155,"enrollment":213,"conditions":18571,"interventions":18572},"NCT04001621","Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer",[90],"2023-05-31",[33],[18558],{"trials":18574,"activeCount":101},[],{"trials":18576,"activeCount":101},[],{"trials":18578,"activeCount":101},[],{"intervention":18580,"totalTrials":651,"cells":18581},"Pyrotinib with Capecitabine",{"EARLY_PHASE1":18582,"PHASE1":18584,"PHASE2":18586,"PHASE3":18601,"PHASE4":18603,"NA":18605},{"trials":18583,"activeCount":101},[],{"trials":18585,"activeCount":101},[],{"trials":18587,"activeCount":101},[18588],{"nctId":18589,"briefTitle":18590,"status":107,"phases":18591,"primaryCompletion":200,"completion":200,"start":18592,"enrollment":529,"conditions":18593,"interventions":18594},"NCT03805399","FUSCC Refractory TNBC Umbrella (FUTURE)",[89,90],"2018-10-18",[161],[18580,18595,18596,18597,18598,18599,18600],"AR inhibitor combined with everolimus","anti PD-1 with nab-paclitaxel","PARP inhibitor included therapy","BLIS with anti-VEGFR included therapy","MES with anti-VEGFR included therapy","mTOR inhibitor with nab-paclitaxel",{"trials":18602,"activeCount":101},[],{"trials":18604,"activeCount":101},[],{"trials":18606,"activeCount":101},[],{"intervention":18595,"totalTrials":651,"cells":18608},{"EARLY_PHASE1":18609,"PHASE1":18611,"PHASE2":18613,"PHASE3":18619,"PHASE4":18621,"NA":18623},{"trials":18610,"activeCount":101},[],{"trials":18612,"activeCount":101},[],{"trials":18614,"activeCount":101},[18615],{"nctId":18589,"briefTitle":18590,"status":107,"phases":18616,"primaryCompletion":200,"completion":200,"start":18592,"enrollment":529,"conditions":18617,"interventions":18618},[89,90],[161],[18580,18595,18596,18597,18598,18599,18600],{"trials":18620,"activeCount":101},[],{"trials":18622,"activeCount":101},[],{"trials":18624,"activeCount":101},[],{"intervention":18596,"totalTrials":651,"cells":18626},{"EARLY_PHASE1":18627,"PHASE1":18629,"PHASE2":18631,"PHASE3":18637,"PHASE4":18639,"NA":18641},{"trials":18628,"activeCount":101},[],{"trials":18630,"activeCount":101},[],{"trials":18632,"activeCount":101},[18633],{"nctId":18589,"briefTitle":18590,"status":107,"phases":18634,"primaryCompletion":200,"completion":200,"start":18592,"enrollment":529,"conditions":18635,"interventions":18636},[89,90],[161],[18580,18595,18596,18597,18598,18599,18600],{"trials":18638,"activeCount":101},[],{"trials":18640,"activeCount":101},[],{"trials":18642,"activeCount":101},[],{"intervention":18597,"totalTrials":651,"cells":18644},{"EARLY_PHASE1":18645,"PHASE1":18647,"PHASE2":18649,"PHASE3":18655,"PHASE4":18657,"NA":18659},{"trials":18646,"activeCount":101},[],{"trials":18648,"activeCount":101},[],{"trials":18650,"activeCount":101},[18651],{"nctId":18589,"briefTitle":18590,"status":107,"phases":18652,"primaryCompletion":200,"completion":200,"start":18592,"enrollment":529,"conditions":18653,"interventions":18654},[89,90],[161],[18580,18595,18596,18597,18598,18599,18600],{"trials":18656,"activeCount":101},[],{"trials":18658,"activeCount":101},[],{"trials":18660,"activeCount":101},[],{"intervention":18598,"totalTrials":651,"cells":18662},{"EARLY_PHASE1":18663,"PHASE1":18665,"PHASE2":18667,"PHASE3":18673,"PHASE4":18675,"NA":18677},{"trials":18664,"activeCount":101},[],{"trials":18666,"activeCount":101},[],{"trials":18668,"activeCount":101},[18669],{"nctId":18589,"briefTitle":18590,"status":107,"phases":18670,"primaryCompletion":200,"completion":200,"start":18592,"enrollment":529,"conditions":18671,"interventions":18672},[89,90],[161],[18580,18595,18596,18597,18598,18599,18600],{"trials":18674,"activeCount":101},[],{"trials":18676,"activeCount":101},[],{"trials":18678,"activeCount":101},[],{"intervention":18599,"totalTrials":651,"cells":18680},{"EARLY_PHASE1":18681,"PHASE1":18683,"PHASE2":18685,"PHASE3":18691,"PHASE4":18693,"NA":18695},{"trials":18682,"activeCount":101},[],{"trials":18684,"activeCount":101},[],{"trials":18686,"activeCount":101},[18687],{"nctId":18589,"briefTitle":18590,"status":107,"phases":18688,"primaryCompletion":200,"completion":200,"start":18592,"enrollment":529,"conditions":18689,"interventions":18690},[89,90],[161],[18580,18595,18596,18597,18598,18599,18600],{"trials":18692,"activeCount":101},[],{"trials":18694,"activeCount":101},[],{"trials":18696,"activeCount":101},[],{"intervention":18600,"totalTrials":651,"cells":18698},{"EARLY_PHASE1":18699,"PHASE1":18701,"PHASE2":18703,"PHASE3":18709,"PHASE4":18711,"NA":18713},{"trials":18700,"activeCount":101},[],{"trials":18702,"activeCount":101},[],{"trials":18704,"activeCount":101},[18705],{"nctId":18589,"briefTitle":18590,"status":107,"phases":18706,"primaryCompletion":200,"completion":200,"start":18592,"enrollment":529,"conditions":18707,"interventions":18708},[89,90],[161],[18580,18595,18596,18597,18598,18599,18600],{"trials":18710,"activeCount":101},[],{"trials":18712,"activeCount":101},[],{"trials":18714,"activeCount":101},[],{"intervention":18716,"totalTrials":651,"cells":18717},"Docetaxel, Cisplatin, 5-Fu",{"EARLY_PHASE1":18718,"PHASE1":18720,"PHASE2":18722,"PHASE3":18731,"PHASE4":18733,"NA":18735},{"trials":18719,"activeCount":101},[],{"trials":18721,"activeCount":101},[],{"trials":18723,"activeCount":101},[18724],{"nctId":18725,"briefTitle":18726,"status":494,"phases":18727,"primaryCompletion":3101,"completion":3101,"start":18728,"enrollment":737,"conditions":18729,"interventions":18730},"NCT00568971","Study of Weekly DCF to Treat Advanced Gastric Cancer",[90],"2007-04",[24],[18716],{"trials":18732,"activeCount":101},[],{"trials":18734,"activeCount":101},[],{"trials":18736,"activeCount":101},[],{"intervention":18738,"totalTrials":651,"cells":18739},"endostar and CHOP",{"EARLY_PHASE1":18740,"PHASE1":18742,"PHASE2":18744,"PHASE3":18754,"PHASE4":18756,"NA":18758},{"trials":18741,"activeCount":101},[],{"trials":18743,"activeCount":101},[],{"trials":18745,"activeCount":101},[18746],{"nctId":18747,"briefTitle":18748,"status":107,"phases":18749,"primaryCompletion":9407,"completion":18750,"start":16001,"enrollment":478,"conditions":18751,"interventions":18753},"NCT00974324","Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma",[90],"2011-09",[18752],"T Cell Lymphoma",[18738],{"trials":18755,"activeCount":101},[],{"trials":18757,"activeCount":101},[],{"trials":18759,"activeCount":101},[],{"intervention":18761,"totalTrials":651,"cells":18762},"UFT",{"EARLY_PHASE1":18763,"PHASE1":18765,"PHASE2":18767,"PHASE3":18776,"PHASE4":18778,"NA":18780},{"trials":18764,"activeCount":101},[],{"trials":18766,"activeCount":101},[],{"trials":18768,"activeCount":101},[18769],{"nctId":18770,"briefTitle":18771,"status":365,"phases":18772,"primaryCompletion":4020,"completion":18773,"start":16001,"enrollment":19,"conditions":18774,"interventions":18775},"NCT02903498","The Maintenance Treatment of UFT in Advanced Gastric Cancer",[90],"2016-09",[24],[18761],{"trials":18777,"activeCount":101},[],{"trials":18779,"activeCount":101},[],{"trials":18781,"activeCount":101},[],{"intervention":9289,"totalTrials":651,"cells":18783},{"EARLY_PHASE1":18784,"PHASE1":18786,"PHASE2":18788,"PHASE3":18794,"PHASE4":18796,"NA":18798},{"trials":18785,"activeCount":101},[],{"trials":18787,"activeCount":101},[],{"trials":18789,"activeCount":101},[18790],{"nctId":9283,"briefTitle":9284,"status":365,"phases":18791,"primaryCompletion":367,"completion":367,"start":9286,"enrollment":1499,"conditions":18792,"interventions":18793},[90],[161],[9289,9274],{"trials":18795,"activeCount":101},[],{"trials":18797,"activeCount":101},[],{"trials":18799,"activeCount":101},[],{"intervention":18801,"totalTrials":651,"cells":18802},"Pamiparib",{"EARLY_PHASE1":18803,"PHASE1":18805,"PHASE2":18807,"PHASE3":18815,"PHASE4":18817,"NA":18819},{"trials":18804,"activeCount":101},[],{"trials":18806,"activeCount":101},[],{"trials":18808,"activeCount":101},[18809],{"nctId":18810,"briefTitle":18811,"status":107,"phases":18812,"primaryCompletion":294,"completion":294,"start":6585,"enrollment":3866,"conditions":18813,"interventions":18814},"NCT05483543","Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy",[90],[3708],[18801],{"trials":18816,"activeCount":101},[],{"trials":18818,"activeCount":101},[],{"trials":18820,"activeCount":101},[],{"intervention":18822,"totalTrials":651,"cells":18823},"L-asp, DXM, IFO, VP-16, DDP",{"EARLY_PHASE1":18824,"PHASE1":18826,"PHASE2":18828,"PHASE3":18836,"PHASE4":18838,"NA":18840},{"trials":18825,"activeCount":101},[],{"trials":18827,"activeCount":101},[],{"trials":18829,"activeCount":101},[18830],{"nctId":18831,"briefTitle":18832,"status":107,"phases":18833,"primaryCompletion":17725,"completion":17725,"start":2500,"enrollment":690,"conditions":18834,"interventions":18835},"NCT00933673","New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK\u002FT-Cell Lymphoma",[90],[17208],[18822],{"trials":18837,"activeCount":101},[],{"trials":18839,"activeCount":101},[],{"trials":18841,"activeCount":101},[],{"intervention":18843,"totalTrials":651,"cells":18844},"Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab",{"EARLY_PHASE1":18845,"PHASE1":18847,"PHASE2":18849,"PHASE3":18859,"PHASE4":18861,"NA":18863},{"trials":18846,"activeCount":101},[],{"trials":18848,"activeCount":101},[],{"trials":18850,"activeCount":101},[18851],{"nctId":18852,"briefTitle":18853,"status":107,"phases":18854,"primaryCompletion":18855,"completion":18855,"start":1346,"enrollment":828,"conditions":18856,"interventions":18858},"NCT04984980","Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer",[90],"2023-07",[9529,18857],"Initially Unresectable",[18843],{"trials":18860,"activeCount":101},[],{"trials":18862,"activeCount":101},[],{"trials":18864,"activeCount":101},[],{"intervention":18866,"totalTrials":651,"cells":18867},"intraperitoneal docetaxel",{"EARLY_PHASE1":18868,"PHASE1":18870,"PHASE2":18872,"PHASE3":18883,"PHASE4":18885,"NA":18887},{"trials":18869,"activeCount":101},[],{"trials":18871,"activeCount":101},[],{"trials":18873,"activeCount":101},[18874],{"nctId":18875,"briefTitle":18876,"status":107,"phases":18877,"primaryCompletion":18878,"completion":18878,"start":18879,"enrollment":97,"conditions":18880,"interventions":18881},"NCT02779608","The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites",[90],"2018-06","2017-01-20",[577,1090],[18866,18882],"oral S-1",{"trials":18884,"activeCount":101},[],{"trials":18886,"activeCount":101},[],{"trials":18888,"activeCount":101},[],{"intervention":18882,"totalTrials":651,"cells":18890},{"EARLY_PHASE1":18891,"PHASE1":18893,"PHASE2":18895,"PHASE3":18901,"PHASE4":18903,"NA":18905},{"trials":18892,"activeCount":101},[],{"trials":18894,"activeCount":101},[],{"trials":18896,"activeCount":101},[18897],{"nctId":18875,"briefTitle":18876,"status":107,"phases":18898,"primaryCompletion":18878,"completion":18878,"start":18879,"enrollment":97,"conditions":18899,"interventions":18900},[90],[577,1090],[18866,18882],{"trials":18902,"activeCount":101},[],{"trials":18904,"activeCount":101},[],{"trials":18906,"activeCount":101},[],{"intervention":163,"totalTrials":651,"cells":18908},{"EARLY_PHASE1":18909,"PHASE1":18911,"PHASE2":18913,"PHASE3":18919,"PHASE4":18921,"NA":18923},{"trials":18910,"activeCount":101},[],{"trials":18912,"activeCount":101},[],{"trials":18914,"activeCount":101},[18915],{"nctId":153,"briefTitle":154,"status":107,"phases":18916,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":18917,"interventions":18918},[90],[161],[163,164,165,166],{"trials":18920,"activeCount":101},[],{"trials":18922,"activeCount":101},[],{"trials":18924,"activeCount":101},[],{"intervention":18926,"totalTrials":651,"cells":18927},"Dexrazoxane hydrochloride",{"EARLY_PHASE1":18928,"PHASE1":18930,"PHASE2":18932,"PHASE3":18940,"PHASE4":18942,"NA":18944},{"trials":18929,"activeCount":101},[],{"trials":18931,"activeCount":101},[],{"trials":18933,"activeCount":101},[18934],{"nctId":18935,"briefTitle":18936,"status":494,"phases":18937,"primaryCompletion":659,"completion":659,"start":2500,"enrollment":2394,"conditions":18938,"interventions":18939},"NCT00955890","Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer",[90],[15],[18926,18926],{"trials":18941,"activeCount":101},[],{"trials":18943,"activeCount":101},[],{"trials":18945,"activeCount":101},[],{"intervention":1921,"totalTrials":651,"cells":18947},{"EARLY_PHASE1":18948,"PHASE1":18950,"PHASE2":18952,"PHASE3":18958,"PHASE4":18960,"NA":18962},{"trials":18949,"activeCount":101},[],{"trials":18951,"activeCount":101},[],{"trials":18953,"activeCount":101},[18954],{"nctId":1915,"briefTitle":1916,"status":107,"phases":18955,"primaryCompletion":426,"completion":426,"start":1918,"enrollment":296,"conditions":18956,"interventions":18957},[90],[1419],[1921,255],{"trials":18959,"activeCount":101},[],{"trials":18961,"activeCount":101},[],{"trials":18963,"activeCount":101},[],{"intervention":18965,"totalTrials":651,"cells":18966},"chidamide combined with rituximab and high-dose methotrexate",{"EARLY_PHASE1":18967,"PHASE1":18969,"PHASE2":18971,"PHASE3":18980,"PHASE4":18982,"NA":18984},{"trials":18968,"activeCount":101},[],{"trials":18970,"activeCount":101},[],{"trials":18972,"activeCount":101},[18973],{"nctId":18974,"briefTitle":18975,"status":107,"phases":18976,"primaryCompletion":632,"completion":7854,"start":1683,"enrollment":11284,"conditions":18977,"interventions":18979},"NCT04516655","A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients",[90],[18978],"Central Nervous System Lymphoma",[18965],{"trials":18981,"activeCount":101},[],{"trials":18983,"activeCount":101},[],{"trials":18985,"activeCount":101},[],{"intervention":18987,"totalTrials":651,"cells":18988},"Rituximab combined with ESHAP",{"EARLY_PHASE1":18989,"PHASE1":18991,"PHASE2":18993,"PHASE3":19001,"PHASE4":19003,"NA":19005},{"trials":18990,"activeCount":101},[],{"trials":18992,"activeCount":101},[],{"trials":18994,"activeCount":101},[18995],{"nctId":18996,"briefTitle":18997,"status":365,"phases":18998,"primaryCompletion":1700,"completion":1700,"start":18728,"enrollment":6587,"conditions":18999,"interventions":19000},"NCT00568815","Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)",[90],[17208],[18987],{"trials":19002,"activeCount":101},[],{"trials":19004,"activeCount":101},[],{"trials":19006,"activeCount":101},[],{"intervention":9263,"totalTrials":651,"cells":19008},{"EARLY_PHASE1":19009,"PHASE1":19011,"PHASE2":19013,"PHASE3":19019,"PHASE4":19021,"NA":19023},{"trials":19010,"activeCount":101},[],{"trials":19012,"activeCount":101},[],{"trials":19014,"activeCount":101},[19015],{"nctId":9255,"briefTitle":9256,"status":107,"phases":19016,"primaryCompletion":1165,"completion":6204,"start":9258,"enrollment":345,"conditions":19017,"interventions":19018},[90],[8780],[9261,9262,9263,9264,2720,9265,9266],{"trials":19020,"activeCount":101},[],{"trials":19022,"activeCount":101},[],{"trials":19024,"activeCount":101},[],{"intervention":9264,"totalTrials":651,"cells":19026},{"EARLY_PHASE1":19027,"PHASE1":19029,"PHASE2":19031,"PHASE3":19037,"PHASE4":19039,"NA":19041},{"trials":19028,"activeCount":101},[],{"trials":19030,"activeCount":101},[],{"trials":19032,"activeCount":101},[19033],{"nctId":9255,"briefTitle":9256,"status":107,"phases":19034,"primaryCompletion":1165,"completion":6204,"start":9258,"enrollment":345,"conditions":19035,"interventions":19036},[90],[8780],[9261,9262,9263,9264,2720,9265,9266],{"trials":19038,"activeCount":101},[],{"trials":19040,"activeCount":101},[],{"trials":19042,"activeCount":101},[],{"intervention":9266,"totalTrials":651,"cells":19044},{"EARLY_PHASE1":19045,"PHASE1":19047,"PHASE2":19049,"PHASE3":19055,"PHASE4":19057,"NA":19059},{"trials":19046,"activeCount":101},[],{"trials":19048,"activeCount":101},[],{"trials":19050,"activeCount":101},[19051],{"nctId":9255,"briefTitle":9256,"status":107,"phases":19052,"primaryCompletion":1165,"completion":6204,"start":9258,"enrollment":345,"conditions":19053,"interventions":19054},[90],[8780],[9261,9262,9263,9264,2720,9265,9266],{"trials":19056,"activeCount":101},[],{"trials":19058,"activeCount":101},[],{"trials":19060,"activeCount":101},[],{"intervention":19062,"totalTrials":651,"cells":19063},"Hetrombopag",{"EARLY_PHASE1":19064,"PHASE1":19066,"PHASE2":19068,"PHASE3":19078,"PHASE4":19080,"NA":19082},{"trials":19065,"activeCount":101},[],{"trials":19067,"activeCount":101},[],{"trials":19069,"activeCount":101},[19070],{"nctId":19071,"briefTitle":19072,"status":107,"phases":19073,"primaryCompletion":354,"completion":1489,"start":19074,"enrollment":14452,"conditions":19075,"interventions":19077},"NCT05442632","Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy",[90],"2022-07-25",[19076],"Hepatopathy",[19062],{"trials":19079,"activeCount":101},[],{"trials":19081,"activeCount":101},[],{"trials":19083,"activeCount":101},[],{"intervention":19085,"totalTrials":651,"cells":19086},"Chidamide combined with R-GDP",{"EARLY_PHASE1":19087,"PHASE1":19089,"PHASE2":19091,"PHASE3":19111,"PHASE4":19113,"NA":19115},{"trials":19088,"activeCount":101},[],{"trials":19090,"activeCount":101},[],{"trials":19092,"activeCount":101},[19093],{"nctId":19094,"briefTitle":19095,"status":107,"phases":19096,"primaryCompletion":3180,"completion":631,"start":19097,"enrollment":5893,"conditions":19098,"interventions":19110},"NCT03373019","Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",[90],"2017-12-21",[19099,19100,19101,19102,582,19103,19104,19105,19106,19107,1385,19108,255,1764,2642,19109],"Chidamide","Lymphoma, B-Cell","Lymphoma, Large B-Cell, Diffuse","Neoplasm by Histology","Lymphoproliferative Disorders","Lymphatic Diseases","Immunoproliferative Disorders","Immune System Diseases","Lymphoma, Non-Hodgkin","Rituximab","HDAC Inhibitor",[19085],{"trials":19112,"activeCount":101},[],{"trials":19114,"activeCount":101},[],{"trials":19116,"activeCount":101},[],{"intervention":2504,"totalTrials":651,"cells":19118},{"EARLY_PHASE1":19119,"PHASE1":19121,"PHASE2":19123,"PHASE3":19129,"PHASE4":19131,"NA":19133},{"trials":19120,"activeCount":101},[],{"trials":19122,"activeCount":101},[],{"trials":19124,"activeCount":101},[19125],{"nctId":2496,"briefTitle":2497,"status":107,"phases":19126,"primaryCompletion":2499,"start":2500,"enrollment":25,"conditions":19127,"interventions":19128},[90],[2502],[2504,1092],{"trials":19130,"activeCount":101},[],{"trials":19132,"activeCount":101},[],{"trials":19134,"activeCount":101},[],{"intervention":9164,"totalTrials":651,"cells":19136},{"EARLY_PHASE1":19137,"PHASE1":19139,"PHASE2":19141,"PHASE3":19147,"PHASE4":19149,"NA":19151},{"trials":19138,"activeCount":101},[],{"trials":19140,"activeCount":101},[],{"trials":19142,"activeCount":101},[19143],{"nctId":9157,"briefTitle":9158,"status":107,"phases":19144,"primaryCompletion":7853,"completion":9160,"start":9161,"enrollment":1499,"conditions":19145,"interventions":19146},[90],[1419],[9164,1151],{"trials":19148,"activeCount":101},[],{"trials":19150,"activeCount":101},[],{"trials":19152,"activeCount":101},[],{"intervention":19154,"totalTrials":651,"cells":19155},"capecitabine plus oxaliplatin",{"EARLY_PHASE1":19156,"PHASE1":19158,"PHASE2":19160,"PHASE3":19169,"PHASE4":19171,"NA":19173},{"trials":19157,"activeCount":101},[],{"trials":19159,"activeCount":101},[],{"trials":19161,"activeCount":101},[19162],{"nctId":19163,"briefTitle":19164,"status":107,"phases":19165,"primaryCompletion":1877,"start":19166,"enrollment":1633,"conditions":19167,"interventions":19168},"NCT02415829","Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients",[90],"2014-11",[18],[19154],{"trials":19170,"activeCount":101},[],{"trials":19172,"activeCount":101},[],{"trials":19174,"activeCount":101},[],{"intervention":19176,"totalTrials":651,"cells":19177},"Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU",{"EARLY_PHASE1":19178,"PHASE1":19180,"PHASE2":19182,"PHASE3":19191,"PHASE4":19193,"NA":19195},{"trials":19179,"activeCount":101},[],{"trials":19181,"activeCount":101},[],{"trials":19183,"activeCount":101},[19184],{"nctId":19185,"briefTitle":19186,"status":107,"phases":19187,"primaryCompletion":1473,"completion":398,"start":19188,"enrollment":2804,"conditions":19189,"interventions":19190},"NCT05982301","Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer",[90],"2023-02-09",[24,3250,7976],[19176],{"trials":19192,"activeCount":101},[],{"trials":19194,"activeCount":101},[],{"trials":19196,"activeCount":101},[],{"intervention":5896,"totalTrials":651,"cells":19198},{"EARLY_PHASE1":19199,"PHASE1":19201,"PHASE2":19203,"PHASE3":19209,"PHASE4":19211,"NA":19213},{"trials":19200,"activeCount":101},[],{"trials":19202,"activeCount":101},[],{"trials":19204,"activeCount":101},[19205],{"nctId":5888,"briefTitle":5889,"status":107,"phases":19206,"primaryCompletion":1681,"completion":5891,"start":5892,"enrollment":5893,"conditions":19207,"interventions":19208},[90],[2109],[5896,278],{"trials":19210,"activeCount":101},[],{"trials":19212,"activeCount":101},[],{"trials":19214,"activeCount":101},[],{"intervention":19216,"totalTrials":651,"cells":19217},"Zanubrutinib + R-CHOP",{"EARLY_PHASE1":19218,"PHASE1":19220,"PHASE2":19222,"PHASE3":19232,"PHASE4":19234,"NA":19236},{"trials":19219,"activeCount":101},[],{"trials":19221,"activeCount":101},[],{"trials":19223,"activeCount":101},[19224],{"nctId":19225,"briefTitle":19226,"status":107,"phases":19227,"primaryCompletion":1473,"completion":724,"start":19228,"enrollment":5881,"conditions":19229,"interventions":19231},"NCT05189197","A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression",[90],"2022-01-18",[19230],"Diffuse Large B-cell Lymphoma(DLBCL)",[19216],{"trials":19233,"activeCount":101},[],{"trials":19235,"activeCount":101},[],{"trials":19237,"activeCount":101},[],{"intervention":19239,"totalTrials":651,"cells":19240},"Fruquintinib+ chemotherapy",{"EARLY_PHASE1":19241,"PHASE1":19243,"PHASE2":19245,"PHASE3":19255,"PHASE4":19257,"NA":19259},{"trials":19242,"activeCount":101},[],{"trials":19244,"activeCount":101},[],{"trials":19246,"activeCount":101},[19247],{"nctId":19248,"briefTitle":19249,"status":107,"phases":19250,"primaryCompletion":726,"completion":726,"start":19251,"enrollment":379,"conditions":19252,"interventions":19253},"NCT05555901","The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer",[90],"2023-06-18",[6157],[19239,19254],"Bevacizumab+ chemotherapy",{"trials":19256,"activeCount":101},[],{"trials":19258,"activeCount":101},[],{"trials":19260,"activeCount":101},[],{"intervention":19254,"totalTrials":651,"cells":19262},{"EARLY_PHASE1":19263,"PHASE1":19265,"PHASE2":19267,"PHASE3":19273,"PHASE4":19275,"NA":19277},{"trials":19264,"activeCount":101},[],{"trials":19266,"activeCount":101},[],{"trials":19268,"activeCount":101},[19269],{"nctId":19248,"briefTitle":19249,"status":107,"phases":19270,"primaryCompletion":726,"completion":726,"start":19251,"enrollment":379,"conditions":19271,"interventions":19272},[90],[6157],[19239,19254],{"trials":19274,"activeCount":101},[],{"trials":19276,"activeCount":101},[],{"trials":19278,"activeCount":101},[],{"intervention":19280,"totalTrials":651,"cells":19281},"envafolimab and lenvatinib combined with paclitaxel-albumin",{"EARLY_PHASE1":19282,"PHASE1":19284,"PHASE2":19286,"PHASE3":19295,"PHASE4":19297,"NA":19299},{"trials":19283,"activeCount":101},[],{"trials":19285,"activeCount":101},[],{"trials":19287,"activeCount":101},[19288],{"nctId":19289,"briefTitle":19290,"status":107,"phases":19291,"primaryCompletion":306,"completion":1530,"start":19292,"enrollment":25,"conditions":19293,"interventions":19294},"NCT06030934","Study of The Second-line Treatment of Advanced Gastric \u002F Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin",[90],"2022-10-24",[11463],[19280],{"trials":19296,"activeCount":101},[],{"trials":19298,"activeCount":101},[],{"trials":19300,"activeCount":101},[],{"intervention":19302,"totalTrials":651,"cells":19303},"Abraxane and Gemcitabine",{"EARLY_PHASE1":19304,"PHASE1":19306,"PHASE2":19308,"PHASE3":19317,"PHASE4":19319,"NA":19321},{"trials":19305,"activeCount":101},[],{"trials":19307,"activeCount":101},[],{"trials":19309,"activeCount":101},[19310],{"nctId":19311,"briefTitle":19312,"status":365,"phases":19313,"primaryCompletion":19314,"completion":211,"start":497,"enrollment":10553,"conditions":19315,"interventions":19316},"NCT01550848","A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer",[90],"2014-07",[33],[19302],{"trials":19318,"activeCount":101},[],{"trials":19320,"activeCount":101},[],{"trials":19322,"activeCount":101},[],{"intervention":19324,"totalTrials":651,"cells":19325},"multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody",{"EARLY_PHASE1":19326,"PHASE1":19328,"PHASE2":19330,"PHASE3":19340,"PHASE4":19342,"NA":19344},{"trials":19327,"activeCount":101},[],{"trials":19329,"activeCount":101},[],{"trials":19331,"activeCount":101},[19332],{"nctId":19333,"briefTitle":19334,"status":365,"phases":19335,"primaryCompletion":294,"completion":294,"start":19336,"enrollment":19337,"conditions":19338,"interventions":19339},"NCT04521348","Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer",[90],"2019-12-30",103,[6616],[19324],{"trials":19341,"activeCount":101},[],{"trials":19343,"activeCount":101},[],{"trials":19345,"activeCount":101},[],{"intervention":19347,"totalTrials":651,"cells":19348},"Lenalidomide combined with R-CHOP",{"EARLY_PHASE1":19349,"PHASE1":19351,"PHASE2":19353,"PHASE3":19365,"PHASE4":19367,"NA":19369},{"trials":19350,"activeCount":101},[],{"trials":19352,"activeCount":101},[],{"trials":19354,"activeCount":101},[19355],{"nctId":19356,"briefTitle":19357,"status":365,"phases":19358,"primaryCompletion":19359,"completion":7854,"start":19360,"enrollment":19361,"conditions":19362,"interventions":19364},"NCT04164368","Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients",[90],"2021-08-09","2019-10-22",67,[19363],"Double Expressor Lymphoma",[19347],{"trials":19366,"activeCount":101},[],{"trials":19368,"activeCount":101},[],{"trials":19370,"activeCount":101},[],{"intervention":18354,"totalTrials":651,"cells":19372},{"EARLY_PHASE1":19373,"PHASE1":19375,"PHASE2":19377,"PHASE3":19383,"PHASE4":19385,"NA":19387},{"trials":19374,"activeCount":101},[],{"trials":19376,"activeCount":101},[],{"trials":19378,"activeCount":101},[19379],{"nctId":18348,"briefTitle":18349,"status":107,"phases":19380,"primaryCompletion":389,"completion":1204,"start":18351,"enrollment":213,"conditions":19381,"interventions":19382},[90],[18],[18354,1482],{"trials":19384,"activeCount":101},[],{"trials":19386,"activeCount":101},[],{"trials":19388,"activeCount":101},[],{"intervention":19390,"totalTrials":651,"cells":19391},"A1: Pyrotinib with nab-paclitaxel",{"EARLY_PHASE1":19392,"PHASE1":19394,"PHASE2":19396,"PHASE3":19414,"PHASE4":19416,"NA":19418},{"trials":19393,"activeCount":101},[],{"trials":19395,"activeCount":101},[],{"trials":19397,"activeCount":101},[19398],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19401,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19403,"interventions":19404},"NCT04395989","An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.",[90],"2020-07-28",[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],"A2: nab-paclitaxel","B1: everolimus with nab-paclitaxel","B2: nab-paclitaxel","C1: PD-1 with nab-paclitaxel and famitinib","C2: nab-paclitaxel","D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine","D2: nab-paclitaxel, with maintenance of capecitabine","E1: everolimus with nab-paclitaxel","E2: nab-paclitaxel",{"trials":19415,"activeCount":101},[],{"trials":19417,"activeCount":101},[],{"trials":19419,"activeCount":101},[],{"intervention":19405,"totalTrials":651,"cells":19421},{"EARLY_PHASE1":19422,"PHASE1":19424,"PHASE2":19426,"PHASE3":19432,"PHASE4":19434,"NA":19436},{"trials":19423,"activeCount":101},[],{"trials":19425,"activeCount":101},[],{"trials":19427,"activeCount":101},[19428],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19429,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19430,"interventions":19431},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19433,"activeCount":101},[],{"trials":19435,"activeCount":101},[],{"trials":19437,"activeCount":101},[],{"intervention":19406,"totalTrials":651,"cells":19439},{"EARLY_PHASE1":19440,"PHASE1":19442,"PHASE2":19444,"PHASE3":19450,"PHASE4":19452,"NA":19454},{"trials":19441,"activeCount":101},[],{"trials":19443,"activeCount":101},[],{"trials":19445,"activeCount":101},[19446],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19447,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19448,"interventions":19449},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19451,"activeCount":101},[],{"trials":19453,"activeCount":101},[],{"trials":19455,"activeCount":101},[],{"intervention":19407,"totalTrials":651,"cells":19457},{"EARLY_PHASE1":19458,"PHASE1":19460,"PHASE2":19462,"PHASE3":19468,"PHASE4":19470,"NA":19472},{"trials":19459,"activeCount":101},[],{"trials":19461,"activeCount":101},[],{"trials":19463,"activeCount":101},[19464],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19465,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19466,"interventions":19467},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19469,"activeCount":101},[],{"trials":19471,"activeCount":101},[],{"trials":19473,"activeCount":101},[],{"intervention":19408,"totalTrials":651,"cells":19475},{"EARLY_PHASE1":19476,"PHASE1":19478,"PHASE2":19480,"PHASE3":19486,"PHASE4":19488,"NA":19490},{"trials":19477,"activeCount":101},[],{"trials":19479,"activeCount":101},[],{"trials":19481,"activeCount":101},[19482],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19483,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19484,"interventions":19485},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19487,"activeCount":101},[],{"trials":19489,"activeCount":101},[],{"trials":19491,"activeCount":101},[],{"intervention":19409,"totalTrials":651,"cells":19493},{"EARLY_PHASE1":19494,"PHASE1":19496,"PHASE2":19498,"PHASE3":19504,"PHASE4":19506,"NA":19508},{"trials":19495,"activeCount":101},[],{"trials":19497,"activeCount":101},[],{"trials":19499,"activeCount":101},[19500],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19501,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19502,"interventions":19503},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19505,"activeCount":101},[],{"trials":19507,"activeCount":101},[],{"trials":19509,"activeCount":101},[],{"intervention":19410,"totalTrials":651,"cells":19511},{"EARLY_PHASE1":19512,"PHASE1":19514,"PHASE2":19516,"PHASE3":19522,"PHASE4":19524,"NA":19526},{"trials":19513,"activeCount":101},[],{"trials":19515,"activeCount":101},[],{"trials":19517,"activeCount":101},[19518],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19519,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19520,"interventions":19521},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19523,"activeCount":101},[],{"trials":19525,"activeCount":101},[],{"trials":19527,"activeCount":101},[],{"intervention":19411,"totalTrials":651,"cells":19529},{"EARLY_PHASE1":19530,"PHASE1":19532,"PHASE2":19534,"PHASE3":19540,"PHASE4":19542,"NA":19544},{"trials":19531,"activeCount":101},[],{"trials":19533,"activeCount":101},[],{"trials":19535,"activeCount":101},[19536],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19537,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19538,"interventions":19539},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19541,"activeCount":101},[],{"trials":19543,"activeCount":101},[],{"trials":19545,"activeCount":101},[],{"intervention":19412,"totalTrials":651,"cells":19547},{"EARLY_PHASE1":19548,"PHASE1":19550,"PHASE2":19552,"PHASE3":19558,"PHASE4":19560,"NA":19562},{"trials":19549,"activeCount":101},[],{"trials":19551,"activeCount":101},[],{"trials":19553,"activeCount":101},[19554],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19555,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19556,"interventions":19557},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19559,"activeCount":101},[],{"trials":19561,"activeCount":101},[],{"trials":19563,"activeCount":101},[],{"intervention":19413,"totalTrials":651,"cells":19565},{"EARLY_PHASE1":19566,"PHASE1":19568,"PHASE2":19570,"PHASE3":19576,"PHASE4":19578,"NA":19580},{"trials":19567,"activeCount":101},[],{"trials":19569,"activeCount":101},[],{"trials":19571,"activeCount":101},[19572],{"nctId":19399,"briefTitle":19400,"status":107,"phases":19573,"primaryCompletion":18570,"completion":294,"start":19402,"enrollment":8312,"conditions":19574,"interventions":19575},[90],[2408],[19390,19405,19406,19407,19408,19409,19410,19411,19412,19413],{"trials":19577,"activeCount":101},[],{"trials":19579,"activeCount":101},[],{"trials":19581,"activeCount":101},[],{"intervention":19583,"totalTrials":651,"cells":19584},"Anti-EGFR monoclonal antibody",{"EARLY_PHASE1":19585,"PHASE1":19587,"PHASE2":19589,"PHASE3":19598,"PHASE4":19600,"NA":19602},{"trials":19586,"activeCount":101},[],{"trials":19588,"activeCount":101},[],{"trials":19590,"activeCount":101},[19591],{"nctId":19592,"briefTitle":19593,"status":107,"phases":19594,"primaryCompletion":1724,"completion":1724,"start":7493,"enrollment":473,"conditions":19595,"interventions":19597},"NCT04508829","Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy",[90],[19596],"Oropharyngeal Carcinoma",[19583],{"trials":19599,"activeCount":101},[],{"trials":19601,"activeCount":101},[],{"trials":19603,"activeCount":101},[],{"intervention":194,"totalTrials":651,"cells":19605},{"EARLY_PHASE1":19606,"PHASE1":19608,"PHASE2":19610,"PHASE3":19616,"PHASE4":19618,"NA":19620},{"trials":19607,"activeCount":101},[],{"trials":19609,"activeCount":101},[],{"trials":19611,"activeCount":101},[19612],{"nctId":185,"briefTitle":186,"status":107,"phases":19613,"primaryCompletion":188,"completion":189,"start":190,"enrollment":25,"conditions":19614,"interventions":19615},[89,90],[192],[96,194],{"trials":19617,"activeCount":101},[],{"trials":19619,"activeCount":101},[],{"trials":19621,"activeCount":101},[],{"intervention":19623,"totalTrials":651,"cells":19624},"Trastuzumab QW, Trastuzumab Q3W",{"EARLY_PHASE1":19625,"PHASE1":19627,"PHASE2":19629,"PHASE3":19637,"PHASE4":19639,"NA":19641},{"trials":19626,"activeCount":101},[],{"trials":19628,"activeCount":101},[],{"trials":19630,"activeCount":101},[19631],{"nctId":19632,"briefTitle":19633,"status":107,"phases":19634,"primaryCompletion":1204,"completion":1204,"start":16001,"enrollment":111,"conditions":19635,"interventions":19636},"NCT01170143","Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer",[90],[15],[19623],{"trials":19638,"activeCount":101},[],{"trials":19640,"activeCount":101},[],{"trials":19642,"activeCount":101},[],{"intervention":19644,"totalTrials":651,"cells":19645},"nab-paclitaxel plus cisplatin plus carilizumab",{"EARLY_PHASE1":19646,"PHASE1":19648,"PHASE2":19650,"PHASE3":19660,"PHASE4":19662,"NA":19664},{"trials":19647,"activeCount":101},[],{"trials":19649,"activeCount":101},[],{"trials":19651,"activeCount":101},[19652],{"nctId":19653,"briefTitle":19654,"status":107,"phases":19655,"primaryCompletion":19656,"completion":2364,"start":19657,"enrollment":8340,"conditions":19658,"interventions":19659},"NCT04537286","First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients",[90],"2024-09-15","2020-08-25",[15],[19644],{"trials":19661,"activeCount":101},[],{"trials":19663,"activeCount":101},[],{"trials":19665,"activeCount":101},[],{"intervention":19667,"totalTrials":651,"cells":19668},"FAD",{"EARLY_PHASE1":19669,"PHASE1":19671,"PHASE2":19673,"PHASE3":19682,"PHASE4":19684,"NA":19686},{"trials":19670,"activeCount":101},[],{"trials":19672,"activeCount":101},[],{"trials":19674,"activeCount":101},[19675],{"nctId":19676,"briefTitle":19677,"status":107,"phases":19678,"primaryCompletion":8679,"completion":8679,"start":563,"enrollment":25,"conditions":19679,"interventions":19681},"NCT00840385","Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)",[90],[19680,310],"T-Cell Lymphomas",[19667],{"trials":19683,"activeCount":101},[],{"trials":19685,"activeCount":101},[],{"trials":19687,"activeCount":101},[],{"intervention":19689,"totalTrials":651,"cells":19690},"Parsaclisib",{"EARLY_PHASE1":19691,"PHASE1":19693,"PHASE2":19695,"PHASE3":19708,"PHASE4":19710,"NA":19712},{"trials":19692,"activeCount":101},[],{"trials":19694,"activeCount":101},[],{"trials":19696,"activeCount":101},[19697],{"nctId":19698,"briefTitle":19699,"status":107,"phases":19700,"primaryCompletion":19701,"completion":398,"start":19702,"enrollment":25,"conditions":19703,"interventions":19707},"NCT05238064","Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL",[89,90],"2025-03","2022-03",[19704,19689,19705,19706],"PI3Kδ Inhibitor","CHOP","PTCL",[19689,19705],{"trials":19709,"activeCount":101},[],{"trials":19711,"activeCount":101},[],{"trials":19713,"activeCount":101},[],{"intervention":19705,"totalTrials":651,"cells":19715},{"EARLY_PHASE1":19716,"PHASE1":19718,"PHASE2":19720,"PHASE3":19726,"PHASE4":19728,"NA":19730},{"trials":19717,"activeCount":101},[],{"trials":19719,"activeCount":101},[],{"trials":19721,"activeCount":101},[19722],{"nctId":19698,"briefTitle":19699,"status":107,"phases":19723,"primaryCompletion":19701,"completion":398,"start":19702,"enrollment":25,"conditions":19724,"interventions":19725},[89,90],[19704,19689,19705,19706],[19689,19705],{"trials":19727,"activeCount":101},[],{"trials":19729,"activeCount":101},[],{"trials":19731,"activeCount":101},[],{"intervention":1943,"totalTrials":651,"cells":19733},{"EARLY_PHASE1":19734,"PHASE1":19736,"PHASE2":19738,"PHASE3":19744,"PHASE4":19746,"NA":19748},{"trials":19735,"activeCount":101},[],{"trials":19737,"activeCount":101},[],{"trials":19739,"activeCount":101},[19740],{"nctId":1933,"briefTitle":1934,"status":107,"phases":19741,"primaryCompletion":1936,"completion":1279,"start":964,"enrollment":1290,"conditions":19742,"interventions":19743},[90],[1938,1939,1940,1941],[1297,255,1943],{"trials":19745,"activeCount":101},[],{"trials":19747,"activeCount":101},[],{"trials":19749,"activeCount":101},[],{"intervention":205,"totalTrials":651,"cells":19751},{"EARLY_PHASE1":19752,"PHASE1":19754,"PHASE2":19756,"PHASE3":19762,"PHASE4":19764,"NA":19766},{"trials":19753,"activeCount":101},[],{"trials":19755,"activeCount":101},[],{"trials":19757,"activeCount":101},[19758],{"nctId":196,"briefTitle":197,"status":107,"phases":19759,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":19760,"interventions":19761},[90],[139],[205,96,115],{"trials":19763,"activeCount":101},[],{"trials":19765,"activeCount":101},[],{"trials":19767,"activeCount":101},[],{"intervention":16448,"totalTrials":651,"cells":19769},{"EARLY_PHASE1":19770,"PHASE1":19772,"PHASE2":19774,"PHASE3":19780,"PHASE4":19782,"NA":19784},{"trials":19771,"activeCount":101},[],{"trials":19773,"activeCount":101},[],{"trials":19775,"activeCount":101},[19776],{"nctId":16441,"briefTitle":16442,"status":107,"phases":19777,"primaryCompletion":1204,"completion":6786,"start":658,"enrollment":6670,"conditions":19778,"interventions":19779},[90],[16445,16446],[16448,16432],{"trials":19781,"activeCount":101},[],{"trials":19783,"activeCount":101},[],{"trials":19785,"activeCount":101},[],{"intervention":19787,"totalTrials":651,"cells":19788},"vinorelbine plus oxaliplatin",{"EARLY_PHASE1":19789,"PHASE1":19791,"PHASE2":19793,"PHASE3":19801,"PHASE4":19803,"NA":19805},{"trials":19790,"activeCount":101},[],{"trials":19792,"activeCount":101},[],{"trials":19794,"activeCount":101},[19795],{"nctId":19796,"briefTitle":19797,"status":107,"phases":19798,"primaryCompletion":2509,"completion":2509,"start":2499,"enrollment":6346,"conditions":19799,"interventions":19800},"NCT01528826","Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial",[90],[15],[19787],{"trials":19802,"activeCount":101},[],{"trials":19804,"activeCount":101},[],{"trials":19806,"activeCount":101},[],{"intervention":216,"totalTrials":651,"cells":19808},{"EARLY_PHASE1":19809,"PHASE1":19811,"PHASE2":19813,"PHASE3":19819,"PHASE4":19821,"NA":19823},{"trials":19810,"activeCount":101},[],{"trials":19812,"activeCount":101},[],{"trials":19814,"activeCount":101},[19815],{"nctId":207,"briefTitle":208,"status":107,"phases":19816,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":19817,"interventions":19818},[90],[15],[96,216],{"trials":19820,"activeCount":101},[],{"trials":19822,"activeCount":101},[],{"trials":19824,"activeCount":101},[],{"intervention":19826,"totalTrials":651,"cells":19827},"Famitinib Malate",{"EARLY_PHASE1":19828,"PHASE1":19830,"PHASE2":19832,"PHASE3":19841,"PHASE4":19843,"NA":19845},{"trials":19829,"activeCount":101},[],{"trials":19831,"activeCount":101},[],{"trials":19833,"activeCount":101},[19834],{"nctId":19835,"briefTitle":19836,"status":365,"phases":19837,"primaryCompletion":19838,"completion":19838,"start":18351,"enrollment":28,"conditions":19839,"interventions":19840},"NCT01653574","A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer",[90],"2013-11",[1882],[19826],{"trials":19842,"activeCount":101},[],{"trials":19844,"activeCount":101},[],{"trials":19846,"activeCount":101},[],{"intervention":19848,"totalTrials":651,"cells":19849},"GQ1001+pyrotinib",{"EARLY_PHASE1":19850,"PHASE1":19852,"PHASE2":19854,"PHASE3":19865,"PHASE4":19867,"NA":19869},{"trials":19851,"activeCount":101},[],{"trials":19853,"activeCount":101},[],{"trials":19855,"activeCount":101},[19856],{"nctId":19857,"briefTitle":19858,"status":107,"phases":19859,"primaryCompletion":367,"completion":367,"start":6392,"enrollment":19860,"conditions":19861,"interventions":19863},"NCT05575804","GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer",[89,90],75,[19862],"Advanced\u002F Metastatic Her-2 Positive Breast Cancer",[19848,19864],"pyrotinib+capecitabine",{"trials":19866,"activeCount":101},[],{"trials":19868,"activeCount":101},[],{"trials":19870,"activeCount":101},[],{"intervention":19864,"totalTrials":651,"cells":19872},{"EARLY_PHASE1":19873,"PHASE1":19875,"PHASE2":19877,"PHASE3":19883,"PHASE4":19885,"NA":19887},{"trials":19874,"activeCount":101},[],{"trials":19876,"activeCount":101},[],{"trials":19878,"activeCount":101},[19879],{"nctId":19857,"briefTitle":19858,"status":107,"phases":19880,"primaryCompletion":367,"completion":367,"start":6392,"enrollment":19860,"conditions":19881,"interventions":19882},[89,90],[19862],[19848,19864],{"trials":19884,"activeCount":101},[],{"trials":19886,"activeCount":101},[],{"trials":19888,"activeCount":101},[],{"intervention":19890,"totalTrials":651,"cells":19891},"3rd generation EGFR-TKI",{"EARLY_PHASE1":19892,"PHASE1":19894,"PHASE2":19896,"PHASE3":19905,"PHASE4":19907,"NA":19909},{"trials":19893,"activeCount":101},[],{"trials":19895,"activeCount":101},[],{"trials":19897,"activeCount":101},[19898],{"nctId":19899,"briefTitle":19900,"status":365,"phases":19901,"primaryCompletion":7739,"completion":6645,"start":631,"enrollment":6576,"conditions":19902,"interventions":19904},"NCT04764214","SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs",[90],[2109,19903],"EGFR Activating Mutation",[19890],{"trials":19906,"activeCount":101},[],{"trials":19908,"activeCount":101},[],{"trials":19910,"activeCount":101},[],{"intervention":19912,"totalTrials":651,"cells":19913},"Camrelizumab and Apatinib",{"EARLY_PHASE1":19914,"PHASE1":19916,"PHASE2":19918,"PHASE3":19926,"PHASE4":19928,"NA":19930},{"trials":19915,"activeCount":101},[],{"trials":19917,"activeCount":101},[],{"trials":19919,"activeCount":101},[19920],{"nctId":19921,"briefTitle":19922,"status":107,"phases":19923,"primaryCompletion":200,"completion":293,"start":9527,"enrollment":6587,"conditions":19924,"interventions":19925},"NCT04612894","Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer",[90],[6616],[19912],{"trials":19927,"activeCount":101},[],{"trials":19929,"activeCount":101},[],{"trials":19931,"activeCount":101},[],{"intervention":19933,"totalTrials":651,"cells":19934},"intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel",{"EARLY_PHASE1":19935,"PHASE1":19937,"PHASE2":19939,"PHASE3":19952,"PHASE4":19954,"NA":19956},{"trials":19936,"activeCount":101},[],{"trials":19938,"activeCount":101},[],{"trials":19940,"activeCount":101},[19941],{"nctId":19942,"briefTitle":19943,"status":365,"phases":19944,"primaryCompletion":19945,"completion":19946,"start":19947,"enrollment":19948,"conditions":19949,"interventions":19951},"NCT05222204","DDP ip Combined With AG in PDAC With Peritoneal Metastasis",[90],"2024-07-08","2024-12-12","2022-05-15",91,[19950],"Pancreatic Neoplasm",[19933],{"trials":19953,"activeCount":101},[],{"trials":19955,"activeCount":101},[],{"trials":19957,"activeCount":101},[],{"intervention":19959,"totalTrials":651,"cells":19960},"Disitamab Vedotin combined with fruquintinib and Tislelizumab",{"EARLY_PHASE1":19961,"PHASE1":19963,"PHASE2":19965,"PHASE3":19976,"PHASE4":19978,"NA":19980},{"trials":19962,"activeCount":101},[],{"trials":19964,"activeCount":101},[],{"trials":19966,"activeCount":101},[19967],{"nctId":19968,"briefTitle":19969,"status":107,"phases":19970,"primaryCompletion":19971,"completion":398,"start":19972,"enrollment":6606,"conditions":19973,"interventions":19975},"NCT05982834","Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC",[89,90],"2025-05","2023-05-09",[19974,1218],"HER2-positive Gastric Cancer",[19959],{"trials":19977,"activeCount":101},[],{"trials":19979,"activeCount":101},[],{"trials":19981,"activeCount":101},[],{"intervention":19983,"totalTrials":651,"cells":19984},"EOF5",{"EARLY_PHASE1":19985,"PHASE1":19987,"PHASE2":19989,"PHASE3":19999,"PHASE4":20001,"NA":20003},{"trials":19986,"activeCount":101},[],{"trials":19988,"activeCount":101},[],{"trials":19990,"activeCount":101},[19991],{"nctId":19992,"briefTitle":19993,"status":365,"phases":19994,"primaryCompletion":562,"completion":7692,"start":19995,"enrollment":19996,"conditions":19997,"interventions":19998},"NCT00767377","Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A\u002FMGC",[90],"2007-05",163,[24],[19983],{"trials":20000,"activeCount":101},[],{"trials":20002,"activeCount":101},[],{"trials":20004,"activeCount":101},[],{"intervention":20006,"totalTrials":651,"cells":20007},"cisplatin, Fluorouracil",{"EARLY_PHASE1":20008,"PHASE1":20010,"PHASE2":20012,"PHASE3":20021,"PHASE4":20023,"NA":20025},{"trials":20009,"activeCount":101},[],{"trials":20011,"activeCount":101},[],{"trials":20013,"activeCount":101},[20014],{"nctId":20015,"briefTitle":20016,"status":107,"phases":20017,"primaryCompletion":15813,"completion":2499,"start":16001,"enrollment":9599,"conditions":20018,"interventions":20020},"NCT00992199","Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer",[90],[20019],"Advanced Gastric Cancer",[20006],{"trials":20022,"activeCount":101},[],{"trials":20024,"activeCount":101},[],{"trials":20026,"activeCount":101},[],{"intervention":2512,"totalTrials":651,"cells":20028},{"EARLY_PHASE1":20029,"PHASE1":20031,"PHASE2":20033,"PHASE3":20039,"PHASE4":20041,"NA":20043},{"trials":20030,"activeCount":101},[],{"trials":20032,"activeCount":101},[],{"trials":20034,"activeCount":101},[20035],{"nctId":2506,"briefTitle":2507,"status":107,"phases":20036,"primaryCompletion":2509,"completion":2509,"start":2499,"enrollment":111,"conditions":20037,"interventions":20038},[90],[15],[2512,1092],{"trials":20040,"activeCount":101},[],{"trials":20042,"activeCount":101},[],{"trials":20044,"activeCount":101},[],{"intervention":20046,"totalTrials":651,"cells":20047},"FOLFOX6",{"EARLY_PHASE1":20048,"PHASE1":20050,"PHASE2":20052,"PHASE3":20060,"PHASE4":20062,"NA":20064},{"trials":20049,"activeCount":101},[],{"trials":20051,"activeCount":101},[],{"trials":20053,"activeCount":101},[20054],{"nctId":20055,"briefTitle":20056,"status":365,"phases":20057,"primaryCompletion":497,"completion":497,"start":16890,"enrollment":111,"conditions":20058,"interventions":20059},"NCT01605305","Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer",[90],[27],[20046],{"trials":20061,"activeCount":101},[],{"trials":20063,"activeCount":101},[],{"trials":20065,"activeCount":101},[],{"intervention":7257,"totalTrials":651,"cells":20067},{"EARLY_PHASE1":20068,"PHASE1":20070,"PHASE2":20072,"PHASE3":20078,"PHASE4":20080,"NA":20082},{"trials":20069,"activeCount":101},[],{"trials":20071,"activeCount":101},[],{"trials":20073,"activeCount":101},[20074],{"nctId":7252,"briefTitle":7253,"status":3025,"phases":20075,"primaryCompletion":1760,"completion":6668,"start":2324,"enrollment":101,"conditions":20076,"interventions":20077},[90],[3946],[7257,1536,52],{"trials":20079,"activeCount":101},[],{"trials":20081,"activeCount":101},[],{"trials":20083,"activeCount":101},[],{"intervention":20085,"totalTrials":651,"cells":20086},"Radiotherapy Combined With Raltitrexed and Irinotecan",{"EARLY_PHASE1":20087,"PHASE1":20089,"PHASE2":20091,"PHASE3":20100,"PHASE4":20102,"NA":20104},{"trials":20088,"activeCount":101},[],{"trials":20090,"activeCount":101},[],{"trials":20092,"activeCount":101},[20093],{"nctId":20094,"briefTitle":20095,"status":107,"phases":20096,"primaryCompletion":1346,"completion":9527,"start":4167,"enrollment":25,"conditions":20097,"interventions":20099},"NCT04499586","A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer",[90],[20098],"Recurrent Colorectal Cancer",[20085],{"trials":20101,"activeCount":101},[],{"trials":20103,"activeCount":101},[],{"trials":20105,"activeCount":101},[],{"intervention":20107,"totalTrials":651,"cells":20108},"A1:SG with SHR3680",{"EARLY_PHASE1":20109,"PHASE1":20111,"PHASE2":20113,"PHASE3":20129,"PHASE4":20131,"NA":20133},{"trials":20110,"activeCount":101},[],{"trials":20112,"activeCount":101},[],{"trials":20114,"activeCount":101},[20115],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20118,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20120,"interventions":20121},"NCT05928780","An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)",[89,90],125,[2408],[20107,20122,20123,20124,20125,20126,20127,20128],"A2:SG","B1:SG with SHR1210","B2:SG","C1:SG with SHR3162","C2:SG","D1:SG with VEGFRI","D2:SG",{"trials":20130,"activeCount":101},[],{"trials":20132,"activeCount":101},[],{"trials":20134,"activeCount":101},[],{"intervention":20122,"totalTrials":651,"cells":20136},{"EARLY_PHASE1":20137,"PHASE1":20139,"PHASE2":20141,"PHASE3":20147,"PHASE4":20149,"NA":20151},{"trials":20138,"activeCount":101},[],{"trials":20140,"activeCount":101},[],{"trials":20142,"activeCount":101},[20143],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20144,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20145,"interventions":20146},[89,90],[2408],[20107,20122,20123,20124,20125,20126,20127,20128],{"trials":20148,"activeCount":101},[],{"trials":20150,"activeCount":101},[],{"trials":20152,"activeCount":101},[],{"intervention":20123,"totalTrials":651,"cells":20154},{"EARLY_PHASE1":20155,"PHASE1":20157,"PHASE2":20159,"PHASE3":20165,"PHASE4":20167,"NA":20169},{"trials":20156,"activeCount":101},[],{"trials":20158,"activeCount":101},[],{"trials":20160,"activeCount":101},[20161],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20162,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20163,"interventions":20164},[89,90],[2408],[20107,20122,20123,20124,20125,20126,20127,20128],{"trials":20166,"activeCount":101},[],{"trials":20168,"activeCount":101},[],{"trials":20170,"activeCount":101},[],{"intervention":20124,"totalTrials":651,"cells":20172},{"EARLY_PHASE1":20173,"PHASE1":20175,"PHASE2":20177,"PHASE3":20183,"PHASE4":20185,"NA":20187},{"trials":20174,"activeCount":101},[],{"trials":20176,"activeCount":101},[],{"trials":20178,"activeCount":101},[20179],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20180,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20181,"interventions":20182},[89,90],[2408],[20107,20122,20123,20124,20125,20126,20127,20128],{"trials":20184,"activeCount":101},[],{"trials":20186,"activeCount":101},[],{"trials":20188,"activeCount":101},[],{"intervention":20125,"totalTrials":651,"cells":20190},{"EARLY_PHASE1":20191,"PHASE1":20193,"PHASE2":20195,"PHASE3":20201,"PHASE4":20203,"NA":20205},{"trials":20192,"activeCount":101},[],{"trials":20194,"activeCount":101},[],{"trials":20196,"activeCount":101},[20197],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20198,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20199,"interventions":20200},[89,90],[2408],[20107,20122,20123,20124,20125,20126,20127,20128],{"trials":20202,"activeCount":101},[],{"trials":20204,"activeCount":101},[],{"trials":20206,"activeCount":101},[],{"intervention":20126,"totalTrials":651,"cells":20208},{"EARLY_PHASE1":20209,"PHASE1":20211,"PHASE2":20213,"PHASE3":20219,"PHASE4":20221,"NA":20223},{"trials":20210,"activeCount":101},[],{"trials":20212,"activeCount":101},[],{"trials":20214,"activeCount":101},[20215],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20216,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20217,"interventions":20218},[89,90],[2408],[20107,20122,20123,20124,20125,20126,20127,20128],{"trials":20220,"activeCount":101},[],{"trials":20222,"activeCount":101},[],{"trials":20224,"activeCount":101},[],{"intervention":20127,"totalTrials":651,"cells":20226},{"EARLY_PHASE1":20227,"PHASE1":20229,"PHASE2":20231,"PHASE3":20237,"PHASE4":20239,"NA":20241},{"trials":20228,"activeCount":101},[],{"trials":20230,"activeCount":101},[],{"trials":20232,"activeCount":101},[20233],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20234,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20235,"interventions":20236},[89,90],[2408],[20107,20122,20123,20124,20125,20126,20127,20128],{"trials":20238,"activeCount":101},[],{"trials":20240,"activeCount":101},[],{"trials":20242,"activeCount":101},[],{"intervention":20128,"totalTrials":651,"cells":20244},{"EARLY_PHASE1":20245,"PHASE1":20247,"PHASE2":20249,"PHASE3":20255,"PHASE4":20257,"NA":20259},{"trials":20246,"activeCount":101},[],{"trials":20248,"activeCount":101},[],{"trials":20250,"activeCount":101},[20251],{"nctId":20116,"briefTitle":20117,"status":107,"phases":20252,"primaryCompletion":1562,"completion":1530,"start":1802,"enrollment":20119,"conditions":20253,"interventions":20254},[89,90],[2408],[20107,20122,20123,20124,20125,20126,20127,20128],{"trials":20256,"activeCount":101},[],{"trials":20258,"activeCount":101},[],{"trials":20260,"activeCount":101},[],{"intervention":20262,"totalTrials":651,"cells":20263},"Vinorelbine plus Epirubicin",{"EARLY_PHASE1":20264,"PHASE1":20266,"PHASE2":20268,"PHASE3":20278,"PHASE4":20280,"NA":20282},{"trials":20265,"activeCount":101},[],{"trials":20267,"activeCount":101},[],{"trials":20269,"activeCount":101},[20270],{"nctId":20271,"briefTitle":20272,"status":365,"phases":20273,"primaryCompletion":20274,"completion":20274,"start":1204,"enrollment":19948,"conditions":20275,"interventions":20276},"NCT02628613","Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations",[90],"2019-02",[15],[20262,20277],"Paclitaxel plus Epirubicin",{"trials":20279,"activeCount":101},[],{"trials":20281,"activeCount":101},[],{"trials":20283,"activeCount":101},[],{"intervention":20277,"totalTrials":651,"cells":20285},{"EARLY_PHASE1":20286,"PHASE1":20288,"PHASE2":20290,"PHASE3":20296,"PHASE4":20298,"NA":20300},{"trials":20287,"activeCount":101},[],{"trials":20289,"activeCount":101},[],{"trials":20291,"activeCount":101},[20292],{"nctId":20271,"briefTitle":20272,"status":365,"phases":20293,"primaryCompletion":20274,"completion":20274,"start":1204,"enrollment":19948,"conditions":20294,"interventions":20295},[90],[15],[20262,20277],{"trials":20297,"activeCount":101},[],{"trials":20299,"activeCount":101},[],{"trials":20301,"activeCount":101},[],{"intervention":20303,"totalTrials":651,"cells":20304},"Envafolimab combined with recombinant human endostatin and first-line chemotherapy",{"EARLY_PHASE1":20305,"PHASE1":20307,"PHASE2":20309,"PHASE3":20321,"PHASE4":20323,"NA":20325},{"trials":20306,"activeCount":101},[],{"trials":20308,"activeCount":101},[],{"trials":20310,"activeCount":101},[20311],{"nctId":20312,"briefTitle":20313,"status":107,"phases":20314,"primaryCompletion":20315,"completion":20316,"start":20317,"enrollment":137,"conditions":20318,"interventions":20320},"NCT06041724","Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma",[90],"2025-09-18","2026-03-18","2023-09-18",[20319],"Advanced Mucosal Melanoma",[20303],{"trials":20322,"activeCount":101},[],{"trials":20324,"activeCount":101},[],{"trials":20326,"activeCount":101},[],{"intervention":20328,"totalTrials":651,"cells":20329},"Camrelizumab plus mFLOT regimen",{"EARLY_PHASE1":20330,"PHASE1":20332,"PHASE2":20334,"PHASE3":20345,"PHASE4":20347,"NA":20349},{"trials":20331,"activeCount":101},[],{"trials":20333,"activeCount":101},[],{"trials":20335,"activeCount":101},[20336],{"nctId":20337,"briefTitle":20338,"status":365,"phases":20339,"primaryCompletion":6054,"completion":6054,"start":20340,"enrollment":737,"conditions":20341,"interventions":20344},"NCT04510064","Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial",[90],"2021-01-06",[1638,20342,20343],"Locally Advanced Gastric Adenocarcinoma","Gastric Cancer Adenocarcinoma Metastatic",[20328],{"trials":20346,"activeCount":101},[],{"trials":20348,"activeCount":101},[],{"trials":20350,"activeCount":101},[],{"intervention":20352,"totalTrials":651,"cells":20353},"chidamide combined with fulvestrant",{"EARLY_PHASE1":20354,"PHASE1":20356,"PHASE2":20358,"PHASE3":20367,"PHASE4":20369,"NA":20371},{"trials":20355,"activeCount":101},[],{"trials":20357,"activeCount":101},[],{"trials":20359,"activeCount":101},[20360],{"nctId":20361,"briefTitle":20362,"status":107,"phases":20363,"primaryCompletion":189,"completion":306,"start":447,"enrollment":9854,"conditions":20364,"interventions":20366},"NCT05806047","Combination of Chidamide and Fulvestrant for HR+\u002FHER2- Breast Cancer That Has Failed Previous CDK4\u002F6 i Adjuvant Therapy",[90],[20365],"Hormone Receptor-positive Advanced Breast Cancer",[20352],{"trials":20368,"activeCount":101},[],{"trials":20370,"activeCount":101},[],{"trials":20372,"activeCount":101},[],{"intervention":252,"totalTrials":651,"cells":20374},{"EARLY_PHASE1":20375,"PHASE1":20377,"PHASE2":20379,"PHASE3":20385,"PHASE4":20387,"NA":20389},{"trials":20376,"activeCount":101},[],{"trials":20378,"activeCount":101},[],{"trials":20380,"activeCount":101},[20381],{"nctId":244,"briefTitle":245,"status":107,"phases":20382,"primaryCompletion":247,"completion":247,"start":248,"enrollment":213,"conditions":20383,"interventions":20384},[90],[250],[252,253,254,176,255,96],{"trials":20386,"activeCount":101},[],{"trials":20388,"activeCount":101},[],{"trials":20390,"activeCount":101},[],{"intervention":20392,"totalTrials":651,"cells":20393},"metroCX",{"EARLY_PHASE1":20394,"PHASE1":20396,"PHASE2":20398,"PHASE3":20406,"PHASE4":20408,"NA":20410},{"trials":20395,"activeCount":101},[],{"trials":20397,"activeCount":101},[],{"trials":20399,"activeCount":101},[20400],{"nctId":20401,"briefTitle":20402,"status":107,"phases":20403,"primaryCompletion":2509,"completion":2509,"start":2499,"enrollment":2355,"conditions":20404,"interventions":20405},"NCT01526512","Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer",[90],[15],[20392],{"trials":20407,"activeCount":101},[],{"trials":20409,"activeCount":101},[],{"trials":20411,"activeCount":101},[],{"intervention":3607,"totalTrials":651,"cells":20413},{"EARLY_PHASE1":20414,"PHASE1":20416,"PHASE2":20418,"PHASE3":20424,"PHASE4":20426,"NA":20428},{"trials":20415,"activeCount":101},[],{"trials":20417,"activeCount":101},[],{"trials":20419,"activeCount":101},[20420],{"nctId":3600,"briefTitle":3601,"status":365,"phases":20421,"primaryCompletion":2499,"completion":2499,"start":3603,"enrollment":737,"conditions":20422,"interventions":20423},[90],[1780],[3606,3607],{"trials":20425,"activeCount":101},[],{"trials":20427,"activeCount":101},[],{"trials":20429,"activeCount":101},[],{"intervention":20431,"totalTrials":651,"cells":20432},"Serplulimab and Chemotherapy",{"EARLY_PHASE1":20433,"PHASE1":20435,"PHASE2":20437,"PHASE3":20448,"PHASE4":20450,"NA":20452},{"trials":20434,"activeCount":101},[],{"trials":20436,"activeCount":101},[],{"trials":20438,"activeCount":101},[20439],{"nctId":20440,"briefTitle":20441,"status":365,"phases":20442,"primaryCompletion":20443,"completion":1530,"start":20444,"enrollment":25,"conditions":20445,"interventions":20447},"NCT05775796","Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)",[90],"2024-05-28","2023-03-15",[2960,20446,1218,240],"Stage II-IIIA",[20431],{"trials":20449,"activeCount":101},[],{"trials":20451,"activeCount":101},[],{"trials":20453,"activeCount":101},[],{"intervention":20455,"totalTrials":651,"cells":20456},"Fuzuloparib Combination with Bevacizumab",{"EARLY_PHASE1":20457,"PHASE1":20459,"PHASE2":20461,"PHASE3":20471,"PHASE4":20473,"NA":20475},{"trials":20458,"activeCount":101},[],{"trials":20460,"activeCount":101},[],{"trials":20462,"activeCount":101},[20463],{"nctId":20464,"briefTitle":20465,"status":107,"phases":20466,"primaryCompletion":1407,"completion":1086,"start":20467,"enrollment":3866,"conditions":20468,"interventions":20470},"NCT05819060","The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab",[90],"2023-04-30",[20469],"Recurrent Ovarian Cancer",[20455],{"trials":20472,"activeCount":101},[],{"trials":20474,"activeCount":101},[],{"trials":20476,"activeCount":101},[],{"intervention":6837,"totalTrials":651,"cells":20478},{"EARLY_PHASE1":20479,"PHASE1":20481,"PHASE2":20483,"PHASE3":20489,"PHASE4":20491,"NA":20493},{"trials":20480,"activeCount":101},[],{"trials":20482,"activeCount":101},[],{"trials":20484,"activeCount":101},[20485],{"nctId":6827,"briefTitle":6828,"status":107,"phases":20486,"primaryCompletion":6830,"completion":6831,"start":6832,"enrollment":97,"conditions":20487,"interventions":20488},[90],[6834,6835],[6837,1196,361,6838],{"trials":20490,"activeCount":101},[],{"trials":20492,"activeCount":101},[],{"trials":20494,"activeCount":101},[],{"intervention":6838,"totalTrials":651,"cells":20496},{"EARLY_PHASE1":20497,"PHASE1":20499,"PHASE2":20501,"PHASE3":20507,"PHASE4":20509,"NA":20511},{"trials":20498,"activeCount":101},[],{"trials":20500,"activeCount":101},[],{"trials":20502,"activeCount":101},[20503],{"nctId":6827,"briefTitle":6828,"status":107,"phases":20504,"primaryCompletion":6830,"completion":6831,"start":6832,"enrollment":97,"conditions":20505,"interventions":20506},[90],[6834,6835],[6837,1196,361,6838],{"trials":20508,"activeCount":101},[],{"trials":20510,"activeCount":101},[],{"trials":20512,"activeCount":101},[],{"intervention":20514,"totalTrials":651,"cells":20515},"taxel plus raltitrexed",{"EARLY_PHASE1":20516,"PHASE1":20518,"PHASE2":20520,"PHASE3":20529,"PHASE4":20531,"NA":20533},{"trials":20517,"activeCount":101},[],{"trials":20519,"activeCount":101},[],{"trials":20521,"activeCount":101},[20522],{"nctId":20523,"briefTitle":20524,"status":107,"phases":20525,"primaryCompletion":4161,"completion":4161,"start":19838,"enrollment":529,"conditions":20526,"interventions":20527},"NCT02072317","Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer",[90],[20019],[20514,20528],"taxol",{"trials":20530,"activeCount":101},[],{"trials":20532,"activeCount":101},[],{"trials":20534,"activeCount":101},[],{"intervention":20528,"totalTrials":651,"cells":20536},{"EARLY_PHASE1":20537,"PHASE1":20539,"PHASE2":20541,"PHASE3":20547,"PHASE4":20549,"NA":20551},{"trials":20538,"activeCount":101},[],{"trials":20540,"activeCount":101},[],{"trials":20542,"activeCount":101},[20543],{"nctId":20523,"briefTitle":20524,"status":107,"phases":20544,"primaryCompletion":4161,"completion":4161,"start":19838,"enrollment":529,"conditions":20545,"interventions":20546},[90],[20019],[20514,20528],{"trials":20548,"activeCount":101},[],{"trials":20550,"activeCount":101},[],{"trials":20552,"activeCount":101},[],{"intervention":266,"totalTrials":651,"cells":20554},{"EARLY_PHASE1":20555,"PHASE1":20557,"PHASE2":20559,"PHASE3":20565,"PHASE4":20567,"NA":20569},{"trials":20556,"activeCount":101},[],{"trials":20558,"activeCount":101},[],{"trials":20560,"activeCount":101},[20561],{"nctId":257,"briefTitle":258,"status":107,"phases":20562,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":20563,"interventions":20564},[90],[15],[266,166],{"trials":20566,"activeCount":101},[],{"trials":20568,"activeCount":101},[],{"trials":20570,"activeCount":101},[],{"intervention":20572,"totalTrials":651,"cells":20573},"DA-EPOCH-R",{"EARLY_PHASE1":20574,"PHASE1":20576,"PHASE2":20578,"PHASE3":20587,"PHASE4":20589,"NA":20591},{"trials":20575,"activeCount":101},[],{"trials":20577,"activeCount":101},[],{"trials":20579,"activeCount":101},[20580],{"nctId":20581,"briefTitle":20582,"status":494,"phases":20583,"primaryCompletion":1204,"completion":485,"start":658,"enrollment":20584,"conditions":20585,"interventions":20586},"NCT01914718","Dose-adjusted EPOCH-R in MYC Positive DLBCL",[90],26,[11751],[20572],{"trials":20588,"activeCount":101},[],{"trials":20590,"activeCount":101},[],{"trials":20592,"activeCount":101},[],{"intervention":20594,"totalTrials":651,"cells":20595},"VCR, CTX, ADM; IFO, VP-16",{"EARLY_PHASE1":20596,"PHASE1":20598,"PHASE2":20600,"PHASE3":20611,"PHASE4":20613,"NA":20615},{"trials":20597,"activeCount":101},[],{"trials":20599,"activeCount":101},[],{"trials":20601,"activeCount":101},[20602],{"nctId":20603,"briefTitle":20604,"status":494,"phases":20605,"primaryCompletion":3603,"completion":20606,"start":20607,"enrollment":1499,"conditions":20608,"interventions":20610},"NCT00568464","Study on VCD\u002FIE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)",[90],"2009-09","2007-03",[20609],"Ewing's Sarcoma",[20594],{"trials":20612,"activeCount":101},[],{"trials":20614,"activeCount":101},[],{"trials":20616,"activeCount":101},[],{"intervention":20618,"totalTrials":651,"cells":20619},"Concurrent chemoradiation",{"EARLY_PHASE1":20620,"PHASE1":20622,"PHASE2":20624,"PHASE3":20633,"PHASE4":20635,"NA":20637},{"trials":20621,"activeCount":101},[],{"trials":20623,"activeCount":101},[],{"trials":20625,"activeCount":101},[20626],{"nctId":20627,"briefTitle":20628,"status":494,"phases":20629,"primaryCompletion":211,"completion":2006,"start":17725,"enrollment":2010,"conditions":20630,"interventions":20632},"NCT01667289","Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK\u002FT-cell Lymphoma",[90],[20631],"Extranodal NK\u002FT-cell Lymphoma, Nasal Type",[20618],{"trials":20634,"activeCount":101},[],{"trials":20636,"activeCount":101},[],{"trials":20638,"activeCount":101},[],{"intervention":20640,"totalTrials":651,"cells":20641},"Camrelizumab for",{"EARLY_PHASE1":20642,"PHASE1":20644,"PHASE2":20646,"PHASE3":20655,"PHASE4":20657,"NA":20659},{"trials":20643,"activeCount":101},[],{"trials":20645,"activeCount":101},[],{"trials":20647,"activeCount":101},[20648],{"nctId":20649,"briefTitle":20650,"status":107,"phases":20651,"primaryCompletion":751,"completion":56,"start":20652,"enrollment":737,"conditions":20653,"interventions":20654},"NCT04593485","Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract",[90],"2020-10-28",[15277],[20640],{"trials":20656,"activeCount":101},[],{"trials":20658,"activeCount":101},[],{"trials":20660,"activeCount":101},[],{"intervention":6591,"totalTrials":651,"cells":20662},{"EARLY_PHASE1":20663,"PHASE1":20665,"PHASE2":20667,"PHASE3":20673,"PHASE4":20675,"NA":20677},{"trials":20664,"activeCount":101},[],{"trials":20666,"activeCount":101},[],{"trials":20668,"activeCount":101},[20669],{"nctId":6582,"briefTitle":6583,"status":107,"phases":20670,"primaryCompletion":6585,"completion":1715,"start":6586,"enrollment":6587,"conditions":20671,"interventions":20672},[90],[6589],[2411,6591],{"trials":20674,"activeCount":101},[],{"trials":20676,"activeCount":101},[],{"trials":20678,"activeCount":101},[],{"intervention":20680,"totalTrials":651,"cells":20681},"camrelizumab in combination with nab-paclitaxel and famitinib",{"EARLY_PHASE1":20682,"PHASE1":20684,"PHASE2":20686,"PHASE3":20694,"PHASE4":20696,"NA":20698},{"trials":20683,"activeCount":101},[],{"trials":20685,"activeCount":101},[],{"trials":20687,"activeCount":101},[20688],{"nctId":20689,"briefTitle":20690,"status":107,"phases":20691,"primaryCompletion":2354,"completion":2354,"start":3137,"enrollment":137,"conditions":20692,"interventions":20693},"NCT04129996","A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)",[90],[1518],[20680],{"trials":20695,"activeCount":101},[],{"trials":20697,"activeCount":101},[],{"trials":20699,"activeCount":101},[],{"intervention":20701,"totalTrials":651,"cells":20702},"Arm C",{"EARLY_PHASE1":20703,"PHASE1":20705,"PHASE2":20707,"PHASE3":20718,"PHASE4":20720,"NA":20722},{"trials":20704,"activeCount":101},[],{"trials":20706,"activeCount":101},[],{"trials":20708,"activeCount":101},[20709],{"nctId":20710,"briefTitle":20711,"status":365,"phases":20712,"primaryCompletion":659,"completion":659,"start":16001,"enrollment":12592,"conditions":20713,"interventions":20715},"NCT01069081","Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer",[90],[15,20714],"Metastasis, Neoplasm",[20701,20716,20717],"Arm B","Arm A",{"trials":20719,"activeCount":101},[],{"trials":20721,"activeCount":101},[],{"trials":20723,"activeCount":101},[],{"intervention":20716,"totalTrials":651,"cells":20725},{"EARLY_PHASE1":20726,"PHASE1":20728,"PHASE2":20730,"PHASE3":20736,"PHASE4":20738,"NA":20740},{"trials":20727,"activeCount":101},[],{"trials":20729,"activeCount":101},[],{"trials":20731,"activeCount":101},[20732],{"nctId":20710,"briefTitle":20711,"status":365,"phases":20733,"primaryCompletion":659,"completion":659,"start":16001,"enrollment":12592,"conditions":20734,"interventions":20735},[90],[15,20714],[20701,20716,20717],{"trials":20737,"activeCount":101},[],{"trials":20739,"activeCount":101},[],{"trials":20741,"activeCount":101},[],{"intervention":20717,"totalTrials":651,"cells":20743},{"EARLY_PHASE1":20744,"PHASE1":20746,"PHASE2":20748,"PHASE3":20754,"PHASE4":20756,"NA":20758},{"trials":20745,"activeCount":101},[],{"trials":20747,"activeCount":101},[],{"trials":20749,"activeCount":101},[20750],{"nctId":20710,"briefTitle":20711,"status":365,"phases":20751,"primaryCompletion":659,"completion":659,"start":16001,"enrollment":12592,"conditions":20752,"interventions":20753},[90],[15,20714],[20701,20716,20717],{"trials":20755,"activeCount":101},[],{"trials":20757,"activeCount":101},[],{"trials":20759,"activeCount":101},[],{"intervention":18170,"totalTrials":651,"cells":20761},{"EARLY_PHASE1":20762,"PHASE1":20764,"PHASE2":20766,"PHASE3":20772,"PHASE4":20774,"NA":20776},{"trials":20763,"activeCount":101},[],{"trials":20765,"activeCount":101},[],{"trials":20767,"activeCount":101},[20768],{"nctId":18163,"briefTitle":18164,"status":107,"phases":20769,"primaryCompletion":18166,"completion":18167,"start":1877,"enrollment":690,"conditions":20770,"interventions":20771},[90],[27],[18170,6882,2962],{"trials":20773,"activeCount":101},[],{"trials":20775,"activeCount":101},[],{"trials":20777,"activeCount":101},[],{"intervention":20779,"totalTrials":651,"cells":20780},"chemotherapy TP regimen combined with Toripalimab",{"EARLY_PHASE1":20781,"PHASE1":20783,"PHASE2":20785,"PHASE3":20795,"PHASE4":20797,"NA":20799},{"trials":20782,"activeCount":101},[],{"trials":20784,"activeCount":101},[],{"trials":20786,"activeCount":101},[20787],{"nctId":20788,"briefTitle":20789,"status":107,"phases":20790,"primaryCompletion":294,"completion":1609,"start":6575,"enrollment":3614,"conditions":20791,"interventions":20794},"NCT04995120","Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal\u002FHypopharyngeal Carcinoma",[90],[6578,20792,20793],"Hypopharynx Cancer","Laryngeal Neoplasms",[20779],{"trials":20796,"activeCount":101},[],{"trials":20798,"activeCount":101},[],{"trials":20800,"activeCount":101},[],{"intervention":20802,"totalTrials":651,"cells":20803},"Fruquintinib,Albumin Paclitaxel,Gemcitabine",{"EARLY_PHASE1":20804,"PHASE1":20806,"PHASE2":20808,"PHASE3":20817,"PHASE4":20819,"NA":20821},{"trials":20805,"activeCount":101},[],{"trials":20807,"activeCount":101},[],{"trials":20809,"activeCount":101},[20810],{"nctId":20811,"briefTitle":20812,"status":107,"phases":20813,"primaryCompletion":6000,"completion":18099,"start":20814,"enrollment":25,"conditions":20815,"interventions":20816},"NCT05168527","The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients",[90],"2021-09-03",[30],[20802],{"trials":20818,"activeCount":101},[],{"trials":20820,"activeCount":101},[],{"trials":20822,"activeCount":101},[],{"intervention":20824,"totalTrials":651,"cells":20825},"HX008，Niraparib",{"EARLY_PHASE1":20826,"PHASE1":20828,"PHASE2":20830,"PHASE3":20843,"PHASE4":20845,"NA":20847},{"trials":20827,"activeCount":101},[],{"trials":20829,"activeCount":101},[],{"trials":20831,"activeCount":101},[20832],{"nctId":20833,"briefTitle":20834,"status":365,"phases":20835,"primaryCompletion":1851,"completion":20836,"start":20837,"enrollment":828,"conditions":20838,"interventions":20840},"NCT04508803","Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer",[90],"2023-02-28","2020-09-14",[20839],"Treatment Efficacy",[20824,20824,20841,20842],"HX008，Niraparib，Trastuzumab","HX008，Niraparib，Pyrrolitinib",{"trials":20844,"activeCount":101},[],{"trials":20846,"activeCount":101},[],{"trials":20848,"activeCount":101},[],{"intervention":20841,"totalTrials":651,"cells":20850},{"EARLY_PHASE1":20851,"PHASE1":20853,"PHASE2":20855,"PHASE3":20861,"PHASE4":20863,"NA":20865},{"trials":20852,"activeCount":101},[],{"trials":20854,"activeCount":101},[],{"trials":20856,"activeCount":101},[20857],{"nctId":20833,"briefTitle":20834,"status":365,"phases":20858,"primaryCompletion":1851,"completion":20836,"start":20837,"enrollment":828,"conditions":20859,"interventions":20860},[90],[20839],[20824,20824,20841,20842],{"trials":20862,"activeCount":101},[],{"trials":20864,"activeCount":101},[],{"trials":20866,"activeCount":101},[],{"intervention":20842,"totalTrials":651,"cells":20868},{"EARLY_PHASE1":20869,"PHASE1":20871,"PHASE2":20873,"PHASE3":20879,"PHASE4":20881,"NA":20883},{"trials":20870,"activeCount":101},[],{"trials":20872,"activeCount":101},[],{"trials":20874,"activeCount":101},[20875],{"nctId":20833,"briefTitle":20834,"status":365,"phases":20876,"primaryCompletion":1851,"completion":20836,"start":20837,"enrollment":828,"conditions":20877,"interventions":20878},[90],[20839],[20824,20824,20841,20842],{"trials":20880,"activeCount":101},[],{"trials":20882,"activeCount":101},[],{"trials":20884,"activeCount":101},[],{"intervention":20886,"totalTrials":651,"cells":20887},"Xeloda",{"EARLY_PHASE1":20888,"PHASE1":20890,"PHASE2":20892,"PHASE3":20902,"PHASE4":20904,"NA":20906},{"trials":20889,"activeCount":101},[],{"trials":20891,"activeCount":101},[],{"trials":20893,"activeCount":101},[20894],{"nctId":20895,"briefTitle":20896,"status":107,"phases":20897,"primaryCompletion":20898,"completion":1204,"start":1600,"enrollment":111,"conditions":20899,"interventions":20900},"NCT01796782","QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer",[90],"2015-08",[1419],[20886,20901],"QYHJ Granules",{"trials":20903,"activeCount":101},[],{"trials":20905,"activeCount":101},[],{"trials":20907,"activeCount":101},[],{"intervention":20901,"totalTrials":651,"cells":20909},{"EARLY_PHASE1":20910,"PHASE1":20912,"PHASE2":20914,"PHASE3":20920,"PHASE4":20922,"NA":20924},{"trials":20911,"activeCount":101},[],{"trials":20913,"activeCount":101},[],{"trials":20915,"activeCount":101},[20916],{"nctId":20895,"briefTitle":20896,"status":107,"phases":20917,"primaryCompletion":20898,"completion":1204,"start":1600,"enrollment":111,"conditions":20918,"interventions":20919},[90],[1419],[20886,20901],{"trials":20921,"activeCount":101},[],{"trials":20923,"activeCount":101},[],{"trials":20925,"activeCount":101},[],{"intervention":20927,"totalTrials":651,"cells":20928},"capecitabine and cyclophosphamide",{"EARLY_PHASE1":20929,"PHASE1":20931,"PHASE2":20933,"PHASE3":20942,"PHASE4":20944,"NA":20946},{"trials":20930,"activeCount":101},[],{"trials":20932,"activeCount":101},[],{"trials":20934,"activeCount":101},[20935],{"nctId":20936,"briefTitle":20937,"status":107,"phases":20938,"primaryCompletion":2958,"completion":2958,"start":20939,"enrollment":111,"conditions":20940,"interventions":20941},"NCT00589901","An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)",[90],"2006-08",[15],[20927],{"trials":20943,"activeCount":101},[],{"trials":20945,"activeCount":101},[],{"trials":20947,"activeCount":101},[],{"intervention":20949,"totalTrials":651,"cells":20950},"Radiotherapy followed by chemotherapy",{"EARLY_PHASE1":20951,"PHASE1":20953,"PHASE2":20955,"PHASE3":20963,"PHASE4":20965,"NA":20967},{"trials":20952,"activeCount":101},[],{"trials":20954,"activeCount":101},[],{"trials":20956,"activeCount":101},[20957],{"nctId":20958,"briefTitle":20959,"status":107,"phases":20960,"primaryCompletion":388,"completion":6786,"start":17725,"enrollment":25,"conditions":20961,"interventions":20962},"NCT01667302","Radiotherapy Followed by Adjuvant Chemotherapy in NK\u002FT-cell Lymphoma",[90],[20631],[20949],{"trials":20964,"activeCount":101},[],{"trials":20966,"activeCount":101},[],{"trials":20968,"activeCount":101},[],{"intervention":20970,"totalTrials":651,"cells":20971},"Abraxane",{"EARLY_PHASE1":20972,"PHASE1":20974,"PHASE2":20976,"PHASE3":20985,"PHASE4":20987,"NA":20989},{"trials":20973,"activeCount":101},[],{"trials":20975,"activeCount":101},[],{"trials":20977,"activeCount":101},[20978],{"nctId":20979,"briefTitle":20980,"status":365,"phases":20981,"primaryCompletion":9527,"completion":262,"start":20982,"enrollment":1992,"conditions":20983,"interventions":20984},"NCT02687490","Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer",[90],"2017-02-24",[33],[20970],{"trials":20986,"activeCount":101},[],{"trials":20988,"activeCount":101},[],{"trials":20990,"activeCount":101},[],{"intervention":20992,"totalTrials":651,"cells":20993},"irinotecan, capecitabine",{"EARLY_PHASE1":20994,"PHASE1":20996,"PHASE2":20998,"PHASE3":21007,"PHASE4":21009,"NA":21011},{"trials":20995,"activeCount":101},[],{"trials":20997,"activeCount":101},[],{"trials":20999,"activeCount":101},[21000],{"nctId":21001,"briefTitle":21002,"status":365,"phases":21003,"primaryCompletion":17408,"completion":9130,"start":21004,"enrollment":473,"conditions":21005,"interventions":21006},"NCT01322152","Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer",[90],"2011-03",[18],[20992],{"trials":21008,"activeCount":101},[],{"trials":21010,"activeCount":101},[],{"trials":21012,"activeCount":101},[],{"intervention":21014,"totalTrials":651,"cells":21015},"Cryoablation Combined with Tirelizumab and Bevacizumab",{"EARLY_PHASE1":21016,"PHASE1":21018,"PHASE2":21020,"PHASE3":21029,"PHASE4":21031,"NA":21033},{"trials":21017,"activeCount":101},[],{"trials":21019,"activeCount":101},[],{"trials":21021,"activeCount":101},[21022],{"nctId":21023,"briefTitle":21024,"status":107,"phases":21025,"primaryCompletion":147,"completion":147,"start":3613,"enrollment":478,"conditions":21026,"interventions":21028},"NCT05303038","Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy",[90],[21027],"Metastatic Breast Cancer in the Liver",[21014],{"trials":21030,"activeCount":101},[],{"trials":21032,"activeCount":101},[],{"trials":21034,"activeCount":101},[],{"intervention":6738,"totalTrials":651,"cells":21036},{"EARLY_PHASE1":21037,"PHASE1":21039,"PHASE2":21041,"PHASE3":21047,"PHASE4":21049,"NA":21051},{"trials":21038,"activeCount":101},[],{"trials":21040,"activeCount":101},[],{"trials":21042,"activeCount":101},[21043],{"nctId":6730,"briefTitle":6731,"status":107,"phases":21044,"primaryCompletion":1609,"completion":1609,"start":6733,"enrollment":16,"conditions":21045,"interventions":21046},[90],[6735,6736,24,1221],[6738,6739,62],{"trials":21048,"activeCount":101},[],{"trials":21050,"activeCount":101},[],{"trials":21052,"activeCount":101},[],{"intervention":21054,"totalTrials":651,"cells":21055},"HAIC+TQB2450+Anlotinib",{"EARLY_PHASE1":21056,"PHASE1":21058,"PHASE2":21060,"PHASE3":21070,"PHASE4":21072,"NA":21074},{"trials":21057,"activeCount":101},[],{"trials":21059,"activeCount":101},[],{"trials":21061,"activeCount":101},[21062],{"nctId":21063,"briefTitle":21064,"status":107,"phases":21065,"primaryCompletion":1203,"completion":56,"start":21066,"enrollment":159,"conditions":21067,"interventions":21069},"NCT05311319","HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection",[90],"2022-01-11",[21068],"Hepatocarcinoma",[21054],{"trials":21071,"activeCount":101},[],{"trials":21073,"activeCount":101},[],{"trials":21075,"activeCount":101},[],{"intervention":1458,"totalTrials":651,"cells":21077},{"EARLY_PHASE1":21078,"PHASE1":21080,"PHASE2":21082,"PHASE3":21088,"PHASE4":21090,"NA":21092},{"trials":21079,"activeCount":101},[],{"trials":21081,"activeCount":101},[],{"trials":21083,"activeCount":101},[21084],{"nctId":1448,"briefTitle":1449,"status":107,"phases":21085,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":1454,"conditions":21086,"interventions":21087},[90],[24,1456],[1458,432],{"trials":21089,"activeCount":101},[],{"trials":21091,"activeCount":101},[],{"trials":21093,"activeCount":101},[],{"intervention":21095,"totalTrials":651,"cells":21096},"Vinorelbine and Capecitabine",{"EARLY_PHASE1":21097,"PHASE1":21099,"PHASE2":21101,"PHASE3":21109,"PHASE4":21111,"NA":21113},{"trials":21098,"activeCount":101},[],{"trials":21100,"activeCount":101},[],{"trials":21102,"activeCount":101},[21103],{"nctId":21104,"briefTitle":21105,"status":365,"phases":21106,"primaryCompletion":16001,"completion":1700,"start":14856,"enrollment":111,"conditions":21107,"interventions":21108},"NCT00629148","Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)",[90],[15,20714],[21095,21095],{"trials":21110,"activeCount":101},[],{"trials":21112,"activeCount":101},[],{"trials":21114,"activeCount":101},[],{"intervention":21116,"totalTrials":651,"cells":21117},"Sorafenib and Zoledronic Acid",{"EARLY_PHASE1":21118,"PHASE1":21120,"PHASE2":21122,"PHASE3":21130,"PHASE4":21132,"NA":21134},{"trials":21119,"activeCount":101},[],{"trials":21121,"activeCount":101},[],{"trials":21123,"activeCount":101},[21124],{"nctId":21125,"briefTitle":21126,"status":107,"phases":21127,"primaryCompletion":17832,"completion":562,"start":212,"enrollment":97,"conditions":21128,"interventions":21129},"NCT01259193","Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC",[90],[21],[21116],{"trials":21131,"activeCount":101},[],{"trials":21133,"activeCount":101},[],{"trials":21135,"activeCount":101},[],{"intervention":21137,"totalTrials":651,"cells":21138},"S-1, Leucovorin",{"EARLY_PHASE1":21139,"PHASE1":21141,"PHASE2":21143,"PHASE3":21152,"PHASE4":21154,"NA":21156},{"trials":21140,"activeCount":101},[],{"trials":21142,"activeCount":101},[],{"trials":21144,"activeCount":101},[21145],{"nctId":21146,"briefTitle":21147,"status":107,"phases":21148,"primaryCompletion":15812,"completion":659,"start":2518,"enrollment":213,"conditions":21149,"interventions":21150},"NCT01193452","S-1\u002FLeucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer",[90],[18],[21137,21151],"leucovorin, 5-fluorouracil",{"trials":21153,"activeCount":101},[],{"trials":21155,"activeCount":101},[],{"trials":21157,"activeCount":101},[],{"intervention":21151,"totalTrials":651,"cells":21159},{"EARLY_PHASE1":21160,"PHASE1":21162,"PHASE2":21164,"PHASE3":21170,"PHASE4":21172,"NA":21174},{"trials":21161,"activeCount":101},[],{"trials":21163,"activeCount":101},[],{"trials":21165,"activeCount":101},[21166],{"nctId":21146,"briefTitle":21147,"status":107,"phases":21167,"primaryCompletion":15812,"completion":659,"start":2518,"enrollment":213,"conditions":21168,"interventions":21169},[90],[18],[21137,21151],{"trials":21171,"activeCount":101},[],{"trials":21173,"activeCount":101},[],{"trials":21175,"activeCount":101},[],{"intervention":18135,"totalTrials":651,"cells":21177},{"EARLY_PHASE1":21178,"PHASE1":21180,"PHASE2":21182,"PHASE3":21188,"PHASE4":21190,"NA":21192},{"trials":21179,"activeCount":101},[],{"trials":21181,"activeCount":101},[],{"trials":21183,"activeCount":101},[21184],{"nctId":18129,"briefTitle":18130,"status":107,"phases":21185,"primaryCompletion":426,"completion":285,"start":18132,"enrollment":296,"conditions":21186,"interventions":21187},[90],[1348],[9124,18135],{"trials":21189,"activeCount":101},[],{"trials":21191,"activeCount":101},[],{"trials":21193,"activeCount":101},[],{"intervention":9125,"totalTrials":651,"cells":21195},{"EARLY_PHASE1":21196,"PHASE1":21198,"PHASE2":21200,"PHASE3":21206,"PHASE4":21208,"NA":21210},{"trials":21197,"activeCount":101},[],{"trials":21199,"activeCount":101},[],{"trials":21201,"activeCount":101},[21202],{"nctId":9118,"briefTitle":9119,"status":107,"phases":21203,"primaryCompletion":2499,"start":1879,"enrollment":1610,"conditions":21204,"interventions":21205},[90],[9122,2960],[9124,2111,9125],{"trials":21207,"activeCount":101},[],{"trials":21209,"activeCount":101},[],{"trials":21211,"activeCount":101},[],{"intervention":21213,"totalTrials":651,"cells":21214},"Recombinant humanized anti-PD-1 monoclonal antibody",{"EARLY_PHASE1":21215,"PHASE1":21217,"PHASE2":21219,"PHASE3":21230,"PHASE4":21232,"NA":21234},{"trials":21216,"activeCount":101},[],{"trials":21218,"activeCount":101},[],{"trials":21220,"activeCount":101},[21221],{"nctId":21222,"briefTitle":21223,"status":107,"phases":21224,"primaryCompletion":447,"completion":21225,"start":21226,"enrollment":2845,"conditions":21227,"interventions":21229},"NCT04848597","PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP",[90],"2023-05-03","2021-05-13",[21228],"Cancer of Unknown Primary",[21213],{"trials":21231,"activeCount":101},[],{"trials":21233,"activeCount":101},[],{"trials":21235,"activeCount":101},[],{"intervention":21237,"totalTrials":651,"cells":21238},"ABX Combined With Cisplatin",{"EARLY_PHASE1":21239,"PHASE1":21241,"PHASE2":21243,"PHASE3":21252,"PHASE4":21254,"NA":21256},{"trials":21240,"activeCount":101},[],{"trials":21242,"activeCount":101},[],{"trials":21244,"activeCount":101},[21245],{"nctId":21246,"briefTitle":21247,"status":365,"phases":21248,"primaryCompletion":1204,"completion":1204,"start":2499,"enrollment":10553,"conditions":21249,"interventions":21250},"NCT01810367","ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC",[90],[2526],[21237,21251],"Gemcitabine Combined With Cisplatin",{"trials":21253,"activeCount":101},[],{"trials":21255,"activeCount":101},[],{"trials":21257,"activeCount":101},[],{"intervention":21251,"totalTrials":651,"cells":21259},{"EARLY_PHASE1":21260,"PHASE1":21262,"PHASE2":21264,"PHASE3":21270,"PHASE4":21272,"NA":21274},{"trials":21261,"activeCount":101},[],{"trials":21263,"activeCount":101},[],{"trials":21265,"activeCount":101},[21266],{"nctId":21246,"briefTitle":21247,"status":365,"phases":21267,"primaryCompletion":1204,"completion":1204,"start":2499,"enrollment":10553,"conditions":21268,"interventions":21269},[90],[2526],[21237,21251],{"trials":21271,"activeCount":101},[],{"trials":21273,"activeCount":101},[],{"trials":21275,"activeCount":101},[],{"intervention":21277,"totalTrials":651,"cells":21278},"R-ESHAP",{"EARLY_PHASE1":21279,"PHASE1":21281,"PHASE2":21283,"PHASE3":21291,"PHASE4":21293,"NA":21295},{"trials":21280,"activeCount":101},[],{"trials":21282,"activeCount":101},[],{"trials":21284,"activeCount":101},[21285],{"nctId":21286,"briefTitle":21287,"status":107,"phases":21288,"primaryCompletion":388,"completion":3924,"start":1700,"enrollment":97,"conditions":21289,"interventions":21290},"NCT01278602","R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma",[90],[11751],[21277],{"trials":21292,"activeCount":101},[],{"trials":21294,"activeCount":101},[],{"trials":21296,"activeCount":101},[],{"intervention":1480,"totalTrials":651,"cells":21298},{"EARLY_PHASE1":21299,"PHASE1":21301,"PHASE2":21303,"PHASE3":21309,"PHASE4":21311,"NA":21313},{"trials":21300,"activeCount":101},[],{"trials":21302,"activeCount":101},[],{"trials":21304,"activeCount":101},[21305],{"nctId":1470,"briefTitle":1471,"status":107,"phases":21306,"primaryCompletion":1164,"completion":1473,"start":1474,"enrollment":1475,"conditions":21307,"interventions":21308},[90],[1477,1478],[432,413,1480,1481,1482,1483,1484],{"trials":21310,"activeCount":101},[],{"trials":21312,"activeCount":101},[],{"trials":21314,"activeCount":101},[],{"intervention":1481,"totalTrials":651,"cells":21316},{"EARLY_PHASE1":21317,"PHASE1":21319,"PHASE2":21321,"PHASE3":21327,"PHASE4":21329,"NA":21331},{"trials":21318,"activeCount":101},[],{"trials":21320,"activeCount":101},[],{"trials":21322,"activeCount":101},[21323],{"nctId":1470,"briefTitle":1471,"status":107,"phases":21324,"primaryCompletion":1164,"completion":1473,"start":1474,"enrollment":1475,"conditions":21325,"interventions":21326},[90],[1477,1478],[432,413,1480,1481,1482,1483,1484],{"trials":21328,"activeCount":101},[],{"trials":21330,"activeCount":101},[],{"trials":21332,"activeCount":101},[],{"intervention":1483,"totalTrials":651,"cells":21334},{"EARLY_PHASE1":21335,"PHASE1":21337,"PHASE2":21339,"PHASE3":21345,"PHASE4":21347,"NA":21349},{"trials":21336,"activeCount":101},[],{"trials":21338,"activeCount":101},[],{"trials":21340,"activeCount":101},[21341],{"nctId":1470,"briefTitle":1471,"status":107,"phases":21342,"primaryCompletion":1164,"completion":1473,"start":1474,"enrollment":1475,"conditions":21343,"interventions":21344},[90],[1477,1478],[432,413,1480,1481,1482,1483,1484],{"trials":21346,"activeCount":101},[],{"trials":21348,"activeCount":101},[],{"trials":21350,"activeCount":101},[],{"intervention":1484,"totalTrials":651,"cells":21352},{"EARLY_PHASE1":21353,"PHASE1":21355,"PHASE2":21357,"PHASE3":21363,"PHASE4":21365,"NA":21367},{"trials":21354,"activeCount":101},[],{"trials":21356,"activeCount":101},[],{"trials":21358,"activeCount":101},[21359],{"nctId":1470,"briefTitle":1471,"status":107,"phases":21360,"primaryCompletion":1164,"completion":1473,"start":1474,"enrollment":1475,"conditions":21361,"interventions":21362},[90],[1477,1478],[432,413,1480,1481,1482,1483,1484],{"trials":21364,"activeCount":101},[],{"trials":21366,"activeCount":101},[],{"trials":21368,"activeCount":101},[],{"intervention":21370,"totalTrials":651,"cells":21371},"PLD and IFO",{"EARLY_PHASE1":21372,"PHASE1":21374,"PHASE2":21376,"PHASE3":21387,"PHASE4":21389,"NA":21391},{"trials":21373,"activeCount":101},[],{"trials":21375,"activeCount":101},[],{"trials":21377,"activeCount":101},[21378],{"nctId":21379,"briefTitle":21380,"status":107,"phases":21381,"primaryCompletion":21382,"completion":21383,"start":21384,"enrollment":737,"conditions":21385,"interventions":21386},"NCT03268772","PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS",[90],"2020-11-30","2020-12-30","2015-04-01",[7857],[21370],{"trials":21388,"activeCount":101},[],{"trials":21390,"activeCount":101},[],{"trials":21392,"activeCount":101},[],{"intervention":21394,"totalTrials":651,"cells":21395},"Camrelizumab+cetuximab+chemotherapy",{"EARLY_PHASE1":21396,"PHASE1":21398,"PHASE2":21400,"PHASE3":21409,"PHASE4":21411,"NA":21413},{"trials":21397,"activeCount":101},[],{"trials":21399,"activeCount":101},[],{"trials":21401,"activeCount":101},[21402],{"nctId":21403,"briefTitle":21404,"status":365,"phases":21405,"primaryCompletion":2844,"completion":1609,"start":21406,"enrollment":5881,"conditions":21407,"interventions":21408},"NCT05673577","Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed\u002FMetastatic HNSCC Patients",[90],"2023-03-22",[9132],[21394],{"trials":21410,"activeCount":101},[],{"trials":21412,"activeCount":101},[],{"trials":21414,"activeCount":101},[],{"intervention":21416,"totalTrials":651,"cells":21417},"Avastin + mFOLFOX6",{"EARLY_PHASE1":21418,"PHASE1":21420,"PHASE2":21422,"PHASE3":21430,"PHASE4":21432,"NA":21434},{"trials":21419,"activeCount":101},[],{"trials":21421,"activeCount":101},[],{"trials":21423,"activeCount":101},[21424],{"nctId":21425,"briefTitle":21426,"status":365,"phases":21427,"primaryCompletion":19838,"completion":19166,"start":18351,"enrollment":2355,"conditions":21428,"interventions":21429},"NCT01658033","Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients",[90],[33],[21416],{"trials":21431,"activeCount":101},[],{"trials":21433,"activeCount":101},[],{"trials":21435,"activeCount":101},[],{"intervention":21437,"totalTrials":651,"cells":21438},"IGEV",{"EARLY_PHASE1":21439,"PHASE1":21441,"PHASE2":21443,"PHASE3":21452,"PHASE4":21454,"NA":21456},{"trials":21440,"activeCount":101},[],{"trials":21442,"activeCount":101},[],{"trials":21444,"activeCount":101},[21445],{"nctId":21446,"briefTitle":21447,"status":107,"phases":21448,"primaryCompletion":2545,"completion":3164,"start":2983,"enrollment":6606,"conditions":21449,"interventions":21451},"NCT01333605","IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma",[90],[21450],"Hodgkin Lymphoma",[21437],{"trials":21453,"activeCount":101},[],{"trials":21455,"activeCount":101},[],{"trials":21457,"activeCount":101},[],{"intervention":21459,"totalTrials":651,"cells":21460},"PD-1\u002FPD-L1 inhibitors",{"EARLY_PHASE1":21461,"PHASE1":21463,"PHASE2":21465,"PHASE3":21473,"PHASE4":21475,"NA":21477},{"trials":21462,"activeCount":101},[],{"trials":21464,"activeCount":101},[],{"trials":21466,"activeCount":101},[21467],{"nctId":21468,"briefTitle":21469,"status":107,"phases":21470,"primaryCompletion":85,"completion":1609,"start":190,"enrollment":3345,"conditions":21471,"interventions":21472},"NCT04767009","SBRT for Oligo-residual NSCLC After Treatment With PD-1\u002FPD-L1 Immune Checkpoint Inhibitors",[90],[2109],[21459],{"trials":21474,"activeCount":101},[],{"trials":21476,"activeCount":101},[],{"trials":21478,"activeCount":101},[],{"intervention":2994,"totalTrials":651,"cells":21480},{"EARLY_PHASE1":21481,"PHASE1":21483,"PHASE2":21485,"PHASE3":21491,"PHASE4":21493,"NA":21495},{"trials":21482,"activeCount":101},[],{"trials":21484,"activeCount":101},[],{"trials":21486,"activeCount":101},[21487],{"nctId":2987,"briefTitle":2988,"status":107,"phases":21488,"primaryCompletion":1724,"completion":1573,"start":2990,"enrollment":2991,"conditions":21489,"interventions":21490},[90],[250],[1764,1466,52,2994],{"trials":21492,"activeCount":101},[],{"trials":21494,"activeCount":101},[],{"trials":21496,"activeCount":101},[],{"intervention":694,"totalTrials":651,"cells":21498},{"EARLY_PHASE1":21499,"PHASE1":21501,"PHASE2":21503,"PHASE3":21509,"PHASE4":21511,"NA":21513},{"trials":21500,"activeCount":101},[],{"trials":21502,"activeCount":101},[],{"trials":21504,"activeCount":101},[21505],{"nctId":685,"briefTitle":686,"status":365,"phases":21506,"primaryCompletion":688,"completion":354,"start":689,"enrollment":690,"conditions":21507,"interventions":21508},[90],[692],[675,694],{"trials":21510,"activeCount":101},[],{"trials":21512,"activeCount":101},[],{"trials":21514,"activeCount":101},[],{"intervention":21516,"totalTrials":651,"cells":21517},"tropisetron",{"EARLY_PHASE1":21518,"PHASE1":21520,"PHASE2":21522,"PHASE3":21533,"PHASE4":21535,"NA":21537},{"trials":21519,"activeCount":101},[],{"trials":21521,"activeCount":101},[],{"trials":21523,"activeCount":101},[21524],{"nctId":21525,"briefTitle":21526,"status":107,"phases":21527,"primaryCompletion":389,"completion":389,"start":9130,"enrollment":2264,"conditions":21528,"interventions":21532},"NCT01895010","Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE",[90],[21529,21530,21531],"Nausea","Vomiting","Metastatic Liver Cancer",[21516],{"trials":21534,"activeCount":101},[],{"trials":21536,"activeCount":101},[],{"trials":21538,"activeCount":101},[],{"intervention":21540,"totalTrials":651,"cells":21541},"S1 combined with cisplatin",{"EARLY_PHASE1":21542,"PHASE1":21544,"PHASE2":21546,"PHASE3":21555,"PHASE4":21557,"NA":21559},{"trials":21543,"activeCount":101},[],{"trials":21545,"activeCount":101},[],{"trials":21547,"activeCount":101},[21548],{"nctId":21549,"briefTitle":21550,"status":365,"phases":21551,"primaryCompletion":1204,"start":109,"enrollment":21552,"conditions":21553,"interventions":21554},"NCT01854749","S1 Combined With Cisplatin in Treatment of Recurrence\u002FMetastasis of ESCC Open-label Single Center Phase II Clinical Study",[90],57,[27],[21540],{"trials":21556,"activeCount":101},[],{"trials":21558,"activeCount":101},[],{"trials":21560,"activeCount":101},[],{"intervention":21562,"totalTrials":651,"cells":21563},"S-1 plus oxaliplatin",{"EARLY_PHASE1":21564,"PHASE1":21566,"PHASE2":21568,"PHASE3":21576,"PHASE4":21578,"NA":21580},{"trials":21565,"activeCount":101},[],{"trials":21567,"activeCount":101},[],{"trials":21569,"activeCount":101},[21570],{"nctId":21571,"briefTitle":21572,"status":494,"phases":21573,"primaryCompletion":389,"completion":1204,"start":17832,"enrollment":1115,"conditions":21574,"interventions":21575},"NCT01403259","SOX as Salvage Treatment in Nasopharyngeal Carcinoma",[90],[35],[21562],{"trials":21577,"activeCount":101},[],{"trials":21579,"activeCount":101},[],{"trials":21581,"activeCount":101},[],{"intervention":21583,"totalTrials":651,"cells":21584},"Anti-EGFR and PD-1 inhibitor arm",{"EARLY_PHASE1":21585,"PHASE1":21587,"PHASE2":21589,"PHASE3":21597,"PHASE4":21599,"NA":21601},{"trials":21586,"activeCount":101},[],{"trials":21588,"activeCount":101},[],{"trials":21590,"activeCount":101},[21591],{"nctId":21592,"briefTitle":21593,"status":107,"phases":21594,"primaryCompletion":1143,"completion":1143,"start":6056,"enrollment":5881,"conditions":21595,"interventions":21596},"NCT06156878","PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy",[90],[35],[21583],{"trials":21598,"activeCount":101},[],{"trials":21600,"activeCount":101},[],{"trials":21602,"activeCount":101},[],{"intervention":16409,"totalTrials":651,"cells":21604},{"EARLY_PHASE1":21605,"PHASE1":21607,"PHASE2":21609,"PHASE3":21615,"PHASE4":21617,"NA":21619},{"trials":21606,"activeCount":101},[],{"trials":21608,"activeCount":101},[],{"trials":21610,"activeCount":101},[21611],{"nctId":16402,"briefTitle":16403,"status":107,"phases":21612,"primaryCompletion":16405,"completion":3121,"start":16406,"enrollment":345,"conditions":21613,"interventions":21614},[90],[15],[16409,16393],{"trials":21616,"activeCount":101},[],{"trials":21618,"activeCount":101},[],{"trials":21620,"activeCount":101},[],{"intervention":21622,"totalTrials":651,"cells":21623},"GVP",{"EARLY_PHASE1":21624,"PHASE1":21626,"PHASE2":21628,"PHASE3":21636,"PHASE4":21638,"NA":21640},{"trials":21625,"activeCount":101},[],{"trials":21627,"activeCount":101},[],{"trials":21629,"activeCount":101},[21630],{"nctId":21631,"briefTitle":21632,"status":107,"phases":21633,"primaryCompletion":15646,"completion":15646,"start":8665,"enrollment":737,"conditions":21634,"interventions":21635},"NCT01192633","Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma",[90],[13430,310],[21622],{"trials":21637,"activeCount":101},[],{"trials":21639,"activeCount":101},[],{"trials":21641,"activeCount":101},[],{"intervention":21643,"totalTrials":651,"cells":21644},"Microwave Ablation combination with chemotherapy",{"EARLY_PHASE1":21645,"PHASE1":21647,"PHASE2":21649,"PHASE3":21660,"PHASE4":21662,"NA":21664},{"trials":21646,"activeCount":101},[],{"trials":21648,"activeCount":101},[],{"trials":21650,"activeCount":101},[21651],{"nctId":21652,"briefTitle":21653,"status":107,"phases":21654,"primaryCompletion":1474,"completion":1203,"start":21655,"enrollment":97,"conditions":21656,"interventions":21659},"NCT04677192","Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis",[90],"2021-01",[21657,21658],"Pancreatic Cancer Metastatic to Liver","Oligometastasis",[21643],{"trials":21661,"activeCount":101},[],{"trials":21663,"activeCount":101},[],{"trials":21665,"activeCount":101},[],{"intervention":21667,"totalTrials":651,"cells":21668},"Songyou",{"EARLY_PHASE1":21669,"PHASE1":21671,"PHASE2":21673,"PHASE3":21682,"PHASE4":21684,"NA":21686},{"trials":21670,"activeCount":101},[],{"trials":21672,"activeCount":101},[],{"trials":21674,"activeCount":101},[21675],{"nctId":21676,"briefTitle":21677,"status":107,"phases":21678,"primaryCompletion":1700,"completion":1700,"start":2958,"enrollment":2728,"conditions":21679,"interventions":21681},"NCT00805896","Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma",[90],[21,21680],"Unresectable",[21667],{"trials":21683,"activeCount":101},[],{"trials":21685,"activeCount":101},[],{"trials":21687,"activeCount":101},[],{"intervention":21689,"totalTrials":651,"cells":21690},"Decitabine",{"EARLY_PHASE1":21691,"PHASE1":21693,"PHASE2":21695,"PHASE3":21704,"PHASE4":21706,"NA":21708},{"trials":21692,"activeCount":101},[],{"trials":21694,"activeCount":101},[],{"trials":21696,"activeCount":101},[21697],{"nctId":21698,"briefTitle":21699,"status":107,"phases":21700,"primaryCompletion":293,"completion":294,"start":1584,"enrollment":111,"conditions":21701,"interventions":21702},"NCT05638984","Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma",[90],[1348],[21689,21703],"tirelizumab",{"trials":21705,"activeCount":101},[],{"trials":21707,"activeCount":101},[],{"trials":21709,"activeCount":101},[],{"intervention":21703,"totalTrials":651,"cells":21711},{"EARLY_PHASE1":21712,"PHASE1":21714,"PHASE2":21716,"PHASE3":21722,"PHASE4":21724,"NA":21726},{"trials":21713,"activeCount":101},[],{"trials":21715,"activeCount":101},[],{"trials":21717,"activeCount":101},[21718],{"nctId":21698,"briefTitle":21699,"status":107,"phases":21719,"primaryCompletion":293,"completion":294,"start":1584,"enrollment":111,"conditions":21720,"interventions":21721},[90],[1348],[21689,21703],{"trials":21723,"activeCount":101},[],{"trials":21725,"activeCount":101},[],{"trials":21727,"activeCount":101},[],{"intervention":21729,"totalTrials":651,"cells":21730},"Docosahexaenoic acid (DHA)",{"EARLY_PHASE1":21731,"PHASE1":21733,"PHASE2":21735,"PHASE3":21745,"PHASE4":21747,"NA":21749},{"trials":21732,"activeCount":101},[],{"trials":21734,"activeCount":101},[],{"trials":21736,"activeCount":101},[21737],{"nctId":21738,"briefTitle":21739,"status":107,"phases":21740,"primaryCompletion":201,"completion":449,"start":21741,"enrollment":2241,"conditions":21742,"interventions":21744},"NCT04242004","Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients",[89,90],"2019-10-30",[21743],"Neurocognitive Impairment",[21729],{"trials":21746,"activeCount":101},[],{"trials":21748,"activeCount":101},[],{"trials":21750,"activeCount":101},[],{"intervention":6369,"totalTrials":651,"cells":21752},{"EARLY_PHASE1":21753,"PHASE1":21755,"PHASE2":21757,"PHASE3":21763,"PHASE4":21765,"NA":21767},{"trials":21754,"activeCount":101},[],{"trials":21756,"activeCount":101},[],{"trials":21758,"activeCount":101},[21759],{"nctId":6363,"briefTitle":6364,"status":107,"phases":21760,"primaryCompletion":56,"completion":56,"start":6366,"enrollment":3614,"conditions":21761,"interventions":21762},[90],[21],[6369,230],{"trials":21764,"activeCount":101},[],{"trials":21766,"activeCount":101},[],{"trials":21768,"activeCount":101},[],{"intervention":21770,"totalTrials":651,"cells":21771},"HAIC-FOLFOX combined with Sintilimab and Regorafenib",{"EARLY_PHASE1":21772,"PHASE1":21774,"PHASE2":21776,"PHASE3":21785,"PHASE4":21787,"NA":21789},{"trials":21773,"activeCount":101},[],{"trials":21775,"activeCount":101},[],{"trials":21777,"activeCount":101},[21778],{"nctId":21779,"briefTitle":21780,"status":107,"phases":21781,"primaryCompletion":14151,"completion":19701,"start":9040,"enrollment":3866,"conditions":21782,"interventions":21784},"NCT05753163","Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study",[90],[21783],"Colorectal Liver Metastasis",[21770],{"trials":21786,"activeCount":101},[],{"trials":21788,"activeCount":101},[],{"trials":21790,"activeCount":101},[],{"intervention":3252,"totalTrials":651,"cells":21792},{"EARLY_PHASE1":21793,"PHASE1":21795,"PHASE2":21797,"PHASE3":21803,"PHASE4":21805,"NA":21807},{"trials":21794,"activeCount":101},[],{"trials":21796,"activeCount":101},[],{"trials":21798,"activeCount":101},[21799],{"nctId":3246,"briefTitle":3247,"status":107,"phases":21800,"primaryCompletion":2354,"completion":295,"start":343,"enrollment":296,"conditions":21801,"interventions":21802},[90],[30,3250],[3252,1297],{"trials":21804,"activeCount":101},[],{"trials":21806,"activeCount":101},[],{"trials":21808,"activeCount":101},[],{"intervention":348,"totalTrials":651,"cells":21810},{"EARLY_PHASE1":21811,"PHASE1":21813,"PHASE2":21815,"PHASE3":21821,"PHASE4":21823,"NA":21825},{"trials":21812,"activeCount":101},[],{"trials":21814,"activeCount":101},[],{"trials":21816,"activeCount":101},[21817],{"nctId":340,"briefTitle":341,"status":107,"phases":21818,"primaryCompletion":343,"completion":201,"start":344,"enrollment":345,"conditions":21819,"interventions":21820},[90],[139],[96,115,348],{"trials":21822,"activeCount":101},[],{"trials":21824,"activeCount":101},[],{"trials":21826,"activeCount":101},[],{"intervention":1223,"totalTrials":651,"cells":21828},{"EARLY_PHASE1":21829,"PHASE1":21831,"PHASE2":21833,"PHASE3":21839,"PHASE4":21841,"NA":21843},{"trials":21830,"activeCount":101},[],{"trials":21832,"activeCount":101},[],{"trials":21834,"activeCount":101},[21835],{"nctId":1210,"briefTitle":1211,"status":494,"phases":21836,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":637,"conditions":21837,"interventions":21838},[90],[577,1216,240,1217,1218,1219,1220,1221],[129,1223,278],{"trials":21840,"activeCount":101},[],{"trials":21842,"activeCount":101},[],{"trials":21844,"activeCount":101},[],{"intervention":21846,"totalTrials":651,"cells":21847},"ct-DNA guided therapy",{"EARLY_PHASE1":21848,"PHASE1":21850,"PHASE2":21852,"PHASE3":21861,"PHASE4":21863,"NA":21865},{"trials":21849,"activeCount":101},[],{"trials":21851,"activeCount":101},[],{"trials":21853,"activeCount":101},[21854],{"nctId":21855,"briefTitle":21856,"status":107,"phases":21857,"primaryCompletion":18405,"completion":1452,"start":3390,"enrollment":737,"conditions":21858,"interventions":21860},"NCT05164510","Value of ctDNA in the Treatment of Multiple Primary Cancers",[90],[21859],"Multiple Primary Cancers",[21846],{"trials":21862,"activeCount":101},[],{"trials":21864,"activeCount":101},[],{"trials":21866,"activeCount":101},[],{"intervention":21868,"totalTrials":651,"cells":21869},"Fruquintinib+mFOLFOX6\u002FFOLFIRI",{"EARLY_PHASE1":21870,"PHASE1":21872,"PHASE2":21874,"PHASE3":21882,"PHASE4":21884,"NA":21886},{"trials":21871,"activeCount":101},[],{"trials":21873,"activeCount":101},[],{"trials":21875,"activeCount":101},[21876],{"nctId":21877,"briefTitle":21878,"status":107,"phases":21879,"primaryCompletion":1622,"completion":2685,"start":17365,"enrollment":263,"conditions":21880,"interventions":21881},"NCT06010888","Fruquintinib With mFOLFOX6\u002FFOLFIRI as First-Line Therapy for Conversion Surgery in mCRC",[90],[18],[21868],{"trials":21883,"activeCount":101},[],{"trials":21885,"activeCount":101},[],{"trials":21887,"activeCount":101},[],{"intervention":21889,"totalTrials":651,"cells":21890},"Fluzoparib and Camrelizumab",{"EARLY_PHASE1":21891,"PHASE1":21893,"PHASE2":21895,"PHASE3":21904,"PHASE4":21906,"NA":21908},{"trials":21892,"activeCount":101},[],{"trials":21894,"activeCount":101},[],{"trials":21896,"activeCount":101},[21897],{"nctId":21898,"briefTitle":21899,"status":107,"phases":21900,"primaryCompletion":294,"completion":1609,"start":21901,"enrollment":2845,"conditions":21902,"interventions":21903},"NCT04978012","Fluzoparib and Camrelizumab in Treating Patients With R\u002FM NPC That Progressed After First-line Chemotherapy",[90],"2021-07-25",[35,6599],[21889],{"trials":21905,"activeCount":101},[],{"trials":21907,"activeCount":101},[],{"trials":21909,"activeCount":101},[],{"intervention":21911,"totalTrials":651,"cells":21912},"Sintilimab plus Chemotherapy",{"EARLY_PHASE1":21913,"PHASE1":21915,"PHASE2":21917,"PHASE3":21927,"PHASE4":21929,"NA":21931},{"trials":21914,"activeCount":101},[],{"trials":21916,"activeCount":101},[],{"trials":21918,"activeCount":101},[21919],{"nctId":21920,"briefTitle":21921,"status":365,"phases":21922,"primaryCompletion":21923,"completion":285,"start":21924,"enrollment":19860,"conditions":21925,"interventions":21926},"NCT03985046","Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC",[90],"2021-05-31","2019-10-10",[27],[21911],{"trials":21928,"activeCount":101},[],{"trials":21930,"activeCount":101},[],{"trials":21932,"activeCount":101},[],{"intervention":383,"totalTrials":651,"cells":21934},{"EARLY_PHASE1":21935,"PHASE1":21937,"PHASE2":21939,"PHASE3":21945,"PHASE4":21947,"NA":21949},{"trials":21936,"activeCount":101},[],{"trials":21938,"activeCount":101},[],{"trials":21940,"activeCount":101},[21941],{"nctId":373,"briefTitle":374,"status":107,"phases":21942,"primaryCompletion":376,"completion":377,"start":378,"enrollment":379,"conditions":21943,"interventions":21944},[90],[18,381],[383,96],{"trials":21946,"activeCount":101},[],{"trials":21948,"activeCount":101},[],{"trials":21950,"activeCount":101},[],{"intervention":21952,"totalTrials":651,"cells":21953},"IFO, VP-16, DDP, DXM",{"EARLY_PHASE1":21954,"PHASE1":21956,"PHASE2":21958,"PHASE3":21966,"PHASE4":21968,"NA":21970},{"trials":21955,"activeCount":101},[],{"trials":21957,"activeCount":101},[],{"trials":21959,"activeCount":101},[21960],{"nctId":21961,"briefTitle":21962,"status":107,"phases":21963,"primaryCompletion":1700,"completion":1700,"start":20607,"enrollment":111,"conditions":21964,"interventions":21965},"NCT00568607","Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK\u002FT Cell Lymphoma",[90],[17208],[21952],{"trials":21967,"activeCount":101},[],{"trials":21969,"activeCount":101},[],{"trials":21971,"activeCount":101},[],{"intervention":21973,"totalTrials":651,"cells":21974},"capecitabine and pseudomonas aeruginosa combination",{"EARLY_PHASE1":21975,"PHASE1":21977,"PHASE2":21979,"PHASE3":21987,"PHASE4":21989,"NA":21991},{"trials":21976,"activeCount":101},[],{"trials":21978,"activeCount":101},[],{"trials":21980,"activeCount":101},[21981],{"nctId":21982,"briefTitle":21983,"status":365,"phases":21984,"primaryCompletion":2509,"completion":2509,"start":17896,"enrollment":213,"conditions":21985,"interventions":21986},"NCT01380808","Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)",[90],[33],[21973],{"trials":21988,"activeCount":101},[],{"trials":21990,"activeCount":101},[],{"trials":21992,"activeCount":101},[],{"intervention":2529,"totalTrials":651,"cells":21994},{"EARLY_PHASE1":21995,"PHASE1":21997,"PHASE2":21999,"PHASE3":22005,"PHASE4":22007,"NA":22009},{"trials":21996,"activeCount":101},[],{"trials":21998,"activeCount":101},[],{"trials":22000,"activeCount":101},[22001],{"nctId":2522,"briefTitle":2523,"status":107,"phases":22002,"primaryCompletion":485,"completion":485,"start":388,"enrollment":334,"conditions":22003,"interventions":22004},[90],[2526],[57,2528,2529],{"trials":22006,"activeCount":101},[],{"trials":22008,"activeCount":101},[],{"trials":22010,"activeCount":101},[],{"intervention":22012,"totalTrials":651,"cells":22013},"L-asparaginase",{"EARLY_PHASE1":22014,"PHASE1":22016,"PHASE2":22018,"PHASE3":22026,"PHASE4":22028,"NA":22030},{"trials":22015,"activeCount":101},[],{"trials":22017,"activeCount":101},[],{"trials":22019,"activeCount":101},[22020],{"nctId":22021,"briefTitle":22022,"status":365,"phases":22023,"primaryCompletion":497,"completion":497,"start":3101,"enrollment":737,"conditions":22024,"interventions":22025},"NCT00854425","L-asparaginase Monotherapy as Salvage Treatment in Patients With NK\u002FT Cell Lymphoma",[90],[17208],[22012],{"trials":22027,"activeCount":101},[],{"trials":22029,"activeCount":101},[],{"trials":22031,"activeCount":101},[],{"intervention":22033,"totalTrials":651,"cells":22034},"ECF-endostar",{"EARLY_PHASE1":22035,"PHASE1":22037,"PHASE2":22039,"PHASE3":22047,"PHASE4":22049,"NA":22051},{"trials":22036,"activeCount":101},[],{"trials":22038,"activeCount":101},[],{"trials":22040,"activeCount":101},[22041],{"nctId":22042,"briefTitle":22043,"status":365,"phases":22044,"primaryCompletion":1700,"completion":1700,"start":563,"enrollment":31,"conditions":22045,"interventions":22046},"NCT00595972","Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer",[90],[24],[22033],{"trials":22048,"activeCount":101},[],{"trials":22050,"activeCount":101},[],{"trials":22052,"activeCount":101},[],{"intervention":22054,"totalTrials":651,"cells":22055},"Abraxane and Cisplatin combination",{"EARLY_PHASE1":22056,"PHASE1":22058,"PHASE2":22060,"PHASE3":22068,"PHASE4":22070,"NA":22072},{"trials":22057,"activeCount":101},[],{"trials":22059,"activeCount":101},[],{"trials":22061,"activeCount":101},[22062],{"nctId":22063,"briefTitle":22064,"status":365,"phases":22065,"primaryCompletion":3908,"completion":109,"start":3166,"enrollment":2123,"conditions":22066,"interventions":22067},"NCT01149798","A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer",[90],[33],[22054],{"trials":22069,"activeCount":101},[],{"trials":22071,"activeCount":101},[],{"trials":22073,"activeCount":101},[],{"intervention":22075,"totalTrials":651,"cells":22076},"Camrelizumab Combined With Apatinib",{"EARLY_PHASE1":22077,"PHASE1":22079,"PHASE2":22081,"PHASE3":22091,"PHASE4":22093,"NA":22095},{"trials":22078,"activeCount":101},[],{"trials":22080,"activeCount":101},[],{"trials":22082,"activeCount":101},[22083],{"nctId":22084,"briefTitle":22085,"status":107,"phases":22086,"primaryCompletion":6036,"completion":1979,"start":7855,"enrollment":1434,"conditions":22087,"interventions":22090},"NCT05265793","Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma",[90],[6736,22088,13433,22089],"VEGFR-TKI","Carcinosarcoma",[22075],{"trials":22092,"activeCount":101},[],{"trials":22094,"activeCount":101},[],{"trials":22096,"activeCount":101},[],{"intervention":22098,"totalTrials":651,"cells":22099},"chewed mint gum",{"EARLY_PHASE1":22100,"PHASE1":22102,"PHASE2":22104,"PHASE3":22115,"PHASE4":22117,"NA":22119},{"trials":22101,"activeCount":101},[],{"trials":22103,"activeCount":101},[],{"trials":22105,"activeCount":101},[22106],{"nctId":22107,"briefTitle":22108,"status":107,"phases":22109,"primaryCompletion":22110,"completion":3180,"start":22111,"enrollment":159,"conditions":22112,"interventions":22114},"NCT03885752","The Effects of Preoperatively Chewing Gum on Sore Throat After General Anaesthesia With a Laryngeal Mask",[89,90],"2019-05-25","2019-03-25",[22113],"Postoperative Sore Throat",[22098],{"trials":22116,"activeCount":101},[],{"trials":22118,"activeCount":101},[],{"trials":22120,"activeCount":101},[],{"intervention":22122,"totalTrials":651,"cells":22123},"Capecitabine combined with lenvatinib and tislelizumab",{"EARLY_PHASE1":22124,"PHASE1":22126,"PHASE2":22128,"PHASE3":22138,"PHASE4":22140,"NA":22142},{"trials":22125,"activeCount":101},[],{"trials":22127,"activeCount":101},[],{"trials":22129,"activeCount":101},[22130],{"nctId":22131,"briefTitle":22132,"status":365,"phases":22133,"primaryCompletion":293,"completion":1609,"start":22134,"enrollment":427,"conditions":22135,"interventions":22137},"NCT05254847","Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC",[90],"2022-02-24",[22136],"Biliary Tract Cancer",[22122],{"trials":22139,"activeCount":101},[],{"trials":22141,"activeCount":101},[],{"trials":22143,"activeCount":101},[],{"intervention":6041,"totalTrials":651,"cells":22145},{"EARLY_PHASE1":22146,"PHASE1":22148,"PHASE2":22150,"PHASE3":22156,"PHASE4":22158,"NA":22160},{"trials":22147,"activeCount":101},[],{"trials":22149,"activeCount":101},[],{"trials":22151,"activeCount":101},[22152],{"nctId":6032,"briefTitle":6033,"status":107,"phases":22153,"primaryCompletion":6035,"completion":6036,"start":6037,"enrollment":1434,"conditions":22154,"interventions":22155},[90],[6039],[278,6041,6042],{"trials":22157,"activeCount":101},[],{"trials":22159,"activeCount":101},[],{"trials":22161,"activeCount":101},[],{"intervention":6042,"totalTrials":651,"cells":22163},{"EARLY_PHASE1":22164,"PHASE1":22166,"PHASE2":22168,"PHASE3":22174,"PHASE4":22176,"NA":22178},{"trials":22165,"activeCount":101},[],{"trials":22167,"activeCount":101},[],{"trials":22169,"activeCount":101},[22170],{"nctId":6032,"briefTitle":6033,"status":107,"phases":22171,"primaryCompletion":6035,"completion":6036,"start":6037,"enrollment":1434,"conditions":22172,"interventions":22173},[90],[6039],[278,6041,6042],{"trials":22175,"activeCount":101},[],{"trials":22177,"activeCount":101},[],{"trials":22179,"activeCount":101},[],{"intervention":22181,"totalTrials":651,"cells":22182},"Zimberelimab",{"EARLY_PHASE1":22183,"PHASE1":22185,"PHASE2":22187,"PHASE3":22197,"PHASE4":22199,"NA":22201},{"trials":22184,"activeCount":101},[],{"trials":22186,"activeCount":101},[],{"trials":22188,"activeCount":101},[22189],{"nctId":22190,"briefTitle":22191,"status":107,"phases":22192,"primaryCompletion":5046,"completion":5046,"start":1451,"enrollment":1146,"conditions":22193,"interventions":22195},"NCT05759312","Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma",[89,90],[22194],"Ovarian Clear Cell Carcinoma",[22181,22196],"Metformin Hydrochloride",{"trials":22198,"activeCount":101},[],{"trials":22200,"activeCount":101},[],{"trials":22202,"activeCount":101},[],{"intervention":22196,"totalTrials":651,"cells":22204},{"EARLY_PHASE1":22205,"PHASE1":22207,"PHASE2":22209,"PHASE3":22215,"PHASE4":22217,"NA":22219},{"trials":22206,"activeCount":101},[],{"trials":22208,"activeCount":101},[],{"trials":22210,"activeCount":101},[22211],{"nctId":22190,"briefTitle":22191,"status":107,"phases":22212,"primaryCompletion":5046,"completion":5046,"start":1451,"enrollment":1146,"conditions":22213,"interventions":22214},[89,90],[22194],[22181,22196],{"trials":22216,"activeCount":101},[],{"trials":22218,"activeCount":101},[],{"trials":22220,"activeCount":101},[],{"intervention":393,"totalTrials":651,"cells":22222},{"EARLY_PHASE1":22223,"PHASE1":22225,"PHASE2":22227,"PHASE3":22233,"PHASE4":22235,"NA":22237},{"trials":22224,"activeCount":101},[],{"trials":22226,"activeCount":101},[],{"trials":22228,"activeCount":101},[22229],{"nctId":385,"briefTitle":386,"status":107,"phases":22230,"primaryCompletion":388,"completion":389,"start":390,"enrollment":296,"conditions":22231,"interventions":22232},[90],[24],[393,129,96],{"trials":22234,"activeCount":101},[],{"trials":22236,"activeCount":101},[],{"trials":22238,"activeCount":101},[],{"intervention":22240,"totalTrials":651,"cells":22241},"HAIC-GEMOX+Cadonilimab+Regorafenib",{"EARLY_PHASE1":22242,"PHASE1":22244,"PHASE2":22246,"PHASE3":22256,"PHASE4":22258,"NA":22260},{"trials":22243,"activeCount":101},[],{"trials":22245,"activeCount":101},[],{"trials":22247,"activeCount":101},[22248],{"nctId":22249,"briefTitle":22250,"status":107,"phases":22251,"primaryCompletion":22252,"completion":6972,"start":22253,"enrollment":1434,"conditions":22254,"interventions":22255},"NCT06335927","HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC",[90],"2025-05-10","2023-05-11",[1492],[22240],{"trials":22257,"activeCount":101},[],{"trials":22259,"activeCount":101},[],{"trials":22261,"activeCount":101},[],{"intervention":2141,"totalTrials":651,"cells":22263},{"EARLY_PHASE1":22264,"PHASE1":22266,"PHASE2":22268,"PHASE3":22274,"PHASE4":22276,"NA":22278},{"trials":22265,"activeCount":101},[],{"trials":22267,"activeCount":101},[],{"trials":22269,"activeCount":101},[22270],{"nctId":2130,"briefTitle":2131,"status":107,"phases":22271,"primaryCompletion":426,"completion":2133,"start":2134,"enrollment":2135,"conditions":22272,"interventions":22273},[90],[2137,2138,2139],[2141,2111,1384],{"trials":22275,"activeCount":101},[],{"trials":22277,"activeCount":101},[],{"trials":22279,"activeCount":101},[],{"intervention":22281,"totalTrials":651,"cells":22282},"the rechallenge regimen",{"EARLY_PHASE1":22283,"PHASE1":22285,"PHASE2":22287,"PHASE3":22297,"PHASE4":22299,"NA":22301},{"trials":22284,"activeCount":101},[],{"trials":22286,"activeCount":101},[],{"trials":22288,"activeCount":101},[22289],{"nctId":22290,"briefTitle":22291,"status":365,"phases":22292,"primaryCompletion":22293,"completion":1802,"start":22294,"enrollment":6606,"conditions":22295,"interventions":22296},"NCT03485027","Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer",[90],"2022-12-24","2018-01-24",[6157,3250],[22281],{"trials":22298,"activeCount":101},[],{"trials":22300,"activeCount":101},[],{"trials":22302,"activeCount":101},[],{"intervention":22304,"totalTrials":651,"cells":22305},"Cetuximab; mFOLFOX6",{"EARLY_PHASE1":22306,"PHASE1":22308,"PHASE2":22310,"PHASE3":22318,"PHASE4":22320,"NA":22322},{"trials":22307,"activeCount":101},[],{"trials":22309,"activeCount":101},[],{"trials":22311,"activeCount":101},[22312],{"nctId":22313,"briefTitle":22314,"status":107,"phases":22315,"primaryCompletion":17725,"completion":388,"start":1700,"enrollment":8340,"conditions":22316,"interventions":22317},"NCT01322178","Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients",[90],[18,1554],[22304],{"trials":22319,"activeCount":101},[],{"trials":22321,"activeCount":101},[],{"trials":22323,"activeCount":101},[],{"intervention":22325,"totalTrials":651,"cells":22326},"Raltitrexed and S-1",{"EARLY_PHASE1":22327,"PHASE1":22329,"PHASE2":22331,"PHASE3":22340,"PHASE4":22342,"NA":22344},{"trials":22328,"activeCount":101},[],{"trials":22330,"activeCount":101},[],{"trials":22332,"activeCount":101},[22333],{"nctId":22334,"briefTitle":22335,"status":107,"phases":22336,"primaryCompletion":15703,"completion":15703,"start":22337,"enrollment":6670,"conditions":22338,"interventions":22339},"NCT02618356","Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer",[90],"2015-12-25",[9002],[22325],{"trials":22341,"activeCount":101},[],{"trials":22343,"activeCount":101},[],{"trials":22345,"activeCount":101},[],{"intervention":22347,"totalTrials":651,"cells":22348},"Granisetron Transdermal Delivery System",{"EARLY_PHASE1":22349,"PHASE1":22351,"PHASE2":22353,"PHASE3":22363,"PHASE4":22365,"NA":22367},{"trials":22350,"activeCount":101},[],{"trials":22352,"activeCount":101},[],{"trials":22354,"activeCount":101},[22355],{"nctId":22356,"briefTitle":22357,"status":107,"phases":22358,"primaryCompletion":22359,"completion":285,"start":22360,"enrollment":111,"conditions":22361,"interventions":22362},"NCT04472143","Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents",[90],"2022-09-18","2020-07-18",[3998],[22347],{"trials":22364,"activeCount":101},[],{"trials":22366,"activeCount":101},[],{"trials":22368,"activeCount":101},[],{"intervention":22370,"totalTrials":651,"cells":22371},"GP+PD-1+Tight",{"EARLY_PHASE1":22372,"PHASE1":22374,"PHASE2":22376,"PHASE3":22384,"PHASE4":22386,"NA":22388},{"trials":22373,"activeCount":101},[],{"trials":22375,"activeCount":101},[],{"trials":22377,"activeCount":101},[22378],{"nctId":22379,"briefTitle":22380,"status":3025,"phases":22381,"primaryCompletion":353,"completion":353,"start":632,"enrollment":101,"conditions":22382,"interventions":22383},"NCT05019677","GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC",[90],[1492],[22370],{"trials":22385,"activeCount":101},[],{"trials":22387,"activeCount":101},[],{"trials":22389,"activeCount":101},[],{"intervention":7878,"totalTrials":651,"cells":22391},{"EARLY_PHASE1":22392,"PHASE1":22394,"PHASE2":22396,"PHASE3":22402,"PHASE4":22404,"NA":22406},{"trials":22393,"activeCount":101},[],{"trials":22395,"activeCount":101},[],{"trials":22397,"activeCount":101},[22398],{"nctId":7872,"briefTitle":7873,"status":107,"phases":22399,"primaryCompletion":486,"completion":56,"start":7875,"enrollment":2991,"conditions":22400,"interventions":22401},[90],[1576],[7878,1170],{"trials":22403,"activeCount":101},[],{"trials":22405,"activeCount":101},[],{"trials":22407,"activeCount":101},[],{"intervention":22409,"totalTrials":651,"cells":22410},"Pyrotinib with or without trastuzumab",{"EARLY_PHASE1":22411,"PHASE1":22413,"PHASE2":22415,"PHASE3":22426,"PHASE4":22428,"NA":22430},{"trials":22412,"activeCount":101},[],{"trials":22414,"activeCount":101},[],{"trials":22416,"activeCount":101},[22417],{"nctId":22418,"briefTitle":22419,"status":107,"phases":22420,"primaryCompletion":22421,"completion":295,"start":6831,"enrollment":111,"conditions":22422,"interventions":22425},"NCT04960943","Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors",[90],"2022-09-09",[22423,22424],"Gastrointestinal Tumor","Effect of Drug",[22409],{"trials":22427,"activeCount":101},[],{"trials":22429,"activeCount":101},[],{"trials":22431,"activeCount":101},[],{"intervention":22433,"totalTrials":651,"cells":22434},"Camrelizumab plus Famitinib with\u002Fwithout nab-Palitaxel",{"EARLY_PHASE1":22435,"PHASE1":22437,"PHASE2":22439,"PHASE3":22447,"PHASE4":22449,"NA":22451},{"trials":22436,"activeCount":101},[],{"trials":22438,"activeCount":101},[],{"trials":22440,"activeCount":101},[22441],{"nctId":22442,"briefTitle":22443,"status":107,"phases":22444,"primaryCompletion":51,"completion":51,"start":295,"enrollment":137,"conditions":22445,"interventions":22446},"NCT05670925","A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.",[90],[1518],[22433],{"trials":22448,"activeCount":101},[],{"trials":22450,"activeCount":101},[],{"trials":22452,"activeCount":101},[],{"intervention":22454,"totalTrials":651,"cells":22455},"Pyrotinib combined with pemetrexed plus carboplatin",{"EARLY_PHASE1":22456,"PHASE1":22458,"PHASE2":22460,"PHASE3":22469,"PHASE4":22471,"NA":22473},{"trials":22457,"activeCount":101},[],{"trials":22459,"activeCount":101},[],{"trials":22461,"activeCount":101},[22462],{"nctId":22463,"briefTitle":22464,"status":107,"phases":22465,"primaryCompletion":426,"completion":285,"start":22466,"enrollment":20584,"conditions":22467,"interventions":22468},"NCT04706949","Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment",[90],"2020-12-07",[2137],[22454],{"trials":22470,"activeCount":101},[],{"trials":22472,"activeCount":101},[],{"trials":22474,"activeCount":101},[],{"intervention":16417,"totalTrials":651,"cells":22476},{"EARLY_PHASE1":22477,"PHASE1":22479,"PHASE2":22481,"PHASE3":22487,"PHASE4":22489,"NA":22491},{"trials":22478,"activeCount":101},[],{"trials":22480,"activeCount":101},[],{"trials":22482,"activeCount":101},[22483],{"nctId":16411,"briefTitle":16412,"status":107,"phases":22484,"primaryCompletion":1203,"completion":1203,"start":16414,"enrollment":1531,"conditions":22485,"interventions":22486},[90],[15],[16393,16417],{"trials":22488,"activeCount":101},[],{"trials":22490,"activeCount":101},[],{"trials":22492,"activeCount":101},[],{"intervention":22494,"totalTrials":651,"cells":22495},"Injection of A166",{"EARLY_PHASE1":22496,"PHASE1":22498,"PHASE2":22500,"PHASE3":22508,"PHASE4":22510,"NA":22512},{"trials":22497,"activeCount":101},[],{"trials":22499,"activeCount":101},[],{"trials":22501,"activeCount":101},[22502],{"nctId":22503,"briefTitle":22504,"status":107,"phases":22505,"primaryCompletion":293,"completion":294,"start":199,"enrollment":2845,"conditions":22506,"interventions":22507},"NCT05346328","HER2-positive Breast Cancer Project Initiated by Investigators",[90],[15],[22494],{"trials":22509,"activeCount":101},[],{"trials":22511,"activeCount":101},[],{"trials":22513,"activeCount":101},[],{"intervention":18260,"totalTrials":651,"cells":22515},{"EARLY_PHASE1":22516,"PHASE1":22518,"PHASE2":22520,"PHASE3":22526,"PHASE4":22528,"NA":22530},{"trials":22517,"activeCount":101},[],{"trials":22519,"activeCount":101},[],{"trials":22521,"activeCount":101},[22522],{"nctId":18253,"briefTitle":18254,"status":107,"phases":22523,"primaryCompletion":8975,"completion":1451,"start":16914,"enrollment":2709,"conditions":22524,"interventions":22525},[90],[8780],[18258,18259,18260,18261,18262],{"trials":22527,"activeCount":101},[],{"trials":22529,"activeCount":101},[],{"trials":22531,"activeCount":101},[],{"intervention":18262,"totalTrials":651,"cells":22533},{"EARLY_PHASE1":22534,"PHASE1":22536,"PHASE2":22538,"PHASE3":22544,"PHASE4":22546,"NA":22548},{"trials":22535,"activeCount":101},[],{"trials":22537,"activeCount":101},[],{"trials":22539,"activeCount":101},[22540],{"nctId":18253,"briefTitle":18254,"status":107,"phases":22541,"primaryCompletion":8975,"completion":1451,"start":16914,"enrollment":2709,"conditions":22542,"interventions":22543},[90],[8780],[18258,18259,18260,18261,18262],{"trials":22545,"activeCount":101},[],{"trials":22547,"activeCount":101},[],{"trials":22549,"activeCount":101},[],{"intervention":454,"totalTrials":651,"cells":22551},{"EARLY_PHASE1":22552,"PHASE1":22554,"PHASE2":22556,"PHASE3":22562,"PHASE4":22564,"NA":22566},{"trials":22553,"activeCount":101},[],{"trials":22555,"activeCount":101},[],{"trials":22557,"activeCount":101},[22558],{"nctId":444,"briefTitle":445,"status":107,"phases":22559,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":22560,"interventions":22561},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":22563,"activeCount":101},[],{"trials":22565,"activeCount":101},[],{"trials":22567,"activeCount":101},[],{"intervention":456,"totalTrials":651,"cells":22569},{"EARLY_PHASE1":22570,"PHASE1":22572,"PHASE2":22574,"PHASE3":22580,"PHASE4":22582,"NA":22584},{"trials":22571,"activeCount":101},[],{"trials":22573,"activeCount":101},[],{"trials":22575,"activeCount":101},[22576],{"nctId":444,"briefTitle":445,"status":107,"phases":22577,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":22578,"interventions":22579},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":22581,"activeCount":101},[],{"trials":22583,"activeCount":101},[],{"trials":22585,"activeCount":101},[],{"intervention":457,"totalTrials":651,"cells":22587},{"EARLY_PHASE1":22588,"PHASE1":22590,"PHASE2":22592,"PHASE3":22598,"PHASE4":22600,"NA":22602},{"trials":22589,"activeCount":101},[],{"trials":22591,"activeCount":101},[],{"trials":22593,"activeCount":101},[22594],{"nctId":444,"briefTitle":445,"status":107,"phases":22595,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":22596,"interventions":22597},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":22599,"activeCount":101},[],{"trials":22601,"activeCount":101},[],{"trials":22603,"activeCount":101},[],{"intervention":460,"totalTrials":651,"cells":22605},{"EARLY_PHASE1":22606,"PHASE1":22608,"PHASE2":22610,"PHASE3":22616,"PHASE4":22618,"NA":22620},{"trials":22607,"activeCount":101},[],{"trials":22609,"activeCount":101},[],{"trials":22611,"activeCount":101},[22612],{"nctId":444,"briefTitle":445,"status":107,"phases":22613,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":22614,"interventions":22615},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":22617,"activeCount":101},[],{"trials":22619,"activeCount":101},[],{"trials":22621,"activeCount":101},[],{"intervention":462,"totalTrials":651,"cells":22623},{"EARLY_PHASE1":22624,"PHASE1":22626,"PHASE2":22628,"PHASE3":22634,"PHASE4":22636,"NA":22638},{"trials":22625,"activeCount":101},[],{"trials":22627,"activeCount":101},[],{"trials":22629,"activeCount":101},[22630],{"nctId":444,"briefTitle":445,"status":107,"phases":22631,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":22632,"interventions":22633},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":22635,"activeCount":101},[],{"trials":22637,"activeCount":101},[],{"trials":22639,"activeCount":101},[],{"intervention":465,"totalTrials":651,"cells":22641},{"EARLY_PHASE1":22642,"PHASE1":22644,"PHASE2":22646,"PHASE3":22652,"PHASE4":22654,"NA":22656},{"trials":22643,"activeCount":101},[],{"trials":22645,"activeCount":101},[],{"trials":22647,"activeCount":101},[22648],{"nctId":444,"briefTitle":445,"status":107,"phases":22649,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":22650,"interventions":22651},[90],[15,452],[454,455,456,433,96,457,458,253,459,460,461,462,463,464,465],{"trials":22653,"activeCount":101},[],{"trials":22655,"activeCount":101},[],{"trials":22657,"activeCount":101},[],{"intervention":22659,"totalTrials":651,"cells":22660},"Systemic therapy",{"EARLY_PHASE1":22661,"PHASE1":22663,"PHASE2":22665,"PHASE3":22674,"PHASE4":22676,"NA":22678},{"trials":22662,"activeCount":101},[],{"trials":22664,"activeCount":101},[],{"trials":22666,"activeCount":101},[22667],{"nctId":22668,"briefTitle":22669,"status":365,"phases":22670,"primaryCompletion":41,"completion":19656,"start":6832,"enrollment":3648,"conditions":22671,"interventions":22673},"NCT03904927","Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma",[90],[22672],"Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma",[22659],{"trials":22675,"activeCount":101},[],{"trials":22677,"activeCount":101},[],{"trials":22679,"activeCount":101},[],{"intervention":22681,"totalTrials":651,"cells":22682},"Capecitabine and Oxaliplatin",{"EARLY_PHASE1":22683,"PHASE1":22685,"PHASE2":22687,"PHASE3":22697,"PHASE4":22699,"NA":22701},{"trials":22684,"activeCount":101},[],{"trials":22686,"activeCount":101},[],{"trials":22688,"activeCount":101},[22689],{"nctId":22690,"briefTitle":22691,"status":1607,"phases":22692,"primaryCompletion":2500,"completion":22693,"start":22694,"enrollment":25,"conditions":22695,"interventions":22696},"NCT00568529","Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer",[90],"2010-02","2007-10",[24],[22681],{"trials":22698,"activeCount":101},[],{"trials":22700,"activeCount":101},[],{"trials":22702,"activeCount":101},[],{"intervention":22704,"totalTrials":651,"cells":22705},"NKG2D-based CAR T-cells",{"EARLY_PHASE1":22706,"PHASE1":22708,"PHASE2":22718,"PHASE3":22720,"PHASE4":22722,"NA":22724},{"trials":22707,"activeCount":101},[],{"trials":22709,"activeCount":101},[22710],{"nctId":22711,"briefTitle":22712,"status":107,"phases":22713,"primaryCompletion":200,"completion":1724,"start":631,"enrollment":1300,"conditions":22714,"interventions":22717},"NCT05131763","NKG2D-based CAR T-cells Immunotherapy for Patient With r\u002Fr NKG2DL+ Solid Tumors",[89],[21,22715,22716,1131],"Glioblastoma","Medulloblastoma",[22704],{"trials":22719,"activeCount":101},[],{"trials":22721,"activeCount":101},[],{"trials":22723,"activeCount":101},[],{"trials":22725,"activeCount":101},[],{"intervention":22727,"totalTrials":651,"cells":22728},"Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle",{"EARLY_PHASE1":22729,"PHASE1":22731,"PHASE2":22741,"PHASE3":22743,"PHASE4":22745,"NA":22747},{"trials":22730,"activeCount":101},[],{"trials":22732,"activeCount":101},[22733],{"nctId":22734,"briefTitle":22735,"status":107,"phases":22736,"primaryCompletion":1203,"completion":486,"start":22737,"enrollment":36,"conditions":22738,"interventions":22740},"NCT04625894","The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer",[89],"2020-12",[22739],"Oligometastatic Gastrointestinal Cancer",[22727],{"trials":22742,"activeCount":101},[],{"trials":22744,"activeCount":101},[],{"trials":22746,"activeCount":101},[],{"trials":22748,"activeCount":101},[],{"intervention":22750,"totalTrials":651,"cells":22751},"HAIC、Bevacizumab、Camrelizumab",{"EARLY_PHASE1":22752,"PHASE1":22754,"PHASE2":22762,"PHASE3":22764,"PHASE4":22766,"NA":22768},{"trials":22753,"activeCount":101},[],{"trials":22755,"activeCount":101},[22756],{"nctId":22757,"briefTitle":22758,"status":107,"phases":22759,"primaryCompletion":751,"completion":717,"start":1203,"enrollment":334,"conditions":22760,"interventions":22761},"NCT05643417","Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy",[89],[21531],[22750],{"trials":22763,"activeCount":101},[],{"trials":22765,"activeCount":101},[],{"trials":22767,"activeCount":101},[],{"trials":22769,"activeCount":101},[],{"intervention":22771,"totalTrials":651,"cells":22772},"JS001 120mg+GP",{"EARLY_PHASE1":22773,"PHASE1":22775,"PHASE2":22787,"PHASE3":22789,"PHASE4":22791,"NA":22793},{"trials":22774,"activeCount":101},[],{"trials":22776,"activeCount":101},[22777],{"nctId":22778,"briefTitle":22779,"status":107,"phases":22780,"primaryCompletion":260,"completion":260,"start":22781,"enrollment":6587,"conditions":22782,"interventions":22783},"NCT03251313","PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients",[89],"2019-05-15",[250],[22771,22784,22785,22786],"JS001 240mg+GP","JS001 480mg+GP","GP followed by JS001",{"trials":22788,"activeCount":101},[],{"trials":22790,"activeCount":101},[],{"trials":22792,"activeCount":101},[],{"trials":22794,"activeCount":101},[],{"intervention":22784,"totalTrials":651,"cells":22796},{"EARLY_PHASE1":22797,"PHASE1":22799,"PHASE2":22805,"PHASE3":22807,"PHASE4":22809,"NA":22811},{"trials":22798,"activeCount":101},[],{"trials":22800,"activeCount":101},[22801],{"nctId":22778,"briefTitle":22779,"status":107,"phases":22802,"primaryCompletion":260,"completion":260,"start":22781,"enrollment":6587,"conditions":22803,"interventions":22804},[89],[250],[22771,22784,22785,22786],{"trials":22806,"activeCount":101},[],{"trials":22808,"activeCount":101},[],{"trials":22810,"activeCount":101},[],{"trials":22812,"activeCount":101},[],{"intervention":22785,"totalTrials":651,"cells":22814},{"EARLY_PHASE1":22815,"PHASE1":22817,"PHASE2":22823,"PHASE3":22825,"PHASE4":22827,"NA":22829},{"trials":22816,"activeCount":101},[],{"trials":22818,"activeCount":101},[22819],{"nctId":22778,"briefTitle":22779,"status":107,"phases":22820,"primaryCompletion":260,"completion":260,"start":22781,"enrollment":6587,"conditions":22821,"interventions":22822},[89],[250],[22771,22784,22785,22786],{"trials":22824,"activeCount":101},[],{"trials":22826,"activeCount":101},[],{"trials":22828,"activeCount":101},[],{"trials":22830,"activeCount":101},[],{"intervention":22786,"totalTrials":651,"cells":22832},{"EARLY_PHASE1":22833,"PHASE1":22835,"PHASE2":22841,"PHASE3":22843,"PHASE4":22845,"NA":22847},{"trials":22834,"activeCount":101},[],{"trials":22836,"activeCount":101},[22837],{"nctId":22778,"briefTitle":22779,"status":107,"phases":22838,"primaryCompletion":260,"completion":260,"start":22781,"enrollment":6587,"conditions":22839,"interventions":22840},[89],[250],[22771,22784,22785,22786],{"trials":22842,"activeCount":101},[],{"trials":22844,"activeCount":101},[],{"trials":22846,"activeCount":101},[],{"trials":22848,"activeCount":101},[],{"intervention":22850,"totalTrials":651,"cells":22851},"Chinese herb",{"EARLY_PHASE1":22852,"PHASE1":22854,"PHASE2":22863,"PHASE3":22865,"PHASE4":22867,"NA":22869},{"trials":22853,"activeCount":101},[],{"trials":22855,"activeCount":101},[22856],{"nctId":22857,"briefTitle":22858,"status":365,"phases":22859,"primaryCompletion":3003,"completion":15838,"start":3003,"enrollment":737,"conditions":22860,"interventions":22862},"NCT01677325","The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine",[89],[22861],"NAFLD( Non-alcoholic Fatty Liver Disease )",[22850],{"trials":22864,"activeCount":101},[],{"trials":22866,"activeCount":101},[],{"trials":22868,"activeCount":101},[],{"trials":22870,"activeCount":101},[],{"intervention":2785,"totalTrials":651,"cells":22872},{"EARLY_PHASE1":22873,"PHASE1":22875,"PHASE2":22881,"PHASE3":22883,"PHASE4":22885,"NA":22887},{"trials":22874,"activeCount":101},[],{"trials":22876,"activeCount":101},[22877],{"nctId":2779,"briefTitle":2780,"status":107,"phases":22878,"primaryCompletion":1530,"completion":354,"start":1802,"enrollment":25,"conditions":22879,"interventions":22880},[89],[2783],[2785,2764],{"trials":22882,"activeCount":101},[],{"trials":22884,"activeCount":101},[],{"trials":22886,"activeCount":101},[],{"trials":22888,"activeCount":101},[],{"intervention":22890,"totalTrials":651,"cells":22891},"cisplatin+Nab-paclitaxel+GEM",{"EARLY_PHASE1":22892,"PHASE1":22894,"PHASE2":22904,"PHASE3":22906,"PHASE4":22908,"NA":22910},{"trials":22893,"activeCount":101},[],{"trials":22895,"activeCount":101},[22896],{"nctId":22897,"briefTitle":22898,"status":107,"phases":22899,"primaryCompletion":22900,"completion":260,"start":622,"enrollment":13384,"conditions":22901,"interventions":22902},"NCT04707118","Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy",[89],"2021-12-30",[7741],[22890,22903],"Nab-paclitaxel+GEM",{"trials":22905,"activeCount":101},[],{"trials":22907,"activeCount":101},[],{"trials":22909,"activeCount":101},[],{"trials":22911,"activeCount":101},[],{"intervention":22903,"totalTrials":651,"cells":22913},{"EARLY_PHASE1":22914,"PHASE1":22916,"PHASE2":22922,"PHASE3":22924,"PHASE4":22926,"NA":22928},{"trials":22915,"activeCount":101},[],{"trials":22917,"activeCount":101},[22918],{"nctId":22897,"briefTitle":22898,"status":107,"phases":22919,"primaryCompletion":22900,"completion":260,"start":622,"enrollment":13384,"conditions":22920,"interventions":22921},[89],[7741],[22890,22903],{"trials":22923,"activeCount":101},[],{"trials":22925,"activeCount":101},[],{"trials":22927,"activeCount":101},[],{"trials":22929,"activeCount":101},[],{"intervention":22931,"totalTrials":651,"cells":22932},"Autologous Tumor Infiltrating Lymphocytes (C-TIL052A)",{"EARLY_PHASE1":22933,"PHASE1":22935,"PHASE2":22943,"PHASE3":22945,"PHASE4":22947,"NA":22949},{"trials":22934,"activeCount":101},[],{"trials":22936,"activeCount":101},[22937],{"nctId":22938,"briefTitle":22939,"status":107,"phases":22940,"primaryCompletion":377,"completion":377,"start":378,"enrollment":1146,"conditions":22941,"interventions":22942},"NCT05475847","Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer",[89],[9602],[22931],{"trials":22944,"activeCount":101},[],{"trials":22946,"activeCount":101},[],{"trials":22948,"activeCount":101},[],{"trials":22950,"activeCount":101},[],{"intervention":22952,"totalTrials":651,"cells":22953},"Herpes virus T3011",{"EARLY_PHASE1":22954,"PHASE1":22956,"PHASE2":22965,"PHASE3":22967,"PHASE4":22969,"NA":22971},{"trials":22955,"activeCount":101},[],{"trials":22957,"activeCount":101},[22958],{"nctId":22959,"briefTitle":22960,"status":107,"phases":22961,"primaryCompletion":1609,"completion":1609,"start":22962,"enrollment":1146,"conditions":22963,"interventions":22964},"NCT06427291","Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients",[89],"2023-09-21",[6207],[22952],{"trials":22966,"activeCount":101},[],{"trials":22968,"activeCount":101},[],{"trials":22970,"activeCount":101},[],{"trials":22972,"activeCount":101},[],{"intervention":22974,"totalTrials":651,"cells":22975},"recombinant human endostatin",{"EARLY_PHASE1":22976,"PHASE1":22978,"PHASE2":22987,"PHASE3":22989,"PHASE4":22991,"NA":22993},{"trials":22977,"activeCount":101},[],{"trials":22979,"activeCount":101},[22980],{"nctId":22981,"briefTitle":22982,"status":107,"phases":22983,"primaryCompletion":17896,"start":2518,"enrollment":478,"conditions":22984,"interventions":22986},"NCT01310478","Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer",[89],[22985],"Colorectal Neoplasm",[22974],{"trials":22988,"activeCount":101},[],{"trials":22990,"activeCount":101},[],{"trials":22992,"activeCount":101},[],{"trials":22994,"activeCount":101},[],{"intervention":22996,"totalTrials":651,"cells":22997},"PD-1 and Lenvatinib Plus TACE",{"EARLY_PHASE1":22998,"PHASE1":23006,"PHASE2":23008,"PHASE3":23010,"PHASE4":23012,"NA":23014},{"trials":22999,"activeCount":101},[23000],{"nctId":23001,"briefTitle":23002,"status":107,"phases":23003,"primaryCompletion":285,"completion":285,"start":190,"enrollment":97,"conditions":23004,"interventions":23005},"NCT04974281","PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B\u002FC HCC",[88],[21],[22996],{"trials":23007,"activeCount":101},[],{"trials":23009,"activeCount":101},[],{"trials":23011,"activeCount":101},[],{"trials":23013,"activeCount":101},[],{"trials":23015,"activeCount":101},[],{"intervention":16457,"totalTrials":771,"cells":23017},{"EARLY_PHASE1":23018,"PHASE1":23020,"PHASE2":23022,"PHASE3":23024,"PHASE4":23030,"NA":23032},{"trials":23019,"activeCount":101},[],{"trials":23021,"activeCount":101},[],{"trials":23023,"activeCount":101},[],{"trials":23025,"activeCount":101},[23026],{"nctId":16452,"briefTitle":16453,"status":107,"phases":23027,"primaryCompletion":3390,"completion":56,"start":14855,"enrollment":2483,"conditions":23028,"interventions":23029},[91],[21,670],[16457,16432],{"trials":23031,"activeCount":101},[],{"trials":23033,"activeCount":101},[23034],{"nctId":8694,"briefTitle":8695,"status":494,"phases":23035,"primaryCompletion":8697,"completion":8697,"start":528,"enrollment":473,"conditions":23036,"interventions":23037},[93],[21],[8668,8700],{"intervention":23039,"totalTrials":771,"cells":23040},"Methylene Blue",{"EARLY_PHASE1":23041,"PHASE1":23043,"PHASE2":23045,"PHASE3":23047,"PHASE4":23049,"NA":23051},{"trials":23042,"activeCount":101},[],{"trials":23044,"activeCount":101},[],{"trials":23046,"activeCount":101},[],{"trials":23048,"activeCount":101},[],{"trials":23050,"activeCount":101},[],{"trials":23052,"activeCount":101},[23053,23061],{"nctId":23054,"briefTitle":23055,"status":365,"phases":23056,"primaryCompletion":20467,"completion":666,"start":368,"enrollment":23057,"conditions":23058,"interventions":23060},"NCT04529265","Methylene Blue and Postoperative Neurocognitive Disorders",[93],314,[23059],"Postoperative Delirium",[23039],{"nctId":23062,"briefTitle":23063,"status":365,"phases":23064,"primaryCompletion":23065,"completion":23066,"start":23067,"enrollment":2293,"conditions":23068,"interventions":23070},"NCT04341844","Intraoperative Infusion of Methylene Blue for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac Surgery",[93],"2020-04-30","2020-07-30","2019-01-14",[23059,23069],"Postoperative Cognitive Dysfunction",[23039],{"intervention":2721,"totalTrials":771,"cells":23072},{"EARLY_PHASE1":23073,"PHASE1":23075,"PHASE2":23077,"PHASE3":23083,"PHASE4":23085,"NA":23087},{"trials":23074,"activeCount":101},[],{"trials":23076,"activeCount":101},[],{"trials":23078,"activeCount":101},[23079],{"nctId":2714,"briefTitle":2715,"status":107,"phases":23080,"primaryCompletion":56,"completion":56,"start":368,"enrollment":181,"conditions":23081,"interventions":23082},[90],[2718,240],[2720,1386,2721,2722],{"trials":23084,"activeCount":101},[],{"trials":23086,"activeCount":101},[],{"trials":23088,"activeCount":101},[23089],{"nctId":8775,"briefTitle":8776,"status":107,"phases":23090,"primaryCompletion":6235,"completion":6235,"start":8778,"enrollment":25,"conditions":23091,"interventions":23092},[],[8780,2796,8781],[8783,2721,2722],{"intervention":23094,"totalTrials":771,"cells":23095},"interferon-alpha",{"EARLY_PHASE1":23096,"PHASE1":23098,"PHASE2":23100,"PHASE3":23102,"PHASE4":23112,"NA":23114},{"trials":23097,"activeCount":101},[],{"trials":23099,"activeCount":101},[],{"trials":23101,"activeCount":101},[],{"trials":23103,"activeCount":101},[23104],{"nctId":23105,"briefTitle":23106,"status":107,"phases":23107,"primaryCompletion":23108,"completion":23108,"start":390,"enrollment":23109,"conditions":23110,"interventions":23111},"NCT01681446","Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression",[91],"2019-08",296,[21],[23094],{"trials":23113,"activeCount":101},[],{"trials":23115,"activeCount":101},[23116],{"nctId":23117,"briefTitle":23118,"status":3025,"phases":23119,"primaryCompletion":3113,"completion":1600,"start":15838,"enrollment":101,"conditions":23120,"interventions":23121},"NCT00838968","The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma",[93],[21],[23094],{"intervention":23123,"totalTrials":651,"cells":23124},"Capecitabine-Irinotecan Combination",{"EARLY_PHASE1":23125,"PHASE1":23127,"PHASE2":23129,"PHASE3":23131,"PHASE4":23133,"NA":23135},{"trials":23126,"activeCount":101},[],{"trials":23128,"activeCount":101},[],{"trials":23130,"activeCount":101},[],{"trials":23132,"activeCount":101},[],{"trials":23134,"activeCount":101},[],{"trials":23136,"activeCount":101},[23137],{"nctId":23138,"briefTitle":23139,"status":107,"phases":23140,"primaryCompletion":1279,"completion":426,"start":7201,"enrollment":5832,"conditions":23141,"interventions":23144},"NCT04227886","Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer",[],[23142,1217,240,23143,1220],"Rectal Neoplasm Malignant Carcinoma","Predictive Biomarkers",[23123],{"intervention":23146,"totalTrials":651,"cells":23147},"Oral Contraceptives, Combined",{"EARLY_PHASE1":23148,"PHASE1":23150,"PHASE2":23152,"PHASE3":23154,"PHASE4":23156,"NA":23158},{"trials":23149,"activeCount":101},[],{"trials":23151,"activeCount":101},[],{"trials":23153,"activeCount":101},[],{"trials":23155,"activeCount":101},[],{"trials":23157,"activeCount":101},[],{"trials":23159,"activeCount":101},[23160],{"nctId":23161,"briefTitle":23162,"status":107,"phases":23163,"primaryCompletion":293,"completion":294,"start":190,"enrollment":213,"conditions":23164,"interventions":23167},"NCT04984070","Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety",[93],[23165,23166],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","Depression, Anxiety",[23146,23168],"Metformin Pill",{"intervention":23168,"totalTrials":651,"cells":23170},{"EARLY_PHASE1":23171,"PHASE1":23173,"PHASE2":23175,"PHASE3":23177,"PHASE4":23179,"NA":23181},{"trials":23172,"activeCount":101},[],{"trials":23174,"activeCount":101},[],{"trials":23176,"activeCount":101},[],{"trials":23178,"activeCount":101},[],{"trials":23180,"activeCount":101},[],{"trials":23182,"activeCount":101},[23183],{"nctId":23161,"briefTitle":23162,"status":107,"phases":23184,"primaryCompletion":293,"completion":294,"start":190,"enrollment":213,"conditions":23185,"interventions":23186},[93],[23165,23166],[23146,23168],{"intervention":23188,"totalTrials":651,"cells":23189},"fish oil and acute ozone exposure",{"EARLY_PHASE1":23190,"PHASE1":23192,"PHASE2":23194,"PHASE3":23196,"PHASE4":23198,"NA":23200},{"trials":23191,"activeCount":101},[],{"trials":23193,"activeCount":101},[],{"trials":23195,"activeCount":101},[],{"trials":23197,"activeCount":101},[],{"trials":23199,"activeCount":101},[],{"trials":23201,"activeCount":101},[23202],{"nctId":23203,"briefTitle":23204,"status":365,"phases":23205,"primaryCompletion":23206,"completion":19336,"start":23207,"enrollment":16376,"conditions":23208,"interventions":23213},"NCT03697499","Effects of Fish Oil in Alleviating Health Hazards Associated With Ozone Exposure",[93],"2018-12-10","2018-09-20",[23209,23210,23211,23212],"Cardiovascular System","Respiratory System","Oxidative Stress","Inflammation",[23188,23214,23215,23216],"fish oil and sham exposure","soy oil and acute ozone exposure","soy oil and sham exposure",{"intervention":23214,"totalTrials":651,"cells":23218},{"EARLY_PHASE1":23219,"PHASE1":23221,"PHASE2":23223,"PHASE3":23225,"PHASE4":23227,"NA":23229},{"trials":23220,"activeCount":101},[],{"trials":23222,"activeCount":101},[],{"trials":23224,"activeCount":101},[],{"trials":23226,"activeCount":101},[],{"trials":23228,"activeCount":101},[],{"trials":23230,"activeCount":101},[23231],{"nctId":23203,"briefTitle":23204,"status":365,"phases":23232,"primaryCompletion":23206,"completion":19336,"start":23207,"enrollment":16376,"conditions":23233,"interventions":23234},[93],[23209,23210,23211,23212],[23188,23214,23215,23216],{"intervention":23215,"totalTrials":651,"cells":23236},{"EARLY_PHASE1":23237,"PHASE1":23239,"PHASE2":23241,"PHASE3":23243,"PHASE4":23245,"NA":23247},{"trials":23238,"activeCount":101},[],{"trials":23240,"activeCount":101},[],{"trials":23242,"activeCount":101},[],{"trials":23244,"activeCount":101},[],{"trials":23246,"activeCount":101},[],{"trials":23248,"activeCount":101},[23249],{"nctId":23203,"briefTitle":23204,"status":365,"phases":23250,"primaryCompletion":23206,"completion":19336,"start":23207,"enrollment":16376,"conditions":23251,"interventions":23252},[93],[23209,23210,23211,23212],[23188,23214,23215,23216],{"intervention":23216,"totalTrials":651,"cells":23254},{"EARLY_PHASE1":23255,"PHASE1":23257,"PHASE2":23259,"PHASE3":23261,"PHASE4":23263,"NA":23265},{"trials":23256,"activeCount":101},[],{"trials":23258,"activeCount":101},[],{"trials":23260,"activeCount":101},[],{"trials":23262,"activeCount":101},[],{"trials":23264,"activeCount":101},[],{"trials":23266,"activeCount":101},[23267],{"nctId":23203,"briefTitle":23204,"status":365,"phases":23268,"primaryCompletion":23206,"completion":19336,"start":23207,"enrollment":16376,"conditions":23269,"interventions":23270},[93],[23209,23210,23211,23212],[23188,23214,23215,23216],{"intervention":23272,"totalTrials":651,"cells":23273},"Treatment Group",{"EARLY_PHASE1":23274,"PHASE1":23276,"PHASE2":23278,"PHASE3":23280,"PHASE4":23282,"NA":23284},{"trials":23275,"activeCount":101},[],{"trials":23277,"activeCount":101},[],{"trials":23279,"activeCount":101},[],{"trials":23281,"activeCount":101},[],{"trials":23283,"activeCount":101},[],{"trials":23285,"activeCount":101},[23286],{"nctId":23287,"briefTitle":23288,"status":107,"phases":23289,"primaryCompletion":293,"completion":294,"start":23290,"enrollment":111,"conditions":23291,"interventions":23292},"NCT05863260","Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer",[],"2020-11-09",[9602,7976,1217],[23272],{"intervention":23294,"totalTrials":651,"cells":23295},"genetic testing",{"EARLY_PHASE1":23296,"PHASE1":23298,"PHASE2":23300,"PHASE3":23302,"PHASE4":23304,"NA":23306},{"trials":23297,"activeCount":101},[],{"trials":23299,"activeCount":101},[],{"trials":23301,"activeCount":101},[],{"trials":23303,"activeCount":101},[],{"trials":23305,"activeCount":101},[],{"trials":23307,"activeCount":101},[23308],{"nctId":23309,"briefTitle":23310,"status":365,"phases":23311,"primaryCompletion":23312,"completion":23312,"start":23313,"enrollment":529,"conditions":23314,"interventions":23316},"NCT05545254","Health-promoting Lifestyle in a Genetic Counseling Clinic",[],"2022-03-04","2019-11-13",[15,23315],"Genetic Testing",[23294],{"intervention":23318,"totalTrials":651,"cells":23319},"GEA",{"EARLY_PHASE1":23320,"PHASE1":23322,"PHASE2":23324,"PHASE3":23326,"PHASE4":23328,"NA":23330},{"trials":23321,"activeCount":101},[],{"trials":23323,"activeCount":101},[],{"trials":23325,"activeCount":101},[],{"trials":23327,"activeCount":101},[],{"trials":23329,"activeCount":101},[],{"trials":23331,"activeCount":101},[23332],{"nctId":23333,"briefTitle":23334,"status":365,"phases":23335,"primaryCompletion":1979,"completion":23336,"start":23337,"enrollment":3910,"conditions":23338,"interventions":23340},"NCT03245346","Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery",[93],"2025-09-24","2017-12-19",[23339],"Cancer of Pancreas",[23318,23341,23342,23343],"PCEA","GA","PCIA",{"intervention":23341,"totalTrials":651,"cells":23345},{"EARLY_PHASE1":23346,"PHASE1":23348,"PHASE2":23350,"PHASE3":23352,"PHASE4":23354,"NA":23356},{"trials":23347,"activeCount":101},[],{"trials":23349,"activeCount":101},[],{"trials":23351,"activeCount":101},[],{"trials":23353,"activeCount":101},[],{"trials":23355,"activeCount":101},[],{"trials":23357,"activeCount":101},[23358],{"nctId":23333,"briefTitle":23334,"status":365,"phases":23359,"primaryCompletion":1979,"completion":23336,"start":23337,"enrollment":3910,"conditions":23360,"interventions":23361},[93],[23339],[23318,23341,23342,23343],{"intervention":23342,"totalTrials":651,"cells":23363},{"EARLY_PHASE1":23364,"PHASE1":23366,"PHASE2":23368,"PHASE3":23370,"PHASE4":23372,"NA":23374},{"trials":23365,"activeCount":101},[],{"trials":23367,"activeCount":101},[],{"trials":23369,"activeCount":101},[],{"trials":23371,"activeCount":101},[],{"trials":23373,"activeCount":101},[],{"trials":23375,"activeCount":101},[23376],{"nctId":23333,"briefTitle":23334,"status":365,"phases":23377,"primaryCompletion":1979,"completion":23336,"start":23337,"enrollment":3910,"conditions":23378,"interventions":23379},[93],[23339],[23318,23341,23342,23343],{"intervention":23343,"totalTrials":651,"cells":23381},{"EARLY_PHASE1":23382,"PHASE1":23384,"PHASE2":23386,"PHASE3":23388,"PHASE4":23390,"NA":23392},{"trials":23383,"activeCount":101},[],{"trials":23385,"activeCount":101},[],{"trials":23387,"activeCount":101},[],{"trials":23389,"activeCount":101},[],{"trials":23391,"activeCount":101},[],{"trials":23393,"activeCount":101},[23394],{"nctId":23333,"briefTitle":23334,"status":365,"phases":23395,"primaryCompletion":1979,"completion":23336,"start":23337,"enrollment":3910,"conditions":23396,"interventions":23397},[93],[23339],[23318,23341,23342,23343],{"intervention":23399,"totalTrials":651,"cells":23400},"Pyrotinib Plus Trastuzumab",{"EARLY_PHASE1":23401,"PHASE1":23403,"PHASE2":23405,"PHASE3":23407,"PHASE4":23409,"NA":23411},{"trials":23402,"activeCount":101},[],{"trials":23404,"activeCount":101},[],{"trials":23406,"activeCount":101},[],{"trials":23408,"activeCount":101},[],{"trials":23410,"activeCount":101},[],{"trials":23412,"activeCount":101},[23413],{"nctId":23414,"briefTitle":23415,"status":365,"phases":23416,"primaryCompletion":51,"completion":51,"start":6392,"enrollment":23417,"conditions":23418,"interventions":23419},"NCT05572645","Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab",[],333,[15],[23399,23420],"Pertuzumab Plus Trastuzumab",{"intervention":23420,"totalTrials":651,"cells":23422},{"EARLY_PHASE1":23423,"PHASE1":23425,"PHASE2":23427,"PHASE3":23429,"PHASE4":23431,"NA":23433},{"trials":23424,"activeCount":101},[],{"trials":23426,"activeCount":101},[],{"trials":23428,"activeCount":101},[],{"trials":23430,"activeCount":101},[],{"trials":23432,"activeCount":101},[],{"trials":23434,"activeCount":101},[23435],{"nctId":23414,"briefTitle":23415,"status":365,"phases":23436,"primaryCompletion":51,"completion":51,"start":6392,"enrollment":23417,"conditions":23437,"interventions":23438},[],[15],[23399,23420],{"intervention":23440,"totalTrials":651,"cells":23441},"insulin detemir",{"EARLY_PHASE1":23442,"PHASE1":23444,"PHASE2":23446,"PHASE3":23448,"PHASE4":23450,"NA":23452},{"trials":23443,"activeCount":101},[],{"trials":23445,"activeCount":101},[],{"trials":23447,"activeCount":101},[],{"trials":23449,"activeCount":101},[],{"trials":23451,"activeCount":101},[],{"trials":23453,"activeCount":101},[23454],{"nctId":23455,"briefTitle":23456,"status":107,"phases":23457,"start":15646,"enrollment":97,"conditions":23458,"interventions":23460},"NCT01310452","Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin",[93],[23459],"Type 2 Diabetes Mellitus",[23440,23461],"neutral protamine insulin",{"intervention":23461,"totalTrials":651,"cells":23463},{"EARLY_PHASE1":23464,"PHASE1":23466,"PHASE2":23468,"PHASE3":23470,"PHASE4":23472,"NA":23474},{"trials":23465,"activeCount":101},[],{"trials":23467,"activeCount":101},[],{"trials":23469,"activeCount":101},[],{"trials":23471,"activeCount":101},[],{"trials":23473,"activeCount":101},[],{"trials":23475,"activeCount":101},[23476],{"nctId":23455,"briefTitle":23456,"status":107,"phases":23477,"start":15646,"enrollment":97,"conditions":23478,"interventions":23479},[93],[23459],[23440,23461],{"intervention":23481,"totalTrials":651,"cells":23482},"Envafolimab",{"EARLY_PHASE1":23483,"PHASE1":23485,"PHASE2":23487,"PHASE3":23489,"PHASE4":23491,"NA":23493},{"trials":23484,"activeCount":101},[],{"trials":23486,"activeCount":101},[],{"trials":23488,"activeCount":101},[],{"trials":23490,"activeCount":101},[],{"trials":23492,"activeCount":101},[],{"trials":23494,"activeCount":101},[23495],{"nctId":23496,"briefTitle":23497,"status":107,"phases":23498,"primaryCompletion":2157,"completion":1334,"start":1584,"enrollment":7627,"conditions":23499,"interventions":23502},"NCT05645094","Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H\u002FdMMR Rectal Cancer",[],[23500,23501],"Locally Advanced Rectal Carcinoma","MSI-High",[23481],{"intervention":23504,"totalTrials":651,"cells":23505},"pabolizumab",{"EARLY_PHASE1":23506,"PHASE1":23508,"PHASE2":23510,"PHASE3":23512,"PHASE4":23514,"NA":23516},{"trials":23507,"activeCount":101},[],{"trials":23509,"activeCount":101},[],{"trials":23511,"activeCount":101},[],{"trials":23513,"activeCount":101},[],{"trials":23515,"activeCount":101},[],{"trials":23517,"activeCount":101},[23518],{"nctId":23519,"briefTitle":23520,"status":107,"phases":23521,"primaryCompletion":426,"completion":285,"start":18132,"enrollment":2709,"conditions":23522,"interventions":23524},"NCT04427475","Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer",[93],[23523],"NSCLC Patients",[23504,23525],"nafulizumab",{"intervention":23525,"totalTrials":651,"cells":23527},{"EARLY_PHASE1":23528,"PHASE1":23530,"PHASE2":23532,"PHASE3":23534,"PHASE4":23536,"NA":23538},{"trials":23529,"activeCount":101},[],{"trials":23531,"activeCount":101},[],{"trials":23533,"activeCount":101},[],{"trials":23535,"activeCount":101},[],{"trials":23537,"activeCount":101},[],{"trials":23539,"activeCount":101},[23540],{"nctId":23519,"briefTitle":23520,"status":107,"phases":23541,"primaryCompletion":426,"completion":285,"start":18132,"enrollment":2709,"conditions":23542,"interventions":23543},[93],[23523],[23504,23525],{"intervention":23545,"totalTrials":651,"cells":23546},"NGF group",{"EARLY_PHASE1":23547,"PHASE1":23549,"PHASE2":23551,"PHASE3":23553,"PHASE4":23555,"NA":23557},{"trials":23548,"activeCount":101},[],{"trials":23550,"activeCount":101},[],{"trials":23552,"activeCount":101},[],{"trials":23554,"activeCount":101},[],{"trials":23556,"activeCount":101},[],{"trials":23558,"activeCount":101},[23559],{"nctId":23560,"briefTitle":23561,"status":365,"phases":23562,"primaryCompletion":3113,"completion":3113,"start":17205,"enrollment":25,"conditions":23563,"interventions":23567},"NCT02032147","Treatment of Cerebral Radiation Necrosis (CRN) With Nerve Growth Factor (NGF)",[],[23564,23565,23566],"Cerebral Necrosis","Nashopharyngeal Cancer","Nerve Growth Factor",[23545],{"intervention":23569,"totalTrials":651,"cells":23570},"Renin-angiotensin system inhibitors",{"EARLY_PHASE1":23571,"PHASE1":23573,"PHASE2":23575,"PHASE3":23577,"PHASE4":23579,"NA":23581},{"trials":23572,"activeCount":101},[],{"trials":23574,"activeCount":101},[],{"trials":23576,"activeCount":101},[],{"trials":23578,"activeCount":101},[],{"trials":23580,"activeCount":101},[],{"trials":23582,"activeCount":101},[23583],{"nctId":23584,"briefTitle":23585,"status":365,"phases":23586,"primaryCompletion":22900,"completion":3612,"start":23587,"enrollment":23588,"conditions":23589,"interventions":23591},"NCT07012538","RASi for Preventing Postoperative Recurrence of Stage II\u002FIII Colon Cancer",[],"2012-01-04",2640,[23590],"Colon Cancer (Stage II &Amp;Amp; III)",[23569,23592],"No renin-angiotensin system inhibitors",{"intervention":23592,"totalTrials":651,"cells":23594},{"EARLY_PHASE1":23595,"PHASE1":23597,"PHASE2":23599,"PHASE3":23601,"PHASE4":23603,"NA":23605},{"trials":23596,"activeCount":101},[],{"trials":23598,"activeCount":101},[],{"trials":23600,"activeCount":101},[],{"trials":23602,"activeCount":101},[],{"trials":23604,"activeCount":101},[],{"trials":23606,"activeCount":101},[23607],{"nctId":23584,"briefTitle":23585,"status":365,"phases":23608,"primaryCompletion":22900,"completion":3612,"start":23587,"enrollment":23588,"conditions":23609,"interventions":23610},[],[23590],[23569,23592],{"intervention":23612,"totalTrials":651,"cells":23613},"Propofol",{"EARLY_PHASE1":23614,"PHASE1":23616,"PHASE2":23618,"PHASE3":23620,"PHASE4":23622,"NA":23624},{"trials":23615,"activeCount":101},[],{"trials":23617,"activeCount":101},[],{"trials":23619,"activeCount":101},[],{"trials":23621,"activeCount":101},[],{"trials":23623,"activeCount":101},[],{"trials":23625,"activeCount":101},[23626],{"nctId":23627,"briefTitle":23628,"status":107,"phases":23629,"primaryCompletion":15746,"completion":485,"start":487,"enrollment":3068,"conditions":23630,"interventions":23631},"NCT02554175","The Effective Effect-Site Propofol Concentration for Induction and Intubation for Schnider Model in Parturients",[93],[16211],[23612],{"intervention":23633,"totalTrials":651,"cells":23634},"Nalbuphine",{"EARLY_PHASE1":23635,"PHASE1":23637,"PHASE2":23639,"PHASE3":23641,"PHASE4":23643,"NA":23645},{"trials":23636,"activeCount":101},[],{"trials":23638,"activeCount":101},[],{"trials":23640,"activeCount":101},[],{"trials":23642,"activeCount":101},[],{"trials":23644,"activeCount":101},[],{"trials":23646,"activeCount":101},[23647],{"nctId":23648,"briefTitle":23649,"status":107,"phases":23650,"primaryCompletion":23651,"completion":2944,"start":1877,"enrollment":334,"conditions":23652,"interventions":23653},"NCT02604797","Analgesia Effects of Nalbuphine vs Sulfentanil",[93],"2017-01",[16211],[23633,23654,23655,23656],"Sufentanil","flurbiprofen axetil","ramosetron",{"intervention":23654,"totalTrials":651,"cells":23658},{"EARLY_PHASE1":23659,"PHASE1":23661,"PHASE2":23663,"PHASE3":23665,"PHASE4":23667,"NA":23669},{"trials":23660,"activeCount":101},[],{"trials":23662,"activeCount":101},[],{"trials":23664,"activeCount":101},[],{"trials":23666,"activeCount":101},[],{"trials":23668,"activeCount":101},[],{"trials":23670,"activeCount":101},[23671],{"nctId":23648,"briefTitle":23649,"status":107,"phases":23672,"primaryCompletion":23651,"completion":2944,"start":1877,"enrollment":334,"conditions":23673,"interventions":23674},[93],[16211],[23633,23654,23655,23656],{"intervention":23655,"totalTrials":651,"cells":23676},{"EARLY_PHASE1":23677,"PHASE1":23679,"PHASE2":23681,"PHASE3":23683,"PHASE4":23685,"NA":23687},{"trials":23678,"activeCount":101},[],{"trials":23680,"activeCount":101},[],{"trials":23682,"activeCount":101},[],{"trials":23684,"activeCount":101},[],{"trials":23686,"activeCount":101},[],{"trials":23688,"activeCount":101},[23689],{"nctId":23648,"briefTitle":23649,"status":107,"phases":23690,"primaryCompletion":23651,"completion":2944,"start":1877,"enrollment":334,"conditions":23691,"interventions":23692},[93],[16211],[23633,23654,23655,23656],{"intervention":23656,"totalTrials":651,"cells":23694},{"EARLY_PHASE1":23695,"PHASE1":23697,"PHASE2":23699,"PHASE3":23701,"PHASE4":23703,"NA":23705},{"trials":23696,"activeCount":101},[],{"trials":23698,"activeCount":101},[],{"trials":23700,"activeCount":101},[],{"trials":23702,"activeCount":101},[],{"trials":23704,"activeCount":101},[],{"trials":23706,"activeCount":101},[23707],{"nctId":23648,"briefTitle":23649,"status":107,"phases":23708,"primaryCompletion":23651,"completion":2944,"start":1877,"enrollment":334,"conditions":23709,"interventions":23710},[93],[16211],[23633,23654,23655,23656],{"intervention":23712,"totalTrials":651,"cells":23713},"Indocyanine Green",{"EARLY_PHASE1":23714,"PHASE1":23716,"PHASE2":23718,"PHASE3":23720,"PHASE4":23722,"NA":23724},{"trials":23715,"activeCount":101},[],{"trials":23717,"activeCount":101},[],{"trials":23719,"activeCount":101},[],{"trials":23721,"activeCount":101},[],{"trials":23723,"activeCount":101},[],{"trials":23725,"activeCount":101},[23726],{"nctId":23727,"briefTitle":23728,"status":107,"phases":23729,"primaryCompletion":6605,"completion":449,"start":23730,"enrollment":213,"conditions":23731,"interventions":23732},"NCT03854890","Fluorescent Lymphography-Guided Lymphadenectomy In Laparoscopic Proctectomy",[93],"2019-07-01",[113],[23712],{"intervention":23734,"totalTrials":651,"cells":23735},"DEBIRI Combined With Chemotherapy and Bevacizumab",{"EARLY_PHASE1":23736,"PHASE1":23738,"PHASE2":23740,"PHASE3":23742,"PHASE4":23744,"NA":23746},{"trials":23737,"activeCount":101},[],{"trials":23739,"activeCount":101},[],{"trials":23741,"activeCount":101},[],{"trials":23743,"activeCount":101},[],{"trials":23745,"activeCount":101},[],{"trials":23747,"activeCount":101},[23748],{"nctId":23749,"briefTitle":23750,"status":107,"phases":23751,"primaryCompletion":367,"completion":179,"start":125,"enrollment":1167,"conditions":23752,"interventions":23753},"NCT06177288","DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases",[93],[1477],[23734],{"intervention":23755,"totalTrials":651,"cells":23756},"3M GnRHa",{"EARLY_PHASE1":23757,"PHASE1":23759,"PHASE2":23761,"PHASE3":23763,"PHASE4":23765,"NA":23767},{"trials":23758,"activeCount":101},[],{"trials":23760,"activeCount":101},[],{"trials":23762,"activeCount":101},[],{"trials":23764,"activeCount":101},[],{"trials":23766,"activeCount":101},[],{"trials":23768,"activeCount":101},[23769],{"nctId":23770,"briefTitle":23771,"status":365,"phases":23772,"primaryCompletion":179,"completion":179,"start":23773,"enrollment":23774,"conditions":23775,"interventions":23778},"NCT05122377","RWE About QOL and Compliance of Patients With OFS in China",[],"2022-03-01",562,[15,23776,23777],"Quality of Life","Hormone Receptor-positive Breast Cancer",[23755,23779],"1M GnRHa",{"intervention":23779,"totalTrials":651,"cells":23781},{"EARLY_PHASE1":23782,"PHASE1":23784,"PHASE2":23786,"PHASE3":23788,"PHASE4":23790,"NA":23792},{"trials":23783,"activeCount":101},[],{"trials":23785,"activeCount":101},[],{"trials":23787,"activeCount":101},[],{"trials":23789,"activeCount":101},[],{"trials":23791,"activeCount":101},[],{"trials":23793,"activeCount":101},[23794],{"nctId":23770,"briefTitle":23771,"status":365,"phases":23795,"primaryCompletion":179,"completion":179,"start":23773,"enrollment":23774,"conditions":23796,"interventions":23797},[],[15,23776,23777],[23755,23779],{"intervention":23799,"totalTrials":651,"cells":23800},"68Ga-HER2 affibody,18F-FDG, 18F-FES",{"EARLY_PHASE1":23801,"PHASE1":23803,"PHASE2":23805,"PHASE3":23807,"PHASE4":23809,"NA":23811},{"trials":23802,"activeCount":101},[],{"trials":23804,"activeCount":101},[],{"trials":23806,"activeCount":101},[],{"trials":23808,"activeCount":101},[],{"trials":23810,"activeCount":101},[],{"trials":23812,"activeCount":101},[23813],{"nctId":23814,"briefTitle":23815,"status":107,"phases":23816,"primaryCompletion":285,"completion":285,"start":1279,"enrollment":97,"conditions":23817,"interventions":23818},"NCT04758416","Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer",[],[15],[23799],{"intervention":23820,"totalTrials":651,"cells":23821},"whole exome sequence",{"EARLY_PHASE1":23822,"PHASE1":23824,"PHASE2":23826,"PHASE3":23828,"PHASE4":23830,"NA":23832},{"trials":23823,"activeCount":101},[],{"trials":23825,"activeCount":101},[],{"trials":23827,"activeCount":101},[],{"trials":23829,"activeCount":101},[],{"trials":23831,"activeCount":101},[],{"trials":23833,"activeCount":101},[23834],{"nctId":23835,"briefTitle":23836,"status":107,"phases":23837,"primaryCompletion":1279,"completion":285,"start":23838,"enrollment":2709,"conditions":23839,"interventions":23842},"NCT04694391","Genomic Study of Relapse Esophageal Cancer After Radiotherapy",[],"2012-09-14",[23840,1602,23841],"Gene Mutation-Related Cancer","Radiation Exposure",[23820],{"intervention":23844,"totalTrials":651,"cells":23845},"Fruquintinib Combined With TAS-102",{"EARLY_PHASE1":23846,"PHASE1":23848,"PHASE2":23850,"PHASE3":23852,"PHASE4":23854,"NA":23856},{"trials":23847,"activeCount":101},[],{"trials":23849,"activeCount":101},[],{"trials":23851,"activeCount":101},[],{"trials":23853,"activeCount":101},[],{"trials":23855,"activeCount":101},[],{"trials":23857,"activeCount":101},[23858],{"nctId":23859,"briefTitle":23860,"status":107,"phases":23861,"primaryCompletion":18099,"completion":18099,"start":964,"enrollment":1146,"conditions":23862,"interventions":23864},"NCT06221423","Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer",[],[18,6157,23863],"Refractory Colorectal Carcinoma",[23844],{"intervention":23866,"totalTrials":651,"cells":23867},"Targeted agent",{"EARLY_PHASE1":23868,"PHASE1":23870,"PHASE2":23872,"PHASE3":23874,"PHASE4":23876,"NA":23878},{"trials":23869,"activeCount":101},[],{"trials":23871,"activeCount":101},[],{"trials":23873,"activeCount":101},[],{"trials":23875,"activeCount":101},[],{"trials":23877,"activeCount":101},[],{"trials":23879,"activeCount":101},[23880],{"nctId":23881,"briefTitle":23882,"status":365,"phases":23883,"primaryCompletion":1584,"completion":1584,"start":23884,"enrollment":440,"conditions":23885,"interventions":23886},"NCT06027775","Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases",[],"2013-01-01",[2816],[23866],{"intervention":23888,"totalTrials":651,"cells":23889},"docetaxel oxaliplatin",{"EARLY_PHASE1":23890,"PHASE1":23892,"PHASE2":23894,"PHASE3":23896,"PHASE4":23898,"NA":23900},{"trials":23891,"activeCount":101},[],{"trials":23893,"activeCount":101},[],{"trials":23895,"activeCount":101},[],{"trials":23897,"activeCount":101},[],{"trials":23899,"activeCount":101},[],{"trials":23901,"activeCount":101},[23902],{"nctId":23903,"briefTitle":23904,"status":23905,"phases":23906,"conditions":23907,"interventions":23909},"NCT01216124","Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients","AVAILABLE",[],[23908],"Triple Negative Local Advanced Breast Cancer",[23888],{"intervention":23911,"totalTrials":651,"cells":23912},"Dexmedetomidine ropivacaine",{"EARLY_PHASE1":23913,"PHASE1":23915,"PHASE2":23917,"PHASE3":23919,"PHASE4":23921,"NA":23923},{"trials":23914,"activeCount":101},[],{"trials":23916,"activeCount":101},[],{"trials":23918,"activeCount":101},[],{"trials":23920,"activeCount":101},[],{"trials":23922,"activeCount":101},[],{"trials":23924,"activeCount":101},[23925],{"nctId":23926,"briefTitle":23927,"status":107,"phases":23928,"primaryCompletion":1346,"completion":1346,"start":23929,"enrollment":23930,"conditions":23931,"interventions":23933},"NCT03622047","Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil",[93],"2018-08-15",1800,[23932],"Pharmacological Action",[23911,23934],"No analgesia labor",{"intervention":23934,"totalTrials":651,"cells":23936},{"EARLY_PHASE1":23937,"PHASE1":23939,"PHASE2":23941,"PHASE3":23943,"PHASE4":23945,"NA":23947},{"trials":23938,"activeCount":101},[],{"trials":23940,"activeCount":101},[],{"trials":23942,"activeCount":101},[],{"trials":23944,"activeCount":101},[],{"trials":23946,"activeCount":101},[],{"trials":23948,"activeCount":101},[23949],{"nctId":23926,"briefTitle":23927,"status":107,"phases":23950,"primaryCompletion":1346,"completion":1346,"start":23929,"enrollment":23930,"conditions":23951,"interventions":23952},[93],[23932],[23911,23934],{"intervention":23954,"totalTrials":651,"cells":23955},"Group SF1",{"EARLY_PHASE1":23956,"PHASE1":23958,"PHASE2":23960,"PHASE3":23962,"PHASE4":23964,"NA":23966},{"trials":23957,"activeCount":101},[],{"trials":23959,"activeCount":101},[],{"trials":23961,"activeCount":101},[],{"trials":23963,"activeCount":101},[],{"trials":23965,"activeCount":101},[],{"trials":23967,"activeCount":101},[23968],{"nctId":23969,"briefTitle":23970,"status":107,"phases":23971,"primaryCompletion":15746,"completion":485,"start":15748,"enrollment":334,"conditions":23972,"interventions":23973},"NCT02595333","Incision Pain and Uterine Contraction Pain After Cesarean Section",[93],[16211],[23954,23974,23975,23976],"Group S1","Group SF2","Group S2",{"intervention":23974,"totalTrials":651,"cells":23978},{"EARLY_PHASE1":23979,"PHASE1":23981,"PHASE2":23983,"PHASE3":23985,"PHASE4":23987,"NA":23989},{"trials":23980,"activeCount":101},[],{"trials":23982,"activeCount":101},[],{"trials":23984,"activeCount":101},[],{"trials":23986,"activeCount":101},[],{"trials":23988,"activeCount":101},[],{"trials":23990,"activeCount":101},[23991],{"nctId":23969,"briefTitle":23970,"status":107,"phases":23992,"primaryCompletion":15746,"completion":485,"start":15748,"enrollment":334,"conditions":23993,"interventions":23994},[93],[16211],[23954,23974,23975,23976],{"intervention":23975,"totalTrials":651,"cells":23996},{"EARLY_PHASE1":23997,"PHASE1":23999,"PHASE2":24001,"PHASE3":24003,"PHASE4":24005,"NA":24007},{"trials":23998,"activeCount":101},[],{"trials":24000,"activeCount":101},[],{"trials":24002,"activeCount":101},[],{"trials":24004,"activeCount":101},[],{"trials":24006,"activeCount":101},[],{"trials":24008,"activeCount":101},[24009],{"nctId":23969,"briefTitle":23970,"status":107,"phases":24010,"primaryCompletion":15746,"completion":485,"start":15748,"enrollment":334,"conditions":24011,"interventions":24012},[93],[16211],[23954,23974,23975,23976],{"intervention":23976,"totalTrials":651,"cells":24014},{"EARLY_PHASE1":24015,"PHASE1":24017,"PHASE2":24019,"PHASE3":24021,"PHASE4":24023,"NA":24025},{"trials":24016,"activeCount":101},[],{"trials":24018,"activeCount":101},[],{"trials":24020,"activeCount":101},[],{"trials":24022,"activeCount":101},[],{"trials":24024,"activeCount":101},[],{"trials":24026,"activeCount":101},[24027],{"nctId":23969,"briefTitle":23970,"status":107,"phases":24028,"primaryCompletion":15746,"completion":485,"start":15748,"enrollment":334,"conditions":24029,"interventions":24030},[93],[16211],[23954,23974,23975,23976],{"intervention":24032,"totalTrials":651,"cells":24033},"pre-oxygen",{"EARLY_PHASE1":24034,"PHASE1":24036,"PHASE2":24038,"PHASE3":24040,"PHASE4":24042,"NA":24044},{"trials":24035,"activeCount":101},[],{"trials":24037,"activeCount":101},[],{"trials":24039,"activeCount":101},[],{"trials":24041,"activeCount":101},[],{"trials":24043,"activeCount":101},[],{"trials":24045,"activeCount":101},[24046],{"nctId":24047,"briefTitle":24048,"status":365,"phases":24049,"primaryCompletion":24050,"completion":24050,"start":4189,"enrollment":1434,"conditions":24051,"interventions":24053},"NCT01968525","The Effect of Chronic Anemia on Safety Period of Tracheal Intubation in Gynecology Patients",[93],"2013-09",[24052],"Chronic Anemia",[24032],{"intervention":24055,"totalTrials":651,"cells":24056},"Adjuvant chemotherapy",{"EARLY_PHASE1":24057,"PHASE1":24059,"PHASE2":24061,"PHASE3":24063,"PHASE4":24065,"NA":24067},{"trials":24058,"activeCount":101},[],{"trials":24060,"activeCount":101},[],{"trials":24062,"activeCount":101},[],{"trials":24064,"activeCount":101},[],{"trials":24066,"activeCount":101},[],{"trials":24068,"activeCount":101},[24069],{"nctId":24070,"briefTitle":24071,"status":365,"phases":24072,"primaryCompletion":1584,"completion":367,"start":2043,"enrollment":24073,"conditions":24074,"interventions":24075},"NCT03789682","CD155 in Bladder Cancer",[],151,[6207],[24055],{"intervention":24077,"totalTrials":651,"cells":24078},"ct-DNA",{"EARLY_PHASE1":24079,"PHASE1":24081,"PHASE2":24083,"PHASE3":24085,"PHASE4":24087,"NA":24089},{"trials":24080,"activeCount":101},[],{"trials":24082,"activeCount":101},[],{"trials":24084,"activeCount":101},[],{"trials":24086,"activeCount":101},[],{"trials":24088,"activeCount":101},[],{"trials":24090,"activeCount":101},[24091],{"nctId":24092,"briefTitle":24093,"status":107,"phases":24094,"primaryCompletion":51,"completion":1530,"start":24095,"enrollment":1290,"conditions":24096,"interventions":24098},"NCT04555369","The Value of ctDNA on Chemotherapy Efficacy for mCRC",[93],"2020-09-23",[24097],"Circulating Tumor DNA",[24077],{"intervention":24100,"totalTrials":651,"cells":24101},"Liraglutide",{"EARLY_PHASE1":24102,"PHASE1":24104,"PHASE2":24106,"PHASE3":24108,"PHASE4":24110,"NA":24112},{"trials":24103,"activeCount":101},[],{"trials":24105,"activeCount":101},[],{"trials":24107,"activeCount":101},[],{"trials":24109,"activeCount":101},[],{"trials":24111,"activeCount":101},[],{"trials":24113,"activeCount":101},[24114],{"nctId":24115,"briefTitle":24116,"status":107,"phases":24117,"primaryCompletion":355,"completion":355,"start":15923,"enrollment":111,"conditions":24118,"interventions":24120},"NCT04137328","Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide",[93],[24119],"Diabetic Neuropathic Pain",[24100,24121],"insulin",{"intervention":24121,"totalTrials":651,"cells":24123},{"EARLY_PHASE1":24124,"PHASE1":24126,"PHASE2":24128,"PHASE3":24130,"PHASE4":24132,"NA":24134},{"trials":24125,"activeCount":101},[],{"trials":24127,"activeCount":101},[],{"trials":24129,"activeCount":101},[],{"trials":24131,"activeCount":101},[],{"trials":24133,"activeCount":101},[],{"trials":24135,"activeCount":101},[24136],{"nctId":24115,"briefTitle":24116,"status":107,"phases":24137,"primaryCompletion":355,"completion":355,"start":15923,"enrollment":111,"conditions":24138,"interventions":24139},[93],[24119],[24100,24121],{"intervention":8783,"totalTrials":651,"cells":24141},{"EARLY_PHASE1":24142,"PHASE1":24144,"PHASE2":24146,"PHASE3":24148,"PHASE4":24150,"NA":24152},{"trials":24143,"activeCount":101},[],{"trials":24145,"activeCount":101},[],{"trials":24147,"activeCount":101},[],{"trials":24149,"activeCount":101},[],{"trials":24151,"activeCount":101},[],{"trials":24153,"activeCount":101},[24154],{"nctId":8775,"briefTitle":8776,"status":107,"phases":24155,"primaryCompletion":6235,"completion":6235,"start":8778,"enrollment":25,"conditions":24156,"interventions":24157},[],[8780,2796,8781],[8783,2721,2722],{"intervention":24159,"totalTrials":651,"cells":24160},"0.25 sufentanil",{"EARLY_PHASE1":24161,"PHASE1":24163,"PHASE2":24165,"PHASE3":24167,"PHASE4":24169,"NA":24171},{"trials":24162,"activeCount":101},[],{"trials":24164,"activeCount":101},[],{"trials":24166,"activeCount":101},[],{"trials":24168,"activeCount":101},[],{"trials":24170,"activeCount":101},[],{"trials":24172,"activeCount":101},[24173],{"nctId":24174,"briefTitle":24175,"status":365,"phases":24176,"primaryCompletion":211,"completion":211,"start":2545,"enrollment":296,"conditions":24177,"interventions":24179},"NCT02488291","Effect of Sufentanil and Ropivacaine",[93],[24178],"Anesthesia Complications",[24159,24180,24181],"0.5µg\u002Fml sufentanil","0.1% ropivacaine",{"intervention":24180,"totalTrials":651,"cells":24183},{"EARLY_PHASE1":24184,"PHASE1":24186,"PHASE2":24188,"PHASE3":24190,"PHASE4":24192,"NA":24194},{"trials":24185,"activeCount":101},[],{"trials":24187,"activeCount":101},[],{"trials":24189,"activeCount":101},[],{"trials":24191,"activeCount":101},[],{"trials":24193,"activeCount":101},[],{"trials":24195,"activeCount":101},[24196],{"nctId":24174,"briefTitle":24175,"status":365,"phases":24197,"primaryCompletion":211,"completion":211,"start":2545,"enrollment":296,"conditions":24198,"interventions":24199},[93],[24178],[24159,24180,24181],{"intervention":24181,"totalTrials":651,"cells":24201},{"EARLY_PHASE1":24202,"PHASE1":24204,"PHASE2":24206,"PHASE3":24208,"PHASE4":24210,"NA":24212},{"trials":24203,"activeCount":101},[],{"trials":24205,"activeCount":101},[],{"trials":24207,"activeCount":101},[],{"trials":24209,"activeCount":101},[],{"trials":24211,"activeCount":101},[],{"trials":24213,"activeCount":101},[24214],{"nctId":24174,"briefTitle":24175,"status":365,"phases":24215,"primaryCompletion":211,"completion":211,"start":2545,"enrollment":296,"conditions":24216,"interventions":24217},[93],[24178],[24159,24180,24181],{"intervention":24219,"totalTrials":651,"cells":24220},"GM1",{"EARLY_PHASE1":24221,"PHASE1":24223,"PHASE2":24225,"PHASE3":24227,"PHASE4":24229,"NA":24231},{"trials":24222,"activeCount":101},[],{"trials":24224,"activeCount":101},[],{"trials":24226,"activeCount":101},[],{"trials":24228,"activeCount":101},[],{"trials":24230,"activeCount":101},[],{"trials":24232,"activeCount":101},[24233],{"nctId":24234,"briefTitle":24235,"status":107,"phases":24236,"primaryCompletion":389,"completion":389,"start":497,"enrollment":25,"conditions":24237,"interventions":24240},"NCT01884987","Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study",[],[1553,35,24238,24239],"Cerebral Radiation Necrosis","MRI",[24219],{"intervention":24242,"totalTrials":651,"cells":24243},"Anti-PD-1 Immune Checkpoint Inhibitors",{"EARLY_PHASE1":24244,"PHASE1":24246,"PHASE2":24248,"PHASE3":24250,"PHASE4":24252,"NA":24254},{"trials":24245,"activeCount":101},[],{"trials":24247,"activeCount":101},[],{"trials":24249,"activeCount":101},[],{"trials":24251,"activeCount":101},[],{"trials":24253,"activeCount":101},[],{"trials":24255,"activeCount":101},[24256],{"nctId":24257,"briefTitle":24258,"status":365,"phases":24259,"primaryCompletion":24260,"completion":1609,"start":3120,"enrollment":24261,"conditions":24262,"interventions":24264},"NCT05142709","Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.",[],"2023-09-30",1197,[24263],"Metastatic Esophageal Squamous Cell Carcinoma",[24242],{"intervention":24266,"totalTrials":651,"cells":24267},"phenylephrine",{"EARLY_PHASE1":24268,"PHASE1":24270,"PHASE2":24272,"PHASE3":24274,"PHASE4":24276,"NA":24278},{"trials":24269,"activeCount":101},[],{"trials":24271,"activeCount":101},[],{"trials":24273,"activeCount":101},[],{"trials":24275,"activeCount":101},[],{"trials":24277,"activeCount":101},[],{"trials":24279,"activeCount":101},[24280],{"nctId":24281,"briefTitle":24282,"status":107,"phases":24283,"primaryCompletion":17996,"completion":4020,"start":16914,"enrollment":213,"conditions":24284,"interventions":24286},"NCT02532270","Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring",[93],[24285],"Hypotension",[24266],{"intervention":24288,"totalTrials":651,"cells":24289},"immunochemotherapies",{"EARLY_PHASE1":24290,"PHASE1":24292,"PHASE2":24294,"PHASE3":24296,"PHASE4":24298,"NA":24300},{"trials":24291,"activeCount":101},[],{"trials":24293,"activeCount":101},[],{"trials":24295,"activeCount":101},[],{"trials":24297,"activeCount":101},[],{"trials":24299,"activeCount":101},[],{"trials":24301,"activeCount":101},[24302],{"nctId":24303,"briefTitle":24304,"status":107,"phases":24305,"primaryCompletion":24306,"completion":24307,"start":24308,"enrollment":14857,"conditions":24309,"interventions":24310},"NCT06170216","Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)",[],"2023-12-19","2026-01-10","2023-01-10",[19107],[24288],{"intervention":24312,"totalTrials":651,"cells":24313},"Docetaxel combined with Trastuzumab±Pertuzumab",{"EARLY_PHASE1":24314,"PHASE1":24316,"PHASE2":24318,"PHASE3":24320,"PHASE4":24322,"NA":24324},{"trials":24315,"activeCount":101},[],{"trials":24317,"activeCount":101},[],{"trials":24319,"activeCount":101},[],{"trials":24321,"activeCount":101},[],{"trials":24323,"activeCount":101},[],{"trials":24325,"activeCount":101},[24326],{"nctId":24327,"briefTitle":24328,"status":107,"phases":24329,"primaryCompletion":293,"completion":293,"start":24330,"enrollment":97,"conditions":24331,"interventions":24332},"NCT04769050","Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment",[],"2021-02-18",[15],[24312,24333],"T-DM1 or Capecitabine combined with Pyrotinib regimen.",{"intervention":24333,"totalTrials":651,"cells":24335},{"EARLY_PHASE1":24336,"PHASE1":24338,"PHASE2":24340,"PHASE3":24342,"PHASE4":24344,"NA":24346},{"trials":24337,"activeCount":101},[],{"trials":24339,"activeCount":101},[],{"trials":24341,"activeCount":101},[],{"trials":24343,"activeCount":101},[],{"trials":24345,"activeCount":101},[],{"trials":24347,"activeCount":101},[24348],{"nctId":24327,"briefTitle":24328,"status":107,"phases":24349,"primaryCompletion":293,"completion":293,"start":24330,"enrollment":97,"conditions":24350,"interventions":24351},[],[15],[24312,24333],{"intervention":24353,"totalTrials":651,"cells":24354},"Standard of care for metastatic prostate cancer",{"EARLY_PHASE1":24355,"PHASE1":24357,"PHASE2":24359,"PHASE3":24361,"PHASE4":24363,"NA":24365},{"trials":24356,"activeCount":101},[],{"trials":24358,"activeCount":101},[],{"trials":24360,"activeCount":101},[],{"trials":24362,"activeCount":101},[],{"trials":24364,"activeCount":101},[],{"trials":24366,"activeCount":101},[24367],{"nctId":24368,"briefTitle":24369,"status":107,"phases":24370,"primaryCompletion":24371,"completion":6097,"start":2583,"enrollment":296,"conditions":24372,"interventions":24373},"NCT03988686","Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone",[93],"2021-03-31",[2795],[24353],{"intervention":24375,"totalTrials":651,"cells":24376},"pemetrexed \u002Fcarboplatin",{"EARLY_PHASE1":24377,"PHASE1":24379,"PHASE2":24381,"PHASE3":24383,"PHASE4":24385,"NA":24387},{"trials":24378,"activeCount":101},[],{"trials":24380,"activeCount":101},[],{"trials":24382,"activeCount":101},[],{"trials":24384,"activeCount":101},[],{"trials":24386,"activeCount":101},[],{"trials":24388,"activeCount":101},[24389],{"nctId":24390,"briefTitle":24391,"status":107,"phases":24392,"primaryCompletion":3924,"start":658,"enrollment":12592,"conditions":24393,"interventions":24394},"NCT01860508","A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers",[93],[2960],[24375],{"intervention":24396,"totalTrials":651,"cells":24397},"third-generation EGFR-TKI",{"EARLY_PHASE1":24398,"PHASE1":24400,"PHASE2":24402,"PHASE3":24404,"PHASE4":24406,"NA":24408},{"trials":24399,"activeCount":101},[],{"trials":24401,"activeCount":101},[],{"trials":24403,"activeCount":101},[],{"trials":24405,"activeCount":101},[],{"trials":24407,"activeCount":101},[],{"trials":24409,"activeCount":101},[24410],{"nctId":24411,"briefTitle":24412,"status":365,"phases":24413,"primaryCompletion":1145,"completion":24414,"start":24415,"enrollment":24416,"conditions":24417,"interventions":24419},"NCT06613633","Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC",[],"2026-02-20","2018-09-01",4000,[24418,3961],"Third-generation TKI",[24396]]